{"paper_id": "c6ca840f6c446c66396c06fc42401af987b88e5d", "metadata": {"title": "The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges THE PROTEASOME AS A DRUGGABLE TARGET WITH MULTIPLE THERAPEUTIC POTENTIALITIES: CUTTING AND NON-CUTTING EDGES", "authors": [{"first": "G", "middle": ["R"], "last": "Tundo", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Rome Tor Vergata", "location": {"settlement": "Rome", "country": "Italy"}}, "email": ""}, {"first": "D", "middle": [], "last": "Sbardella", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Rome Tor Vergata", "location": {"settlement": "Rome", "country": "Italy"}}, "email": ""}, {"first": "A", "middle": ["M"], "last": "Santoro", "suffix": "", "affiliation": {"laboratory": "", "institution": "CNR IBB", "location": {"region": "Catania", "country": "Italy"}}, "email": ""}, {"first": "A", "middle": [], "last": "Coletta", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Aarhus", "location": {"settlement": "Aarhus", "country": "Denmark"}}, "email": "coletta@med.uniroma2.it"}, {"first": "F", "middle": [], "last": "Oddone", "suffix": "", "affiliation": {}, "email": ""}, {"first": "G", "middle": [], "last": "Grasso", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Catania", "location": {"region": "Catania", "country": "Italy"}}, "email": ""}, {"first": "D", "middle": [], "last": "Milardi", "suffix": "", "affiliation": {"laboratory": "", "institution": "CNR IBB", "location": {"region": "Catania", "country": "Italy"}}, "email": ""}, {"first": "P", "middle": [], "last": "Lacal", "suffix": "", "affiliation": {"laboratory": "Laboratory of Molecular Oncology", "institution": "IDI-IRCCS", "location": {"settlement": "Rome", "country": "Italy"}}, "email": ""}, {"first": "S", "middle": [], "last": "Marini", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Rome Tor Vergata", "location": {"settlement": "Rome", "country": "Italy"}}, "email": ""}, {"first": "P", "middle": [], "last": "Purrello", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Catania", "location": {"region": "Catania", "country": "Italy"}}, "email": ""}, {"first": "G", "middle": [], "last": "Graziani", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Rome Tor Vergata", "location": {"settlement": "Rome", "country": "Italy"}}, "email": ""}, {"first": "M", "middle": [], "last": "Coletta", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Rome Tor Vergata", "location": {"settlement": "Rome", "country": "Italy"}}, "email": ""}, {"first": "Grazia", "middle": ["Tundo@libero"], "last": "It", "suffix": "", "affiliation": {}, "email": ""}, {"first": "M", "middle": [], "last": "It", "suffix": "", "affiliation": {}, "email": ""}, {"first": "", "middle": [], "last": "Coletta", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Rome Tor Vergata", "location": {"settlement": "Rome", "country": "Italy"}}, "email": ""}]}, "abstract": [{"text": "Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that sustains proteostasis network under a large variety of physiopathological conditions. Its dysregulation is often associated with the onset and progression of human diseases; hence, UPS modulation has emerged as a promising new avenue for the development of treatments of several relevant pathologies, such as cancer and neurodegeneration. The clinical interest in proteasome inhibition has considerably increased after the FDA approval in 2003 of bortezomib for relapsed/refractory multiple myeloma, which is now used in the front-line setting. Thereafter, two other proteasome inhibitors (carfilzomib and ixazomib), designed to overcome resistance to bortezomib, have been approved for treatment-experienced patients, and a variety of novel inhibitors are currently under preclinical and clinical investigation not only for hematological malignancies but also for solid tumors. However, since UPS collapse leads to toxic misfolded proteins accumulation, proteasome is attracting even more interest as a target for the care of neurodegenerative diseases, which are sustained by UPS impairment. Thus, conceptually, proteasome activation represents an innovative 1 G.R. Tundo and D. Sbardella have equally contributed to this work J o u r n a l P r e -p r o o f Journal Pre-proof 2 and largely unexplored target for drug development. According to a multidisciplinary approach, spanning from chemistry, biochemistry, molecular biology to pharmacology, this review will summarize the most recent available literature regarding different aspects of proteasome biology, focusing on structure, function and regulation of proteasome in physiological and pathological processes, mostly cancer and neurodegenerative diseases, connecting biochemical features and clinical studies of proteasome targeting drugs.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "intracellular proteolytic systems, namely Ubiquitin-Proteasome-System (UPS) and autophagy (Klaips et al., 2018; Ciechanover and Kwon, 2017; Sala et al., 2017) . Furthermore, a myriad of regulatory proteins (such as transcription and metabolic factors, chromatin remodelling factors, and regulators of posttranslational modifications) act as PN auxiliary and coordinate the cross-talk between the PN compartments accounting for the afore mentioned plasticity of the PN (Labbadia and Morimoto, 2015; Klaips et al., 2018) . Therefore, unlike early scientists, who considered proteins essentially stable and prone to only a minor \"wear and tear\" (Schoenheimer et al., 1939; Schoenheimer, 1942; Thibaudeau and Smith, 2019) , it is now known that proteome is highly dynamic, and proteins constantly undergo turn over at different rates, according to their biological role (Lecker et al., 2006; Thibaudeau and Smith, 2019) .", "cite_spans": [{"start": 90, "end": 111, "text": "(Klaips et al., 2018;", "ref_id": null}, {"start": 112, "end": 139, "text": "Ciechanover and Kwon, 2017;", "ref_id": "BIBREF49"}, {"start": 140, "end": 158, "text": "Sala et al., 2017)", "ref_id": "BIBREF559"}, {"start": 482, "end": 497, "text": "Morimoto, 2015;", "ref_id": null}, {"start": 498, "end": 518, "text": "Klaips et al., 2018)", "ref_id": null}, {"start": 642, "end": 669, "text": "(Schoenheimer et al., 1939;", "ref_id": "BIBREF613"}, {"start": 670, "end": 689, "text": "Schoenheimer, 1942;", "ref_id": null}, {"start": 690, "end": 717, "text": "Thibaudeau and Smith, 2019)", "ref_id": "BIBREF708"}, {"start": 866, "end": 887, "text": "(Lecker et al., 2006;", "ref_id": "BIBREF263"}, {"start": 888, "end": 915, "text": "Thibaudeau and Smith, 2019)", "ref_id": "BIBREF708"}], "ref_spans": [], "section": ""}, {"text": "In the 1950s, the discovery of autophagy-lysosome system as \"intracellular exergonic digestive system\" by de Duve and colleagues was the first step in understanding intracellular and extracellular protein breakdown (de Duve et al., 1953; de Duve et al., 1955; de Duve and Wattiaux, 1966; Sabatini and Adesnik, 2013) . Over the same years, Simpson showed for the first time that intracellular proteolysis in mammalian cells requires energy, suggesting the existence of an additional mechanism of protein degradation (Simpson et al., 1953) . However, this observation was considered with scepticism, since hydrolysis of the peptide bond is exergonic, and there is no apparent thermodynamic advantage in energy use (Wilkinson et al., 2005) . However, the seminal Simpson's discovery found support in the 1970s, when Goldberg and colleagues identified a novel, cytosolic ATP-dependent proteolytic system (Goldberg, 1972; Goldberg and Dice, 1974; Goldberg and St John, 1974; Etlinger and Goldberg, 1977; Bigelow et al., 1981; Wilkinson et al., 2005; Thibaudeau and Smith, 2019) . Some years later, Wilk and Orlowski purified a 700-kDa \"multicatalytic proteinase complex\", which was able to cleave peptides after hydrophobic, acidic and basic residues, suggesting the existence of multiple active sites in its structure (Wilk and Orlowski, 1980; Wilk and Orlowski, 1983) . This \"stacked donut ring\" complex (which later was shown to be the 20S) was tnamed \"proteasome\", and its orthologues were identified in all life domains (Tanaka et al., 1983; Tanaka et al., 1988; Arrigo et al., 1998; Thibaudeau and Smith, 2019) . A milestone in protein degradation field was the discovery by Ciechanover and colleagues of a 8-kDa heat-stable protein, APF-1 (later renamed \"ubiquitin\"), whose ATP-dependent covalent conjugation with proteins targeted them for degradation by a downstream protease, that was then identified as the 26S proteasome (Ciechanover et al., 1978; Ciechanover et al., 1980; Ciechanover et al., 1982; Hershko et al., 1980; Hershko et al., 1982; Ciechanover et al., 1984; Hough et al., 1986;  J o u r n a l P r e -p r o o f Journal Pre-proof specificity (Hough et al., 1986; Pickart et al., 2001; Glickman and Ciechanover, 2002; Windheim et al., 2008; Ciechanover, 2013; Leestemaker and Ovaa, 2017; Pao et al 2018) . The end-point of UPS is the 26S complex (hereafter referred to as 26S), a multifunctional 2500 kDa proteolytic molecular machine, composed by the 20S proteasome core particle (CP, hereafter referred to as 20S), which houses the proteolytic activity. The 20S is capped by one or two 19S regulatory particle(s) (RP) (hereafter referred to as 19S), which carry out the ATP-dependent recognition, unfolding and translocation into the 20S of the poly-ubiquitinated substrate (Ciechanover, 2015; Glickman and Ciechanover, 2002; Kunjappu and Hochstrasser, 2014; Pao et al., 2018 , see also sections 2.2 and 2.3). Over the last decades, several alternative regulators of 20S have been described, namely PA28 protein family and Blm10/PA200, whose structure, substrate specificities, and biological roles go beyond the scope of this review and are extensively reviewed elsewhere (Rechsteiner and Hill, 2005; Tanaka et al., 2009; Huang and Chen. 2009; Kish-Trier, 2013; Schmidt and Finley, 2014; Jiang et al., 2018; Limanaqi et al., 2019) .", "cite_spans": [{"start": 215, "end": 237, "text": "(de Duve et al., 1953;", "ref_id": "BIBREF64"}, {"start": 238, "end": 259, "text": "de Duve et al., 1955;", "ref_id": null}, {"start": 260, "end": 287, "text": "de Duve and Wattiaux, 1966;", "ref_id": "BIBREF63"}, {"start": 288, "end": 315, "text": "Sabatini and Adesnik, 2013)", "ref_id": "BIBREF553"}, {"start": 515, "end": 537, "text": "(Simpson et al., 1953)", "ref_id": "BIBREF651"}, {"start": 712, "end": 736, "text": "(Wilkinson et al., 2005)", "ref_id": "BIBREF808"}, {"start": 900, "end": 916, "text": "(Goldberg, 1972;", "ref_id": "BIBREF101"}, {"start": 917, "end": 941, "text": "Goldberg and Dice, 1974;", "ref_id": "BIBREF103"}, {"start": 942, "end": 969, "text": "Goldberg and St John, 1974;", "ref_id": null}, {"start": 970, "end": 998, "text": "Etlinger and Goldberg, 1977;", "ref_id": null}, {"start": 999, "end": 1020, "text": "Bigelow et al., 1981;", "ref_id": null}, {"start": 1021, "end": 1044, "text": "Wilkinson et al., 2005;", "ref_id": "BIBREF808"}, {"start": 1045, "end": 1072, "text": "Thibaudeau and Smith, 2019)", "ref_id": "BIBREF708"}, {"start": 1314, "end": 1339, "text": "(Wilk and Orlowski, 1980;", "ref_id": "BIBREF805"}, {"start": 1340, "end": 1364, "text": "Wilk and Orlowski, 1983)", "ref_id": "BIBREF806"}, {"start": 1520, "end": 1541, "text": "(Tanaka et al., 1983;", "ref_id": null}, {"start": 1542, "end": 1562, "text": "Tanaka et al., 1988;", "ref_id": "BIBREF8"}, {"start": 1563, "end": 1583, "text": "Arrigo et al., 1998;", "ref_id": null}, {"start": 1584, "end": 1611, "text": "Thibaudeau and Smith, 2019)", "ref_id": "BIBREF708"}, {"start": 1928, "end": 1954, "text": "(Ciechanover et al., 1978;", "ref_id": null}, {"start": 1955, "end": 1980, "text": "Ciechanover et al., 1980;", "ref_id": "BIBREF48"}, {"start": 1981, "end": 2006, "text": "Ciechanover et al., 1982;", "ref_id": null}, {"start": 2007, "end": 2028, "text": "Hershko et al., 1980;", "ref_id": "BIBREF48"}, {"start": 2029, "end": 2050, "text": "Hershko et al., 1982;", "ref_id": null}, {"start": 2051, "end": 2076, "text": "Ciechanover et al., 1984;", "ref_id": null}, {"start": 2077, "end": 2096, "text": "Hough et al., 1986;", "ref_id": null}, {"start": 2097, "end": 2097, "text": "", "ref_id": null}, {"start": 2147, "end": 2179, "text": "specificity (Hough et al., 1986;", "ref_id": null}, {"start": 2180, "end": 2201, "text": "Pickart et al., 2001;", "ref_id": "BIBREF457"}, {"start": 2202, "end": 2233, "text": "Glickman and Ciechanover, 2002;", "ref_id": "BIBREF98"}, {"start": 2234, "end": 2256, "text": "Windheim et al., 2008;", "ref_id": "BIBREF810"}, {"start": 2257, "end": 2275, "text": "Ciechanover, 2013;", "ref_id": null}, {"start": 2276, "end": 2303, "text": "Leestemaker and Ovaa, 2017;", "ref_id": "BIBREF272"}, {"start": 2304, "end": 2319, "text": "Pao et al 2018)", "ref_id": "BIBREF431"}, {"start": 2792, "end": 2811, "text": "(Ciechanover, 2015;", "ref_id": null}, {"start": 2812, "end": 2843, "text": "Glickman and Ciechanover, 2002;", "ref_id": "BIBREF98"}, {"start": 2844, "end": 2876, "text": "Kunjappu and Hochstrasser, 2014;", "ref_id": "BIBREF245"}, {"start": 2877, "end": 2893, "text": "Pao et al., 2018", "ref_id": "BIBREF431"}, {"start": 3191, "end": 3219, "text": "(Rechsteiner and Hill, 2005;", "ref_id": "BIBREF494"}, {"start": 3220, "end": 3240, "text": "Tanaka et al., 2009;", "ref_id": "BIBREF557"}, {"start": 3241, "end": 3262, "text": "Huang and Chen. 2009;", "ref_id": null}, {"start": 3263, "end": 3280, "text": "Kish-Trier, 2013;", "ref_id": null}, {"start": 3281, "end": 3306, "text": "Schmidt and Finley, 2014;", "ref_id": "BIBREF606"}, {"start": 3307, "end": 3326, "text": "Jiang et al., 2018;", "ref_id": "BIBREF194"}, {"start": 3327, "end": 3349, "text": "Limanaqi et al., 2019)", "ref_id": "BIBREF298"}], "ref_spans": [], "section": ""}, {"text": "Although the initial dogma on proteasome recognition mechanism states that the 26S hydrolyses only proteins tagged with at least four ubiquitin molecules, emerging evidences show that polyubiquitin chains are not the unique signal. In fact, in some cases, multiple or single monoubiquitination appears to be sufficient to label a substrate for proteasomal degradation (Shabek, 2012; Kravtsova-Ivantsiv, 2009 ). Moreover, ornithine decarboxylase has been the first of a long series of protein substrates (i.e., Rpn4, thymidylate synthase, myelin) reported to be degraded by the 26S regardless of ubiquitination (Rosenberg-Hasson et al., 1989; Bercovich et al., 1989; Murakami et al., 1992; Sheaff et al., 2000; Jim et al., 2003; Ju et al., 2004; Forsthoefel et al., 2004; Li et al., 2006; Chen et al., 2007; . This implies the existence of alternative molecular signals (also named \"degrons\"), such as specific amino acidic sequence or structural elements, that mediate proteasome recognition and degradation of substrates independently on their ubiquitination levels (Baugh et al., 2009; .", "cite_spans": [{"start": 368, "end": 382, "text": "(Shabek, 2012;", "ref_id": "BIBREF621"}, {"start": 383, "end": 407, "text": "Kravtsova-Ivantsiv, 2009", "ref_id": "BIBREF227"}, {"start": 610, "end": 641, "text": "(Rosenberg-Hasson et al., 1989;", "ref_id": "BIBREF539"}, {"start": 642, "end": 665, "text": "Bercovich et al., 1989;", "ref_id": "BIBREF539"}, {"start": 666, "end": 688, "text": "Murakami et al., 1992;", "ref_id": "BIBREF375"}, {"start": 689, "end": 709, "text": "Sheaff et al., 2000;", "ref_id": null}, {"start": 710, "end": 727, "text": "Jim et al., 2003;", "ref_id": null}, {"start": 728, "end": 744, "text": "Ju et al., 2004;", "ref_id": "BIBREF200"}, {"start": 745, "end": 770, "text": "Forsthoefel et al., 2004;", "ref_id": "BIBREF79"}, {"start": 771, "end": 787, "text": "Li et al., 2006;", "ref_id": null}, {"start": 788, "end": 806, "text": "Chen et al., 2007;", "ref_id": "BIBREF430"}, {"start": 1067, "end": 1087, "text": "(Baugh et al., 2009;", "ref_id": "BIBREF18"}], "ref_spans": [], "section": ""}, {"text": "The biological significance of ubiquitin-independent degradation of substrates by the 26S is a topic deserving great attention in order to decipher its physiological meaning in tissue homeostasis. Two proposed explanations envisage that it could be \"only\" a remnant of evolution, or else it could be rather a mechanism that provides, under selected circumstances, an alternative strategy to overcome Rpn4 and of proteasome in the case of inappropriate ubiquitin conjugation (Ju and Xie, 2004; Hanna et al., 2007; Erales and Coffino, 2014) .", "cite_spans": [{"start": 474, "end": 492, "text": "(Ju and Xie, 2004;", "ref_id": "BIBREF200"}, {"start": 493, "end": 512, "text": "Hanna et al., 2007;", "ref_id": "BIBREF148"}, {"start": 513, "end": 538, "text": "Erales and Coffino, 2014)", "ref_id": null}], "ref_spans": [], "section": ""}, {"text": "In this regard, an intriguing example of how ubiquitin-dependent and ubiquitin-independent pathways cooperate to survey cellular homeostasis comes from the regulation of the proteome of lipid droplets (LDs), that are ubiquitous, endoplasmic reticulum-derived storage organelles from which neutral lipids are rapidly mobilized in response to cellular demands. In fact, some proteins of LDs are degraded by proteasome through the canonical ubiquitination pathway, whereas some others only when the \"degron\" signals they hold become unmasked upon protein insertion into the lipid monolayer (Bersuker and Olzmann 2017) . Interestingly, it has been reported that proteasome mediates ubiquitin-dependent degradation of patatin-like phospholipase domain-containing protein 3 (PNPLA3), whose sequence variant 148M is resistant to ubiquitination and to proteasome degradation, and accumulates into LDs, contributing to non-alcoholic fatty liver disease pathogenesis (Speliotes et al., 2011; Kozlitina et al., 2014; Basu Ray et al., 2019 ).", "cite_spans": [{"start": 601, "end": 614, "text": "Olzmann 2017)", "ref_id": null}, {"start": 957, "end": 981, "text": "(Speliotes et al., 2011;", "ref_id": "BIBREF680"}, {"start": 982, "end": 1005, "text": "Kozlitina et al., 2014;", "ref_id": null}, {"start": 1006, "end": 1027, "text": "Basu Ray et al., 2019", "ref_id": "BIBREF16"}], "ref_spans": [], "section": ""}, {"text": "An additional issue in deciphering the mechanisms of proteasome degradation is the ubiquitinindependent degradation in vitro of macromolecular substrates by the uncapped 20S. In fact, several studies demonstrate that the 20S is able to degrade natively unfolded as well as oxidized and misfolded proteins (Davies, 1993; Pacifici et al., 1993; Grune et al., 1996; Reinheckel et al., 1998; Davies, 2001; Shringarpure et al., 2003; Raynes et al., 2016) . Indeed, oxidative stress induces chemical alterations, bringing about conformational changes and exposure of hydrophobic residues on damaged protein surfaces (Carrard et al., 2002; Raynes et al., 2016) . These surface hydrophobic patches stimulate, in an allosteric fashion, the translocation of the substrate into the 20S proteolytic chamber (see section 2.2 for details) (Giulivi et al., 1994; Coux et al., 1996; Davies, 2001; Kisselev et al., 2002) , since under oxidative stress conditions this form is more stable than the 26S, which is quickly and reversibly inactivated likely through dissociation into free 20S and 19S particles (Reinheckel et al., 1998; Reinheckel et al., 2000; Shringarpure et al., 2003; . Moreover, also the E1-E2-E3 cascade is transiently inactivated during oxidative stress, supporting a ubiquitin-independent degradation of oxidized proteins (Grune et al., 2011) .", "cite_spans": [{"start": 305, "end": 319, "text": "(Davies, 1993;", "ref_id": "BIBREF60"}, {"start": 320, "end": 342, "text": "Pacifici et al., 1993;", "ref_id": null}, {"start": 343, "end": 362, "text": "Grune et al., 1996;", "ref_id": "BIBREF125"}, {"start": 363, "end": 387, "text": "Reinheckel et al., 1998;", "ref_id": "BIBREF499"}, {"start": 388, "end": 401, "text": "Davies, 2001;", "ref_id": "BIBREF61"}, {"start": 402, "end": 428, "text": "Shringarpure et al., 2003;", "ref_id": "BIBREF644"}, {"start": 429, "end": 449, "text": "Raynes et al., 2016)", "ref_id": "BIBREF493"}, {"start": 610, "end": 632, "text": "(Carrard et al., 2002;", "ref_id": null}, {"start": 633, "end": 653, "text": "Raynes et al., 2016)", "ref_id": "BIBREF493"}, {"start": 825, "end": 847, "text": "(Giulivi et al., 1994;", "ref_id": "BIBREF94"}, {"start": 848, "end": 866, "text": "Coux et al., 1996;", "ref_id": null}, {"start": 867, "end": 880, "text": "Davies, 2001;", "ref_id": "BIBREF61"}, {"start": 881, "end": 903, "text": "Kisselev et al., 2002)", "ref_id": null}, {"start": 1089, "end": 1114, "text": "(Reinheckel et al., 1998;", "ref_id": "BIBREF499"}, {"start": 1115, "end": 1139, "text": "Reinheckel et al., 2000;", "ref_id": "BIBREF500"}, {"start": 1140, "end": 1166, "text": "Shringarpure et al., 2003;", "ref_id": "BIBREF644"}, {"start": 1325, "end": 1345, "text": "(Grune et al., 2011)", "ref_id": "BIBREF126"}], "ref_spans": [], "section": ""}, {"text": "Thus, the current view is that 20S activity on oxidized and damaged proteins might compensate for the loss of the ubiquitin-dependent activity of the 26S under redox imbalance.", "cite_spans": [], "ref_spans": [], "section": ""}, {"text": "intra-subunits interactions, constituting \"the gate\", which regulates the substrate access through a 13 \u00c5 entry pore into the antechamber (i.e, at \u03b17-\u03b27 interface). This passageway keeps the substrate in an unfolded state, directing it towards the catalytic chamber (i.e., at \u03b27-\u03b27 interface) Unno et al., 2002; Bajorek and Glickman, 2004; Marques et al., 2009; Ruschak et al., 2010;  Gaczynska and Osmulski, 2014) ( Figure 1C ). The insertion of the substrate through this \"Nterminal gate\" is the rate-limiting step of proteasome activity and prevents unwanted protein degradation (Akopian et al., 1997; Kohler et al., 2001) . In fact, RP binding induces the N-terminal tails displacement and opens the gate, facilitating the substrate translocation (see section 2.3) (Sledz et al., 2013; Matyskiela et al., 2013; Choi et al., 2016; Marshall and Vierstra, 2019) . However, it is worth recalling that RP binding to 20S is not an absolute requirement for proteasome activation, since 20S can switch from an inactive \"closed\" conformation to an active \"open\" conformation spontaneously or after chemical treatment (e.g., SDS) Forster et al., 2003; Bajorek and Glickman, 2004) . Noteworthy, since the \u03b13 tail points toward the centre of the channel and maintains a close interaction with all other Ntermini of \u03b1 subunits (Kohler et al., 2001a; Kohler et al., 2001b) , the deletion of first nine residues in \u03b13 subunit N-tail in yeast 20S induces a general disorder in the neighbouring tails, stimulating the opening of the entry pore (Kohler et al., 2001a; Kohler et al., 2001b) . Thus, the \u03b13\u0394n mutant is in a constitutively activated \"open\" state and its basal proteolytic activity toward small peptides is consistently enhanced, as compared to that of wild-type (wt) 20S (Kohler et al., 2001a; Kohler et al., 2001b; Bajorek and Glickman, 200) . Conversely, the double mutant \u03b13-\u03b17\u0394n more efficiently degrades macromolecular substrates with respect to either single mutants, suggesting that the interaction between these opposite tails is crucial in the regulation of gate opening (Bajorek et al, 2003; Bajorek and Glickman, 2004) . Interestingly, the \u03b13\u0394n mutation does not alter the assembly of 26, as demonstrated by the evidence that the abundance and activity of mutant 26S are similar to those of wt-26S ; accordingly, human cell lines stably expressing \u03b13\u0394N subunits show enhanced activity of both free 20S and holoenzyme complexes.", "cite_spans": [{"start": 293, "end": 311, "text": "Unno et al., 2002;", "ref_id": "BIBREF744"}, {"start": 312, "end": 339, "text": "Bajorek and Glickman, 2004;", "ref_id": null}, {"start": 340, "end": 361, "text": "Marques et al., 2009;", "ref_id": "BIBREF320"}, {"start": 362, "end": 383, "text": "Ruschak et al., 2010;", "ref_id": "BIBREF552"}, {"start": 384, "end": 384, "text": "", "ref_id": null}, {"start": 582, "end": 604, "text": "(Akopian et al., 1997;", "ref_id": null}, {"start": 605, "end": 625, "text": "Kohler et al., 2001)", "ref_id": null}, {"start": 769, "end": 789, "text": "(Sledz et al., 2013;", "ref_id": null}, {"start": 790, "end": 814, "text": "Matyskiela et al., 2013;", "ref_id": "BIBREF338"}, {"start": 815, "end": 833, "text": "Choi et al., 2016;", "ref_id": "BIBREF39"}, {"start": 834, "end": 862, "text": "Marshall and Vierstra, 2019)", "ref_id": "BIBREF321"}, {"start": 1124, "end": 1145, "text": "Forster et al., 2003;", "ref_id": null}, {"start": 1146, "end": 1173, "text": "Bajorek and Glickman, 2004)", "ref_id": null}, {"start": 1318, "end": 1340, "text": "(Kohler et al., 2001a;", "ref_id": null}, {"start": 1341, "end": 1362, "text": "Kohler et al., 2001b)", "ref_id": null}, {"start": 1531, "end": 1553, "text": "(Kohler et al., 2001a;", "ref_id": null}, {"start": 1554, "end": 1575, "text": "Kohler et al., 2001b)", "ref_id": null}, {"start": 1767, "end": 1793, "text": "20S (Kohler et al., 2001a;", "ref_id": null}, {"start": 1794, "end": 1815, "text": "Kohler et al., 2001b;", "ref_id": null}, {"start": 1816, "end": 1842, "text": "Bajorek and Glickman, 200)", "ref_id": null}, {"start": 2080, "end": 2101, "text": "(Bajorek et al, 2003;", "ref_id": null}, {"start": 2102, "end": 2129, "text": "Bajorek and Glickman, 2004)", "ref_id": null}], "ref_spans": [{"start": 417, "end": 426, "text": "Figure 1C", "ref_id": "FIGREF35"}], "section": ""}, {"text": "This turns out in an increase of the degradation rate of poly-ubiquitinated proteins, reinforcing the Proteasome maturation refers to the process that drives the proper incorporation of individual subunits to assemble into a proteolytically active 26S. Whilst 19S assembly is largely uncovered yet (see section 2.3.2), the 20S assembly has been uncoiled at a great molecular detail also by virtue of the extensive similarity between yeast and mammalian pathways. This similarity has widened the repertoire of methodological approaches suitable to uncover the molecular insights. In eukaryotes, the stepwise recruitment of individual \u03b1and \u03b2-subunits to constitute a fully mature 20S requires the presence of five molecular chaperones, called Proteasome Assembly Chaperones (PAC1-4 in human, Pba1-4 in yeast) and Proteasome Maturation Protein (POMP in human, hUmp-1 in yeast) (Ramos et al., 2008; Le Tallec et al., 2007; Hirano et al., 2006) . These chaperones drive the sequential insertion of the subunits preventing the formation of off-target assemblies presumably through non-catalytic activities (Burri et al., PNAS 2000; Fricke et al., 2007, EMBO) . First, PAC1-PAC2 and PAC3-PAC4 work as heterodimers in recruiting the \u03b1-subunits during the earliest steps of biogenesis, that is the \u03b1-ring formation (Wu et al., 2018; Le Tallec et al., 2007; Hirano et al., 2006; Hirano et al., 2005; Matias et al., 2010) . Very recent advances in the field propose that in human cells \u03b14, \u03b15, \u03b16 and \u03b17 subunits first assemble to form a core tetrameric \u03b1-ring intermediate (\u03b14-\u03b17) , being driven by PAC3-PAC4 heterodimers, which localize at the inner side of the nascent \u03b1-ring (Wu et al., 2018; Satoh et al., 2019) . Recently, crystallographic data have allowed to identify a hydrophobic surface, surrounded by charged residues in PAC4, which is complementary to that of PAC3, thus providing a clue for the interaction between the two partners (Kurimoto et al., 2017) .", "cite_spans": [{"start": 874, "end": 894, "text": "(Ramos et al., 2008;", "ref_id": "BIBREF486"}, {"start": 895, "end": 918, "text": "Le Tallec et al., 2007;", "ref_id": "BIBREF258"}, {"start": 919, "end": 939, "text": "Hirano et al., 2006)", "ref_id": null}, {"start": 1100, "end": 1125, "text": "(Burri et al., PNAS 2000;", "ref_id": null}, {"start": 1126, "end": 1152, "text": "Fricke et al., 2007, EMBO)", "ref_id": null}, {"start": 1306, "end": 1323, "text": "(Wu et al., 2018;", "ref_id": "BIBREF820"}, {"start": 1324, "end": 1347, "text": "Le Tallec et al., 2007;", "ref_id": "BIBREF258"}, {"start": 1348, "end": 1368, "text": "Hirano et al., 2006;", "ref_id": null}, {"start": 1369, "end": 1389, "text": "Hirano et al., 2005;", "ref_id": null}, {"start": 1390, "end": 1410, "text": "Matias et al., 2010)", "ref_id": "BIBREF333"}, {"start": 1563, "end": 1570, "text": "(\u03b14-\u03b17)", "ref_id": null}, {"start": 1668, "end": 1685, "text": "(Wu et al., 2018;", "ref_id": "BIBREF820"}, {"start": 1686, "end": 1705, "text": "Satoh et al., 2019)", "ref_id": "BIBREF588"}, {"start": 1935, "end": 1958, "text": "(Kurimoto et al., 2017)", "ref_id": "BIBREF248"}], "ref_spans": [], "section": ""}, {"text": "Notably, PACs surface was also found to display a charge complementarity with proteasomal \u03b14 and \u03b15 subunits, envisaging the first structural basis for the binding of the heterodimer PAC3-PAC4 to the nascent 20S (Kurimoto et al., 2017) .", "cite_spans": [{"start": 212, "end": 235, "text": "(Kurimoto et al., 2017)", "ref_id": "BIBREF248"}], "ref_spans": [], "section": ""}, {"text": "Thereafter, the PAC1-PAC2 heterodimer binds the outer side of this assembly, favouring the recruitment of \u03b11, \u03b12 and \u03b13 subunits, thus leading to the formation of a mature heptameric \u03b1-ring (Wu et al., 2018) . Besides correctly introducing the \u03b1-subunit, the presence of the chaperones prevents the formation of aberrant off-pathway \u03b1-ring dimers, an occurrence potentially favoured by is released and pro-\u03b25, pro-\u03b26 and pro-\u03b21 subunits assemble (Hirano et al., 2006; Hirano et al., 2005; Satoh et al., 2019) . Remarkably, structural insights suggest that the pro-peptide is not merely involved in preventing the early activation of the catalytic Thr in the catalytically active subunit (see section 2.1), but is necessary for further stepwise incorporation of subunits, likely through an allosteric mechanism. The pro-peptides of \u03b22 and \u03b25 are essential for recruitment and incorporation of \u03b23 and \u03b26, respectively, whereas the \u03b25 pro-peptide is necessary for the specific interaction with POMP (Hoefer et al., 2006) . The ultimate step of \u03b2-ring formation is the pro-\u03b27 insertion and the formation of a half 20S (i.e., the 15S complex) which, upon dimerization, forms the mature 20S.", "cite_spans": [{"start": 190, "end": 207, "text": "(Wu et al., 2018)", "ref_id": "BIBREF820"}, {"start": 446, "end": 467, "text": "(Hirano et al., 2006;", "ref_id": null}, {"start": 468, "end": 488, "text": "Hirano et al., 2005;", "ref_id": null}, {"start": 489, "end": 508, "text": "Satoh et al., 2019)", "ref_id": "BIBREF588"}, {"start": 991, "end": 1017, "text": "POMP (Hoefer et al., 2006)", "ref_id": null}], "ref_spans": [], "section": ""}, {"text": "Although it is proven that full activation of 20S requires a) shedding of the \u03b2-subunits pro-peptides, b) PAC1-PAC2 detachment and/or clearance and c) POMP clearance, it is not fully clear whether the degradation of the chaperones is carried out by the 20S itself or if PAC chaperones are actually cleaved or released intact to be recycled for further maturation processes. It is further widely envisaged that additional unidentified factors may take part in the maturation process with activities overlapping with those of PACs depending on the cell metabolic needs.", "cite_spans": [], "ref_spans": [], "section": ""}, {"text": "The deepening of the molecular insights of proteasome maturation, both in terms of transcriptional regulation and of dynamics of proteins interaction, is expected to offer a new perspective for the development of therapeutic strategies based on the modulation of proteasome availability in selected tissues . Clinical and molecular studies envisage that increased POMP translation and bioavailability upon down-regulation of miR-101 (which targets POMP mRNA) is an oncogenic stimulus for breast cancer cells . Thus, the consequent increased proteasome intracellular content would confer protection from the proteotoxic insult to which highly proliferating cells are likely exposed, favouring cell survival .", "cite_spans": [], "ref_spans": [], "section": ""}, {"text": "Furthermore, POMP up-regulation enhanced the bulk proteasome activity under proteo-toxic conditions, providing a metabolic advantage under redox insult . As a matter of fact, recent genetic studies on POMP promoter have identified mutations at the 3'UTR region and splicing variants in different skin inflammatory disorders, such as CANDLE syndrome (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature) or proteasome-associated autoinflammatory syndrome (PRAAS). Furthermore, increased POMP levels were observed in psoriatic skin lesions (Dahlqvist et al., 2010; Ebstein et al., 2019; Poli et al., 2018;  ubiquitin (PRU) domain, whereas the C-terminal region of Rp4-Rpt5 extends out from the base body without interaction with other proteasome subunits, at least in the resting state ( Figure 2 ) (Djuranovic et al., 2009; Zhang et al., 2009; Husnjak et al., 2008; Tomko et al., 2010; Beck et al., 2012; Luan et al., 2016; VanderLinden et al., 2017; Budenholzer et al., 2017; Hemmis et al., 2019) . The first identified ubiquitin receptor was Rpn10, that is not considered part of the base, but functions as a bridge between the lid and the base, stabilizing their interaction (Martin et al., 2008; Maillard et al., 2011; Aubin-Tam et al., 2011; Beckwith et al., 2013; Erales et al., 2012) , as further suggested by the lid and base disassembly when Rpn10 is mutated (Deveraux et al., 1994; Isasa et al., 2010; Keren-kaplan et al., 2016) . Importantly, mono-ubiquitination of Rpn10, which is modulated by stressful conditions, regulates its association with proteasome, and thus proteasome activity and stability (Isasa et al., 2010; Keren-kaplan et al., 2016; Budenholzer et al., 2017) . An additional intrinsic ubiquitin receptor is the T1 toroidal region of the Rpn1 (Elsasser et al., 2004; Shi et al., 2016) , which, like Rpn10 and Rpn13, also recognizes ubiquitin like domains (UBLs) of extrinsic ubiquitin receptors (i.e., HR23/Rad23, PLIC2/DsK2 and Ddi1), stimulating the proteasome-mediated degradation of ubiquitinated substrates (Saeki et al., 2002; Leggett et al, 2002; Raasi et al., 2005; Shi et al., 2016; Spyracopoulos, 2016) . It remains unclear why proteasome contains such an array of ubiquitin-binding receptors, and what differential roles they might play in substrate recognition and degradation (Hamazaki et al., 2015; Bard et al., 2018; Cundiff et al., 2019) .", "cite_spans": [{"start": 571, "end": 595, "text": "(Dahlqvist et al., 2010;", "ref_id": null}, {"start": 596, "end": 617, "text": "Ebstein et al., 2019;", "ref_id": null}, {"start": 618, "end": 636, "text": "Poli et al., 2018;", "ref_id": "BIBREF466"}, {"start": 637, "end": 637, "text": "", "ref_id": null}, {"start": 830, "end": 855, "text": "(Djuranovic et al., 2009;", "ref_id": null}, {"start": 856, "end": 875, "text": "Zhang et al., 2009;", "ref_id": "BIBREF844"}, {"start": 876, "end": 897, "text": "Husnjak et al., 2008;", "ref_id": null}, {"start": 898, "end": 917, "text": "Tomko et al., 2010;", "ref_id": "BIBREF722"}, {"start": 918, "end": 936, "text": "Beck et al., 2012;", "ref_id": "BIBREF21"}, {"start": 937, "end": 955, "text": "Luan et al., 2016;", "ref_id": null}, {"start": 956, "end": 982, "text": "VanderLinden et al., 2017;", "ref_id": "BIBREF756"}, {"start": 983, "end": 1008, "text": "Budenholzer et al., 2017;", "ref_id": null}, {"start": 1009, "end": 1029, "text": "Hemmis et al., 2019)", "ref_id": "BIBREF172"}, {"start": 1210, "end": 1231, "text": "(Martin et al., 2008;", "ref_id": "BIBREF322"}, {"start": 1232, "end": 1254, "text": "Maillard et al., 2011;", "ref_id": "BIBREF317"}, {"start": 1255, "end": 1278, "text": "Aubin-Tam et al., 2011;", "ref_id": null}, {"start": 1279, "end": 1301, "text": "Beckwith et al., 2013;", "ref_id": "BIBREF22"}, {"start": 1302, "end": 1322, "text": "Erales et al., 2012)", "ref_id": null}, {"start": 1400, "end": 1423, "text": "(Deveraux et al., 1994;", "ref_id": "BIBREF65"}, {"start": 1424, "end": 1443, "text": "Isasa et al., 2010;", "ref_id": "BIBREF178"}, {"start": 1444, "end": 1470, "text": "Keren-kaplan et al., 2016)", "ref_id": "BIBREF221"}, {"start": 1646, "end": 1666, "text": "(Isasa et al., 2010;", "ref_id": "BIBREF178"}, {"start": 1667, "end": 1693, "text": "Keren-kaplan et al., 2016;", "ref_id": "BIBREF221"}, {"start": 1694, "end": 1719, "text": "Budenholzer et al., 2017)", "ref_id": null}, {"start": 1798, "end": 1826, "text": "Rpn1 (Elsasser et al., 2004;", "ref_id": null}, {"start": 1827, "end": 1844, "text": "Shi et al., 2016)", "ref_id": "BIBREF641"}, {"start": 2072, "end": 2092, "text": "(Saeki et al., 2002;", "ref_id": "BIBREF556"}, {"start": 2093, "end": 2113, "text": "Leggett et al, 2002;", "ref_id": "BIBREF277"}, {"start": 2114, "end": 2133, "text": "Raasi et al., 2005;", "ref_id": "BIBREF480"}, {"start": 2134, "end": 2151, "text": "Shi et al., 2016;", "ref_id": "BIBREF641"}, {"start": 2152, "end": 2172, "text": "Spyracopoulos, 2016)", "ref_id": "BIBREF684"}, {"start": 2349, "end": 2372, "text": "(Hamazaki et al., 2015;", "ref_id": "BIBREF139"}, {"start": 2373, "end": 2391, "text": "Bard et al., 2018;", "ref_id": null}, {"start": 2392, "end": 2413, "text": "Cundiff et al., 2019)", "ref_id": null}], "ref_spans": [{"start": 819, "end": 827, "text": "Figure 2", "ref_id": "FIGREF32"}], "section": ""}, {"text": "Upon recognition by intrinsic and extrinsic ubiquitin receptor, substrates are engaged with the AAA + motor of the highly dynamic Rpt1-6 hexameric ring that couples ATP hydrolysis to substrate unfolding and translocation, converting chemical energy into mechanical work (Pena et al., 2018; Eisele et al., 2018; Dong et al., 2019) . The C-terminal tails of Rpt2, Rpt3 and Rpt5 contain the conserved HbYX motif (see also section 2.3.2) that fits into the groove between adjacent \u03b1-subunits of 20S inducing a conformational change into their N-termini which drives 20S gate opening (Smith Panasenko and Collart, 2011; Park et al., 2011; De La Mota-Peynado et al., 2013; .", "cite_spans": [{"start": 270, "end": 289, "text": "(Pena et al., 2018;", "ref_id": null}, {"start": 290, "end": 310, "text": "Eisele et al., 2018;", "ref_id": null}, {"start": 311, "end": 329, "text": "Dong et al., 2019)", "ref_id": "BIBREF849"}, {"start": 579, "end": 614, "text": "(Smith Panasenko and Collart, 2011;", "ref_id": null}, {"start": 615, "end": 633, "text": "Park et al., 2011;", "ref_id": "BIBREF442"}, {"start": 634, "end": 666, "text": "De La Mota-Peynado et al., 2013;", "ref_id": null}], "ref_spans": [], "section": ""}, {"text": "A main breakthrough for understanding the structural basis of 26S came from a series of Cryo-EM studies on proteasome holoenzyme from different species, such as yeast, rat and humans (Lasker et al., 2012; Lander et al., 2012; Matyskiela et al., 2013; Unverdorben et al., 2014; Wehmer et al., 2017; Wehmer and Sakata, 2016 \\1q2 ; Bard et al., 2018) .", "cite_spans": [{"start": 183, "end": 204, "text": "(Lasker et al., 2012;", "ref_id": "BIBREF447"}, {"start": 205, "end": 225, "text": "Lander et al., 2012;", "ref_id": null}, {"start": 226, "end": 250, "text": "Matyskiela et al., 2013;", "ref_id": "BIBREF338"}, {"start": 251, "end": 276, "text": "Unverdorben et al., 2014;", "ref_id": null}, {"start": 277, "end": 297, "text": "Wehmer et al., 2017;", "ref_id": null}, {"start": 298, "end": 326, "text": "Wehmer and Sakata, 2016 \\1q2", "ref_id": null}, {"start": 329, "end": 347, "text": "Bard et al., 2018)", "ref_id": null}], "ref_spans": [], "section": "Structural conformation of the proteasome holoenzyme"}, {"text": "These studies have revealed the existence of at least four distinct human 26S conformational states (i.e., SA, SB, SC and SD, mirrored in yeast 26S by s1, s2, s3 and s4), that appear conserved among species. The numeric order of these main states is suggested by a structural comparison that reveals progressive and sequential movements from SA (s1) state through SB (s2) and SC (s3), to SD (s4), which is similar to SA ( Bard et al., 2018; Wehmer and Sakata, 2016) . In all identified conformations, the architecture and structure of 20S remains essentially unaltered, whereas the two subcomplexes of 19S, the lid and the base (see section 2.3.1) are highly dynamic, changing the relative orientation with respect to each other and to core particles; these movements are coupled to the functional cycle of 26S (Chen et al., Unverdorben et al., 2014; Wehmer et al., 2017) .", "cite_spans": [{"start": 422, "end": 440, "text": "Bard et al., 2018;", "ref_id": null}, {"start": 441, "end": 465, "text": "Wehmer and Sakata, 2016)", "ref_id": null}, {"start": 825, "end": 850, "text": "Unverdorben et al., 2014;", "ref_id": null}, {"start": 851, "end": 871, "text": "Wehmer et al., 2017)", "ref_id": null}], "ref_spans": [], "section": "Structural conformation of the proteasome holoenzyme"}, {"text": "However, despite the advance in knowledge on 26S structure, we have to recall that an intriguing aspect, which has never been deeply investigated, concerns the conformational transition, occurring after the binding of the first 19S, on the opposite end of 20S, where one free \u03b1-ring surface is available for the binding of a second 19S particle, which yields a double capped 30S proteasome, whose real structure, as well as the function, remains poorly understood .", "cite_spans": [], "ref_spans": [], "section": "Structural conformation of the proteasome holoenzyme"}, {"text": "The yeast s1 is a low energy ATP-bound ground state, that is assumed to be the primary substratebinding conformation (Matyskiela et al., 2013; Sledz et al., 2013; Unverboden et al., 2014; Wehmer et al., 2017; Ding et al., 2017; Zhu et al., 2017) . In the s1 state, the 20S gate is closed, since the substrate translocation channel of ATPase ring is not aligned with the 20S gate, and the active site of Rpn11 is 25\u01fa away from substrate entry pore (Wehmer et al., 2017; Eisele et al., 2018; Finley and Prado, 2019) . The transition toward the s2 state is driven mainly by the lid rotation, which drives Rpn11 to a position above the central processing pore of the base. On the other hand, the progression from s2 to s3 is mediated by a rearrangement of Rpt1-Rpt6, wherefore N-ring of Rpts and AAA+ domains shift toward Rpn1, thus generating a wider channel aligned with core particle axial pore (Matyskiela et al., 2013; Unverboden et al., 2014; Wehmer et al., 2017; . Therefore, the s3 state is characterized by the axial alignment of the essential J o u r n a l P r e -p r o o f DUB Rpn11 (see also section 2.3.1), 19S translocation channel, and 20S gate. However, in spite of these rearrangements and of the evidence that s2 and s3 states are primed for substrate degradation, the 20S gate is still mostly occluded, preventing substrate entry (Matyskiela et al., 2013; Sledz et al., 2013; Bard et al., 2018; Finely and Prado 2019) . The gate becomes fully opened only during the transition from s3 to s4, inducing the entry of the substrate into the catalytic core; thus, gate opening is a consequence of the insertion of \"HbYX\" motif of C-termini of Rpt2-Rpt3-Rpt5 subunits into 20S pocket (see section 2.3.1). Stable docking of HbYX motifs into the 20S is insufficient to promote gate opening, which is completed only in the s4 state upon engagement of the C-termini of Rpt6 and Rpt1 into the \u03b1-ring (Eisele et al., 2018; Finley and Prado, 2019) . Besides these four states, further structural and biochemical studies have revealed recently the presence of two additional open gate states in yeast proteasome (i.e., s5 and s6) (Eisele et al., 2018) . In the case of human 26S proteasome Cryo-EM studies showed that the substrate Sic1 PY (i.e., the Cdk inhibitor Sic1 from Saccharomyces cerevisiae with a Pro-Pro-Pro-Ser motif inserted into N-terminal) exists in seven conformational states, EA1, EA2, EB, EC1, EC2, ED1, ED2 (Dong et al., 2019) . EA1 and EA2 states represent two initial ubiquitin recognition states; EB2 is the \"de-ubiquitination\" state, in which the iso-peptide bond between Rpn11 and substrate is close to the zinc-active site of Rpn11; EC1 and EC2 are conformations at the onset of substrate translocation; ED1 and ED2 carry on and complete substrate translocation (Dong et al., 2019) . Functional models of 26 activity, derived both from cryo-EM and biochemical analysis, couple ATP hydrolytic cycle to substrate translocation (Matyskiela et al., 2013; de la Pena et al., 2018; Dong et al., 2019) . Therefore, sequential ATP hydrolysis and phosphate release, which are coordinated within the ATPase motor, seem to supply \"the power\" to induce conformational changes that drive the substrate through the central pore (de la Pena et al., 2018; Eisele et al., 2018; Tundo et al., 2018; Dong et al., 2019) . In agreement with a \"rotatory\" mechanism, a hydrolytic event in a single Rpt subunit is followed by another one in the nearby subunit, thus proceeding throughout the entire ring (de la Pena et al., 2018; Eisele et al., 2018; Tundo et al., 2018; Dong et al., 2019) . In fact, it has been proposed that a specific Rpt subunit binds ATP and engages substrate at the uppermost position; then, this subunit hydrolyses ATP (when at the penultimate position of the staircase), releasing the phosphate moiety and disengaging from substrate, which proceeds to the next hydrolytic step (Eisele et al., 2018; de la Pena et al., Importantly, cryo-electron tomography approaches have also visualized proteasome particles in their native conformation in living cells, allowing to have an insight on the percentage of different populations that harbour the cells (Asano et al., 2015; Guo et al., 2018; Finley and Prado, 2019) . In intact hippocampal neurons, a molecular census of proteasome conformational states showed that, in the absence of proteotoxic stress, only 20% of the 26S was engaged in substrate processing, whereas the remaining portion was in the substrate-accepting ground state; it suggests that the capacity of the proteasome system is not fully exploited by the cell under physiological conditions (Asano et al., 2015) . Interestingly, poly-Gly-Ala (poly-GA) aggregates, which result from aberrant expansion of GGGGCC repeat in C9orf72 gene (i.e., the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia), recruits 26S molecules which are in the s4 state (Guo et al., 2018) , unlike the general pool of proteasome. However, since poly-GA are not favourable proteasome substrates, 26S sequestration and consequent inhibition has been proposed to cover a crucial role in neurodegeneration (Guo et al., 2018; Finley and Prado, 2019) .", "cite_spans": [{"start": 117, "end": 142, "text": "(Matyskiela et al., 2013;", "ref_id": "BIBREF338"}, {"start": 143, "end": 162, "text": "Sledz et al., 2013;", "ref_id": null}, {"start": 163, "end": 187, "text": "Unverboden et al., 2014;", "ref_id": null}, {"start": 188, "end": 208, "text": "Wehmer et al., 2017;", "ref_id": null}, {"start": 209, "end": 227, "text": "Ding et al., 2017;", "ref_id": null}, {"start": 228, "end": 245, "text": "Zhu et al., 2017)", "ref_id": null}, {"start": 447, "end": 468, "text": "(Wehmer et al., 2017;", "ref_id": null}, {"start": 469, "end": 489, "text": "Eisele et al., 2018;", "ref_id": null}, {"start": 490, "end": 513, "text": "Finley and Prado, 2019)", "ref_id": null}, {"start": 894, "end": 919, "text": "(Matyskiela et al., 2013;", "ref_id": "BIBREF338"}, {"start": 920, "end": 944, "text": "Unverboden et al., 2014;", "ref_id": null}, {"start": 945, "end": 965, "text": "Wehmer et al., 2017;", "ref_id": null}, {"start": 1345, "end": 1370, "text": "(Matyskiela et al., 2013;", "ref_id": "BIBREF338"}, {"start": 1371, "end": 1390, "text": "Sledz et al., 2013;", "ref_id": null}, {"start": 1391, "end": 1409, "text": "Bard et al., 2018;", "ref_id": null}, {"start": 1410, "end": 1432, "text": "Finely and Prado 2019)", "ref_id": null}, {"start": 1904, "end": 1925, "text": "(Eisele et al., 2018;", "ref_id": null}, {"start": 1926, "end": 1949, "text": "Finley and Prado, 2019)", "ref_id": null}, {"start": 2131, "end": 2152, "text": "(Eisele et al., 2018)", "ref_id": null}, {"start": 2428, "end": 2447, "text": "(Dong et al., 2019)", "ref_id": "BIBREF849"}, {"start": 2789, "end": 2808, "text": "(Dong et al., 2019)", "ref_id": "BIBREF849"}, {"start": 2952, "end": 2977, "text": "(Matyskiela et al., 2013;", "ref_id": "BIBREF338"}, {"start": 2978, "end": 3002, "text": "de la Pena et al., 2018;", "ref_id": null}, {"start": 3003, "end": 3021, "text": "Dong et al., 2019)", "ref_id": "BIBREF849"}, {"start": 3241, "end": 3266, "text": "(de la Pena et al., 2018;", "ref_id": null}, {"start": 3267, "end": 3287, "text": "Eisele et al., 2018;", "ref_id": null}, {"start": 3288, "end": 3307, "text": "Tundo et al., 2018;", "ref_id": "BIBREF736"}, {"start": 3308, "end": 3326, "text": "Dong et al., 2019)", "ref_id": "BIBREF849"}, {"start": 3507, "end": 3532, "text": "(de la Pena et al., 2018;", "ref_id": null}, {"start": 3533, "end": 3553, "text": "Eisele et al., 2018;", "ref_id": null}, {"start": 3554, "end": 3573, "text": "Tundo et al., 2018;", "ref_id": "BIBREF736"}, {"start": 3574, "end": 3592, "text": "Dong et al., 2019)", "ref_id": "BIBREF849"}, {"start": 3905, "end": 3926, "text": "(Eisele et al., 2018;", "ref_id": null}, {"start": 3927, "end": 3945, "text": "de la Pena et al.,", "ref_id": null}, {"start": 4177, "end": 4197, "text": "(Asano et al., 2015;", "ref_id": null}, {"start": 4198, "end": 4215, "text": "Guo et al., 2018;", "ref_id": null}, {"start": 4216, "end": 4239, "text": "Finley and Prado, 2019)", "ref_id": null}, {"start": 4632, "end": 4652, "text": "(Asano et al., 2015)", "ref_id": null}, {"start": 4924, "end": 4942, "text": "(Guo et al., 2018)", "ref_id": null}, {"start": 5156, "end": 5174, "text": "(Guo et al., 2018;", "ref_id": null}, {"start": 5175, "end": 5198, "text": "Finley and Prado, 2019)", "ref_id": null}], "ref_spans": [], "section": "Structural conformation of the proteasome holoenzyme"}, {"text": "Over the last decades, hallmarks of cancer cells have been described to provide a sort of universal definition which would account for the multi-step development of human tumours (Hanahan and Weinberg, 2011) . These hallmarks, which are complementary features that enable tumour growth and metastatic dissemination, include proliferative signalling, growth suppressors inactivation, cell death resistance, replicative immortality, angiogenesis, invasiveness and dissemination, cell metabolism reprogramming and immune-surveillance evasion (Hanahan and Weiberg, 2000; Hanahan and Weinberg, 2011; Tundo et al., 2019) . Recently, resistance to proteostasis unbalance has been proposed as a new malignant hallmark of cancer, envisaging the possibility that this acquired property cooperates with the other altered circuits to allow cancer cell survival, progression, novel properties to promote their survival (Calderwood et al., 2006; Vahid et al., 2017) .", "cite_spans": [{"start": 179, "end": 207, "text": "(Hanahan and Weinberg, 2011)", "ref_id": null}, {"start": 539, "end": 566, "text": "(Hanahan and Weiberg, 2000;", "ref_id": null}, {"start": 567, "end": 594, "text": "Hanahan and Weinberg, 2011;", "ref_id": null}, {"start": 595, "end": 614, "text": "Tundo et al., 2019)", "ref_id": "BIBREF738"}, {"start": 906, "end": 931, "text": "(Calderwood et al., 2006;", "ref_id": null}, {"start": 932, "end": 951, "text": "Vahid et al., 2017)", "ref_id": "BIBREF749"}], "ref_spans": [], "section": "Proteostasis network in cancer"}, {"text": "In recent years, three main reasons have gained considerable insight as to why PNs are altered in human tumours, namely 1) genomic instability; 2) persistence of stressful conditions in the tumour micro-environment, and 3) age-related proteome imbalance (Dong and Cui, 2018) .", "cite_spans": [{"start": 254, "end": 274, "text": "(Dong and Cui, 2018)", "ref_id": null}], "ref_spans": [], "section": "Proteostasis network in cancer"}, {"text": "First, cancer cell genome is highly unstable and builds up several point mutations in protein coding sequence and/or genome mutations (e.g., large duplications, deletions, inversions, and translocations as well as altered copy numbers of entire chromosomes, such as aneuploidy). This may turn out in an inappropriate repression or activation of tumour suppressors and oncogenes, respectively, excessive protein synthesis, and/or translation of mutated proteins with altered folding, function and turn-over (Weaver and Cleveland, 2006; Benbrook and Long, 2012; Vogelstein et al., 2013; Kim and Zaret, 2015) . It has been estimated that over 90% of human solid tumours harbour aneuploidies that lead to an excess in protein synthesis (Weaver and Cleveland, 2006; Williams and Amon, 2006; Dai et al., 2012) ; indeed, this is a relevant issue mainly for proteins that become functional upon assembly in stoichiometric complexes such as in the case of ribosomes (Deshaies et al., 2014) . Therefore, genomic alterations support a proteostasis unbalance (also referred as proteotoxic crisis) that renders cancer cells more dependent than normal cells on PNs clearance mechanisms, including UPS (Deshaies et al., 2014) . Accordingly, yeast cells with one-third of single chromosomal aneuploidies are hypersensitive to proteasome inhibitors, and some cells \"adapted\" to aneuploidy harbour mutations that depress UPS activity (Torres et al., 2007; Torres et al., 2008; Torres et al., 2010) .", "cite_spans": [{"start": 506, "end": 534, "text": "(Weaver and Cleveland, 2006;", "ref_id": "BIBREF796"}, {"start": 535, "end": 559, "text": "Benbrook and Long, 2012;", "ref_id": null}, {"start": 560, "end": 584, "text": "Vogelstein et al., 2013;", "ref_id": "BIBREF779"}, {"start": 585, "end": 605, "text": "Kim and Zaret, 2015)", "ref_id": null}, {"start": 732, "end": 760, "text": "(Weaver and Cleveland, 2006;", "ref_id": "BIBREF796"}, {"start": 761, "end": 785, "text": "Williams and Amon, 2006;", "ref_id": null}, {"start": 786, "end": 803, "text": "Dai et al., 2012)", "ref_id": null}, {"start": 957, "end": 980, "text": "(Deshaies et al., 2014)", "ref_id": null}, {"start": 1183, "end": 1210, "text": "UPS (Deshaies et al., 2014)", "ref_id": null}, {"start": 1416, "end": 1437, "text": "(Torres et al., 2007;", "ref_id": "BIBREF726"}, {"start": 1438, "end": 1458, "text": "Torres et al., 2008;", "ref_id": "BIBREF727"}, {"start": 1459, "end": 1479, "text": "Torres et al., 2010)", "ref_id": "BIBREF725"}], "ref_spans": [], "section": "Proteostasis network in cancer"}, {"text": "Secondly, during tumour development, tumour cells are continuously exposed to a variety of extrinsic perturbations, such as nutrient deprivation, hypoxia, and acidosis. Despite this pressure, tumour cells successfully proliferate and efficiently withstand this challenge by adapting to the fluctuations of the microenvironment, reprogramming their proteome and fully exploiting the cell defence mechanisms against proteotoxic stress. Thus, ultimately, stressful conditions lead to a disruption of the proteostasis balance, which is associated to the promotion of malignant properties (such as invasiveness, immune surveillance escape, and metabolism reprogramming), achieving a plethora of PN alterations (Oromendia and Amon 2014; Dufey et al., 2015; Nam and Joe, 2019) . culminates in PNs alteration (Sklirou et al., 2018; Dong and Cui, 2018) . Thus, in a vicious circle, unbalanced PNs lead to the proteotoxic crisis, which favours tumourigenesis (Miller et al., 2014; Arnsburg et al., 2014) . As a matter of fact, in accordance with the proteotoxic crisis hypothesis, reprogramming the proteome might represent a novel therapeutic approach, since agents that target components of different PN pathways are expected to be more toxic for cancer cells than for normal cells (Deshaies, 2014; Yuan et al., 2018) . In the next paragraphs, we will review the biological rationale for targeting proteasome in the context of UPS as a strategy to treat cancer.", "cite_spans": [{"start": 705, "end": 730, "text": "(Oromendia and Amon 2014;", "ref_id": "BIBREF414"}, {"start": 731, "end": 750, "text": "Dufey et al., 2015;", "ref_id": null}, {"start": 751, "end": 769, "text": "Nam and Joe, 2019)", "ref_id": null}, {"start": 801, "end": 823, "text": "(Sklirou et al., 2018;", "ref_id": null}, {"start": 824, "end": 843, "text": "Dong and Cui, 2018)", "ref_id": null}, {"start": 949, "end": 970, "text": "(Miller et al., 2014;", "ref_id": "BIBREF353"}, {"start": 971, "end": 993, "text": "Arnsburg et al., 2014)", "ref_id": "BIBREF6"}, {"start": 1274, "end": 1290, "text": "(Deshaies, 2014;", "ref_id": null}, {"start": 1291, "end": 1309, "text": "Yuan et al., 2018)", "ref_id": null}], "ref_spans": [], "section": "Proteostasis network in cancer"}, {"text": "A number of preclinical studies have reported alterations of proteasome expression and activity in different type of cancers, including haematological malignancies, lung, breast, pancreatic, head and neck, and thyroid cancers (Kumatori et al., 1990; , Chen et al., 2005 Artl et al., 2009; Roeten et al., 2018) . The reason of this high proteasome activity is not well understood, even though it is likely linked to stressful conditions (e.g., hypoxia, reperfusion, alteration of growth factors and cytokines levels), which evolve in the context of a heterogeneous tumour microenvironment. Deregulation of the proteasome activity can destabilize and/or disrupt the balance between tumour suppressors and oncoproteins, promoting cancer progression (Ogiso, 1999; Kaplan et al., 2017, Chang and Ding, 2018) . An element of complexity in understanding the role of proteasome in carcinogenesis is also represented by the fact that most investigations are carried out in unsorted cancer cells, which do not include cancer stem cells (Voutsadakis, 2017) ; thus, cancer stem cell theory states that all tumour cells derive by a small percentage of cancer stem cells capable of repopulating tumours after therapy (Simons and Clevers, 2011; Hanahan and Weinberg, 2011) . Noteworthy, the proteasome function is decreased in these cells with respect to the bulk of tumour population, revealing that a better understanding of proteasome regulation in different cell sub-sets might unveil further opportunities in cancer therapy (Banno et al., 2016; Voutsadakis, 2017) . Despite the criticism, there are many key proteins, degraded by proteasome, that are involved in carcinogenesis; below are listed examples of proteins, which are considered crucial in cancer progression and are reported to mediate cell death after exposure to proteasome inhibitors (Ciechanover et al., 2001; Evan and Vousden, 2001; Soave et al., 2017; Johnson et al., 2015; Jang et al., 2018) (Figure 3 ).", "cite_spans": [{"start": 226, "end": 249, "text": "(Kumatori et al., 1990;", "ref_id": null}, {"start": 250, "end": 269, "text": ", Chen et al., 2005", "ref_id": null}, {"start": 270, "end": 288, "text": "Artl et al., 2009;", "ref_id": null}, {"start": 289, "end": 309, "text": "Roeten et al., 2018)", "ref_id": "BIBREF532"}, {"start": 746, "end": 759, "text": "(Ogiso, 1999;", "ref_id": null}, {"start": 760, "end": 790, "text": "Kaplan et al., 2017, Chang and", "ref_id": null}, {"start": 791, "end": 802, "text": "Ding, 2018)", "ref_id": "BIBREF740"}, {"start": 1026, "end": 1045, "text": "(Voutsadakis, 2017)", "ref_id": null}, {"start": 1203, "end": 1229, "text": "(Simons and Clevers, 2011;", "ref_id": null}, {"start": 1230, "end": 1257, "text": "Hanahan and Weinberg, 2011)", "ref_id": null}, {"start": 1514, "end": 1534, "text": "(Banno et al., 2016;", "ref_id": null}, {"start": 1535, "end": 1553, "text": "Voutsadakis, 2017)", "ref_id": null}, {"start": 1838, "end": 1864, "text": "(Ciechanover et al., 2001;", "ref_id": "BIBREF47"}, {"start": 1865, "end": 1888, "text": "Evan and Vousden, 2001;", "ref_id": null}, {"start": 1889, "end": 1908, "text": "Soave et al., 2017;", "ref_id": null}, {"start": 1909, "end": 1930, "text": "Johnson et al., 2015;", "ref_id": "BIBREF198"}, {"start": 1931, "end": 1949, "text": "Jang et al., 2018)", "ref_id": null}], "ref_spans": [{"start": 1950, "end": 1959, "text": "(Figure 3", "ref_id": "FIGREF37"}], "section": "Degradation of cancer-related proteins by proteasome"}, {"text": "J o u r n a l P r e -p r o o f NF-kB is a crucial transcription factor that induces the expression of a wide range of genes involved in cell proliferation, apoptosis, inflammation and angiogenesis (Karin et al., 2002; Wu and Shi, 2013; Qureshi et al., 2018) . Alteration of NF-kB pathway has been documented in a series of human tumours, including breast, lung, prostate, pancreatic cancer and melanoma, as well as in haematological malignancies, such as Hodgkin's/Non-Hodgkin's lymphoma and multiple myeloma (Kim et al., 2006; Karin et al., 2005; Braun et al., 2006; Aggarwal et al., 2004; Van Waes 2007; Johnson 2015; Perkins 2012; Kaplan et al., 2018) . It is generally accepted that NF-kB promotes cancer progression by inhibiting apoptosis, and that also chemo-and radiotherapy treatments activate NF-kB signalling, inducing acquired resistance to conventional cancer therapy (Baldwin, 2001; Nakanishi and Toi, 2005; Wu and Shi, 2013) . Under unstimulated conditions, NF-kB homoor hetero-dimers are sequestered in an inactive form in the cytoplasm by its inhibitor IkB. Different stimuli, including stress and chemotherapy, activate IkB kinase (i.e., IKKB) that phosphorylates IkB, leading to its ubiquitination and degradation by the proteasome. Free NF-kB dimers then translocate into the nucleus wherein they induce the transcription of target genes (Baldwin et al., 1996; Schwartz et al., 1999; Traenckner et al., 1995) (Figure 3 ). Mammals express five NF-\u03baB proteins, namely RelA (p65), RelB, c-Rel, p50 and p52. Proteasome is involved in the maturation process of p50 and p52, which are synthesized as large precursors of p105 and p100 respectively (Fan et al., 1991; Beinke and Ley, 2004) . Treatment with proteasome inhibitors (PI), such as bortezomib, blocks p105 and p100 processing, and/or IkB degradation, thus inhibiting the NF-kBmediated cancer promoting activity (Kaplan et al., 2017; Wu8 et al, 2013; Johnson et al., 2015) . Indeed, NF-kB activation seems to play a major role in the antitumor effect of bortezomib, particularly in multiple myeloma and melanoma cells (Hideshima et al., 2002; Amiri et al., 2004) . Among the numerous proteins regulated by NF-kB signalling, cyclin D1 plays a crucial role in cancer progression, since it is a key regulator of late G1 phase of cell cycle. The cyclin D1-Cdk4/6 complexes generate the phosphorylated form of the Rb protein, resulting in the release of EF2 transcription factors, inducing its activation. This is followed by the expression of cyclin E, which interacts with Cdk2 bringing about the hyper-phosphorylation of Rb, cyclin A and genes involved in DNA synthesis. These steps anticipate the S phase progression.", "cite_spans": [{"start": 197, "end": 217, "text": "(Karin et al., 2002;", "ref_id": null}, {"start": 218, "end": 235, "text": "Wu and Shi, 2013;", "ref_id": null}, {"start": 236, "end": 257, "text": "Qureshi et al., 2018)", "ref_id": null}, {"start": 509, "end": 527, "text": "(Kim et al., 2006;", "ref_id": "BIBREF743"}, {"start": 528, "end": 547, "text": "Karin et al., 2005;", "ref_id": null}, {"start": 548, "end": 567, "text": "Braun et al., 2006;", "ref_id": null}, {"start": 568, "end": 590, "text": "Aggarwal et al., 2004;", "ref_id": null}, {"start": 591, "end": 605, "text": "Van Waes 2007;", "ref_id": "BIBREF755"}, {"start": 606, "end": 619, "text": "Johnson 2015;", "ref_id": "BIBREF198"}, {"start": 620, "end": 633, "text": "Perkins 2012;", "ref_id": null}, {"start": 634, "end": 654, "text": "Kaplan et al., 2018)", "ref_id": null}, {"start": 881, "end": 896, "text": "(Baldwin, 2001;", "ref_id": null}, {"start": 897, "end": 921, "text": "Nakanishi and Toi, 2005;", "ref_id": null}, {"start": 922, "end": 939, "text": "Wu and Shi, 2013)", "ref_id": null}, {"start": 1358, "end": 1380, "text": "(Baldwin et al., 1996;", "ref_id": null}, {"start": 1381, "end": 1403, "text": "Schwartz et al., 1999;", "ref_id": null}, {"start": 1404, "end": 1428, "text": "Traenckner et al., 1995)", "ref_id": null}, {"start": 1661, "end": 1679, "text": "(Fan et al., 1991;", "ref_id": null}, {"start": 1680, "end": 1701, "text": "Beinke and Ley, 2004)", "ref_id": null}, {"start": 1884, "end": 1905, "text": "(Kaplan et al., 2017;", "ref_id": null}, {"start": 1906, "end": 1922, "text": "Wu8 et al, 2013;", "ref_id": null}, {"start": 1923, "end": 1944, "text": "Johnson et al., 2015)", "ref_id": "BIBREF198"}, {"start": 2090, "end": 2114, "text": "(Hideshima et al., 2002;", "ref_id": "BIBREF262"}, {"start": 2115, "end": 2134, "text": "Amiri et al., 2004)", "ref_id": null}], "ref_spans": [{"start": 1429, "end": 1438, "text": "(Figure 3", "ref_id": "FIGREF37"}], "section": "NF-kB"}, {"text": "P53 is a nuclear transcription factor that regulates apoptosis, DNA repair, angiogenesis, cell growth and senescence (Vogelstein et al., 2000; ; thus, regulation of its level is fundamental to guarantee cell homeostasis. This protein is characterized by a very rich functional spectrum that is the consequence of a structural complexity which renders it able to interact with a myriad of partners. P53 exists as a dynamic ensemble of different \"proteoforms\", and this structural plasticity is due to the presence of intrinsically disordered regions, as well as to several modifications at transcriptional and post-translational level. Several p53 mutants form amyloid structures that aggregate in the cell in a \"prion-like\" fashion with a gain-of-function effect (Rangel et al., 2019) . It is noteworthy that p53 unfolded mutant forms are shared in cancer and in Alzheimer's disease (AD) tissues, actually entering in the list of biomarkers that can be used for their diagnosis (Amor-Gutierrez et al., 2020) Under normal conditions, p53 degradation is a complex and finely regulated process, which is predominately orchestrated by the MDM2 protein, a RING-finger E3-ligase that promotes the polyubiquitination of p53, and, thus, its degradation by the 26S (Figure 3 ) (Haupt et al., 1997; Momand et al., 2000; Poyurovsky et al., 2007; Brown et al., 2009; Devine et al, 2013) . P53 pro/apoptotic function covers a prominent role in tumour suppression, and mutations of p53 gene are among the most frequent genetic events in human tumours (Kandoth et al., 2013; Walerych et al., 2015; Walerych et al., 2016; Niazi et al., 2018) . Additionally, tumours expressing wt-p53 often have different mechanisms to bypass its activity, such as the overexpression of MDM2 Chene et al., 2003; Quesnel et al., 1994) . A series of studies, performed in different cancer cell models, including melanoma, head and neck and colon cancer, reveal that one of the main mechanisms of cell death induction by proteasome inhibition, is the p53 pathway stabilization (Fernandez et al., 2005; Qin et al., 2005b; Zhu et al., 2005; Concannon et al., 2007; Gomez-Bougie et al., 2007; Voortman et al., 2007; Li et al., 2008; Morsi et al., 2018; Lopes et al., 1997; MacLaren et al., 2001; Yu and al., 2007) . Accordingly, pro-apoptotic factors, such as Noxa and Bax, are primary p53-responsive elements ( Figure 3 ) (Oda et al., 2000; Albert et al., 2014) . However, controversial results are still reported, since the killing of some cancer cells was shown to involve a p53-independent mechanism of Noxa induction, providing evidences for a novel strategy to bypass the apoptotic resistance of tumour cells (Perez-Gal\u00e1n, 2006; Qin et al., 2005; Strauss et al., 2007; Devine and Dai, 2013; Yerlikaya et al., 2012; ", "cite_spans": [{"start": 117, "end": 142, "text": "(Vogelstein et al., 2000;", "ref_id": null}, {"start": 763, "end": 784, "text": "(Rangel et al., 2019)", "ref_id": "BIBREF488"}, {"start": 978, "end": 1007, "text": "(Amor-Gutierrez et al., 2020)", "ref_id": null}, {"start": 1268, "end": 1288, "text": "(Haupt et al., 1997;", "ref_id": null}, {"start": 1289, "end": 1309, "text": "Momand et al., 2000;", "ref_id": null}, {"start": 1310, "end": 1334, "text": "Poyurovsky et al., 2007;", "ref_id": null}, {"start": 1335, "end": 1354, "text": "Brown et al., 2009;", "ref_id": null}, {"start": 1355, "end": 1374, "text": "Devine et al, 2013)", "ref_id": null}, {"start": 1537, "end": 1559, "text": "(Kandoth et al., 2013;", "ref_id": null}, {"start": 1560, "end": 1582, "text": "Walerych et al., 2015;", "ref_id": null}, {"start": 1583, "end": 1605, "text": "Walerych et al., 2016;", "ref_id": null}, {"start": 1606, "end": 1625, "text": "Niazi et al., 2018)", "ref_id": null}, {"start": 1759, "end": 1778, "text": "Chene et al., 2003;", "ref_id": null}, {"start": 1779, "end": 1800, "text": "Quesnel et al., 1994)", "ref_id": null}, {"start": 2041, "end": 2065, "text": "(Fernandez et al., 2005;", "ref_id": null}, {"start": 2066, "end": 2084, "text": "Qin et al., 2005b;", "ref_id": null}, {"start": 2085, "end": 2102, "text": "Zhu et al., 2005;", "ref_id": null}, {"start": 2103, "end": 2126, "text": "Concannon et al., 2007;", "ref_id": null}, {"start": 2127, "end": 2153, "text": "Gomez-Bougie et al., 2007;", "ref_id": null}, {"start": 2154, "end": 2176, "text": "Voortman et al., 2007;", "ref_id": null}, {"start": 2177, "end": 2193, "text": "Li et al., 2008;", "ref_id": "BIBREF310"}, {"start": 2194, "end": 2213, "text": "Morsi et al., 2018;", "ref_id": null}, {"start": 2214, "end": 2233, "text": "Lopes et al., 1997;", "ref_id": null}, {"start": 2234, "end": 2256, "text": "MacLaren et al., 2001;", "ref_id": null}, {"start": 2257, "end": 2274, "text": "Yu and al., 2007)", "ref_id": null}, {"start": 2384, "end": 2402, "text": "(Oda et al., 2000;", "ref_id": null}, {"start": 2403, "end": 2423, "text": "Albert et al., 2014)", "ref_id": null}, {"start": 2676, "end": 2695, "text": "(Perez-Gal\u00e1n, 2006;", "ref_id": null}, {"start": 2696, "end": 2713, "text": "Qin et al., 2005;", "ref_id": null}, {"start": 2714, "end": 2735, "text": "Strauss et al., 2007;", "ref_id": null}, {"start": 2736, "end": 2757, "text": "Devine and Dai, 2013;", "ref_id": null}, {"start": 2758, "end": 2781, "text": "Yerlikaya et al., 2012;", "ref_id": null}], "ref_spans": [{"start": 1256, "end": 1265, "text": "(Figure 3", "ref_id": "FIGREF37"}, {"start": 2373, "end": 2381, "text": "Figure 3", "ref_id": "FIGREF37"}], "section": "p53"}, {"text": "J o u r n a l P r e -p r o o f One of the main hallmarks of carcinogenesis is the loss of cell division control. Proteasome is involved in the regulation of the cell cycle, since it degrades cyclin dependent kinases (Cdk) and", "cite_spans": [], "ref_spans": [], "section": "p21 and p27 Cdk inhibitors"}, {"text": "Cdk inhibitors (CdkIs) (Glickman and Ciechanover, 2002; Diehl and Ponugoti, 2010) . Generally, the main function of CdkIs consists in the inhibition of cyclin/Cdk complexes, blocking cell division; p21 and p27 CdkIs expression is frequently suppressed in cancer, favouring the dysregulation of cell proliferation (Chu et al., 2008, Abbas and Dutta, 2009 ). P27 is a well-known negative regulator of cell cycle progression in mammalian cells which binds and suppresses the activity of two crucial complexes (i.e., Cdk2/cyclin E and Cdk2/cyclin A), mediating G1 progression and G1/S transition (Sherr and Roberts; Slingerland and Pagano, 2000) . P27 is ubiquitinated by the E3-ligase complex SCF Skp2 and then degraded by the 26S (Abbas and Dutta, 2009; Chu et al., 2008; Slingerland and Pagano, 2000; Rastogi and Mishra, 2012) . Low levels of p27 are reported in different cancers (including prostate, breast, and colorectal), as a consequence of an increased UPS activity, which leads to its accelerated degradation (Loda et al., 1997 , Tsihlias et al., 1999 Glickman and Ciechanover, 2002) . Moreover, consistent with the oncogenic role of SCF Skp2 , its overexpression is associated with low levels of p27, and thus with the deregulation of cell cycle progression (Gstaiger et al., 2001; Lee et al., 2016b) . P21, whose stability is essential for cell fate decision, binds Cdk2/cyclin E complex (blocking the onset of the cell S phase) and cyclin B/Cdk1 complex (leading to a growth arrest in the G2 phase) (Abbas and Dutta, 2009; Rastogi and Mishra 2012) ( Figure 3 ). Moreover, p21 binds the proliferating cell nuclear antigen (PCNA), interfering with PCNA-dependent DNA polymerase activity, inhibiting DNA replication and modulating PCNA-dependent DNA repair processes (Mortusewicz et al., 2005; Walsh and Xu, 2006; Moldovan et al., 2007; Abbas and Dutta, 2009 ).", "cite_spans": [{"start": 23, "end": 55, "text": "(Glickman and Ciechanover, 2002;", "ref_id": "BIBREF98"}, {"start": 56, "end": 81, "text": "Diehl and Ponugoti, 2010)", "ref_id": null}, {"start": 313, "end": 341, "text": "(Chu et al., 2008, Abbas and", "ref_id": null}, {"start": 342, "end": 353, "text": "Dutta, 2009", "ref_id": null}, {"start": 592, "end": 611, "text": "(Sherr and Roberts;", "ref_id": null}, {"start": 612, "end": 641, "text": "Slingerland and Pagano, 2000)", "ref_id": null}, {"start": 724, "end": 751, "text": "26S (Abbas and Dutta, 2009;", "ref_id": null}, {"start": 752, "end": 769, "text": "Chu et al., 2008;", "ref_id": null}, {"start": 770, "end": 799, "text": "Slingerland and Pagano, 2000;", "ref_id": null}, {"start": 800, "end": 825, "text": "Rastogi and Mishra, 2012)", "ref_id": null}, {"start": 1016, "end": 1034, "text": "(Loda et al., 1997", "ref_id": null}, {"start": 1035, "end": 1058, "text": ", Tsihlias et al., 1999", "ref_id": null}, {"start": 1059, "end": 1090, "text": "Glickman and Ciechanover, 2002)", "ref_id": "BIBREF98"}, {"start": 1266, "end": 1289, "text": "(Gstaiger et al., 2001;", "ref_id": null}, {"start": 1290, "end": 1308, "text": "Lee et al., 2016b)", "ref_id": null}, {"start": 1774, "end": 1800, "text": "(Mortusewicz et al., 2005;", "ref_id": null}, {"start": 1801, "end": 1820, "text": "Walsh and Xu, 2006;", "ref_id": null}, {"start": 1821, "end": 1843, "text": "Moldovan et al., 2007;", "ref_id": null}, {"start": 1844, "end": 1865, "text": "Abbas and Dutta, 2009", "ref_id": null}], "ref_spans": [{"start": 1560, "end": 1568, "text": "Figure 3", "ref_id": "FIGREF37"}], "section": "p21 and p27 Cdk inhibitors"}, {"text": "Under normal conditions, p21 levels are controlled at a transcriptional level mainly by p53. In several cancer types, proteasome inhibition brings about accumulation of p53, enhancing its nuclear export, and thereby the expression of transcriptional target genes, including p21, counteracting the proliferation stimulus associated to low p21 levels (Brugarolas et al., 1995; Deng et al., 1995; Roninson, 2002; Eastman, 2004; Abbas and Dutta, 2009) . Beside a transcriptional control by p53, p21 levels are modulated through either (i) a ubiquitin-dependent degradation by the 26S, and (ii) a ubiquitin independent pathway of degradation by the uncapped 20S, which has been proposed for the free form of p21 ( Figure 3 ) (Sheaff et al., 2000; Touitou et al., 2001; Li et al., 2007; Chen et al., 2007; Deng et al., 2018) . In particular, case (i) requires p21 ubiquitination by three E3 ligases (i.e., SCFS KP2 , L4 CDT 2 and APC/ C CDC20 ) at specific stages in an unperturbed cell cycle, which occurs only when p21 is bound to cyclin/Cdk complexes, and PCNA. Consistent with these studies, J o u r n a l P r e -p r o o f proteasome inhibition has been reported to considerably increase the intracellular level of p27 and p21 in many cancers, favouring cell cycle arrest (Sterz et al., 2010; Mi et al. 2011; Huang et al., 2011; Rastogi and Mishra 2012; Li et al., 2018) .", "cite_spans": [{"start": 349, "end": 374, "text": "(Brugarolas et al., 1995;", "ref_id": null}, {"start": 375, "end": 393, "text": "Deng et al., 1995;", "ref_id": null}, {"start": 394, "end": 409, "text": "Roninson, 2002;", "ref_id": null}, {"start": 410, "end": 424, "text": "Eastman, 2004;", "ref_id": null}, {"start": 425, "end": 447, "text": "Abbas and Dutta, 2009)", "ref_id": null}, {"start": 720, "end": 741, "text": "(Sheaff et al., 2000;", "ref_id": null}, {"start": 742, "end": 763, "text": "Touitou et al., 2001;", "ref_id": null}, {"start": 764, "end": 780, "text": "Li et al., 2007;", "ref_id": null}, {"start": 781, "end": 799, "text": "Chen et al., 2007;", "ref_id": "BIBREF430"}, {"start": 800, "end": 818, "text": "Deng et al., 2018)", "ref_id": null}, {"start": 1270, "end": 1290, "text": "(Sterz et al., 2010;", "ref_id": null}, {"start": 1291, "end": 1306, "text": "Mi et al. 2011;", "ref_id": null}, {"start": 1307, "end": 1326, "text": "Huang et al., 2011;", "ref_id": null}, {"start": 1327, "end": 1351, "text": "Rastogi and Mishra 2012;", "ref_id": null}, {"start": 1352, "end": 1368, "text": "Li et al., 2018)", "ref_id": "BIBREF312"}], "ref_spans": [{"start": 709, "end": 717, "text": "Figure 3", "ref_id": "FIGREF37"}], "section": "p21 and p27 Cdk inhibitors"}, {"text": "Although more than one thousand proteins belong to the UPS function in the ubiquitination and recognition of ubiquitinated protein substrates, the vast majority of currently available inhibitors, which have been designed and synthesized to block this pathway, target the proteolytic core of 20S.", "cite_spans": [], "ref_spans": [], "section": "Proteasome inhibitors for cancer therapy"}, {"text": "These proteasome inhibitors are broadly categorized into different groups, according to the origin (e.g., synthetic or natural products), the kinetic mechanism of inhibition (e.g., competitive or noncompetitive) or else the chemical structure/reactivity. This chapter and the following one will deal with the discussion on the most promising and clinically available inhibitors, pointing out, wherever possible, their molecular action as well as their pharmacological profile and therapeutic outcome of their usage in clinic.", "cite_spans": [], "ref_spans": [], "section": "Proteasome inhibitors for cancer therapy"}, {"text": "Proteasome inhibitors were initially developed to prevent cancer-related cachexia, in view of proteasome role in protein turnover (Manasanch and Orlowski, 2017) . To date, UPS is universally considered a \"bona fide\" target for the development of anti-cancer drugs (Adams, 2004a,b; Cloos et al., 2017; Gandolfi et al., 2017; King et al., 1996; Landis-Piwowar et al., 2006; Niewerth et al., 2015; Bullova et al., 2017; Roeten et al., 2018; . Indeed, PIs represent the reference treatment of multiple myeloma (MM), in view of its high sensitivity to this class of anticancer agents (Chauhan et al., 2005; Roccaro et al., 2006; Fricker, 2020; Gandolfi et al., 2017; . It is important to recall that MM is an aggressive and often incurable plasma cell dyscrasia characterized by uncontrolled proliferation of abnormal plasma cells, which invade the bone marrow, producing abnormal monoclonal immunoglobulins, which circulate in blood. The poor prognosis of MM, which reflects the genomic complexity of the disease, has dramatically improved after the introduction of PIs in disease management, mainly for patients displaying a refractory MM (RMM) and relapsed and refractory MM (RRMM), as discussed in the next section Leleu et al., 2018) . As reported previously (see Section 3.2), proteasome inhibition results in multiple deleterious downstream effects in cancer cells, including down-regulation of NF-\u03baB signaling, stabilization of p53, cell cycle arrest, which all lead to apoptosis. Moreover, PIs downregulate adhesion molecules and secretion of cytokines (Read et al., 1995) , inhibit angiogenesis (Sunwoo et al., 2001) and induce DNA-damage (\u0141uczkowska et al., 2020) .", "cite_spans": [{"start": 130, "end": 160, "text": "(Manasanch and Orlowski, 2017)", "ref_id": null}, {"start": 264, "end": 280, "text": "(Adams, 2004a,b;", "ref_id": null}, {"start": 281, "end": 300, "text": "Cloos et al., 2017;", "ref_id": null}, {"start": 301, "end": 323, "text": "Gandolfi et al., 2017;", "ref_id": null}, {"start": 324, "end": 342, "text": "King et al., 1996;", "ref_id": null}, {"start": 343, "end": 371, "text": "Landis-Piwowar et al., 2006;", "ref_id": null}, {"start": 372, "end": 394, "text": "Niewerth et al., 2015;", "ref_id": null}, {"start": 395, "end": 416, "text": "Bullova et al., 2017;", "ref_id": null}, {"start": 417, "end": 437, "text": "Roeten et al., 2018;", "ref_id": "BIBREF532"}, {"start": 579, "end": 601, "text": "(Chauhan et al., 2005;", "ref_id": null}, {"start": 602, "end": 623, "text": "Roccaro et al., 2006;", "ref_id": null}, {"start": 624, "end": 638, "text": "Fricker, 2020;", "ref_id": null}, {"start": 639, "end": 661, "text": "Gandolfi et al., 2017;", "ref_id": null}, {"start": 1214, "end": 1233, "text": "Leleu et al., 2018)", "ref_id": "BIBREF281"}, {"start": 1557, "end": 1576, "text": "(Read et al., 1995)", "ref_id": null}, {"start": 1600, "end": 1621, "text": "(Sunwoo et al., 2001)", "ref_id": "BIBREF692"}, {"start": 1633, "end": 1669, "text": "DNA-damage (\u0141uczkowska et al., 2020)", "ref_id": null}], "ref_spans": [], "section": "Proteasome inhibitors for cancer therapy"}, {"text": "The effort to develop PIs has a long history and many different approaches have been adopted, ranging from the use of endogenous and/or natural compounds to the synthesis of new ones (Buac et al., 2013) . Initially, proteasome targeting for cancer therapy has been viewed with scepticism, mainly because of the fundamental and crucial roles of proteasome in regulating cell homeostasis in all living cells (Park et al., 2018) . Although the reason for the increased cytotoxicity of PIs on proliferating tumour cells is not completely understood, it is widely reported (Chauhan et al., 2005) that cancer cells are more dependent on proteasomal activity, likely because of the higher protein turnover they experience, thus being also more sensitive to its blockage (Almond and Cohen, 2002) .", "cite_spans": [{"start": 183, "end": 202, "text": "(Buac et al., 2013)", "ref_id": "BIBREF857"}, {"start": 406, "end": 425, "text": "(Park et al., 2018)", "ref_id": "BIBREF441"}, {"start": 568, "end": 590, "text": "(Chauhan et al., 2005)", "ref_id": null}, {"start": 763, "end": 787, "text": "(Almond and Cohen, 2002)", "ref_id": null}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Tumour cells have a proteasome pathway more active than normal cells, since an increased capability for synthesis, movement and modification of proteins is necessary to preserve their uncontrolled cell proliferation and their high metastatic potential high capacity (Chen and Madura, 2005 Fricker, 2020; Gandolfi et al., 2017) . Although the availability of PIs has led to an improvement of patients' survival rate, the therapeutic potentiality of these drugs is limited by several drawbacks, including the low potency and specificity of approved molecules, adverse effects and development of drug resistance (Assaraf et al., 2019; Cree and Charlton, 2017; Gacche and Assaraf, 2018; Gonen and Assaraf, 2012; Wijdeven et al., 2016; Zhitomirsky and Assaraf, 2016) . Furthermore, the therapeutic potential of bortezomib is negatively affected by pharmacokinetic issues and by the very limited distribution to solid tumours which require exceedingly high and toxic doses (Huang et al., 2014; Grigoreva et al., 2015) . The use of more recently approved carfilzomib and ixazomib has only partially allowed to overcome these issues (see Section 3.3.2.1). Therefore, there is a growing demand of novel inhibitors with different mechanisms of action and more favourable pharmacological profiles. Additionally, it emerges that the antitumor activity of PIs is markedly improved in combination with conventional therapeutic strategies or with other molecular targeting agents, such as cell surface death receptor, autophagy, STAT3 and HDAC inhibitors (Pei et al., 2004; Li et al., 2008; Li et al., 2009; Li et al., 2010a; Seki et al., 2010; Yoshiba et al., 2011; Li and Johnson, 2012) . Accordingly, a number of preclinical and clinical studies are ongoing to evaluate further new drug combinations, and to optimize administration schedules of therapeutic protocol J o u r n a l P r e -p r o o f already used (Berenson et al., 2007; Chen et al., 2011a; Johnson, 2015; Wallington-Beddoe et al., 2018) .", "cite_spans": [{"start": 266, "end": 288, "text": "(Chen and Madura, 2005", "ref_id": null}, {"start": 289, "end": 303, "text": "Fricker, 2020;", "ref_id": null}, {"start": 304, "end": 326, "text": "Gandolfi et al., 2017)", "ref_id": null}, {"start": 609, "end": 631, "text": "(Assaraf et al., 2019;", "ref_id": null}, {"start": 632, "end": 656, "text": "Cree and Charlton, 2017;", "ref_id": null}, {"start": 657, "end": 682, "text": "Gacche and Assaraf, 2018;", "ref_id": null}, {"start": 683, "end": 707, "text": "Gonen and Assaraf, 2012;", "ref_id": null}, {"start": 708, "end": 730, "text": "Wijdeven et al., 2016;", "ref_id": null}, {"start": 731, "end": 761, "text": "Zhitomirsky and Assaraf, 2016)", "ref_id": null}, {"start": 967, "end": 987, "text": "(Huang et al., 2014;", "ref_id": null}, {"start": 988, "end": 1011, "text": "Grigoreva et al., 2015)", "ref_id": "BIBREF116"}, {"start": 1540, "end": 1558, "text": "(Pei et al., 2004;", "ref_id": null}, {"start": 1559, "end": 1575, "text": "Li et al., 2008;", "ref_id": "BIBREF310"}, {"start": 1576, "end": 1592, "text": "Li et al., 2009;", "ref_id": "BIBREF301"}, {"start": 1593, "end": 1610, "text": "Li et al., 2010a;", "ref_id": null}, {"start": 1611, "end": 1629, "text": "Seki et al., 2010;", "ref_id": null}, {"start": 1630, "end": 1651, "text": "Yoshiba et al., 2011;", "ref_id": null}, {"start": 1652, "end": 1673, "text": "Li and Johnson, 2012)", "ref_id": null}, {"start": 1898, "end": 1921, "text": "(Berenson et al., 2007;", "ref_id": null}, {"start": 1922, "end": 1941, "text": "Chen et al., 2011a;", "ref_id": null}, {"start": 1942, "end": 1956, "text": "Johnson, 2015;", "ref_id": "BIBREF198"}, {"start": 1957, "end": 1988, "text": "Wallington-Beddoe et al., 2018)", "ref_id": null}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Generally, PIs are electrophilic molecular species that react covalently with the threonine residues of the proteasome active sites (Harer et al., 2012) . The first PIs were analogs of serine protease inhibitors, characterized by hydrophobic peptide aldehydes, mimicking substrates of the proteasome \u03b25 active site and reacting with the nucleophilic hydroxyl group of threonine to form reversible hemiacetal adducts. However, first aldehyde inhibitors turned out to have additional targets in the cell besides the proteasome, also inhibiting cathepsin B and calpains (Kisselev & Goldberg, 2001) .", "cite_spans": [{"start": 132, "end": 152, "text": "(Harer et al., 2012)", "ref_id": "BIBREF154"}, {"start": 567, "end": 594, "text": "(Kisselev & Goldberg, 2001)", "ref_id": null}], "ref_spans": [], "section": "Chemical Structure and Mechanism of Action"}, {"text": "For this reason, other molecular scaffolds have been investigated and peptide boronates (such as bortezomib and ixazomib) as well as epoxyketones (i.e., carfilzomib and oprozomib) have been synthesized. These new and more specific PIs have experienced great success in clinics (as extensively discussed in section 3.3.2), and most of them are currently used as therapeutic drugs, even though some of them still retain activity towards non-proteasome targets. In fact, bortezomib and most second-generation boronates also co-inhibit caspase-like sites (Kisselev et al., 2012) . In the next section, the main chemical properties of PIs approved and/or ongoing in clinical trials are discussed.", "cite_spans": [{"start": 551, "end": 574, "text": "(Kisselev et al., 2012)", "ref_id": null}], "ref_spans": [], "section": "Chemical Structure and Mechanism of Action"}, {"text": "Bortezomib is a dipeptide containing phenylalanine and leucine with a boronic acid instead of a carboxylic acid, and a pyrazinoic acid moiety to protect the N-terminus. The structure of bortezomib bound to the 20S has been solved, elucidating the binding mode and mechanism of action at the molecular level (Groll et al., 2006) (Figure 4A ). Bortezomib binds reversibly to the chymotryptic-like (CT-L) \u03b25 subunit of the proteasome, even though it has also been reported to bind the caspase-like (C-L) \u03b21 and trypsin-like (T-L) \u03b22 subunits with lower affinity (Buac et al., 2013) ; however, a good selectivity of bortezomib towards specific proteasome subunits is dictated by the composition of their substrate binding pockets, which differs in the three catalytic \u03b2-subunits.", "cite_spans": [{"start": 307, "end": 327, "text": "(Groll et al., 2006)", "ref_id": "BIBREF120"}, {"start": 559, "end": 578, "text": "(Buac et al., 2013)", "ref_id": "BIBREF857"}], "ref_spans": [{"start": 328, "end": 338, "text": "(Figure 4A", "ref_id": "FIGREF7"}], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "In the presence of bortezomib, an anti-parallel \u03b2 sheet conformation is adopted by domains in the catalytic clefts, and direct hydrogen bonds are formed between the conserved residues (i.e., Gly47N, Thr21N, Thr21O, and Ala49O) of the proteasome \u03b2-type subunits and the main chain atoms of the drug, stabilizing the complex ( Figure 4A ). The boronic acid is responsible for the J o u r n a l P r e -p r o o f actual inhibition, ensuring an increased specificity for the proteasome. Indeed, the boron atom covalently binds the oxygen of Thr1O\u03b3 (the electrophilic functional group that normally reacts with peptide bonds of substrates, see section 2.2.1), while the acidic boronate hydroxyl groups are bound to Gly47N, bringing about a stabilization of the oxyanion hole. Further stabilization of the tetrahedral boronate adduct comes from a second acidic boronate hydroxyl moiety, which works as a catalytic proton acceptor and is H-bridged to the N-terminal threonine amine atom. A wide range of specific inhibitors has been developed, but usually peptide boron esters and acids are powerful inhibitors of serine proteases, as they interact covalently but reversibly with the active hydroxyl site of this class of the enzymes (Harer et al., 2012) . Furthermore, these peptide boron esters are less reactive toward circulating nucleophiles in aqueous solutions than their aldehyde counterparts (Adams et al., 1998) .", "cite_spans": [{"start": 1226, "end": 1246, "text": "(Harer et al., 2012)", "ref_id": "BIBREF154"}, {"start": 1393, "end": 1413, "text": "(Adams et al., 1998)", "ref_id": null}], "ref_spans": [{"start": 325, "end": 334, "text": "Figure 4A", "ref_id": "FIGREF7"}], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "Bortezomib induces toxicity in cancer cells through different mechanisms, including (i) inhibition of the NF-kB pathway, which has been envisaged as the main target of bortezomib clinically efficacy; (ii) stabilization of p53 pathway, which leads to apoptosis mainly by increasing the level of proapoptotic factors, such as NOXA and Bcl-2; (iii) modulation of CdkIs levels. Moreover, bortezomib inhibits tumor angiogenesis probably as a result of reduced vascular endothelial growth factor receptor (VEGFRs), which seems to be linked to the inhibition of NF-kB (Hideshima et al., 2001; Sunwoo et al., 2001; Qin et al., 2005; Pandit and Gartel, 2011; Nunes & Annunziata, 2017) . Despite the plethora of mechanisms of actions responsible for the high toxicity of bortezomib towards cancer cells and the high specificity towards serine proteases, peptide boron esters containing acids, such as bortezomib, can become bioactivated to chemically reactive imine amide metabolites inducing drug toxicity (A. C. . As a matter of fact, carbinolamides metabolites have been detected after incubation with human liver proteins and the formation of GSH conjugates was also observed, both likely stemming from electrophilic reactions of the imine amides with the nucleophilic GSH. The observed metabolites seem to be produced via oxidative de-boronation, catalyzed by hepatic cytochrome P450 enzyme, and bortezomib toxicity has been ascribed to their formation and high reactivity (see also section 3.3.2.1). A way to reduce these adverse effects of bortezomib treatment is the use of appropriate methods for administering this agent, such as early-dose reduction and once-weekly and subcutaneous administration.", "cite_spans": [{"start": 561, "end": 585, "text": "(Hideshima et al., 2001;", "ref_id": null}, {"start": 586, "end": 606, "text": "Sunwoo et al., 2001;", "ref_id": "BIBREF692"}, {"start": 607, "end": 624, "text": "Qin et al., 2005;", "ref_id": null}, {"start": 625, "end": 649, "text": "Pandit and Gartel, 2011;", "ref_id": "BIBREF428"}, {"start": 650, "end": 675, "text": "Nunes & Annunziata, 2017)", "ref_id": "BIBREF393"}], "ref_spans": [], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "A crucial drawback, encountered when bortezomib is used as a therapeutic drug, is the rapid development of resistance in response to the treatment (Barrio et al., 2018) . Many studies have described a plethora of strategies the cancer cells may evolve to acquire bortezomib resistance. In J o u r n a l P r e -p r o o f this regards, selective down-regulation of specific 19S subunits and the consequent reduced flux of substrates through proteasome has been reported to be a major strategy several cancer cells may adopt to cope with proteasome inhibition (Tsvetkov et al., 2015; Tsvetkov et al., 2017) . Somatic mutations in the catalytic cleft of \u03b25 and involved in the binding to bortezomib have been further described in patients with MM who underwent prolonged therapy with PIs: in this case, resistance induction was acquired through missense mutations and resistance was effective, though at a variable extent, also to next generation PIs (see next paragrapshs) (Barrio et al., 2019) .", "cite_spans": [{"start": 147, "end": 168, "text": "(Barrio et al., 2018)", "ref_id": null}, {"start": 557, "end": 580, "text": "(Tsvetkov et al., 2015;", "ref_id": "BIBREF734"}, {"start": 581, "end": 603, "text": "Tsvetkov et al., 2017)", "ref_id": "BIBREF735"}, {"start": 970, "end": 991, "text": "(Barrio et al., 2019)", "ref_id": "BIBREF14"}], "ref_spans": [], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "Further, a selective overexpression (up to 60-fold) of a mutant \u03b25 protein has been proposed at the origin of the bortezomib resistance, whereas marked changes in CT-L proteasome activity are not found (Oerlemans et al., 2008) . On the other hand, other studies have reported a significant decrease of the CT-L proteasome activity after 1 h in four different cell lines, maintaining such an inhibitory activity for as long as 24 h (Bonvini et al., 2007) . Furthermore, an increase in the accumulation of the \u03b25 precursor form was observed, even though no significant alteration in the expression profile of the mature form was detected (Yerlikaya & Okur, 2019) . Analogously, it has been also reported that \u03b15 promotes the tumourigenic process of prostate cancer cells and is linked to bortezomib resistance (Fu et al., 2019) . Other changes in bortezomib resistant cell lines, such as increased expression of \u03b21 and \u03b25 proteasome subunits, upregulation of pro-apoptotic proteins of the Bcl-2 protein family, Bax and Noxa have been also reported . Moreover, the lack of some proteins, such as XBP1, which decreases the endoplasmic reticulum burden and affects the unfolded protein response, has also been proposed as a possible cause of bortezomib resistance (Fall et al., 2014) . Interestingly, certain factors have been proposed as predictive markers of response to bortezomib treatment. Among others, KLF9, CDK5, Nampt and accumulation of unfolded proteins in the endoplasmic reticulum (ER stress) and UPR-associated markers (XBP1, ATF3, and AFT4) have been identified to play an important role in bortezomib sensitivity. It is therefore clear that further studies are demanded in order to better understand the underlying mechanisms which limit the use of this compound for cancer treatment.", "cite_spans": [{"start": 202, "end": 226, "text": "(Oerlemans et al., 2008)", "ref_id": "BIBREF399"}, {"start": 431, "end": 453, "text": "(Bonvini et al., 2007)", "ref_id": null}, {"start": 636, "end": 660, "text": "(Yerlikaya & Okur, 2019)", "ref_id": null}, {"start": 808, "end": 825, "text": "(Fu et al., 2019)", "ref_id": null}, {"start": 1259, "end": 1278, "text": "(Fall et al., 2014)", "ref_id": null}], "ref_spans": [], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "In general, epoxyketone PI are characterized by a short peptide core, and a terminal \u03b1,\u03b2epoxyketone dual electrophilic reactive warhead, which determines their activity (Schrader et al., 2016) . The most important representative of this PI class is carfilzomib, a tetrapeptide with a terminal epoxyketone group, which seems to be highly specific for the proteasome (see sections 3.3.1.1 and 3.3.2.2.2) (Muz et al., 2016) , It displays an inhibitory power equivalent to that of bortezomib for CT-L subunits of the proteasome (IC 50 = 6 nM), whereas C-L and T-L sites are only very weakly inhibited by carfilzomib (IC 50 = 2400 and 3600 nM, respectively); thus it is considered a selective inhibitor of CT-L activity (Demo et al., 2007; Boccon-Gibod et al., 2020) . Carfilzomib forms a covalent adduct between its C-terminal ketone moiety and Thr1O of each inhibited subunit ( Figure 4B ). Additionally, unlike peptide boronates, such as bortezomib and ixazomib, carfilzomib forms a stable morpholine ring between Thr1 N-terminal amino group and epoxide \u03b1 carbon. These further covalent interactions dramatically enhance the specificity of epoxyketones for proteasome with respect to other proteases, making this PI class essentially irreversible under physiologicaltreatment conditions (Huber et al., 2012; . Crystallographic studies on human 20S proteasome in complex with carfilzomib clarify the structural basis for the high in vivo drug's selectivity for CT-L activity. The high specificity for CT-L activity can be attributed to van der Waals interactions between carfilzomib and S1, S3, and S4 pockets of \u03b25 subunits, whereas in the T-L \u03b22 subunit, carfilzomib forms favorable van der Waals interactions only with S3 and S4", "cite_spans": [{"start": 169, "end": 192, "text": "(Schrader et al., 2016)", "ref_id": "BIBREF614"}, {"start": 402, "end": 420, "text": "(Muz et al., 2016)", "ref_id": "BIBREF379"}, {"start": 715, "end": 734, "text": "(Demo et al., 2007;", "ref_id": null}, {"start": 735, "end": 761, "text": "Boccon-Gibod et al., 2020)", "ref_id": null}, {"start": 1285, "end": 1305, "text": "(Huber et al., 2012;", "ref_id": null}], "ref_spans": [{"start": 875, "end": 884, "text": "Figure 4B", "ref_id": "FIGREF38"}], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "pockets, but not with S1 ( Figure 4B ). In fact, the main differences between CT-L and T-L sites mostly reside in the S1 pocket size, which is much wider in the T-L subunit than in the CT-L one, rendering less effective the van der Waals contacts between the P1 leucyl group of carfilzomib and the S1 pocket of the T-L subunit. In addition, His116 of \u03b27 subunit sterically blocks the entry of carfilzomib P4 phenyl group into the S4 pocket of the T-L subunit, shifting P4 up to 3.7 \u01fa away from the S4. Furthermore, the polarity of the C-L S1 pocket impairs an interaction with the carfilzomib hydrophobic P1 leucyl group ( Figure 4B ). As a whole, these differences lead to a disordered N-terminus of carfilzomib, likely contributing to the higher IC 50 value of C-L activity (Harshbarger et al., 2015) .", "cite_spans": [{"start": 776, "end": 802, "text": "(Harshbarger et al., 2015)", "ref_id": "BIBREF161"}], "ref_spans": [{"start": 27, "end": 36, "text": "Figure 4B", "ref_id": "FIGREF38"}, {"start": 623, "end": 632, "text": "Figure 4B", "ref_id": "FIGREF38"}], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "The mechanisms through which carfilzomib induce cell death are less known than for bortezomib, even though several studies demonstrated that it elicits programmed cell death acting in different ways, such as (i) activating c-Jun-N-terminal kinase, (ii) promoting mitochondrial membrane depolarization and favouring cytochrome c release, (iii) increasing the levels of pro-apoptotic factor Noxa, and activating caspase-3 and caspase-7 (Parlati et al., 2009 , Naraynan et al., 2020 . The introduction of carfilzomib in clinical therapy has allowed to overcome some criticisms related to bortezomib administration, like a reduced incidence of adverse effects (e.g., severe peripheral J o u r n a l P r e -p r o o f neuropathy) and acquired resistance; therefore, it has become a key option for the treatment of refractory MM patients (see section 3.3.2.2.1). However, a number of patients also display intrinsic resistance or develop resistance to carfilzomib treatment (Shah et al., 2018) . The reasons for this might stem from mutations or overexpression of proteasome catalytic subunits, but a likely contributor to carfilzomib resistance could also be the overexpression of the efflux pump Pglycoprotein (P-gp), reducing the drug intracellular concentration, since carfilzomib is a recognized substrate of this enzyme (Ao et al., 2012; Zang et al., 2014; Besse et al., 2019; Zheng et al., 2017;  Lee er t al., 2019).", "cite_spans": [{"start": 434, "end": 455, "text": "(Parlati et al., 2009", "ref_id": "BIBREF445"}, {"start": 456, "end": 479, "text": ", Naraynan et al., 2020", "ref_id": null}, {"start": 967, "end": 986, "text": "(Shah et al., 2018)", "ref_id": "BIBREF623"}, {"start": 1319, "end": 1336, "text": "(Ao et al., 2012;", "ref_id": "BIBREF0"}, {"start": 1337, "end": 1355, "text": "Zang et al., 2014;", "ref_id": null}, {"start": 1356, "end": 1375, "text": "Besse et al., 2019;", "ref_id": "BIBREF14"}, {"start": 1376, "end": 1395, "text": "Zheng et al., 2017;", "ref_id": "BIBREF866"}, {"start": 1396, "end": 1396, "text": "", "ref_id": null}], "ref_spans": [], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "Oprozomib is an orally bioavailable peptide epoxyketone, currently tested in ongoing clinical trials.", "cite_spans": [], "ref_spans": [], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "It is a tripeptide structural analogue of carfilzomib, which was synthesized to improve drug absorption. In fact, it is thought that smaller peptides are absorbed more effectively across the small intestine wall (Hamman et al., 2005; Zhou et al., 2009) . Like carfilzomib, oprozomib primarily exhibits irreversible binding kinetics to CT-L subunit (Rajan and Kumar, 2016) , and the co-crystal structure of human 20S and oprozomib enhanced the knowledge of how proteasome active sites interact with peptide epoxyketone inhibitors (Schrader et al., 2016) . Oprozomib, like other epoxyketone inhibitors, forms a seven-membered, 1,4-oxazepano adduct with the catalytic Thr within the \u03b25 active site, whereas (as also reported for carfilzomib) previous findings reported the formation of a 1,4-morpholino adduct. Therefore, these novel solved structures have indicated that, during the second step of the inhibitory reaction, the Thr N-terminal amino group attacks the \u03b2 carbon rather than the \u03b1 carbon of the inhibitor's epoxide (Schrader et al., 2016; Carmony et al., 2017) . Concerning the mechanism through which oprozomib mediates cancer cell death, it has been demonstrated that oprozomib induces apoptosis through the activation of caspase 3, 8 and 9 (Chauhan et al., 2015) , PARP cleavage, and, interestingly, it seems to block angiogenesis that it is known to play a key role in MM progression (Podar et al., 2001; Chauhan et al., 2010; Giuliani et al., 2011; Zhu et al., 2019) .", "cite_spans": [{"start": 212, "end": 233, "text": "(Hamman et al., 2005;", "ref_id": "BIBREF144"}, {"start": 234, "end": 252, "text": "Zhou et al., 2009)", "ref_id": null}, {"start": 348, "end": 371, "text": "(Rajan and Kumar, 2016)", "ref_id": "BIBREF484"}, {"start": 529, "end": 552, "text": "(Schrader et al., 2016)", "ref_id": "BIBREF614"}, {"start": 1025, "end": 1048, "text": "(Schrader et al., 2016;", "ref_id": "BIBREF614"}, {"start": 1049, "end": 1070, "text": "Carmony et al., 2017)", "ref_id": null}, {"start": 1253, "end": 1275, "text": "(Chauhan et al., 2015)", "ref_id": null}, {"start": 1398, "end": 1418, "text": "(Podar et al., 2001;", "ref_id": null}, {"start": 1419, "end": 1440, "text": "Chauhan et al., 2010;", "ref_id": "BIBREF654"}, {"start": 1441, "end": 1463, "text": "Giuliani et al., 2011;", "ref_id": "BIBREF93"}, {"start": 1464, "end": 1481, "text": "Zhu et al., 2019)", "ref_id": "BIBREF870"}], "ref_spans": [], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "Ixazomib and delazomib are both orally available structural analogues of bortezomib with a boronic acid as pharmacofore. In particular, ixazomib, which is currently approved by EMA and FDA, is a dipeptidyl leucine boronic acid, that was developed through a large-scale screening of boroncontaining PIs in the search of compounds with an increased efficacy and reduced side effects with respect to bortezomib (Kupperman et al., 2010; Chauhan et al., 2011; Offidani et al., 2014) . Since it belongs to the same chemical class of bortezomib, it is not surprising that its acts through a similar mechanism of action. In fact, proteasome subunit inhibition occurs when boric acid group forms a covalent bond with the hydroxyl group of the catalytic N-terminal threonine residue (Muz et al., J o u r n a l P r e -p r o o f 2016) . Like bortezomib, ixazomib reversibly blocks the chymotrypsin-like activity of the \u03b25 subunit (IC 50 =3.4 nmol/L for ixazomib vs 2.7 nmol/L for bortezomib) (Chauhan et al., 2011; ) ( Figure 4C ). Noteworthy, proteasome dissociation half-life for ixazomib is relatively shorter that for bortezomib (18 min for ixazomib and 110 for bortezomib), improving its general tissue distribution, rendering this drug more \"re-available\" (see section 3.3.2.2.2) (Kupperman et al., 2010; . Biochemical analysis and in vitro studies showed that at high concentrations ixazomib (like bortezomib) inhibits also other proteolytic sites of 20S proteasome (Chauhan et al., 2011) ; however, the most important advancement of ixazomib with respect to bortezomib is the possibility of an oral administration; thus, ixazomib can be formulated as an ester citrate prodrug (MLN2238), which is rapidly hydrolyzed in aqueous solution (e.g., plasma) to the pharmacologically active metabolite MLN2238 with free boric acid (Kupperman et al., 2010; Chauhan et al., 2011; Okazuka and Ishida, 2018; Gupta et al., 2019) . Like bortezomib, the apoptotic activity of ixazomib is mediated by caspase 3-8-9 activation through a stabilization of the p53 pathway (see section 3.2.2 and 3.2.3) (Muz et al., 2016) . Interestingly, microRNA studies in MM cells revealed that ixazomib induces upregulation of the tumour suppresso miR33b, leading to apoptosis by blocking proto-oncogene PIM-1 (Tian et al., 2012) .", "cite_spans": [{"start": 408, "end": 432, "text": "(Kupperman et al., 2010;", "ref_id": "BIBREF246"}, {"start": 433, "end": 454, "text": "Chauhan et al., 2011;", "ref_id": "BIBREF467"}, {"start": 455, "end": 477, "text": "Offidani et al., 2014)", "ref_id": "BIBREF400"}, {"start": 773, "end": 785, "text": "(Muz et al.,", "ref_id": null}, {"start": 817, "end": 822, "text": "2016)", "ref_id": null}, {"start": 980, "end": 1002, "text": "(Chauhan et al., 2011;", "ref_id": "BIBREF467"}, {"start": 1274, "end": 1298, "text": "(Kupperman et al., 2010;", "ref_id": "BIBREF246"}, {"start": 1461, "end": 1483, "text": "(Chauhan et al., 2011)", "ref_id": "BIBREF467"}, {"start": 1818, "end": 1842, "text": "(Kupperman et al., 2010;", "ref_id": "BIBREF246"}, {"start": 1843, "end": 1864, "text": "Chauhan et al., 2011;", "ref_id": "BIBREF467"}, {"start": 1865, "end": 1890, "text": "Okazuka and Ishida, 2018;", "ref_id": "BIBREF403"}, {"start": 1891, "end": 1910, "text": "Gupta et al., 2019)", "ref_id": null}, {"start": 2078, "end": 2096, "text": "(Muz et al., 2016)", "ref_id": "BIBREF379"}, {"start": 2273, "end": 2292, "text": "(Tian et al., 2012)", "ref_id": "BIBREF713"}], "ref_spans": [{"start": 1007, "end": 1016, "text": "Figure 4C", "ref_id": "FIGREF38"}], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "Another peptide boronate is delazomib, which reversibly inhibits CT-L subunit with a magnitude and a mechanism of action similar to bortezomib and ixazomib (Dorsey et al., 2008; Piva et al., 2008) . Moreover, like bortezomib, in vitro studies have revealed that Delazomib primary target is the inhibition of NF-kB pathway, with a consequent alteration of the expression of several NF-kB downstream effectors (Piva et al., 2008; Kubiczkova et al., 2014) .", "cite_spans": [{"start": 156, "end": 177, "text": "(Dorsey et al., 2008;", "ref_id": null}, {"start": 178, "end": 196, "text": "Piva et al., 2008)", "ref_id": "BIBREF463"}, {"start": 408, "end": 427, "text": "(Piva et al., 2008;", "ref_id": "BIBREF463"}, {"start": 428, "end": 452, "text": "Kubiczkova et al., 2014)", "ref_id": "BIBREF230"}], "ref_spans": [], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "The main representative of the PI third class is marizomib, also named Salinosporamide A, which is a natural product deriving from a sediment obligate marine actinomycete identified as Salinospora tropica (strain CNB-392) (Feling et al., 2003; Pott and Lam, 2010; Pereira et al., 2019) . It is characterized by a different non-peptide-based structure with respect to other PIs so far described.", "cite_spans": [{"start": 222, "end": 243, "text": "(Feling et al., 2003;", "ref_id": null}, {"start": 244, "end": 263, "text": "Pott and Lam, 2010;", "ref_id": null}, {"start": 264, "end": 285, "text": "Pereira et al., 2019)", "ref_id": "BIBREF451"}], "ref_spans": [], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "Its unique structure displays a fused \u03b3-lactam-\u03b2-lactone ring system containing a cyclohexenyl carbinol and chloroethyl functional groups. Marizomib is an irreversible inhibitor of all catalytic subunits of 20S, with IC 50 values ranging from the low pM to mid nM range (Feling et al., 2003; Fenical et al., 2009) , and it produces a prolonged 20S inhibition (\u226572 h) (Pott et al., 2011) .", "cite_spans": [{"start": 270, "end": 291, "text": "(Feling et al., 2003;", "ref_id": null}, {"start": 292, "end": 313, "text": "Fenical et al., 2009)", "ref_id": null}, {"start": 367, "end": 386, "text": "(Pott et al., 2011)", "ref_id": null}], "ref_spans": [], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "Crystallographic structure of the complex between Salinosporamide A and yeast 20S showed that the drug perfectly occupies the active sites of all three pairs of catalytic subunits of 20S (Groll et al., 2006; Fenical et al., 2009) (Figure 4D ). These findings provided a detailed understanding of the proteasome-ligand interactions at the molecular level, revealing a unique mechanism of action that J o u r n a l P r e -p r o o f renders the inhibitor irreversible. The first step of interaction is represented by the formation of a covalent ester bound between the catalytic N-terminal Thr1O\u03b3 of each 20S subunit and the carbonyl of the \u03b2-lactone ring of the inhibitor ( Figure 5C ). \u03b2-lactone ring opening is followed by chlorine elimination, giving rise to a stable a 5-membered cyclic ether (Groll et al., 2006) . One of the main downstream effect observed after proteasome inactivation by marizomib is the inhibition of NF-\u03baB activation, in a fashion similar to other PIs . Remarkably, as also discussed in section 3.3.2.2.3, the main advantage of marizomib is the capability to overcome the blood-brain barrier, which opened a novel therapeutic potential for this inhibitor, eliciting the research in attempt to improve its pharmacological profile (Singh et al., 2010; Park et al., 2018) .", "cite_spans": [{"start": 187, "end": 207, "text": "(Groll et al., 2006;", "ref_id": "BIBREF120"}, {"start": 208, "end": 229, "text": "Fenical et al., 2009)", "ref_id": null}, {"start": 795, "end": 815, "text": "(Groll et al., 2006)", "ref_id": "BIBREF120"}, {"start": 1254, "end": 1274, "text": "(Singh et al., 2010;", "ref_id": "BIBREF654"}, {"start": 1275, "end": 1293, "text": "Park et al., 2018)", "ref_id": "BIBREF441"}], "ref_spans": [{"start": 230, "end": 240, "text": "(Figure 4D", "ref_id": "FIGREF38"}, {"start": 672, "end": 681, "text": "Figure 5C", "ref_id": null}], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "An intriguing point on proteasome biology, which reflects on the identification of more clinically effective PIs and/or novel combination therapy, concerns the individual role and the functional meaning of different proteasome subunits. Although these crucial aspects are poorly understood, \u03b25 subunit was initially identified as the rate limiting protease for proteasome-dependent protein turnover (Heinemeyer et al., 1997; Arendt and Hochstrasser, 1997; Groll et al., 1999) .", "cite_spans": [{"start": 399, "end": 424, "text": "(Heinemeyer et al., 1997;", "ref_id": "BIBREF169"}, {"start": 425, "end": 455, "text": "Arendt and Hochstrasser, 1997;", "ref_id": null}, {"start": 456, "end": 475, "text": "Groll et al., 1999)", "ref_id": "BIBREF122"}], "ref_spans": [], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "Consequently, PIs were designed to target \u03b25 subunits, as it comes from the above reported chemical features of main PIs (Kubiczkova et al., 2014; Kisselev et al., 2012) . However, advanced chemical manipulations, which allowed to monitor the activity of each individual proteolytic subunit, have pointed out that, at higher concentrations, all \u03b25-targeted PIs lose their subunit selectivity and inhibit also the \u03b21 and/or \u03b22 types of proteasome subunits (Kraus et al., 2015; Bruin et al., 2016) . These co-inhibition patterns differ among individual PIs and seem to be responsible for the overcoming of drug resistance observed at higher concentrations. In this respect, recent investigations have revealed that \u03b25 and \u03b22 co-inhibition, exclusively achieved by high levels of carfilzomib, is the most effective proteasome inhibition profile in MM (Besse et al., 2019).", "cite_spans": [{"start": 121, "end": 146, "text": "(Kubiczkova et al., 2014;", "ref_id": "BIBREF230"}, {"start": 147, "end": 169, "text": "Kisselev et al., 2012)", "ref_id": null}, {"start": 455, "end": 475, "text": "(Kraus et al., 2015;", "ref_id": null}, {"start": 476, "end": 495, "text": "Bruin et al., 2016)", "ref_id": "BIBREF62"}], "ref_spans": [], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "Therefore, it has been proposed that a better comprehension of the significance of different coinhibitory patterns should help to understand the differential activity and toxicity observed during treatment with different PIs as well as with different doses of the same drug (Besse et al., 2019).", "cite_spans": [], "ref_spans": [], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "Moreover, these findings could provide the rationale for preclinical and clinical investigations of a novel treatment schedules. These results showed that differences on the functional proteasomeinteracting groups of the PI (i.e., epoxyketone, \u03b2-lactone, or boronate) cannot account for the observed differences in the clinical efficacy of the various drugs (reversible versus irreversible proteasome binding); differences in the PIs affinity towards the various proteasome subunits should be considered instead. The observed differences in PIs affinities are mainly due to different interactions of the specific PI side chains with each of the proteasome subunits. The chemical J o u r n a l P r e -p r o o f interpretation of the different PIs inhibition capability for the various proteasome subunits (Gozzetti et al., 2017) also explains why drugs combination is more effective than monotherapy.", "cite_spans": [{"start": 804, "end": 827, "text": "(Gozzetti et al., 2017)", "ref_id": "BIBREF112"}], "ref_spans": [], "section": "First-generation proteasome inhibitors: bortezomib"}, {"text": "In the 1990s, the reversible PI bortezomib (formerly named as PS-341) PI, was initially developed as anti-inflammatory and anti-cachectic agent. However, preclinical studies soon unravelled that bortezomib was highly effective against different tumours, in particular MM, inducing growth arrest and apoptosis and inhibiting angiogenesis (Mitch et al., 1996; Adams et al., 1998; Adams et al., 1999; Teicher et al., 1999; Hideshima et al., 2001; LeBlanc et al., 2002; Ma et al., 2003; Mitsiades et al., 2003; S\u00e1nchez-Serrano. 2006; Caravita et al., 2006) . Additionally, in vitro studies revealed that bortezomib increased in vitro tumour chemosensitivity and overcame chemoresistance to dexamethasone, doxorubicin, and melphalan, suggesting also its use in combination therapies (Hideshima et al., 2001; Mitsiades et al., 2003; Ma et al., 2003) . The overall bulk of in vitro and in vivo studies supported clinical investigations of bortezomib in patients with MM, who had received at least two prior therapies and have demonstrated disease progression after the last therapy (Caravita et al., 2006; Park et al., 2018; , leading to the first global approval of a first PI for cancer treatment.", "cite_spans": [{"start": 337, "end": 357, "text": "(Mitch et al., 1996;", "ref_id": "BIBREF356"}, {"start": 358, "end": 377, "text": "Adams et al., 1998;", "ref_id": null}, {"start": 378, "end": 397, "text": "Adams et al., 1999;", "ref_id": "BIBREF704"}, {"start": 398, "end": 419, "text": "Teicher et al., 1999;", "ref_id": "BIBREF704"}, {"start": 420, "end": 443, "text": "Hideshima et al., 2001;", "ref_id": null}, {"start": 444, "end": 465, "text": "LeBlanc et al., 2002;", "ref_id": "BIBREF262"}, {"start": 466, "end": 482, "text": "Ma et al., 2003;", "ref_id": "BIBREF314"}, {"start": 483, "end": 506, "text": "Mitsiades et al., 2003;", "ref_id": "BIBREF357"}, {"start": 507, "end": 529, "text": "S\u00e1nchez-Serrano. 2006;", "ref_id": "BIBREF570"}, {"start": 530, "end": 552, "text": "Caravita et al., 2006)", "ref_id": null}, {"start": 778, "end": 802, "text": "(Hideshima et al., 2001;", "ref_id": null}, {"start": 803, "end": 826, "text": "Mitsiades et al., 2003;", "ref_id": "BIBREF357"}, {"start": 827, "end": 843, "text": "Ma et al., 2003)", "ref_id": "BIBREF314"}, {"start": 1075, "end": 1098, "text": "(Caravita et al., 2006;", "ref_id": null}, {"start": 1099, "end": 1117, "text": "Park et al., 2018;", "ref_id": "BIBREF441"}], "ref_spans": [], "section": "First-generation of proteasome inhibitors: bortezomib"}, {"text": "A pivotal early phase I study investigated the maximum-tolerated dose, dose-limiting toxicity, and pharmacodynamics of bortezomib in patients with refractory hematological malignancies, showing activity against RMM (Orlowski et al., 2002) . Subsequently, a phase II study (CREST) showed the efficacy of the PI, as single agent or in combination with dexamethasone, in patients with relapsed MM after frontline therapy (Jagannath et al. 2004 ). These observations provided the rationale for a phase 2 open-label, single-arm (SUMMIT) trial, which included 202 patients with RRMM receiving at least two prior therapies, in which bortezomib (1.3 mg/m 2 ) was administered by intravenous bolus twice weekly for 2 weeks, followed by 1 week without treatment, for up to eight cycles (24 weeks). This study reported 27.7% complete or partial response rate, a median response of 12 months and manageable adverse effects . Moreover, bortezomib increased the time to progression to a higher extent (2-4 folds) compared to the last treatment patients received before entering the clinical trial. These impressive results led to the accelerated approval of bortezomib for the treatment of patients with RRMM who had received at least two prior therapies, a particularly difficult-to-treat patient population. An extended follow-up of the SUMMIT study J o u r n a l P r e -p r o o f reported a median time to progression of 13.9 months for responding patients, whereas of 1.3 months for those with progressive disease or not evaluable . The phase 3 trial, APEX, comparing bortezomib with high-dose dexamethasone for RRMM after one to three previous lines of treatment, showed a significant increased survival in patients treated with the PI (one-year survival rates of 80% versus 66%, P=0.003; the hazard ratio for overall survival (OS)= was 0.57, P=0.001) (Richardson et al., 2005) and these results led in 2005 to the regular approval to bortezomib. The superiority of bortezomib was further confirmed after an extended follow-up, in which the reported median OS was 29.8 months for bortezomib and 23.7 months for high-dose dexamethasone, despite crossover from dexamethasone to bortezomib arm (Richardson et al., 2007) . Thereafter, in 2007 FDA approved label expansion of bortezomib to include patients with impaired kidney function, without the requirement of dose adjustments).", "cite_spans": [{"start": 215, "end": 238, "text": "(Orlowski et al., 2002)", "ref_id": "BIBREF413"}, {"start": 418, "end": 440, "text": "(Jagannath et al. 2004", "ref_id": "BIBREF182"}, {"start": 1843, "end": 1868, "text": "(Richardson et al., 2005)", "ref_id": null}, {"start": 2182, "end": 2207, "text": "(Richardson et al., 2007)", "ref_id": "BIBREF519"}], "ref_spans": [], "section": "First-generation of proteasome inhibitors: bortezomib"}, {"text": "Bortezomib was also tested in multidrug regimens, since the shift in clinical practice to a more aggressive approach, including PIs (as also discussed in Section 3.2), has improved survival outcomes (Leleu et al., 2019) . In the DOXIL-MMY-3001 phase III study the safety and efficacy of bortezomib in combination with pegylated liposomal doxorubicin were compared to those of bortezomib as a single agent in patients with RRMM who had received at least one prior treatment.", "cite_spans": [{"start": 199, "end": 219, "text": "(Leleu et al., 2019)", "ref_id": "BIBREF280"}], "ref_spans": [], "section": "First-generation of proteasome inhibitors: bortezomib"}, {"text": "The doublet therapy was more effective than monotherapy, even though associated with a higher incidence of grade 3/4 (80 vs 64%, respectively) myelosuppression, gastrointestinal events, and hand-foot syndrome (Orlowski et al., 2007) . However, despite the significant increase in time to progression observed in the group treated with the drug combination, the final results of OS analysis after a median follow-up of 103 months indicated no significant differences between the two treatments (Orlowski et al, 2016) . The triple combination bortezomib-thalidomide-dexamethasone resulted in increased median time to progression (19.5 versus 13.8 months; hazard ratio, 0.59; P<0.001) compared to the dual combination of the immunomodulatory agent thalidomide plus dexamethasone, in patients with MM progressing or relapsing after autologous stem-cell transplantation (ASCT), as demonstrated in a phase III study (MMVAR/IFM 2005-04) (Garderet et al., 2012) . Although a direct comparison between trials is not possible, the observed time to progression was higher than that observed in the APEX trial where bortezomib was tested as single agent (6.2 months) or in the DOXIL-MMY-3001 trial where the PI was combined with liposomal doxorubicin (9.3 month). The addition of bortezomib to thalidomide-dexamethasone was associated with a substantial increase of cumulative, dose-related grade 3 peripheral sensory neuropathy (Garderet et al., 2012) . Since thalidomide is also neurotoxic, in the triple combination this agent was replaced by lenalidomide, which is a better-tolerated analogue. Indeed, a phase II trial demonstrated a similar median time to progression of 19.5 months, but a markedly lower rate of J o u r n a l P r e -p r o o f grade 3 peripheral neuropathy compared to the triple combination including thalidomide (2% versus 29%) . The current guidelines recommend the triple combination of bortezomib, lenalidomide and dexamethasone as a preferred salvage regimen for previously treated multiple myeloma and as first-line therapy irrespective of transplantation eligibility (National In the phase 3 CASTOR trial, the addition of darutumumab resulted in significantly longer PFS (median PFS 16.7 vs. 7.1 months, HR = 0.31) compared to bortezomib plus dexamethasone, but it was associated to infusion-related reactions and higher rates of thrombocytopenia and neutropenia .", "cite_spans": [{"start": 209, "end": 232, "text": "(Orlowski et al., 2007)", "ref_id": null}, {"start": 493, "end": 515, "text": "(Orlowski et al, 2016)", "ref_id": "BIBREF410"}, {"start": 930, "end": 953, "text": "(Garderet et al., 2012)", "ref_id": "BIBREF88"}, {"start": 1417, "end": 1440, "text": "(Garderet et al., 2012)", "ref_id": "BIBREF88"}], "ref_spans": [], "section": "First-generation of proteasome inhibitors: bortezomib"}, {"text": "Panabinostat was the first pan-HDAC inhibitor approved to treat MM, which acts via epigenetic modification and inhibition of the aggresome pathway (i.e. a proteasome-independent pathway that eliminates misfolded proteins). The approval for RRMM was based on the results from the pivotal A phase 2 study has also investigated the combination of bortezomib plus dexamethasone with the immunomodulatory agent elotuzumab, a monoclonal antibody against SLAMF7 (signalling lymphocytic activation molecule F7), reporting encouraging results (median PFS 9.7 vs. 6.9 months) . Based on the results of this study, the National Comprehensive J o u r n a l P r e -p r o o f Once bortezomib efficacy was established for RRMM in the early 2000s, attention turned to patients with newly diagnosed disease (NDMM), in whom its efficacy was tested with or without dexamethasone, showing that the combined treatment was associated with improved response rate without additional severe toxicities compared to PI monotherapy (Jagannath et al., 2005; Harousseau et al., 2010; Okazuka and Ishida, 2018) . In 2008, the key phase 3 trials VISTA led to the approval of bortezomib, in combination with melphalan and prednisone, by FDA for previously untreated MM and by EMA for previously untreated MM not eligible for high dose chemotherapy and stem-cell transplantation (SCT) . Melphalan plus prednisone, was the standard of care for NDMM patients over 65 years old, being instead high-dose chemotherapy followed by SCT the preferred treatment for patients under the age of 65 years (Barlogie et al., 1997; Alexanian et al., 1969; . In the VISTA trial, 682 patients were with previously untreated MM, eligible for high dose chemotherapy followed by SCT. Thereafter, the bortezomib-lenalinomide-dexamethasone triplet regimen has become one of the standard induction therapies before SCT (Okazuka and Ishida, 2018) . In two different phase 2 studies (i.e., IFM and IFM/DFCI 2009) this therapeutic regimen was tested in patients with NDMM eligible for SCT as induction therapy, and as induction and consolidation therapy, respectively, with encouraging results in terms of PFS (Richardson et al., 2010; Roussel et al., 2014) . Additionally, results from a phase 3 clinical trial demonstrated that the lenalidomide-containing triplet therapy (RVD) followed by high-dose chemotherapy plus SCT was associated with significantly longer PFS than the RVD therapy alone, even though OS did not differ significantly between the two approaches (Attal et al., 2017) . A more recent study also confirmed the efficacy of the RVD regimen in the pre-transplant induction therapy so that it has to be considered as a standard of care Initially, intravenous injection was the standard administration route for bortezomib. Thereafter, a large randomized phase 3 clinical trial, compared the efficacy and safety of subcutaneous versus intravenous treatment, at the approved 1.3 mg/ml dose and twice per week schedule in patients with RRMM, showing that subcutaneous administration induced similar effect in terms of overall response rate, but with improved tolerability and reduction of the incidence of peripheral neuropathy. Thus, currently subcutaneous injection is the preferred method of bortezomib administration, since this route is also more convenient for patients (Moreau et al., 2011; Arnulf et al. 2012) .", "cite_spans": [{"start": 1004, "end": 1028, "text": "(Jagannath et al., 2005;", "ref_id": null}, {"start": 1029, "end": 1053, "text": "Harousseau et al., 2010;", "ref_id": "BIBREF158"}, {"start": 1054, "end": 1079, "text": "Okazuka and Ishida, 2018)", "ref_id": "BIBREF403"}, {"start": 1558, "end": 1581, "text": "(Barlogie et al., 1997;", "ref_id": "BIBREF12"}, {"start": 1582, "end": 1605, "text": "Alexanian et al., 1969;", "ref_id": null}, {"start": 1861, "end": 1887, "text": "(Okazuka and Ishida, 2018)", "ref_id": "BIBREF403"}, {"start": 2149, "end": 2174, "text": "(Richardson et al., 2010;", "ref_id": "BIBREF331"}, {"start": 2175, "end": 2196, "text": "Roussel et al., 2014)", "ref_id": "BIBREF546"}, {"start": 2522, "end": 2527, "text": "2017)", "ref_id": null}, {"start": 3328, "end": 3349, "text": "(Moreau et al., 2011;", "ref_id": "BIBREF363"}, {"start": 3350, "end": 3369, "text": "Arnulf et al. 2012)", "ref_id": "BIBREF7"}], "ref_spans": [], "section": "First-generation of proteasome inhibitors: bortezomib"}, {"text": "Common adverse effects associated with bortezomib administration are fatigue, gastrointestinal toxicity, trombocytopenia, anorexia, and peripheral neuropathy (i.e., hyperesthesia, hypoesthesia, neuropathic pain, weakness), which is one of the most important complications that negatively affects the patient's quality life and daily activity (Seval and Beksac, 2018) . Peripheral neuropathy has been regarded as an off-target effect, since it is due to inhibition of HtrA2/Omi, a serine protease involved in neuronal survival with potency near or equivalent to that for the proteasome (Arastu-Kapur 2011; Park et al., 2018) .", "cite_spans": [{"start": 342, "end": 366, "text": "(Seval and Beksac, 2018)", "ref_id": null}, {"start": 605, "end": 623, "text": "Park et al., 2018)", "ref_id": "BIBREF441"}], "ref_spans": [], "section": "First-generation of proteasome inhibitors: bortezomib"}, {"text": "Moreover, other adverse events described so far are: (i) tumour lysis syndrome (Sanagawa et al., 2020) ; (ii) cardiovascular toxicities (Enrico et al., 2007; Grandin et al., 2015) , (iii) acute interstitial nephritis and rarely (iv) a severe syndrome of inappropriate anti-diuresis (SIAD) (Peng et al., 2017;  J o u r n a l P r e -p r o o f Cheungpasitporn et al., 2015) . Furthermore, treatment with bortezomib is associated with an increased risk of Varicella Zoster Virus (VZV) infection, and a continuous prophylaxis with antiviral agents, such as acyclovir and valacyclovir, is recommended (Aoki et al., 2011; Chanan-Khan et al., 2008; Teh et al., 2016; .", "cite_spans": [{"start": 79, "end": 102, "text": "(Sanagawa et al., 2020)", "ref_id": "BIBREF565"}, {"start": 136, "end": 157, "text": "(Enrico et al., 2007;", "ref_id": null}, {"start": 158, "end": 179, "text": "Grandin et al., 2015)", "ref_id": "BIBREF114"}, {"start": 289, "end": 308, "text": "(Peng et al., 2017;", "ref_id": "BIBREF450"}, {"start": 309, "end": 309, "text": "", "ref_id": null}, {"start": 341, "end": 370, "text": "Cheungpasitporn et al., 2015)", "ref_id": "BIBREF35"}, {"start": 595, "end": 614, "text": "(Aoki et al., 2011;", "ref_id": "BIBREF1"}, {"start": 615, "end": 640, "text": "Chanan-Khan et al., 2008;", "ref_id": null}, {"start": 641, "end": 658, "text": "Teh et al., 2016;", "ref_id": "BIBREF703"}], "ref_spans": [], "section": "First-generation of proteasome inhibitors: bortezomib"}, {"text": "The pharmacokinetics of bortezomib is poorly documented mostly due to analytical difficulties (Leveque et al., 2007) . Two different studies on patients with prostate cancer and MM suggested that its kinetic profile is characterized by a large distribution volume (Vd), 721-1270L, high systemic clearance, ranging from 1095 mL/min to 1866 mL/min, and terminal half-life ranging between 10 h and 31 h (calculated over a 24 h period) (Papandreou et al., 2004; Leveque et al., 2007) .", "cite_spans": [{"start": 94, "end": 116, "text": "(Leveque et al., 2007)", "ref_id": null}, {"start": 432, "end": 457, "text": "(Papandreou et al., 2004;", "ref_id": "BIBREF435"}, {"start": 458, "end": 479, "text": "Leveque et al., 2007)", "ref_id": null}], "ref_spans": [], "section": "First-generation of proteasome inhibitors: bortezomib"}, {"text": "For what concerns bortezomib clearance, the drug is converted into inactive de-boronated metabolites by different cytocrome P450 enzymes (CYPs) (e.g., 1A2, 2C9, 2C19, 2D6, and 3A4) (Uttamsingh et al., 2005; Pekol et al., 2005) , as also confirmed by studies in which the coadministration of ketoconazole, a CYP3A4 inhibitor, and rifampicin, a CYP3A4 inducer, increased and decreased patients' exposure to bortezomib, respectively (Venkatakrishnan et al., 2009; Hellmann et al., 2011) . Since bortezomib undergoes oxidative metabolism in the liver, a study was carried out on whether patients with a reduced hepatic functionality require dose adjustment investigation (Venner et al., 2012; Mikhael et al., 2012; Palladini et al., 2014; Kastritis et al., 2019; . In recent years, the introduction of bortezomib has had a great impact in the cure of Mantle cell Lymphoma (MCL), a non-Hodgkin lymphoma with a short remission duration to standard therapies, and a median OS of approximately 6-7 years (Banks et al., 1992; Fisher et al., 1995; Teodorovic et al., 1995; Weisenburger et al.,2000; Vose et al., 2017) . Therefore, there is a great need of therapeutic strategies directed against novel molecular targets. The chromosomal translocation t(11;14)-(q13;q32) is the molecular hallmark of MCL, resulting in overexpression of cyclin D1, which is not typically expressed in normal lymphocytes (Vose, 2017) , and the constitutive activation of NF-kB, which also plays a key role in MCL growth and survival (by controlling cyclin D1 expression, as reported in a previous section (see Section 3.2.1) (Rosenberg et al., 1991 , Pham et al., 2003 . Therefore, proteasome inhibition has been envisaged as an achievable therapeutic strategy, which was confirmed by in vitro studies showing that NF-kB inhibition mediated by bortezomib leads to cell cycle arrest and apoptosis in MCL cells (Pham et al., 2003) .", "cite_spans": [{"start": 181, "end": 206, "text": "(Uttamsingh et al., 2005;", "ref_id": "BIBREF748"}, {"start": 207, "end": 226, "text": "Pekol et al., 2005)", "ref_id": "BIBREF449"}, {"start": 430, "end": 460, "text": "(Venkatakrishnan et al., 2009;", "ref_id": "BIBREF759"}, {"start": 461, "end": 483, "text": "Hellmann et al., 2011)", "ref_id": "BIBREF171"}, {"start": 667, "end": 688, "text": "(Venner et al., 2012;", "ref_id": "BIBREF760"}, {"start": 689, "end": 710, "text": "Mikhael et al., 2012;", "ref_id": "BIBREF351"}, {"start": 711, "end": 734, "text": "Palladini et al., 2014;", "ref_id": null}, {"start": 735, "end": 758, "text": "Kastritis et al., 2019;", "ref_id": "BIBREF210"}, {"start": 996, "end": 1016, "text": "(Banks et al., 1992;", "ref_id": null}, {"start": 1017, "end": 1037, "text": "Fisher et al., 1995;", "ref_id": null}, {"start": 1038, "end": 1062, "text": "Teodorovic et al., 1995;", "ref_id": null}, {"start": 1063, "end": 1088, "text": "Weisenburger et al.,2000;", "ref_id": "BIBREF799"}, {"start": 1089, "end": 1107, "text": "Vose et al., 2017)", "ref_id": "BIBREF782"}, {"start": 1391, "end": 1403, "text": "(Vose, 2017)", "ref_id": "BIBREF782"}, {"start": 1595, "end": 1618, "text": "(Rosenberg et al., 1991", "ref_id": "BIBREF538"}, {"start": 1619, "end": 1638, "text": ", Pham et al., 2003", "ref_id": "BIBREF454"}, {"start": 1879, "end": 1898, "text": "(Pham et al., 2003)", "ref_id": "BIBREF454"}], "ref_spans": [], "section": "First-generation of proteasome inhibitors: bortezomib"}, {"text": "Based on preclinical studies and a phase 1 trial in patients with refractory hematologic malignancies, including, besides MM (see above), MCL and follicular lymphomas (Orlowski et al., 2002) , achieved an objective response), and bortezomib plus cyclophosphamide-doxorubicin-vincristineprednisone (CHOP) (OS= 36.6 for patients treated with bortezomib plus CHOP and 11.6 months for J o u r n a l P r e -p r o o f whom treated with CHOP alone) (Weigert et al., 2009; Orciuolo et al., 2010; Agathocleous et al., 2010; Furtado et al., 2015; Kouroukis et al., 2011; Lamm et al., 2011; Friederberg et al., 2011) .", "cite_spans": [{"start": 167, "end": 190, "text": "(Orlowski et al., 2002)", "ref_id": "BIBREF413"}, {"start": 442, "end": 464, "text": "(Weigert et al., 2009;", "ref_id": "BIBREF797"}, {"start": 465, "end": 487, "text": "Orciuolo et al., 2010;", "ref_id": "BIBREF407"}, {"start": 488, "end": 514, "text": "Agathocleous et al., 2010;", "ref_id": null}, {"start": 515, "end": 536, "text": "Furtado et al., 2015;", "ref_id": null}, {"start": 537, "end": 560, "text": "Kouroukis et al., 2011;", "ref_id": null}, {"start": 561, "end": 579, "text": "Lamm et al., 2011;", "ref_id": null}, {"start": 580, "end": 605, "text": "Friederberg et al., 2011)", "ref_id": null}], "ref_spans": [], "section": "First-generation of proteasome inhibitors: bortezomib"}, {"text": "Bortezomib as single agent was tested also in previously untreated MCL, demonstrating clinical activity (Belch et al., 2007; . However, more promising results were obtained when bortezomib was combined with rituximab-CHOP (R-CHOP), as demonstrated by: (i)", "cite_spans": [{"start": 104, "end": 124, "text": "(Belch et al., 2007;", "ref_id": null}], "ref_spans": [], "section": "First-generation of proteasome inhibitors: bortezomib"}, {"text": "phase 1/2 studies on previously untreated patients with MCL (Ruan et al., 2011; Till et al., 2016; Vos et al., 2017) ; (ii) a phase 2 study on patients with newly diagnosed MCL, who received also bortezomib as maintenance therapy (Ruan et al., 2011; Till et al., 2016) . These trials demonstrated that the combination of R-CHOP with bortezomib followed by bortezomib maintenance improves PFS, as compared with R-CHOP alone, with acceptable toxicity, suggesting further investigation (Ruan et al., 2011; Till et al., 2016) . In a large, randomized phase 3 trial, 487 patients with untreated, newly diagnosed MCL, who were not eligible for transplantation, were randomly assigned to two groups, one receiving R-CHOP and a modified R-CHOP regimen with bortezomib ", "cite_spans": [{"start": 60, "end": 79, "text": "(Ruan et al., 2011;", "ref_id": null}, {"start": 80, "end": 98, "text": "Till et al., 2016;", "ref_id": null}, {"start": 99, "end": 116, "text": "Vos et al., 2017)", "ref_id": null}, {"start": 230, "end": 249, "text": "(Ruan et al., 2011;", "ref_id": null}, {"start": 250, "end": 268, "text": "Till et al., 2016)", "ref_id": null}, {"start": 483, "end": 502, "text": "(Ruan et al., 2011;", "ref_id": null}, {"start": 503, "end": 521, "text": "Till et al., 2016)", "ref_id": null}], "ref_spans": [], "section": "First-generation of proteasome inhibitors: bortezomib"}, {"text": "On the basis of bortezomib success in haematological malignancies, its potential application in the treatment of solid tumours has been explored (Roeten et al., 2017) . A large amount of data has been collected in vitro and in vivo aiming at characterizing the possible activity of bortezomib in different models, such as pancreatic and breast cancers, hepatocellular and anaplastic thyroid carcinoma, with contradictory results (Chen et al., Roeten et al., 2018) .", "cite_spans": [{"start": 145, "end": 166, "text": "(Roeten et al., 2017)", "ref_id": null}, {"start": 443, "end": 463, "text": "Roeten et al., 2018)", "ref_id": "BIBREF532"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "One of the most promising strategy is the combination of bortezomib with radiotherapy, which results in synergistic effects as a consequence of the bortezomib-induced cell accumulation at the Table 1 ), revealing, as for preclinical studies, conflicting results. Due to their poor prognosis, two types of solid tumours have been mainly investigated, namely: (iv) resistance to apoptosis induction, even though the exact role of each one of these mechanisms needs to be further investigated. Interestingly, to overcome the poor penetration of bortezomib in solid tumours, an alternative strategy currently investigated consists in a delivery system based on nanoparticles or micelle formulation, as also studied for other PIs Ao et al., 2015; Coelho et al., 2016) .", "cite_spans": [{"start": 725, "end": 741, "text": "Ao et al., 2015;", "ref_id": null}, {"start": 742, "end": 762, "text": "Coelho et al., 2016)", "ref_id": null}], "ref_spans": [{"start": 192, "end": 199, "text": "Table 1", "ref_id": "TABREF5"}], "section": "J o u r n a l P r e -p r o o f"}, {"text": "The strategy of proteasome activity inhibition and the introduction of bortezomib in clinical practice have dramatically changed the battle against MM, even though it was immediately evident that this J o u r n a l P r e -p r o o f drug suffers from several drawbacks that needed to be overcome. For example, (i) mutation in the \u03b25 subunits, (ii) induction of drug efflux from cells and (iii) activation of signaling cascades promoting cell survival are all resistance mechanisms that have been identified in bortezomibresistant cell lines (Oerlemans et al., 2008; Sherman and Li, 2020) . Therefore, second-generation", "cite_spans": [{"start": 540, "end": 564, "text": "(Oerlemans et al., 2008;", "ref_id": "BIBREF399"}, {"start": 565, "end": 586, "text": "Sherman and Li, 2020)", "ref_id": "BIBREF640"}], "ref_spans": [], "section": "Second-generation of proteasome inhibitors"}, {"text": "PIs have been designed and tested, including carfilzomib, ixazomib, delanozomib, oprozomib and marizomib, whose properties will be discussed in the next sections. Particular emphasis will be given to carfilzomib and ixazomib, which are both FDA-and EMA-approved.", "cite_spans": [], "ref_spans": [], "section": "Second-generation of proteasome inhibitors"}, {"text": "As mentioned in the previous section, two main limitation in the clinical use of bortezomib are (i) the extent of proteasome inhibition and (ii) proteasome recovery after inhibition (Deshaies et al., 2014) . These issues stimulated an intense research, which culminated with the discovery of the natural compound epoxomicin, a covalent and irreversible inhibitor of the \u03b25 subunit (Hanada et al., 1992; Meng et al., 1999; Myung et al., 2001; Deshaies et al., 2014) , which was isolated by an unidentified Actinomycetes strain (see also Section 3.3.1.2). Importantly, epoxomicin owned unprecedented and exceptional selectivity for proteasome with respect to the proteasome inhibitors already available Kim and Crews, 2013) . This high selectivity was supposed to guarantee more physiological tolerability, and a more favourable pharmacological profile than bortezomib. Moreover, the ability to irreversibly bind the \u03b25 subunit implies that the only way to recover proteasome activity is the induction of novel synthesis of functional proteasome particles and dexamethasone as supplemental application for the treatment of patients with MM, who had received one to three prior lines of therapy Stewart et al., 2016) . In this trials, 792 patients with RRMM were randomly assigned in a 1:1 ratio to the carfilzomib group, in which the drug was part of a triple combination therapy with lenalidomide and dexamethasone, or to the lenalidomide plus dexamethasone control group . Carfilzomib was administrated for 18 cycles, at a starting dose of 20 mg/m 2 on the first cycle with subsequent escalation to reach the target dose of 27 mg/m 2 in the following cycles. The addition of carfilzomib significantly increased the median PFS as compared with lenalidomide and dexamethasone alone (26.3 months vs. 17.6 months; HR for progression or death, 0.69; P=0.0001). Furthermore, the J o u r n a l P r e -p r o o f triplet therapy showed a favourable risk-benefit profile and improved the health-related quality of life of RRMM patients Stewart et al., 2016) . Moreover, in 2016 FDA extended carfilzomib approval, in combination with dexamethasone, to patients with RRMM, who had received one to three lines of therapy, on the basis of results of phase 3 randomized, open label, ENDEAVOR study (NCT01568866). In this head-to head comparative study of bortezomib and carfilzomib, 929 patients with RMM were randomly assigned to receive carfilzomib plus low-dose dexamethasone or bortezomib plus low-dose dexamethasone . In this study, carfilzomib regimen was 27 mg/m 2 in the first cycle and 56 mg/m 2 thereafter, infused over 30 minutes, which is the maximum tolerated dose of carfilzomib tested in combination with dexamethasone in phase 1/2 clinical trials (Papadopulos et al., 2015; . The primary endpoint of the trial was PFS that was reported to be longer for the carfilzomib group, as compared to the bortezomib one (18.7 versus 9.4 months, HR=0.53; P<0.0001) . In another interim analysis aimed at comparing the OS between the two PI, it has been shown that patients treated with carfilzomib had a statistically significant and clinically meaningful improvement in OS than those treated with bortezomib ( with RRMM, who had received at least two (but no more than three) prior therapies (including bortezomib and an immunomodulatory drug), were assigned to receive a 30-minute infusion of once-weekly (70 mg/m 2 ) carfilzomib vs a 10-minute infusion of twice-weekly (27 mg/m 2 ). All patients also received the same dose of dexamethasone . The primary endpoint of the trial, PFS, was 11.2 months for the once-weekly regimen versus 7.6 months for the twiceweekly one (HR=0.69; P=0.0014). The ORR in patients treated with the once-weekly regimen was 62.9% versus 40.8 % for those treated with twice-weekly (p<0.0001) Moreau et al., 2020) . Thus, the once-weekly carfilzomib was safe and more effective as compared to the twice weekly schedule.", "cite_spans": [{"start": 182, "end": 205, "text": "(Deshaies et al., 2014)", "ref_id": null}, {"start": 381, "end": 402, "text": "(Hanada et al., 1992;", "ref_id": "BIBREF146"}, {"start": 403, "end": 421, "text": "Meng et al., 1999;", "ref_id": "BIBREF347"}, {"start": 422, "end": 441, "text": "Myung et al., 2001;", "ref_id": "BIBREF383"}, {"start": 442, "end": 464, "text": "Deshaies et al., 2014)", "ref_id": null}, {"start": 701, "end": 721, "text": "Kim and Crews, 2013)", "ref_id": null}, {"start": 1192, "end": 1213, "text": "Stewart et al., 2016)", "ref_id": "BIBREF686"}, {"start": 2026, "end": 2047, "text": "Stewart et al., 2016)", "ref_id": "BIBREF686"}, {"start": 2748, "end": 2774, "text": "(Papadopulos et al., 2015;", "ref_id": null}, {"start": 3811, "end": 3831, "text": "Moreau et al., 2020)", "ref_id": null}], "ref_spans": [], "section": "Carfilzomib"}, {"text": "As mentioned above, early phase 1/2 trials suggested that carfilzomib in combination with other agents, such as melphalan and prednisone (Moreaue et al., 2015), lenalidomide and low-dose dexamethasone (Jakubowiak et al., 2013) , or thalidomide and low-dose dexamethasone (Wester et al., 2019) , could be a therapeutic opportunity also for NDMM patients, although the outcomes and the related adverse events are still not convincing. Carfilzomib seems to have a distinct pattern of adverse effects with respect to bortezomib. In fact, the rate of peripheral neuropathy is lower than J o u r n a l P r e -p r o o f for bortezomib, whereas some patients are affected by cardiovascular complication, such as hypertension and heart failure, rendering the ecocardiography assessment advisable before the onset of treatment. Additionally, unlike bortezomib, carfilzomib can lead to renal failure Chari et al., 2014; Korde et al., 2015; Manasanch and Orlowski, 2017) . Adverse events in common with bortezomib are fatigue, anemia, nausea and thrombocytopenia .", "cite_spans": [{"start": 201, "end": 226, "text": "(Jakubowiak et al., 2013)", "ref_id": "BIBREF187"}, {"start": 271, "end": 292, "text": "(Wester et al., 2019)", "ref_id": "BIBREF803"}, {"start": 889, "end": 908, "text": "Chari et al., 2014;", "ref_id": null}, {"start": 909, "end": 928, "text": "Korde et al., 2015;", "ref_id": null}, {"start": 929, "end": 958, "text": "Manasanch and Orlowski, 2017)", "ref_id": null}], "ref_spans": [], "section": "Carfilzomib"}, {"text": "Currently, a great number of clinical studies on carfilzomib are listed in clinical trial.com. Besides MM, carfilzomib is evaluated in clinical trials for solid tumours, including lung, refractory renal, and metastatic prostate cancers (Table 2 ). However, like bortezomib, its therapeutic potential is limited by the low distribution within the tumour mass, thus requiring very high and toxic doses to elicit a response (Huang et al., 2014; Grigoreva et al., 2015; Johnson, 2015) . Quach et al., 2017) . This is of particular relevance, taking into account that renal insufficiency is a common and often severe complication occurring in MM patients.", "cite_spans": [{"start": 421, "end": 441, "text": "(Huang et al., 2014;", "ref_id": null}, {"start": 442, "end": 465, "text": "Grigoreva et al., 2015;", "ref_id": "BIBREF116"}, {"start": 466, "end": 480, "text": "Johnson, 2015)", "ref_id": "BIBREF198"}, {"start": 483, "end": 502, "text": "Quach et al., 2017)", "ref_id": "BIBREF476"}], "ref_spans": [{"start": 236, "end": 244, "text": "(Table 2", "ref_id": "TABREF6"}], "section": "Carfilzomib"}, {"text": "Both bortezomib and carfilzomib require parental administration, and are associated to the development of specific toxic effects (see Sections 3.3.1.1 and 3.3.2.1a), mainly peripheral neuropathy and cardiovascular adverse events (carfilzomib) Dimopoulus et al., 2011; Richardsone et al., 2012; Dimopoulos et al., 2017; Waxman et al., 2018) . In fact, although the weekly dosing and subcutaneous administration of bortezomib have attenuated the risk of peripheral neuropathy with bortezomib, this adverse effect is still an important concern. Moreover, bortezomib has a limited tissue distribution, due to its slow dissociation rate from red blood cells. Thus, development of an orally available PIs with improved pharmacokinetics properties and better tolerability profile was required (Gupta et al., 2019) . Accordingly, ixazomib J o u r n a l P r e -p r o o f (Ninlaro) represents the first orally administered PI approved for clinical use by FDA and EMA.", "cite_spans": [{"start": 243, "end": 267, "text": "Dimopoulus et al., 2011;", "ref_id": null}, {"start": 268, "end": 293, "text": "Richardsone et al., 2012;", "ref_id": null}, {"start": 294, "end": 318, "text": "Dimopoulos et al., 2017;", "ref_id": "BIBREF235"}, {"start": 319, "end": 339, "text": "Waxman et al., 2018)", "ref_id": "BIBREF795"}, {"start": 786, "end": 806, "text": "(Gupta et al., 2019)", "ref_id": null}], "ref_spans": [], "section": "Ixazomib"}, {"text": "This agent is a reversible inhibitor that preferentially binds the \u03b25 site of the 20S proteasome. In vitro and in vivo preclinical studies reported for ixazomib a therapeutic efficacy greater than for bortezomib in different cancer models, including MM, as well as improved pharmacokinetics, pharmacodynamics, and antitumour activity in xenograft models. In particular, in MM xenograft models, mice treated with ixazomib presented a significant longer survival time than those treated with bortezomib (Chauhan et al., 2005; Kupperman et al., 2010; Chauhan et al., 2011; . In addition, ixazomib induced apoptosis in MM cells resistant to bortezomib without affecting the viability of normal cells, suggesting a potential efficacy in patients with disease relapse after treatment with bortezomib-containing regimens (Chauhan et al., 2011) . Therefore, based on the encouraging results observed in these preclincal studies, together with its more convenient oral administration, ixazomib rapidly advanced in phase 1 clinical trials on RRMM to evaluate its safety and tolerability, as single-agent administered once-weekly (NCT00963820) or twice-weekly (NCT00932698) (Kumar et al., 2014 a; . In the once-weekly dosing study, the maximum tolerated dose was determined to be 2.97 mg/m 2 , whereas in the twiceweekly dosing was 2 mg/m 2 . Overall, ixazomib was generally well tolerated; no severe neuropathy was reported and most of the observed toxicities were manageable. These studies also indicated that ixazomib absorption is rapid, with a maximum plasma concentration at approximatively 1 h postdose. After multiple dosing, the terminal half-life was 3.3-7.4 days and 3.6-11.3 days in the onceweekly and twice-weekly regimes, respectively. The ORR were 18% and 15% for one weekly and twice-weekly treatments, respectively, supporting the use of both schedules (Kumar et al., 2014 a; . The efficacy of ixazomib as a single agent (5.5 mg/m 2 weekly for 3-4 weeks) was confirmed in the first part of a phase 2 trial recruiting 33 patients with relapsed MM who were PI na\u00efve or previously exposed to bortezomib but were not refractory to this agent (NCT01415882) (Kumar et al., 2015) . Moreover, in a second phase of this trial the efficacy and tolerability of ixazomib were evaluated in combination with dexamethasone in patients showing lack of adequate response or disease progression. The ORR was 34% and the main toxic effects observed were nausea, thrombocytopenia and fatigue that were in line with the ixazomib toxicity profile (Kumar et al., 2015) . The efficacy of the ixazomib (weekly doses of 4 or 5.5 mg/m 2 ) and", "cite_spans": [{"start": 501, "end": 523, "text": "(Chauhan et al., 2005;", "ref_id": null}, {"start": 524, "end": 547, "text": "Kupperman et al., 2010;", "ref_id": "BIBREF246"}, {"start": 548, "end": 569, "text": "Chauhan et al., 2011;", "ref_id": "BIBREF467"}, {"start": 814, "end": 836, "text": "(Chauhan et al., 2011)", "ref_id": "BIBREF467"}, {"start": 1163, "end": 1185, "text": "(Kumar et al., 2014 a;", "ref_id": null}, {"start": 1859, "end": 1881, "text": "(Kumar et al., 2014 a;", "ref_id": null}, {"start": 2158, "end": 2178, "text": "(Kumar et al., 2015)", "ref_id": "BIBREF237"}, {"start": 2531, "end": 2551, "text": "(Kumar et al., 2015)", "ref_id": "BIBREF237"}], "ref_spans": [], "section": "Ixazomib"}, {"text": "dexamethasone combination was further investigated in another phase 2 trial recruiting patients with MM that had relapsed after at least 1 previous therapy but not refractory to bortezomib. The results of this study revealed that the ixazomib-dexamethasone doublet had promising efficacy and acceptable tolerability (ORR = 31% and 51% with 4.0 mg and 5.5 mg, respectively). However, the J o u r n a l P r e -p r o o f combination with the higher dose of ixazomib was more toxic albeit, indicating the potential requirement of dose reductions to attenuate adverse effects .", "cite_spans": [], "ref_spans": [], "section": "Ixazomib"}, {"text": "In preclinical studies ixazomib was shown to exert synergistic effects with lenalidomide, and the results of these studies provided the rationale for the clinical testing of the PI with lenalidomide plus desamethasone (Chauhan et al., 2010) . The clinical efficacy and manageability of adverse events reported in early trials , were confirmed in the phase 3, randomized, double-blind, placebo-controlled TOURMALINE-MM1 trial (NCT01564537), whose results led to FDA (2015) and EMA (2016) approval of the triplet regimen combining ixazomib with lenalidomide and dexamethasone in MM patients, who had received at least one prior therapy . In this trial, 722 patients, who had RMM or RRMM, were randomly assigned to receive ixazomib plus lenalidomide-dexamethasone (ixazomib group) or placebo plus lenalidomide-dexamethasone (placebo group). Interim results demonstrated that the addition of ixazomib significantly prolonged PFS compared to the control group (median 20.6 vs. 14.7 months; HR= 0.74; P=0.01). Importantly, a benefit in terms of PFS was observed with ixazomib regimen in all patient subgroups, including subjects with high-risk cytogenetic abnormalities (del(17p), t(4;14), and/or t(14;16)), who are known to be burdened by a very severe prognosis Avet-Loiseau et al., 2016) . An arm of the TOURMALINE-MM1 trial also included patients previously treated with prior PI therapy and prior thalidomide/ lenalidomide combination therapy;", "cite_spans": [{"start": 218, "end": 240, "text": "(Chauhan et al., 2010)", "ref_id": "BIBREF654"}, {"start": 461, "end": 471, "text": "FDA (2015)", "ref_id": null}, {"start": 1258, "end": 1284, "text": "Avet-Loiseau et al., 2016)", "ref_id": null}], "ref_spans": [], "section": "Ixazomib"}, {"text": "results demonstrated a substantial clinical benefit in terms of prolonged PFS with the ixazomiblenalidomide/dexamethasone triplet regardless of prior administered therapy . , 2017) . Importantly, the combination of ixazomib with the lenalidomidedexamethasone regimen was associated with a limited additional toxicity, and had no adverse impact on patient-reported quality of life. Commonly reported grade \u22653 adverse events with ixazomib include gastrointestinal symptoms, rash, thrombocytopenia, and arrhythmia Hou et al., 2017; Leleu et al., 2018; Hari et al., 2018) . For what concerns the peripheral", "cite_spans": [{"start": 173, "end": 180, "text": ", 2017)", "ref_id": null}, {"start": 511, "end": 528, "text": "Hou et al., 2017;", "ref_id": null}, {"start": 529, "end": 548, "text": "Leleu et al., 2018;", "ref_id": "BIBREF281"}, {"start": 549, "end": 567, "text": "Hari et al., 2018)", "ref_id": "BIBREF155"}], "ref_spans": [], "section": "Ixazomib"}, {"text": "The triplet regimen ixazomib-lenalidomide-dexamethasone followed, when feasible, by singleagent ixazomib as maintenance therapy, was investigated also in patients with NDMM in different trials. In in a phase 1/2 study (NCT01217957), the combination therapy was well tolerated and associated with high ORR (92%) (Kumar et al., 2014) . Furthermore, analysis of the long-term efficacy and safety of this regimen, confirmed that ixazomib-lenalidomide-dexamethasone followed by ixazomib maintenance was highly active and caused manageable toxicity in this clinical setting.", "cite_spans": [{"start": 311, "end": 331, "text": "(Kumar et al., 2014)", "ref_id": null}], "ref_spans": [], "section": "Ixazomib"}, {"text": "In particular, out of 65 enrolled patients, 23 patients discontinued induction for SCT, whereas in the remaining 42 patients, the ORR was 80%, including 63% very good partial response and 32% complete responses; these data underscore the feasibility of long-term maintenance treatment with single-agent ixazomib . Furthermore, in NDMM patients, a phase 1/2 doseescalation study investigated the all-oral ixazomib-melphalan-prednisone regimen, followed by single-agent ixazomib maintenance, in transplant ineligible patients with encouraging results (San-Miguel et al., 2018) . Recently, the TOURMALINE-MM3 trial (NCT02181413) investigated the ixazomib suitability versus placebo as a maintenance therapy in NDMM to delay disease progression and prolong patients' survival following ASCT. The results of this study revealed that ixazomib induced a 28% reduction in the risk of progression or death compared to placebo (median PFS 26.5 months vs 21.3 months; HR= 0.72; P=0.0023), thus representing an additional therapeutic option for these patients . Promising results come also from an ongoing phase 3 trial where ixazomib is administered in patients with RMM as post-ASCT maintenance strategy (Striha et al., 2018) .", "cite_spans": [{"start": 549, "end": 574, "text": "(San-Miguel et al., 2018)", "ref_id": null}, {"start": 1194, "end": 1215, "text": "(Striha et al., 2018)", "ref_id": "BIBREF689"}], "ref_spans": [], "section": "Ixazomib"}, {"text": "Several studies are currently investigating the activity of ixazomib in patients with immunoglobulin light chain (AL) amyloidosis, Waldestrom Macroglobulinemia, bone plasmocytome and other nonhaematological malignancies (Smith et al., 2015; Smolewski and Rydygier, 2019; clinical trials.gov) . Until now the best results were obtained in a phase 1/2 study which evaluated the safety, tolerability, and preliminary efficacy of ixazomib in patients with relapsed/refractory AL amyloidosis, paving the road to a phase 3 study which is currently ongoing (NCT01659658) (Sanchorawala et al., 2017; Smolewski and Rydygier, 2019) .", "cite_spans": [{"start": 220, "end": 240, "text": "(Smith et al., 2015;", "ref_id": "BIBREF662"}, {"start": 241, "end": 270, "text": "Smolewski and Rydygier, 2019;", "ref_id": "BIBREF672"}, {"start": 271, "end": 291, "text": "clinical trials.gov)", "ref_id": null}, {"start": 564, "end": 591, "text": "(Sanchorawala et al., 2017;", "ref_id": "BIBREF571"}, {"start": 592, "end": 621, "text": "Smolewski and Rydygier, 2019)", "ref_id": "BIBREF672"}], "ref_spans": [], "section": "Ixazomib"}, {"text": "Using all collected clinical data, ixazomib pharmacokinetics was characterized by an absolute oral bioavailability of 58%, terminal long half-life of 9.5 days, large distribution volume of 543 L, and systemic clearance of approximately 1.86 L/h Park et al., 2018; . The faster dissociation rate of ixazomib compared to bortezomib, which allows it to associate and dissociate consecutively with more than one proteasome particle, likely contributes to the improved drug distribution into tissues (Kupperman et al., 2010) . Moreover, it has been shown J o u r n a l P r e -p r o o f that plasma exposure increases linearly with higher administered dose, and no dose adjustment is required on the basis of race, age, sex, body weight, mild-moderate renal impairment, and mild hepatic impairment Gupta et al., 2016; Gupta et al., 2019) . At clinical doses, ixazomib is mainly metabolized by non-CYP enzymes; in fact, no significant effect on its pharmacokinetics has been reported after the concomitant administration of CYP3A inhibitors, such as ketoconazole and clarithromycin, in patients with advanced solid tumours and lymphoma (NCT01454076) . However, the concomitant administration of the CYP3A-inducer rifampin causes a clinically relevant reduction in ixazomib activity, supporting the advice to avoid this combined treatment schedule, and underlying the complexity of ixazomib metabolism Gupta et al., 2019) . In all clinical trials so far described, ixazomib was administered on an empty stomach (Gupta et al., 2019) . However, since the absorption and metabolism of an oral drug can change with food, according to the US regulatory guidance (Singh et al., 2004 ; United States Food and Drug Administration), a phase 1 study in adult patients with advanced solid tumours or lymphoma was carried out to evaluate whether pharmacokinetics of ixazomib might be altered when administered after a high-calorie, high-fat meal (Gupta et al., 2016; Gupta et al., 2019) . Currently, 139 clinical studies on ixazomib are reported in clincaltrials.gov, also including the studies on solid tumors ( Table 2 ). The results of this study showed that a high-fat meal reduces the rate and extent of absorption of ixazomib, supporting its administration on empty stomach, at least 1 hour before or at least 2 hours after food intake. These recommendations are inserted in the ixazomib prescribing information (Gupta et al., 2016; Gupta et al., 2019) .", "cite_spans": [{"start": 245, "end": 263, "text": "Park et al., 2018;", "ref_id": "BIBREF441"}, {"start": 495, "end": 519, "text": "(Kupperman et al., 2010)", "ref_id": "BIBREF246"}, {"start": 792, "end": 811, "text": "Gupta et al., 2016;", "ref_id": "BIBREF130"}, {"start": 812, "end": 831, "text": "Gupta et al., 2019)", "ref_id": null}, {"start": 1394, "end": 1413, "text": "Gupta et al., 2019)", "ref_id": null}, {"start": 1503, "end": 1523, "text": "(Gupta et al., 2019)", "ref_id": null}, {"start": 1649, "end": 1668, "text": "(Singh et al., 2004", "ref_id": "BIBREF655"}, {"start": 1926, "end": 1946, "text": "(Gupta et al., 2016;", "ref_id": "BIBREF130"}, {"start": 1947, "end": 1966, "text": "Gupta et al., 2019)", "ref_id": null}, {"start": 2398, "end": 2418, "text": "(Gupta et al., 2016;", "ref_id": "BIBREF130"}, {"start": 2419, "end": 2438, "text": "Gupta et al., 2019)", "ref_id": null}], "ref_spans": [{"start": 2093, "end": 2100, "text": "Table 2", "ref_id": "TABREF6"}], "section": "Ixazomib"}, {"text": "To overcome the clinical limitations of FDA/EMA approved PIs, a number of novel compounds have been identified over the last years. However, the only three drugs currently under evaluation in clinical trials are: oprozomib (PER-047 and ONX 0912); marizomib (NPI-0052, salinosporamide A) and delanzomib (CEP-18770) ( Table 3) .", "cite_spans": [], "ref_spans": [{"start": 316, "end": 324, "text": "Table 3)", "ref_id": "TABREF0"}], "section": "Investigational PIs: oprozomib, marizomib and delanzomib"}, {"text": "Oprozomib is an oral drug designed to improve the absorption rate, dosing flexibility, and to overcome two established bortezomib-resistance mechanisms, such as mutations in the proteasome \u03b25 subunit, and drug efflux mediated by ATP-binding cassette transporters (Zhou et al., 2009; Verbrugge et al., 2012) . Preclinical studies showed that oprozomib has an antitumour activity comparable to that of carfilzomib, stimulating early clinical investigation (Chauhan et al., Park et al., 2018) . Some phase 1b/2 trials have evaluated oprozomib efficacy and safety profile as The pharmacokinetic profile of oprozomib was first investigated in preclinical models: the drug was rapidly absorbed (2-3 minutes) in duodenum and jejunum with an estimated absolute oral bioavailability of approximately 39% (Zhou et al., 2009; Park et al., 2018) . Moreover, phase I studies revealed a plasma half-life of about 1 h and a clearance that exceeded the hepatic blood flow, indicating extra-hepatic contribution to its metabolism. Accordingly, the epoxide hydrolase, which seems to be the primary enzyme involved in oprozomib metabolism, is expressed in many other tissues beyond the liver (Fang et al., 2015; . Therefore, though developed to J o u r n a l P r e -p r o o f improve carfilzomib pharmacokinetics properties, oprozomib still displays a high systemic clearance and a short half-life Fang et al., 2015) .", "cite_spans": [{"start": 263, "end": 282, "text": "(Zhou et al., 2009;", "ref_id": null}, {"start": 283, "end": 306, "text": "Verbrugge et al., 2012)", "ref_id": "BIBREF762"}, {"start": 471, "end": 489, "text": "Park et al., 2018)", "ref_id": "BIBREF441"}, {"start": 795, "end": 814, "text": "(Zhou et al., 2009;", "ref_id": null}, {"start": 815, "end": 833, "text": "Park et al., 2018)", "ref_id": "BIBREF441"}, {"start": 1173, "end": 1192, "text": "(Fang et al., 2015;", "ref_id": null}, {"start": 1379, "end": 1397, "text": "Fang et al., 2015)", "ref_id": null}], "ref_spans": [], "section": "Investigational PIs: oprozomib, marizomib and delanzomib"}, {"text": "Marizomib is different from the structural point of view with respect to other PIs, and this translates into a different mechanism of proteasome inhibition, efficacy and toxicity profile (Gozzetti et al., 2017) . In vitro and in vivo studies demonstrated that marizomib induces apoptosis in MM and other haematological and solid malignancies with a lower toxicity compared to bortezomib (Ruiz et al., 2006; Pott et al., 2011) . Importantly, marizomib induced apoptosis even in tumour cells from MM patients relapsing after various prior therapies including bortezomib and/or thalidomide (Pott et al., 2011; Chauhan et al., 2005; Singh et al., 2010) . Early phase clinical trials testing different treatment schedules of the PI as single agent in patients with advanced malignancies, reported marizomib activity mainly in patients with RRMM. Remarkably, marizomib did not exhibit severe peripheral neuropathy, warranting further evaluation Levin et al., 2016) . The most important adverse events observed in the phase 1 trials were fatigue, nausea, diarrhoea, and infusion site pain . In accordance with preclinical models in which marizomib was found to synergistically act with immunomodulatory agents (Chauhan et al., Das et al., 2015) , a phase 1 clinical trial demonstrated that the triplet combination of marizomib, pomalidomide and low-dose dexamethasone was well tolerated and endowed with promising activity in heavily pretreated, high-risk RRMM patients, without increasing the incidence of adverse events . As mentioned in previous sections, PIs are relatively ineffective in treating solid tumours (Dou & Zonder, 2014) . Thanks to its more lipophilic structure, an additional differential feature of marizomib compared to other PIs is the ability to cross the blood brain barrier in different species.", "cite_spans": [{"start": 187, "end": 210, "text": "(Gozzetti et al., 2017)", "ref_id": "BIBREF112"}, {"start": 387, "end": 406, "text": "(Ruiz et al., 2006;", "ref_id": "BIBREF551"}, {"start": 407, "end": 425, "text": "Pott et al., 2011)", "ref_id": null}, {"start": 587, "end": 606, "text": "(Pott et al., 2011;", "ref_id": null}, {"start": 607, "end": 628, "text": "Chauhan et al., 2005;", "ref_id": null}, {"start": 629, "end": 648, "text": "Singh et al., 2010)", "ref_id": "BIBREF654"}, {"start": 939, "end": 958, "text": "Levin et al., 2016)", "ref_id": "BIBREF283"}, {"start": 1220, "end": 1237, "text": "Das et al., 2015)", "ref_id": null}, {"start": 1609, "end": 1629, "text": "(Dou & Zonder, 2014)", "ref_id": null}], "ref_spans": [], "section": "Investigational PIs: oprozomib, marizomib and delanzomib"}, {"text": "Accordingly, preclinical studies demonstrated that oral administration of marizomib inhibits proteasome activity in the brain, and displays a greater activity than bortezomib in a range of solid tumour xenograft models (Pott et al., 2011; Shabaneh et al., 2013; Di et al., 2016) . In fact, marizomib was found to induce apoptosis in glioma cells, with minimal toxic effect on normal neurons Manton et al., 2016) . Based on these studies, this PI is currently evaluated in a clinical trial (NCT03345095) for treating newly diagnosed glioblastoma, the most common aggressive malignant primary brain tumour in adults, having a median survival of about 12 months, after debulking surgery and radiotherapy (Weller et al., 2019) .", "cite_spans": [{"start": 219, "end": 238, "text": "(Pott et al., 2011;", "ref_id": null}, {"start": 239, "end": 261, "text": "Shabaneh et al., 2013;", "ref_id": "BIBREF620"}, {"start": 262, "end": 278, "text": "Di et al., 2016)", "ref_id": "BIBREF66"}, {"start": 391, "end": 411, "text": "Manton et al., 2016)", "ref_id": "BIBREF319"}, {"start": 701, "end": 722, "text": "(Weller et al., 2019)", "ref_id": "BIBREF801"}], "ref_spans": [], "section": "Investigational PIs: oprozomib, marizomib and delanzomib"}, {"text": "The pharmacokinetics profile of intravenously administered marizomib was investigated in a phase 1 clinical trial on patients with advanced solid malignancies, indicating a short half-life (lower than 30 minutes), rapid clearance (0.9-22 L/min), and a large volume of distribution (15-416 L) . Although the involvement of extra-hepatic clearance in the overall J o u r n a l P r e -p r o o f Journal Pre-proof marizomib elimination has been proposed, detailed studies on excretion, metabolism, and in general pharmacokinetics-pharmacodinamic profiles are not available (Pott et al., 2011; Harrison et al. 2016; Park et al., 2018) .", "cite_spans": [{"start": 569, "end": 588, "text": "(Pott et al., 2011;", "ref_id": null}, {"start": 589, "end": 610, "text": "Harrison et al. 2016;", "ref_id": "BIBREF160"}, {"start": 611, "end": 629, "text": "Park et al., 2018)", "ref_id": "BIBREF441"}], "ref_spans": [], "section": "Investigational PIs: oprozomib, marizomib and delanzomib"}, {"text": "Delanzomib is an oral PI that in vitro has shown significant activity on MM and a panel of solid tumours. Furthermore, both intravenous and oral administration resulted in complete tumour regression in MM xenograft models, and increased mice survival in a systemic model of human MM (Piva et al., 2008) . Moreover, administration of delanzomib in combination with other conventional anti-MM therapies, such as melphalan plus bortezomib and dexamethasone plus lenalidomide, was more effective than treatment with either agent alone (Sanchez et al., 2010; Sanchez et al., 2012) . Nevertheless, the results of early phase trials were not so encouraging (Gallerani et al., 2013; Vogl et al., 2017) . In a phase 1 trial, delanzomib showed a linear plasma pharmacokinetics profile, lack of peripheral neuropathy, but a very high incidence of severe skin toxicity in 53% of patients (Gallerani et al., 2013) . In a second multicentre phase 1/2 study delanzomib as single-agent was investigated in patients with RRMM, but no efficacy was reported, whereas severe adverse events, such as rash and thrombocytopenia were reported. Thus, development of delanzomib for myeloma was discontinued (Vogl et al., 2017) . To date, it is not clear the rationale of different clinical and preclinical investigations (Park et al., 2018) .", "cite_spans": [{"start": 283, "end": 302, "text": "(Piva et al., 2008)", "ref_id": "BIBREF463"}, {"start": 531, "end": 553, "text": "(Sanchez et al., 2010;", "ref_id": "BIBREF567"}, {"start": 554, "end": 575, "text": "Sanchez et al., 2012)", "ref_id": "BIBREF566"}, {"start": 650, "end": 674, "text": "(Gallerani et al., 2013;", "ref_id": "BIBREF85"}, {"start": 675, "end": 693, "text": "Vogl et al., 2017)", "ref_id": "BIBREF780"}, {"start": 876, "end": 900, "text": "(Gallerani et al., 2013)", "ref_id": "BIBREF85"}, {"start": 1181, "end": 1200, "text": "(Vogl et al., 2017)", "ref_id": "BIBREF780"}, {"start": 1295, "end": 1314, "text": "(Park et al., 2018)", "ref_id": "BIBREF441"}], "ref_spans": [], "section": "Investigational PIs: oprozomib, marizomib and delanzomib"}, {"text": "Beside the inhibitors, described in Section 3.3, which switch off directly the enzymatic activity of the proteasome by locking out the active site(s) through a chemical bond with specific residues, new class(es) of molecules is/are emerging, which act(s) instead as a modulator(s) of the proteasome activity rather than directly inhibiting it. Obviously, they are not alternative to other inhibitors, which often inhibit more efficiently the proteasome enzymatic action, but they rather affect the UPS activity in a variable extent and fashion, interfering at a different level, such as the interaction with", "cite_spans": [], "ref_spans": [], "section": "New Concepts for proteasome inhibitors"}, {"text": "Porphyrins are an old class of antitumour agents which is now again at the center of renewed scientific interests for the possible role as multifunctional (antitumoural) drug. They are organic heterocyclic macrocycles with an extended \u03c0 system that on one hand makes them highly hydrophobic and, on the other hand, provides porphyrins with a remarkably high extinction coefficient together with additional photo-physical properties. The latter properties make them wellsuited to accomplish, for example, both clinical phototherapy (PDT) and cancer imaging, rendering them suitable to be employed in a multi-tasking role as theranostic tools (Tsolekile et al.2019 ).", "cite_spans": [{"start": 641, "end": 662, "text": "(Tsolekile et al.2019", "ref_id": null}], "ref_spans": [], "section": "New Concepts for proteasome inhibitors"}, {"text": "Apparently, their poor aqueous solubility might represent a major restriction to their application in proteasome, encouraging to screen the ability of porphyrins to inhibit the proteasome activity.", "cite_spans": [], "ref_spans": [], "section": "New Concepts for proteasome inhibitors"}, {"text": "The first evidence that porphyrins, in particular hemin, could reduce \"the protein degradation ATP dependent\", not yet known as proteasome, dates back to 40 years ago (J.D. Etlinger and A.", "cite_spans": [], "ref_spans": [], "section": "New Concepts for proteasome inhibitors"}, {"text": "J o u r n a l P r e -p r o o f Goldberg, 1980) . Afterwards, many reports showed that hemin effect on ubiquitin-dependent proteolysis is not restricted to erythroid cells but hemin is a negative UPS modulator in all eukaryotic cells (Haas and Rose, 1981; Vierstra and Sullivan, 1988 ).", "cite_spans": [{"start": 31, "end": 46, "text": "Goldberg, 1980)", "ref_id": null}, {"start": 233, "end": 254, "text": "(Haas and Rose, 1981;", "ref_id": "BIBREF137"}, {"start": 255, "end": 282, "text": "Vierstra and Sullivan, 1988", "ref_id": "BIBREF770"}], "ref_spans": [], "section": "New Concepts for proteasome inhibitors"}, {"text": "The first molecular investigation on purified 20S has demonstrated that micromolar amounts of cationic porphyrins inhibit reversibly all three main protease activities of the proteasome (Santoro et al., 2012) . Quite interestingly, porphyrins activity is finely modulated (tuned) both by the nature and reciprocal topology of peripheral substituents and by the stereochemistry of the macrocyclic ring center. Thus, the inhibitory efficiency of the cationic macrocycles increases with the number of positive substituents in the meso position. As far as the porphyrin core is concerned, it is evident from the experimental data that among the various metallo-derivatives, the most active ones are those with no axial ligands, the activity decreasing going from penta-to hexa-coordinated metals. In particular, the naked cationic porphyrins are the most active ones, indicating that the molecule should be flat in order to interact effectively with the proteasome. Interestingly, thanks to their high extinction coefficient these molecules are \"visible inhibitors\", and in this sense they behave as very efficient spectroscopic \"probes\" for UV-Vis stopped-flow kinetic analysis. The latter studies, combined with NMR and computational study, helped in defining the tetra-cationic H 2 T 4 as a competitive inhibitor which binds the gate area on the \u03b1-ring, hindering the substrate access to catalytic chamber .", "cite_spans": [{"start": 186, "end": 208, "text": "(Santoro et al., 2012)", "ref_id": null}], "ref_spans": [], "section": "New Concepts for proteasome inhibitors"}, {"text": "Starting from the first evidence, an accurate kinetic and computational analysis of the surface of the \u03b1-subunit ring revealed then that the positive charges play a critical role in the inhibition of the 20S,", "cite_spans": [], "ref_spans": [], "section": "New Concepts for proteasome inhibitors"}, {"text": "showing that cationic porphyrins may act as tuneable gatekeepers of the 20S (see Fig. 9 in . Indeed, the \u03b1-ring represents a receptor-like region physiologically involved in ionic interactions with canonical RPs; as a matter of fact, the regular arrangement of aminoacidic residues in these surfaces has been found to represent a sort of electrostatic code, exploited by the 19S, and regulating the gating phenomena (see Sections 2.2.1 and 2.3.1). The charges of porphyrins represent the keys able to interfere with this \"electrostatic code\", and, depending on their spatial distribution, a high variety of binding modes and inhibition mechanisms have been observed (Di Dato et al., 2017) . Furthermore, some functional effects, characterized by cooperative phenomena, are the resulting of conformational rearrangements that can reverberate onto the \u03b25 subunit (Arba M, et al., 2018) . Finally, additional binding modes involve interactions with both the \u03b1-and \u03b2-rings regions, acting directly on the \u03b25 catalytic subunit.", "cite_spans": [{"start": 666, "end": 688, "text": "(Di Dato et al., 2017)", "ref_id": null}, {"start": 861, "end": 883, "text": "(Arba M, et al., 2018)", "ref_id": "BIBREF3"}], "ref_spans": [{"start": 81, "end": 87, "text": "Fig. 9", "ref_id": null}], "section": "New Concepts for proteasome inhibitors"}, {"text": "In conclusion, porphyrins are excellent candidates for multi-tasking biological active molecules. As an example, quite recently it was shown (Vallelian et al., 2015) that high levels of intracellular ", "cite_spans": [{"start": 141, "end": 165, "text": "(Vallelian et al., 2015)", "ref_id": null}], "ref_spans": [], "section": "New Concepts for proteasome inhibitors"}, {"text": "The use of metal complexes as anticancer drugs has been adopted since early 1960s with the discovery and development of cisplatin and its derivatives (Alderden et al., 2006) . The first metal complexes used as anticancer agents were designed to interact with the cancerous cell DNA, inducing apoptosis of cancer cells, but it has been also demonstrated that they can alter the cellular redox chemistry through binding of the metal or ligand redox centers to biomolecules involved in cellular redox pathway. Since tumor cells have a more reducing environment than normal cells (due to the accelerated metabolic activity, high rates of cell growth and proliferation), selectivity can be reached by using metal complexes which contain redox active metal ions; these are then reduced in the reducing environment of the cancer cell and metal complex drugs become activated. Therefore, the reduced metal ion (Co 2+ , Pt 2+ , Fe 2+ , Cu + , etc.) exerts its anticancer activity with a marked selectivity for cancer cells, as the unique ability of metal complexes to undergo redox activation processes involves both metal and ligand redox centers and it can be tuned to specific potentials (P. Zhang & Sadler, 2017) . However, the idea of using metal complexes to disrupt proteasome activity in order to have an anticancer effect is relatively recent (Shagufta & Ahmad, 2020) . Disulfiram was the first metal complex containing copper capable of inducing apoptosis in cancer cells by inhibiting proteasome activity (Chen et al., 2006) . It was later demonstrated that disulfiram rapidly converts in vivo to its reduced metabolite diethyldithiocarbamate (DDTC) before exerting its anticancer activity (Pang et al., 2007) . Interestingly, in most cases the presence of the metal ion turned out to be fundamental to have proteasome activity inhibition, since the non-metallated ligand has been demonstrated to be ineffective for this purpose. For example, the asymmetric ligands, containing pyridine and 4,6-substituted phenol moieties alone, do not have any influence on proteasome activity (Shakya et al., 2006) ; conversely, the copper (II) chloride salt of this compound inhibited the proteasome activity in cell free conditions and, for this reason, it has been proposed that the copper complex works as a carrier to cross the cell membrane. Such an assumption would However, elucidating the molecular mechanisms by which copper ions are able to inhibit proteasome activity is a very challenging task, due to the very complex cellular environment and the difficulty in monitoring the fate of intracellular copper ions (Satriano et al., 2013) . Indeed, it has been reported in cell-free conditions that Cu (II) ions promote conformational changes associated to an impaired channel gating, without catalyzing redox reactions nor disrupting the assembly of the 20S proteasome . On the contrary, HeLa cells, grown in a Cu (II)supplemented medium, exhibit a decreased proteasome activity, which was then restored in the presence of an antioxidant. For this reason, it has been proposed that, although the Cu(II)-inhibited 20S activities may be associated to proteasome conformational changes, favoring the closed state of the core particle, other effects may occur, such as ROS-mediated proteasome flooding and disassembly of the 26S proteasome into its 20S and 19S components.", "cite_spans": [{"start": 150, "end": 173, "text": "(Alderden et al., 2006)", "ref_id": null}, {"start": 1186, "end": 1207, "text": "Zhang & Sadler, 2017)", "ref_id": "BIBREF851"}, {"start": 1343, "end": 1367, "text": "(Shagufta & Ahmad, 2020)", "ref_id": "BIBREF622"}, {"start": 1507, "end": 1526, "text": "(Chen et al., 2006)", "ref_id": null}, {"start": 1692, "end": 1711, "text": "(Pang et al., 2007)", "ref_id": "BIBREF430"}, {"start": 2081, "end": 2102, "text": "(Shakya et al., 2006)", "ref_id": "BIBREF626"}, {"start": 2612, "end": 2635, "text": "(Satriano et al., 2013)", "ref_id": "BIBREF589"}], "ref_spans": [], "section": "Metal complexes"}, {"text": "Beside copper, other metal ions have been used in complex with various ligands to inhibit proteasome activity. For example, cadmium, though carcinogenic for humans, has been tested in complex with several organic ligands, such as indole-3-butyric acid and indole-3-propionic acid.", "cite_spans": [], "ref_spans": [], "section": "Metal complexes"}, {"text": "Strikingly, proteasomal inhibition, as well as accumulation of ubiquitinated proteins and induction of apoptosis, were observed in MDA MB 231 breast cancer cells, whereas non-tumourigenic breast MCF10A cells were much less sensitive to the cadmium complexes, indicating cell-specific apoptotic death . Cadmium complexes with heterocycle-L-tryptophan Schiff base ligands such as 2-acetylpyrazine-L-tryptophan, 5-methylfurfural-L-tryptophan and 5-bromo-2thiophenecarbaldehyde-L-tryptophan have also been synthesized and tested for cancer specific proteasome inhibitory and apoptosis inducing activities. Results show that the inhibition of the proteasomal CT-L activity is strongly depending on the ligand; thus, while the Cd complex with 2acetylpyrazine-L-tryptophan and 5-methylfurfural-L-tryptophan were powerful inhibitors, the use of 5-bromo-2-thiophenecarbaldehyde-L-tryptophan as ligand produced an inactive complex (N. .", "cite_spans": [], "ref_spans": [], "section": "Metal complexes"}, {"text": "Manganese and gold complexes have also been investigated for their inhibitory activity on proteasome in cancer. In particular, the cefepime-Mn complex has been demonstrated to inhibit the proteasomal CT-L activity and to induce the apoptosis of breast cancer cells in a dose-and timedependent manner .", "cite_spans": [], "ref_spans": [], "section": "Metal complexes"}, {"text": "Gold(III) and gold(I) dithiocarbamate complexes have also been reported to be strong proteasomal CT-L activity inhibitors with IC 50 values ~ 1.1 \u03bcM. Interestingly, the different oxidation states of the gold ion seem to affect the mechanism of inhibition, as only the higher gold oxidation state has been reported to produce significant levels of reactive oxygen species (X. Zhang et al., 2010) .", "cite_spans": [{"start": 375, "end": 394, "text": "Zhang et al., 2010)", "ref_id": "BIBREF853"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Several additional gold complexes have been reported to have IC 50 in the \u03bcM range towards all three main proteasome catalytic activity, such as mononuclear gold, dinuclear(III) complexes and gold(I) phosphine complexes, whereas aurofin, an established gold(I) drug (currently in clinical use for the treatment of rheumatoid arthritis), has been demonstrated to be completely inactive in the modulation of proteasome activity (Micale et al., 2014) . The gold(III) complex AuL12", "cite_spans": [{"start": 426, "end": 447, "text": "(Micale et al., 2014)", "ref_id": "BIBREF349"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "(dibromo[ethyl-N-(dithiocarboxy-kS,kS')-N-methylglycinate]) has shown attractive properties in terms of anticancer activity and toxicity. AuL12 was found to inhibit proteasome activity in living cells with an efficiency comparable to that of bortezomib (Tomasello et al., 2017) . Furthermore, AuL12 also inhibits Lys48-linked polyubiquitination in vitro at a concentration of about 7 \u00b5M, interfering with Ub activation reactions catalyzed by E1 enzymes. Another approach, based on the use of metal complexes to inhibit the function of the UPS system in cancerous cells, is to target deubiquitinases instead of the proteasome. As an example, nickel, as well as gold(I), pyrithione complexes were tested for their anticancer activity and it was found that both complexes are able to inhibit the UPS by targeting the 19S-associated deubiquitinases without directly affecting proteasome activity Zhao et al., 2016) .", "cite_spans": [{"start": 253, "end": 277, "text": "(Tomasello et al., 2017)", "ref_id": "BIBREF718"}, {"start": 892, "end": 910, "text": "Zhao et al., 2016)", "ref_id": "BIBREF860"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Finally, it is worth mentioning that metal ions, such as copper, have a strong inhibitory effect also on other different enzymes (Grasso et al., 2011 (Grasso et al., , 2012 , which have been found to be associated with the proteasome and to be able to modulate its activity . For this reason, the use of metal complexes to modulate proteasome activity should consider all possible mechanisms and actors involved in the UPS system, including the interaction of the metal complexes with regulatory proteins, such as IDE .", "cite_spans": [{"start": 129, "end": 149, "text": "(Grasso et al., 2011", "ref_id": null}, {"start": 150, "end": 172, "text": "(Grasso et al., , 2012", "ref_id": null}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Although proteins are generally found in the right folded and functional state in healthy cells, unfolded configurations are present, mostly occurring upon exposure to environmental stressors; furthermore, they may originate from multi-faceted alterations in translation, folding and intracellular trafficking. Under physiological conditions, the misfolded variant of proteins are J o u r n a l P r e -p r o o f either: (i) tagged for degradation via UPS or autophagy pathways, or (ii) correctly refolded back to the native state by chaperones, or else (iii) sequestered into intracellular compartments, such as aggresomes, which preserve them for the following refolding or degradation (Hartl et al., 2009; Chen et al., 2011; Escusa-Torret, 2013; Hipp et al., 2014; Sontag et al., 2014; Sweeney et al., 2017) .", "cite_spans": [{"start": 687, "end": 707, "text": "(Hartl et al., 2009;", "ref_id": "BIBREF163"}, {"start": 708, "end": 726, "text": "Chen et al., 2011;", "ref_id": null}, {"start": 727, "end": 747, "text": "Escusa-Torret, 2013;", "ref_id": null}, {"start": 748, "end": 766, "text": "Hipp et al., 2014;", "ref_id": null}, {"start": 767, "end": 787, "text": "Sontag et al., 2014;", "ref_id": "BIBREF679"}, {"start": 788, "end": 809, "text": "Sweeney et al., 2017)", "ref_id": "BIBREF694"}], "ref_spans": [], "section": "Proteasome alteration in neurodegeneration"}, {"text": "Misfolded proteins can aggregate to form high-molecular weight species of different nature, such as soluble oligomers, prefibrillar species and highly ordered amyloid structure, which often consist of different aggregated-prone and normally folded proteins (Olzscha et al., 2011; Hong et al., 2011; Brettschneider et al., 2013; Sweeney et al., 2017; Olzscha et al., 2019) . Although there is compelling evidence that many proteins (if not all) can form amyloid-like structures under stressful conditions, nonetheless disease-associated amyloidogenic proteins are characterized by intrinsic structurally disordered elements in their free soluble form (Guijarro et al., 1998; Tzotzos et al., 2010) . Thus, a common hallmark of neurodegenerative diseases is the accumulation of misfolded protein aggregates into affected tissues, leading to a derangement of PN, and, ultimately, to progressive death of neurons (Bredesen et al., 2006; Goedert, et al., 2010; McAlary et al., 2019) . In Neurons, as well as each post-mitotic cell, are very susceptible to proteostasis unbalance mainly due to their long lifespan, morphology and enhanced metabolism (Tai and Schuman, 2008) . In particular, UPS is crucial in synaptic protein turnover, calcium flux dynamics, long-terminal plasticity and memory (Lopez-Salon et al., 2001; Colledge et al., 2003; Bingol and Schuman, 2004; Bingol, and Schuman, 2006; Fonseca et al, 2006; Guo, and Wang, 2007; Tai and Schuman, 2008; Djakovic et al., 2009; Wu et al., 2009; Djakovic et al., 2012) ; furthermore, besides the intracellular proteasome, a membrane-associated proteasome complex, specific for the nervous system, has been recently discovered (Ramachandran et al., 2017) . This complex seems to be involved in the modulation of neuronal function by degrading intracellular proteins into peptides that are then released into synaptic cleft, where they stimulate postsynaptic N-methyl-D-aspartate neuronal signalling (Ramachandran et al., 2017) . Impaired proteasome activity is reported in idiopathic neurodegenerative diseases, and some hereditary form of neurodegeneration is due to mutations in UPS components, such as PARK1 and PINK (see next paragraphs) (Ciechanover and Brundin, 2003; Ortega et al., 2007; McKinnon and Tabrizi, 2014; Thibaudeau and Smith, 2019) . A wide range of studies support the notion that a decrease of proteasome activity with age positively correlates with misfolded protein accumulation. This culminates then, in the presence of other J o u r n a l P r e -p r o o f pathological stressors at which aged people are exposed, with the progressive development of neurodegeneration Vigouroux et al., 2004; Mattson and Magnus, 2006; Zabel et al., 2010; Tomaru et al., 2012) . Accordingly, targeted proteasome inhibition in brain of animal models of neurodegeneration reproduces some clinical and neuropathological signatures of human diseases (McNaught et al., 2002 , McNaught et al., 2004 Ciechanover and Brundin, 2003; Bedford et al., 2008; Li et al., 2010) . Despite this evidence, it is still unclear whether reduced proteasome functionality is a primary event in neurodegeneration onset or the consequence of misfolded protein aggregation (Dantuma and Bott, 2014; Ciechanover and Brundin, 2003; Ortega et al., 2007; Thibaudeau and Smith, 2019) . Soluble oligomers, which are believed to be the most toxic and pathologically significant species among the different forms of aggregates, have been shown to impair proteasome activity (Cecarini et al, 2008; Tseng et al., 2008; Diaz-Hernandez et al., 2006; Bence et al., 2001; Deriziotis et al., 2011; Dantuma and Bott, 2014) .", "cite_spans": [{"start": 257, "end": 279, "text": "(Olzscha et al., 2011;", "ref_id": "BIBREF405"}, {"start": 280, "end": 298, "text": "Hong et al., 2011;", "ref_id": null}, {"start": 299, "end": 327, "text": "Brettschneider et al., 2013;", "ref_id": null}, {"start": 328, "end": 349, "text": "Sweeney et al., 2017;", "ref_id": "BIBREF694"}, {"start": 350, "end": 371, "text": "Olzscha et al., 2019)", "ref_id": "BIBREF404"}, {"start": 650, "end": 673, "text": "(Guijarro et al., 1998;", "ref_id": "BIBREF128"}, {"start": 674, "end": 695, "text": "Tzotzos et al., 2010)", "ref_id": null}, {"start": 908, "end": 931, "text": "(Bredesen et al., 2006;", "ref_id": "BIBREF29"}, {"start": 932, "end": 954, "text": "Goedert, et al., 2010;", "ref_id": "BIBREF99"}, {"start": 955, "end": 976, "text": "McAlary et al., 2019)", "ref_id": "BIBREF340"}, {"start": 1143, "end": 1166, "text": "(Tai and Schuman, 2008)", "ref_id": "BIBREF696"}, {"start": 1288, "end": 1314, "text": "(Lopez-Salon et al., 2001;", "ref_id": "BIBREF305"}, {"start": 1315, "end": 1337, "text": "Colledge et al., 2003;", "ref_id": null}, {"start": 1338, "end": 1363, "text": "Bingol and Schuman, 2004;", "ref_id": null}, {"start": 1364, "end": 1390, "text": "Bingol, and Schuman, 2006;", "ref_id": null}, {"start": 1391, "end": 1411, "text": "Fonseca et al, 2006;", "ref_id": "BIBREF76"}, {"start": 1412, "end": 1432, "text": "Guo, and Wang, 2007;", "ref_id": "BIBREF129"}, {"start": 1433, "end": 1455, "text": "Tai and Schuman, 2008;", "ref_id": "BIBREF696"}, {"start": 1456, "end": 1478, "text": "Djakovic et al., 2009;", "ref_id": null}, {"start": 1479, "end": 1495, "text": "Wu et al., 2009;", "ref_id": "BIBREF819"}, {"start": 1496, "end": 1518, "text": "Djakovic et al., 2012)", "ref_id": null}, {"start": 1676, "end": 1703, "text": "(Ramachandran et al., 2017)", "ref_id": "BIBREF485"}, {"start": 1948, "end": 1975, "text": "(Ramachandran et al., 2017)", "ref_id": "BIBREF485"}, {"start": 2191, "end": 2222, "text": "(Ciechanover and Brundin, 2003;", "ref_id": "BIBREF46"}, {"start": 2223, "end": 2243, "text": "Ortega et al., 2007;", "ref_id": null}, {"start": 2244, "end": 2271, "text": "McKinnon and Tabrizi, 2014;", "ref_id": "BIBREF342"}, {"start": 2272, "end": 2299, "text": "Thibaudeau and Smith, 2019)", "ref_id": "BIBREF708"}, {"start": 2641, "end": 2664, "text": "Vigouroux et al., 2004;", "ref_id": "BIBREF771"}, {"start": 2665, "end": 2690, "text": "Mattson and Magnus, 2006;", "ref_id": "BIBREF337"}, {"start": 2691, "end": 2710, "text": "Zabel et al., 2010;", "ref_id": null}, {"start": 2711, "end": 2731, "text": "Tomaru et al., 2012)", "ref_id": "BIBREF717"}, {"start": 2901, "end": 2923, "text": "(McNaught et al., 2002", "ref_id": "BIBREF344"}, {"start": 2924, "end": 2947, "text": ", McNaught et al., 2004", "ref_id": "BIBREF345"}, {"start": 2948, "end": 2978, "text": "Ciechanover and Brundin, 2003;", "ref_id": "BIBREF46"}, {"start": 2979, "end": 3000, "text": "Bedford et al., 2008;", "ref_id": null}, {"start": 3001, "end": 3017, "text": "Li et al., 2010)", "ref_id": "BIBREF295"}, {"start": 3202, "end": 3226, "text": "(Dantuma and Bott, 2014;", "ref_id": "BIBREF52"}, {"start": 3227, "end": 3257, "text": "Ciechanover and Brundin, 2003;", "ref_id": "BIBREF46"}, {"start": 3258, "end": 3278, "text": "Ortega et al., 2007;", "ref_id": null}, {"start": 3279, "end": 3306, "text": "Thibaudeau and Smith, 2019)", "ref_id": "BIBREF708"}, {"start": 3494, "end": 3516, "text": "(Cecarini et al, 2008;", "ref_id": "BIBREF25"}, {"start": 3517, "end": 3536, "text": "Tseng et al., 2008;", "ref_id": "BIBREF732"}, {"start": 3537, "end": 3565, "text": "Diaz-Hernandez et al., 2006;", "ref_id": null}, {"start": 3566, "end": 3585, "text": "Bence et al., 2001;", "ref_id": null}, {"start": 3586, "end": 3610, "text": "Deriziotis et al., 2011;", "ref_id": null}, {"start": 3611, "end": 3634, "text": "Dantuma and Bott, 2014)", "ref_id": "BIBREF52"}], "ref_spans": [], "section": "Proteasome alteration in neurodegeneration"}, {"text": "Recently, a common mechanism has been proposed, according to which oligomers of different diseases-related proteins inhibit the 20S proteasome activity through an allosteric-driven interaction (Thibaudeau et al., 2018; . Specifically, the soluble oligomers, which adopt a similar three-dimensional conformation, were reported to bind the 20S, stabilizing the gate in the closed configuration. Oligomers-induced proteasome impairment seems then to be counteracted by HbYX peptides, which mimic the gate physiological opening induced by HbYX motifs of 19S ATPase (see also Section 2.3.2) (Thibaudeau et al., 2018) . Accordingly, \u03b13\u0394n-HEK293 cells exhibit increased degradation of proteasome substrates, including neurodegenerative disease-related proteins (see also Section 2.3.2) (Choi et al., 2016) . These results support the scientific hypothesis that drugs which directly open the 20S gate, might have a relevant therapeutic potential in the management of neurodegenerations (Thibaudeau et al., 2018; Thibaudeau and Smith, 2019; VerPlank et al., 2019) . In this respect, it should be pointed out that the action of porphyrins (see Section 3.4.1) looks very promising (Di Dato et al., 2017) .", "cite_spans": [{"start": 193, "end": 218, "text": "(Thibaudeau et al., 2018;", "ref_id": "BIBREF709"}, {"start": 586, "end": 611, "text": "(Thibaudeau et al., 2018)", "ref_id": "BIBREF709"}, {"start": 779, "end": 798, "text": "(Choi et al., 2016)", "ref_id": "BIBREF39"}, {"start": 978, "end": 1003, "text": "(Thibaudeau et al., 2018;", "ref_id": "BIBREF709"}, {"start": 1004, "end": 1031, "text": "Thibaudeau and Smith, 2019;", "ref_id": "BIBREF708"}, {"start": 1032, "end": 1054, "text": "VerPlank et al., 2019)", "ref_id": "BIBREF768"}, {"start": 1170, "end": 1192, "text": "(Di Dato et al., 2017)", "ref_id": null}], "ref_spans": [], "section": "Proteasome alteration in neurodegeneration"}, {"text": "However, although it was generally accepted that, once formed, amyloid aggregates are resistant to proteasome degradation (Sweeney et al., 2017) , it has been recently reported that proteasome holoenzyme seems to possess a \"fibril-fragmenting activity\", being able to reduce the size of large tau and \u03b1-synuclein fibrils into smaller entities in vitro, thus opening a novel perspective in understanding proteasome role in neurodegeneration (Cliffe et al., 2019; Ye et al., 2020) . In the rest of this chapter, the contribution of proteasome to the onset and progression of main neurodegenerative diseases is reported. Additionally, we will focus on strategies developed so far to enhance proteasome activity.", "cite_spans": [{"start": 122, "end": 144, "text": "(Sweeney et al., 2017)", "ref_id": "BIBREF694"}, {"start": 440, "end": 461, "text": "(Cliffe et al., 2019;", "ref_id": null}, {"start": 462, "end": 478, "text": "Ye et al., 2020)", "ref_id": "BIBREF837"}], "ref_spans": [], "section": "Proteasome alteration in neurodegeneration"}, {"text": "J o u r n a l P r e -p r o o f", "cite_spans": [], "ref_spans": [], "section": "Proteasome alteration in neurodegeneration"}, {"text": "In the late 1901, the German neuropathologist Alois Alzheimer reported about the presence of amyloid plaques and neurofibrillary tangles (NFTs) in the brain of a woman suffering from progressive cognitive decline (Stelzma et al., 1995) . This was the very first paper reporting a case of senile dementia, a neurodegenerative disease that will be later commonly recognized as Alzheimer's Disease (AD). Almost 80 years after this ground-breaking report, protein aggregates present in amyloid senile plaques (i.e. amyloid peptides) (Glenner & Wong, 1984) and NFTs (i.e.", "cite_spans": [{"start": 213, "end": 235, "text": "(Stelzma et al., 1995)", "ref_id": "BIBREF685"}, {"start": 529, "end": 551, "text": "(Glenner & Wong, 1984)", "ref_id": "BIBREF97"}], "ref_spans": [], "section": "Alzheimer's Disease"}, {"text": "hyperphosphorylated tau) (V. M. Lee et al., 1991) were fully characterized. However, only over the last two decades, attention in the area of protein aggregation has increased considerably, transforming it into a key subject of study in diverse research areas ranging from chemistry to biology and medicine. The most important reason for the rising attention in this field is that most of the disorders are associated with amyloid aggregation (Chiti & Dobson, 2006) and neurodegeneration, which are becoming more and more expensive in terms of health care and social cost worldwide (Alzheimer's Disease International, 2010). After an initial enthusiasm in targeting amyloid protein aggregation as a possible therapeutic approach to treat AD, other protective mechanisms associated with properties of the cellular environment, such as the existence of molecular chaperones and degradation mechanisms have attracted increasing attention Morimoto, 2008) . Substantial shreds of evidence point to UPS malfunction as an important factor playing a key role in A\u03b2 amyloid growth and AD pathogenesis. This is not surprising if one bears in mind that UPS surveillance is needed for a tightly regulated maintenance of all proteome components involved in memory formation, as well as synaptic plasticity and functioning (Lopez-Salon et al., 2001; Tai & Schuman, 2008; Djakovic et al., 2012) .", "cite_spans": [{"start": 32, "end": 49, "text": "Lee et al., 1991)", "ref_id": "BIBREF269"}, {"start": 443, "end": 465, "text": "(Chiti & Dobson, 2006)", "ref_id": "BIBREF36"}, {"start": 935, "end": 950, "text": "Morimoto, 2008)", "ref_id": "BIBREF367"}, {"start": 1309, "end": 1335, "text": "(Lopez-Salon et al., 2001;", "ref_id": "BIBREF305"}, {"start": 1336, "end": 1356, "text": "Tai & Schuman, 2008;", "ref_id": "BIBREF696"}, {"start": 1357, "end": 1379, "text": "Djakovic et al., 2012)", "ref_id": null}], "ref_spans": [], "section": "Alzheimer's Disease"}, {"text": "However, a deeper understanding of all components of the proteome quality control network is needed to allow us to envisage a successful regulation of all pathogenic pathways. As an example, it is critical to single out all the key components of the UPS, including the upstream processes, involved in AD pathogenesis to allow the design of small molecules with higher efficiency and less severe side effects (Cao et al., 2019) . In particular proteasome function (if compared to agematched controls) declines in AD brains, whereas other proteasome isoforms, such as immunoproteasome, are overexpressed in astrocytes (Keller et al., 2000; Nijholt et al., 2011) . As a matter of fact, several studies underscored that immunoproteasome is upregulated in glial cells surrounding A\u03b2 plaques present in affected brains (Yeo et al., 2019) . The same work reported that YU102, a specific PI, abolished the production of inflammation cytokines from glial cells and J o u r n a l P r e -p r o o f improved cognitive performance in AD mice without any evident effect on A\u03b2 plaques deposition.", "cite_spans": [{"start": 408, "end": 426, "text": "(Cao et al., 2019)", "ref_id": null}, {"start": 616, "end": 637, "text": "(Keller et al., 2000;", "ref_id": "BIBREF218"}, {"start": 638, "end": 659, "text": "Nijholt et al., 2011)", "ref_id": "BIBREF389"}, {"start": 813, "end": 831, "text": "(Yeo et al., 2019)", "ref_id": "BIBREF838"}], "ref_spans": [], "section": "Alzheimer's Disease"}, {"text": "Hence, the proteasome is now emerging as a major target in the treatment of memory loss and cognitive impairment in AD. (Hegde et al., 2019; Al Mamun et al., 2020) . A very recent study, involving 48 AD patients and 50 healthy volunteers, has clearly shown that proteasome levels are significantly decreased in erythrocytes of patients affected by AD. Moreover, the same study revealed that ubiquitin is overexpressed in red blood cells of AD individuals, thus suggesting that (i) the UPS is heavily involved in the pathogenesis of the disease and (ii) both Ub and proteasome may be investigated as AD biomarkers (Lv et al., 2020) . The role of proteasome inactivation in AD development, was addressed in vivo by studies using transgenic mice. In particular, APPswe/PS1de9 AD mice were crossed with mice expressing a green fluorescent protein (GFP) fused to a degradation signal (CL-1) targeted by the proteasome; these studies revealed that GFP protein-linked proteasome substrates build up in the hippocampus and cortex of AD mice at 4 weeks of age, and they were also confirmed by a concomitant accumulation of p53, an endogenous proteasome substrate, and of poly-ubiquitinated proteins. Altogether, these results suggest that the proteasome function is altered in AD mice even at a very young age, well before cognitive impairment and amyloid fibril deposition (Liu et al., 2014) .", "cite_spans": [{"start": 120, "end": 140, "text": "(Hegde et al., 2019;", "ref_id": "BIBREF168"}, {"start": 141, "end": 163, "text": "Al Mamun et al., 2020)", "ref_id": null}, {"start": 613, "end": 630, "text": "(Lv et al., 2020)", "ref_id": "BIBREF313"}, {"start": 1365, "end": 1383, "text": "(Liu et al., 2014)", "ref_id": "BIBREF509"}], "ref_spans": [], "section": "Alzheimer's Disease"}, {"text": "Although it is known that A\u03b2 is a proteasome substrate, it may also, in turn, inhibit 20S peptidase activity; in this respect, scanning transmission electron microscopy ( Hyperphosphorylated tau oligomers build up at synaptic and postsynaptic junctions in AD, and tau insoluble assemblies inhibit proteasome activity, leading to an accumulation of poly-ubiquitinated proteins (Myeku et al., 2016) . It has also been shown that CHIP (C-terminus of Hsp70-interacting proteins) E3 ligase, is overexpressed in AD patients and its downregulation brings out the accumulation of ubiquitinated tau proteins (Dickey et al., 2007; Petrucelli et al., 2004; Shimura et al., 2004) . Recently, it has been demonstrated that toxic A\u03b2 oligomeric assemblies may bind proteasome, impairing its activity by interfering with gating phenomena. Moreover, as mentioned previously, other different proteins (e.g., \u03b1-synuclein and huntingtin), known to selfassemble into similar 3D structures, have the potential to inhibit 20S activity by a similar J o u r n a l P r e -p r o o f mechanism, thus pointing to a general oligomer-driven model of proteasome inhibition (Thibaudeau et al., 2018) . Notably, clearance of full-length monomeric tau was ATP-independent, whereas on the contrary, fibrillar tau hydrolysis was strictly related to the ATPase activity of the proteasome Besides A\u03b2/tau aggregation in toxic oligomers, other causes are known to come into play for proteasome impairment in AD, including abnormal generation of ROS (de Vrij et al., 2004) . Indeed, high intracellular levels of the redox-active metal ions Cu(II) are known to be associated to both A\u03b2 and tau pathologies, even though it is known that only Cu(I) is internalized into the cells by the plasma transporter Ctr1 (Maryon et al., 2007) . In this respect, it should be outlined that Cu(II) ions are present at relatively high concentration in the brain and their levels are known to increase with age (Morita et al., 1994; Tarohda et al., 2004) . As a matter of fact, Cu(II) ions are also found in amyloid plaques present in the AD brain (Lovell et al., 1998; Suh et al., 2000) co-purifying with A\u03b2 from AD brain tissues (Opazo et al., 2002) . Intriguingly, several Cu(II) complexes exhibit remarkable proteasome inhibitory capacities (Daniel et al., 2004; Marzano et al., 2009 ). All these findings reconcile with recent reports that demonstrate that Cu ( facilitating the ubiquitination of the \u03b2-secretase and its degradation by the proteasome, leading to a decrease of amyloid A\u03b2 generation; notably, both Fbx2 and Uch-L1 increase synaptic plasticity and memory function in AD mice . It was also reported that UBB +1 , a ubiquitin form arising from a pathogenic mutation in the Ub gene through addiction of 19 residues to the Cterminus of the protein, inhibits proteasome activity and is present in neurofibrillary tangles of AD patients (Fischer et al., 2003) . Proteasome activation by exogenous agents may represent a promising strategy for AD therapy; in fact, feeding wild-type Caenorhabditis elegans with 18\u03b1glycyrrhetinic acid (18\u03b1-GA), a known proteasome activator, resulted in an increased proteasome activities and increased lifespan of worms. Moreover, higher proteasome activity was related to lower paralysis rates in C. elegans AD models. Notably, analogous promising results were confirmed also when murine and human neuronal cells were treated with 18\u03b1-GA (Papaevgeniou et al., 2016) .", "cite_spans": [{"start": 376, "end": 396, "text": "(Myeku et al., 2016)", "ref_id": "BIBREF382"}, {"start": 599, "end": 620, "text": "(Dickey et al., 2007;", "ref_id": "BIBREF69"}, {"start": 621, "end": 645, "text": "Petrucelli et al., 2004;", "ref_id": "BIBREF453"}, {"start": 646, "end": 667, "text": "Shimura et al., 2004)", "ref_id": "BIBREF643"}, {"start": 1141, "end": 1166, "text": "(Thibaudeau et al., 2018)", "ref_id": "BIBREF709"}, {"start": 1508, "end": 1530, "text": "(de Vrij et al., 2004)", "ref_id": null}, {"start": 1766, "end": 1787, "text": "(Maryon et al., 2007)", "ref_id": "BIBREF323"}, {"start": 1952, "end": 1973, "text": "(Morita et al., 1994;", "ref_id": "BIBREF368"}, {"start": 1974, "end": 1995, "text": "Tarohda et al., 2004)", "ref_id": null}, {"start": 2089, "end": 2110, "text": "(Lovell et al., 1998;", "ref_id": null}, {"start": 2111, "end": 2128, "text": "Suh et al., 2000)", "ref_id": "BIBREF690"}, {"start": 2172, "end": 2192, "text": "(Opazo et al., 2002)", "ref_id": "BIBREF406"}, {"start": 2286, "end": 2307, "text": "(Daniel et al., 2004;", "ref_id": "BIBREF51"}, {"start": 2308, "end": 2328, "text": "Marzano et al., 2009", "ref_id": "BIBREF325"}, {"start": 2892, "end": 2914, "text": "(Fischer et al., 2003)", "ref_id": null}, {"start": 3448, "end": 3453, "text": "2016)", "ref_id": null}], "ref_spans": [], "section": "Alzheimer's Disease"}, {"text": "A defective proteasome activity has been also related to increased levels of the APP-derived intracellular C-terminal membrane fragment \u03b2 (CTF\u03b2), a neurotoxic peptide with significant roles in AD pathogenesis (Bustamante et al., 2018).", "cite_spans": [], "ref_spans": [], "section": "Alzheimer's Disease"}, {"text": "Parkinson's Disease (PD) is a multi-factorial neurodegenerative disease, which primarily affects the nigro-striatal dopaminergic motor neurons. The pathognomonic histological lesion of PD, though not shared by all disease variants, is the formation of peri-nuclear intracellular aggregates, called Lewy Bodies (LB) (extremely rich in a proto-typical amyloidogenic protein, i.e. \u03b1-synuclein, and ubiquitinated proteins) through a process referred to as aggresome formation. It is still debated whether aggresome formation is a pathogenic event in PD progression or it rather represents a protective pathway activated to limit the high toxicity of the soluble amyloidogenic oligomers, which chronologically precedes aggregates formation (Wakabayashi et al., 2007; Wakabayashi et al., 2013; Raiss et al., 2016) . In support of this second hypothesis, which is the prevalent one, aggresomes formation is a phenomenon orchestrated by several proteins (including HSP10, p62, extensive crosstalk between the UPS and autophagy is expected to tightly balance aggresome growth and to avoid the protein imbalance of neurons . According to this PD pathogenesis framework, inherited and acquired conditions which predispose to the disease onset would impair this sophisticated mechanism of proteostasis maintenance.", "cite_spans": [{"start": 735, "end": 761, "text": "(Wakabayashi et al., 2007;", "ref_id": "BIBREF785"}, {"start": 762, "end": 787, "text": "Wakabayashi et al., 2013;", "ref_id": "BIBREF786"}, {"start": 788, "end": 807, "text": "Raiss et al., 2016)", "ref_id": "BIBREF483"}], "ref_spans": [], "section": "Parkinson's Disease"}, {"text": "Although very recently it has been reported that Ub-positive inclusions in LB mostly deal with K63 (e.g., autophagy-related) rather than UPS-specific K48 linkages, extensive studies on the genetically Furthermore, exceedingly high concentrations of metal ions, such as Zn 2+ , Cu 2+ and iron have been long detected in post-mortem brain biopsies (Le et al., 2014) ; in particular, in murine models it has J o u r n a l P r e -p r o o f been observed that, besides metal-related toxicity, Zn 2+ ions also trigger the expression and oligomerization-propensity of \u03b1-synuclein in nigrostriatal tissues and the selective loss of specific proteasome subunits, such as \u03b25 and Rpt6 (Kumar et al., 2018) . Additionally, copper metabolism appears to be implicated in inducing cell death, since over-expression of \u03b1-synuclein and copper transporters stimulated loss of proteasome function, regardless of the tendency to form aggregates (Anandhan et al., 2015 Lan et al., 2016 .", "cite_spans": [{"start": 346, "end": 363, "text": "(Le et al., 2014)", "ref_id": null}, {"start": 674, "end": 694, "text": "(Kumar et al., 2018)", "ref_id": "BIBREF504"}, {"start": 943, "end": 947, "text": "2015", "ref_id": "BIBREF198"}, {"start": 948, "end": 964, "text": "Lan et al., 2016", "ref_id": "BIBREF253"}], "ref_spans": [], "section": "Parkinson's Disease"}, {"text": "A bulk of molecular evidences on PD pathogenesis comes from studies on genetic inheritance of the disease. Mutations of at least six genes have been linked with hereditary PD, namely \u03b1-synuclein (SNCA or PARK1), Parkin (PARK2), ubiquitin carboxyhydroxylase L1 (UCH-L1 or PARK5), PTEN-induced putative kinase 1 (PINK-1 or PARK6), DJ-1 (PARK7), and leucine-rich repeat kinase 2 (LRRK2 or PARK8) (Nuytemans et al., 2010; Janda et al., 2012) . Interestingly, all proteins, encoded by these genes, were found to interact at some level with proteasome or ubiquitinconjugating enzymes.", "cite_spans": [{"start": 393, "end": 417, "text": "(Nuytemans et al., 2010;", "ref_id": "BIBREF394"}, {"start": 418, "end": 437, "text": "Janda et al., 2012)", "ref_id": "BIBREF190"}], "ref_spans": [], "section": "Parkinson's Disease"}, {"text": "In particular, DJ-1 is an intracellular protein with pleiotropic activities which encompass cell morphology, functionality of mitochondria and ROS balance (Irrcher et al., 2010) ; most notably, it has been shown to positively regulate the transcriptional activity of Nrf-2 upon inactivation of PTEN and activation of PI3kinase/Akt/mTOR pathway. Nrf2 is a master regulator of anti-oxidant defence systems including transcription of proteasome genes (Niki et al., 2020) . A tight link between DJ-1 and Akt/mTOR pathway has been reported also in Drosophila melanogaster,", "cite_spans": [{"start": 155, "end": 177, "text": "(Irrcher et al., 2010)", "ref_id": "BIBREF177"}, {"start": 448, "end": 467, "text": "(Niki et al., 2020)", "ref_id": "BIBREF390"}], "ref_spans": [], "section": "Parkinson's Disease"}, {"text": "underscoring the degree of conservation across evolution of such a relevant pathway for neuron homeostasis (Yang et al., 2005) . Interestingly, detection of hyper-stimulated autophagy in DJ-1 deficient neurons is another indirect proof of the pivotal role of DJ-1 in stimulating the Akt/mTOR signalling, since this kinase is the major autophagy inhibitor. In this framework, it looks relevant to clarify the potentially controversial inhibitory activity of DJ-1 on the 20S catalytic activity both on synthetic and natural substrates, recently described (Moscovitz et al., 2015) . However, the authors propose that DJ-1 up-regulates the expression of proteasome subunits whilst repressing the catalytic activity of 20S assemblies, thus finely tuning the 20S proteasome bulk proteolytic activity. This activity would be necessary to address the cell need in balancing the clearance of oxidatively damaged proteins and that of native intrinsically unstructured proteins, which coordinate regulatory and signalling events (Moscovitz et al., 2015) .", "cite_spans": [{"start": 107, "end": 126, "text": "(Yang et al., 2005)", "ref_id": "BIBREF833"}, {"start": 553, "end": 577, "text": "(Moscovitz et al., 2015)", "ref_id": "BIBREF371"}, {"start": 1018, "end": 1042, "text": "(Moscovitz et al., 2015)", "ref_id": "BIBREF371"}], "ref_spans": [], "section": "Parkinson's Disease"}, {"text": "Another gene, critically involved in PD, is LKKR2 and the clinical features of LRRK2-PD are often indistinguishable from idiopathic PD, with accumulation of \u03b1-synuclein and/or tau and/or ubiquitin in intraneuronal aggregates (Lichtenberg et al., 2011) . Although the mechanisms through which J o u r n a l P r e -p r o o f LKKR2 mediates toxicity are unknown, its mutation brings about a gain of functional mechanisms by means of an increased kinase-activity, which was shown to stimulate \u03b1-synuclein aggregation and cytotoxicity . Furthermore, LRRK2 overexpression in cells and in vivo downregulates UPS activity which turns out into the accumulation of intracellular substrates (Lichtenberg et al., 2011) .", "cite_spans": [{"start": 225, "end": 251, "text": "(Lichtenberg et al., 2011)", "ref_id": "BIBREF296"}, {"start": 680, "end": 706, "text": "(Lichtenberg et al., 2011)", "ref_id": "BIBREF296"}], "ref_spans": [], "section": "Parkinson's Disease"}, {"text": "Probably, the most studied protein in PD is the ring-finger E2-dependent E3 ubiquitin-protein Biological function of parkin deals with turn-over of a plethora of intracellular substrates.", "cite_spans": [], "ref_spans": [], "section": "Parkinson's Disease"}, {"text": "A direct clue between parkin and \u03b1-synuclein was originally provided by identifying the selective ubiquitination of a specialised form of \u03b1-synuclein expressed in neurons, \u03b122SYn (Shimura et al., 2001 ).", "cite_spans": [{"start": 179, "end": 200, "text": "(Shimura et al., 2001", "ref_id": "BIBREF642"}], "ref_spans": [], "section": "Parkinson's Disease"}, {"text": "Additional substrates have been then identified, supporting a broader relevance of parkin activity in neuron homeostasis. A non-exhaustive list of substrates includes (i) CDCrel-1, which is the synaptic vesicle associated protein, (ii) p62, which is ubiquitinated at K13 by parkin, and (iii) p62 J o u r n a l P r e -p r o o f intracellular abundance, which follows an inverse linearity with parkin expression (Song et al., 2016; Okatsu et al., 2010) . Being p62 involved in aggresome formation, this finding elicits additional considerations on the cross-talk between the contribution of the key players of proteostasis in PD.", "cite_spans": [{"start": 410, "end": 429, "text": "(Song et al., 2016;", "ref_id": "BIBREF676"}, {"start": 430, "end": 450, "text": "Okatsu et al., 2010)", "ref_id": "BIBREF402"}], "ref_spans": [], "section": "Parkinson's Disease"}, {"text": "Another substrate of parkin is STEP6, which builds up in the striatum of PD subjects and also in murine models of the disease. The increase in STEP6, which follows parkin loss, is associated with a decrease in the phosphorylation of ERK1/2 and its downstream target, pCREB [phospho-CREB (cAMP response element-binding protein)] (Kurup et al., 2015) . Interestingly, dopamine signalling affects the de-phosphorylation of STEP6 and its catalytic activity; thus, in dopamine-deficient neurons STEP6 would be more active, depressing the ERK1/2 signalling pathway mentioned above, and grossly impacting on neuron homeostasis. Furthermore, STEP6 and BDNF are regulated through a reciprocal feedback mechanism and this may outline the loss of the neuron growth factor in PD.", "cite_spans": [{"start": 328, "end": 348, "text": "(Kurup et al., 2015)", "ref_id": "BIBREF249"}], "ref_spans": [], "section": "Parkinson's Disease"}, {"text": "Remarkably, one of the most relevant items about parkin biological role is its interaction with PINK, a Ser/Thr protein kinase encoded by the PINK1 gene, a major surveyor of mitochondria quality control, by targeting damaged mitochondria to autophagy-mediated clearance (e.g., In healthy mitochondria, PINK1 is quickly degraded by several mitochondrial peptidase, whereas in de-polarized mitochondria it is no longer cleaved and becomes exposed to the mitochondrial membrane, recruiting parkin for ubiquitination of various mitochondrial proteins thereby labelling the organelles for mitophagy (Greene et al., 2012) . Thus, down-regulation in parkin bioavailability turns out into a reduced clearance of damaged mitochondria which become a major source of ROS, dramatically contributing to the redox imbalance.", "cite_spans": [{"start": 594, "end": 615, "text": "(Greene et al., 2012)", "ref_id": null}], "ref_spans": [], "section": "Parkinson's Disease"}, {"text": "Furthermore, upon enzymatic shedding, PINK1 is further released as a soluble cytosolic form, called PINK1-s, which assists recruitment of parkin to the mitochondrial membrane and further contributes to the delivery of aggregating-prone protein to the forming aggresomes during proteasome inhibition. Thus, PINK1-s works as a sensor that links the proteasomal deficiency signal to the aggresome formation process Fedorowicz et al., 2014) .", "cite_spans": [{"start": 412, "end": 436, "text": "Fedorowicz et al., 2014)", "ref_id": null}], "ref_spans": [], "section": "Parkinson's Disease"}, {"text": "As a whole, molecular insights on PD strongly support that tailored strategies of UPS modulation would provide a significant therapeutic efficacy in delaying disease progression.", "cite_spans": [], "ref_spans": [], "section": "Parkinson's Disease"}, {"text": "Huntington disease (HD) is a neuro-degenerative disorder with autosomal dominant inheritance caused by a triplet expansion (i.e., CAG) in the huntingtin gene (Htt) which induces the protein to hold an exceedingly long poly-glutamine (polyQ) stretch at the N-terminus. A polyQ length >35 residues render pathogenic Htt (hereafter referred to as mHtt), which then acquires aggregatingprone properties (Di Figlia et al., 1997; Boland et al., 2018) ; the removal of the poly-Q stretch appears to be sufficient to rescue neuron homeostasis and to milder neuro-degeneration in murine models of HD (Zheng et al., 2010) . Abnormal synaptic transmission was reported to induce proteasome impairment in murine models of HD and a molecular mechanism through an increased cAMP signalling and the concomitant decreased PKA activity was proposed to explain this feature in neurons. Nonetheless, the cAMP/PKA pathway has been long considered central to HD pathogenesis by virtue of the pivotal role played by the two molecular pathways in neuron homeostasis and plasticity. The PKA holoenzyme, which is catalytically inactive in the absence of cAMP, is made up of two PKA-Rs and two catalytic subunits (Lin et al., 2013) ; in the presence of cAMP, cAMP-bound PKA-Rs dissociate from the catalytic subunits, which are then degraded by the proteasome. As a consequence, an impaired proteasome activity would allow the PKA-Rs to gather up reducing the amounts of free PKA catalytic subunits and thereby impairing PKA activity. On the other hand, PKA carries out the phosphorylation of Rpt6 at Ser120, a post-translational modification which enhances the activity of the proteasome and the constitution of capped particles (Lin et al., 2013) . Furthermore, during synaptic sprouting Rpt6 can also be phosphorylated by Ca 2+ /calmodulin-dependent protein kinase II\u03b1 (CaMKII\u03b1) in a neuronal activity-dependent manner (Jarome et al., 2013) . Therefore, the HD onset might be correlated to a vicious cycle wherefore proteasome content drops down, due to its seizure, and the PKA-mediated stimulation of proteolysis fades out.", "cite_spans": [{"start": 399, "end": 423, "text": "(Di Figlia et al., 1997;", "ref_id": null}, {"start": 424, "end": 444, "text": "Boland et al., 2018)", "ref_id": null}, {"start": 591, "end": 611, "text": "(Zheng et al., 2010)", "ref_id": "BIBREF865"}, {"start": 1187, "end": 1205, "text": "(Lin et al., 2013)", "ref_id": "BIBREF299"}, {"start": 1703, "end": 1721, "text": "(Lin et al., 2013)", "ref_id": "BIBREF299"}, {"start": 1895, "end": 1916, "text": "(Jarome et al., 2013)", "ref_id": "BIBREF192"}], "ref_spans": [], "section": "Huntington Disease"}, {"text": "A significant contribution to HD pathogenesis further comes from the iPSC model of HD.", "cite_spans": [], "ref_spans": [], "section": "Huntington Disease"}, {"text": "Remarkably, HD-iPSCs display constitutive increased proteasome activity, which was found to regulate the levels of both normal and mutated Htt, contributing to suppress polyQ-expanded Htt J o u r n a l P r e -p r o o f aggregation (Koyuncu et al., . As a matter of fact, HD iPSCs do not accumulate polyQ-expanded Htt aggregates even after multiple passages. Accordingly, a dysfunction in proteasome activity results in impaired Htt levels and aggregation of mHtt also in HD-iPSCs.", "cite_spans": [], "ref_spans": [], "section": "Huntington Disease"}, {"text": "In iPSC, a major role in facilitating Htt clearance seems to be played by the E3 ligase UBR5.", "cite_spans": [], "ref_spans": [], "section": "Huntington Disease"}, {"text": "Although loss of UBR5 did not impair pluripotency markers in human control iPSCs, it induced instead the formation of misfolded protein aggregates (i.e., aggresomes) (Koyuncu et al., 2018) .", "cite_spans": [{"start": 183, "end": 188, "text": "2018)", "ref_id": "BIBREF243"}], "ref_spans": [], "section": "Huntington Disease"}, {"text": "The iPSCs experimental model has allowed to cast further light on the transcriptional activity of As mentioned above, several E3-ligases tag mutant Htt and are sequestered in aggregates. In different cell lines, mHtt clearance is usually carried out by canonical E3 ligases, such as UBR1, UBE3A, HSP and also non-canonical E3 ligases, such as Herp which, however, contain(s) a UBL domain (Luo et al., 2018) . Conversely, a role of de-ubiquitinase ataxin-3, involved in the pathogenesis of other neurodegenerative disorders (such as spino-cerebellar ataxia type 3), has not been confirmed in HTT progression by studies in murine models (Zeng et al., 2013) . Moreover, atypical ubiquitination of mHtt by some E3 ligases, such as WWP1, may favour disease progression .", "cite_spans": [{"start": 388, "end": 406, "text": "(Luo et al., 2018)", "ref_id": "BIBREF312"}, {"start": 635, "end": 654, "text": "(Zeng et al., 2013)", "ref_id": "BIBREF841"}], "ref_spans": [], "section": "Huntington Disease"}, {"text": "Conversely, ubiquilin-1, a highly conserved family of proteins which facilitate protein disposal through autophagy and UPS and which is down-regulated in early HD, improves the clearance of Htt (Safren et al., 2014) Similarly, Usp14 has a favourable effect in cells expressing mutant Htt cells by decreasing the aggregate load and by enhancing cell viability (Hyrskyluoto et al., 2014) J o u r n a l P r e -p r o o f Finally, although UBE3A overexpression is known to promote UPS-mediated degradation of transfected mHtt in cultured cells, it is still unclear how UBE3A expression levels impact HD pathology. Remarkably, when the E3-ligase was up-regulated a drop in K63 ubiquitination of mHtt was observed (Bhat et al., 2014) . In this study, the presence of the pathological polyQ stretch was proposed to alter the overall folding of mHtt favouring the formation of K63 Ub linkages, also through cooperation of p62/SQSTM1, which are more prone to aggregation (Lim et al., 2015) .", "cite_spans": [{"start": 194, "end": 215, "text": "(Safren et al., 2014)", "ref_id": "BIBREF558"}, {"start": 359, "end": 385, "text": "(Hyrskyluoto et al., 2014)", "ref_id": "BIBREF174"}, {"start": 707, "end": 726, "text": "(Bhat et al., 2014)", "ref_id": null}, {"start": 961, "end": 979, "text": "(Lim et al., 2015)", "ref_id": "BIBREF297"}], "ref_spans": [], "section": "Huntington Disease"}, {"text": "Thus, to stimulate the UBE3A activity would be relevant to limit the toxicity of mHtt.", "cite_spans": [], "ref_spans": [], "section": "Huntington Disease"}, {"text": "By virtue of its anatomical localization retina is also called the \"window to the brain\" ( (Naash et al., 1997; Fukuhara et al., 2001; Knowles et al., 2009; Fan et al., 2013) .", "cite_spans": [{"start": 91, "end": 111, "text": "(Naash et al., 1997;", "ref_id": "BIBREF384"}, {"start": 112, "end": 134, "text": "Fukuhara et al., 2001;", "ref_id": null}, {"start": 135, "end": 156, "text": "Knowles et al., 2009;", "ref_id": null}, {"start": 157, "end": 174, "text": "Fan et al., 2013)", "ref_id": "BIBREF857"}], "ref_spans": [{"start": 89, "end": 90, "text": "(", "ref_id": null}], "section": "Involvement of UPS in retinal diseases"}, {"text": "Moreover, surprisingly, murine transgenic models and human ex-vivo models of eye-diseases point toward a major role of non-canonical proteasome assemblies in retina development and J o u r n a l P r e -p r o o f homeostasis. A predominant contribution seems to be played by the immunoproteasome, by means of either PA28 expression and incorporation of inducible proteasome subunits in 20S assemblies, which is over-expressed to an exceptionally high degree in synaptic terminals and in photoreceptors (Hussong et al., 2010; Hussong et al., 2011; Shang et al., 2012; Lobanova et al., 2018; Aghdam and Mahmoudpour, 2016) . In detail, differentiation of murine retinal progenitor cells into their mature lineages requires the mTORC1-dependent STAT1 activation, which triggers the transcriptional upregulation of PSMB9 gene (which encodes for a catalytic subunit of immunoproteasome) but not of PSMB6 or PSMB7 (which encode for canonical subunits with trypsin-like and caspase-like proteolytic activities) (Choi et al., 2018) . Assembly of functional immunoproteasome is supposed to assist the 26S in clearing the bulk of short half-life proteins that accumulate in highly replicating cells (Choi et al., 2018) . Nonetheless, this finding envisages that the immunoproteasome might have a higher affinity than 26S for cell cycle substrates and for oxidized and unfolded proteins which may accumulate during replication. This last possibility is consistent with biochemical properties reported to date for the immunoproteasome and with the finding on a murine model of an inherited retinal degeneration wherefore photoreceptors carry a rhodopsin allele mutation (i.e., P23H); this mutation renders the protein unfolded and aggregating-prone, while the overexpression of PA28 counteracts the degeneration improving photoreceptor survival in such a murine model (Raule et al., 2014a; Raule et al., 2014b; Lobanova et al., 2018) .", "cite_spans": [{"start": 501, "end": 523, "text": "(Hussong et al., 2010;", "ref_id": null}, {"start": 524, "end": 545, "text": "Hussong et al., 2011;", "ref_id": "BIBREF173"}, {"start": 546, "end": 565, "text": "Shang et al., 2012;", "ref_id": "BIBREF628"}, {"start": 566, "end": 588, "text": "Lobanova et al., 2018;", "ref_id": null}, {"start": 589, "end": 618, "text": "Aghdam and Mahmoudpour, 2016)", "ref_id": "BIBREF825"}, {"start": 1002, "end": 1021, "text": "(Choi et al., 2018)", "ref_id": "BIBREF38"}, {"start": 1187, "end": 1206, "text": "(Choi et al., 2018)", "ref_id": "BIBREF38"}, {"start": 1854, "end": 1875, "text": "(Raule et al., 2014a;", "ref_id": null}, {"start": 1876, "end": 1896, "text": "Raule et al., 2014b;", "ref_id": null}, {"start": 1897, "end": 1919, "text": "Lobanova et al., 2018)", "ref_id": null}], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "The role of immunoproteasome and its substrate specificities gains further relevance when we consider that retina is an immune-privileged organ so that the processing of antigenic peptides, as well as their presentation, follow highly specific dynamics to regulate local immune response and immune-surveillance of this tissue, mostly concerning the maintenance of immune tolerance versus retinal self-antigens (Schuld et al., 2015; Voigt et al., 2017; Lipski et al., 2017; McPherson et al., 2014) .", "cite_spans": [{"start": 410, "end": 431, "text": "(Schuld et al., 2015;", "ref_id": "BIBREF615"}, {"start": 432, "end": 451, "text": "Voigt et al., 2017;", "ref_id": "BIBREF781"}, {"start": 452, "end": 472, "text": "Lipski et al., 2017;", "ref_id": null}, {"start": 473, "end": 496, "text": "McPherson et al., 2014)", "ref_id": "BIBREF346"}], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "Although indirectly, the Rett Syndrome (RTT) case (see also paragraph biogenesis) might further offer a clue for studying the specific regulation of proteasome biogenesis in retinal cells. RTT is a neurodevelopmental disorder classified as rare X-linked genetic disease (Amir et al., 1999) . In more than 95% of cases, girls, affected by the syndrome harbour a de-novo mutation in the MeCP2 gene, which encodes for an epigenetic transcriptional regulator with largely unknown biological functions (Chahrour et al., 2008) .", "cite_spans": [{"start": 270, "end": 289, "text": "(Amir et al., 1999)", "ref_id": null}, {"start": 497, "end": 520, "text": "(Chahrour et al., 2008)", "ref_id": null}], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "Whilst several brain areas display neuroanatomical abnormalities, retina as well as vision appear to be unaffected during RTT onset and progression (Jain et al., 2010; Rose et al., 2019) . underscoring onset and progression of these diseases are extensively discussed elsewhere and will not be discussed herein (Tarr et al., 2013; Lombardo et al., 2013; Parravano et al., 2013; Picconi et al., 2018) . However, they represent two eye disorders wherefore UPS and alteration of the PN appear to follow a specular pattern and for which pharmacological strategies targeting the UPS might provide a valid therapeutic opportunity.", "cite_spans": [{"start": 148, "end": 167, "text": "(Jain et al., 2010;", "ref_id": null}, {"start": 168, "end": 186, "text": "Rose et al., 2019)", "ref_id": null}, {"start": 311, "end": 330, "text": "(Tarr et al., 2013;", "ref_id": "BIBREF700"}, {"start": 331, "end": 353, "text": "Lombardo et al., 2013;", "ref_id": null}, {"start": 354, "end": 377, "text": "Parravano et al., 2013;", "ref_id": "BIBREF446"}, {"start": 378, "end": 399, "text": "Picconi et al., 2018)", "ref_id": "BIBREF455"}], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "Contribution of the UPS in DR onset is poorly studied, even though several lines of research support a pivotal role played by the proteasome in regulating the nuclear activity of key transcription factors and the release of cytokines in the early vascular response to the hyperglycemic insult (Aghdam et al., 2013; Campello et al., 2013; Rahimi et al., 2012) .", "cite_spans": [{"start": 293, "end": 314, "text": "(Aghdam et al., 2013;", "ref_id": null}, {"start": 315, "end": 337, "text": "Campello et al., 2013;", "ref_id": null}, {"start": 338, "end": 358, "text": "Rahimi et al., 2012)", "ref_id": "BIBREF482"}], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "Although choroidal endothelial cells seem to contribute only marginally to this phenomenon, an aberrant proliferation of retinal endothelial cells (which ultimately lead to micro-haemorragic lesion, vessel leakage and irreversible fibrosis) follows the increased secretion and bio-availability of VEGFs. Several independent research teams suggest that the retinal cell type, which first sense the hyper-glycemia is the Muller glia, and indeed metabolism of this cell type appears to be sensitive, through unknown mechanisms, to fluctuations in glucose concentration, as those occurring in vivo in diabetic subjects Le,2017; Picconi et al., 2019; Picconi et al., 2017; Voigt et al., 2017; Matteucci et al., 2014) . This insult stimulates the secretion of VEGFs as well as of other pro-inflammatory cytokines. VEGFs synthesis is mostly regulated by the transcriptional activity of NF-kB and HIF-1\u03b1 whose nuclear translocation is regulated by J o u r n a l P r e -p r o o f proteasome proteolytic activity (see Section 3.2.1) (Alkalay et al., 1995; Traencker et al., 1994; Chen et al., 1995; Ferrara et al., 2004) .", "cite_spans": [{"start": 615, "end": 623, "text": "Le,2017;", "ref_id": null}, {"start": 624, "end": 645, "text": "Picconi et al., 2019;", "ref_id": "BIBREF456"}, {"start": 646, "end": 667, "text": "Picconi et al., 2017;", "ref_id": null}, {"start": 668, "end": 687, "text": "Voigt et al., 2017;", "ref_id": "BIBREF781"}, {"start": 688, "end": 711, "text": "Matteucci et al., 2014)", "ref_id": "BIBREF336"}, {"start": 1023, "end": 1045, "text": "(Alkalay et al., 1995;", "ref_id": null}, {"start": 1046, "end": 1069, "text": "Traencker et al., 1994;", "ref_id": null}, {"start": 1070, "end": 1088, "text": "Chen et al., 1995;", "ref_id": null}, {"start": 1089, "end": 1110, "text": "Ferrara et al., 2004)", "ref_id": null}], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "Therefore, a better understanding of the molecular mechanisms of enhanced protein turn-over upon hyper-glycemia in Muller glia and, possibly, in additional retina cell types would allow to envisage selective therapeutic approaches to target VEGF synthesis rather than its biological cascade once secreted. In fact, clinical regimens for DR treatment mostly deal with VEGF inhibitors which however do not distinguish between the physiological and pathological angiogenesis with the former being as much relevant for retina homeostasis as blocking the latter would be for DR progression (Ferrara et al., 2004; Lacal et al., 2018) . Thus, selective targeting of factors, that regulate the proteasome-mediated turn-over of players in DR progression, would help to overcome the limitation of traditional proteasome inhibition strategies, which stop bulky proteolytic burden thereby compromising PN.", "cite_spans": [{"start": 585, "end": 607, "text": "(Ferrara et al., 2004;", "ref_id": null}, {"start": 608, "end": 627, "text": "Lacal et al., 2018)", "ref_id": null}], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "The involvement of proteasome in the onset of glaucoma appears to follow an opposite path to that observed in Muller glia cells in DR. In fact, there is a compelling evidence that PN might be dysregulated in both main clinical forms of glaucoma, namely (i) primary open-angle glaucoma (POAG) and (ii) normal-tension glaucoma Quaranta et al., 2016; Agarwal et al., 2009; Weinreb et al., 2014; Wunderlich et al., 2002; Caballero et al., 2003; Caballero et al., 2013) .", "cite_spans": [{"start": 325, "end": 347, "text": "Quaranta et al., 2016;", "ref_id": "BIBREF477"}, {"start": 348, "end": 369, "text": "Agarwal et al., 2009;", "ref_id": null}, {"start": 370, "end": 391, "text": "Weinreb et al., 2014;", "ref_id": "BIBREF798"}, {"start": 392, "end": 416, "text": "Wunderlich et al., 2002;", "ref_id": "BIBREF821"}, {"start": 417, "end": 440, "text": "Caballero et al., 2003;", "ref_id": null}, {"start": 441, "end": 464, "text": "Caballero et al., 2013)", "ref_id": null}], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "In this regard, the term glaucoma encompasses a heterogeneous group of neurodegenerative disorders characterized by the loss of retinal ganglion cells (RGC) and atrophy of the optic nerve their axons generate Swarup and Sayyad, 2018; Minegishi et al., 2016) . leading to RGCs loss, optic nerve degeneration and visual decline. Therapy with glucocorticoids has been long known to induce acute iatrogenic form of glaucoma by affecting the TMC metabolism, but the primary alteration of such a cell after GC administration is unknown (Roberti et al., 2020) . Interestingly, TMCs express a ubiquitous protein, called myocilin (i.e., myoc) (i.e., from the MYOC gene), whose expression is up-regulated in TMCs when exposed to GC, but also oxidative stress and cytokines (Qiu et al., 2014; Wang et al., 2019; Resch and Fautsch et al., 2009; Micera et al., 2016) ; when over-expressed, this protein is supposed to pose a metabolic threat to", "cite_spans": [{"start": 209, "end": 233, "text": "Swarup and Sayyad, 2018;", "ref_id": "BIBREF693"}, {"start": 234, "end": 257, "text": "Minegishi et al., 2016)", "ref_id": "BIBREF355"}, {"start": 530, "end": 552, "text": "(Roberti et al., 2020)", "ref_id": "BIBREF528"}, {"start": 763, "end": 781, "text": "(Qiu et al., 2014;", "ref_id": "BIBREF475"}, {"start": 782, "end": 800, "text": "Wang et al., 2019;", "ref_id": "BIBREF787"}, {"start": 801, "end": 832, "text": "Resch and Fautsch et al., 2009;", "ref_id": "BIBREF501"}, {"start": 833, "end": 853, "text": "Micera et al., 2016)", "ref_id": "BIBREF350"}], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "TMCs through unexplored gain of function mechanisms Jain et al., 2017) . This pathogenic effect may occur either in the intracellular or extracellular compartments, in accordance with the broad localization of the protein. Furthermore, mutations in MYOC gene are the most studied cause of the juvenile form of glaucoma and, among the different point mutations described so far, the most prevalent ones (e.g., Pro370Leu) render myocilin amyloidogenic and aggregatingprone (Yam et al., 2007; Wang et al., 2019) . Myocilinis a proteasome substrate, and, in the absence of GC therapy, proteasome activity appears to decline in TMCs culture isolated from patients suffering from glaucoma in an age-dependent manner; further, myocilin expression in HeLA cells was found to decrease the bioavailability of some 20S subunits (Qiu et al., 2014) . Conversely, the GC effect on MYOC processing and proteasome regulation is unknown. Nonetheless, the role of proteasome impairment in driving cell senescence and the role of proteasome re-activation in delaying this phenomenon is well studied in several cell types but not in TMCs Deschenes-Simard et al., 2014) .", "cite_spans": [{"start": 52, "end": 70, "text": "Jain et al., 2017)", "ref_id": "BIBREF184"}, {"start": 471, "end": 489, "text": "(Yam et al., 2007;", "ref_id": "BIBREF826"}, {"start": 490, "end": 508, "text": "Wang et al., 2019)", "ref_id": "BIBREF787"}, {"start": 817, "end": 835, "text": "(Qiu et al., 2014)", "ref_id": "BIBREF475"}, {"start": 1118, "end": 1148, "text": "Deschenes-Simard et al., 2014)", "ref_id": null}], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "Even though transgenic models do not always support an unequivocal role of MYOC in glaucoma onset, the interactome of this protein is worth being studied to address the metabolism of TMC Senatorov et al., 2006; Zhou et al., 2008; Joe et al., 2015; Jain et al., 2017) .", "cite_spans": [{"start": 187, "end": 210, "text": "Senatorov et al., 2006;", "ref_id": "BIBREF619"}, {"start": 211, "end": 229, "text": "Zhou et al., 2008;", "ref_id": "BIBREF869"}, {"start": 230, "end": 247, "text": "Joe et al., 2015;", "ref_id": "BIBREF197"}, {"start": 248, "end": 266, "text": "Jain et al., 2017)", "ref_id": "BIBREF184"}], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "Therefore, to study the dynamics of myocilin digestion in TMCs and how proteasome might undergo dysregulation under metabolic conditions that are commonly seen in glaucoma subjects, it might help to explore the molecular insights of pharmacological strategies based on UPS rescue.", "cite_spans": [], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "Differently from POAG, normal-tension glaucoma is not supported by an increased intra-ocular pressure and the degeneration of the optic nerve likely depends on a primary insult on RGCs. Even in this case, a tight involvement of intracellular proteolytic pathways is largely envisaged.", "cite_spans": [], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "Optineurin (OPN) gene encodes for a protein involved in intracellular vesicle trafficking, and expression of mutated forms of optineurin induces a severe dysregulation of the UPS and of autophagy Shen et al., 2011; Sirohi et al., 2016) .", "cite_spans": [{"start": 196, "end": 214, "text": "Shen et al., 2011;", "ref_id": "BIBREF638"}, {"start": 215, "end": 235, "text": "Sirohi et al., 2016)", "ref_id": "BIBREF656"}], "ref_spans": [], "section": "Involvement of UPS in retinal diseases"}, {"text": "Besides the molecular findings discussed above, a major suggestion for the relevance of proteasome in handling the PN in retina comes indirectly from biochemical pharmacology (Sbardella et al., 2020b) . Several clinical trials worldwide support the therapeutic efficacy of citicoline for glaucoma treatment (Roberti et al., 2015; Parisi et al., 2008; Parisi et al., 2018; Parisi et al., 2019; Carnevale et al., 2019) . Citicoline, also known as CDP choline, is a drug made up by choline and cytidine diphosphate which displays optimal bioavailability and easily crosses the blood brain barrier (Faiq et al., 2019) . Although the mechanisms of action of citicoline have never been identified at molecular detail, its wide usage in clinical regimens is based on its outstanding safety profile and on the efficacy also in neurological disorders, including neurodegenerative disease, such as the early phases of AD and PD onset, though the trials having been run are still limited (Eberhardt et al., 1990) .", "cite_spans": [{"start": 175, "end": 200, "text": "(Sbardella et al., 2020b)", "ref_id": null}, {"start": 307, "end": 329, "text": "(Roberti et al., 2015;", "ref_id": null}, {"start": 330, "end": 350, "text": "Parisi et al., 2008;", "ref_id": "BIBREF438"}, {"start": 351, "end": 371, "text": "Parisi et al., 2018;", "ref_id": "BIBREF440"}, {"start": 372, "end": 392, "text": "Parisi et al., 2019;", "ref_id": "BIBREF439"}, {"start": 393, "end": 416, "text": "Carnevale et al., 2019)", "ref_id": "BIBREF439"}, {"start": 594, "end": 613, "text": "(Faiq et al., 2019)", "ref_id": null}, {"start": 977, "end": 1001, "text": "(Eberhardt et al., 1990)", "ref_id": null}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Our group has very recently reported that citicoline is an allosteric modulator of proteasome in vitro and in vivo, wherefore citicoline binds the 20S with a very high affinity (i.e., in the low nanomolar range), stimulating the clearance of synthetic substrates as well as of \u03b1-synuclein (Sbardella et al., 2020b) . Surprisingly, in neuron-derived cells, citicoline was found to both stimulate 20S activity and to promote the assembly of proteolytic active capped assemblies (i.e., 26S and 30S, see Section 2.3.2) (Sbardella et al., 2020b) . As a matter of fact, cells stimulated with citicoline experience a very significant increase in the overall proteolytic burden by the UPS. Therefore, although it is reasonable that the proteasome stimulation is not the only therapeutic effect, the neuro-protective role of citicoline highlights the relevance of proteasome functionality in maintaining the postmitotic cells homeostasis. Nonetheless, citicoline experience in clinical trials might be looked as a proof of concept that the activation of UPS is a valid strategy to delay the progression of pathologies sustained by proteo-toxicity.", "cite_spans": [{"start": 289, "end": 314, "text": "(Sbardella et al., 2020b)", "ref_id": null}, {"start": 515, "end": 540, "text": "(Sbardella et al., 2020b)", "ref_id": null}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Neurodegenerative diseases are clinically heterogeneous proteinopathies sustained by the accumulation of aggregates of misfolded disease associated proteins (see also Section 4.1). The prevalence and incidence of neurodegeneration increases dramatically with age, and, since people life expectancy rises worldwide, also the number of individuals suffering from these pathologies is expected to dramatically increase in the next years (McAlary et al., 2019; Jones and Tepe, 2019) .", "cite_spans": [{"start": 434, "end": 456, "text": "(McAlary et al., 2019;", "ref_id": "BIBREF340"}, {"start": 457, "end": 478, "text": "Jones and Tepe, 2019)", "ref_id": "BIBREF199"}], "ref_spans": [], "section": "Targeting proteasome as novel tool against proteotoxic diseases"}, {"text": "Despite social and economic relevance, no effective cure still exists; therefore, the development of novel therapeutic approaches is essential.", "cite_spans": [], "ref_spans": [], "section": "Targeting proteasome as novel tool against proteotoxic diseases"}, {"text": "As discussed above (see Section 4.1), UPS alteration contributes to disease onset and progression, leading to an intense research effort with the purpose of identifying therapeutic strategies targeting UPS. Different approaches to enhance UPS functionality have been proposed, spanning from stimulation of ubiquitination and/or inhibition of de-ubiquitination (Box 2), or inhibition of protein aggregation, being this last strategy founded on evidences that monomeric proteins are better degraded by proteasome than oligomers (Dantuma and Bott, 2014; Wertz and Murray, 2019) . In addition, modern strategies envisage the direct proteasome stimulation by either (i) drugs which specifically target proteasome particles increasing their bulk proteolytic activities (see also Section 2.2.1) or (ii) phosphorylation of proteasome subunits (Myeku and Duff, 2018) .", "cite_spans": [{"start": 526, "end": 550, "text": "(Dantuma and Bott, 2014;", "ref_id": "BIBREF52"}, {"start": 551, "end": 574, "text": "Wertz and Murray, 2019)", "ref_id": "BIBREF802"}, {"start": 835, "end": 857, "text": "(Myeku and Duff, 2018)", "ref_id": "BIBREF380"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "According to the first point, the identification of \"drug-like\" molecules, which directly activate proteasome, is challenging. Notably, a chemical genetics screening of over 2750 compounds using a proteasome activity probe as a readout in a high-throughput live-cell fluorescence-activated cell sorting-based assay has led to the identification of more than ten compounds that increase proteasome activity (Leestemaker et al., 2017) . A promising, but still poorly explored strategy, is the development of therapeutic peptides and/or peptidomimetics, designed on the basis of specific binding regions of natural proteasome regulators (Wilk et al., 1997; Fosgerau et al., 2015; Jones and Tepe, 2019) . In general, the advantage of peptide usage seems to deal with the higher specificity and selectivity with respect to molecular target; however, beside the complex synthesis, they suffer from low metabolic stability and poor membrane permeability (Fosgerau et al., 2015; . The most common class of synthetic peptide acting as proteasome activators are based on the HbYX motif (see Sections 2.3.2 and 4) . In this context, it has been shown that peptides derived from C-termini Rpt2 and Rp5, and a 14-mer peptide, based on the Cterminal fragment of Blm10 (the yeast ortholog of PA200, see box 1) and containing the HbYX motif, efficiently stimulated proteasome activity in vitro (Sadre-Bazzaz et al., 2010; Karpowicz et al., 2015) . Recently, it has been reported that upon introduction of the HbYX sequence, the proline-and arginine-rich peptide (PR11), which is a 20S allosteric inhibitor, turned to be a proteasome activator in vitro and in cell model (Osmulski et al., 2020; . Another example of a \"drug-like\" molecule with a different unknown mechanism of action is the proteasome-activating peptide 1 (PAP1), which increases the chymotrypsin-like proteasomal catalytic activity in vitro and in cell models and is further able to halt protein aggregation (Dal Vecchio et al., 2014) . Among proteasome activators, natural compounds, such as oleuropein, betulinic acid and fatty acids deserve particular attention, and their features will be discussed in the next sections.", "cite_spans": [{"start": 406, "end": 432, "text": "(Leestemaker et al., 2017)", "ref_id": "BIBREF272"}, {"start": 634, "end": 653, "text": "(Wilk et al., 1997;", "ref_id": "BIBREF804"}, {"start": 654, "end": 676, "text": "Fosgerau et al., 2015;", "ref_id": "BIBREF81"}, {"start": 677, "end": 698, "text": "Jones and Tepe, 2019)", "ref_id": "BIBREF199"}, {"start": 947, "end": 970, "text": "(Fosgerau et al., 2015;", "ref_id": "BIBREF81"}, {"start": 1378, "end": 1405, "text": "(Sadre-Bazzaz et al., 2010;", "ref_id": "BIBREF554"}, {"start": 1406, "end": 1429, "text": "Karpowicz et al., 2015)", "ref_id": "BIBREF209"}, {"start": 1654, "end": 1677, "text": "(Osmulski et al., 2020;", "ref_id": "BIBREF416"}, {"start": 1959, "end": 1985, "text": "(Dal Vecchio et al., 2014)", "ref_id": null}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Concerning the phosphorylation strategy, a bulk of studies have shown that reversible phosphorylation of proteasome subunits positively regulates its function (VerPlank and Goldberg, 2017; Myeku and Duff, 2018; VerPlank et al., 2019) . Accordingly, protein kinase A (PKA)-dependent phosphorylation is involved in the regulation of multiple aspects of proteasome functionality, such as: (i) enhancement of Rpt6 ATPase activity through phosphorylation which further stimulates the association of 20S and 19S in vitro (Box 3); increase in the proteasome capacity to clear ubiquitinated proteins, peptides and ATP as well as the degradation of aggregation-prone proteins in cells upon phosphorylation of Rpn6 at serine14 (Box 3) Lu et al., 2008; Jarome et al., 2013; Asai et al., 2009; Lokireddy et al., 2015) .", "cite_spans": [{"start": 173, "end": 188, "text": "Goldberg, 2017;", "ref_id": "BIBREF765"}, {"start": 189, "end": 210, "text": "Myeku and Duff, 2018;", "ref_id": "BIBREF380"}, {"start": 211, "end": 233, "text": "VerPlank et al., 2019)", "ref_id": "BIBREF768"}, {"start": 725, "end": 741, "text": "Lu et al., 2008;", "ref_id": "BIBREF310"}, {"start": 742, "end": 762, "text": "Jarome et al., 2013;", "ref_id": "BIBREF192"}, {"start": 763, "end": 781, "text": "Asai et al., 2009;", "ref_id": "BIBREF9"}, {"start": 782, "end": 805, "text": "Lokireddy et al., 2015)", "ref_id": null}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Moreover, phosphorylation of Rpt6 by kinase CaMKII\u03b1 induces 26S translocation into dendritic spines in primary neurons, promoting local protein breakdown and driving the formation of synaptic connections (Djakovic et al., 2009; Bingol et al., 2010; Hamilton et al., 2012; Jarome et al., 2013) .", "cite_spans": [{"start": 204, "end": 227, "text": "(Djakovic et al., 2009;", "ref_id": null}, {"start": 228, "end": 248, "text": "Bingol et al., 2010;", "ref_id": null}, {"start": 249, "end": 271, "text": "Hamilton et al., 2012;", "ref_id": "BIBREF143"}, {"start": 272, "end": 292, "text": "Jarome et al., 2013)", "ref_id": "BIBREF192"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Therefore, proteasome subunit phosphorylation has been suggested to rescue proteasome function and it could represent a promising strategy to treat neurodegeneration (VerPlank and Goldberg, 2017; Myeku and Duff, 2018) . Recently, it has been reported that, in hyppocampal neurons, only 20% of proteasome seems to be in a \"active\" substrate-engaged state, whereas the remaining part is in an \"inactive\" substrate-accepting ground state. Therefore, it has been speculated that phosphorylation increases the percentage of active forms of proteasome, recruiting \"idle\" particles as well as directly stimulating their activities (Asano et al., 2015; Myeku and Duff, 2018) . As a matter of the fact, a promising strategy should be the stimulation of PKA activity through the modulation of the amplitude of cAMP signal. The cAMP level is curtailed by cyclic nucleotide phosphor-di-esterases (PDE), which acts negatively by regulating PKA signals. Inhibition of PDE stimulates cAMP/PKA axis and activates proteasome, opening to a novel potential use of PDE inhibitors in the CNS diseases treatment (VerPlank and Goldberg, 2017; Myeku and Duff, 2018) .", "cite_spans": [{"start": 180, "end": 195, "text": "Goldberg, 2017;", "ref_id": "BIBREF765"}, {"start": 196, "end": 217, "text": "Myeku and Duff, 2018)", "ref_id": "BIBREF380"}, {"start": 624, "end": 644, "text": "(Asano et al., 2015;", "ref_id": null}, {"start": 645, "end": 666, "text": "Myeku and Duff, 2018)", "ref_id": "BIBREF380"}, {"start": 1104, "end": 1119, "text": "Goldberg, 2017;", "ref_id": "BIBREF765"}, {"start": 1120, "end": 1141, "text": "Myeku and Duff, 2018)", "ref_id": "BIBREF380"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Accordingly, it has been shown that PDE4 selective inhibition by rolipram induces phosphorylation of several subunits of 26S, leading to an increase in mouse models of UPS-mediated clearance of tau and amyloid aggregate, accompanied by a reduced cognitive impairment (Vitolo et al., 2002; Smith et al., 2009; Myeku et al., 2016) . Moreover, cAMP/PKA axis activation, which follows PDE10 inhibition, reduces Htt aggregation through a proteasome-dependent mechanism, and ameliorates motor and cognitive deficit in Htt mouse model (Giamp\u00e0 et al., 2010; Lin et al., 2013; Beaumont et al., 2016; Harada et al., 2017) . Furthermore, the administration of the FDA approved PDE3 inhibitor, cilostazol, to a mouse model of tauopathy enhanced proteasome function and attenuated the tauopathy and cognitive decline in rTg4510 mice, suggesting that this drug could be potentially repurposed for the treatment of patients with early-stage tauopathy (Schaler and Myeku, J o u r n a l P r e -p r o o f 2018) . As a whole, despite some early encouraging results in mouse model, it seems clear that the broad range of biological functions, mediated by cAMP, can reduce the clinical efficacy of PDE inhibitors, due to their adverse effects (Myeku and Duff, 2018; Heckman et al., 2018) . It is worth recalling that cAMP/PKA pathway transduces the intracellular signalling of a number of hormones:", "cite_spans": [{"start": 267, "end": 288, "text": "(Vitolo et al., 2002;", "ref_id": null}, {"start": 289, "end": 308, "text": "Smith et al., 2009;", "ref_id": "BIBREF663"}, {"start": 309, "end": 328, "text": "Myeku et al., 2016)", "ref_id": "BIBREF382"}, {"start": 528, "end": 549, "text": "(Giamp\u00e0 et al., 2010;", "ref_id": "BIBREF91"}, {"start": 550, "end": 567, "text": "Lin et al., 2013;", "ref_id": "BIBREF299"}, {"start": 568, "end": 590, "text": "Beaumont et al., 2016;", "ref_id": "BIBREF20"}, {"start": 591, "end": 611, "text": "Harada et al., 2017)", "ref_id": "BIBREF151"}, {"start": 936, "end": 955, "text": "(Schaler and Myeku,", "ref_id": null}, {"start": 987, "end": 992, "text": "2018)", "ref_id": "BIBREF243"}, {"start": 1222, "end": 1244, "text": "(Myeku and Duff, 2018;", "ref_id": "BIBREF380"}, {"start": 1245, "end": 1266, "text": "Heckman et al., 2018)", "ref_id": "BIBREF166"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "thus, in such a way, proteasome function can be regulated by hormonal and metabolic stimuli (Box 3) (VerPlank and .", "cite_spans": [], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Many organisms have developed a large number of small molecules, which modulate the activity of UPS components (Rousseau and Bertolotti, 2016) . Those of nutraceutical origin, (contained in fruits, in vegetables and their extracts) are very attractive for their positive effects as antiaging and in the treatment and the prevention of a wide range of pathologies. In fact, dietary phytochemicals exhibit broad and different biological activities, including antioxidant action, free radical scavenging, anti-inflammatory and metal-chelating properties, that represent the evolutive result of the vegetable system defence. All of them are secondary metabolites that plants produce to counteract against various stresses (Murakami, 2013) ; thus, they can be considered \"multifunctional drug-like molecules\", and it is not surprising such high variety of targets, since they are small molecules with very simple chemical structures.", "cite_spans": [{"start": 111, "end": 142, "text": "(Rousseau and Bertolotti, 2016)", "ref_id": "BIBREF543"}, {"start": 718, "end": 734, "text": "(Murakami, 2013)", "ref_id": "BIBREF374"}], "ref_spans": [], "section": "Direct enhancing proteasome activity by natural compounds"}, {"text": "Concerning the activity of these compounds on proteasome, those able to activate/enhance proteasome activity are rare, (Bonfili et al., 2008; Dahlmann, 1993; Huang and Chen, 2009 ) and they are often characterized by an ambivalent behaviour, acting alternatively as inhibitors and/or activators according to diverse conditions. As an example, the effects of curcumin (Cuanalo-Contreras and Moreno-Gonzalez, 2019) (1E,6E)-1,7-bis-(4-idrossi-3-metossifenil)-epta-1,6-dien-3,5-dione) on the UPS reflects the hormesis principle (e.g., the biphasic dose-response to an environmental agent characterized by a low dose stimulation or beneficial effect and a high dose inhibitory or toxic effect), being characterized by an inverted U shape dose-response (Ali and Rattan, 2006) ; thus, curcumin treatment (up 1 \u00b5M for 24h) increases proteasome activity in keratinocytes, but it displays an inhibitory effect at 10 \u00b5M (Murakami, 2013) . In particular, curcumin induces 26S perturbation, leading to an impairment of cell proliferation in various cancer cells and reduction of cancer burden in mice (Banerjeeaet al.,2018) .", "cite_spans": [{"start": 119, "end": 141, "text": "(Bonfili et al., 2008;", "ref_id": "BIBREF25"}, {"start": 142, "end": 157, "text": "Dahlmann, 1993;", "ref_id": null}, {"start": 158, "end": 178, "text": "Huang and Chen, 2009", "ref_id": null}, {"start": 756, "end": 769, "text": "Rattan, 2006)", "ref_id": null}, {"start": 909, "end": 925, "text": "(Murakami, 2013)", "ref_id": "BIBREF374"}, {"start": 1088, "end": 1110, "text": "(Banerjeeaet al.,2018)", "ref_id": null}], "ref_spans": [], "section": "Direct enhancing proteasome activity by natural compounds"}, {"text": "By analogy, quercetin (3,3',4',5,7-pentahydroxyflavonethe), the most abundant flavonoid found in fruits and vegetables, which has been initially reported to be a 20S inhibitor (Chen, 2005) (IC 50 = J o u r n a l P r e -p r o o f 3.5 \u03bcM), it has been shown to enhance the proteasome activity in vivo and to reduce the A\u03b2induced toxicity in a dose-dependent manner when administered to a Caenorhabditis elegans AD model (Chondroianni et al., 2010) . Likewise, the polyphenol resveratrol, that was previously described as a natural direct PI Qureshi et al.,2012) , recently has been reported to enhance proteasome activity recovering the impaired proteostasis in a C. elegans AD model, and in AD transgenic mice (Regitz et al., 2016) ; in addition, resveratrol has been shown to enhance cognitive activity by increasing 20S proteasome subunits levels and stimulating proteasome activity (Corpas et al., 2019) .", "cite_spans": [{"start": 418, "end": 445, "text": "(Chondroianni et al., 2010)", "ref_id": null}, {"start": 539, "end": 559, "text": "Qureshi et al.,2012)", "ref_id": "BIBREF478"}, {"start": 709, "end": 730, "text": "(Regitz et al., 2016)", "ref_id": "BIBREF497"}, {"start": 884, "end": 905, "text": "(Corpas et al., 2019)", "ref_id": null}], "ref_spans": [], "section": "Direct enhancing proteasome activity by natural compounds"}, {"text": "Hereafter, we focus only on bioactive compounds that directly target the naked catalytic particle, 20S, thus enhancing the ubiquitin-ATP-independent proteolysis, the main pathway degrading the oxidatively damaged and intrinsically disordered proteins (Ben-Nissan and Sharon, 2014) .", "cite_spans": [{"start": 267, "end": 280, "text": "Sharon, 2014)", "ref_id": null}], "ref_spans": [], "section": "Direct enhancing proteasome activity by natural compounds"}, {"text": "Oleuropein, the most abundant phenolic compound extracted from Olea europaea (leaf and olives), enhances all three proteasome activities in vitro and promotes cellular resistance to oxidants, prolonging human fibroblasts lifespan (Katsiki et al., 2007) . Furthermore, it indirectly promoted the enhancement of proteasomes activity by regulating rpn1 expression and downregulation of the apoptosis pathway gene, egl-1 (Tsai, et al., 2017) . Interestingly, betulinic acid has shown a neuroprotective effect in vascular dementia rat models, re-establishing the cerebral blood flow, restoring behaviour parameters and significantly improving the BDNF levels, with a restrain of the oxidative stress and of inflammatory parameters (Kaundala et al., 2018) .", "cite_spans": [{"start": 230, "end": 252, "text": "(Katsiki et al., 2007)", "ref_id": "BIBREF211"}, {"start": 417, "end": 437, "text": "(Tsai, et al., 2017)", "ref_id": "BIBREF731"}, {"start": 726, "end": 749, "text": "(Kaundala et al., 2018)", "ref_id": null}], "ref_spans": [], "section": "Direct enhancing proteasome activity by natural compounds"}, {"text": "Besides the proteasomal effect, oleuropein and betulinic acid could be also considered as pleiotropic small molecules, for their anti-HIV (Mayaux JF et al., 1994; Yang et al., 2016) and anti-tumour activity towards some cancer cell lines (Kessler et al.,2007; Pisha et al., 1995; Saeed et al., 2018) .", "cite_spans": [{"start": 138, "end": 162, "text": "(Mayaux JF et al., 1994;", "ref_id": null}, {"start": 163, "end": 181, "text": "Yang et al., 2016)", "ref_id": "BIBREF829"}, {"start": 238, "end": 259, "text": "(Kessler et al.,2007;", "ref_id": null}, {"start": 260, "end": 279, "text": "Pisha et al., 1995;", "ref_id": null}, {"start": 280, "end": 299, "text": "Saeed et al., 2018)", "ref_id": null}], "ref_spans": [], "section": "Direct enhancing proteasome activity by natural compounds"}, {"text": "Although both oleuropein and betulinic acid have been previously reported to be natural proteasome activators (Darci et al., 2017) , some authors recently clarified that the stimulatory activity is J o u r n a l P r e -p r o o f restricted to fluorogenic substrates, and no effect has been reported on the turnover of a mis-folded protein in vitro or in living cells.", "cite_spans": [{"start": 110, "end": 130, "text": "(Darci et al., 2017)", "ref_id": null}], "ref_spans": [], "section": "Direct enhancing proteasome activity by natural compounds"}, {"text": "Among naturally occurring activators of 20S proteasome there are some physiological cellular components, such as mucopolisaccarides (e.g., heparin), glycolipids (e.g., ceramides, lysophosphatidyl-inositol and cardiolipin) (Ohkubo et al., 1991; Matsumura and Aketa 1991; Ruiz de Mena, 1993) , and some proteins (not included in the physiological UPS control), such as the arginine-rich histone H3, a chromatin binding protein able to selectively enhance protein degradation by the proteasome (Orlowski, 2001) .", "cite_spans": [{"start": 222, "end": 243, "text": "(Ohkubo et al., 1991;", "ref_id": null}, {"start": 244, "end": 269, "text": "Matsumura and Aketa 1991;", "ref_id": "BIBREF335"}, {"start": 270, "end": 289, "text": "Ruiz de Mena, 1993)", "ref_id": "BIBREF550"}, {"start": 491, "end": 507, "text": "(Orlowski, 2001)", "ref_id": null}], "ref_spans": [], "section": "Direct enhancing proteasome activity by natural compounds"}, {"text": "The detailed mechanism by which these compounds regulate 20S degradation is still largely undetermined, but it might be related to the gate opening, mimicking the RP (or naturals Proteasome Activators) interaction (see Sections 2.2.1 and 2.3.1).", "cite_spans": [], "ref_spans": [], "section": "Direct enhancing proteasome activity by natural compounds"}, {"text": "Fatty acids are likely the first small molecules that were first described as 20S proteasome modulators. Indeed, our basic knowledge of proteasome function is rooted on the pioneering studies conducted throughout the 80s and 90s (Orlowski and Wilk ,1981; Ishiura, 1986; Folco, 1988) , using fatty acids and SDS as activators. The first systematic study on proteasome peptidase activity reported the effects of several saturated and unsaturated fatty acids examining various carbon-chain lengths and underlining that the optimal 20S activation potency may be achieved by using fatty acids with a C18-C20 chain carbon; thus, the oleic acid resulted the most active compound, with an activating effect 50-fold higher than SDS (Dahlmann et al., 1985) . Although our knowledge of proteasome structure and function was still in its infancy, in those early reports it was proposed that activation mechanism could be basically related to conformational changes occurring in the enzyme. Furthermore, they also proposed that fatty acids, abundant in muscle, could participate in the physiological regulation of proteasome-mediated protein degradation. Later on, Orlowski et al.", "cite_spans": [{"start": 229, "end": 254, "text": "(Orlowski and Wilk ,1981;", "ref_id": null}, {"start": 255, "end": 269, "text": "Ishiura, 1986;", "ref_id": "BIBREF181"}, {"start": 270, "end": 282, "text": "Folco, 1988)", "ref_id": "BIBREF75"}, {"start": 723, "end": 746, "text": "(Dahlmann et al., 1985)", "ref_id": null}], "ref_spans": [], "section": "Fatty acids"}, {"text": "performed a detailed kinetic analysis, reporting that lauric acid activates the PGPH activity like SDS; increasing concentrations of lauric acid caused a shift in the apparent K m toward lower substrate concentrations with a concomitant increase in V max (Orlowski et al. 1991) . However, unlike the SDS-mediated one, this activation occurred with a sigmoidal shape of the velocity curve,", "cite_spans": [{"start": 255, "end": 277, "text": "(Orlowski et al. 1991)", "ref_id": "BIBREF409"}], "ref_spans": [], "section": "Fatty acids"}, {"text": "suggesting the presence of two (or more) substrate binding sites interacting cooperatively. In other words, in the absence of an external activator only part of this activity is manifested, thus underlining the cooperative control of allosteric sites and the concepts of \"latency\" and of \"multi-J o u r n a l P r e -p r o o f proteasic complex\"; however, there is still some controversy concerning the ability of most fatty acids to enhance the three main 20S proteolytic activities. Actually, fatty acids often exhibit a double-faced nature, behaving as activators and/or inhibitors, according to the type of activity measured. In ostrich liver the PGPH proteasome activity was found to be activated by all (with the exception of decanoic acid) types of fatty acids in a concentration-dependent fashion, whereas the chymotryptic and tryptic-like activities were differentially inhibited (Klinkradt et al., 1997 ). An attempt to clarify the intricate mechanism by which the three peptidasic activities of 20S proteasome are regulated by fatty acids was made by Yamada and co-authors, who reported that the pattern of activation of the trypsin-type peptidase is distinctly different from those of ChT-L and PHPH-L; thus, linoleic and oleic acids strongly activated both the chymotrypsin-type and the peptidyl glutamyl-peptide (PGP) hydrolase-type activities in a biphasic activation pattern (Yamada et al.,1998) . Conversely, the activation pattern of tryptic-type peptidase occurs in a tri-phasic manner through an inhibition over the low concentration range, activation in a middle concentration range and inhibition again over a higher concentration range. These apparently conflicting results were explained by hypothesizing the existence of two classes of binding sites, namely \"latency sites\" and \"activation sites\", and the fatty acid activation or inhibition phenomena have been interpreted as the result of binding to these different sites.", "cite_spans": [{"start": 888, "end": 911, "text": "(Klinkradt et al., 1997", "ref_id": null}, {"start": 1390, "end": 1410, "text": "(Yamada et al.,1998)", "ref_id": "BIBREF827"}], "ref_spans": [], "section": "Fatty acids"}, {"text": "Over last decades, the studies on isolated/purified proteasome have been replaced by investigations performed through cellular or clinical studies. Some of these reports focused on the role of polyunsaturated fatty acid on protein-breakdown in muscle mass of cachectic cancer patients. As an example, the neuroprotective effects of (Undurti et al.", "cite_spans": [], "ref_spans": [], "section": "Fatty acids"}, {"text": "Acids (LCPUFA) have been ascribed to some modulatory effects on the UPS, albeit no evidences on direct interaction with 20S proteasome have been reported. Docosahexaenoic acid, the most unsaturated omega-3 fatty acid, displaying pro-apoptotic activity against tumour cells, was reported to exert its anti-cancer activity acting on UPS, even though no evidence of a direct interaction with 20S has been reported (Jing et al., 2014) . There is also evidence describing the inhibitory (Hamel, 2009 ) effect on proteasome by the saturated fatty acid palmitate; this fatty acid is believed to contribute to type-2 diabetes, blocking UPS activity with a consequent lipotoxic effect on pancreatic Furthermore, a greatly diminished capacity to stimulate the 20S was observed when the phenolic amide was substituted by aryl groups. These derivatives still need a careful pharmacological evaluation, also taking into account that, beyond their role as a nutritional energy source, fatty acids have several molecular targets, such as enzymes, receptors, and they are increasingly considered as important signalling molecules that can induce several physiological and pathophysiological effects.", "cite_spans": [{"start": 411, "end": 430, "text": "(Jing et al., 2014)", "ref_id": "BIBREF196"}, {"start": 482, "end": 494, "text": "(Hamel, 2009", "ref_id": "BIBREF141"}], "ref_spans": [], "section": "2004) Long-Chain Polyunsaturated Fatty"}, {"text": "Although over the last decade our knowledge of human diseases has greatly increased, its translation into new drugs and therapeutic benefits has been much slower than expected (Ashburn et. al.2004; Scannell et al., 2012) The reasons that may explain this apparent incongruity are multifaceted and include the increased time needed to pipeline new drugs to the market, a high attrition rate of drug candidates in clinical trials (Pammolli, 2011) , and rapidly changing regulatory requirements. Some reports estimate that, on average, for every dollar invested by the pharmaceutical industry in research and development (R&D) less than a dollar is returned, thus suggesting that investments on R&D will rapidly decline in the very next future (Pushpakom et al.,2019) .", "cite_spans": [{"start": 176, "end": 197, "text": "(Ashburn et. al.2004;", "ref_id": null}, {"start": 198, "end": 220, "text": "Scannell et al., 2012)", "ref_id": "BIBREF600"}, {"start": 428, "end": 444, "text": "(Pammolli, 2011)", "ref_id": "BIBREF425"}, {"start": 741, "end": 764, "text": "(Pushpakom et al.,2019)", "ref_id": "BIBREF470"}], "ref_spans": [], "section": "Repositioning \"old drugs\" to activate the proteasome: the case of aminopyrine"}, {"text": "Therefore, drug repositioning (or repurposing), an approach to identify new medical applications for drugs, already approved for different therapeutic uses, (Nosengo, 2016) offers a number of advantages over the development of entirely new drugs, such as (i) the reduced costs in the case of failure, and (ii) the shorter time interval for the transfer to the market because safety assessment has been already completed. Thus, given the urgent need to find a treatment for neurodegenerative diseases (such as AD, PD and ALS), it is not surprising that an increasingly large number of existing drugs are tested for these disorders; in this respect, an important example is the repositioning of galantamine, one of the drugs now available on the market for the treatment of AD (Dur\u00e3es et al., 2018) .", "cite_spans": [{"start": 157, "end": 172, "text": "(Nosengo, 2016)", "ref_id": "BIBREF392"}, {"start": 775, "end": 796, "text": "(Dur\u00e3es et al., 2018)", "ref_id": null}], "ref_spans": [], "section": "Repositioning \"old drugs\" to activate the proteasome: the case of aminopyrine"}, {"text": "Despite many examples of drug repositioning have been based on serendipity, a rational development of a repurposed drug implies a detailed knowledge of the pathways involved. As an example, there is evidence that AD development is associated to aggregation of the neurotoxic amyloid \u03b2 (A\u03b2) peptide (Kang, 1987) , being the consequence of a failure of proteasome function and a consequent accumulation of poly-ubiquitinated substrates, as detected in AD neuronal tissues (Perry, 1987) . In particular, in response to the increased oxidative and proteotoxic stress, the J o u r n a l P r e -p r o o f percentage of uncapped 20S proteasome is significantly increased in AD neuronal tissues in comparison to healthy cells . Moreover, the A\u03b2 peptide, as well as other intrinsically disordered proteins (IDPs), is a substrate of the 20S proteasome.", "cite_spans": [{"start": 298, "end": 310, "text": "(Kang, 1987)", "ref_id": "BIBREF208"}, {"start": 470, "end": 483, "text": "(Perry, 1987)", "ref_id": "BIBREF452"}], "ref_spans": [], "section": "Repositioning \"old drugs\" to activate the proteasome: the case of aminopyrine"}, {"text": "On these premises, it has been reported that pyrazolones, a class of small molecules extensively used in the past as painkillers and antipyretic drugs, induce proteasome activation in mice models of ALS (Trippier, 2014) . In a recent report, it was demonstrated that some members of this class of molecules (i.e., aminopyrine, 4-aminoantiypirine and nifenazone) may enhance ChT-L proteasome activity in tube tests (Santoro et al., 2019) . Proteasome activity assays, carried out in parallel in the presence of an excess of reducing agents (i.e., ascorbic acid or glutathione), underscored that proteasome activation by pyrazolones is not directly related to their antioxidant properties, thus suggesting that an alternative mechanism of action should be proposed. In the case of aminopyrine the evidence that it is able to activate native 20S, but it is ineffective on a mutant (i.e., \u03b13\u0394N, which has a permanently opened gate, see Section 2.2.2), envisaged that its effect on proteasome activity is mainly related to enhanced dynamics of the outer \u03b1-rings, which is a common mechanism of proteasome activation by small molecules (see Section 2.2.2) (Njomen, 2019). Furthermore, the effects on the different cellular proteasome forms (i.e., uncapped 20S, singly capped 26S and doubly capped 30S, see Sections 2.2.2 and 2.3.2) were also assayed in neuroblastoma SH-SY5Y cells by separating proteasome assemblies in non-denaturing gels. It was observed that proteasome assemblies resulted significantly stimulated two hours after the treatment with the drug, even though this effect vanishes over 24 h after stimulation, reflecting the pharmacokinetics properties of aminopyrine (with a half-life in blood serum of approximately 2 h). Docking simulations, performed using aminopyrine, antipyrine, 4-aminoantipyrine and nifenazone as ligands of human 20S, have outlined that they interact with \u03b1-rings, involving the \u03b11/\u03b12 and \u03b15/\u03b16 binding pockets; the most active molecules display a binding free energy ~ 30 Kcal/mol more favorable than the less active ones. In particular, it was observed that aminopyrine bridges \u03b11and \u03b12 subunits since its phenyl ring is involved in hydrophobic interactions with residues L22, Y25, E26, A126, and A157 of the \u03b11 subunit; the oxygen atom of aminopyrine is also H-bonded with Y159 and the N-methyl group with residue A32 of the same subunit. Moreover, residues G30, G31 and A32 of the \u03b12 subunit are linked by non-polar interactions to the 4-(dimethylamino) group of aminopyrine. Next, T-shaped stacking interactions bridge the residue F162 of the \u03b15 subunit with the phenyl ring of aminopyrine, and the residue Q60 of the \u03b16 subunit turns out to be H-bonded to the oxygen atom of the ligand. It is important to remind here that the \u03b11/\u03b12 grooves are the preferential anchoring sites of the HbYX motif which binds the 20S with the Rpt3 subunit of the regulatory particle 19S (see Sections 2.2.2 and 2.3.2) ; furthermore, small molecules, known to mobilize 20S J o u r n a l P r e -p r o o f gating dynamics, bind the \u03b15/\u03b16 grooves (Di Dato et al., 2017) . Notably, the inactive compound antipyrine mainly interacts through T-shaped aromatic interactions and H-bonds with two residues of \u03b12 subunit Y159 and Y160, respectively, but no bridging interactions with any other subunit of the \u03b1-ring are observed ( Figure 5 A\u03b2 proteotoxicity with a mechanism of protection mostly related to proteasome activation. These results are likely to stimulate further studies focusing on proteasome activation by repurposed drugs and, ultimately, to relaunch investments from pharmaceutical industries in this risky area.", "cite_spans": [{"start": 203, "end": 219, "text": "(Trippier, 2014)", "ref_id": null}, {"start": 414, "end": 436, "text": "(Santoro et al., 2019)", "ref_id": null}, {"start": 3066, "end": 3088, "text": "(Di Dato et al., 2017)", "ref_id": null}], "ref_spans": [{"start": 3343, "end": 3351, "text": "Figure 5", "ref_id": null}], "section": "Repositioning \"old drugs\" to activate the proteasome: the case of aminopyrine"}, {"text": "Although not deeply investigated yet, proteasome inhibitors discussed so far display a known antiinflammatory activity, envisaging a therapeutic efficacy in combined regimen in subjects with acute severe inflammatory processes, such as in viral infections. This potentiality assumes a particularly updated importance nowadays during the recent pandemia due to SARS-Cov-2, which is likely to infect millions of people worldwide with a significant lethality rate. Besides the public health and victim tolls, which are by far the most urgent topics, disease spread is dramatically impacting on world social and economic activities, making even more urgent the identification of a specific therapy or a vaccine (Andersen et al., 2020; Sheeren et al., 2020; Baden and Rubin, 2020; Lipsitch et al., 2020) .", "cite_spans": [{"start": 707, "end": 730, "text": "(Andersen et al., 2020;", "ref_id": null}, {"start": 731, "end": 752, "text": "Sheeren et al., 2020;", "ref_id": null}, {"start": 753, "end": 775, "text": "Baden and Rubin, 2020;", "ref_id": null}, {"start": 776, "end": 798, "text": "Lipsitch et al., 2020)", "ref_id": null}], "ref_spans": [], "section": "Covid19 therapy?"}, {"text": "The limited clinical and laboratory data available so far suggest that in most cases SARS-Cov-2 infection evolves through symptoms overlapping those of canonical flu, even though a very large number of subjects do not develop symptoms (Baden and Rubin, 2020; . In a limited, but significant, especially for the health assistance burden, number of cases, infection progresses toward a clinical picture of interstitial pneumonia sustained by the massive stimulation of the immune system the virus appears to be able to elicit (Baden and Rubin, 2020; .", "cite_spans": [{"start": 246, "end": 258, "text": "Rubin, 2020;", "ref_id": null}, {"start": 535, "end": 547, "text": "Rubin, 2020;", "ref_id": null}], "ref_spans": [], "section": "Covid19 therapy?"}, {"text": "The cytokine storm which underscores this disease progression often induces Acute Respiratory Distress Syndrome (ARDS) and diffuse thrombotic angiopathy which are, to date, the prevalent cause of death of ill patients.", "cite_spans": [], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Nonetheless, the massive inflammatory response rather than virus replication is gaining increasingly relevance as the real target of therapy. This is emphasized by the apparent efficacy of therapies based on biological drugs which target the pro-inflammatory cytokines (Baden and Rubin, 2020) . In any case, specific trials will definitively address the therapeutic efficacy of these approaches, hopefully allowing to identify a therapeutic regimen which can be early undertaken to prevent disease complication and sanitarian costs. including the marked innate immune inflammatory cytokine release (Ma et al., 2010) .", "cite_spans": [{"start": 280, "end": 292, "text": "Rubin, 2020)", "ref_id": null}, {"start": 598, "end": 615, "text": "(Ma et al., 2010)", "ref_id": "BIBREF315"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Among studies, reported to date, there is a compelling evidence that the UPS could regulate the virus infectious cycle at multiple levels, with the exception of virus internalisation which occurs through endocytosis following recognition of Angiotensin Converting Enzyme-2 (ACE2) receptor on host cells by the spike protein (S) (Mathewson et al., 2008; Li et al., 2007; Li et al., 2003) .", "cite_spans": [{"start": 328, "end": 352, "text": "(Mathewson et al., 2008;", "ref_id": null}, {"start": 353, "end": 369, "text": "Li et al., 2007;", "ref_id": null}, {"start": 370, "end": 386, "text": "Li et al., 2003)", "ref_id": "BIBREF293"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Interestingly, chemical inhibitors of proteasome induced the virus particles to accumulate in late endosomes and lysosomes, suggesting a UPS role in virus release from endosomes (Yu and Lai, 2005) . Once released in the cytoplasm, the nucleic acid of SARS-Cov (a positively single stranded RNA) encodes four structural proteins, nucleocapsid (N), envelope (E), membrane (M) and spike (S) proteins and about 16 non-structural proteins which are translated as a single poly-protein (Yu and Lai, 2005; Li et al., 2007; Schneider et al., 2012) . The highly antigenic protein N of SARS-CoV, which is an extensively glycosylated and positively charged protein of the nucleocapsid, forms a helical ribonucleoprotein complex with the viral RNA, and it was found to interact with ATPase 6 (i.e., a 19S subunit) in lung fibroblasts infected with the virus .", "cite_spans": [{"start": 178, "end": 196, "text": "(Yu and Lai, 2005)", "ref_id": "BIBREF840"}, {"start": 480, "end": 498, "text": "(Yu and Lai, 2005;", "ref_id": "BIBREF840"}, {"start": 499, "end": 515, "text": "Li et al., 2007;", "ref_id": null}, {"start": 516, "end": 539, "text": "Schneider et al., 2012)", "ref_id": "BIBREF611"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Therefore, although further studies are required to confirm this hypothesis, a direct down-regulation of proteasome complexes by SARS-CoV can be envisaged, since in the intracellular space the ATPase 6 subunit (because of its position in the multi-subunits complex, see Studies on non-structural proteins, which intervene either in the virus replication and in the interaction with the host machineries, besides confirming that the UPS does not affect virus internalization, envisaged that virus-UPS interaction may account for the mechanisms of immune system evasion (Wong et al., 2018; Liu et al., 2014; Hu et al., 2012) . In this respect, the SARS-CoV", "cite_spans": [{"start": 568, "end": 587, "text": "(Wong et al., 2018;", "ref_id": "BIBREF816"}, {"start": 588, "end": 605, "text": "Liu et al., 2014;", "ref_id": "BIBREF509"}, {"start": 606, "end": 622, "text": "Hu et al., 2012)", "ref_id": "BIBREF713"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Papain-like proteasome (PL pro ), which, along with the main protease M pro (also called 3CL pro ), is essential for the cleavage and processing of the viral poly-protein, was found to repress IFN\u03b3 synthesis and secretion in lung cell cultures by targeting IRF3 phosphorylation and nuclear translocation (Devaraj et al., 2007; . Interestingly, PL pro was reported to have DUB activity in human cells by recognizing the LXGG consensus de-ubiquitination motif and by directly binding to the proteasome through the N-terminal Ub-like domain which is present in its structure (Ma et al., 2010) . Although the DUB activity was shown to be ineffective in altering the repertoire of host poly-Ub proteins, since Ub-conjugation is a post-translational mechanism of regulation of intracellular trafficking and receptor signalling, it would be relevant to uncover the link between IRF3 signalling and Ub-labelling by PL pro .", "cite_spans": [{"start": 304, "end": 326, "text": "(Devaraj et al., 2007;", "ref_id": null}, {"start": 572, "end": 589, "text": "(Ma et al., 2010)", "ref_id": "BIBREF315"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "In this framework, viral accessory protein 3a was reported to promote IFN-I receptor ubiquitination and proteasome degradation (Minakshi et al., 2009) . Along with this, accessory proteins 8a and 8b or 8ab, which were found to be expressed either as a single protein or spliced protein in different viruses at different stages of SARS-CoV infection spread in 2003, were found to bind to intracellular ubiquitinated proteins through an extensively glycosylated functional domain which account for ubiquitin binding and ubiquitin conjugation . Interestingly, 8b and 8ab appears to stimulate the UPS-mediated degradation of IRF3 at later stages of virus replication than PL pro was supposed to do (Wong et al., 2018) . Remarkably, proteasome inhibition was found to be reveal that a major role for the UPS is to drive antigenic processing and inflammation activation especially in monocytes/macrophages (Silswal et al., 2017; Horan et al., 2013; Forget et al., 2005) .", "cite_spans": [{"start": 127, "end": 150, "text": "(Minakshi et al., 2009)", "ref_id": "BIBREF354"}, {"start": 694, "end": 713, "text": "(Wong et al., 2018)", "ref_id": "BIBREF816"}, {"start": 900, "end": 922, "text": "(Silswal et al., 2017;", "ref_id": "BIBREF650"}, {"start": 923, "end": 942, "text": "Horan et al., 2013;", "ref_id": null}, {"start": 943, "end": 963, "text": "Forget et al., 2005)", "ref_id": "BIBREF77"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Furthermore, proteasome dysfunction in alveolar type II epithelial cells is associated with ARDS in the alveolar space of Rpt3-KO mice (Sitaraman et al., 2019) . From the second point of view, besides the known contribution in modulating the transcriptional activity of nuclear factors, such as NF-kB (extensively discussed in paragraph 3.2.1), additional tissue-specific mechanisms which should intervene in coronavirus infection are expected to take part to the pathogenesis. In this regard, the clearance of specific proteins, such as elafin by the exceedingly activated UPS might be a relevant factor in sustaining inflammation. In fact, elafin is a serine-proteasome inhibitor and its inhibitory activity resides within the C-terminal domain which has specificity for NE and proteinase 3. Notably, transglutaminase substrate binding motif (GQDPVK) is present at the N-terminus which allows it to cross-link extracellular matrix proteins (Kerrin et al., 2013) .", "cite_spans": [{"start": 135, "end": 159, "text": "(Sitaraman et al., 2019)", "ref_id": "BIBREF657"}, {"start": 942, "end": 963, "text": "(Kerrin et al., 2013)", "ref_id": "BIBREF222"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "In addition, clinical studies highlight that the 20S proteasome is released in the alveolar space during ARDS in an active configuration, and that immune-proteasome subunits are increased in the alveolar space envisaging a prognostic relevance of its quantification (Sixt et al., 2009; Sixt et al., 2012) . As a whole, the disastrous SARS-Cov-2 experience suggests that multi-faceted efforts by the scientific community are demanded to clarify the pathogenesis of coronaviruses especially in view of the concrete possibility that additional spill-overs in the next future might come up posing new pandemic threats. The central role of the UPS in regulating the complex dynamic of interactions between the pathogen and the host, along with the growing interest in the development of UPS modulators, could provide further clues for the identification of valid approaches which allow to limit the sanitarian, social and economic costs of similar pandemia.", "cite_spans": [{"start": 266, "end": 285, "text": "(Sixt et al., 2009;", "ref_id": "BIBREF659"}, {"start": 286, "end": 304, "text": "Sixt et al., 2012)", "ref_id": "BIBREF658"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "The authors declare that there are no conflicts of interest.", "cite_spans": [], "ref_spans": [], "section": "Conflict of Interest Statement"}, {"text": "Proteasome is a highly dynamic complex as demonstrated by the existence of alternative forms of proteasome which deal with specific biological roles. The immune-proteasome is the most studied alternative form of proteasome and its proteolytic activity has been long linked only to generation of antigenic peptides for MHC class I presentation Rousseau and Bertolotti, 2018) . However, a number of studies have reported a role for immune-proteasome in B and T cell differentiation, monocytes and dendritic cells activation, in the maintenance of pluripotency of stem cells (Atkinson et al., 2012) , in the differentiation of non-immune cells, such as skeletal muscle ones and also in the homeostasis of nervous cells (Kaur and Batra, 2016; Kimura et al., 2015) .", "cite_spans": [{"start": 343, "end": 373, "text": "Rousseau and Bertolotti, 2018)", "ref_id": "BIBREF544"}, {"start": 572, "end": 595, "text": "(Atkinson et al., 2012)", "ref_id": null}, {"start": 716, "end": 738, "text": "(Kaur and Batra, 2016;", "ref_id": "BIBREF214"}, {"start": 739, "end": 759, "text": "Kimura et al., 2015)", "ref_id": null}], "ref_spans": [], "section": "BOX 1 Elements in proteasome heterogeneity"}, {"text": "Along with this, immune-proteasome dysregulation has also been associated with various human diseases, including cancer, immune and inflammatory disorders: in fact, either hyper-activation or hypo-activation may turn out into a hyper-immune or hypo-immune phenotype (Eskandari et al., 2017) . Therefore, there has been a great effort to develop specific immune-proteasome inhibitors, which showed minimal cross-reactivity with constitutive proteasome. From the structural point of view, the immune-proteasome differs from the canonical 26S for the replacement of catalytic subunits with its immune highly homolog counterparts b1i (LMP2), b2i (MECL1), and b5i (LMP7) Sherman and Li, 2020) . Remarkably, these immune-proteasome subunits are constitutively expressed in different tissues, such as thymus and spleen. Moreover, non-immune cells preferentially incorporate them during the assembly de novo of 20S particles following exposition to proinflammatory stimuli (e.g., IFN-\u03b3, TNF-\u03b1, and lipopolysaccharide) or cytokineindependent stressors (e.g., oxidative stress) (Griffin et al., 1998; Heink et al., 2005; Ferrington et al., 2012; Murata et al., 2018) . Immune-subunits incorporation has been proposed to proceed cooperatively, since the direct binding of \u03b25i to chaperone POMP is followed by the quick recruitment of b1i and b2i. Therefore, the rate of their assembly is about four times faster than that of canonical subunits in the forming 20S, a finding consistent with the primary biological role of immune-proteasome, which is demanded to cope with patho-physiological challenges in a dynamic and highly efficient manner (Groettrup et al., 1997; Griffin et al., 1998; Murata et al., 2018) . The subunit substitution accounts for a shift in the catalytic preferences and activity; in fact, immuneproteasome exhibits elevated level of CT-L and T-L activities which favour the production of peptides with terminal basic or hydrophobic residues that fit better into the cleft of the MHC class I molecule (Rousseau and Bertolotti, 2018; Murata et al., 2018) .", "cite_spans": [{"start": 266, "end": 290, "text": "(Eskandari et al., 2017)", "ref_id": null}, {"start": 666, "end": 687, "text": "Sherman and Li, 2020)", "ref_id": "BIBREF640"}, {"start": 1068, "end": 1090, "text": "(Griffin et al., 1998;", "ref_id": "BIBREF115"}, {"start": 1091, "end": 1110, "text": "Heink et al., 2005;", "ref_id": "BIBREF170"}, {"start": 1111, "end": 1135, "text": "Ferrington et al., 2012;", "ref_id": null}, {"start": 1136, "end": 1156, "text": "Murata et al., 2018)", "ref_id": "BIBREF377"}, {"start": 1632, "end": 1656, "text": "(Groettrup et al., 1997;", "ref_id": "BIBREF117"}, {"start": 1657, "end": 1678, "text": "Griffin et al., 1998;", "ref_id": "BIBREF115"}, {"start": 1679, "end": 1699, "text": "Murata et al., 2018)", "ref_id": "BIBREF377"}, {"start": 2011, "end": 2042, "text": "(Rousseau and Bertolotti, 2018;", "ref_id": "BIBREF544"}, {"start": 2043, "end": 2063, "text": "Murata et al., 2018)", "ref_id": "BIBREF377"}], "ref_spans": [], "section": "BOX 1 Elements in proteasome heterogeneity"}, {"text": "IFN-\u03b3 also induces the expression of another important regulator, besides 19S, of 20S activity, the 11S regulator (PA28) (Sherman and Li, 2020; Cascio et al., 2001; .", "cite_spans": [{"start": 121, "end": 143, "text": "(Sherman and Li, 2020;", "ref_id": "BIBREF640"}, {"start": 144, "end": 164, "text": "Cascio et al., 2001;", "ref_id": null}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Mammalian cells express three different subunits of 11S regulator: PA28\u03b1, PA28\u03b2, and PA28\u03b3.", "cite_spans": [], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "PA28\u03b1 and PA28\u03b1 assemble into a hetero-heptameric complex, primarily located in the cytoplasm, while homo-heptameric PA28\u03b3 is mainly present inside the nucleus (W\u00f3jcik et al., 1998; . Although the role of these regulators is not clear, it has been reported that both forms increase after oxidative stress, suggesting their involvement in the degradation of damaged proteins (Pickering et al., 2010; Pickering et al., 2012; Kors et al., 2019; Thibaudeau and Smith, 2018) .", "cite_spans": [{"start": 160, "end": 181, "text": "(W\u00f3jcik et al., 1998;", "ref_id": "BIBREF814"}, {"start": 374, "end": 398, "text": "(Pickering et al., 2010;", "ref_id": "BIBREF460"}, {"start": 399, "end": 422, "text": "Pickering et al., 2012;", "ref_id": "BIBREF458"}, {"start": 423, "end": 441, "text": "Kors et al., 2019;", "ref_id": null}, {"start": 442, "end": 469, "text": "Thibaudeau and Smith, 2018)", "ref_id": "BIBREF709"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Accordingly, PA28\u03b1-\u03b2 association with the 20S does not enhance the degradation of polyubiquitinated protein/peptide substrates in vitro Lobanova et al., 2018) . In addition to its role in preserving cellular homeostasis after oxidative stress, the PA28 role in the regulation of the immune response has been extensively studied (Tanahashi et al., 1997; Fr\u00fch and Yang, 1999; Preckel et al., 1999; . In fact, following INF\u03b3 stimulation, the level of PA28\u03b1-\u03b2 binding to inducible 20S increases, enhancing its proteolytic activity and mediating the generation of antigenic peptides (Groettrup et al., 1996; Sijts et al., 2002; Fort et al., 2015) . Unlike PA28\u03b1-\u03b2, PA28\u03b3 is not induced by IFN\u03b3, suggesting a different biological role for PA28\u03b3-20S complex. Although the role of this complex remains elusive, a number of studies imply an involvement in the cell cycle progression (Kors et al., 2019) .", "cite_spans": [{"start": 136, "end": 158, "text": "Lobanova et al., 2018)", "ref_id": null}, {"start": 328, "end": 352, "text": "(Tanahashi et al., 1997;", "ref_id": null}, {"start": 353, "end": 373, "text": "Fr\u00fch and Yang, 1999;", "ref_id": "BIBREF84"}, {"start": 374, "end": 395, "text": "Preckel et al., 1999;", "ref_id": null}, {"start": 578, "end": 602, "text": "(Groettrup et al., 1996;", "ref_id": null}, {"start": 603, "end": 622, "text": "Sijts et al., 2002;", "ref_id": "BIBREF647"}, {"start": 623, "end": 641, "text": "Fort et al., 2015)", "ref_id": "BIBREF80"}, {"start": 874, "end": 893, "text": "(Kors et al., 2019)", "ref_id": null}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "In addition to immune-proteasome, other tissue-specialized forms of proteasome are thymoproteasome and testis-proteasome (spermato-proteasome). The first one is expressed by cortical thymic epithelial cells and contains two immune catalytic subunits, B1i and B2i, and a thymus specific subunit (B5t), that, unlike \u03b25 and \u03b25i, is characterized by a number of hydrophilic amino acids in its catalytic pocket. Thus, thymo-proteasome produces a distinct spectrum of peptide fragments, and cells expressing it display a unique set of peptides associated with MHC-I molecules (Murata et al., 2007; Florea et al., 2010; Sasaki et al., 2015) . Thymo-proteasome role accounts for the positive selection of developing T cells, since it is essential to optimize the release of the repertoire of peptides for CD8 + T cell (Nitta et al., 2010; Xing et al., 2013; Takada et al., 2015; Murata et al., 2018) .", "cite_spans": [{"start": 570, "end": 591, "text": "(Murata et al., 2007;", "ref_id": "BIBREF376"}, {"start": 592, "end": 612, "text": "Florea et al., 2010;", "ref_id": "BIBREF74"}, {"start": 613, "end": 633, "text": "Sasaki et al., 2015)", "ref_id": "BIBREF586"}, {"start": 810, "end": 830, "text": "(Nitta et al., 2010;", "ref_id": "BIBREF391"}, {"start": 831, "end": 849, "text": "Xing et al., 2013;", "ref_id": "BIBREF823"}, {"start": 850, "end": 870, "text": "Takada et al., 2015;", "ref_id": "BIBREF698"}, {"start": 871, "end": 891, "text": "Murata et al., 2018)", "ref_id": "BIBREF377"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "Spermato-proteasome is a testis-specific form of proteasome (described exclusively in spermatocytes, spermatids and sperm), and it is characterized by a chronologically defined expression. It contains a specific \u03b14 subunit (\u03b14s) (PMSA8 gene) in the place of corresponding constitutive \u03b1-subunit, whose incorporation into a newly formed 20S is mutually exclusive and does not alter the catalytic preferences of the constitutive 20S Uechi et al., 2014;  J o u r n a l P r e -p r o o f Morozov and Karpov, 2019) . Elevated expression of PSMA8 has been identified in different tumours, such as large B-cell lymphoma, thymoma, and testicular germ cell tumours. However, the biological significance and the possibility to make \u03b14s a therapeutic target candidate has not been elucidated yet (Bruggerman et al., 2018; Morozov and Karpov, 2019) . The incorporation of \u03b14s in spermato-proteasome seems to favour the 20S association with another gate-activating RP, namely PA200 (Blm10 in yeast) . PA200 is a nuclear-specific proteasome activator and it is expressed in all mammalian tissues, but it is particularly abundant in the testis, where it plays a crucial role in spermatogenesis (Ustrell et al., 2005; Khor et al., 2006) . Accordingly, PA200", "cite_spans": [{"start": 431, "end": 450, "text": "Uechi et al., 2014;", "ref_id": "BIBREF739"}, {"start": 451, "end": 451, "text": "", "ref_id": null}, {"start": 483, "end": 508, "text": "Morozov and Karpov, 2019)", "ref_id": "BIBREF369"}, {"start": 784, "end": 809, "text": "(Bruggerman et al., 2018;", "ref_id": null}, {"start": 810, "end": 835, "text": "Morozov and Karpov, 2019)", "ref_id": "BIBREF369"}, {"start": 1178, "end": 1200, "text": "(Ustrell et al., 2005;", "ref_id": "BIBREF747"}, {"start": 1201, "end": 1219, "text": "Khor et al., 2006)", "ref_id": "BIBREF223"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "deletion markedly reduces fertility of male mice (Khor et al., 2006) , and the PA200/20S spermatoproteasome complex catalyses ubiquitin-independent degradation of acetylated core histones during DNA repair and spermatogenesis . PA200 also binds constitutive proteasome and the amount of PA200/constitutive 20S, as well as of PA28/20S complex, increases upon 26S", "cite_spans": [{"start": 49, "end": 68, "text": "(Khor et al., 2006)", "ref_id": "BIBREF223"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "inhibition, contributing to adapt the pool of different proteasome populations to the cell condition (Welk et al., 2016) . The crystal structure of this complex has revealed that C-terminal HbYX motif in PA200 fits between \u03b15 and \u03b16 inter-subunit pocket, mediating 20S gate opening (Sadre-Bazzaz et al., 2010; Witkowska et al., 2017) . Interestingly, it strongly stimulates the rate of C-L activity, although its biological significance is poorly clear yet (Ustrell et al., 2002) . Recently, it has been reported the identification of a non-canonical variant of constitutive 20S in mammalian cells, previously identified in yeast. It is known as alternative '\u03b14-\u03b14' proteasome, which assembles upon replacement of \u03b13 with an additional \u03b14 subunit in the position normally occupied by the former (Velichutina et al., 2004; Kusmierczyk et al., 2008; Padmanabhan et al., 2016) . Importantly, mammalian cells, primed to assemble these alternative proteasomes, exhibit enhanced resistance to cellular stress induced by metal ions (Padmanabhan et al., 2016) .", "cite_spans": [{"start": 101, "end": 120, "text": "(Welk et al., 2016)", "ref_id": "BIBREF800"}, {"start": 282, "end": 309, "text": "(Sadre-Bazzaz et al., 2010;", "ref_id": "BIBREF554"}, {"start": 310, "end": 333, "text": "Witkowska et al., 2017)", "ref_id": "BIBREF812"}, {"start": 457, "end": 479, "text": "(Ustrell et al., 2002)", "ref_id": "BIBREF745"}, {"start": 795, "end": 821, "text": "(Velichutina et al., 2004;", "ref_id": "BIBREF758"}, {"start": 822, "end": 847, "text": "Kusmierczyk et al., 2008;", "ref_id": null}, {"start": 848, "end": 873, "text": "Padmanabhan et al., 2016)", "ref_id": "BIBREF418"}, {"start": 1025, "end": 1051, "text": "(Padmanabhan et al., 2016)", "ref_id": "BIBREF418"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "The existence of interchangeable subunits, and thus, of alternative proteasome forms above described, as well as the identification of hybrid proteasome particles (i.e., ) whose biological function is poorly known, underlie how cells modify proteasome repertoire in relation to its specific need (Cascio et al., 2002; Morozov and Karpov, 2019; Thibaudeau and Smith, 2019) .", "cite_spans": [{"start": 163, "end": 169, "text": "(i.e.,", "ref_id": null}, {"start": 296, "end": 317, "text": "(Cascio et al., 2002;", "ref_id": null}, {"start": 318, "end": 343, "text": "Morozov and Karpov, 2019;", "ref_id": "BIBREF369"}, {"start": 344, "end": 371, "text": "Thibaudeau and Smith, 2019)", "ref_id": "BIBREF708"}], "ref_spans": [], "section": "J o u r n a l P r e -p r o o f"}, {"text": "De-ubiquitinases (DUBs), which catalyse ubiquitin moieties removal from target proteins, are key components of the UPS, being involved in ubiquitin recycling and editing (Yuan et al. 2018) . Three", "cite_spans": [{"start": 170, "end": 188, "text": "(Yuan et al. 2018)", "ref_id": null}], "ref_spans": [], "section": "BOX 2: Inhibition of UPS targetting deubiquitinases: Usp14 at a glance."}, {"text": "DUBs are associated with the proteasome: Rpn11, a Zn 2+ metallo-protease, which is part of the lid, J o u r n a l P r e -p r o o f USP14 and Uch37 which are two cysteine proteases, extrinsically associated with the base (see section 2.3.1) (D'Arcy et al., 2015) . Several studies have proposed that de-ubiquitination by Rpn11 stimulates the substrate degradation by removing bulky ubiquitin chain that otherwise might impair further substrate translocation into the proteasome (Poot et al., 2017) ; on the other hand, the ATP/independent de-ubiquitination by Usp14 and Uch37 is envisaged to suppress substrate degradation, promoting its premature dissociation from the proteasome (Lam et al., 1997; Hanna et al., 2006; Lee et al., 2016b) . Among the three DUBs, Usp14 is the most attractive way of intervention to regulate proteasome activity (Wertz and Murray, 2019; Chakraborty et al., 2018) . Human USP14 consists of two domains, namely (i) a N-terminal ubiquitin-like domain (UBL) and (ii) a C-terminal DUB domain, which contains the catalytic triad, Cys114, His435, and Asp451. In the free unbound state, the catalytic domain of Usp14 is characterized by a low level of de-ubiquitinase activity, whereas when it binds proteasome its activity is increased about 800-fold and shows a preference for substrates ubiquitinated at more than one site (Koulich et al., 2008; Hu et al., 2005; Lee et al., 2016b) . It has been shown that Usp14 inhibition stimulates the degradation of some specific proteasome substrates in mammalian cells, such as cancer and neurodegeneration related proteins Homma et al., 2015; Zhu et al., 2016; McKinnon et al., 2016; Boselli et al., 2017; Liao et al., 2017; Poot et al., 2017) . Additionally, Usp14 activation through phosphorylation of Ser432 residue by AKT results in the suppression of the degradation of short-lived proteins, that may in turn promote tumour cell proliferation (Xu et al., 2015; Wei et al., 2017; Kim and Goldberg, 2017) . Some evidences also suggest that Usp14 expression is closely related to the onset of different tumours, including breast, gastric and lung cancer (Wu et al., 2013; Zhu et al., 2016 (b) ; Fu et al., 2018) and its activity is required for nervous system development and functioning (Wilson et al., 2002; Chen et al., 2011; Vaden et al., 2015; Kiprowska et al., 2017) . Thus, considerable efforts have been dedicated to the discovery of small molecules that functionally inhibit Usp14 and several ones have been identified, such as b-AP15, auranofin, WP1130 and curcumin analogue AC17 (Kapuria et al., 2010; Zhou et al., 2013; Wang et al., 2014; Coughlin et al., 2014; Liu et al., 2014; D'Arcy et al., 2015; Xia et al., 2019; Wertz and Murray, 2019) . A common feature of most of these compounds is the presence of \u03b1,\u03b2-unsaturated carbonyl groups which can form covalent adducts with free thiols in the active site by Michael addition (D'Arcy et al., 2015; . Unfortunately, these compounds usually have poor selectivity across the DUB family, since most of them are cysteine enzymes which are easily \"druggable\" by compounds containing Michael acceptors (D'Arcy et al., 2015) . The small molecule IU1 was the first specific inhibitor identified, exhibiting excellent selectivity for USP14 over other DUBs . Co-crystal studies reveal J o u r n a l P r e -p r o o f a unique mechanism of action of IU1 that exerts its inhibitory activity by binding to the thumb-palm cleft region of Usp14 catalytic domain, sterically preventing ubiquitin binding to the C-terminal of Usp14 . Interestingly, the prion protein shows accelerated degradation upon IU1 treatment, and a more powerful analogue (IU1-47) enhances tau degradation in neurons (Homma et al., 2015; McKinnon et al., 2016; Boselli et al., 2017) , rendering it an intriguing target also for neurodegenerative diseases. VLX1570 is an analogue of b-AP15, being characterized by a higher potency and an improved solubility, which shows consistent anti-tumour activity in orthotopic and xenograft models of MM, lymphoma, Ewing's sarcoma, and other malignancies (D'Arcy et al., 2014; Chitta et al., 2015; Shukla et al., 2016) . Moreover, VLX1570 retains prominent activity in bortezomib-resistant MM cells (Shukla et al., 2016; Rowinsky et al., 2020) .", "cite_spans": [{"start": 240, "end": 261, "text": "(D'Arcy et al., 2015)", "ref_id": null}, {"start": 477, "end": 496, "text": "(Poot et al., 2017)", "ref_id": null}, {"start": 680, "end": 698, "text": "(Lam et al., 1997;", "ref_id": null}, {"start": 699, "end": 718, "text": "Hanna et al., 2006;", "ref_id": null}, {"start": 719, "end": 737, "text": "Lee et al., 2016b)", "ref_id": null}, {"start": 843, "end": 867, "text": "(Wertz and Murray, 2019;", "ref_id": "BIBREF802"}, {"start": 868, "end": 893, "text": "Chakraborty et al., 2018)", "ref_id": null}, {"start": 1349, "end": 1371, "text": "(Koulich et al., 2008;", "ref_id": null}, {"start": 1372, "end": 1388, "text": "Hu et al., 2005;", "ref_id": null}, {"start": 1389, "end": 1407, "text": "Lee et al., 2016b)", "ref_id": null}, {"start": 1590, "end": 1609, "text": "Homma et al., 2015;", "ref_id": null}, {"start": 1610, "end": 1627, "text": "Zhu et al., 2016;", "ref_id": "BIBREF676"}, {"start": 1628, "end": 1650, "text": "McKinnon et al., 2016;", "ref_id": null}, {"start": 1651, "end": 1672, "text": "Boselli et al., 2017;", "ref_id": null}, {"start": 1673, "end": 1691, "text": "Liao et al., 2017;", "ref_id": null}, {"start": 1692, "end": 1710, "text": "Poot et al., 2017)", "ref_id": null}, {"start": 1915, "end": 1932, "text": "(Xu et al., 2015;", "ref_id": "BIBREF249"}, {"start": 1933, "end": 1950, "text": "Wei et al., 2017;", "ref_id": null}, {"start": 1951, "end": 1974, "text": "Kim and Goldberg, 2017)", "ref_id": null}, {"start": 2123, "end": 2140, "text": "(Wu et al., 2013;", "ref_id": null}, {"start": 2141, "end": 2161, "text": "Zhu et al., 2016 (b)", "ref_id": "BIBREF676"}, {"start": 2164, "end": 2180, "text": "Fu et al., 2018)", "ref_id": null}, {"start": 2257, "end": 2278, "text": "(Wilson et al., 2002;", "ref_id": null}, {"start": 2279, "end": 2297, "text": "Chen et al., 2011;", "ref_id": null}, {"start": 2298, "end": 2317, "text": "Vaden et al., 2015;", "ref_id": null}, {"start": 2318, "end": 2341, "text": "Kiprowska et al., 2017)", "ref_id": null}, {"start": 2559, "end": 2581, "text": "(Kapuria et al., 2010;", "ref_id": null}, {"start": 2582, "end": 2600, "text": "Zhou et al., 2013;", "ref_id": "BIBREF779"}, {"start": 2601, "end": 2619, "text": "Wang et al., 2014;", "ref_id": "BIBREF509"}, {"start": 2620, "end": 2642, "text": "Coughlin et al., 2014;", "ref_id": null}, {"start": 2643, "end": 2660, "text": "Liu et al., 2014;", "ref_id": "BIBREF509"}, {"start": 2661, "end": 2681, "text": "D'Arcy et al., 2015;", "ref_id": null}, {"start": 2682, "end": 2699, "text": "Xia et al., 2019;", "ref_id": "BIBREF822"}, {"start": 2700, "end": 2723, "text": "Wertz and Murray, 2019)", "ref_id": "BIBREF802"}, {"start": 2909, "end": 2930, "text": "(D'Arcy et al., 2015;", "ref_id": null}, {"start": 3128, "end": 3149, "text": "(D'Arcy et al., 2015)", "ref_id": null}, {"start": 3705, "end": 3725, "text": "(Homma et al., 2015;", "ref_id": null}, {"start": 3726, "end": 3748, "text": "McKinnon et al., 2016;", "ref_id": null}, {"start": 3749, "end": 3770, "text": "Boselli et al., 2017)", "ref_id": null}, {"start": 4082, "end": 4103, "text": "(D'Arcy et al., 2014;", "ref_id": null}, {"start": 4104, "end": 4124, "text": "Chitta et al., 2015;", "ref_id": null}, {"start": 4125, "end": 4145, "text": "Shukla et al., 2016)", "ref_id": null}, {"start": 4226, "end": 4247, "text": "(Shukla et al., 2016;", "ref_id": null}, {"start": 4248, "end": 4270, "text": "Rowinsky et al., 2020)", "ref_id": null}], "ref_spans": [], "section": "BOX 2: Inhibition of UPS targetting deubiquitinases: Usp14 at a glance."}, {"text": "These studies together with the good tolerability profile, reported in preclinical models, provided the rationale for investigating this drug in clinical trials on patients with RRMM (Rowinsky et al., 2020) . Thus, in a phase 1 study fourteen patients with RRMM were enrolled and treated with escalating doses of intravenous infusion of VLX1570 ranging from 0.05 to 1.2 mg/kg and antimyeloma effects were observed at dose of 0.6 mg/kg or more. Unfortunately, two patients treated with 1.2 mg/kg dose experienced severe and progressive respiratory insufficiency, culminating in death; thus, due to severity of the toxicity, the study was discontinued (Rowinsky et al., 2020) .", "cite_spans": [{"start": 178, "end": 206, "text": "RRMM (Rowinsky et al., 2020)", "ref_id": null}, {"start": 650, "end": 673, "text": "(Rowinsky et al., 2020)", "ref_id": null}], "ref_spans": [], "section": "BOX 2: Inhibition of UPS targetting deubiquitinases: Usp14 at a glance."}, {"text": "Beside this molecule, no other inhibitors targeting DUBs have entered into clinical trial so far.", "cite_spans": [], "ref_spans": [], "section": "BOX 2: Inhibition of UPS targetting deubiquitinases: Usp14 at a glance."}, {"text": "However, since they are abnormally expressed in a variety of tumours and/or in tumour microenvironment (Yuan et al. 2018) , making them ideal anticancer target candidates, the identification of selective small-molecule inhibitors for Usp14 and in general for other specific DUBs remains an active and extremely challenging task.", "cite_spans": [{"start": 103, "end": 121, "text": "(Yuan et al. 2018)", "ref_id": null}], "ref_spans": [], "section": "BOX 2: Inhibition of UPS targetting deubiquitinases: Usp14 at a glance."}, {"text": "The regulation of metabolic control of proteasome function is a challenging point in proteasome biology, which deserves particular attention, although many aspects are obscures yet. The coordinated balance of the two post-translational modifications, i.e., O-linked N-acetylglucosamine (O-GlcNAcylation) and phosphorylation appears to be crucial in this process (Zhang et al., 2003; Zhang et al., 2007; Rousseau and Bertolotti, 2018) . proteins, by using as substrate a product of hexosamine biosynthesis, the UDP-GlcNAc, whose availability is influenced by nutritional conditions. In fact, an increase in glucose availability raises UDP-GlcNAc levels and consequently promotes protein O-GlcNAcylation (Comer and Hart, 2000; Zachara and Hart, 2004) . It has been reported that 26S proteasome function is inhibited by the addiction of sugar moieties to the Rpt2 subunit (Zhang et al., 2003) , a finding which provides a link between glucose metabolism and protein turnover . In the liver and muscle tissues of mouse models, when blood glucose drops (e.g., under fasting conditions or during exercise) the PKA increase stimulates 26S activity selectively toward the clearance of short-lived regulatory proteins, with no alterations in proteasome content, confirming that proteasome activation occurs through post-synthetic modification of already existing particles (Rousseau and Bertolotti, 2018; VerPlank et al., 2019) . The low level of glucose also reduces the entry of this mono-saccharide into the hexosamine pathway, limiting the availability of UDP-GlcNAc; as a consequence, the O-GlcNAc modification of Rpt2 decreases thus removing the signal that inhibits proteasome function (Zhang et al., 2003; Zhang et al., 2007) . Moreover, it has been shown that lack of nutrient rapidly inhibits the stress and nutrient response of the mTOR complex. It results into the enhancement of autophagic process and of the rate of long-lived protein ubiquitination and, therefore, of their degradation by UPS . All these events bring to a general activation of proteolysis, promoting cellular adaptation, facilitating damaged and potentially toxic protein clearance, and providing essential amino acids for the synthesis of proteins necessary for cell survival and energy production VerPlank and Goldberg, 2015; Rosseau and Bertolotti, 2016) . A. Structure of the 20S proteasome particle as viewed from the top (top panel) or the side (bottom panel). The protein backbone of the subunits is presented as ribbon. B. Active site a threonine peptidase subunit (\u03b25) of the proteasome. The protein backbone of the \u03b25 subunit is represented as turquoise ribbon, catalytic residue (Thr1) and other residues that helps maintains the structural stability of the catalytic site (Lys33, Asp17, Ser129, Asp166 and Ser169) are represented as sticks. Polar interactions are indicated as black dashed lines together with the corresponding distances. C. left: Schematic representation of the relative orientation of the subunits of the 20S particle. right: vertical cross-section of the 19S particle, the \u03b1-subunit rings are represented as red ribbons, the \u03b2subunit rings as blue ribbons, the outline of the internal cavity and the internal \"chambers\" are highlighted with a black dashed line. J o u r n a l P r e -p r o o f levels are also modulated through the ubiquitin-dependent degradation by the 26S, and further by a ubiquitin independent pathway by the 20S.", "cite_spans": [{"start": 362, "end": 382, "text": "(Zhang et al., 2003;", "ref_id": "BIBREF843"}, {"start": 383, "end": 402, "text": "Zhang et al., 2007;", "ref_id": null}, {"start": 403, "end": 433, "text": "Rousseau and Bertolotti, 2018)", "ref_id": "BIBREF544"}, {"start": 686, "end": 724, "text": "O-GlcNAcylation (Comer and Hart, 2000;", "ref_id": null}, {"start": 725, "end": 748, "text": "Zachara and Hart, 2004)", "ref_id": null}, {"start": 869, "end": 889, "text": "(Zhang et al., 2003)", "ref_id": "BIBREF843"}, {"start": 1364, "end": 1395, "text": "(Rousseau and Bertolotti, 2018;", "ref_id": "BIBREF544"}, {"start": 1396, "end": 1418, "text": "VerPlank et al., 2019)", "ref_id": "BIBREF768"}, {"start": 1684, "end": 1704, "text": "(Zhang et al., 2003;", "ref_id": "BIBREF843"}, {"start": 1705, "end": 1724, "text": "Zhang et al., 2007)", "ref_id": null}, {"start": 2273, "end": 2301, "text": "VerPlank and Goldberg, 2015;", "ref_id": null}, {"start": 2302, "end": 2331, "text": "Rosseau and Bertolotti, 2016)", "ref_id": null}], "ref_spans": [], "section": "BOX 3: Metabolic control of proteasome function"}, {"text": "Figure legend is restricted to NF-kB and p53, whose mechanisms of transcription induction is not sketched. PIs stands for Proteasome Inhibitors and the red arrows indicate the steps of NF-kB, p53 and p21 turn-over which are blocked by this class of drugs. ; are reported. The \u03b2-5 subunit is represented as turquoise ribbon, the \u03b2-1 subunit is represented as purple ribbon, the inhibitors are represented as orange sticks and the protein residues interacting with the inhibitors as grey sticks. Alkalay, I., Yaron, A., Hatzubai, A., Orian, A., Ciechanover, A., & Ben-Neriah, Y. (1995) . Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proceedings of the National Academy of Sciences of the United States of America, 92 (23) Bigelow, S., Hough, R., & Rechsteiner, M. (1981) . The selective degradation of injected proteins occurs principally in the cytosol rather than in lysosomes. Cell, 25 (1) Thomas, S. N., Jeng, Y., Yang, F., Davies, P., & Yang, A. J. (2006) . Alzheimer diseasespecific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. The Journal of Biological Chemistry, 281 (16) Dahlqvist, J., Klar, J., Tiwari, N., Schuster, J., T\u00f6rm\u00e4, H., Badhai, J., Pujol, R., van Steensel, M. A. M., Brinkhuizen, T., Brinkhuijzen, T., Gijezen, L., Chaves, A., Tadini, G., Vahlquist, A., & Dahl, N. (2010) . A single-nucleotide deletion in the POMP 5' UTR causes a transcriptional switch and altered epidermal proteasome distribution in KLICK genodermatosis. American Journal of Human Genetics, 86 (4) J o u r n a l P r e -p r o o f de Duve, C., Pressman, B. C., Gianetto, R., Wattiaux, R., & Appelmans, F. (1955) . Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochemical Journal, 60 (4) Drach, J., Huang, H., Samoilova, O., Belch, A., Farber, C., Bosly, A., Novak, J., Zaucha, J., Dascalescu, A., Bunworasate, U., Masliak, Z., Vilchevskaya, K., Robak, T., Pei, L., Rooney, B., van de Velde, H., & Cavalli, F. (2018) . Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study. Leukemia & Lymphoma, 59 (4) Eytan, E., Ganoth, D., Armon, T., & Hershko, A. (1989) . ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin. Proceedings of the National Academy of Sciences of the United States of America, 86 (20) Leonardi, G., Rizzo, M., Falcone, A. P., Gottardi, D., \u2026 Boccadoro, M. (2010) . Bortezomibmelphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28 (34) Takahashi, M., Kitaura, H., Kakita, A., Kakihana, T., Katsuragi, Y., Nameta, M., Zhang, L., Iwakura, Y., Nawa, H., Higuchi, M., Komatsu, M., & Fujii, M. (2018) . USP10 Is a Driver of Ubiquitinated Protein Aggregation and Aggresome Formation to Inhibit Apoptosis. IScience, 9, 433-450. https://doi.org/10.1016 IScience, 9, 433-450. https://doi.org/10. /j.isci.2018 Tanahashi, N., Yokota, K., Ahn, J. Y., Chung, C. H., Fujiwara, T., Takahashi, E., DeMartino, G. N., Slaughter, C. A., Toyonaga, T., Yamamura, K., Shimbara, N., & Tanaka, K. (1997) . Molecular properties of the proteasome activator PA28 family proteins and \u03b3-interferon regulation. Genes to Cells, 2(3), 195-211. https://doi.org/10.1046/j. 1365 -2443 .d01-308.x Tanaka, K, Waxman, L., & Goldberg, A. L. (1983 . ATP serves two distinct roles in protein degradation in reticulocytes, one requiring and one independent of ubiquitin. The Journal of Cell Biology, 96 (6) Tang, X., Wu, C., Li, X., Song, Y., Yao, X., Wu, X., Duan, Y., Zhang, H., Wang, Y., Qian, Z., Cui, J., & Lu, J. (n.d.) . On the origin and continuing evolution of SARS-CoV-2. National Science Review. https://doi.org/10.1093/nsr/nwaa036 Tanji, K., Miki, Y., Maruyama, A., Mori, F., Mimura, J., Itoh, K., Kamitani, T., & Wakabayashi, K. (2016) . The role of NUB1 in \u03b1-synuclein degradation in Lewy body disease model mice. Tanji, K., Mori, F., Mimura, J., Itoh, K., Kakita, A., Takahashi, H., & Wakabayashi, K. (2010) . Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice. Acta Neuropathologica, 120(2), 145-154. https://doi.org/10.1007/s00401-010-0676-z Tarohda, T., Yamamoto, M., & Amamo, R. (2004). Regional distribution of manganese, iron, copper, and zinc in the rat brain during development. Analytical and Bioanalytical Chemistry, 380 (2) ", "cite_spans": [{"start": 543, "end": 583, "text": "Ciechanover, A., & Ben-Neriah, Y. (1995)", "ref_id": null}, {"start": 838, "end": 862, "text": "& Rechsteiner, M. (1981)", "ref_id": null}, {"start": 985, "end": 1052, "text": "Thomas, S. N., Jeng, Y., Yang, F., Davies, P., & Yang, A. J. (2006)", "ref_id": null}, {"start": 1450, "end": 1482, "text": "Vahlquist, A., & Dahl, N. (2010)", "ref_id": null}, {"start": 1754, "end": 1790, "text": "Wattiaux, R., & Appelmans, F. (1955)", "ref_id": null}, {"start": 2116, "end": 2150, "text": "de Velde, H., & Cavalli, F. (2018)", "ref_id": null}, {"start": 2434, "end": 2454, "text": "Leukemia & Lymphoma,", "ref_id": null}, {"start": 2455, "end": 2457, "text": "59", "ref_id": null}, {"start": 2485, "end": 2516, "text": "Armon, T., & Hershko, A. (1989)", "ref_id": null}, {"start": 2792, "end": 2798, "text": "(2010)", "ref_id": null}, {"start": 3198, "end": 3276, "text": "Zhang, L., Iwakura, Y., Nawa, H., Higuchi, M., Komatsu, M., & Fujii, M. (2018)", "ref_id": null}, {"start": 3380, "end": 3425, "text": "IScience, 9, 433-450. https://doi.org/10.1016", "ref_id": null}, {"start": 3426, "end": 3480, "text": "IScience, 9, 433-450. https://doi.org/10. /j.isci.2018", "ref_id": null}, {"start": 3613, "end": 3660, "text": "Yamamura, K., Shimbara, N., & Tanaka, K. (1997)", "ref_id": null}, {"start": 3820, "end": 3824, "text": "1365", "ref_id": null}, {"start": 3825, "end": 3830, "text": "-2443", "ref_id": null}, {"start": 3831, "end": 3888, "text": ".d01-308.x Tanaka, K, Waxman, L., & Goldberg, A. L. (1983", "ref_id": null}, {"start": 4109, "end": 4164, "text": "Zhang, H., Wang, Y., Qian, Z., Cui, J., & Lu, J. (n.d.)", "ref_id": null}, {"start": 4363, "end": 4387, "text": "& Wakabayashi, K. (2016)", "ref_id": null}, {"start": 4537, "end": 4561, "text": "& Wakabayashi, K. (2010)", "ref_id": null}], "ref_spans": [], "section": "BOX 3: Metabolic control of proteasome function"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib", "authors": [{"first": "L", "middle": [], "last": "Ao", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wu", "suffix": ""}, {"first": "D", "middle": [], "last": "Kim", "suffix": ""}, {"first": "E", "middle": ["R"], "last": "Jang", "suffix": ""}, {"first": "K", "middle": [], "last": "Kim", "suffix": ""}, {"first": "D.-M", "middle": [], "last": "Lee", "suffix": ""}, {"first": "K", "middle": ["B"], "last": "Kim", "suffix": ""}, {"first": "W", "middle": [], "last": "Lee", "suffix": ""}], "year": 2012, "venue": "Molecular Pharmaceutics", "volume": "9", "issn": "8", "pages": "2197--2205", "other_ids": {"DOI": ["10.1021/mp300044b"]}}, "BIBREF1": {"ref_id": "b1", "title": "Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study", "authors": [{"first": "T", "middle": [], "last": "Aoki", "suffix": ""}, {"first": "T", "middle": [], "last": "Nishiyama", "suffix": ""}, {"first": "N", "middle": [], "last": "Imahashi", "suffix": ""}, {"first": "K", "middle": [], "last": "Kitamura", "suffix": ""}], "year": 2011, "venue": "Japanese Journal of Clinical Oncology", "volume": "41", "issn": "7", "pages": "876--881", "other_ids": {"DOI": ["10.1093/jjco/hyr063"]}}, "BIBREF2": {"ref_id": "b2", "title": "Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events", "authors": [{"first": "S", "middle": [], "last": "Arastu-Kapur", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Anderl", "suffix": ""}, {"first": "M", "middle": [], "last": "Kraus", "suffix": ""}, {"first": "F", "middle": [], "last": "Parlati", "suffix": ""}, {"first": "K", "middle": ["D"], "last": "Shenk", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Lee", "suffix": ""}, {"first": "T", "middle": [], "last": "Muchamuel", "suffix": ""}, {"first": "M", "middle": ["K"], "last": "Bennett", "suffix": ""}, {"first": "C", "middle": [], "last": "Driessen", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Ball", "suffix": ""}, {"first": "C", "middle": ["J"], "last": "Kirk", "suffix": ""}], "year": 2011, "venue": "Clinical Cancer Research: An Official Journal of the American Association for Cancer Research", "volume": "17", "issn": "9", "pages": "2734--2743", "other_ids": {"DOI": ["10.1158/1078-0432.CCR-10-1950"]}}, "BIBREF3": {"ref_id": "b3", "title": "Molecular modeling on porphyrin derivatives as \u03b25 subunit inhibitor of 20S proteasome", "authors": [{"first": "M", "middle": [], "last": "Arba", "suffix": ""}, {"first": "A", "middle": [], "last": "Nur-Hidayat", "suffix": ""}, {"first": "", "middle": [], "last": "Ruslin", "suffix": ""}, {"first": "M", "middle": [], "last": "Yusuf", "suffix": ""}, {"first": "", "middle": [], "last": "Sumarlin", "suffix": ""}, {"first": "R", "middle": [], "last": "Hertadi", "suffix": ""}, {"first": "S", "middle": ["T"], "last": "Wahyudi", "suffix": ""}, {"first": "S", "middle": ["I"], "last": "Surantaadmaja", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Tjahjono", "suffix": ""}], "year": 2018, "venue": "Computational Biology and Chemistry", "volume": "74", "issn": "", "pages": "230--238", "other_ids": {"DOI": ["10.1016/j.compbiolchem.2018.03.002"]}}, "BIBREF4": {"ref_id": "b4", "title": "Eukaryotic 20S proteasome catalytic subunit propeptides prevent active site inactivation by N-terminal acetylation and promote particle assembly", "authors": [{"first": "C", "middle": ["S"], "last": "Arendt", "suffix": ""}, {"first": "M", "middle": [], "last": "Hochstrasser", "suffix": ""}], "year": 1999, "venue": "The EMBO Journal", "volume": "18", "issn": "13", "pages": "3575--3585", "other_ids": {"DOI": ["10.1093/emboj/18.13.3575"]}}, "BIBREF5": {"ref_id": "b5", "title": "Assembly of the 26 S complex that degrades proteins ligated to ubiquitin is accompanied by the formation of ATPase activity", "authors": [{"first": "T", "middle": [], "last": "Armon", "suffix": ""}, {"first": "D", "middle": [], "last": "Ganoth", "suffix": ""}, {"first": "A", "middle": [], "last": "Hershko", "suffix": ""}], "year": 1990, "venue": "The Journal of Biological Chemistry", "volume": "265", "issn": "34", "pages": "20723--20726", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Interrelation between protein synthesis, proteostasis and life span", "authors": [{"first": "K", "middle": [], "last": "Arnsburg", "suffix": ""}, {"first": "J", "middle": [], "last": "Kirstein-Miles", "suffix": ""}], "year": 2014, "venue": "Current Genomics", "volume": "15", "issn": "1", "pages": "66--75", "other_ids": {"DOI": ["10.2174/1389202915666140210210542"]}}, "BIBREF7": {"ref_id": "b7", "title": "Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma", "authors": [{"first": "B", "middle": [], "last": "Arnulf", "suffix": ""}, {"first": "H", "middle": [], "last": "Pylypenko", "suffix": ""}, {"first": "S", "middle": [], "last": "Grosicki", "suffix": ""}, {"first": "I", "middle": [], "last": "Karamanesht", "suffix": ""}, {"first": "X", "middle": [], "last": "Leleu", "suffix": ""}, {"first": "H", "middle": [], "last": "Van De Velde", "suffix": ""}, {"first": "H", "middle": [], "last": "Feng", "suffix": ""}, {"first": "A", "middle": [], "last": "Cakana", "suffix": ""}, {"first": "W", "middle": [], "last": "Deraedt", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}], "year": 2012, "venue": "Haematologica", "volume": "", "issn": "12", "pages": "1925--1928", "other_ids": {"DOI": ["10.3324/haematol.2012.067793"]}}, "BIBREF8": {"ref_id": "b8", "title": "Identity of the 19S \"prosome\" particle with the large multifunctional protease complex of mammalian cells (the proteasome)", "authors": [{"first": "A", "middle": ["P"], "last": "Arrigo", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}, {"first": "W", "middle": ["J"], "last": "Welch", "suffix": ""}], "year": 1988, "venue": "Nature", "volume": "", "issn": "6152", "pages": "192--194", "other_ids": {"DOI": ["10.1038/331192a0"]}}, "BIBREF9": {"ref_id": "b9", "title": "PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts", "authors": [{"first": "M", "middle": [], "last": "Asai", "suffix": ""}, {"first": "O", "middle": [], "last": "Tsukamoto", "suffix": ""}, {"first": "T", "middle": [], "last": "Minamino", "suffix": ""}, {"first": "H", "middle": [], "last": "Asanuma", "suffix": ""}, {"first": "M", "middle": [], "last": "Fujita", "suffix": ""}, {"first": "Y", "middle": [], "last": "Asano", "suffix": ""}, {"first": "H", "middle": [], "last": "Takahama", "suffix": ""}, {"first": "H", "middle": [], "last": "Sasaki", "suffix": ""}, {"first": "S", "middle": [], "last": "Higo", "suffix": ""}, {"first": "M", "middle": [], "last": "Asakura", "suffix": ""}, {"first": "S", "middle": [], "last": "Takashima", "suffix": ""}, {"first": "M", "middle": [], "last": "Hori", "suffix": ""}, {"first": "M", "middle": [], "last": "Kitakaze", "suffix": ""}], "year": 2009, "venue": "Journal of Molecular and Cellular Cardiology", "volume": "46", "issn": "4", "pages": "637--640", "other_ids": {"DOI": ["10.1016/j.yjmcc.2008.11.001"]}}, "BIBREF11": {"ref_id": "b11", "title": "Structure and Function of the 26S Proteasome", "authors": [], "year": null, "venue": "Annual Review of Biochemistry", "volume": "87", "issn": "", "pages": "697--724", "other_ids": {"DOI": ["10.1146/annurev-biochem-062917-011931"]}}, "BIBREF12": {"ref_id": "b12", "title": "Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma", "authors": [{"first": "B", "middle": [], "last": "Barlogie", "suffix": ""}, {"first": "S", "middle": [], "last": "Jagannath", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Vesole", "suffix": ""}, {"first": "S", "middle": [], "last": "Naucke", "suffix": ""}, {"first": "B", "middle": [], "last": "Cheson", "suffix": ""}, {"first": "S", "middle": [], "last": "Mattox", "suffix": ""}, {"first": "D", "middle": [], "last": "Bracy", "suffix": ""}, {"first": "S", "middle": [], "last": "Salmon", "suffix": ""}, {"first": "J", "middle": [], "last": "Jacobson", "suffix": ""}, {"first": "J", "middle": [], "last": "Crowley", "suffix": ""}, {"first": "G", "middle": [], "last": "Tricot", "suffix": ""}], "year": 1997, "venue": "Blood", "volume": "89", "issn": "3", "pages": "789--793", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "Dual functions of the Hsm3 protein in chaperoning and scaffolding regulatory particle subunits during the proteasome assembly", "authors": [{"first": "M.-B", "middle": [], "last": "Barrault", "suffix": ""}, {"first": "N", "middle": [], "last": "Richet", "suffix": ""}, {"first": "C", "middle": [], "last": "Godard", "suffix": ""}, {"first": "B", "middle": [], "last": "Murciano", "suffix": ""}, {"first": "B", "middle": [], "last": "Le Tallec", "suffix": ""}, {"first": "E", "middle": [], "last": "Rousseau", "suffix": ""}, {"first": "P", "middle": [], "last": "Legrand", "suffix": ""}, {"first": "J.-B", "middle": [], "last": "Charbonnier", "suffix": ""}, {"first": "M.-H", "middle": [], "last": "Le Du", "suffix": ""}, {"first": "R", "middle": [], "last": "Gu\u00e9rois", "suffix": ""}, {"first": "F", "middle": [], "last": "Ochsenbein", "suffix": ""}, {"first": "A", "middle": [], "last": "Peyroche", "suffix": ""}], "year": 2012, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "109", "issn": "", "pages": "1001--1010", "other_ids": {"DOI": ["10.1073/pnas.1116538109"]}}, "BIBREF14": {"ref_id": "b14", "title": "Spectrum and functional validation of PSMB5 mutations in multiple myeloma", "authors": [{"first": "S", "middle": [], "last": "Barrio", "suffix": ""}, {"first": "T", "middle": [], "last": "St\u00fchmer", "suffix": ""}, {"first": "M", "middle": [], "last": "Da-Vi\u00e1", "suffix": ""}, {"first": "C", "middle": [], "last": "Barrio-Garcia", "suffix": ""}, {"first": "N", "middle": [], "last": "Lehners", "suffix": ""}, {"first": "A", "middle": [], "last": "Besse", "suffix": ""}, {"first": "I", "middle": [], "last": "Cuenca", "suffix": ""}, {"first": "A", "middle": [], "last": "Garitano-Trojaola", "suffix": ""}, {"first": "S", "middle": [], "last": "Fink", "suffix": ""}, {"first": "E", "middle": [], "last": "Leich", "suffix": ""}, {"first": "M", "middle": [], "last": "Chatterjee", "suffix": ""}, {"first": "C", "middle": [], "last": "Driessen", "suffix": ""}, {"first": "J", "middle": [], "last": "Martinez-Lopez", "suffix": ""}, {"first": "A", "middle": [], "last": "Rosenwald", "suffix": ""}, {"first": "R", "middle": [], "last": "Beckmann", "suffix": ""}, {"first": "R", "middle": ["C"], "last": "Bargou", "suffix": ""}, {"first": "E", "middle": [], "last": "Braggio", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Stewart", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Raab", "suffix": ""}, {"first": "K", "middle": ["M"], "last": "Kort\u00fcm", "suffix": ""}], "year": 2019, "venue": "Leukemia", "volume": "33", "issn": "2", "pages": "447--456", "other_ids": {"DOI": ["10.1038/s41375-018-0216-8"]}}, "BIBREF15": {"ref_id": "b15", "title": "The immunoproteasome: a novel drug target for autoimmune diseases", "authors": [{"first": "M", "middle": [], "last": "Basler", "suffix": ""}, {"first": "S", "middle": [], "last": "Mundt", "suffix": ""}, {"first": "A", "middle": [], "last": "Bitzer", "suffix": ""}, {"first": "C", "middle": [], "last": "Schmidt", "suffix": ""}, {"first": "M", "middle": [], "last": "Groettrup", "suffix": ""}], "year": 2015, "venue": "Clinical and Experimental Rheumatology", "volume": "33", "issn": "4", "pages": "74--79", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease", "authors": [{"first": "S", "middle": [], "last": "Basu Ray", "suffix": ""}], "year": 2019, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF18": {"ref_id": "b18", "title": "Proteasomes can degrade a significant proportion of cellular proteins independent of ubiquitination", "authors": [{"first": "J", "middle": ["M"], "last": "Baugh", "suffix": ""}, {"first": "E", "middle": ["G"], "last": "Viktorova", "suffix": ""}, {"first": "E", "middle": ["V"], "last": "Pilipenko", "suffix": ""}], "year": 2009, "venue": "Journal of Molecular Biology", "volume": "386", "issn": "3", "pages": "814--827", "other_ids": {"DOI": ["10.1016/j.jmb.2008.12.081"]}}, "BIBREF19": {"ref_id": "b19", "title": "Electron microscopy and image analysis of the multicatalytic proteinase", "authors": [{"first": "W", "middle": [], "last": "Baumeister", "suffix": ""}, {"first": "B", "middle": [], "last": "Dahlmann", "suffix": ""}, {"first": "R", "middle": [], "last": "Hegerl", "suffix": ""}, {"first": "F", "middle": [], "last": "Kopp", "suffix": ""}, {"first": "L", "middle": [], "last": "Kuehn", "suffix": ""}, {"first": "G", "middle": [], "last": "Pfeifer", "suffix": ""}], "year": 1988, "venue": "FEBS Letters", "volume": "", "issn": "1-2", "pages": "239--245", "other_ids": {"DOI": ["10.1016/0014-5793(88)81069-x"]}}, "BIBREF20": {"ref_id": "b20", "title": "Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models", "authors": [{"first": "V", "middle": [], "last": "Beaumont", "suffix": ""}, {"first": "S", "middle": [], "last": "Zhong", "suffix": ""}, {"first": "H", "middle": [], "last": "Lin", "suffix": ""}, {"first": "W", "middle": [], "last": "Xu", "suffix": ""}, {"first": "A", "middle": [], "last": "Bradaia", "suffix": ""}, {"first": "E", "middle": [], "last": "Steidl", "suffix": ""}, {"first": "M", "middle": [], "last": "Gleyzes", "suffix": ""}, {"first": "K", "middle": [], "last": "Wadel", "suffix": ""}, {"first": "B", "middle": [], "last": "Buisson", "suffix": ""}, {"first": "F", "middle": ["E"], "last": "Padovan-Neto", "suffix": ""}, {"first": "S", "middle": [], "last": "Chakroborty", "suffix": ""}, {"first": "K", "middle": ["M"], "last": "Ward", "suffix": ""}, {"first": "J", "middle": ["F"], "last": "Harms", "suffix": ""}, {"first": "J", "middle": [], "last": "Beltran", "suffix": ""}, {"first": "M", "middle": [], "last": "Kwan", "suffix": ""}, {"first": "A", "middle": [], "last": "Ghavami", "suffix": ""}, {"first": "J", "middle": [], "last": "H\u00e4ggkvist", "suffix": ""}, {"first": "M", "middle": [], "last": "T\u00f3th", "suffix": ""}, {"first": "C", "middle": [], "last": "Halldin", "suffix": ""}, {"first": "I", "middle": [], "last": "Munoz-Sanjuan", "suffix": ""}], "year": 2016, "venue": "Neuron", "volume": "92", "issn": "6", "pages": "1220--1237", "other_ids": {"DOI": ["10.1016/j.neuron.2016.10.064"]}}, "BIBREF21": {"ref_id": "b21", "title": "Near-atomic resolution structural model of the yeast 26S proteasome", "authors": [{"first": "F", "middle": [], "last": "Beck", "suffix": ""}, {"first": "P", "middle": [], "last": "Unverdorben", "suffix": ""}, {"first": "S", "middle": [], "last": "Bohn", "suffix": ""}, {"first": "A", "middle": [], "last": "Schweitzer", "suffix": ""}, {"first": "G", "middle": [], "last": "Pfeifer", "suffix": ""}, {"first": "E", "middle": [], "last": "Sakata", "suffix": ""}, {"first": "S", "middle": [], "last": "Nickell", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Plitzko", "suffix": ""}, {"first": "E", "middle": [], "last": "Villa", "suffix": ""}, {"first": "W", "middle": [], "last": "Baumeister", "suffix": ""}, {"first": "F", "middle": [], "last": "F\u00f6rster", "suffix": ""}], "year": 2012, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "109", "issn": "", "pages": "14870--14875", "other_ids": {"DOI": ["10.1073/pnas.1213333109"]}}, "BIBREF22": {"ref_id": "b22", "title": "Reconstitution of the 26S proteasome reveals functional asymmetries in its AAA+ unfoldase", "authors": [{"first": "R", "middle": [], "last": "Beckwith", "suffix": ""}, {"first": "E", "middle": [], "last": "Estrin", "suffix": ""}, {"first": "E", "middle": ["J"], "last": "Worden", "suffix": ""}, {"first": "A", "middle": [], "last": "Martin", "suffix": ""}], "year": 2013, "venue": "Nature Structural & Molecular Biology", "volume": "20", "issn": "10", "pages": "1164--1172", "other_ids": {"DOI": ["10.1038/nsmb.2659"]}}, "BIBREF24": {"ref_id": "b24", "title": "Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing", "authors": [], "year": null, "venue": "Nature Reviews. Drug Discovery", "volume": "17", "issn": "9", "pages": "660--688", "other_ids": {"DOI": ["10.1038/nrd.2018.109"]}}, "BIBREF25": {"ref_id": "b25", "title": "Natural polyphenols as proteasome modulators and their role as anti-cancer compounds", "authors": [{"first": "L", "middle": [], "last": "Bonfili", "suffix": ""}, {"first": "V", "middle": [], "last": "Cecarini", "suffix": ""}, {"first": "M", "middle": [], "last": "Amici", "suffix": ""}, {"first": "M", "middle": [], "last": "Cuccioloni", "suffix": ""}, {"first": "M", "middle": [], "last": "Angeletti", "suffix": ""}, {"first": "J", "middle": ["N"], "last": "Keller", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Eleuteri", "suffix": ""}], "year": 2008, "venue": "FEBS Journal", "volume": "275", "issn": "22", "pages": "5512--5526", "other_ids": {"DOI": ["10.1111/j.1742-4658.2008.06696.x"]}}, "BIBREF26": {"ref_id": "b26", "title": "Safety of ixazomib for the treatment of multiple myeloma", "authors": [{"first": "A", "middle": [], "last": "Bonnet", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}], "year": 2017, "venue": "Expert Opinion on Drug Safety", "volume": "16", "issn": "8", "pages": "973--980", "other_ids": {"DOI": ["10.1080/14740338.2017.1344212"]}}, "BIBREF27": {"ref_id": "b27", "title": "20S proteasome and its inhibitors: crystallographic knowledge for drug development", "authors": [{"first": "L", "middle": [], "last": "Borissenko", "suffix": ""}, {"first": "M", "middle": [], "last": "Groll", "suffix": ""}], "year": 2007, "venue": "Chemical Reviews", "volume": "107", "issn": "3", "pages": "687--717", "other_ids": {"DOI": ["10.1021/cr0502504"]}}, "BIBREF28": {"ref_id": "b28", "title": "A protein catalytic framework with an N-terminal nucleophile is capable of self-activation", "authors": [{"first": "J", "middle": ["A"], "last": "Brannigan", "suffix": ""}, {"first": "G", "middle": [], "last": "Dodson", "suffix": ""}, {"first": "H", "middle": ["J"], "last": "Duggleby", "suffix": ""}, {"first": "P", "middle": ["C"], "last": "Moody", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Smith", "suffix": ""}, {"first": "D", "middle": ["R"], "last": "Tomchick", "suffix": ""}, {"first": "A", "middle": ["G"], "last": "Murzin", "suffix": ""}], "year": 1995, "venue": "Nature", "volume": "378", "issn": "6555", "pages": "416--419", "other_ids": {"DOI": ["10.1038/378416a0"]}}, "BIBREF29": {"ref_id": "b29", "title": "Cell death in the nervous system", "authors": [{"first": "D", "middle": ["E"], "last": "Bredesen", "suffix": ""}, {"first": "R", "middle": ["V"], "last": "Rao", "suffix": ""}, {"first": "P", "middle": [], "last": "Mehlen", "suffix": ""}], "year": 2006, "venue": "Nature", "volume": "443", "issn": "7113", "pages": "796--802", "other_ids": {"DOI": ["10.1038/nature05293"]}}, "BIBREF31": {"ref_id": "b31", "title": "Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production", "authors": [], "year": null, "venue": "The Journal of Clinical Investigation", "volume": "125", "issn": "11", "pages": "4196--4211", "other_ids": {}}, "BIBREF33": {"ref_id": "b33", "title": "Spreading of pathology in neurodegenerative diseases: a focus on human studies", "authors": [{"first": "J", "middle": [], "last": "Brettschneider", "suffix": ""}, {"first": "K", "middle": [], "last": "Del Tredici", "suffix": ""}, {"first": "V", "middle": ["M"], "last": "Lee", "suffix": ""}, {"first": ".-Y", "middle": [], "last": "Trojanowski", "suffix": ""}, {"first": "J", "middle": ["Q"], "last": "", "suffix": ""}], "year": 2015, "venue": "Nature Reviews. Neuroscience", "volume": "16", "issn": "2", "pages": "109--120", "other_ids": {"DOI": ["10.1038/nrn3887"]}}, "BIBREF34": {"ref_id": "b34", "title": "Massive expression of germ cell-specific genes is a hallmark of cancer and a potential target for novel treatment development", "authors": [{"first": "J", "middle": ["W"], "last": "Bruggeman", "suffix": ""}, {"first": "J", "middle": [], "last": "Koster", "suffix": ""}, {"first": "P", "middle": [], "last": "Lodder", "suffix": ""}, {"first": "S", "middle": [], "last": "Repping", "suffix": ""}, {"first": "G", "middle": [], "last": "Hamer", "suffix": ""}], "year": 2018, "venue": "Oncogene", "volume": "37", "issn": "42", "pages": "5694--5700", "other_ids": {"DOI": ["10.1038/s41388-018-0357-2"]}}, "BIBREF35": {"ref_id": "b35", "title": "Bortezomib-induced acute interstitial nephritis. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association -European Renal Association", "authors": [{"first": "W", "middle": [], "last": "Cheungpasitporn", "suffix": ""}, {"first": "N", "middle": [], "last": "Leung", "suffix": ""}, {"first": "S", "middle": ["V"], "last": "Rajkumar", "suffix": ""}, {"first": "L", "middle": ["D"], "last": "Cornell", "suffix": ""}, {"first": "S", "middle": [], "last": "Sethi", "suffix": ""}, {"first": "A", "middle": [], "last": "Angioi", "suffix": ""}, {"first": "F", "middle": ["C"], "last": "Fervenza", "suffix": ""}], "year": 2015, "venue": "", "volume": "30", "issn": "", "pages": "1225--1229", "other_ids": {"DOI": ["10.1093/ndt/gfv222"]}}, "BIBREF36": {"ref_id": "b36", "title": "Protein Misfolding, Functional Amyloid, and Human Disease", "authors": [{"first": "F", "middle": [], "last": "Chiti", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Dobson", "suffix": ""}], "year": 2006, "venue": "Annual Review of Biochemistry", "volume": "75", "issn": "1", "pages": "333--366", "other_ids": {}}, "BIBREF38": {"ref_id": "b38", "title": "mTORC1 accelerates retinal development via the immunoproteasome", "authors": [{"first": "J.-H", "middle": [], "last": "Choi", "suffix": ""}, {"first": "H", "middle": ["S"], "last": "Jo", "suffix": ""}, {"first": "S", "middle": [], "last": "Lim", "suffix": ""}, {"first": "H.-T", "middle": [], "last": "Kim", "suffix": ""}, {"first": "K", "middle": ["W"], "last": "Lee", "suffix": ""}, {"first": "K", "middle": ["H"], "last": "Moon", "suffix": ""}, {"first": "T", "middle": [], "last": "Ha", "suffix": ""}, {"first": "S", "middle": ["S"], "last": "Kwak", "suffix": ""}, {"first": "Y", "middle": [], "last": "Kim", "suffix": ""}, {"first": "E", "middle": ["J"], "last": "Lee", "suffix": ""}, {"first": "C", "middle": ["O"], "last": "Joe", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Kim", "suffix": ""}], "year": 2018, "venue": "Nature Communications", "volume": "9", "issn": "1", "pages": "", "other_ids": {"DOI": ["10.1038/s41467-018-04774-9"]}}, "BIBREF39": {"ref_id": "b39", "title": "Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation", "authors": [{"first": "W", "middle": ["H"], "last": "Choi", "suffix": ""}, {"first": "S", "middle": ["A H"], "last": "De Poot", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Lee", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Kim", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Han", "suffix": ""}, {"first": "Y", "middle": ["K"], "last": "Kim", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Lee", "suffix": ""}], "year": 2016, "venue": "Nature Communications", "volume": "7", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/ncomms10963"]}}, "BIBREF40": {"ref_id": "b40", "title": "Proteasome inhibition induces a senescence-like phenotype in primary human fibroblasts cultures", "authors": [{"first": "N", "middle": [], "last": "Chondrogianni", "suffix": ""}, {"first": "E", "middle": ["S"], "last": "Gonos", "suffix": ""}], "year": 2004, "venue": "Biogerontology", "volume": "5", "issn": "1", "pages": "55--61", "other_ids": {}}, "BIBREF42": {"ref_id": "b42", "title": "Overexpression of hUMP1/POMP proteasome accessory protein enhances proteasome-mediated antioxidant defence", "authors": [{"first": "N", "middle": [], "last": "Chondrogianni", "suffix": ""}, {"first": "E", "middle": ["S"], "last": "Gonos", "suffix": ""}], "year": 2007, "venue": "Experimental Gerontology", "volume": "42", "issn": "9", "pages": "899--903", "other_ids": {"DOI": ["10.1016/j.exger.2007.01.012"]}}, "BIBREF43": {"ref_id": "b43", "title": "Proteasome Function Determines Cellular Homeostasis and the Rate of Aging", "authors": [{"first": "N", "middle": [], "last": "Chondrogianni", "suffix": ""}, {"first": "E", "middle": ["S"], "last": "Gonos", "suffix": ""}], "year": 2010, "venue": "Protein Metabolism and Homeostasis in Aging", "volume": "", "issn": "", "pages": "38--46", "other_ids": {"DOI": ["10.1007/978-1-4419-7002-2_4"]}}, "BIBREF45": {"ref_id": "b45", "title": "Anti-ageing and rejuvenating effects of quercetin", "authors": [], "year": null, "venue": "Experimental Gerontology", "volume": "45", "issn": "10", "pages": "763--771", "other_ids": {"DOI": ["10.1016/j.exger.2010.07.001"]}}, "BIBREF46": {"ref_id": "b46", "title": "The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg", "authors": [{"first": "A", "middle": [], "last": "Ciechanover", "suffix": ""}, {"first": "P", "middle": [], "last": "Brundin", "suffix": ""}], "year": 2003, "venue": "Neuron", "volume": "40", "issn": "2", "pages": "427--446", "other_ids": {"DOI": ["10.1016/s0896-6273(03)00606-8"]}}, "BIBREF47": {"ref_id": "b47", "title": "Mechanisms of ubiquitin-mediated, limited processing of the NF-kappaB1 precursor protein p105", "authors": [{"first": "A", "middle": [], "last": "Ciechanover", "suffix": ""}, {"first": "H", "middle": [], "last": "Gonen", "suffix": ""}, {"first": "B", "middle": [], "last": "Bercovich", "suffix": ""}, {"first": "S", "middle": [], "last": "Cohen", "suffix": ""}, {"first": "I", "middle": [], "last": "Fajerman", "suffix": ""}, {"first": "A", "middle": [], "last": "Isra\u00ebl", "suffix": ""}, {"first": "F", "middle": [], "last": "Mercurio", "suffix": ""}, {"first": "C", "middle": [], "last": "Kahana", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Schwartz", "suffix": ""}, {"first": "K", "middle": [], "last": "Iwai", "suffix": ""}, {"first": "A", "middle": [], "last": "Orian", "suffix": ""}], "year": 2001, "venue": "Biochimie", "volume": "83", "issn": "3-4", "pages": "1239--1240", "other_ids": {"DOI": ["10.1016/s0300-9084(01"]}}, "BIBREF48": {"ref_id": "b48", "title": "ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation", "authors": [{"first": "A", "middle": [], "last": "Ciechanover", "suffix": ""}, {"first": "H", "middle": [], "last": "Heller", "suffix": ""}, {"first": "S", "middle": [], "last": "Elias", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Haas", "suffix": ""}, {"first": "A", "middle": [], "last": "Hershko", "suffix": ""}], "year": 1980, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "77", "issn": "", "pages": "1365--1368", "other_ids": {"DOI": ["10.1073/pnas.77.3.1365"]}}, "BIBREF49": {"ref_id": "b49", "title": "Protein Quality Control by Molecular Chaperones in Neurodegeneration", "authors": [{"first": "Aaron", "middle": [], "last": "Ciechanover", "suffix": ""}, {"first": "Y", "middle": ["T"], "last": "Kwon", "suffix": ""}], "year": 2017, "venue": "Frontiers in Neuroscience", "volume": "11", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3389/fnins.2017.00185"]}}, "BIBREF50": {"ref_id": "b50", "title": "Atomic structure of the 26S proteasome lid reveals the mechanism of deubiquitinase inhibition. ELife, 5, e13027", "authors": [{"first": "C", "middle": ["M"], "last": "Dambacher", "suffix": ""}, {"first": "E", "middle": ["J"], "last": "Worden", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Herzik", "suffix": ""}, {"first": "A", "middle": [], "last": "Martin", "suffix": ""}, {"first": "G", "middle": ["C"], "last": "Lander", "suffix": ""}], "year": 2016, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.7554/eLife.13027"]}}, "BIBREF51": {"ref_id": "b51", "title": "Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells", "authors": [{"first": "K", "middle": ["G"], "last": "Daniel", "suffix": ""}, {"first": "P", "middle": [], "last": "Gupta", "suffix": ""}, {"first": "R", "middle": ["H"], "last": "Harbach", "suffix": ""}, {"first": "W", "middle": ["C"], "last": "Guida", "suffix": ""}, {"first": "Q", "middle": ["P"], "last": "Dou", "suffix": ""}], "year": 2004, "venue": "Biochemical Pharmacology", "volume": "67", "issn": "6", "pages": "1139--1151", "other_ids": {"DOI": ["10.1016/j.bcp.2003.10.031"]}}, "BIBREF52": {"ref_id": "b52", "title": "The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution", "authors": [{"first": "N", "middle": ["P"], "last": "Dantuma", "suffix": ""}, {"first": "L", "middle": ["C"], "last": "Bott", "suffix": ""}], "year": 2014, "venue": "Frontiers in Molecular Neuroscience", "volume": "7", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3389/fnmol.2014.00070"]}}, "BIBREF54": {"ref_id": "b54", "title": "Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD\u00ae immunomodulatory drug pomalidomide", "authors": [], "year": null, "venue": "British Journal of Haematology", "volume": "171", "issn": "5", "pages": "798--812", "other_ids": {"DOI": ["10.1111/bjh.13780"]}}, "BIBREF55": {"ref_id": "b55", "title": "Essential fatty acids in Huntington's disease", "authors": [{"first": "U", "middle": ["N"], "last": "Das", "suffix": ""}, {"first": "K", "middle": ["S"], "last": "Vaddadi", "suffix": ""}], "year": 2004, "venue": "Nutrition", "volume": "20", "issn": "10", "pages": "942--947", "other_ids": {"DOI": ["10.1016/j.nut.2004.06.017"]}}, "BIBREF56": {"ref_id": "b56", "title": "Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease", "authors": [{"first": "S", "middle": [], "last": "Dasgupta", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Fishman", "suffix": ""}, {"first": "H", "middle": [], "last": "Mahallati", "suffix": ""}, {"first": "L", "middle": ["M"], "last": "Castro", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Tashima", "suffix": ""}, {"first": "E", "middle": ["S"], "last": "Ferro", "suffix": ""}, {"first": "L", "middle": ["D"], "last": "Fricker", "suffix": ""}], "year": 2015, "venue": "PloS One", "volume": "10", "issn": "12", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0145333"]}}, "BIBREF58": {"ref_id": "b58", "title": "Electrostatic Map Of Proteasome \u03b1-Rings Encodes The Design of Allosteric Porphyrin-Based Inhibitors Able To Affect 20S Conformation By Cooperative Binding", "authors": [], "year": null, "venue": "Scientific Reports", "volume": "7", "issn": "1", "pages": "", "other_ids": {"DOI": ["10.1038/s41598-017-17008-7"]}}, "BIBREF59": {"ref_id": "b59", "title": "Proteasomal degradation of tau protein", "authors": [{"first": "D", "middle": ["C"], "last": "David", "suffix": ""}, {"first": "R", "middle": [], "last": "Layfield", "suffix": ""}, {"first": "L", "middle": [], "last": "Serpell", "suffix": ""}, {"first": "Y", "middle": [], "last": "Narain", "suffix": ""}, {"first": "M", "middle": [], "last": "Goedert", "suffix": ""}, {"first": "M", "middle": ["G"], "last": "Spillantini", "suffix": ""}], "year": 2002, "venue": "Journal of Neurochemistry", "volume": "83", "issn": "1", "pages": "176--185", "other_ids": {"DOI": ["10.1046/j.1471-4159.2002.01137.x"]}}, "BIBREF60": {"ref_id": "b60", "title": "Protein modification by oxidants and the role of proteolytic enzymes", "authors": [{"first": "K", "middle": ["J"], "last": "Davies", "suffix": ""}], "year": 1993, "venue": "Biochemical Society Transactions", "volume": "21", "issn": "2", "pages": "346--353", "other_ids": {"DOI": ["10.1042/bst0210346"]}}, "BIBREF61": {"ref_id": "b61", "title": "Degradation of oxidized proteins by the 20S proteasome", "authors": [{"first": "K", "middle": ["J"], "last": "Davies", "suffix": ""}], "year": 2001, "venue": "Biochimie", "volume": "83", "issn": "3-4", "pages": "301--310", "other_ids": {"DOI": ["10.1016/s0300-9084(01)01250-0"]}}, "BIBREF62": {"ref_id": "b62", "title": "A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities", "authors": [{"first": "G", "middle": [], "last": "De Bruin", "suffix": ""}, {"first": "B", "middle": ["T"], "last": "Xin", "suffix": ""}, {"first": "M", "middle": [], "last": "Kraus", "suffix": ""}, {"first": "M", "middle": [], "last": "Van Der Stelt", "suffix": ""}, {"first": "G", "middle": ["A"], "last": "Van Der Marel", "suffix": ""}, {"first": "A", "middle": ["F"], "last": "Kisselev", "suffix": ""}, {"first": "C", "middle": [], "last": "Driessen", "suffix": ""}, {"first": "B", "middle": ["I"], "last": "Florea", "suffix": ""}, {"first": "H", "middle": ["S"], "last": "Overkleeft", "suffix": ""}], "year": 2016, "venue": "International Ed. in English)", "volume": "55", "issn": "13", "pages": "4199--4203", "other_ids": {"DOI": ["10.1002/anie.201509092"]}}, "BIBREF63": {"ref_id": "b63", "title": "Functions of lysosomes", "authors": [{"first": "C", "middle": [], "last": "De Duve", "suffix": ""}, {"first": "R", "middle": [], "last": "Wattiaux", "suffix": ""}], "year": 1966, "venue": "Annual Review of Physiology", "volume": "28", "issn": "", "pages": "435--492", "other_ids": {"DOI": ["10.1146/annurev.ph.28.030166.002251"]}}, "BIBREF64": {"ref_id": "b64", "title": "Enzymic content of the mitochondria fraction", "authors": [{"first": "C", "middle": [], "last": "De Duve", "suffix": ""}, {"first": "R", "middle": [], "last": "Gianetto", "suffix": ""}, {"first": "F", "middle": [], "last": "Appelmans", "suffix": ""}, {"first": "R", "middle": [], "last": "Wattiaux", "suffix": ""}], "year": 1953, "venue": "Nature", "volume": "172", "issn": "4390", "pages": "1143--1144", "other_ids": {"DOI": ["10.1038/1721143a0"]}}, "BIBREF65": {"ref_id": "b65", "title": "A 26 S protease subunit that binds ubiquitin conjugates", "authors": [{"first": "Q", "middle": [], "last": "Deveraux", "suffix": ""}, {"first": "V", "middle": [], "last": "Ustrell", "suffix": ""}, {"first": "C", "middle": [], "last": "Pickart", "suffix": ""}, {"first": "M", "middle": [], "last": "Rechsteiner", "suffix": ""}], "year": 1994, "venue": "The Journal of Biological Chemistry", "volume": "269", "issn": "10", "pages": "7059--7061", "other_ids": {}}, "BIBREF66": {"ref_id": "b66", "title": "Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier", "authors": [{"first": "K", "middle": [], "last": "Di", "suffix": ""}, {"first": "G", "middle": ["K"], "last": "Lloyd", "suffix": ""}, {"first": "V", "middle": [], "last": "Abraham", "suffix": ""}, {"first": "A", "middle": [], "last": "Maclaren", "suffix": ""}, {"first": "F", "middle": ["J"], "last": "Burrows", "suffix": ""}, {"first": "A", "middle": [], "last": "Desjardins", "suffix": ""}, {"first": "M", "middle": [], "last": "Trikha", "suffix": ""}, {"first": "D", "middle": ["A"], "last": "Bota", "suffix": ""}], "year": 2016, "venue": "Neuro-Oncology", "volume": "18", "issn": "6", "pages": "840--848", "other_ids": {"DOI": ["10.1093/neuonc/nov299"]}}, "BIBREF67": {"ref_id": "b67", "title": "Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain", "authors": [{"first": "M", "middle": [], "last": "D\u00edaz-Hern\u00e1ndez", "suffix": ""}, {"first": "A", "middle": ["G"], "last": "Valera", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Mor\u00e1n", "suffix": ""}, {"first": "P", "middle": [], "last": "G\u00f3mez-Ramos", "suffix": ""}, {"first": "B", "middle": [], "last": "Alvarez-Castelao", "suffix": ""}, {"first": "J", "middle": ["G"], "last": "Casta\u00f1o", "suffix": ""}, {"first": "F", "middle": [], "last": "Hern\u00e1ndez", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Lucas", "suffix": ""}], "year": 2006, "venue": "Journal of Neurochemistry", "volume": "98", "issn": "5", "pages": "1585--1596", "other_ids": {"DOI": ["10.1111/j.1471-4159.2006.03968.x"]}}, "BIBREF68": {"ref_id": "b68", "title": "Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants", "authors": [{"first": "T", "middle": ["P"], "last": "Dick", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Nussbaum", "suffix": ""}, {"first": "M", "middle": [], "last": "Deeg", "suffix": ""}, {"first": "W", "middle": [], "last": "Heinemeyer", "suffix": ""}, {"first": "M", "middle": [], "last": "Groll", "suffix": ""}, {"first": "M", "middle": [], "last": "Schirle", "suffix": ""}, {"first": "W", "middle": [], "last": "Keilholz", "suffix": ""}, {"first": "S", "middle": [], "last": "Stevanovi\u0107", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Wolf", "suffix": ""}, {"first": "R", "middle": [], "last": "Huber", "suffix": ""}, {"first": "H", "middle": ["G"], "last": "Rammensee", "suffix": ""}, {"first": "H", "middle": [], "last": "Schild", "suffix": ""}], "year": 1998, "venue": "The Journal of Biological Chemistry", "volume": "273", "issn": "40", "pages": "25637--25646", "other_ids": {"DOI": ["10.1074/jbc.273.40.25637"]}}, "BIBREF69": {"ref_id": "b69", "title": "The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins", "authors": [{"first": "C", "middle": ["A"], "last": "Dickey", "suffix": ""}, {"first": "A", "middle": [], "last": "Kamal", "suffix": ""}, {"first": "K", "middle": [], "last": "Lundgren", "suffix": ""}, {"first": "N", "middle": [], "last": "Klosak", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Bailey", "suffix": ""}, {"first": "J", "middle": [], "last": "Dunmore", "suffix": ""}, {"first": "P", "middle": [], "last": "Ash", "suffix": ""}, {"first": "S", "middle": [], "last": "Shoraka", "suffix": ""}, {"first": "J", "middle": [], "last": "Zlatkovic", "suffix": ""}, {"first": "C", "middle": ["B"], "last": "Eckman", "suffix": ""}, {"first": "C", "middle": [], "last": "Patterson", "suffix": ""}, {"first": "D", "middle": ["W"], "last": "Dickson", "suffix": ""}, {"first": "N", "middle": ["S"], "last": "Nahman", "suffix": ""}, {"first": "M", "middle": [], "last": "Hutton", "suffix": ""}, {"first": "F", "middle": [], "last": "Burrows", "suffix": ""}, {"first": "L", "middle": [], "last": "Petrucelli", "suffix": ""}], "year": 2007, "venue": "The Journal of Clinical Investigation", "volume": "117", "issn": "3", "pages": "648--658", "other_ids": {"DOI": ["10.1172/JCI29715"]}}, "BIBREF70": {"ref_id": "b70", "title": "Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain", "authors": [{"first": "M", "middle": [], "last": "Difiglia", "suffix": ""}, {"first": "E", "middle": [], "last": "Sapp", "suffix": ""}, {"first": "K", "middle": ["O"], "last": "Chase", "suffix": ""}, {"first": "S", "middle": ["W"], "last": "Davies", "suffix": ""}, {"first": "G", "middle": ["P"], "last": "Bates", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Vonsattel", "suffix": ""}, {"first": "N", "middle": [], "last": "Aronin", "suffix": ""}], "year": 1997, "venue": "Science", "volume": "", "issn": "5334", "pages": "1990--1993", "other_ids": {}}, "BIBREF72": {"ref_id": "b72", "title": "Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised", "authors": [{"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}, {"first": "F", "middle": [], "last": "Gay", "suffix": ""}, {"first": "F", "middle": [], "last": "Schjesvold", "suffix": ""}, {"first": "M", "middle": [], "last": "Beksac", "suffix": ""}, {"first": "R", "middle": [], "last": "Hajek", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Weisel", "suffix": ""}, {"first": "H", "middle": [], "last": "Goldschmidt", "suffix": ""}, {"first": "V", "middle": [], "last": "Maisnar", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "C", "middle": ["K"], "last": "Min", "suffix": ""}, {"first": "A", "middle": [], "last": "Pluta", "suffix": ""}, {"first": "W.-J", "middle": [], "last": "Chng", "suffix": ""}, {"first": "M", "middle": [], "last": "Kaiser", "suffix": ""}, {"first": "S", "middle": [], "last": "Zweegman", "suffix": ""}, {"first": "M.-V", "middle": [], "last": "Mateos", "suffix": ""}, {"first": "A", "middle": [], "last": "Spencer", "suffix": ""}, {"first": "S", "middle": [], "last": "Iida", "suffix": ""}, {"first": "G", "middle": [], "last": "Morgan", "suffix": ""}, {"first": "K", "middle": [], "last": "Suryanarayan", "suffix": ""}, {"first": "M", "middle": [], "last": "Janakiram", "suffix": ""}], "year": 2019, "venue": "The Lancet", "volume": "393", "issn": "", "pages": "253--264", "other_ids": {"DOI": ["10.1016/S0140-6736(18)33003-4"]}}, "BIBREF73": {"ref_id": "b73", "title": "Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma", "authors": [{"first": "Richard", "middle": ["I"], "last": "Fisher", "suffix": ""}, {"first": "S", "middle": ["H"], "last": "Bernstein", "suffix": ""}, {"first": "B", "middle": ["S"], "last": "Kahl", "suffix": ""}, {"first": "B", "middle": [], "last": "Djulbegovic", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Robertson", "suffix": ""}, {"first": "S", "middle": [], "last": "De Vos", "suffix": ""}, {"first": "E", "middle": [], "last": "Epner", "suffix": ""}, {"first": "A", "middle": [], "last": "Krishnan", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Leonard", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonial", "suffix": ""}, {"first": "E", "middle": ["A"], "last": "Stadtmauer", "suffix": ""}, {"first": "O", "middle": ["A"], "last": "O&apos;connor", "suffix": ""}, {"first": "H", "middle": [], "last": "Shi", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Boral", "suffix": ""}, {"first": "A", "middle": [], "last": "Goy", "suffix": ""}], "year": 2006, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "24", "issn": "30", "pages": "4867--4874", "other_ids": {"DOI": ["10.1200/JCO.2006.07.9665"]}}, "BIBREF74": {"ref_id": "b74", "title": "Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t", "authors": [{"first": "B", "middle": ["I"], "last": "Florea", "suffix": ""}, {"first": "M", "middle": [], "last": "Verdoes", "suffix": ""}, {"first": "N", "middle": [], "last": "Li", "suffix": ""}, {"first": "W", "middle": ["A"], "last": "Van Der Linden", "suffix": ""}, {"first": "P", "middle": ["P"], "last": "Geurink", "suffix": ""}, {"first": "H", "middle": [], "last": "Van Den Elst", "suffix": ""}, {"first": "T", "middle": [], "last": "Hofmann", "suffix": ""}, {"first": "A", "middle": [], "last": "De Ru", "suffix": ""}, {"first": "P", "middle": ["A"], "last": "Van Veelen", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "K", "middle": [], "last": "Sasaki", "suffix": ""}, {"first": "S", "middle": [], "last": "Murata", "suffix": ""}, {"first": "H", "middle": [], "last": "Den Dulk", "suffix": ""}, {"first": "J", "middle": [], "last": "Brouwer", "suffix": ""}, {"first": "F", "middle": ["A"], "last": "Ossendorp", "suffix": ""}, {"first": "A", "middle": ["F"], "last": "Kisselev", "suffix": ""}, {"first": "H", "middle": ["S"], "last": "Overkleeft", "suffix": ""}], "year": 2010, "venue": "Chemistry & Biology", "volume": "17", "issn": "8", "pages": "795--801", "other_ids": {"DOI": ["10.1016/j.chembiol.2010.05.027"]}}, "BIBREF75": {"ref_id": "b75", "title": "Multicatalytic Proteinase in Fish Muscle", "authors": [{"first": "E", "middle": ["J"], "last": "Folco", "suffix": ""}, {"first": "L", "middle": [], "last": "Busconi", "suffix": ""}, {"first": "C", "middle": ["B"], "last": "Martone", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Sanchez", "suffix": ""}], "year": 1988, "venue": "Archives of Biochemistry and Biophysics", "volume": "267", "issn": "2", "pages": "599--605", "other_ids": {"DOI": ["10.1016/0003"]}}, "BIBREF76": {"ref_id": "b76", "title": "A balance of protein synthesis and proteasome-dependent degradation determines the maintenance of LTP", "authors": [{"first": "R", "middle": [], "last": "Fonseca", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Vabulas", "suffix": ""}, {"first": "F", "middle": ["U"], "last": "Hartl", "suffix": ""}, {"first": "T", "middle": [], "last": "Bonhoeffer", "suffix": ""}, {"first": "U", "middle": ["V"], "last": "N\u00e4gerl", "suffix": ""}], "year": 2006, "venue": "Neuron", "volume": "52", "issn": "2", "pages": "239--245", "other_ids": {"DOI": ["10.1016/j.neuron.2006.08.015"]}}, "BIBREF77": {"ref_id": "b77", "title": "Proteasome-mediated degradation of STAT1alpha following infection of macrophages with Leishmania donovani", "authors": [{"first": "G", "middle": [], "last": "Forget", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Gregory", "suffix": ""}, {"first": "M", "middle": [], "last": "Olivier", "suffix": ""}], "year": 2005, "venue": "The Journal of Biological Chemistry", "volume": "280", "issn": "34", "pages": "30542--30549", "other_ids": {"DOI": ["10.1074/jbc.M414126200"]}}, "BIBREF78": {"ref_id": "b78", "title": "The pore of activated 20S proteasomes has an ordered 7-fold symmetric conformation", "authors": [{"first": "A", "middle": [], "last": "F\u00f6rster", "suffix": ""}, {"first": "F", "middle": ["G"], "last": "Whitby", "suffix": ""}, {"first": "C", "middle": ["P"], "last": "Hill", "suffix": ""}], "year": 2003, "venue": "The EMBO Journal", "volume": "22", "issn": "17", "pages": "4356--4364", "other_ids": {"DOI": ["10.1093/emboj/cdg436"]}}, "BIBREF79": {"ref_id": "b79", "title": "Structural determinants for the intracellular degradation of human thymidylate synthase", "authors": [{"first": "A", "middle": ["M"], "last": "Forsthoefel", "suffix": ""}, {"first": "M", "middle": ["M O"], "last": "Pe\u00f1a", "suffix": ""}, {"first": "Y", "middle": ["Y"], "last": "Xing", "suffix": ""}, {"first": "Z", "middle": [], "last": "Rafique", "suffix": ""}, {"first": "F", "middle": ["G"], "last": "Berger", "suffix": ""}], "year": 2004, "venue": "Biochemistry", "volume": "43", "issn": "7", "pages": "1972--1979", "other_ids": {"DOI": ["10.1021/bi035894p"]}}, "BIBREF80": {"ref_id": "b80", "title": "Evolution of proteasome regulators in eukaryotes", "authors": [{"first": "P", "middle": [], "last": "Fort", "suffix": ""}, {"first": "A", "middle": ["V"], "last": "Kajava", "suffix": ""}, {"first": "F", "middle": [], "last": "Delsuc", "suffix": ""}, {"first": "O", "middle": [], "last": "Coux", "suffix": ""}], "year": 2015, "venue": "Genome Biology and Evolution", "volume": "7", "issn": "5", "pages": "1363--1379", "other_ids": {"DOI": ["10.1093/gbe/evv068"]}}, "BIBREF81": {"ref_id": "b81", "title": "Peptide therapeutics: current status and future directions", "authors": [{"first": "K", "middle": [], "last": "Fosgerau", "suffix": ""}, {"first": "T", "middle": [], "last": "Hoffmann", "suffix": ""}], "year": 2015, "venue": "Drug Discovery Today", "volume": "20", "issn": "1", "pages": "122--128", "other_ids": {"DOI": ["10.1016/j.drudis.2014.10.003"]}}, "BIBREF82": {"ref_id": "b82", "title": "The proteasome maturation protein POMP facilitates major steps of 20S proteasome formation at the endoplasmic reticulum", "authors": [{"first": "B", "middle": [], "last": "Fricke", "suffix": ""}, {"first": "S", "middle": [], "last": "Heink", "suffix": ""}, {"first": "J", "middle": [], "last": "Steffen", "suffix": ""}, {"first": "P.-M", "middle": [], "last": "Kloetzel", "suffix": ""}, {"first": "E", "middle": [], "last": "Kr\u00fcger", "suffix": ""}], "year": 2007, "venue": "EMBO Reports", "volume": "8", "issn": "12", "pages": "1170--1175", "other_ids": {"DOI": ["10.1038/sj.embor.7401091"]}}, "BIBREF83": {"ref_id": "b83", "title": "The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma", "authors": [{"first": "J", "middle": ["W"], "last": "Friedberg", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Vose", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Kelly", "suffix": ""}, {"first": "F", "middle": [], "last": "Young", "suffix": ""}, {"first": "S", "middle": ["H"], "last": "Bernstein", "suffix": ""}, {"first": "D", "middle": [], "last": "Peterson", "suffix": ""}, {"first": "L", "middle": [], "last": "Rich", "suffix": ""}, {"first": "S", "middle": [], "last": "Blumel", "suffix": ""}, {"first": "N", "middle": ["K"], "last": "Proia", "suffix": ""}, {"first": "J", "middle": [], "last": "Liesveld", "suffix": ""}, {"first": "R", "middle": ["I"], "last": "Fisher", "suffix": ""}, {"first": "J", "middle": ["O"], "last": "Armitage", "suffix": ""}, {"first": "S", "middle": [], "last": "Grant", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Leonard", "suffix": ""}], "year": 2011, "venue": "Blood", "volume": "117", "issn": "10", "pages": "2807--2812", "other_ids": {"DOI": ["10.1182/blood-2010-11-314708"]}}, "BIBREF84": {"ref_id": "b84", "title": "Antigen presentation by MHC class I and its regulation by interferon gamma", "authors": [{"first": "K", "middle": [], "last": "Fr\u00fch", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yang", "suffix": ""}], "year": 1999, "venue": "Current Opinion in Immunology", "volume": "11", "issn": "1", "pages": "76--81", "other_ids": {"DOI": ["10.1016/s0952-"]}}, "BIBREF85": {"ref_id": "b85", "title": "A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma", "authors": [{"first": "E", "middle": [], "last": "Gallerani", "suffix": ""}, {"first": "M", "middle": [], "last": "Zucchetti", "suffix": ""}, {"first": "D", "middle": [], "last": "Brunelli", "suffix": ""}, {"first": "E", "middle": [], "last": "Marangon", "suffix": ""}, {"first": "C", "middle": [], "last": "Noberasco", "suffix": ""}, {"first": "D", "middle": [], "last": "Hess", "suffix": ""}, {"first": "A", "middle": [], "last": "Delmonte", "suffix": ""}, {"first": "G", "middle": [], "last": "Martinelli", "suffix": ""}, {"first": "S", "middle": [], "last": "B\u00f6hm", "suffix": ""}, {"first": "C", "middle": [], "last": "Driessen", "suffix": ""}, {"first": "F", "middle": [], "last": "De Braud", "suffix": ""}, {"first": "S", "middle": [], "last": "Marsoni", "suffix": ""}, {"first": "R", "middle": [], "last": "Cereda", "suffix": ""}, {"first": "F", "middle": [], "last": "Sala", "suffix": ""}, {"first": "M", "middle": [], "last": "D&apos;incalci", "suffix": ""}, {"first": "C", "middle": [], "last": "Sessa", "suffix": ""}], "year": 2013, "venue": "European Journal of Cancer", "volume": "49", "issn": "2", "pages": "290--296", "other_ids": {"DOI": ["10.1016/j.ejca.2012.09.009"]}}, "BIBREF86": {"ref_id": "b86", "title": "Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicleassociated protein, CDCrel-1", "authors": [{"first": "J", "middle": [], "last": "Gao", "suffix": ""}, {"first": "K", "middle": ["K"], "last": "Chung", "suffix": ""}, {"first": "H", "middle": [], "last": "Huang", "suffix": ""}, {"first": "V", "middle": ["L"], "last": "Dawson", "suffix": ""}, {"first": "T", "middle": ["M"], "last": "Dawson", "suffix": ""}], "year": 2000, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "97", "issn": "", "pages": "13354--13359", "other_ids": {"DOI": ["10.1073/pnas.240347797"]}}, "BIBREF87": {"ref_id": "b87", "title": "Cytosolic PINK1 promotes the targeting of ubiquitinated proteins to the aggresome-autophagy pathway during proteasomal stress", "authors": [{"first": "Ju", "middle": [], "last": "Gao", "suffix": ""}, {"first": "M", "middle": [], "last": "Li", "suffix": ""}, {"first": "S", "middle": [], "last": "Qin", "suffix": ""}, {"first": "T", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "S", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Hu", "suffix": ""}, {"first": "Y", "middle": [], "last": "Deng", "suffix": ""}, {"first": "C", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "D", "middle": [], "last": "You", "suffix": ""}, {"first": "H", "middle": [], "last": "Li", "suffix": ""}, {"first": "D", "middle": [], "last": "Mu", "suffix": ""}, {"first": "Z", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "C", "middle": [], "last": "Jiang", "suffix": ""}], "year": 2016, "venue": "Autophagy", "volume": "12", "issn": "4", "pages": "632--647", "other_ids": {"DOI": ["10.1080/15548627.2016.1147667"]}}, "BIBREF88": {"ref_id": "b88", "title": "Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomidedexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation", "authors": [{"first": "L", "middle": [], "last": "Garderet", "suffix": ""}, {"first": "S", "middle": [], "last": "Iacobelli", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "M", "middle": [], "last": "Dib", "suffix": ""}, {"first": "I", "middle": [], "last": "Lafon", "suffix": ""}, {"first": "D", "middle": [], "last": "Niederwieser", "suffix": ""}, {"first": "T", "middle": [], "last": "Masszi", "suffix": ""}, {"first": "J", "middle": [], "last": "Fontan", "suffix": ""}, {"first": "M", "middle": [], "last": "Michallet", "suffix": ""}, {"first": "A", "middle": [], "last": "Gratwohl", "suffix": ""}, {"first": "G", "middle": [], "last": "Milone", "suffix": ""}, {"first": "C", "middle": [], "last": "Doyen", "suffix": ""}, {"first": "B", "middle": [], "last": "Pegourie", "suffix": ""}, {"first": "R", "middle": [], "last": "Hajek", "suffix": ""}, {"first": "P", "middle": [], "last": "Casassus", "suffix": ""}, {"first": "B", "middle": [], "last": "Kolb", "suffix": ""}, {"first": "C", "middle": [], "last": "Chaleteix", "suffix": ""}, {"first": "B", "middle": [], "last": "Hertenstein", "suffix": ""}, {"first": "F", "middle": [], "last": "Onida", "suffix": ""}, {"first": "G", "middle": [], "last": "Gahrton", "suffix": ""}], "year": 2012, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "30", "issn": "20", "pages": "2475--2482", "other_ids": {"DOI": ["10.1200/JCO.2011.37.4918"]}}, "BIBREF89": {"ref_id": "b89", "title": "Drug combinations with proteasome inhibitors in antitumor therapy", "authors": [{"first": "L", "middle": [], "last": "Gatti", "suffix": ""}, {"first": "V", "middle": [], "last": "Zuco", "suffix": ""}, {"first": "N", "middle": [], "last": "Zaffaroni", "suffix": ""}, {"first": "P", "middle": [], "last": "Perego", "suffix": ""}], "year": 2013, "venue": "Current Pharmaceutical Design", "volume": "19", "issn": "22", "pages": "4094--4114", "other_ids": {"DOI": ["10.2174/1381612811319220015"]}}, "BIBREF90": {"ref_id": "b90", "title": "A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenstr\u00f6m Macroglobulinemia", "authors": [{"first": "I", "middle": ["M"], "last": "Ghobrial", "suffix": ""}, {"first": "R", "middle": [], "last": "Vij", "suffix": ""}, {"first": "D", "middle": [], "last": "Siegel", "suffix": ""}, {"first": "A", "middle": [], "last": "Badros", "suffix": ""}, {"first": "J", "middle": [], "last": "Kaufman", "suffix": ""}, {"first": "N", "middle": [], "last": "Raje", "suffix": ""}, {"first": "A", "middle": [], "last": "Jakubowiak", "suffix": ""}, {"first": "M", "middle": ["R"], "last": "Savona", "suffix": ""}, {"first": "M", "middle": [], "last": "Obreja", "suffix": ""}, {"first": "J", "middle": ["G"], "last": "Berdeja", "suffix": ""}], "year": 2019, "venue": "Clinical Cancer Research: An Official Journal of the American Association for Cancer Research", "volume": "25", "issn": "16", "pages": "4907--4916", "other_ids": {"DOI": ["10.1158/1078-0432.CCR-18-3728"]}}, "BIBREF91": {"ref_id": "b91", "title": "Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease", "authors": [{"first": "C", "middle": [], "last": "Giamp\u00e0", "suffix": ""}, {"first": "D", "middle": [], "last": "Laurenti", "suffix": ""}, {"first": "S", "middle": [], "last": "Anzilotti", "suffix": ""}, {"first": "G", "middle": [], "last": "Bernardi", "suffix": ""}, {"first": "F", "middle": ["S"], "last": "Menniti", "suffix": ""}, {"first": "F", "middle": ["R"], "last": "Fusco", "suffix": ""}], "year": 2010, "venue": "PloS One", "volume": "5", "issn": "10", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0013417"]}}, "BIBREF92": {"ref_id": "b92", "title": "Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group", "authors": [{"first": "J", "middle": [], "last": "Gilbert", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Lee", "suffix": ""}, {"first": "A", "middle": [], "last": "Argiris", "suffix": ""}, {"first": "M", "middle": [], "last": "Haigentz", "suffix": ""}, {"first": "L", "middle": ["E"], "last": "Feldman", "suffix": ""}, {"first": "M", "middle": [], "last": "Jang", "suffix": ""}, {"first": "P", "middle": [], "last": "Arun", "suffix": ""}, {"first": "C", "middle": [], "last": "Van Waes", "suffix": ""}, {"first": "A", "middle": ["A"], "last": "Forastiere", "suffix": ""}], "year": 2013, "venue": "Head & Neck", "volume": "35", "issn": "7", "pages": "942--948", "other_ids": {"DOI": ["10.1002/hed.23046"]}}, "BIBREF93": {"ref_id": "b93", "title": "Angiogenesis and Multiple Myeloma", "authors": [{"first": "N", "middle": [], "last": "Giuliani", "suffix": ""}, {"first": "P", "middle": [], "last": "Storti", "suffix": ""}, {"first": "M", "middle": [], "last": "Bolzoni", "suffix": ""}, {"first": "B", "middle": ["D"], "last": "Palma", "suffix": ""}, {"first": "S", "middle": [], "last": "Bonomini", "suffix": ""}], "year": 2011, "venue": "Cancer Microenvironment", "volume": "4", "issn": "3", "pages": "325--337", "other_ids": {"DOI": ["10.1007/s12307-011-0072-9"]}}, "BIBREF94": {"ref_id": "b94", "title": "Exposure of hydrophobic moieties promotes the selective degradation of hydrogen peroxide-modified hemoglobin by the multicatalytic proteinase complex, proteasome", "authors": [{"first": "C", "middle": [], "last": "Giulivi", "suffix": ""}, {"first": "R", "middle": ["E"], "last": "Pacifici", "suffix": ""}, {"first": "K", "middle": ["J"], "last": "Davies", "suffix": ""}], "year": 1994, "venue": "Archives of Biochemistry and Biophysics", "volume": "311", "issn": "2", "pages": "329--341", "other_ids": {"DOI": ["10.1006/abbi.1994.1245"]}}, "BIBREF95": {"ref_id": "b95", "title": "Proline-and Arginine-Rich Peptides as Flexible Allosteric Modulators of Human Proteasome Activity", "authors": [{"first": "M", "middle": [], "last": "Gi\u017cy\u0144ska", "suffix": ""}, {"first": "J", "middle": [], "last": "Witkowska", "suffix": ""}, {"first": "P", "middle": [], "last": "Karpowicz", "suffix": ""}, {"first": "R", "middle": [], "last": "Rostankowski", "suffix": ""}, {"first": "E", "middle": ["S"], "last": "Chocron", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Pickering", "suffix": ""}, {"first": "P", "middle": [], "last": "Osmulski", "suffix": ""}, {"first": "M", "middle": [], "last": "Gaczynska", "suffix": ""}, {"first": "E", "middle": [], "last": "Jankowska", "suffix": ""}], "year": 2019, "venue": "Journal of Medicinal Chemistry", "volume": "62", "issn": "1", "pages": "359--370", "other_ids": {"DOI": ["10.1021/acs.jmedchem.8b01025"]}}, "BIBREF96": {"ref_id": "b96", "title": "Proline-and Arginine-Rich Peptides as Flexible Allosteric Modulators of Human Proteasome Activity", "authors": [{"first": "M", "middle": [], "last": "Gi\u017cy\u0144ska", "suffix": ""}, {"first": "J", "middle": [], "last": "Witkowska", "suffix": ""}, {"first": "P", "middle": [], "last": "Karpowicz", "suffix": ""}, {"first": "R", "middle": [], "last": "Rostankowski", "suffix": ""}, {"first": "E", "middle": ["S"], "last": "Chocron", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Pickering", "suffix": ""}, {"first": "P", "middle": [], "last": "Osmulski", "suffix": ""}, {"first": "M", "middle": [], "last": "Gaczynska", "suffix": ""}, {"first": "E", "middle": [], "last": "Jankowska", "suffix": ""}], "year": 2019, "venue": "Journal of Medicinal Chemistry", "volume": "62", "issn": "1", "pages": "359--370", "other_ids": {"DOI": ["10.1021/acs.jmedchem.8b01025"]}}, "BIBREF97": {"ref_id": "b97", "title": "Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein", "authors": [{"first": "G", "middle": ["G"], "last": "Glenner", "suffix": ""}, {"first": "C", "middle": ["W"], "last": "Wong", "suffix": ""}], "year": 1984, "venue": "Biochemical and Biophysical Research Communications", "volume": "120", "issn": "3", "pages": "885--890", "other_ids": {}}, "BIBREF98": {"ref_id": "b98", "title": "The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction", "authors": [{"first": "M", "middle": ["H"], "last": "Glickman", "suffix": ""}, {"first": "A", "middle": [], "last": "Ciechanover", "suffix": ""}], "year": 2002, "venue": "Physiological Reviews", "volume": "82", "issn": "2", "pages": "373--428", "other_ids": {"DOI": ["10.1152/physrev.00027.2001"]}}, "BIBREF99": {"ref_id": "b99", "title": "The propagation of prion-like protein inclusions in neurodegenerative diseases", "authors": [{"first": "M", "middle": [], "last": "Goedert", "suffix": ""}, {"first": "F", "middle": [], "last": "Clavaguera", "suffix": ""}, {"first": "M", "middle": [], "last": "Tolnay", "suffix": ""}], "year": 2010, "venue": "Trends in Neurosciences", "volume": "33", "issn": "7", "pages": "317--325", "other_ids": {}}, "BIBREF101": {"ref_id": "b101", "title": "Degradation of abnormal proteins in Escherichia coli (protein breakdownprotein structure-mistranslation-amino acid analogs-puromycin)", "authors": [{"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}], "year": 1972, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "69", "issn": "", "pages": "422--426", "other_ids": {}}, "BIBREF103": {"ref_id": "b103", "title": "Intracellular protein degradation in mammalian and bacterial cells", "authors": [{"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}, {"first": "J", "middle": ["F"], "last": "Dice", "suffix": ""}], "year": 1974, "venue": "Annual Review of Biochemistry", "volume": "43", "issn": "0", "pages": "835--869", "other_ids": {}}, "BIBREF105": {"ref_id": "b105", "title": "Intracellular protein degradation in mammalian and bacterial cells: Part 2", "authors": [{"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}, {"first": "A", "middle": ["C"], "last": "St John", "suffix": ""}], "year": 1976, "venue": "Annual Review of Biochemistry", "volume": "45", "issn": "", "pages": "747--803", "other_ids": {}}, "BIBREF107": {"ref_id": "b107", "title": "Blocking Cancer Growth with Less POMP or Proteasomes", "authors": [{"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}, {"first": "J", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "G", "middle": ["A"], "last": "Collins", "suffix": ""}], "year": 2015, "venue": "Molecular Cell", "volume": "59", "issn": "2", "pages": "143--145", "other_ids": {"DOI": ["10.1016/j.molcel.2015.07.005"]}}, "BIBREF108": {"ref_id": "b108", "title": "The ubiquitinproteasome system: Potential therapeutic targets for alzheimer's disease and spinal cord injury", "authors": [{"first": "B", "middle": [], "last": "Gong", "suffix": ""}, {"first": "M", "middle": [], "last": "Radulovic", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Figueiredo-Pereira", "suffix": ""}, {"first": "C", "middle": [], "last": "Cardozo", "suffix": ""}], "year": 2016, "venue": "Frontiers in Molecular Neuroscience", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3389/fnmol.2016.00004"]}}, "BIBREF109": {"ref_id": "b109", "title": "Associations of human retinal very long-chain polyunsaturated fatty acids with dietary lipid biomarkers", "authors": [{"first": "A", "middle": [], "last": "Gorusupudi", "suffix": ""}, {"first": "A", "middle": [], "last": "Liu", "suffix": ""}, {"first": "G", "middle": ["S"], "last": "Hageman", "suffix": ""}, {"first": "P", "middle": ["S"], "last": "Bernstein", "suffix": ""}], "year": 2016, "venue": "Journal of Lipid Research", "volume": "57", "issn": "3", "pages": "499--508", "other_ids": {"DOI": ["10.1194/jlr.P065540"]}}, "BIBREF110": {"ref_id": "b110", "title": "Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study", "authors": [{"first": "A", "middle": [], "last": "Goy", "suffix": ""}, {"first": "S", "middle": ["H"], "last": "Bernstein", "suffix": ""}, {"first": "B", "middle": ["S"], "last": "Kahl", "suffix": ""}, {"first": "B", "middle": [], "last": "Djulbegovic", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Robertson", "suffix": ""}, {"first": "S", "middle": [], "last": "De Vos", "suffix": ""}, {"first": "E", "middle": [], "last": "Epner", "suffix": ""}, {"first": "A", "middle": [], "last": "Krishnan", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Leonard", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonial", "suffix": ""}, {"first": "S", "middle": [], "last": "Nasta", "suffix": ""}, {"first": "O", "middle": ["A"], "last": "O&apos;connor", "suffix": ""}, {"first": "H", "middle": [], "last": "Shi", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Boral", "suffix": ""}, {"first": "R", "middle": ["I"], "last": "Fisher", "suffix": ""}], "year": 2009, "venue": "Annals of Oncology", "volume": "20", "issn": "3", "pages": "520--525", "other_ids": {"DOI": ["10.1093/annonc/mdn656"]}}, "BIBREF111": {"ref_id": "b111", "title": "Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma", "authors": [{"first": "Andre", "middle": [], "last": "Goy", "suffix": ""}, {"first": "A", "middle": [], "last": "Younes", "suffix": ""}, {"first": "P", "middle": [], "last": "Mclaughlin", "suffix": ""}, {"first": "B", "middle": [], "last": "Pro", "suffix": ""}, {"first": "J", "middle": ["E"], "last": "Romaguera", "suffix": ""}, {"first": "F", "middle": [], "last": "Hagemeister", "suffix": ""}, {"first": "L", "middle": [], "last": "Fayad", "suffix": ""}, {"first": "N", "middle": ["H"], "last": "Dang", "suffix": ""}, {"first": "F", "middle": [], "last": "Samaniego", "suffix": ""}, {"first": "M", "middle": [], "last": "Wang", "suffix": ""}, {"first": "K", "middle": [], "last": "Broglio", "suffix": ""}, {"first": "B", "middle": [], "last": "Samuels", "suffix": ""}, {"first": "F", "middle": [], "last": "Gilles", "suffix": ""}, {"first": "A", "middle": ["H"], "last": "Sarris", "suffix": ""}, {"first": "S", "middle": [], "last": "Hart", "suffix": ""}, {"first": "E", "middle": [], "last": "Trehu", "suffix": ""}, {"first": "D", "middle": [], "last": "Schenkein", "suffix": ""}, {"first": "F", "middle": [], "last": "Cabanillas", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Rodriguez", "suffix": ""}], "year": 2005, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "23", "issn": "4", "pages": "667--675", "other_ids": {"DOI": ["10.1200/JCO.2005.03.108"]}}, "BIBREF112": {"ref_id": "b112", "title": "Second Generation Proteasome Inhibitors in Multiple Myeloma. Anti-Cancer Agents in Medicinal Chemistry", "authors": [{"first": "A", "middle": [], "last": "Gozzetti", "suffix": ""}, {"first": "G", "middle": [], "last": "Papini", "suffix": ""}, {"first": "V", "middle": [], "last": "Candi", "suffix": ""}, {"first": "C", "middle": ["Z"], "last": "Brambilla", "suffix": ""}, {"first": "S", "middle": [], "last": "Sirianni", "suffix": ""}, {"first": "M", "middle": [], "last": "Bocchia", "suffix": ""}], "year": 2017, "venue": "", "volume": "17", "issn": "", "pages": "920--926", "other_ids": {"DOI": ["10.2174/1871520616666160902101622"]}}, "BIBREF113": {"ref_id": "b113", "title": "The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo", "authors": [{"first": "C", "middle": ["L"], "last": "Grand", "suffix": ""}, {"first": "H", "middle": [], "last": "Han", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "M\u0169noz", "suffix": ""}, {"first": "S", "middle": [], "last": "Weitman", "suffix": ""}, {"first": "D", "middle": ["D"], "last": "Von Hoff", "suffix": ""}, {"first": "L", "middle": ["H"], "last": "Hurley", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Bearss", "suffix": ""}], "year": 2003, "venue": "Molecular Cancer Therapeutics", "volume": "2", "issn": "2", "pages": "", "other_ids": {}}, "BIBREF114": {"ref_id": "b114", "title": "Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma", "authors": [{"first": "E", "middle": ["W"], "last": "Grandin", "suffix": ""}, {"first": "B", "middle": [], "last": "Ky", "suffix": ""}, {"first": "R", "middle": ["F"], "last": "Cornell", "suffix": ""}, {"first": "J", "middle": [], "last": "Carver", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Lenihan", "suffix": ""}], "year": 2015, "venue": "Journal of Cardiac Failure", "volume": "21", "issn": "2", "pages": "138--144", "other_ids": {"DOI": ["10.1016/j.cardfail.2014.11.008"]}}, "BIBREF115": {"ref_id": "b115", "title": "Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFNgamma)-inducible subunits", "authors": [{"first": "T", "middle": ["A"], "last": "Griffin", "suffix": ""}, {"first": "D", "middle": [], "last": "Nandi", "suffix": ""}, {"first": "M", "middle": [], "last": "Cruz", "suffix": ""}, {"first": "H", "middle": ["J"], "last": "Fehling", "suffix": ""}, {"first": "L", "middle": ["V"], "last": "Kaer", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Monaco", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Colbert", "suffix": ""}], "year": 1998, "venue": "The Journal of Experimental Medicine", "volume": "187", "issn": "1", "pages": "97--104", "other_ids": {"DOI": ["10.1084/jem.187.1.97"]}}, "BIBREF116": {"ref_id": "b116", "title": "The 26S proteasome is a multifaceted target for anti-cancer therapies", "authors": [{"first": "T", "middle": ["A"], "last": "Grigoreva", "suffix": ""}, {"first": "V", "middle": ["G"], "last": "Tribulovich", "suffix": ""}, {"first": "A", "middle": ["V"], "last": "Garabadzhiu", "suffix": ""}, {"first": "G", "middle": [], "last": "Melino", "suffix": ""}, {"first": "N", "middle": ["A"], "last": "Barlev", "suffix": ""}], "year": 2015, "venue": "Oncotarget", "volume": "6", "issn": "28", "pages": "24733--24749", "other_ids": {}}, "BIBREF117": {"ref_id": "b117", "title": "The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome", "authors": [{"first": "M", "middle": [], "last": "Groettrup", "suffix": ""}, {"first": "S", "middle": [], "last": "Standera", "suffix": ""}, {"first": "R", "middle": [], "last": "Stohwasser", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Kloetzel", "suffix": ""}], "year": 1997, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "94", "issn": "", "pages": "8970--8975", "other_ids": {}}, "BIBREF118": {"ref_id": "b118", "title": "A gated channel into the proteasome core particle", "authors": [{"first": "M", "middle": [], "last": "Groll", "suffix": ""}, {"first": "M", "middle": [], "last": "Bajorek", "suffix": ""}, {"first": "A", "middle": [], "last": "K\u00f6hler", "suffix": ""}, {"first": "L", "middle": [], "last": "Moroder", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Rubin", "suffix": ""}, {"first": "R", "middle": [], "last": "Huber", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Glickman", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}], "year": 2000, "venue": "Nature Structural Biology", "volume": "7", "issn": "11", "pages": "1062--1067", "other_ids": {"DOI": ["10.1038/80992"]}}, "BIBREF119": {"ref_id": "b119", "title": "A gated channel into the proteasome core particle", "authors": [{"first": "M", "middle": [], "last": "Groll", "suffix": ""}, {"first": "M", "middle": [], "last": "Bajorek", "suffix": ""}, {"first": "A", "middle": [], "last": "K\u00f6hler", "suffix": ""}, {"first": "L", "middle": [], "last": "Moroder", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Rubin", "suffix": ""}, {"first": "R", "middle": [], "last": "Huber", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Glickman", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}], "year": 2000, "venue": "Nature Structural Biology", "volume": "7", "issn": "11", "pages": "1062--1067", "other_ids": {"DOI": ["10.1038/80992"]}}, "BIBREF120": {"ref_id": "b120", "title": "Crystal structure of the boronic acidbased proteasome inhibitor bortezomib in complex with the yeast 20S proteasome", "authors": [{"first": "M", "middle": [], "last": "Groll", "suffix": ""}, {"first": "C", "middle": ["R"], "last": "Berkers", "suffix": ""}, {"first": "H", "middle": ["L"], "last": "Ploegh", "suffix": ""}, {"first": "H", "middle": [], "last": "Ovaa", "suffix": ""}], "year": 1993, "venue": "Structure", "volume": "14", "issn": "3", "pages": "451--456", "other_ids": {"DOI": ["10.1016/j.str.2005.11.019"]}}, "BIBREF121": {"ref_id": "b121", "title": "Structure of 20S proteasome from yeast at 2.4 A resolution", "authors": [{"first": "M", "middle": [], "last": "Groll", "suffix": ""}, {"first": "L", "middle": [], "last": "Ditzel", "suffix": ""}, {"first": "J", "middle": [], "last": "L\u00f6we", "suffix": ""}, {"first": "D", "middle": [], "last": "Stock", "suffix": ""}, {"first": "M", "middle": [], "last": "Bochtler", "suffix": ""}, {"first": "H", "middle": ["D"], "last": "Bartunik", "suffix": ""}, {"first": "R", "middle": [], "last": "Huber", "suffix": ""}], "year": 1997, "venue": "Nature", "volume": "386", "issn": "6624", "pages": "463--471", "other_ids": {"DOI": ["10.1038/386463a0"]}}, "BIBREF122": {"ref_id": "b122", "title": "The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study", "authors": [{"first": "M", "middle": [], "last": "Groll", "suffix": ""}, {"first": "W", "middle": [], "last": "Heinemeyer", "suffix": ""}, {"first": "S", "middle": [], "last": "J\u00e4ger", "suffix": ""}, {"first": "T", "middle": [], "last": "Ullrich", "suffix": ""}, {"first": "M", "middle": [], "last": "Bochtler", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Wolf", "suffix": ""}, {"first": "R", "middle": [], "last": "Huber", "suffix": ""}], "year": 1999, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "96", "issn": "", "pages": "10976--10983", "other_ids": {"DOI": ["10.1073/pnas.96.20.10976"]}}, "BIBREF123": {"ref_id": "b123", "title": "Substrate access and processing by the 20S proteasome core particle", "authors": [{"first": "Michael", "middle": [], "last": "Groll", "suffix": ""}, {"first": "R", "middle": [], "last": "Huber", "suffix": ""}], "year": 2003, "venue": "The International Journal of Biochemistry & Cell Biology", "volume": "35", "issn": "5", "pages": "606--616", "other_ids": {"DOI": ["10.1016/s1357-2725(02)00390-4"]}}, "BIBREF124": {"ref_id": "b124", "title": "Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome", "authors": [{"first": "Michael", "middle": [], "last": "Groll", "suffix": ""}, {"first": "T", "middle": [], "last": "Nazif", "suffix": ""}, {"first": "R", "middle": [], "last": "Huber", "suffix": ""}, {"first": "M", "middle": [], "last": "Bogyo", "suffix": ""}], "year": 2002, "venue": "Chemistry & Biology", "volume": "9", "issn": "5", "pages": "655--662", "other_ids": {"DOI": ["10.1016/s1074-5521(02)00144-8"]}}, "BIBREF125": {"ref_id": "b125", "title": "Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome", "authors": [{"first": "T", "middle": [], "last": "Grune", "suffix": ""}, {"first": "T", "middle": [], "last": "Reinheckel", "suffix": ""}, {"first": "K", "middle": ["J"], "last": "Davies", "suffix": ""}], "year": 1996, "venue": "The Journal of Biological Chemistry", "volume": "271", "issn": "26", "pages": "15504--15509", "other_ids": {"DOI": ["10.1074/jbc.271.26.15504"]}}, "BIBREF126": {"ref_id": "b126", "title": "HSP70 mediates dissociation and reassociation of the 26S proteasome during adaptation to oxidative stress", "authors": [{"first": "Tilman", "middle": [], "last": "Grune", "suffix": ""}, {"first": "B", "middle": [], "last": "Catalgol", "suffix": ""}, {"first": "A", "middle": [], "last": "Licht", "suffix": ""}, {"first": "G", "middle": [], "last": "Ermak", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Pickering", "suffix": ""}, {"first": "J", "middle": ["K"], "last": "Ngo", "suffix": ""}, {"first": "K", "middle": ["J A"], "last": "Davies", "suffix": ""}], "year": 2011, "venue": "Free Radical Biology & Medicine", "volume": "51", "issn": "7", "pages": "1355--1364", "other_ids": {}}, "BIBREF128": {"ref_id": "b128", "title": "Amyloid fibril formation by an SH3 domain", "authors": [{"first": "J", "middle": ["I"], "last": "Guijarro", "suffix": ""}, {"first": "M", "middle": [], "last": "Sunde", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Jones", "suffix": ""}, {"first": "I", "middle": ["D"], "last": "Campbell", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Dobson", "suffix": ""}], "year": 1998, "venue": "Proceedings of the National Academy of Sciences", "volume": "95", "issn": "8", "pages": "4224--4228", "other_ids": {"DOI": ["10.1073/pnas.95.8.4224"]}}, "BIBREF129": {"ref_id": "b129", "title": "Glutamate stimulates glutamate receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of GluR2", "authors": [{"first": "L", "middle": [], "last": "Guo", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wang", "suffix": ""}], "year": 2007, "venue": "Neuroscience", "volume": "145", "issn": "1", "pages": "100--109", "other_ids": {"DOI": ["10.1016/j.neuroscience.2006.11.042"]}}, "BIBREF130": {"ref_id": "b130", "title": "Retinal Anatomy and Pathology", "authors": [{"first": "M", "middle": ["P"], "last": "Gupta", "suffix": ""}, {"first": "A", "middle": ["A"], "last": "Herzlich", "suffix": ""}, {"first": "T", "middle": [], "last": "Sauer", "suffix": ""}, {"first": "C.-C", "middle": [], "last": "Chan", "suffix": ""}], "year": 2016, "venue": "Developments in Ophthalmology", "volume": "55", "issn": "", "pages": "7--17", "other_ids": {"DOI": ["10.1159/000431128"]}}, "BIBREF131": {"ref_id": "b131", "title": "Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis", "authors": [{"first": "N", "middle": [], "last": "Gupta", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Hanley", "suffix": ""}, {"first": "K", "middle": [], "last": "Venkatakrishnan", "suffix": ""}, {"first": "A", "middle": [], "last": "Bessudo", "suffix": ""}, {"first": "D", "middle": ["W"], "last": "Rasco", "suffix": ""}, {"first": "S", "middle": [], "last": "Sharma", "suffix": ""}, {"first": "B", "middle": ["H"], "last": "O&apos;neil", "suffix": ""}, {"first": "B", "middle": [], "last": "Wang", "suffix": ""}, {"first": "G", "middle": [], "last": "Liu", "suffix": ""}, {"first": "A", "middle": [], "last": "Ke", "suffix": ""}, {"first": "C", "middle": [], "last": "Patel", "suffix": ""}, {"first": "K", "middle": [], "last": "Rowland Yeo", "suffix": ""}, {"first": "C", "middle": [], "last": "Xia", "suffix": ""}, {"first": "X", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "D.-L", "middle": [], "last": "Esseltine", "suffix": ""}, {"first": "J", "middle": [], "last": "Nemunaitis", "suffix": ""}], "year": 2018, "venue": "Journal of Clinical Pharmacology", "volume": "58", "issn": "2", "pages": "180--192", "other_ids": {"DOI": ["10.1002/jcph.988"]}}, "BIBREF133": {"ref_id": "b133", "title": "Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor", "authors": [], "year": null, "venue": "Clinical Pharmacokinetics", "volume": "58", "issn": "4", "pages": "431--449", "other_ids": {"DOI": ["10.1007/s40262-018-0702-1"]}}, "BIBREF134": {"ref_id": "b134", "title": "A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors", "authors": [{"first": "N", "middle": [], "last": "Gupta", "suffix": ""}, {"first": "S", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "S", "middle": [], "last": "Pusalkar", "suffix": ""}, {"first": "M", "middle": [], "last": "Plesescu", "suffix": ""}, {"first": "S", "middle": [], "last": "Chowdhury", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Hanley", "suffix": ""}, {"first": "B", "middle": [], "last": "Wang", "suffix": ""}, {"first": "C", "middle": [], "last": "Xia", "suffix": ""}, {"first": "X", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "K", "middle": [], "last": "Venkatakrishnan", "suffix": ""}, {"first": "D", "middle": ["R"], "last": "Shepard", "suffix": ""}], "year": 2018, "venue": "Investigational New Drugs", "volume": "36", "issn": "3", "pages": "407--415", "other_ids": {"DOI": ["10.1007/s10637-017-0509-1"]}}, "BIBREF135": {"ref_id": "b135", "title": "Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis", "authors": [{"first": "N", "middle": [], "last": "Gupta", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "A.-M", "middle": [], "last": "Hui", "suffix": ""}, {"first": "D.-L", "middle": [], "last": "Esseltine", "suffix": ""}, {"first": "K", "middle": [], "last": "Venkatakrishnan", "suffix": ""}], "year": 2015, "venue": "British Journal of Clinical Pharmacology", "volume": "79", "issn": "5", "pages": "789--800", "other_ids": {"DOI": ["10.1111/bcp.12542"]}}, "BIBREF136": {"ref_id": "b136", "title": "Complementary roles for Rpn11 and Ubp6 in deubiquitination and proteolysis by the proteasome", "authors": [{"first": "A", "middle": [], "last": "Guterman", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Glickman", "suffix": ""}], "year": 2004, "venue": "The Journal of Biological Chemistry", "volume": "279", "issn": "3", "pages": "1729--1738", "other_ids": {"DOI": ["10.1074/jbc.M307050200"]}}, "BIBREF137": {"ref_id": "b137", "title": "Hemin inhibits ATP-dependent ubiquitin-dependent proteolysis: Role of hemin in regulating ubiquitin conjugate degradation", "authors": [{"first": "A", "middle": ["L"], "last": "Haas", "suffix": ""}, {"first": "I", "middle": ["A"], "last": "Rose", "suffix": ""}], "year": 1981, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "78", "issn": "", "pages": "6845--6848", "other_ids": {}}, "BIBREF139": {"ref_id": "b139", "title": "Redundant Roles of Rpn10 and Rpn13 in Recognition of Ubiquitinated Proteins and Cellular Homeostasis", "authors": [{"first": "J", "middle": [], "last": "Hamazaki", "suffix": ""}, {"first": "S", "middle": [], "last": "Hirayama", "suffix": ""}, {"first": "S", "middle": [], "last": "Murata", "suffix": ""}], "year": 2015, "venue": "PLoS Genetics", "volume": "11", "issn": "7", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pgen.1005401"]}}, "BIBREF140": {"ref_id": "b140", "title": "A novel proteasome interacting protein recruits the deubiquitinating enzyme UCH37 to 26S proteasomes", "authors": [{"first": "J", "middle": [], "last": "Hamazaki", "suffix": ""}, {"first": "S.-I", "middle": [], "last": "Iemura", "suffix": ""}, {"first": "T", "middle": [], "last": "Natsume", "suffix": ""}, {"first": "H", "middle": [], "last": "Yashiroda", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "S", "middle": [], "last": "Murata", "suffix": ""}], "year": 2006, "venue": "The EMBO Journal", "volume": "25", "issn": "19", "pages": "4524--4536", "other_ids": {"DOI": ["10.1038/sj.emboj.7601338"]}}, "BIBREF141": {"ref_id": "b141", "title": "Preliminary report: inhibition of cellular proteasome activity by free fatty acids", "authors": [{"first": "F", "middle": ["G"], "last": "Hamel", "suffix": ""}], "year": 2009, "venue": "Metabolism: Clinical and Experimental", "volume": "58", "issn": "8", "pages": "1047--1049", "other_ids": {}}, "BIBREF143": {"ref_id": "b143", "title": "Activity-dependent growth of new dendritic spines is regulated by the proteasome", "authors": [{"first": "A", "middle": ["M"], "last": "Hamilton", "suffix": ""}, {"first": "W", "middle": ["C"], "last": "Oh", "suffix": ""}, {"first": "H", "middle": [], "last": "Vega-Ramirez", "suffix": ""}, {"first": "I", "middle": ["S"], "last": "Stein", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Hell", "suffix": ""}, {"first": "G", "middle": ["N"], "last": "Patrick", "suffix": ""}, {"first": "K", "middle": [], "last": "Zito", "suffix": ""}], "year": 2012, "venue": "Neuron", "volume": "74", "issn": "6", "pages": "1023--1030", "other_ids": {"DOI": ["10.1016/j.neuron.2012.04.031"]}}, "BIBREF144": {"ref_id": "b144", "title": "Oral delivery of peptide drugs: barriers and developments", "authors": [{"first": "J", "middle": ["H"], "last": "Hamman", "suffix": ""}, {"first": "G", "middle": ["M"], "last": "Enslin", "suffix": ""}, {"first": "A", "middle": ["F"], "last": "Kotz\u00e9", "suffix": ""}], "year": 2005, "venue": "BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy", "volume": "19", "issn": "3", "pages": "165--177", "other_ids": {"DOI": ["10.2165/00063030-200519030-00003"]}}, "BIBREF145": {"ref_id": "b145", "title": "Direct cellular delivery of human proteasomes to delay tau aggregation", "authors": [{"first": "D", "middle": ["H"], "last": "Han", "suffix": ""}, {"first": "H.-K", "middle": [], "last": "Na", "suffix": ""}, {"first": "W", "middle": ["H"], "last": "Choi", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Lee", "suffix": ""}, {"first": "Y", "middle": ["K"], "last": "Kim", "suffix": ""}, {"first": "C", "middle": [], "last": "Won", "suffix": ""}, {"first": "S.-H", "middle": [], "last": "Lee", "suffix": ""}, {"first": "K", "middle": ["P"], "last": "Kim", "suffix": ""}, {"first": "J", "middle": [], "last": "Kuret", "suffix": ""}, {"first": "D.-H", "middle": [], "last": "Min", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Lee", "suffix": ""}], "year": 2014, "venue": "Nature Communications", "volume": "5", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/ncomms6633"]}}, "BIBREF146": {"ref_id": "b146", "title": "Epoxomicin, a new antitumor agent of microbial origin", "authors": [{"first": "M", "middle": [], "last": "Hanada", "suffix": ""}, {"first": "K", "middle": [], "last": "Sugawara", "suffix": ""}, {"first": "K", "middle": [], "last": "Kaneta", "suffix": ""}, {"first": "S", "middle": [], "last": "Toda", "suffix": ""}, {"first": "Y", "middle": [], "last": "Nishiyama", "suffix": ""}, {"first": "K", "middle": [], "last": "Tomita", "suffix": ""}, {"first": "H", "middle": [], "last": "Yamamoto", "suffix": ""}, {"first": "M", "middle": [], "last": "Konishi", "suffix": ""}, {"first": "T", "middle": [], "last": "Oki", "suffix": ""}], "year": 1992, "venue": "The Journal of Antibiotics", "volume": "45", "issn": "11", "pages": "1746--1752", "other_ids": {"DOI": ["10.7164/antibiotics.45.1746"]}}, "BIBREF147": {"ref_id": "b147", "title": "The hallmarks of cancer", "authors": [{"first": "D", "middle": [], "last": "Hanahan", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Weinberg", "suffix": ""}], "year": 2000, "venue": "Cell", "volume": "100", "issn": "1", "pages": "57--70", "other_ids": {"DOI": ["10.1016/s0092-8674(00)81683-9"]}}, "BIBREF148": {"ref_id": "b148", "title": "A ubiquitin stress response induces altered proteasome composition", "authors": [{"first": "J", "middle": [], "last": "Hanna", "suffix": ""}, {"first": "A", "middle": [], "last": "Meides", "suffix": ""}, {"first": "D", "middle": ["P"], "last": "Zhang", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}], "year": 2007, "venue": "Cell", "volume": "129", "issn": "4", "pages": "747--759", "other_ids": {"DOI": ["10.1016/j.cell.2007.03.042"]}}, "BIBREF150": {"ref_id": "b150", "title": "An inducible chaperone adapts proteasome assembly to stress", "authors": [], "year": null, "venue": "Molecular Cell", "volume": "55", "issn": "4", "pages": "566--577", "other_ids": {"DOI": ["10.1016/j.molcel.2014.06.017"]}}, "BIBREF151": {"ref_id": "b151", "title": "TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease", "authors": [{"first": "A", "middle": [], "last": "Harada", "suffix": ""}, {"first": "K", "middle": [], "last": "Suzuki", "suffix": ""}, {"first": "H", "middle": [], "last": "Kimura", "suffix": ""}], "year": 2017, "venue": "The Journal of Pharmacology and Experimental Therapeutics", "volume": "360", "issn": "1", "pages": "75--83", "other_ids": {"DOI": ["10.1124/jpet.116.237388"]}}, "BIBREF152": {"ref_id": "b152", "title": "Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities", "authors": [{"first": "R", "middle": ["J"], "last": "Harding", "suffix": ""}, {"first": "Y.-F", "middle": [], "last": "Tong", "suffix": ""}], "year": 2018, "venue": "Acta Pharmacologica Sinica", "volume": "39", "issn": "5", "pages": "754--769", "other_ids": {}}, "BIBREF154": {"ref_id": "b154", "title": "Proteasome inhibitors mechanism; source for design of newer therapeutic agents", "authors": [{"first": "S", "middle": ["L"], "last": "Harer", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Bhatia", "suffix": ""}, {"first": "N", "middle": ["M"], "last": "Bhatia", "suffix": ""}], "year": 2012, "venue": "The Journal of Antibiotics", "volume": "65", "issn": "6", "pages": "279--288", "other_ids": {"DOI": ["10.1038/ja.2011.84"]}}, "BIBREF155": {"ref_id": "b155", "title": "Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma", "authors": [{"first": "P", "middle": [], "last": "Hari", "suffix": ""}, {"first": "H", "middle": ["M"], "last": "Lin", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "D", "middle": [], "last": "Berg", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}], "year": 2018, "venue": "Journal of Medical Economics", "volume": "21", "issn": "8", "pages": "793--798", "other_ids": {"DOI": ["10.1080/13696998.2018.1474745"]}}, "BIBREF156": {"ref_id": "b156", "title": "Oprozomib in patients with newly diagnosed multiple myeloma", "authors": [{"first": "P", "middle": [], "last": "Hari", "suffix": ""}, {"first": "J", "middle": ["V"], "last": "Matous", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Voorhees", "suffix": ""}, {"first": "K", "middle": ["H"], "last": "Shain", "suffix": ""}, {"first": "M", "middle": [], "last": "Obreja", "suffix": ""}, {"first": "J", "middle": [], "last": "Frye", "suffix": ""}, {"first": "H", "middle": [], "last": "Fujii", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Jakubowiak", "suffix": ""}, {"first": "D", "middle": [], "last": "Rossi", "suffix": ""}, {"first": "P", "middle": [], "last": "Sonneveld", "suffix": ""}], "year": 2019, "venue": "Blood Cancer Journal", "volume": "9", "issn": "9", "pages": "", "other_ids": {"DOI": ["10.1038/s41408-019-0232-6"]}}, "BIBREF157": {"ref_id": "b157", "title": "Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma", "authors": [{"first": "P", "middle": [], "last": "Hari", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "Paba-Prada", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Voorhees", "suffix": ""}, {"first": "J", "middle": [], "last": "Frye", "suffix": ""}, {"first": "Y.-L", "middle": [], "last": "Chang", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "J", "middle": [], "last": "Zonder", "suffix": ""}, {"first": "R", "middle": [], "last": "Boccia", "suffix": ""}, {"first": "K", "middle": ["H"], "last": "Shain", "suffix": ""}], "year": 2019, "venue": "Leukemia Research", "volume": "83", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.leukres.2019.106172"]}}, "BIBREF158": {"ref_id": "b158", "title": "Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stemcell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial", "authors": [{"first": "J.-L", "middle": [], "last": "Harousseau", "suffix": ""}, {"first": "M", "middle": [], "last": "Attal", "suffix": ""}, {"first": "H", "middle": [], "last": "Avet-Loiseau", "suffix": ""}, {"first": "G", "middle": [], "last": "Marit", "suffix": ""}, {"first": "D", "middle": [], "last": "Caillot", "suffix": ""}, {"first": "M", "middle": [], "last": "Mohty", "suffix": ""}, {"first": "P", "middle": [], "last": "Lenain", "suffix": ""}, {"first": "C", "middle": [], "last": "Hulin", "suffix": ""}, {"first": "T", "middle": [], "last": "Facon", "suffix": ""}, {"first": "P", "middle": [], "last": "Casassus", "suffix": ""}, {"first": "M", "middle": [], "last": "Michallet", "suffix": ""}, {"first": "H", "middle": [], "last": "Maisonneuve", "suffix": ""}, {"first": "L", "middle": [], "last": "Benboubker", "suffix": ""}, {"first": "F", "middle": [], "last": "Maloisel", "suffix": ""}, {"first": "M.-O", "middle": [], "last": "Petillon", "suffix": ""}, {"first": "I", "middle": [], "last": "Webb", "suffix": ""}, {"first": "C", "middle": [], "last": "Mathiot", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}], "year": 2010, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "28", "issn": "30", "pages": "4621--4629", "other_ids": {"DOI": ["10.1200/JCO.2009.27.9158"]}}, "BIBREF159": {"ref_id": "b159", "title": "Release of a macromolecular protein component from human erythrocyte ghosts", "authors": [{"first": "J", "middle": ["R"], "last": "Harris", "suffix": ""}], "year": 1968, "venue": "Biochimica Et Biophysica Acta", "volume": "150", "issn": "3", "pages": "90157--90157", "other_ids": {"DOI": ["10.1016/0005-2736"]}}, "BIBREF160": {"ref_id": "b160", "title": "Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results", "authors": [{"first": "S", "middle": ["J"], "last": "Harrison", "suffix": ""}, {"first": "P", "middle": [], "last": "Mainwaring", "suffix": ""}, {"first": "T", "middle": [], "last": "Price", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Millward", "suffix": ""}, {"first": "P", "middle": [], "last": "Padrik", "suffix": ""}, {"first": "C", "middle": ["R"], "last": "Underhill", "suffix": ""}, {"first": "P", "middle": ["K"], "last": "Cannell", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Reich", "suffix": ""}, {"first": "M", "middle": [], "last": "Trikha", "suffix": ""}, {"first": "A", "middle": [], "last": "Spencer", "suffix": ""}], "year": 2016, "venue": "Clinical Cancer Research: An Official Journal of the American Association for Cancer Research", "volume": "22", "issn": "18", "pages": "4559--4566", "other_ids": {"DOI": ["10.1158/1078-0432.CCR-15-2616"]}}, "BIBREF161": {"ref_id": "b161", "title": "Crystal structure of the human 20S proteasome in complex with carfilzomib", "authors": [{"first": "W", "middle": [], "last": "Harshbarger", "suffix": ""}, {"first": "C", "middle": [], "last": "Miller", "suffix": ""}, {"first": "C", "middle": [], "last": "Diedrich", "suffix": ""}, {"first": "J", "middle": [], "last": "Sacchettini", "suffix": ""}], "year": 1993, "venue": "Structure", "volume": "23", "issn": "2", "pages": "418--424", "other_ids": {"DOI": ["10.1016/j.str.2014.11.017"]}}, "BIBREF162": {"ref_id": "b162", "title": "Cycling of O-linked \u03b2-N -acetylglucosamine on nucleocytoplasmic proteins", "authors": [{"first": "G", "middle": ["W"], "last": "Hart", "suffix": ""}, {"first": "M", "middle": ["P"], "last": "Housley", "suffix": ""}, {"first": "C", "middle": [], "last": "Slawson", "suffix": ""}], "year": 2007, "venue": "Nature", "volume": "446", "issn": "7139", "pages": "1017--1022", "other_ids": {"DOI": ["10.1038/nature05815"]}}, "BIBREF163": {"ref_id": "b163", "title": "Converging concepts of protein folding in vitro and in vivo", "authors": [{"first": "F", "middle": ["U"], "last": "Hartl", "suffix": ""}, {"first": "M", "middle": [], "last": "Hayer-Hartl", "suffix": ""}], "year": 2009, "venue": "Nature Structural & Molecular Biology", "volume": "16", "issn": "6", "pages": "574--581", "other_ids": {"DOI": ["10.1038/nsmb.1591"]}}, "BIBREF164": {"ref_id": "b164", "title": "Molecular chaperones in protein folding and proteostasis", "authors": [{"first": "F", "middle": ["U"], "last": "Hartl", "suffix": ""}, {"first": "A", "middle": [], "last": "Bracher", "suffix": ""}, {"first": "M", "middle": [], "last": "Hayer-Hartl", "suffix": ""}], "year": 2011, "venue": "Nature", "volume": "475", "issn": "7356", "pages": "324--332", "other_ids": {"DOI": ["10.1038/nature10317"]}}, "BIBREF165": {"ref_id": "b165", "title": "The structure of the 26S proteasome subunit Rpn2 reveals its PC repeat domain as a closed toroid of two concentric \u03b1-helical rings", "authors": [{"first": "J", "middle": [], "last": "He", "suffix": ""}, {"first": "K", "middle": [], "last": "Kulkarni", "suffix": ""}, {"first": "P", "middle": ["C A"], "last": "Da Fonseca", "suffix": ""}, {"first": "D", "middle": [], "last": "Krutauz", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Glickman", "suffix": ""}, {"first": "D", "middle": [], "last": "Barford", "suffix": ""}, {"first": "E", "middle": ["P"], "last": "Morris", "suffix": ""}], "year": 1993, "venue": "Structure", "volume": "20", "issn": "3", "pages": "513--521", "other_ids": {"DOI": ["10.1016/j.str.2011.12.015"]}}, "BIBREF166": {"ref_id": "b166", "title": "Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations", "authors": [{"first": "P", "middle": ["R A"], "last": "Heckman", "suffix": ""}, {"first": "A", "middle": [], "last": "Blokland", "suffix": ""}, {"first": "E", "middle": ["P P"], "last": "Bollen", "suffix": ""}, {"first": "J", "middle": [], "last": "Prickaerts", "suffix": ""}], "year": 2018, "venue": "Neuroscience & Biobehavioral Reviews", "volume": "87", "issn": "", "pages": "233--254", "other_ids": {}}, "BIBREF168": {"ref_id": "b168", "title": "Perturbations of Ubiquitin-Proteasome-Mediated Proteolysis in Aging and Alzheimer's Disease. Frontiers in Aging Neuroscience, 11", "authors": [{"first": "A", "middle": ["N"], "last": "Hegde", "suffix": ""}, {"first": "S", "middle": ["G"], "last": "Smith", "suffix": ""}, {"first": "L", "middle": ["M"], "last": "Duke", "suffix": ""}, {"first": "A", "middle": [], "last": "Pourquoi", "suffix": ""}, {"first": "S", "middle": [], "last": "Vaz", "suffix": ""}], "year": 2019, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3389/fnagi.2019.00324"]}}, "BIBREF169": {"ref_id": "b169", "title": "The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing", "authors": [{"first": "W", "middle": [], "last": "Heinemeyer", "suffix": ""}, {"first": "M", "middle": [], "last": "Fischer", "suffix": ""}, {"first": "T", "middle": [], "last": "Krimmer", "suffix": ""}, {"first": "U", "middle": [], "last": "Stachon", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Wolf", "suffix": ""}], "year": 1997, "venue": "The Journal of Biological Chemistry", "volume": "272", "issn": "40", "pages": "25200--25209", "other_ids": {"DOI": ["10.1074/jbc.272.40.25200"]}}, "BIBREF170": {"ref_id": "b170", "title": "IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response", "authors": [{"first": "S", "middle": [], "last": "Heink", "suffix": ""}, {"first": "D", "middle": [], "last": "Ludwig", "suffix": ""}, {"first": "P.-M", "middle": [], "last": "Kloetzel", "suffix": ""}, {"first": "E", "middle": [], "last": "Kr\u00fcger", "suffix": ""}], "year": 2005, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "102", "issn": "", "pages": "9241--9246", "other_ids": {"DOI": ["10.1073/pnas.0501711102"]}}, "BIBREF171": {"ref_id": "b171", "title": "Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma", "authors": [{"first": "A", "middle": [], "last": "Hellmann", "suffix": ""}, {"first": "S", "middle": [], "last": "Rule", "suffix": ""}, {"first": "J", "middle": [], "last": "Walewski", "suffix": ""}, {"first": "O", "middle": [], "last": "Shpilberg", "suffix": ""}, {"first": "H", "middle": [], "last": "Feng", "suffix": ""}, {"first": "H", "middle": [], "last": "Van De Velde", "suffix": ""}, {"first": "H", "middle": [], "last": "Patel", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Skee", "suffix": ""}, {"first": "S", "middle": [], "last": "Girgis", "suffix": ""}, {"first": "V", "middle": ["J"], "last": "Louw", "suffix": ""}], "year": 2011, "venue": "Clinical Pharmacokinetics", "volume": "50", "issn": "12", "pages": "781--791", "other_ids": {"DOI": ["10.2165/11594410-000000000-00000"]}}, "BIBREF172": {"ref_id": "b172", "title": "Phosphorylation of Tyr-950 in the proteasome scaffolding protein RPN2 modulates its interaction with the ubiquitin receptor RPN13", "authors": [{"first": "C", "middle": ["W"], "last": "Hemmis", "suffix": ""}, {"first": "S", "middle": ["C"], "last": "Heard", "suffix": ""}, {"first": "C", "middle": ["P"], "last": "Hill", "suffix": ""}], "year": 2019, "venue": "The Journal of Biological Chemistry", "volume": "294", "issn": "25", "pages": "9659--9665", "other_ids": {"DOI": ["10.1074/jbc.AC119.008881"]}}, "BIBREF173": {"ref_id": "b173", "title": "A novel role for the immunoproteasome in retinal function", "authors": [{"first": "S", "middle": ["A"], "last": "Hussong", "suffix": ""}, {"first": "H", "middle": [], "last": "Roehrich", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Kapphahn", "suffix": ""}, {"first": "M", "middle": [], "last": "Maldonado", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Pardue", "suffix": ""}, {"first": "D", "middle": ["A"], "last": "Ferrington", "suffix": ""}], "year": 2011, "venue": "Investigative Ophthalmology & Visual Science", "volume": "52", "issn": "2", "pages": "714--723", "other_ids": {"DOI": ["10.1167/iovs.10-6032"]}}, "BIBREF174": {"ref_id": "b174", "title": "Ubiquitin-specific protease-14 reduces cellular aggregates and protects against mutant huntingtin-induced cell degeneration: involvement of the proteasome and ER stress-activated kinase IRE1\u03b1", "authors": [{"first": "A", "middle": [], "last": "Hyrskyluoto", "suffix": ""}, {"first": "C", "middle": [], "last": "Bruelle", "suffix": ""}, {"first": "S", "middle": ["H"], "last": "Lundh", "suffix": ""}, {"first": "H", "middle": ["T"], "last": "Do", "suffix": ""}, {"first": "J", "middle": [], "last": "Kivinen", "suffix": ""}, {"first": "E", "middle": [], "last": "Rappou", "suffix": ""}, {"first": "S", "middle": [], "last": "Reijonen", "suffix": ""}, {"first": "T", "middle": [], "last": "Waltimo", "suffix": ""}, {"first": "\u00c5", "middle": [], "last": "Peters\u00e9n", "suffix": ""}, {"first": "D", "middle": [], "last": "Lindholm", "suffix": ""}, {"first": "L", "middle": [], "last": "Korhonen", "suffix": ""}], "year": 2014, "venue": "Human Molecular Genetics", "volume": "23", "issn": "22", "pages": "5928--5939", "other_ids": {"DOI": ["10.1093/hmg/ddu317"]}}, "BIBREF175": {"ref_id": "b175", "title": "The molecular chaperone Hsp90 plays a role in the assembly and maintenance of the 26S proteasome", "authors": [{"first": "J", "middle": [], "last": "Imai", "suffix": ""}, {"first": "M", "middle": [], "last": "Maruya", "suffix": ""}, {"first": "H", "middle": [], "last": "Yashiroda", "suffix": ""}, {"first": "I", "middle": [], "last": "Yahara", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}], "year": 2003, "venue": "The EMBO Journal", "volume": "22", "issn": "14", "pages": "3557--3567", "other_ids": {"DOI": ["10.1093/emboj/cdg349"]}}, "BIBREF176": {"ref_id": "b176", "title": "A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors", "authors": [{"first": "J", "middle": ["R"], "last": "Infante", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Mendelson", "suffix": ""}, {"first": "H", "middle": ["A"], "last": "Burris", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Bendell", "suffix": ""}, {"first": "A", "middle": ["W"], "last": "Tolcher", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Gordon", "suffix": ""}, {"first": "H", "middle": ["H"], "last": "Gillenwater", "suffix": ""}, {"first": "S", "middle": [], "last": "Arastu-Kapur", "suffix": ""}, {"first": "H", "middle": ["L"], "last": "Wong", "suffix": ""}, {"first": "K", "middle": ["P"], "last": "Papadopoulos", "suffix": ""}], "year": 2016, "venue": "Investigational New Drugs", "volume": "34", "issn": "2", "pages": "216--224", "other_ids": {"DOI": ["10.1007/s10637-016-0327-x"]}}, "BIBREF177": {"ref_id": "b177", "title": "Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics", "authors": [{"first": "I", "middle": [], "last": "Irrcher", "suffix": ""}, {"first": "H", "middle": [], "last": "Aleyasin", "suffix": ""}, {"first": "E", "middle": ["L"], "last": "Seifert", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Hewitt", "suffix": ""}, {"first": "S", "middle": [], "last": "Chhabra", "suffix": ""}, {"first": "M", "middle": [], "last": "Phillips", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Lutz", "suffix": ""}, {"first": "M", "middle": ["W C"], "last": "Rousseaux", "suffix": ""}, {"first": "L", "middle": [], "last": "Bevilacqua", "suffix": ""}, {"first": "A", "middle": [], "last": "Jahani-Asl", "suffix": ""}, {"first": "S", "middle": [], "last": "Callaghan", "suffix": ""}, {"first": "J", "middle": ["G"], "last": "Maclaurin", "suffix": ""}, {"first": "K", "middle": ["F"], "last": "Winklhofer", "suffix": ""}, {"first": "P", "middle": [], "last": "Rizzu", "suffix": ""}, {"first": "P", "middle": [], "last": "Rippstein", "suffix": ""}, {"first": "R", "middle": ["H"], "last": "Kim", "suffix": ""}, {"first": "C", "middle": ["X"], "last": "Chen", "suffix": ""}, {"first": "E", "middle": ["A"], "last": "Fon", "suffix": ""}, {"first": "R", "middle": ["S"], "last": "Slack", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Park", "suffix": ""}], "year": 2010, "venue": "Human Molecular Genetics", "volume": "19", "issn": "19", "pages": "3734--3746", "other_ids": {"DOI": ["10.1093/hmg/ddq288"]}}, "BIBREF178": {"ref_id": "b178", "title": "Monoubiquitination of RPN10 regulates substrate recruitment to the proteasome", "authors": [{"first": "M", "middle": [], "last": "Isasa", "suffix": ""}, {"first": "E", "middle": ["J"], "last": "Katz", "suffix": ""}, {"first": "W", "middle": [], "last": "Kim", "suffix": ""}, {"first": "V", "middle": [], "last": "Yugo", "suffix": ""}, {"first": "S", "middle": [], "last": "Gonz\u00e1lez", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Kirkpatrick", "suffix": ""}, {"first": "T", "middle": ["M"], "last": "Thomson", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Gygi", "suffix": ""}, {"first": "B", "middle": [], "last": "Crosas", "suffix": ""}], "year": 2010, "venue": "Molecular Cell", "volume": "38", "issn": "5", "pages": "733--745", "other_ids": {"DOI": ["10.1016/j.molcel.2010.05.001"]}}, "BIBREF179": {"ref_id": "b179", "title": "Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease", "authors": [{"first": "P", "middle": ["K"], "last": "Iseri", "suffix": ""}, {"first": "O", "middle": [], "last": "Altina\u015f", "suffix": ""}, {"first": "T", "middle": [], "last": "Tokay", "suffix": ""}, {"first": "N", "middle": [], "last": "Y\u00fcksel", "suffix": ""}], "year": 2006, "venue": "Journal of Neuro-Ophthalmology: The Official Journal of the North American Neuro-Ophthalmology Society", "volume": "26", "issn": "1", "pages": "18--24", "other_ids": {"DOI": ["10.1097/01.wno.0000204645.56873.26"]}}, "BIBREF180": {"ref_id": "b180", "title": "Therapeutic antibodies for multiple myeloma", "authors": [{"first": "T", "middle": [], "last": "Ishida", "suffix": ""}], "year": 2018, "venue": "Japanese Journal of Clinical Oncology", "volume": "48", "issn": "11", "pages": "957--963", "other_ids": {"DOI": ["10.1093/jjco/hyy133"]}}, "BIBREF181": {"ref_id": "b181", "title": "Effects of linoleic acid and cations on the activity of a novel high-molecular weight protease, ingensin, from human placent", "authors": [{"first": "S", "middle": [], "last": "Ishiura", "suffix": ""}, {"first": "J", "middle": [], "last": "Nojima", "suffix": ""}, {"first": "M", "middle": [], "last": "Yamamoto", "suffix": ""}, {"first": "T", "middle": [], "last": "Fuchiwaki", "suffix": ""}, {"first": "T", "middle": [], "last": "", "suffix": ""}], "year": 1986, "venue": "International Journal Biochemestry", "volume": "18", "issn": "9", "pages": "", "other_ids": {"DOI": ["10.1016/0020-711x(86)90051-0"]}}, "BIBREF182": {"ref_id": "b182", "title": "A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma", "authors": [{"first": "S", "middle": [], "last": "Jagannath", "suffix": ""}, {"first": "B", "middle": [], "last": "Barlogie", "suffix": ""}, {"first": "J", "middle": [], "last": "Berenson", "suffix": ""}, {"first": "D", "middle": [], "last": "Siegel", "suffix": ""}, {"first": "D", "middle": [], "last": "Irwin", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "R", "middle": [], "last": "Niesvizky", "suffix": ""}, {"first": "R", "middle": [], "last": "Alexanian", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Limentani", "suffix": ""}, {"first": "M", "middle": [], "last": "Alsina", "suffix": ""}, {"first": "J", "middle": [], "last": "Adams", "suffix": ""}, {"first": "M", "middle": [], "last": "Kauffman", "suffix": ""}, {"first": "D.-L", "middle": [], "last": "Esseltine", "suffix": ""}, {"first": "D", "middle": ["P"], "last": "Schenkein", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}], "year": 2004, "venue": "British Journal of Haematology", "volume": "127", "issn": "2", "pages": "165--172", "other_ids": {}}, "BIBREF184": {"ref_id": "b184", "title": "CRISPR-Cas9-based treatment of myocilin-associated glaucoma", "authors": [{"first": "A", "middle": [], "last": "Jain", "suffix": ""}, {"first": "G", "middle": [], "last": "Zode", "suffix": ""}, {"first": "R", "middle": ["B"], "last": "Kasetti", "suffix": ""}, {"first": "F", "middle": ["A"], "last": "Ran", "suffix": ""}, {"first": "W", "middle": [], "last": "Yan", "suffix": ""}, {"first": "T", "middle": ["P"], "last": "Sharma", "suffix": ""}, {"first": "K", "middle": [], "last": "Bugge", "suffix": ""}, {"first": "C", "middle": ["C"], "last": "Searby", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Fingert", "suffix": ""}, {"first": "F", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "A", "middle": ["F"], "last": "Clark", "suffix": ""}, {"first": "V", "middle": ["C"], "last": "Sheffield", "suffix": ""}], "year": 2017, "venue": "Proceedings of the National Academy of Sciences", "volume": "114", "issn": "42", "pages": "11199--11204", "other_ids": {"DOI": ["10.1073/pnas.1706193114"]}}, "BIBREF186": {"ref_id": "b186", "title": "Ocular MECP2 protein expression in patients with and without Rett syndrome", "authors": [], "year": null, "venue": "Pediatric Neurology", "volume": "43", "issn": "1", "pages": "35--40", "other_ids": {"DOI": ["10.1016/j.pediatrneurol.2010.02.018"]}}, "BIBREF187": {"ref_id": "b187", "title": "Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up", "authors": [{"first": "A", "middle": ["J"], "last": "Jakubowiak", "suffix": ""}, {"first": "D", "middle": [], "last": "Dytfeld", "suffix": ""}, {"first": "K", "middle": ["A"], "last": "Griffith", "suffix": ""}, {"first": "J", "middle": [], "last": "Jasielec", "suffix": ""}, {"first": "K", "middle": [], "last": "Mcdonnell", "suffix": ""}, {"first": "D", "middle": [], "last": "Lebovic", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Vesole", "suffix": ""}, {"first": "S", "middle": [], "last": "Jagannath", "suffix": ""}, {"first": "E", "middle": ["G"], "last": "Chottiner", "suffix": ""}, {"first": "T", "middle": ["B"], "last": "Anderson", "suffix": ""}, {"first": "K", "middle": [], "last": "Detweiler-Short", "suffix": ""}, {"first": "K", "middle": [], "last": "Stockerl-Goldstein", "suffix": ""}, {"first": "A", "middle": ["Z"], "last": "Ahmed", "suffix": ""}, {"first": "T", "middle": ["L"], "last": "Jobkar", "suffix": ""}, {"first": "D", "middle": ["E"], "last": "Durecki", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Mietzel", "suffix": ""}, {"first": "D", "middle": ["R"], "last": "Couriel", "suffix": ""}, {"first": "R", "middle": [], "last": "Vij", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Kaminski", "suffix": ""}], "year": 2013, "venue": "Journal of Clinical Oncology", "volume": "", "issn": "15_suppl", "pages": "8543--8543", "other_ids": {}}, "BIBREF189": {"ref_id": "b189", "title": "Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM", "authors": [{"first": "A", "middle": [], "last": "Jakubowiak", "suffix": ""}, {"first": "M", "middle": [], "last": "Offidani", "suffix": ""}, {"first": "B", "middle": [], "last": "P\u00e9gourie", "suffix": ""}, {"first": "J", "middle": [], "last": "De La Rubia", "suffix": ""}, {"first": "L", "middle": [], "last": "Garderet", "suffix": ""}, {"first": "K", "middle": [], "last": "Laribi", "suffix": ""}, {"first": "A", "middle": [], "last": "Bosi", "suffix": ""}, {"first": "R", "middle": [], "last": "Marasca", "suffix": ""}, {"first": "J", "middle": [], "last": "Laubach", "suffix": ""}, {"first": "A", "middle": [], "last": "Mohrbacher", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Carella", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Singhal", "suffix": ""}, {"first": "L", "middle": ["C"], "last": "Tsao", "suffix": ""}, {"first": "M", "middle": [], "last": "Lynch", "suffix": ""}, {"first": "E", "middle": [], "last": "Bleickardt", "suffix": ""}, {"first": "Y.-M", "middle": [], "last": "Jou", "suffix": ""}, {"first": "M", "middle": [], "last": "Robbins", "suffix": ""}, {"first": "A", "middle": [], "last": "Palumbo", "suffix": ""}], "year": 2016, "venue": "Blood", "volume": "127", "issn": "23", "pages": "2833--2840", "other_ids": {"DOI": ["10.1182/blood-2016-01-694604"]}}, "BIBREF190": {"ref_id": "b190", "title": "Defective autophagy in Parkinson's disease: role of oxidative stress", "authors": [{"first": "E", "middle": [], "last": "Janda", "suffix": ""}, {"first": "C", "middle": [], "last": "Isidoro", "suffix": ""}, {"first": "C", "middle": [], "last": "Carresi", "suffix": ""}, {"first": "V", "middle": [], "last": "Mollace", "suffix": ""}], "year": 2012, "venue": "Molecular Neurobiology", "volume": "46", "issn": "3", "pages": "639--661", "other_ids": {}}, "BIBREF192": {"ref_id": "b192", "title": "CaMKII, but not protein kinase A, regulates Rpt6 phosphorylation and proteasome activity during the formation of longterm memories", "authors": [{"first": "T", "middle": ["J"], "last": "Jarome", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Kwapis", "suffix": ""}, {"first": "W", "middle": ["L"], "last": "Ruenzel", "suffix": ""}, {"first": "F", "middle": ["J"], "last": "Helmstetter", "suffix": ""}], "year": 2013, "venue": "Frontiers in Behavioral Neuroscience", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3389/fnbeh.2013.00115"]}}, "BIBREF193": {"ref_id": "b193", "title": "Interaction between pathogenic proteins in neurodegenerative disorders", "authors": [{"first": "K", "middle": ["A"], "last": "Jellinger", "suffix": ""}], "year": 2012, "venue": "Journal of Cellular and Molecular Medicine", "volume": "16", "issn": "6", "pages": "1166--1183", "other_ids": {"DOI": ["10.1111/j.1582-4934.2011.01507.x"]}}, "BIBREF194": {"ref_id": "b194", "title": "Substrate receptors of proteasomes", "authors": [{"first": "T.-X", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "M", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "X.-B", "middle": [], "last": "Qiu", "suffix": ""}], "year": 2018, "venue": "Biological Reviews of the Cambridge Philosophical Society", "volume": "93", "issn": "4", "pages": "1765--1777", "other_ids": {}}, "BIBREF196": {"ref_id": "b196", "title": "Docosahexaenoic acid induces the degradation of HPV E6/E7 oncoproteins by activating the ubiquitin-proteasome system", "authors": [{"first": "K", "middle": [], "last": "Jing", "suffix": ""}, {"first": "S", "middle": [], "last": "Shin", "suffix": ""}, {"first": "S", "middle": [], "last": "Jeong", "suffix": ""}, {"first": "S", "middle": [], "last": "Kim", "suffix": ""}, {"first": "K", "middle": ["S"], "last": "Song", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Park", "suffix": ""}, {"first": "J", "middle": ["Y"], "last": "Heo", "suffix": ""}, {"first": "K", "middle": ["S"], "last": "Seo", "suffix": ""}, {"first": "S", "middle": ["K"], "last": "Park", "suffix": ""}, {"first": "G", "middle": ["R"], "last": "Kweon", "suffix": ""}, {"first": "T", "middle": [], "last": "Wu", "suffix": ""}, {"first": "J", "middle": ["I"], "last": "Park", "suffix": ""}, {"first": "K", "middle": [], "last": "Lim", "suffix": ""}], "year": 2014, "venue": "Cell Death and Disease", "volume": "5", "issn": "11", "pages": "", "other_ids": {"DOI": ["10.1038/cddis.2014.477"]}}, "BIBREF197": {"ref_id": "b197", "title": "Mutated myocilin and heterozygous Sod2 deficiency act synergistically in a mouse model of open-angle glaucoma", "authors": [{"first": "M", "middle": ["K"], "last": "Joe", "suffix": ""}, {"first": "N", "middle": [], "last": "Nakaya", "suffix": ""}, {"first": "M", "middle": [], "last": "Abu-Asab", "suffix": ""}, {"first": "S", "middle": ["I"], "last": "Tomarev", "suffix": ""}], "year": 2015, "venue": "Human Molecular Genetics", "volume": "24", "issn": "12", "pages": "3322--3334", "other_ids": {"DOI": ["10.1093/hmg/ddv082"]}}, "BIBREF198": {"ref_id": "b198", "title": "The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors", "authors": [{"first": "D", "middle": ["E"], "last": "Johnson", "suffix": ""}], "year": 2015, "venue": "Endocrine-Related Cancer", "volume": "22", "issn": "1", "pages": "1--17", "other_ids": {"DOI": ["10.1530/ERC-14-0005"]}}, "BIBREF199": {"ref_id": "b199", "title": "Proteasome Activation to Combat Proteotoxicity", "authors": [{"first": "C", "middle": ["L"], "last": "Jones", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Tepe", "suffix": ""}], "year": 2019, "venue": "Molecules", "volume": "", "issn": "15", "pages": "", "other_ids": {"DOI": ["10.3390/molecules24152841"]}}, "BIBREF200": {"ref_id": "b200", "title": "Proteasomal Degradation of RPN4 via Two Distinct Mechanisms, Ubiquitin-dependent and -independent", "authors": [{"first": "D", "middle": [], "last": "Ju", "suffix": ""}, {"first": "Y", "middle": [], "last": "Xie", "suffix": ""}], "year": 2004, "venue": "Journal of Biological Chemistry", "volume": "279", "issn": "23", "pages": "23851--23854", "other_ids": {"DOI": ["10.1074/jbc.C400111200"]}}, "BIBREF201": {"ref_id": "b201", "title": "Dynamic recruitment of ubiquitin to mutant huntingtin inclusion bodies", "authors": [{"first": "K", "middle": [], "last": "Juenemann", "suffix": ""}, {"first": "A", "middle": ["H P"], "last": "Jansen", "suffix": ""}, {"first": "L", "middle": [], "last": "Van Riel", "suffix": ""}, {"first": "R", "middle": [], "last": "Merkx", "suffix": ""}, {"first": "M", "middle": ["P C"], "last": "Mulder", "suffix": ""}, {"first": "H", "middle": [], "last": "An", "suffix": ""}, {"first": "A", "middle": [], "last": "Statsyuk", "suffix": ""}, {"first": "J", "middle": [], "last": "Kirstein", "suffix": ""}, {"first": "H", "middle": [], "last": "Ovaa", "suffix": ""}, {"first": "E", "middle": ["A"], "last": "Reits", "suffix": ""}], "year": 2018, "venue": "Scientific Reports", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/s41598-018-19538-0"]}}, "BIBREF202": {"ref_id": "b202", "title": "Expanded polyglutamine-containing N-terminal huntingtin fragments are entirely degraded by mammalian proteasomes", "authors": [{"first": "K", "middle": [], "last": "Juenemann", "suffix": ""}, {"first": "S", "middle": [], "last": "Schipper-Krom", "suffix": ""}, {"first": "A", "middle": [], "last": "Wiemhoefer", "suffix": ""}, {"first": "A", "middle": [], "last": "Kloss", "suffix": ""}, {"first": "A", "middle": [], "last": "Sanz Sanz", "suffix": ""}, {"first": "E", "middle": ["A J"], "last": "Reits", "suffix": ""}], "year": 2013, "venue": "The Journal of Biological Chemistry", "volume": "288", "issn": "38", "pages": "27068--27084", "other_ids": {"DOI": ["10.1074/jbc.M113.486076"]}}, "BIBREF203": {"ref_id": "b203", "title": "Detection of ubiquitinated huntingtin species in intracellular aggregates", "authors": [{"first": "K", "middle": [], "last": "Juenemann", "suffix": ""}, {"first": "A", "middle": [], "last": "Wiemhoefer", "suffix": ""}, {"first": "E", "middle": ["A"], "last": "Reits", "suffix": ""}], "year": 2015, "venue": "Frontiers in Molecular Neuroscience", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3389/fnmol.2015.00001"]}}, "BIBREF204": {"ref_id": "b204", "title": "Discovery, Development, and clinical applications of bortezomib", "authors": [{"first": "L", "middle": [], "last": "Jung", "suffix": ""}, {"first": "L", "middle": [], "last": "Holle", "suffix": ""}, {"first": "W", "middle": ["S"], "last": "Dalton", "suffix": ""}], "year": 2004, "venue": "Oncology", "volume": "18", "issn": "14", "pages": "4--13", "other_ids": {}}, "BIBREF206": {"ref_id": "b206", "title": "Parkin promotes proteasomal degradation of synaptotagmin IV by accelerating polyubiquitination", "authors": [], "year": null, "venue": "Molecular and Cellular Neurosciences", "volume": "80", "issn": "", "pages": "89--99", "other_ids": {"DOI": ["10.1016/j.mcn.2017.02.006"]}}, "BIBREF207": {"ref_id": "b207", "title": "Chemical proteasome inhibition as a novel animal model of inner retinal degeneration in rats", "authors": [{"first": "M", "middle": [], "last": "Kageyama", "suffix": ""}, {"first": "T", "middle": [], "last": "Ota", "suffix": ""}, {"first": "M", "middle": [], "last": "Sasaoka", "suffix": ""}, {"first": "O", "middle": [], "last": "Katsuta", "suffix": ""}, {"first": "K", "middle": [], "last": "Shinomiya", "suffix": ""}], "year": 2019, "venue": "PloS One", "volume": "14", "issn": "5", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0217945"]}}, "BIBREF208": {"ref_id": "b208", "title": "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor", "authors": [{"first": "J", "middle": [], "last": "Kang", "suffix": ""}, {"first": "H", "middle": ["G"], "last": "Lemaire", "suffix": ""}, {"first": "A", "middle": [], "last": "Unterbeck", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Salbaum", "suffix": ""}, {"first": "C", "middle": ["L"], "last": "Masters", "suffix": ""}, {"first": "K", "middle": ["H"], "last": "Grzeschik", "suffix": ""}, {"first": "G", "middle": [], "last": "Multhaup", "suffix": ""}, {"first": "K", "middle": [], "last": "Beyreuther", "suffix": ""}, {"first": "B", "middle": [], "last": "M\u00fcller-Hill", "suffix": ""}], "year": 1987, "venue": "Nature", "volume": "325", "issn": "6106", "pages": "733--736", "other_ids": {"DOI": ["10.1038/325733a0"]}}, "BIBREF209": {"ref_id": "b209", "title": "Interplay between Structure and Charge as a Key to Allosteric Modulation of Human 20S Proteasome by the Basic Fragment of HIV-1 Tat Protein", "authors": [{"first": "P", "middle": [], "last": "Karpowicz", "suffix": ""}, {"first": "P", "middle": ["A"], "last": "Osmulski", "suffix": ""}, {"first": "J", "middle": [], "last": "Witkowska", "suffix": ""}, {"first": "E", "middle": [], "last": "Sikorska", "suffix": ""}, {"first": "M", "middle": [], "last": "Gi\u017cy\u0144ska", "suffix": ""}, {"first": "A", "middle": [], "last": "Belczyk-Ciesielska", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Gaczynska", "suffix": ""}, {"first": "E", "middle": [], "last": "Jankowska", "suffix": ""}], "year": 2015, "venue": "PLOS ONE", "volume": "10", "issn": "11", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0143038"]}}, "BIBREF210": {"ref_id": "b210", "title": "Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone", "authors": [{"first": "E", "middle": [], "last": "Kastritis", "suffix": ""}, {"first": "I", "middle": [], "last": "Dialoupi", "suffix": ""}, {"first": "M", "middle": [], "last": "Gavriatopoulou", "suffix": ""}, {"first": "M", "middle": [], "last": "Roussou", "suffix": ""}, {"first": "N", "middle": [], "last": "Kanellias", "suffix": ""}, {"first": "D", "middle": [], "last": "Fotiou", "suffix": ""}, {"first": "I", "middle": [], "last": "Ntanasis-Stathopoulos", "suffix": ""}, {"first": "E", "middle": [], "last": "Papadopoulou", "suffix": ""}, {"first": "D", "middle": ["C"], "last": "Ziogas", "suffix": ""}, {"first": "K", "middle": [], "last": "Stamatelopoulos", "suffix": ""}, {"first": "E", "middle": [], "last": "Manios", "suffix": ""}, {"first": "A", "middle": [], "last": "Ntalianis", "suffix": ""}, {"first": "E", "middle": [], "last": "Eleutherakis-Papaiakovou", "suffix": ""}, {"first": "A", "middle": [], "last": "Papanikolaou", "suffix": ""}, {"first": "M", "middle": [], "last": "Migkou", "suffix": ""}, {"first": "A.-M", "middle": [], "last": "Papanota", "suffix": ""}, {"first": "H", "middle": [], "last": "Gakiopoulou", "suffix": ""}, {"first": "E", "middle": [], "last": "Psimenou", "suffix": ""}, {"first": "M", "middle": ["I"], "last": "Tselegkidi", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}], "year": 2019, "venue": "Blood Advances", "volume": "3", "issn": "20", "pages": "3002--3009", "other_ids": {"DOI": ["10.1182/bloodadvances.2019000147"]}}, "BIBREF211": {"ref_id": "b211", "title": "The olive constituent oleuropein exhibits proteasome stimulatory properties in vitro and confers life span extension of human embryonic fibroblasts", "authors": [{"first": "M", "middle": [], "last": "Katsiki", "suffix": ""}, {"first": "N", "middle": [], "last": "Chondrogianni", "suffix": ""}, {"first": "I", "middle": [], "last": "Chinou", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Rivett", "suffix": ""}, {"first": "E", "middle": ["S"], "last": "Gonos", "suffix": ""}], "year": 2007, "venue": "Rejuvenation Research", "volume": "10", "issn": "2", "pages": "157--172", "other_ids": {}}, "BIBREF213": {"ref_id": "b213", "title": "Betulinic acid, a natural PDE inhibitor restores hippocampal cAMP/cGMP and BDNF, improve cerebral blood flow and recover memory deficits in permanent BCCAO induced vascular dementia in rats", "authors": [{"first": "M", "middle": [], "last": "Kaundal", "suffix": ""}, {"first": "S", "middle": [], "last": "Zameer", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Najmi", "suffix": ""}, {"first": "S", "middle": [], "last": "Parvez", "suffix": ""}, {"first": "M", "middle": [], "last": "Akhtar", "suffix": ""}], "year": 2018, "venue": "European Journal Pharmacology", "volume": "832", "issn": "", "pages": "56--66", "other_ids": {"DOI": ["10.1016/j.ejphar.2018.05.015"]}}, "BIBREF214": {"ref_id": "b214", "title": "Emerging role of immunoproteasomes in pathophysiology", "authors": [{"first": "G", "middle": [], "last": "Kaur", "suffix": ""}, {"first": "S", "middle": [], "last": "Batra", "suffix": ""}], "year": 2016, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF216": {"ref_id": "b216", "title": "Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease", "authors": [{"first": "S", "middle": [], "last": "Keck", "suffix": ""}, {"first": "R", "middle": [], "last": "Nitsch", "suffix": ""}, {"first": "T", "middle": [], "last": "Grune", "suffix": ""}, {"first": "O", "middle": [], "last": "Ullrich", "suffix": ""}], "year": 2003, "venue": "Journal of Neurochemistry", "volume": "85", "issn": "1", "pages": "115--122", "other_ids": {}}, "BIBREF217": {"ref_id": "b217", "title": "A lipid-droplet-targeted O-GlcNAcase isoform is a key regulator of the proteasome", "authors": [{"first": "C", "middle": ["N"], "last": "Keembiyehetty", "suffix": ""}, {"first": "A", "middle": [], "last": "Krzeslak", "suffix": ""}, {"first": "D", "middle": ["C"], "last": "Love", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Hanover", "suffix": ""}], "year": 2011, "venue": "Journal of Cell Science", "volume": "124", "issn": "16", "pages": "2851--2860", "other_ids": {"DOI": ["10.1242/jcs.083287"]}}, "BIBREF218": {"ref_id": "b218", "title": "Impaired proteasome function in Alzheimer's disease", "authors": [{"first": "J", "middle": ["N"], "last": "Keller", "suffix": ""}, {"first": "K", "middle": ["B"], "last": "Hanni", "suffix": ""}, {"first": "W", "middle": ["R"], "last": "Markesbery", "suffix": ""}], "year": 2000, "venue": "Journal of Neurochemistry", "volume": "75", "issn": "1", "pages": "436--439", "other_ids": {}}, "BIBREF219": {"ref_id": "b219", "title": "SARS coronavirus 8b reduces viral replication by down-regulating E via an ubiquitinindependent proteasome pathway", "authors": [{"first": "C.-T", "middle": [], "last": "Keng", "suffix": ""}, {"first": "S", "middle": [], "last": "Akerstr\u00f6m", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Leung", "suffix": ""}, {"first": ".-W", "middle": [], "last": "Poon", "suffix": ""}, {"first": "L", "middle": ["L M"], "last": "Peiris", "suffix": ""}, {"first": "J", "middle": ["S M"], "last": "Mirazimi", "suffix": ""}, {"first": "A", "middle": [], "last": "Tan", "suffix": ""}, {"first": "Y.-J", "middle": [], "last": "", "suffix": ""}], "year": 2011, "venue": "Microbes and Infection", "volume": "13", "issn": "2", "pages": "179--188", "other_ids": {}}, "BIBREF221": {"ref_id": "b221", "title": "Structure of ubiquitylated-Rpn10 provides insight into its autoregulation mechanism", "authors": [{"first": "T", "middle": [], "last": "Keren-Kaplan", "suffix": ""}, {"first": "L", "middle": [], "last": "Zeev Peters", "suffix": ""}, {"first": "O", "middle": [], "last": "Levin-Kravets", "suffix": ""}, {"first": "I", "middle": [], "last": "Attali", "suffix": ""}, {"first": "O", "middle": [], "last": "Kleifeld", "suffix": ""}, {"first": "N", "middle": [], "last": "Shohat", "suffix": ""}, {"first": "S", "middle": [], "last": "Artzi", "suffix": ""}, {"first": "O", "middle": [], "last": "Zucker", "suffix": ""}, {"first": "I", "middle": [], "last": "Pilzer", "suffix": ""}, {"first": "N", "middle": [], "last": "Reis", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Glickman", "suffix": ""}, {"first": "S", "middle": [], "last": "Ben-Aroya", "suffix": ""}, {"first": "G", "middle": [], "last": "Prag", "suffix": ""}], "year": 2016, "venue": "Nature Communications", "volume": "7", "issn": "1", "pages": "1--12", "other_ids": {"DOI": ["10.1038/ncomms12960"]}}, "BIBREF222": {"ref_id": "b222", "title": "Proteolytic cleavage of elafin by 20S proteasome may contribute to inflammation in acute lung injury", "authors": [{"first": "A", "middle": [], "last": "Kerrin", "suffix": ""}, {"first": "S", "middle": [], "last": "Weldon", "suffix": ""}, {"first": "A", "middle": ["H"], "last": "Chung", "suffix": ""}, {"first": ".-K", "middle": [], "last": "Craig", "suffix": ""}, {"first": "T", "middle": [], "last": "Simpson", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "O&apos;kane", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Mcauley", "suffix": ""}, {"first": "D", "middle": ["F"], "last": "Taggart", "suffix": ""}, {"first": "C", "middle": ["C"], "last": "", "suffix": ""}], "year": 2013, "venue": "Thorax", "volume": "68", "issn": "4", "pages": "315--321", "other_ids": {"DOI": ["10.1136/thoraxjnl-2012-202536"]}}, "BIBREF223": {"ref_id": "b223", "title": "Proteasome activator PA200 is required for normal spermatogenesis", "authors": [{"first": "B", "middle": [], "last": "Khor", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Bredemeyer", "suffix": ""}, {"first": "C.-Y", "middle": [], "last": "Huang", "suffix": ""}, {"first": "I", "middle": ["R"], "last": "Turnbull", "suffix": ""}, {"first": "R", "middle": [], "last": "Evans", "suffix": ""}, {"first": "L", "middle": ["B"], "last": "Maggi", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "White", "suffix": ""}, {"first": "L", "middle": ["M"], "last": "Walker", "suffix": ""}, {"first": "K", "middle": [], "last": "Carnes", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Hess", "suffix": ""}, {"first": "B", "middle": ["P"], "last": "Sleckman", "suffix": ""}], "year": 2006, "venue": "Molecular and Cellular Biology", "volume": "26", "issn": "8", "pages": "2999--3007", "other_ids": {"DOI": ["10.1128/MCB.26.8.2999-3007.2006"]}}, "BIBREF224": {"ref_id": "b224", "title": "Protein homeostasis in models of aging and age-related conformational disease", "authors": [{"first": "E", "middle": ["A"], "last": "Kikis", "suffix": ""}, {"first": "T", "middle": [], "last": "Gidalevitz", "suffix": ""}, {"first": "R", "middle": ["I"], "last": "Morimoto", "suffix": ""}], "year": 2010, "venue": "Advances in Experimental Medicine and Biology", "volume": "694", "issn": "", "pages": "138--159", "other_ids": {}}, "BIBREF225": {"ref_id": "b225", "title": "Targeted Disruption of the Myocilin Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function", "authors": [{"first": "B", "middle": ["S"], "last": "Kim", "suffix": ""}, {"first": "O", "middle": ["V"], "last": "Savinova", "suffix": ""}, {"first": "M", "middle": ["V"], "last": "Reedy", "suffix": ""}, {"first": "J", "middle": [], "last": "Martin", "suffix": ""}, {"first": "Y", "middle": [], "last": "Lun", "suffix": ""}, {"first": "L", "middle": [], "last": "Gan", "suffix": ""}, {"first": "R", "middle": ["S"], "last": "Smith", "suffix": ""}, {"first": "S", "middle": ["I"], "last": "Tomarev", "suffix": ""}, {"first": "S", "middle": ["W"], "last": "John", "suffix": ""}, {"first": "R", "middle": ["L"], "last": "Johnson", "suffix": ""}], "year": 2001, "venue": "Molecular and Cellular Biology", "volume": "21", "issn": "22", "pages": "7707--7713", "other_ids": {"DOI": ["10.1128/MCB.21.22.7707-7713.2001"]}}, "BIBREF226": {"ref_id": "b226", "title": "synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells", "authors": [], "year": null, "venue": "Haematologica", "volume": "100", "issn": "10", "pages": "1350--1360", "other_ids": {"DOI": ["10.3324/haematol.2014.109421"]}}, "BIBREF227": {"ref_id": "b227", "title": "Modification by single ubiquitin moieties rather than polyubiquitination is sufficient for proteasomal processing of the p105 NF-kappaB precursor", "authors": [{"first": "Y", "middle": [], "last": "Kravtsova-Ivantsiv", "suffix": ""}, {"first": "S", "middle": [], "last": "Cohen", "suffix": ""}, {"first": "A", "middle": [], "last": "Ciechanover", "suffix": ""}], "year": 2009, "venue": "Molecular Cell", "volume": "33", "issn": "4", "pages": "496--504", "other_ids": {"DOI": ["10.1016/j.molcel.2009.01.023"]}}, "BIBREF228": {"ref_id": "b228", "title": "Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1", "authors": [{"first": "G", "middle": [], "last": "Krebiehl", "suffix": ""}, {"first": "S", "middle": [], "last": "Ruckerbauer", "suffix": ""}, {"first": "L", "middle": ["F"], "last": "Burbulla", "suffix": ""}, {"first": "N", "middle": [], "last": "Kieper", "suffix": ""}, {"first": "B", "middle": [], "last": "Maurer", "suffix": ""}, {"first": "J", "middle": [], "last": "Waak", "suffix": ""}, {"first": "H", "middle": [], "last": "Wolburg", "suffix": ""}, {"first": "Z", "middle": [], "last": "Gizatullina", "suffix": ""}, {"first": "F", "middle": ["N"], "last": "Gellerich", "suffix": ""}, {"first": "D", "middle": [], "last": "Woitalla", "suffix": ""}, {"first": "O", "middle": [], "last": "Riess", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Kahle", "suffix": ""}, {"first": "T", "middle": [], "last": "Proikas-Cezanne", "suffix": ""}, {"first": "R", "middle": [], "last": "Kr\u00fcger", "suffix": ""}], "year": 2010, "venue": "PloS One", "volume": "5", "issn": "2", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0009367"]}}, "BIBREF229": {"ref_id": "b229", "title": "20S proteasome biogenesis", "authors": [{"first": "E", "middle": [], "last": "Kr\u00fcger", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Kloetzel", "suffix": ""}, {"first": "C", "middle": [], "last": "Enenkel", "suffix": ""}], "year": 2001, "venue": "", "volume": "83", "issn": "", "pages": "289--293", "other_ids": {"DOI": ["10.1016/s0300-9084(01)01241-x"]}}, "BIBREF230": {"ref_id": "b230", "title": "Proteasome inhibitors -molecular basis and current perspectives in multiple myeloma", "authors": [{"first": "L", "middle": [], "last": "Kubiczkova", "suffix": ""}, {"first": "L", "middle": [], "last": "Pour", "suffix": ""}, {"first": "L", "middle": [], "last": "Sedlarikova", "suffix": ""}, {"first": "R", "middle": [], "last": "Hajek", "suffix": ""}, {"first": "S", "middle": [], "last": "Sevcikova", "suffix": ""}], "year": 2014, "venue": "Journal of Cellular and Molecular Medicine", "volume": "18", "issn": "6", "pages": "947--961", "other_ids": {"DOI": ["10.1111/jcmm.12279"]}}, "BIBREF231": {"ref_id": "b231", "title": "Proteasome: a Nanomachinery of Creative Destruction", "authors": [{"first": "A", "middle": ["A"], "last": "Kudriaeva", "suffix": ""}, {"first": "A", "middle": ["A"], "last": "Belogurov", "suffix": ""}], "year": 2019, "venue": "Biochemistry. Biokhimiia", "volume": "84", "issn": "", "pages": "159--192", "other_ids": {}}, "BIBREF233": {"ref_id": "b233", "title": "Chargemediated proteasome targeting", "authors": [{"first": "A", "middle": [], "last": "Kudriaeva", "suffix": ""}, {"first": "E", "middle": ["S"], "last": "Kuzina", "suffix": ""}, {"first": "O", "middle": [], "last": "Zubenko", "suffix": ""}, {"first": "I", "middle": ["V"], "last": "Smirnov", "suffix": ""}, {"first": "A", "middle": [], "last": "Belogurov", "suffix": ""}], "year": 2019, "venue": "FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology", "volume": "33", "issn": "6", "pages": "6852--6866", "other_ids": {"DOI": ["10.1096/fj.201802237R"]}}, "BIBREF234": {"ref_id": "b234", "title": "Loss-less Nano-fractionator for High Sensitivity", "authors": [{"first": "N", "middle": ["A"], "last": "Kulak", "suffix": ""}, {"first": "P", "middle": ["E"], "last": "Geyer", "suffix": ""}, {"first": "M", "middle": [], "last": "Mann", "suffix": ""}], "year": 2017, "venue": "High Coverage Proteomics", "volume": "16", "issn": "", "pages": "694--705", "other_ids": {"DOI": ["10.1074/mcp.O116.065136"]}}, "BIBREF235": {"ref_id": "b235", "title": "Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study", "authors": [{"first": "S", "middle": ["K"], "last": "Kumar", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}, {"first": "E", "middle": [], "last": "Kastritis", "suffix": ""}, {"first": "E", "middle": [], "last": "Terpos", "suffix": ""}, {"first": "H", "middle": [], "last": "Nahi", "suffix": ""}, {"first": "H", "middle": [], "last": "Goldschmidt", "suffix": ""}, {"first": "J", "middle": [], "last": "Hillengass", "suffix": ""}, {"first": "X", "middle": [], "last": "Leleu", "suffix": ""}, {"first": "M", "middle": [], "last": "Beksac", "suffix": ""}, {"first": "M", "middle": [], "last": "Alsina", "suffix": ""}, {"first": "A", "middle": [], "last": "Oriol", "suffix": ""}, {"first": "M", "middle": [], "last": "Cavo", "suffix": ""}, {"first": "E", "middle": ["M"], "last": "Ocio", "suffix": ""}, {"first": "M", "middle": ["V"], "last": "Mateos", "suffix": ""}, {"first": "E", "middle": ["K"], "last": "O&apos;donnell", "suffix": ""}, {"first": "R", "middle": [], "last": "Vij", "suffix": ""}, {"first": "H", "middle": ["M"], "last": "Lokhorst", "suffix": ""}, {"first": "N", "middle": ["W C J"], "last": "Van De Donk", "suffix": ""}, {"first": "C", "middle": [], "last": "Min", "suffix": ""}, {"first": "", "middle": [], "last": "Durie", "suffix": ""}], "year": 2017, "venue": "", "volume": "", "issn": "", "pages": "2443--2448", "other_ids": {}}, "BIBREF237": {"ref_id": "b237", "title": "Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib", "authors": [{"first": "S", "middle": ["K"], "last": "Kumar", "suffix": ""}, {"first": "B", "middle": [], "last": "Laplant", "suffix": ""}, {"first": "V", "middle": [], "last": "Roy", "suffix": ""}, {"first": "C", "middle": ["B"], "last": "Reeder", "suffix": ""}, {"first": "M", "middle": ["Q"], "last": "Lacy", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Gertz", "suffix": ""}, {"first": "K", "middle": [], "last": "Laumann", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Thompson", "suffix": ""}, {"first": "T", "middle": ["E"], "last": "Witzig", "suffix": ""}, {"first": "F", "middle": ["K"], "last": "Buadi", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "Rivera", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Mikhael", "suffix": ""}, {"first": "P", "middle": ["L"], "last": "Bergsagel", "suffix": ""}, {"first": "P", "middle": [], "last": "Kapoor", "suffix": ""}, {"first": "L", "middle": [], "last": "Hwa", "suffix": ""}, {"first": "R", "middle": [], "last": "Fonseca", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Stewart", "suffix": ""}, {"first": "A", "middle": [], "last": "Chanan-Khan", "suffix": ""}, {"first": "S", "middle": ["V"], "last": "Rajkumar", "suffix": ""}, {"first": "A", "middle": [], "last": "Dispenzieri", "suffix": ""}], "year": 2015, "venue": "Blood Cancer Journal", "volume": "5", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/bcj.2015.60"]}}, "BIBREF238": {"ref_id": "b238", "title": "Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study", "authors": [{"first": "N", "middle": [], "last": "Gupta", "suffix": ""}, {"first": "A.-M", "middle": [], "last": "Hui", "suffix": ""}, {"first": "V", "middle": [], "last": "Rajkumar", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}], "year": 2014, "venue": "The Lancet. Oncology", "volume": "15", "issn": "13", "pages": "1503--1512", "other_ids": {"DOI": ["10.1016/S1470-2045(14)71125-8"]}}, "BIBREF239": {"ref_id": "b239", "title": "Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance", "authors": [{"first": "Shaji", "middle": ["K"], "last": "Kumar", "suffix": ""}, {"first": "J", "middle": ["G"], "last": "Berdeja", "suffix": ""}, {"first": "R", "middle": [], "last": "Niesvizky", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonial", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Laubach", "suffix": ""}, {"first": "M", "middle": [], "last": "Hamadani", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Stewart", "suffix": ""}, {"first": "P", "middle": [], "last": "Hari", "suffix": ""}, {"first": "V", "middle": [], "last": "Roy", "suffix": ""}, {"first": "R", "middle": [], "last": "Vescio", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Kaufman", "suffix": ""}, {"first": "D", "middle": [], "last": "Berg", "suffix": ""}, {"first": "E", "middle": [], "last": "Liao", "suffix": ""}, {"first": "S", "middle": ["V"], "last": "Rajkumar", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}], "year": 2019, "venue": "Leukemia", "volume": "33", "issn": "7", "pages": "1736--1746", "other_ids": {"DOI": ["10.1038/s41375-019-0384-1"]}}, "BIBREF240": {"ref_id": "b240", "title": "Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib", "authors": [{"first": "Shaji", "middle": ["K"], "last": "Kumar", "suffix": ""}, {"first": "B", "middle": ["R"], "last": "Laplant", "suffix": ""}, {"first": "C", "middle": ["B"], "last": "Reeder", "suffix": ""}, {"first": "V", "middle": [], "last": "Roy", "suffix": ""}, {"first": "A", "middle": ["E"], "last": "Halvorson", "suffix": ""}, {"first": "F", "middle": [], "last": "Buadi", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Gertz", "suffix": ""}, {"first": "P", "middle": ["L"], "last": "Bergsagel", "suffix": ""}, {"first": "A", "middle": [], "last": "Dispenzieri", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Thompson", "suffix": ""}, {"first": "J", "middle": [], "last": "Crawley", "suffix": ""}, {"first": "P", "middle": [], "last": "Kapoor", "suffix": ""}, {"first": "J", "middle": [], "last": "Mikhael", "suffix": ""}, {"first": "K", "middle": [], "last": "Stewart", "suffix": ""}, {"first": "S", "middle": ["R"], "last": "Hayman", "suffix": ""}, {"first": "Y", "middle": ["L"], "last": "Hwa", "suffix": ""}, {"first": "W", "middle": [], "last": "Gonsalves", "suffix": ""}, {"first": "T", "middle": ["E"], "last": "Witzig", "suffix": ""}, {"first": "S", "middle": [], "last": "Ailawadhi", "suffix": ""}, {"first": "M", "middle": ["Q"], "last": "Lacy", "suffix": ""}], "year": 2016, "venue": "Blood", "volume": "128", "issn": "20", "pages": "2415--2422", "other_ids": {"DOI": ["10.1182/blood-2016-05-717769"]}}, "BIBREF241": {"ref_id": "b241", "title": "Multiple myeloma", "authors": [{"first": "Shaji", "middle": ["K"], "last": "Kumar", "suffix": ""}, {"first": "V", "middle": [], "last": "Rajkumar", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Kyle", "suffix": ""}, {"first": "M", "middle": [], "last": "Van Duin", "suffix": ""}, {"first": "P", "middle": [], "last": "Sonneveld", "suffix": ""}, {"first": "M.-V", "middle": [], "last": "Mateos", "suffix": ""}, {"first": "F", "middle": [], "last": "Gay", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}], "year": 2017, "venue": "Nature Reviews. Disease Primers", "volume": "3", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/nrdp.2017.46"]}}, "BIBREF243": {"ref_id": "b243", "title": "Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease", "authors": [], "year": null, "venue": "Molecular and Cellular Biochemistry", "volume": "444", "issn": "1-2", "pages": "149--160", "other_ids": {"DOI": ["10.1007/s11010-017-3239-y"]}}, "BIBREF244": {"ref_id": "b244", "title": "An archaeal homolog of proteasome assembly factor functions as a proteasome activator", "authors": [{"first": "K", "middle": [], "last": "Kumoi", "suffix": ""}, {"first": "T", "middle": [], "last": "Satoh", "suffix": ""}, {"first": "K", "middle": [], "last": "Murata", "suffix": ""}, {"first": "T", "middle": [], "last": "Hiromoto", "suffix": ""}, {"first": "T", "middle": [], "last": "Mizushima", "suffix": ""}, {"first": "Y", "middle": [], "last": "Kamiya", "suffix": ""}, {"first": "M", "middle": [], "last": "Noda", "suffix": ""}, {"first": "S", "middle": [], "last": "Uchiyama", "suffix": ""}, {"first": "H", "middle": [], "last": "Yagi", "suffix": ""}, {"first": "K", "middle": [], "last": "Kato", "suffix": ""}], "year": 2013, "venue": "PloS One", "volume": "8", "issn": "3", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0060294"]}}, "BIBREF245": {"ref_id": "b245", "title": "Assembly of the 20S proteasome", "authors": [{"first": "M", "middle": ["J"], "last": "Kunjappu", "suffix": ""}, {"first": "M", "middle": [], "last": "Hochstrasser", "suffix": ""}], "year": 2014, "venue": "Biochimica Et Biophysica Acta", "volume": "1843", "issn": "1", "pages": "2--12", "other_ids": {"DOI": ["10.1016/j.bbamcr.2013.03.008"]}}, "BIBREF246": {"ref_id": "b246", "title": "Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer", "authors": [{"first": "E", "middle": [], "last": "Kupperman", "suffix": ""}, {"first": "E", "middle": ["C"], "last": "Lee", "suffix": ""}, {"first": "Y", "middle": [], "last": "Cao", "suffix": ""}, {"first": "B", "middle": [], "last": "Bannerman", "suffix": ""}, {"first": "M", "middle": [], "last": "Fitzgerald", "suffix": ""}, {"first": "A", "middle": [], "last": "Berger", "suffix": ""}, {"first": "J", "middle": [], "last": "Yu", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yang", "suffix": ""}, {"first": "P", "middle": [], "last": "Hales", "suffix": ""}, {"first": "F", "middle": [], "last": "Bruzzese", "suffix": ""}, {"first": "J", "middle": [], "last": "Liu", "suffix": ""}, {"first": "J", "middle": [], "last": "Blank", "suffix": ""}, {"first": "K", "middle": [], "last": "Garcia", "suffix": ""}, {"first": "C", "middle": [], "last": "Tsu", "suffix": ""}, {"first": "L", "middle": [], "last": "Dick", "suffix": ""}, {"first": "P", "middle": [], "last": "Fleming", "suffix": ""}, {"first": "L", "middle": [], "last": "Yu", "suffix": ""}, {"first": "M", "middle": [], "last": "Manfredi", "suffix": ""}, {"first": "M", "middle": [], "last": "Rolfe", "suffix": ""}, {"first": "J", "middle": [], "last": "Bolen", "suffix": ""}], "year": 2010, "venue": "Cancer Research", "volume": "70", "issn": "5", "pages": "1970--1980", "other_ids": {}}, "BIBREF248": {"ref_id": "b248", "title": "Crystal structure of human proteasome assembly chaperone PAC4 involved in proteasome formation", "authors": [{"first": "E", "middle": [], "last": "Kurimoto", "suffix": ""}, {"first": "T", "middle": [], "last": "Satoh", "suffix": ""}, {"first": "Y", "middle": [], "last": "Ito", "suffix": ""}, {"first": "E", "middle": [], "last": "Ishihara", "suffix": ""}, {"first": "K", "middle": [], "last": "Okamoto", "suffix": ""}, {"first": "M", "middle": [], "last": "Yagi-Utsumi", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "K", "middle": [], "last": "Kato", "suffix": ""}], "year": 2017, "venue": "Protein Science: A Publication of the Protein Society", "volume": "26", "issn": "5", "pages": "1080--1085", "other_ids": {"DOI": ["10.1002/pro.3153"]}}, "BIBREF249": {"ref_id": "b249", "title": "STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease", "authors": [{"first": "P", "middle": ["K"], "last": "Kurup", "suffix": ""}, {"first": "J", "middle": [], "last": "Xu", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Videira", "suffix": ""}, {"first": "C", "middle": [], "last": "Ononenyi", "suffix": ""}, {"first": "G", "middle": [], "last": "Baltazar", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Lombroso", "suffix": ""}, {"first": "A", "middle": ["C"], "last": "Nairn", "suffix": ""}], "year": 2015, "venue": "Proceedings of the National Academy of Sciences", "volume": "112", "issn": "4", "pages": "1202--1207", "other_ids": {}}, "BIBREF252": {"ref_id": "b252", "title": "Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma", "authors": [], "year": null, "venue": "Haematologica", "volume": "", "issn": "7", "pages": "1008--1014", "other_ids": {"DOI": ["10.3324/haematol.2011.041392"]}}, "BIBREF253": {"ref_id": "b253", "title": "The neurotoxicity of iron, copper and cobalt in Parkinson's disease through ROS-mediated mechanisms", "authors": [{"first": "A", "middle": ["P"], "last": "Lan", "suffix": ""}, {"first": "J", "middle": [], "last": "Chen", "suffix": ""}, {"first": "Z", "middle": ["F"], "last": "Chai", "suffix": ""}, {"first": "Y", "middle": [], "last": "Hu", "suffix": ""}], "year": 2016, "venue": "BioMetals", "volume": "29", "issn": "4", "pages": "665--678", "other_ids": {"DOI": ["10.1007/s10534-016-9942-4"]}}, "BIBREF255": {"ref_id": "b255", "title": "Complete subunit architecture of the proteasome regulatory particle", "authors": [], "year": null, "venue": "Nature", "volume": "482", "issn": "7384", "pages": "186--191", "other_ids": {"DOI": ["10.1038/nature10774"]}}, "BIBREF256": {"ref_id": "b256", "title": "Therapeutic peptides: Historical perspectives, current development trends, and future directions", "authors": [{"first": "J", "middle": ["L"], "last": "Lau", "suffix": ""}, {"first": "M", "middle": ["K"], "last": "Dunn", "suffix": ""}], "year": 2018, "venue": "Bioorganic & Medicinal Chemistry", "volume": "26", "issn": "10", "pages": "2700--2707", "other_ids": {"DOI": ["10.1016/j.bmc.2017.06.052"]}}, "BIBREF257": {"ref_id": "b257", "title": "Therapeutic peptides: Historical perspectives, current development trends, and future directions", "authors": [{"first": "J", "middle": ["L"], "last": "Lau", "suffix": ""}, {"first": "M", "middle": ["K"], "last": "Dunn", "suffix": ""}], "year": 2018, "venue": "Bioorganic & Medicinal Chemistry", "volume": "26", "issn": "10", "pages": "2700--2707", "other_ids": {"DOI": ["10.1016/j.bmc.2017.06.052"]}}, "BIBREF258": {"ref_id": "b258", "title": "20S proteasome assembly is orchestrated by two distinct pairs of chaperones in yeast and in mammals", "authors": [{"first": "Le", "middle": [], "last": "Tallec", "suffix": ""}, {"first": "B", "middle": [], "last": "Barrault", "suffix": ""}, {"first": "M.-B", "middle": [], "last": "Courbeyrette", "suffix": ""}, {"first": "R", "middle": [], "last": "Gu\u00e9rois", "suffix": ""}, {"first": "R", "middle": [], "last": "Marsolier-Kergoat", "suffix": ""}, {"first": "M.-C", "middle": [], "last": "Peyroche", "suffix": ""}, {"first": "A", "middle": [], "last": "", "suffix": ""}], "year": 2007, "venue": "Molecular Cell", "volume": "27", "issn": "4", "pages": "660--674", "other_ids": {}}, "BIBREF261": {"ref_id": "b261", "title": "Expression, post-translational modification and biochemical characterization of proteins encoded by subgenomic mRNA8 of the severe acute respiratory syndrome coronavirus", "authors": [], "year": null, "venue": "The FEBS Journal", "volume": "274", "issn": "16", "pages": "4211--4222", "other_ids": {"DOI": ["10.1111/j.1742-4658.2007.05947.x"]}}, "BIBREF262": {"ref_id": "b262", "title": "Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model", "authors": [{"first": "R", "middle": [], "last": "Leblanc", "suffix": ""}, {"first": "L", "middle": ["P"], "last": "Catley", "suffix": ""}, {"first": "T", "middle": [], "last": "Hideshima", "suffix": ""}, {"first": "S", "middle": [], "last": "Lentzsch", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Mitsiades", "suffix": ""}, {"first": "N", "middle": [], "last": "Mitsiades", "suffix": ""}, {"first": "D", "middle": [], "last": "Neuberg", "suffix": ""}, {"first": "O", "middle": [], "last": "Goloubeva", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Pien", "suffix": ""}, {"first": "J", "middle": [], "last": "Adams", "suffix": ""}, {"first": "D", "middle": [], "last": "Gupta", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "N", "middle": ["C"], "last": "Munshi", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}], "year": 2002, "venue": "Cancer Research", "volume": "62", "issn": "17", "pages": "4996--5000", "other_ids": {}}, "BIBREF263": {"ref_id": "b263", "title": "Protein degradation by the ubiquitinproteasome pathway in normal and disease states", "authors": [{"first": "S", "middle": ["H"], "last": "Lecker", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}, {"first": "W", "middle": ["E"], "last": "Mitch", "suffix": ""}], "year": 2006, "venue": "Journal of the American Society of Nephrology: JASN", "volume": "17", "issn": "7", "pages": "1807--1819", "other_ids": {"DOI": ["10.1681/ASN.2006010083"]}}, "BIBREF264": {"ref_id": "b264", "title": "Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies", "authors": [{"first": "E", "middle": ["C"], "last": "Lee", "suffix": ""}, {"first": "M", "middle": [], "last": "Fitzgerald", "suffix": ""}, {"first": "B", "middle": [], "last": "Bannerman", "suffix": ""}, {"first": "J", "middle": [], "last": "Donelan", "suffix": ""}, {"first": "K", "middle": [], "last": "Bano", "suffix": ""}, {"first": "J", "middle": [], "last": "Terkelsen", "suffix": ""}, {"first": "D", "middle": ["P"], "last": "Bradley", "suffix": ""}, {"first": "O", "middle": [], "last": "Subakan", "suffix": ""}, {"first": "M", "middle": ["D"], "last": "Silva", "suffix": ""}, {"first": "R", "middle": [], "last": "Liu", "suffix": ""}, {"first": "M", "middle": [], "last": "Pickard", "suffix": ""}, {"first": "Z", "middle": [], "last": "Li", "suffix": ""}, {"first": "O", "middle": [], "last": "Tayber", "suffix": ""}, {"first": "P", "middle": [], "last": "Li", "suffix": ""}, {"first": "P", "middle": [], "last": "Hales", "suffix": ""}, {"first": "M", "middle": [], "last": "Carsillo", "suffix": ""}, {"first": "V", "middle": ["T"], "last": "Neppalli", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Berger", "suffix": ""}, {"first": "E", "middle": [], "last": "Kupperman", "suffix": ""}, {"first": "S", "middle": [], "last": "Janz", "suffix": ""}], "year": 2011, "venue": "Clinical Cancer Research: An Official Journal of the American Association for Cancer Research", "volume": "17", "issn": "23", "pages": "7313--7323", "other_ids": {"DOI": ["10.1158/1078-0432.CCR-11-0636"]}}, "BIBREF265": {"ref_id": "b265", "title": "Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system", "authors": [{"first": "M", "middle": ["J"], "last": "Lee", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Lee", "suffix": ""}, {"first": "D", "middle": ["C"], "last": "Rubinsztein", "suffix": ""}], "year": 2013, "venue": "Progress in Neurobiology", "volume": "105", "issn": "", "pages": "49--59", "other_ids": {"DOI": ["10.1016/j.pneurobio.2013.03.001"]}}, "BIBREF266": {"ref_id": "b266", "title": "H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth", "authors": [{"first": "M", "middle": ["J"], "last": "Lee", "suffix": ""}, {"first": "Z", "middle": [], "last": "Miller", "suffix": ""}, {"first": "J", "middle": ["E"], "last": "Park", "suffix": ""}, {"first": "D", "middle": [], "last": "Bhattarai", "suffix": ""}, {"first": "W", "middle": [], "last": "Lee", "suffix": ""}, {"first": "K", "middle": ["B"], "last": "Kim", "suffix": ""}], "year": 2019, "venue": "Scientific Reports", "volume": "9", "issn": "1", "pages": "1--9", "other_ids": {"DOI": ["10.1038/s41598-019-40635-1"]}}, "BIBREF267": {"ref_id": "b267", "title": "Loss of Rpt5 protein interactions with the core particle and Nas2 protein causes the formation of faulty proteasomes that are inhibited by Ecm29 protein", "authors": [{"first": "S", "middle": ["Y"], "last": "Lee", "suffix": ""}, {"first": ".-C", "middle": [], "last": "De La Mota-Peynado", "suffix": ""}, {"first": "A", "middle": [], "last": "Roelofs", "suffix": ""}, {"first": "J", "middle": [], "last": "", "suffix": ""}], "year": 2011, "venue": "The Journal of Biological Chemistry", "volume": "286", "issn": "42", "pages": "36641--36651", "other_ids": {}}, "BIBREF269": {"ref_id": "b269", "title": "A68: a major subunit of paired helical filaments and derivatized forms of normal Tau", "authors": [{"first": "V", "middle": ["M"], "last": "Lee", "suffix": ""}, {"first": "B", "middle": ["J"], "last": "Balin", "suffix": ""}, {"first": "L", "middle": [], "last": "Otvos", "suffix": ""}, {"first": "J", "middle": ["Q"], "last": "Trojanowski", "suffix": ""}], "year": 1991, "venue": "Science", "volume": "", "issn": "4994", "pages": "675--678", "other_ids": {}}, "BIBREF270": {"ref_id": "b270", "title": "Structural requirements within protoporphyrin IX in the inhibition of heat shock protein 90", "authors": [{"first": "W", "middle": ["H"], "last": "Lee", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Lee", "suffix": ""}, {"first": "C", "middle": [], "last": "Lim", "suffix": ""}, {"first": "S", "middle": [], "last": "Kim", "suffix": ""}, {"first": "S", "middle": ["G"], "last": "Kim", "suffix": ""}], "year": 2013, "venue": "Chemico-Biological Interactions", "volume": "204", "issn": "1", "pages": "49--57", "other_ids": {"DOI": ["10.1016/j.cbi.2013.04.006"]}}, "BIBREF271": {"ref_id": "b271", "title": "iRhom1 regulates proteasome activity via PAC1/2 under ER stress", "authors": [{"first": "W", "middle": [], "last": "Lee", "suffix": ""}, {"first": "Y", "middle": [], "last": "Kim", "suffix": ""}, {"first": "J", "middle": [], "last": "Park", "suffix": ""}, {"first": "S", "middle": [], "last": "Shim", "suffix": ""}, {"first": "J", "middle": [], "last": "Lee", "suffix": ""}, {"first": "S", "middle": [], "last": "Hong", "suffix": ""}, {"first": "H.-H", "middle": [], "last": "Ahn", "suffix": ""}, {"first": "H", "middle": [], "last": "Lee", "suffix": ""}, {"first": "Y.-K", "middle": [], "last": "Jung", "suffix": ""}], "year": 2015, "venue": "Scientific Reports", "volume": "5", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/srep11559"]}}, "BIBREF272": {"ref_id": "b272", "title": "Tools to investigate the ubiquitin proteasome system", "authors": [{"first": "Y", "middle": [], "last": "Leestemaker", "suffix": ""}, {"first": "H", "middle": [], "last": "Ovaa", "suffix": ""}], "year": 2017, "venue": "Drug Discovery Today. Technologies", "volume": "26", "issn": "", "pages": "25--31", "other_ids": {"DOI": ["10.1016/j.ddtec.2017.11.006"]}}, "BIBREF277": {"ref_id": "b277", "title": "Multiple associated proteins regulate proteasome structure and function", "authors": [{"first": "D", "middle": ["S"], "last": "Leggett", "suffix": ""}, {"first": "J", "middle": [], "last": "Hanna", "suffix": ""}, {"first": "A", "middle": [], "last": "Borodovsky", "suffix": ""}, {"first": "B", "middle": [], "last": "Crosas", "suffix": ""}, {"first": "M", "middle": [], "last": "Schmidt", "suffix": ""}, {"first": "R", "middle": ["T"], "last": "Baker", "suffix": ""}, {"first": "T", "middle": [], "last": "Walz", "suffix": ""}, {"first": "H", "middle": [], "last": "Ploegh", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}], "year": 2002, "venue": "Molecular Cell", "volume": "10", "issn": "3", "pages": "495--507", "other_ids": {"DOI": ["10.1016/s1097-2765(02)00638-x"]}}, "BIBREF278": {"ref_id": "b278", "title": "Ecm29 fulfils quality control functions in proteasome assembly", "authors": [{"first": "A", "middle": [], "last": "Lehmann", "suffix": ""}, {"first": "A", "middle": [], "last": "Niewienda", "suffix": ""}, {"first": "K", "middle": [], "last": "Jechow", "suffix": ""}, {"first": "K", "middle": [], "last": "Janek", "suffix": ""}, {"first": "C", "middle": [], "last": "Enenkel", "suffix": ""}], "year": 2010, "venue": "Molecular Cell", "volume": "38", "issn": "6", "pages": "879--888", "other_ids": {}}, "BIBREF280": {"ref_id": "b280", "title": "Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma", "authors": [{"first": "X", "middle": [], "last": "Leleu", "suffix": ""}, {"first": "T", "middle": ["G"], "last": "Martin", "suffix": ""}, {"first": "H", "middle": [], "last": "Einsele", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Lyons", "suffix": ""}, {"first": "B", "middle": ["G M"], "last": "Durie", "suffix": ""}, {"first": "K", "middle": ["S"], "last": "Iskander", "suffix": ""}, {"first": "S", "middle": [], "last": "Ailawadhi", "suffix": ""}], "year": 2019, "venue": "Clinical Lymphoma, Myeloma & Leukemia", "volume": "19", "issn": "1", "pages": "9--22", "other_ids": {"DOI": ["10.1016/j.clml.2018.08.016"]}}, "BIBREF281": {"ref_id": "b281", "title": "Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebolenalidomide-dexamethasone in relapsed/refractory multiple myeloma", "authors": [{"first": "X", "middle": [], "last": "Leleu", "suffix": ""}, {"first": "T", "middle": [], "last": "Masszi", "suffix": ""}, {"first": "N", "middle": ["J"], "last": "Bahlis", "suffix": ""}, {"first": "L", "middle": [], "last": "Viterbo", "suffix": ""}, {"first": "B", "middle": [], "last": "Baker", "suffix": ""}, {"first": "P", "middle": [], "last": "Gimsing", "suffix": ""}, {"first": "V", "middle": [], "last": "Maisnar", "suffix": ""}, {"first": "O", "middle": [], "last": "Samoilova", "suffix": ""}, {"first": "L", "middle": [], "last": "Rosi\u00f1ol", "suffix": ""}, {"first": "C", "middle": [], "last": "Langer", "suffix": ""}, {"first": "K", "middle": [], "last": "Song", "suffix": ""}, {"first": "T", "middle": [], "last": "Izumi", "suffix": ""}, {"first": "C", "middle": [], "last": "Cleeland", "suffix": ""}, {"first": "D", "middle": [], "last": "Berg", "suffix": ""}, {"first": "H", "middle": ["M"], "last": "Lin", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "T", "middle": [], "last": "Skacel", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}], "year": 2018, "venue": "American Journal of Hematology", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1002/ajh.25134"]}}, "BIBREF282": {"ref_id": "b282", "title": "Review. Clinical pharmacokinetics of bortezomib", "authors": [{"first": "D", "middle": [], "last": "Lev\u00eaque", "suffix": ""}, {"first": "M", "middle": ["C M"], "last": "Carvalho", "suffix": ""}, {"first": "F", "middle": [], "last": "Maloisel", "suffix": ""}], "year": 2007, "venue": "In Vivo", "volume": "21", "issn": "2", "pages": "273--278", "other_ids": {}}, "BIBREF283": {"ref_id": "b283", "title": "Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients", "authors": [{"first": "N", "middle": [], "last": "Levin", "suffix": ""}, {"first": "A", "middle": [], "last": "Spencer", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Harrison", "suffix": ""}, {"first": "D", "middle": [], "last": "Chauhan", "suffix": ""}, {"first": "F", "middle": ["J"], "last": "Burrows", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Reich", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "M", "middle": [], "last": "Trikha", "suffix": ""}], "year": 2016, "venue": "British Journal of Haematology", "volume": "174", "issn": "5", "pages": "711--720", "other_ids": {"DOI": ["10.1111/bjh.14113"]}}, "BIBREF284": {"ref_id": "b284", "title": "Boronic acid-containing proteasome inhibitors: alert to potential pharmaceutical bioactivation", "authors": [{"first": "A", "middle": ["C"], "last": "Li", "suffix": ""}, {"first": "E", "middle": [], "last": "Yu", "suffix": ""}, {"first": "S", "middle": ["C"], "last": "Ring", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Chovan", "suffix": ""}], "year": 2013, "venue": "Chemical Research in Toxicology", "volume": "26", "issn": "4", "pages": "608--615", "other_ids": {"DOI": ["10.1021/tx400032n"]}}, "BIBREF285": {"ref_id": "b285", "title": "The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma", "authors": [{"first": "B", "middle": [], "last": "Li", "suffix": ""}, {"first": "J", "middle": [], "last": "Fu", "suffix": ""}, {"first": "P", "middle": [], "last": "Chen", "suffix": ""}, {"first": "X", "middle": [], "last": "Ge", "suffix": ""}, {"first": "Y", "middle": [], "last": "Li", "suffix": ""}, {"first": "I", "middle": [], "last": "Kuiatse", "suffix": ""}, {"first": "H", "middle": [], "last": "Wang", "suffix": ""}, {"first": "H", "middle": [], "last": "Wang", "suffix": ""}, {"first": "X", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "R", "middle": ["Z"], "last": "Orlowski", "suffix": ""}], "year": 2015, "venue": "The Journal of Biological Chemistry", "volume": "290", "issn": "50", "pages": "29854--29868", "other_ids": {"DOI": ["10.1074/jbc.M115.664953"]}}, "BIBREF286": {"ref_id": "b286", "title": "Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest", "authors": [{"first": "C", "middle": [], "last": "Li", "suffix": ""}, {"first": "D", "middle": ["E"], "last": "Johnson", "suffix": ""}], "year": 2013, "venue": "Cell Cycle", "volume": "", "issn": "6", "pages": "923--934", "other_ids": {"DOI": ["10.4161/cc.23882"]}}, "BIBREF287": {"ref_id": "b287", "title": "Nucleotide-dependent switch in proteasome assembly mediated by the Nas6 chaperone", "authors": [{"first": "F", "middle": [], "last": "Li", "suffix": ""}, {"first": "G", "middle": [], "last": "Tian", "suffix": ""}, {"first": "D", "middle": [], "last": "Langager", "suffix": ""}, {"first": "V", "middle": [], "last": "Sokolova", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}, {"first": "S", "middle": [], "last": "Park", "suffix": ""}], "year": 2017, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "114", "issn": "", "pages": "1548--1553", "other_ids": {"DOI": ["10.1073/pnas.1612922114"]}}, "BIBREF288": {"ref_id": "b288", "title": "Binding States of Protein-Metal Complexes in Cells", "authors": [{"first": "G", "middle": [], "last": "Li", "suffix": ""}, {"first": "S", "middle": [], "last": "Yuan", "suffix": ""}, {"first": "Y", "middle": [], "last": "Pan", "suffix": ""}, {"first": "Y", "middle": [], "last": "Liu", "suffix": ""}, {"first": "G", "middle": [], "last": "Huang", "suffix": ""}], "year": 2016, "venue": "Analytical Chemistry", "volume": "88", "issn": "22", "pages": "10860--10866", "other_ids": {}}, "BIBREF290": {"ref_id": "b290", "title": "Enhancement of proteasome function by PA28\u03b1 overexpression protects against oxidative stress", "authors": [{"first": "J", "middle": [], "last": "Li", "suffix": ""}, {"first": "S", "middle": ["R"], "last": "Powell", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}], "year": 2011, "venue": "The FASEB Journal", "volume": "25", "issn": "3", "pages": "883--893", "other_ids": {"DOI": ["10.1096/fj.10-160895"]}}, "BIBREF291": {"ref_id": "b291", "title": "Correlation between TGF-\u03b21 expression and proteomic profiling induced by severe acute respiratory syndrome coronavirus papain-like protease", "authors": [{"first": "S.-W", "middle": [], "last": "Li", "suffix": ""}, {"first": "T.-C", "middle": [], "last": "Yang", "suffix": ""}, {"first": "L", "middle": [], "last": "Wan", "suffix": ""}, {"first": "Y.-J", "middle": [], "last": "Lin", "suffix": ""}, {"first": "F.-J", "middle": [], "last": "Tsai", "suffix": ""}, {"first": "C.-C", "middle": [], "last": "Lai", "suffix": ""}, {"first": "C.-W", "middle": [], "last": "Lin", "suffix": ""}], "year": 2012, "venue": "Proteomics", "volume": "12", "issn": "21", "pages": "3193--3205", "other_ids": {}}, "BIBREF293": {"ref_id": "b293", "title": "Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus", "authors": [{"first": "W", "middle": [], "last": "Li", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Moore", "suffix": ""}, {"first": "N", "middle": [], "last": "Vasilieva", "suffix": ""}, {"first": "J", "middle": [], "last": "Sui", "suffix": ""}, {"first": "S", "middle": ["K"], "last": "Wong", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Berne", "suffix": ""}, {"first": "M", "middle": [], "last": "Somasundaran", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Sullivan", "suffix": ""}, {"first": "K", "middle": [], "last": "Luzuriaga", "suffix": ""}, {"first": "T", "middle": ["C"], "last": "Greenough", "suffix": ""}, {"first": "H", "middle": [], "last": "Choe", "suffix": ""}, {"first": "M", "middle": [], "last": "Farzan", "suffix": ""}], "year": 2003, "venue": "Nature", "volume": "426", "issn": "6965", "pages": "450--454", "other_ids": {"DOI": ["10.1038/nature02145"]}}, "BIBREF294": {"ref_id": "b294", "title": "A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth", "authors": [{"first": "X", "middle": [], "last": "Li", "suffix": ""}, {"first": "Q", "middle": [], "last": "Huang", "suffix": ""}, {"first": "H", "middle": [], "last": "Long", "suffix": ""}, {"first": "P", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "H", "middle": [], "last": "Su", "suffix": ""}, {"first": "J", "middle": [], "last": "Liu", "suffix": ""}], "year": 2019, "venue": "EBioMedicine", "volume": "39", "issn": "", "pages": "159--172", "other_ids": {"DOI": ["10.1016/j.ebiom.2018.11.047"]}}, "BIBREF295": {"ref_id": "b295", "title": "Inhibiting the ubiquitinproteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments", "authors": [{"first": "X", "middle": [], "last": "Li", "suffix": ""}, {"first": "C.-E", "middle": [], "last": "Wang", "suffix": ""}, {"first": "S", "middle": [], "last": "Huang", "suffix": ""}, {"first": "X", "middle": [], "last": "Xu", "suffix": ""}, {"first": "X.-J", "middle": [], "last": "Li", "suffix": ""}, {"first": "H", "middle": [], "last": "Li", "suffix": ""}, {"first": "S", "middle": [], "last": "Li", "suffix": ""}], "year": 2010, "venue": "Human Molecular Genetics", "volume": "19", "issn": "12", "pages": "2445--2455", "other_ids": {"DOI": ["10.1093/hmg/ddq127"]}}, "BIBREF296": {"ref_id": "b296", "title": "The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity", "authors": [{"first": "M", "middle": [], "last": "Lichtenberg", "suffix": ""}, {"first": "A", "middle": [], "last": "Mansilla", "suffix": ""}, {"first": "V", "middle": ["R"], "last": "Zecchini", "suffix": ""}, {"first": "A", "middle": [], "last": "Fleming", "suffix": ""}, {"first": "D", "middle": ["C"], "last": "Rubinsztein", "suffix": ""}], "year": 2011, "venue": "Cell Death & Disease", "volume": "2", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/cddis.2011.81"]}}, "BIBREF297": {"ref_id": "b297", "title": "Proteotoxic stress induces phosphorylation of p62/SQSTM1 by ULK1 to regulate selective autophagic clearance of protein aggregates", "authors": [{"first": "J", "middle": [], "last": "Lim", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Lachenmayer", "suffix": ""}, {"first": "S", "middle": [], "last": "Wu", "suffix": ""}, {"first": "W", "middle": [], "last": "Liu", "suffix": ""}, {"first": "M", "middle": [], "last": "Kundu", "suffix": ""}, {"first": "R", "middle": [], "last": "Wang", "suffix": ""}, {"first": "M", "middle": [], "last": "Komatsu", "suffix": ""}, {"first": "Y", "middle": ["J"], "last": "Oh", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "Z", "middle": [], "last": "Yue", "suffix": ""}], "year": 2015, "venue": "PLoS Genetics", "volume": "11", "issn": "2", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pgen.1004987"]}}, "BIBREF298": {"ref_id": "b298", "title": "A Sentinel in the Crosstalk Between the Nervous and Immune System: The (Immuno)-Proteasome", "authors": [{"first": "F", "middle": [], "last": "Limanaqi", "suffix": ""}, {"first": "F", "middle": [], "last": "Biagioni", "suffix": ""}, {"first": "A", "middle": [], "last": "Gaglione", "suffix": ""}, {"first": "C", "middle": ["L"], "last": "Busceti", "suffix": ""}, {"first": "F", "middle": [], "last": "Fornai", "suffix": ""}], "year": 2019, "venue": "Frontiers in Immunology", "volume": "10", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3389/fimmu.2019.00628"]}}, "BIBREF299": {"ref_id": "b299", "title": "Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease", "authors": [{"first": "J.-T", "middle": [], "last": "Lin", "suffix": ""}, {"first": "W.-C", "middle": [], "last": "Chang", "suffix": ""}, {"first": "H.-M", "middle": [], "last": "Chen", "suffix": ""}, {"first": "H.-L", "middle": [], "last": "Lai", "suffix": ""}, {"first": "C.-Y", "middle": [], "last": "Chen", "suffix": ""}, {"first": "M.-H", "middle": [], "last": "Tao", "suffix": ""}, {"first": "Y", "middle": [], "last": "Chern", "suffix": ""}], "year": 2013, "venue": "Molecular and Cellular Biology", "volume": "33", "issn": "5", "pages": "1073--1084", "other_ids": {"DOI": ["10.1128/MCB.01434-12"]}}, "BIBREF300": {"ref_id": "b300", "title": "Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin", "authors": [{"first": "L", "middle": [], "last": "Lin", "suffix": ""}, {"first": "Z", "middle": [], "last": "Jin", "suffix": ""}, {"first": "H", "middle": [], "last": "Tan", "suffix": ""}, {"first": "Q", "middle": [], "last": "Xu", "suffix": ""}, {"first": "T", "middle": [], "last": "Peng", "suffix": ""}, {"first": "H", "middle": [], "last": "Li", "suffix": ""}], "year": 2016, "venue": "Brain Research", "volume": "1643", "issn": "", "pages": "103--112", "other_ids": {"DOI": ["10.1016/j.brainres.2016.03.027"]}}, "BIBREF301": {"ref_id": "b301", "title": "Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein", "authors": [{"first": "X", "middle": [], "last": "Lin", "suffix": ""}, {"first": "L", "middle": [], "last": "Parisiadou", "suffix": ""}, {"first": "X.-L", "middle": [], "last": "Gu", "suffix": ""}, {"first": "L", "middle": [], "last": "Wang", "suffix": ""}, {"first": "H", "middle": [], "last": "Shim", "suffix": ""}, {"first": "L", "middle": [], "last": "Sun", "suffix": ""}, {"first": "C", "middle": [], "last": "Xie", "suffix": ""}, {"first": "C.-X", "middle": [], "last": "Long", "suffix": ""}, {"first": "W.-J", "middle": [], "last": "Yang", "suffix": ""}, {"first": "J", "middle": [], "last": "Ding", "suffix": ""}, {"first": "Z", "middle": ["Z"], "last": "Chen", "suffix": ""}, {"first": "P", "middle": ["E"], "last": "Gallant", "suffix": ""}, {"first": "J.-H", "middle": [], "last": "Tao-Cheng", "suffix": ""}, {"first": "G", "middle": [], "last": "Rudow", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Troncoso", "suffix": ""}, {"first": "Z", "middle": [], "last": "Liu", "suffix": ""}, {"first": "Z", "middle": [], "last": "Li", "suffix": ""}, {"first": "H", "middle": [], "last": "Cai", "suffix": ""}], "year": 2009, "venue": "Neuron", "volume": "64", "issn": "6", "pages": "807--827", "other_ids": {}}, "BIBREF303": {"ref_id": "b303", "title": "CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells", "authors": [{"first": "Y.-C", "middle": [], "last": "Lin", "suffix": ""}, {"first": "K.-C", "middle": [], "last": "Chen", "suffix": ""}, {"first": "C.-C", "middle": [], "last": "Chen", "suffix": ""}, {"first": "A.-L", "middle": [], "last": "Cheng", "suffix": ""}, {"first": "K.-F", "middle": [], "last": "Chen", "suffix": ""}], "year": 2012, "venue": "Oral Oncology", "volume": "48", "issn": "7", "pages": "585--593", "other_ids": {"DOI": ["10.1016/j.oraloncology.2012.01.012"]}}, "BIBREF304": {"ref_id": "b304", "title": "Relationship between beta-amyloid degradation and the 26S proteasome in neural cells", "authors": [{"first": "M", "middle": [], "last": "Lopez Salon", "suffix": ""}, {"first": "L", "middle": [], "last": "Pasquini", "suffix": ""}, {"first": "M", "middle": [], "last": "Besio Moreno", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Pasquini", "suffix": ""}, {"first": "E", "middle": [], "last": "Soto", "suffix": ""}], "year": 2003, "venue": "Experimental Neurology", "volume": "180", "issn": "2", "pages": "131--143", "other_ids": {}}, "BIBREF305": {"ref_id": "b305", "title": "The ubiquitin-proteasome cascade is required for mammalian longterm memory formation", "authors": [{"first": "M", "middle": [], "last": "Lopez-Salon", "suffix": ""}, {"first": "M", "middle": [], "last": "Alonso", "suffix": ""}, {"first": "M", "middle": ["R"], "last": "Vianna", "suffix": ""}, {"first": "H", "middle": [], "last": "Viola", "suffix": ""}, {"first": "T", "middle": [], "last": "Mello E Souza", "suffix": ""}, {"first": "I", "middle": [], "last": "Izquierdo", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Pasquini", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Medina", "suffix": ""}], "year": 2001, "venue": "The European Journal of Neuroscience", "volume": "14", "issn": "11", "pages": "1820--1826", "other_ids": {"DOI": ["10.1046/j.0953-816x.2001.01806.x"]}}, "BIBREF306": {"ref_id": "b306", "title": "Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432", "authors": [{"first": "P", "middle": ["M"], "last": "Lorusso", "suffix": ""}, {"first": "K", "middle": [], "last": "Venkatakrishnan", "suffix": ""}, {"first": "R", "middle": ["K"], "last": "Ramanathan", "suffix": ""}, {"first": "J", "middle": [], "last": "Sarantopoulos", "suffix": ""}, {"first": "D", "middle": [], "last": "Mulkerin", "suffix": ""}, {"first": "S", "middle": ["I"], "last": "Shibata", "suffix": ""}, {"first": "A", "middle": [], "last": "Hamilton", "suffix": ""}, {"first": "A", "middle": [], "last": "Dowlati", "suffix": ""}, {"first": "S", "middle": [], "last": "Mani", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Rudek", "suffix": ""}, {"first": "C", "middle": ["H"], "last": "Takimoto", "suffix": ""}, {"first": "R", "middle": [], "last": "Neuwirth", "suffix": ""}, {"first": "D.-L", "middle": [], "last": "Esseltine", "suffix": ""}, {"first": "P", "middle": [], "last": "Ivy", "suffix": ""}], "year": 2012, "venue": "Clinical Cancer Research: An Official Journal of the American Association for Cancer Research", "volume": "18", "issn": "10", "pages": "2954--2963", "other_ids": {"DOI": ["10.1158/1078-0432.CCR-11-2873"]}}, "BIBREF308": {"ref_id": "b308", "title": "Copper, iron and zinc in Alzheimer's disease senile plaques", "authors": [], "year": null, "venue": "Journal of the Neurological Sciences", "volume": "158", "issn": "1", "pages": "47--52", "other_ids": {}}, "BIBREF310": {"ref_id": "b310", "title": "Revealing the dynamics of the 20 S proteasome phosphoproteome: a combined CID and electron transfer dissociation approach", "authors": [{"first": "H", "middle": [], "last": "Lu", "suffix": ""}, {"first": "C", "middle": [], "last": "Zong", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wang", "suffix": ""}, {"first": "G", "middle": ["W"], "last": "Young", "suffix": ""}, {"first": "N", "middle": [], "last": "Deng", "suffix": ""}, {"first": "P", "middle": [], "last": "Souda", "suffix": ""}, {"first": "X", "middle": [], "last": "Li", "suffix": ""}, {"first": "J", "middle": [], "last": "Whitelegge", "suffix": ""}, {"first": "O", "middle": [], "last": "Drews", "suffix": ""}, {"first": "P.-Y", "middle": [], "last": "Yang", "suffix": ""}, {"first": "P", "middle": [], "last": "Ping", "suffix": ""}], "year": 2008, "venue": "Molecular & Cellular Proteomics: MCP", "volume": "7", "issn": "11", "pages": "2073--2089", "other_ids": {"DOI": ["10.1074/mcp.M800064-MCP200"]}}, "BIBREF311": {"ref_id": "b311", "title": "Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma", "authors": [{"first": "H", "middle": [], "last": "Ludwig", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}, {"first": "M.-V", "middle": [], "last": "Mateos", "suffix": ""}, {"first": "M", "middle": [], "last": "Kaiser", "suffix": ""}, {"first": "R", "middle": [], "last": "Hajek", "suffix": ""}, {"first": "S", "middle": [], "last": "Feng", "suffix": ""}, {"first": "K", "middle": [], "last": "Cocks", "suffix": ""}, {"first": "J", "middle": [], "last": "Buchanan", "suffix": ""}, {"first": "K", "middle": [], "last": "Weisel", "suffix": ""}], "year": 2019, "venue": "Blood Cancer Journal", "volume": "9", "issn": "3", "pages": "", "other_ids": {"DOI": ["10.1038/s41408-019-0181-0"]}}, "BIBREF312": {"ref_id": "b312", "title": "Herp Promotes Degradation of Mutant Huntingtin: Involvement of the Proteasome and Molecular Chaperones", "authors": [{"first": "H", "middle": [], "last": "Luo", "suffix": ""}, {"first": "L", "middle": [], "last": "Cao", "suffix": ""}, {"first": "X", "middle": [], "last": "Liang", "suffix": ""}, {"first": "A", "middle": [], "last": "Du", "suffix": ""}, {"first": "T", "middle": [], "last": "Peng", "suffix": ""}, {"first": "H", "middle": [], "last": "Li", "suffix": ""}], "year": 2018, "venue": "Molecular Neurobiology", "volume": "55", "issn": "10", "pages": "7652--7668", "other_ids": {"DOI": ["10.1007/s12035-018-0900-8"]}}, "BIBREF313": {"ref_id": "b313", "title": "20S proteasome and glyoxalase 1 activities decrease in erythrocytes derived from Alzheimer's disease patients", "authors": [{"first": "H", "middle": [], "last": "Lv", "suffix": ""}, {"first": "G.-Y", "middle": [], "last": "Wei", "suffix": ""}, {"first": "C.-S", "middle": [], "last": "Guo", "suffix": ""}, {"first": "Y.-F", "middle": [], "last": "Deng", "suffix": ""}, {"first": "Y.-M", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "C", "middle": [], "last": "Gao", "suffix": ""}, {"first": "C.-D", "middle": [], "last": "Jian", "suffix": ""}], "year": 2020, "venue": "Neural Regeneration Research", "volume": "15", "issn": "1", "pages": "178--183", "other_ids": {"DOI": ["10.4103/1673-5374.264473"]}}, "BIBREF314": {"ref_id": "b314", "title": "The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents", "authors": [{"first": "M", "middle": ["H"], "last": "Ma", "suffix": ""}, {"first": "H", "middle": ["H"], "last": "Yang", "suffix": ""}, {"first": "K", "middle": [], "last": "Parker", "suffix": ""}, {"first": "S", "middle": [], "last": "Manyak", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Friedman", "suffix": ""}, {"first": "C", "middle": [], "last": "Altamirano", "suffix": ""}, {"first": "Z", "middle": [], "last": "Wu", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Borad", "suffix": ""}, {"first": "M", "middle": [], "last": "Frantzen", "suffix": ""}, {"first": "E", "middle": [], "last": "Roussos", "suffix": ""}, {"first": "J", "middle": [], "last": "Neeser", "suffix": ""}, {"first": "A", "middle": [], "last": "Mikail", "suffix": ""}, {"first": "J", "middle": [], "last": "Adams", "suffix": ""}, {"first": "N", "middle": [], "last": "Sjak-Shie", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Vescio", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Berenson", "suffix": ""}], "year": 2003, "venue": "Clinical Cancer Research: An Official Journal of the American Association for Cancer Research", "volume": "9", "issn": "3", "pages": "1136--1144", "other_ids": {}}, "BIBREF315": {"ref_id": "b315", "title": "Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome", "authors": [{"first": "X.-Z", "middle": [], "last": "Ma", "suffix": ""}, {"first": "A", "middle": [], "last": "Bartczak", "suffix": ""}, {"first": "J", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "R", "middle": [], "last": "Khattar", "suffix": ""}, {"first": "L", "middle": [], "last": "Chen", "suffix": ""}, {"first": "M", "middle": ["F"], "last": "Liu", "suffix": ""}, {"first": "A", "middle": [], "last": "Edwards", "suffix": ""}, {"first": "G", "middle": [], "last": "Levy", "suffix": ""}, {"first": "I", "middle": ["D"], "last": "Mcgilvray", "suffix": ""}], "year": 2010, "venue": "Journal of Virology", "volume": "84", "issn": "23", "pages": "12419--12428", "other_ids": {"DOI": ["10.1128/JVI.01219-10"]}}, "BIBREF316": {"ref_id": "b316", "title": "c-Abl phosphorylates \u03b1-synuclein and regulates its degradation: implication for \u03b1-synuclein clearance and contribution to the pathogenesis of Parkinson's disease", "authors": [{"first": "A.-L", "middle": [], "last": "Mahul-Mellier", "suffix": ""}, {"first": "B", "middle": [], "last": "Fauvet", "suffix": ""}, {"first": "A", "middle": [], "last": "Gysbers", "suffix": ""}, {"first": "I", "middle": [], "last": "Dikiy", "suffix": ""}, {"first": "A", "middle": [], "last": "Oueslati", "suffix": ""}, {"first": "S", "middle": [], "last": "Georgeon", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Lamontanara", "suffix": ""}, {"first": "A", "middle": [], "last": "Bisquertt", "suffix": ""}, {"first": "D", "middle": [], "last": "Eliezer", "suffix": ""}, {"first": "E", "middle": [], "last": "Masliah", "suffix": ""}, {"first": "G", "middle": [], "last": "Halliday", "suffix": ""}, {"first": "O", "middle": [], "last": "Hantschel", "suffix": ""}, {"first": "H", "middle": ["A"], "last": "Lashuel", "suffix": ""}], "year": 2014, "venue": "Human Molecular Genetics", "volume": "23", "issn": "11", "pages": "2858--2879", "other_ids": {"DOI": ["10.1093/hmg/ddt674"]}}, "BIBREF317": {"ref_id": "b317", "title": "ClpX(P) generates mechanical force to unfold and translocate its protein substrates", "authors": [{"first": "R", "middle": ["A"], "last": "Maillard", "suffix": ""}, {"first": "G", "middle": [], "last": "Chistol", "suffix": ""}, {"first": "M", "middle": [], "last": "Sen", "suffix": ""}, {"first": "M", "middle": [], "last": "Righini", "suffix": ""}, {"first": "J", "middle": [], "last": "Tan", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Kaiser", "suffix": ""}, {"first": "C", "middle": [], "last": "Hodges", "suffix": ""}, {"first": "A", "middle": [], "last": "Martin", "suffix": ""}, {"first": "C", "middle": [], "last": "Bustamante", "suffix": ""}], "year": 2011, "venue": "Cell", "volume": "145", "issn": "3", "pages": "459--469", "other_ids": {"DOI": ["10.1016/j.cell.2011.04.010"]}}, "BIBREF318": {"ref_id": "b318", "title": "Proteasome inhibitors in cancer therapy", "authors": [{"first": "E", "middle": ["E"], "last": "Manasanch", "suffix": ""}, {"first": "R", "middle": ["Z"], "last": "Orlowski", "suffix": ""}], "year": 2017, "venue": "Nature Reviews. Clinical Oncology", "volume": "14", "issn": "7", "pages": "417--433", "other_ids": {"DOI": ["10.1038/nrclinonc.2016.206"]}}, "BIBREF319": {"ref_id": "b319", "title": "Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo", "authors": [{"first": "C", "middle": ["A"], "last": "Manton", "suffix": ""}, {"first": "B", "middle": [], "last": "Johnson", "suffix": ""}, {"first": "M", "middle": [], "last": "Singh", "suffix": ""}, {"first": "C", "middle": ["P"], "last": "Bailey", "suffix": ""}, {"first": "L", "middle": [], "last": "Bouchier-Hayes", "suffix": ""}, {"first": "J", "middle": [], "last": "Chandra", "suffix": ""}], "year": 2016, "venue": "Scientific Reports", "volume": "6", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/srep18953"]}}, "BIBREF320": {"ref_id": "b320", "title": "Catalytic mechanism and assembly of the proteasome", "authors": [{"first": "A", "middle": ["J"], "last": "Marques", "suffix": ""}, {"first": "R", "middle": [], "last": "Palanimurugan", "suffix": ""}, {"first": "A", "middle": ["C"], "last": "Matias", "suffix": ""}, {"first": "P", "middle": ["C"], "last": "Ramos", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Dohmen", "suffix": ""}], "year": 2009, "venue": "Chemical Reviews", "volume": "109", "issn": "4", "pages": "1509--1536", "other_ids": {"DOI": ["10.1021/cr8004857"]}}, "BIBREF321": {"ref_id": "b321", "title": "Dynamic Regulation of the 26S Proteasome: From Synthesis to Degradation", "authors": [{"first": "R", "middle": ["S"], "last": "Marshall", "suffix": ""}, {"first": "R", "middle": ["D"], "last": "Vierstra", "suffix": ""}], "year": 2019, "venue": "Frontiers in Molecular Biosciences", "volume": "6", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3389/fmolb.2019.00040"]}}, "BIBREF322": {"ref_id": "b322", "title": "Pore loops of the AAA+ ClpX machine grip substrates to drive translocation and unfolding", "authors": [{"first": "A", "middle": [], "last": "Martin", "suffix": ""}, {"first": "T", "middle": ["A"], "last": "Baker", "suffix": ""}, {"first": "R", "middle": ["T"], "last": "Sauer", "suffix": ""}], "year": 2008, "venue": "Nature Structural & Molecular Biology", "volume": "15", "issn": "11", "pages": "1147--1151", "other_ids": {"DOI": ["10.1038/nsmb.1503"]}}, "BIBREF323": {"ref_id": "b323", "title": "Copper entry into human cells: progress and unanswered questions", "authors": [{"first": "E", "middle": ["B"], "last": "Maryon", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Molloy", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Zimnicka", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Kaplan", "suffix": ""}], "year": 2007, "venue": "BioMetals", "volume": "20", "issn": "3-4", "pages": "355--364", "other_ids": {}}, "BIBREF325": {"ref_id": "b325", "title": "Copper complexes as anticancer agents. Anti-Cancer Agents in Medicinal Chemistry", "authors": [{"first": "C", "middle": [], "last": "Marzano", "suffix": ""}, {"first": "M", "middle": [], "last": "Pellei", "suffix": ""}, {"first": "F", "middle": [], "last": "Tisato", "suffix": ""}, {"first": "C", "middle": [], "last": "Santini", "suffix": ""}], "year": 2009, "venue": "", "volume": "9", "issn": "", "pages": "185--211", "other_ids": {}}, "BIBREF326": {"ref_id": "b326", "title": "Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial", "authors": [{"first": "Maria", "middle": ["-"], "last": "Mateos", "suffix": ""}, {"first": "", "middle": [], "last": "Victoria", "suffix": ""}, {"first": "M", "middle": [], "last": "Cavo", "suffix": ""}, {"first": "J", "middle": [], "last": "Blade", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}, {"first": "K", "middle": [], "last": "Suzuki", "suffix": ""}, {"first": "A", "middle": [], "last": "Jakubowiak", "suffix": ""}, {"first": "S", "middle": [], "last": "Knop", "suffix": ""}, {"first": "C", "middle": [], "last": "Doyen", "suffix": ""}, {"first": "P", "middle": [], "last": "Lucio", "suffix": ""}, {"first": "Z", "middle": [], "last": "Nagy", "suffix": ""}, {"first": "L", "middle": [], "last": "Pour", "suffix": ""}, {"first": "M", "middle": [], "last": "Cook", "suffix": ""}, {"first": "S", "middle": [], "last": "Grosicki", "suffix": ""}, {"first": "A", "middle": [], "last": "Crepaldi", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Liberati", "suffix": ""}, {"first": "P", "middle": [], "last": "Campbell", "suffix": ""}, {"first": "T", "middle": [], "last": "Shelekhova", "suffix": ""}, {"first": "S.-S", "middle": [], "last": "Yoon", "suffix": ""}, {"first": "G", "middle": [], "last": "Iosava", "suffix": ""}, {"first": "J", "middle": [], "last": "San-Miguel", "suffix": ""}], "year": 2020, "venue": "Lancet", "volume": "", "issn": "", "pages": "132--141", "other_ids": {"DOI": ["10.1016/S0140-6736(19)32956-3"]}}, "BIBREF327": {"ref_id": "b327", "title": "Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression", "authors": [{"first": "Mar\u00eda-Victoria", "middle": [], "last": "Mateos", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Hern\u00e1ndez", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Hern\u00e1ndez", "suffix": ""}, {"first": "N", "middle": ["C"], "last": "Guti\u00e9rrez", "suffix": ""}, {"first": "L", "middle": [], "last": "Palomera", "suffix": ""}, {"first": "M", "middle": [], "last": "Fuertes", "suffix": ""}, {"first": "P", "middle": [], "last": "Garcia-Sanchez", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Lahuerta", "suffix": ""}, {"first": "J", "middle": [], "last": "De La Rubia", "suffix": ""}, {"first": "M.-J", "middle": [], "last": "Terol", "suffix": ""}, {"first": "A", "middle": [], "last": "Sureda", "suffix": ""}, {"first": "J", "middle": [], "last": "Bargay", "suffix": ""}, {"first": "P", "middle": [], "last": "Ribas", "suffix": ""}, {"first": "A", "middle": [], "last": "Alegre", "suffix": ""}, {"first": "F", "middle": [], "last": "De Arriba", "suffix": ""}, {"first": "A", "middle": [], "last": "Oriol", "suffix": ""}, {"first": "D", "middle": [], "last": "Carrera", "suffix": ""}, {"first": "J", "middle": [], "last": "Garc\u00eda-Lara\u00f1a", "suffix": ""}, {"first": "R", "middle": [], "last": "Garc\u00eda-Sanz", "suffix": ""}, {"first": "J", "middle": ["F"], "last": "\u2026 San Miguel", "suffix": ""}], "year": 2008, "venue": "Haematologica", "volume": "93", "issn": "4", "pages": "560--565", "other_ids": {"DOI": ["10.3324/haematol.12106"]}}, "BIBREF328": {"ref_id": "b328", "title": "Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study", "authors": [{"first": "Mar\u00eda-Victoria", "middle": [], "last": "Mateos", "suffix": ""}, {"first": "J.-M", "middle": [], "last": "Hern\u00e1ndez", "suffix": ""}, {"first": "M.-T", "middle": [], "last": "Hern\u00e1ndez", "suffix": ""}, {"first": "N.-C", "middle": [], "last": "Guti\u00e9rrez", "suffix": ""}, {"first": "L", "middle": [], "last": "Palomera", "suffix": ""}, {"first": "M", "middle": [], "last": "Fuertes", "suffix": ""}, {"first": "J", "middle": [], "last": "D\u00edaz-Mediavilla", "suffix": ""}, {"first": "J.-J", "middle": [], "last": "Lahuerta", "suffix": ""}, {"first": "J", "middle": [], "last": "De La Rubia", "suffix": ""}, {"first": "M.-J", "middle": [], "last": "Terol", "suffix": ""}, {"first": "A", "middle": [], "last": "Sureda", "suffix": ""}, {"first": "J", "middle": [], "last": "Bargay", "suffix": ""}, {"first": "P", "middle": [], "last": "Ribas", "suffix": ""}, {"first": "F", "middle": [], "last": "De Arriba", "suffix": ""}, {"first": "A", "middle": [], "last": "Alegre", "suffix": ""}, {"first": "A", "middle": [], "last": "Oriol", "suffix": ""}, {"first": "D", "middle": [], "last": "Carrera", "suffix": ""}, {"first": "J", "middle": [], "last": "Garc\u00eda-Lara\u00f1a", "suffix": ""}, {"first": "R", "middle": [], "last": "Garc\u00eda-Sanz", "suffix": ""}, {"first": "", "middle": [], "last": "San", "suffix": ""}], "year": 2006, "venue": "Blood", "volume": "108", "issn": "7", "pages": "2165--2172", "other_ids": {"DOI": ["10.1182/blood-2006-04-019778"]}}, "BIBREF329": {"ref_id": "b329", "title": "Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs", "authors": [{"first": "Mar\u00eda-Victoria", "middle": [], "last": "Mateos", "suffix": ""}, {"first": "T", "middle": [], "last": "Masszi", "suffix": ""}, {"first": "N", "middle": [], "last": "Grzasko", "suffix": ""}, {"first": "M", "middle": [], "last": "Hansson", "suffix": ""}, {"first": "I", "middle": [], "last": "Sandhu", "suffix": ""}, {"first": "L", "middle": [], "last": "Pour", "suffix": ""}, {"first": "L", "middle": [], "last": "Viterbo", "suffix": ""}, {"first": "S", "middle": ["R"], "last": "Jackson", "suffix": ""}, {"first": "A.-M", "middle": [], "last": "Stoppa", "suffix": ""}, {"first": "P", "middle": [], "last": "Gimsing", "suffix": ""}, {"first": "M", "middle": [], "last": "Hamadani", "suffix": ""}, {"first": "G", "middle": [], "last": "Borsaru", "suffix": ""}, {"first": "D", "middle": [], "last": "Berg", "suffix": ""}, {"first": "J", "middle": [], "last": "Lin", "suffix": ""}, {"first": "A", "middle": [], "last": "Di Bacco", "suffix": ""}, {"first": "H", "middle": [], "last": "Van De Velde", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}], "year": 2017, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF331": {"ref_id": "b331", "title": "Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial", "authors": [{"first": "Maria", "middle": ["-"], "last": "Mateos", "suffix": ""}, {"first": "", "middle": [], "last": "Victoria", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "R", "middle": [], "last": "Schlag", "suffix": ""}, {"first": "N", "middle": ["K"], "last": "Khuageva", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}, {"first": "O", "middle": [], "last": "Shpilberg", "suffix": ""}, {"first": "M", "middle": [], "last": "Kropff", "suffix": ""}, {"first": "I", "middle": [], "last": "Spicka", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Petrucci", "suffix": ""}, {"first": "A", "middle": [], "last": "Palumbo", "suffix": ""}, {"first": "O", "middle": ["S"], "last": "Samoilova", "suffix": ""}, {"first": "A", "middle": [], "last": "Dmoszynska", "suffix": ""}, {"first": "K", "middle": ["M"], "last": "Abdulkadyrov", "suffix": ""}, {"first": "R", "middle": [], "last": "Schots", "suffix": ""}, {"first": "B", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "D", "middle": ["L"], "last": "Esseltine", "suffix": ""}, {"first": "K", "middle": [], "last": "Liu", "suffix": ""}, {"first": "A", "middle": [], "last": "Cakana", "suffix": ""}, {"first": "H", "middle": [], "last": "Van De Velde", "suffix": ""}, {"first": "J", "middle": ["F"], "last": "San Miguel", "suffix": ""}], "year": 2010, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "28", "issn": "13", "pages": "2259--2266", "other_ids": {}}, "BIBREF333": {"ref_id": "b333", "title": "Chaperone-assisted assembly of the proteasome core particle", "authors": [{"first": "A", "middle": ["C"], "last": "Matias", "suffix": ""}, {"first": "P", "middle": ["C"], "last": "Ramos", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Dohmen", "suffix": ""}], "year": 2010, "venue": "Biochemical Society Transactions", "volume": "38", "issn": "", "pages": "29--33", "other_ids": {}}, "BIBREF335": {"ref_id": "b335", "title": "Proteasome (multicatalytic proteinase) of sea urchin sperm and its possible participation in the acrosome reaction", "authors": [{"first": "K", "middle": [], "last": "Matsumura", "suffix": ""}, {"first": "K", "middle": [], "last": "Aketa", "suffix": ""}], "year": 1991, "venue": "Molecular Reproduction Development", "volume": "29", "issn": "2", "pages": "189--199", "other_ids": {"DOI": ["10.1002/mrd.1080290215"]}}, "BIBREF336": {"ref_id": "b336", "title": "Neuroprotection by rat M\u00fcller glia against high glucose-induced neurodegeneration through a mechanism involving ERK1/2 activation", "authors": [{"first": "A", "middle": [], "last": "Matteucci", "suffix": ""}, {"first": "L", "middle": [], "last": "Gaddini", "suffix": ""}, {"first": "M", "middle": [], "last": "Villa", "suffix": ""}, {"first": "M", "middle": [], "last": "Varano", "suffix": ""}, {"first": "M", "middle": [], "last": "Parravano", "suffix": ""}, {"first": "V", "middle": [], "last": "Monteleone", "suffix": ""}, {"first": "F", "middle": [], "last": "Cavallo", "suffix": ""}, {"first": "L", "middle": [], "last": "Leo", "suffix": ""}, {"first": "C", "middle": [], "last": "Mallozzi", "suffix": ""}, {"first": "F", "middle": [], "last": "Malchiodi-Albedi", "suffix": ""}, {"first": "F", "middle": [], "last": "Pricci", "suffix": ""}], "year": 2014, "venue": "Experimental Eye Research", "volume": "125", "issn": "", "pages": "20--29", "other_ids": {"DOI": ["10.1016/j.exer.2014.05.011"]}}, "BIBREF337": {"ref_id": "b337", "title": "Aging and Neuronal Vulnerability", "authors": [{"first": "M", "middle": ["P"], "last": "Mattson", "suffix": ""}, {"first": "T", "middle": [], "last": "Magnus", "suffix": ""}], "year": 2006, "venue": "Nature Reviews. Neuroscience", "volume": "7", "issn": "4", "pages": "278--294", "other_ids": {"DOI": ["10.1038/nrn1886"]}}, "BIBREF338": {"ref_id": "b338", "title": "Conformational switching of the 26S proteasome enables substrate degradation", "authors": [{"first": "M", "middle": ["E"], "last": "Matyskiela", "suffix": ""}, {"first": "G", "middle": ["C"], "last": "Lander", "suffix": ""}, {"first": "A", "middle": [], "last": "Martin", "suffix": ""}], "year": 2013, "venue": "Nature Structural & Molecular Biology", "volume": "20", "issn": "7", "pages": "781--788", "other_ids": {"DOI": ["10.1038/nsmb.2616"]}}, "BIBREF339": {"ref_id": "b339", "title": "Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells", "authors": [{"first": "J", "middle": ["F"], "last": "Mayaux", "suffix": ""}, {"first": "A", "middle": [], "last": "Bousseau", "suffix": ""}, {"first": "R", "middle": [], "last": "Pauwels", "suffix": ""}, {"first": "T", "middle": [], "last": "Huet", "suffix": ""}, {"first": "Y", "middle": [], "last": "H\u00e9nin", "suffix": ""}, {"first": "N", "middle": [], "last": "Dereu", "suffix": ""}, {"first": "M", "middle": [], "last": "Evers", "suffix": ""}, {"first": "F", "middle": [], "last": "Soler", "suffix": ""}, {"first": "C", "middle": [], "last": "Poujade", "suffix": ""}, {"first": "E", "middle": [], "last": "De Clercq", "suffix": ""}, {"first": "J", "middle": ["B"], "last": "Le Pecq", "suffix": ""}], "year": 1994, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "91", "issn": "", "pages": "3564--3568", "other_ids": {"DOI": ["10.1073/pnas.91.9.3564"]}}, "BIBREF340": {"ref_id": "b340", "title": "Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases", "authors": [{"first": "L", "middle": [], "last": "Mcalary", "suffix": ""}, {"first": "S", "middle": ["S"], "last": "Plotkin", "suffix": ""}, {"first": "N", "middle": ["R"], "last": "Cashman", "suffix": ""}], "year": 2019, "venue": "CNS Drugs", "volume": "33", "issn": "9", "pages": "883--904", "other_ids": {}}, "BIBREF342": {"ref_id": "b342", "title": "The ubiquitin-proteasome system in neurodegeneration", "authors": [{"first": "C", "middle": [], "last": "Mckinnon", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Tabrizi", "suffix": ""}], "year": 2014, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF344": {"ref_id": "b344", "title": "Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures", "authors": [{"first": "K", "middle": ["S P"], "last": "Mcnaught", "suffix": ""}, {"first": "C", "middle": [], "last": "Mytilineou", "suffix": ""}, {"first": "R", "middle": [], "last": "Jnobaptiste", "suffix": ""}, {"first": "J", "middle": [], "last": "Yabut", "suffix": ""}, {"first": "P", "middle": [], "last": "Shashidharan", "suffix": ""}, {"first": "P", "middle": [], "last": "Jennert", "suffix": ""}, {"first": "C", "middle": ["W"], "last": "Olanow", "suffix": ""}], "year": 2002, "venue": "Journal of Neurochemistry", "volume": "81", "issn": "2", "pages": "301--306", "other_ids": {"DOI": ["10.1046/j.1471-4159.2002.00821.x"]}}, "BIBREF345": {"ref_id": "b345", "title": "Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease", "authors": [{"first": "K", "middle": ["S P"], "last": "Mcnaught", "suffix": ""}, {"first": "D", "middle": ["P"], "last": "Perl", "suffix": ""}, {"first": "A.-L", "middle": [], "last": "Brownell", "suffix": ""}, {"first": "C", "middle": ["W"], "last": "Olanow", "suffix": ""}], "year": 2004, "venue": "Annals of Neurology", "volume": "56", "issn": "1", "pages": "149--162", "other_ids": {"DOI": ["10.1002/ana.20186"]}}, "BIBREF346": {"ref_id": "b346", "title": "Retinal antigen-specific regulatory T cells protect against spontaneous and induced autoimmunity and require local dendritic cells", "authors": [{"first": "S", "middle": ["W"], "last": "Mcpherson", "suffix": ""}, {"first": "N", "middle": ["D"], "last": "Heuss", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Pierson", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Gregerson", "suffix": ""}], "year": 2014, "venue": "Journal of Neuroinflammation", "volume": "11", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1186/s12974-014-0205-4"]}}, "BIBREF347": {"ref_id": "b347", "title": "Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity", "authors": [{"first": "L", "middle": [], "last": "Meng", "suffix": ""}, {"first": "R", "middle": [], "last": "Mohan", "suffix": ""}, {"first": "B", "middle": ["H"], "last": "Kwok", "suffix": ""}, {"first": "M", "middle": [], "last": "Elofsson", "suffix": ""}, {"first": "N", "middle": [], "last": "Sin", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Crews", "suffix": ""}], "year": 1999, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "96", "issn": "", "pages": "10403--10408", "other_ids": {"DOI": ["10.1073/pnas.96.18.10403"]}}, "BIBREF348": {"ref_id": "b348", "title": "Coordination between proteasome impairment and caspase activation leading to TAU pathology: neuroprotection by cAMP", "authors": [{"first": "M", "middle": ["J"], "last": "Metcalfe", "suffix": ""}, {"first": "Q", "middle": [], "last": "Huang", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Figueiredo-Pereira", "suffix": ""}], "year": 2012, "venue": "Cell Death {&} Disease", "volume": "3", "issn": "6", "pages": "", "other_ids": {"DOI": ["10.1038/cddis.2012.70"]}}, "BIBREF349": {"ref_id": "b349", "title": "Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities", "authors": [{"first": "N", "middle": [], "last": "Micale", "suffix": ""}, {"first": "T", "middle": [], "last": "Schirmeister", "suffix": ""}, {"first": "R", "middle": [], "last": "Ettari", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Cinellu", "suffix": ""}, {"first": "L", "middle": [], "last": "Maiore", "suffix": ""}, {"first": "M", "middle": [], "last": "Serratrice", "suffix": ""}, {"first": "C", "middle": [], "last": "Gabbiani", "suffix": ""}, {"first": "L", "middle": [], "last": "Massai", "suffix": ""}, {"first": "L", "middle": [], "last": "Messori", "suffix": ""}], "year": 2014, "venue": "Journal of Inorganic Biochemistry", "volume": "141", "issn": "", "pages": "79--82", "other_ids": {"DOI": ["10.1016/j.jinorgbio.2014.08.001"]}}, "BIBREF350": {"ref_id": "b350", "title": "Differential Protein Expression Profiles in Glaucomatous Trabecular Meshwork: An Evaluation Study on a Small Primary Open Angle Glaucoma Population", "authors": [{"first": "A", "middle": [], "last": "Micera", "suffix": ""}, {"first": "L", "middle": [], "last": "Quaranta", "suffix": ""}, {"first": "G", "middle": [], "last": "Esposito", "suffix": ""}, {"first": "I", "middle": [], "last": "Floriani", "suffix": ""}, {"first": "A", "middle": [], "last": "Pocobelli", "suffix": ""}, {"first": "S", "middle": ["C"], "last": "Sacc\u00e0", "suffix": ""}, {"first": "I", "middle": [], "last": "Riva", "suffix": ""}, {"first": "G", "middle": [], "last": "Manni", "suffix": ""}, {"first": "F", "middle": [], "last": "Oddone", "suffix": ""}], "year": 2016, "venue": "Advances in Therapy", "volume": "33", "issn": "2", "pages": "252--267", "other_ids": {"DOI": ["10.1007/s12325-016-0285-x"]}}, "BIBREF351": {"ref_id": "b351", "title": "Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis", "authors": [{"first": "J", "middle": ["R"], "last": "Mikhael", "suffix": ""}, {"first": "S", "middle": ["R"], "last": "Schuster", "suffix": ""}, {"first": "V", "middle": ["H"], "last": "Jimenez-Zepeda", "suffix": ""}, {"first": "N", "middle": [], "last": "Bello", "suffix": ""}, {"first": "J", "middle": [], "last": "Spong", "suffix": ""}, {"first": "C", "middle": ["B"], "last": "Reeder", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Stewart", "suffix": ""}, {"first": "P", "middle": ["L"], "last": "Bergsagel", "suffix": ""}, {"first": "R", "middle": [], "last": "Fonseca", "suffix": ""}], "year": 2012, "venue": "Blood", "volume": "119", "issn": "19", "pages": "4391--4394", "other_ids": {"DOI": ["10.1182/blood-2011-11-390930"]}}, "BIBREF352": {"ref_id": "b352", "title": "Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington's disease", "authors": [{"first": "Y", "middle": [], "last": "Miki", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanji", "suffix": ""}, {"first": "F", "middle": [], "last": "Mori", "suffix": ""}, {"first": "K", "middle": [], "last": "Wakabayashi", "suffix": ""}], "year": 2015, "venue": "Neurobiology of Disease", "volume": "74", "issn": "", "pages": "25--31", "other_ids": {"DOI": ["10.1016/j.nbd.2014.11.005"]}}, "BIBREF353": {"ref_id": "b353", "title": "The measurement of protein synthesis for assessing proteostasis in studies of slowed aging", "authors": [{"first": "B", "middle": ["F"], "last": "Miller", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Drake", "suffix": ""}, {"first": "B", "middle": [], "last": "Naylor", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Price", "suffix": ""}, {"first": "K", "middle": ["L"], "last": "Hamilton", "suffix": ""}], "year": 2014, "venue": "Ageing Research Reviews", "volume": "18", "issn": "", "pages": "106--111", "other_ids": {"DOI": ["10.1016/j.arr.2014.09.005"]}}, "BIBREF354": {"ref_id": "b354", "title": "The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor", "authors": [{"first": "R", "middle": [], "last": "Minakshi", "suffix": ""}, {"first": "K", "middle": [], "last": "Padhan", "suffix": ""}, {"first": "M", "middle": [], "last": "Rani", "suffix": ""}, {"first": "N", "middle": [], "last": "Khan", "suffix": ""}, {"first": "F", "middle": [], "last": "Ahmad", "suffix": ""}, {"first": "S", "middle": [], "last": "Jameel", "suffix": ""}], "year": 2009, "venue": "PloS One", "volume": "4", "issn": "12", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0008342"]}}, "BIBREF355": {"ref_id": "b355", "title": "CCT2 Mutations Evoke Leber Congenital Amaurosis due to Chaperone Complex Instability", "authors": [{"first": "Y", "middle": [], "last": "Minegishi", "suffix": ""}, {"first": "X", "middle": [], "last": "Sheng", "suffix": ""}, {"first": "K", "middle": [], "last": "Yoshitake", "suffix": ""}, {"first": "Y", "middle": [], "last": "Sergeev", "suffix": ""}, {"first": "D", "middle": [], "last": "Iejima", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shibagaki", "suffix": ""}, {"first": "N", "middle": [], "last": "Monma", "suffix": ""}, {"first": "K", "middle": [], "last": "Ikeo", "suffix": ""}, {"first": "M", "middle": [], "last": "Furuno", "suffix": ""}, {"first": "W", "middle": [], "last": "Zhuang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Liu", "suffix": ""}, {"first": "W", "middle": [], "last": "Rong", "suffix": ""}, {"first": "S", "middle": [], "last": "Hattori", "suffix": ""}, {"first": "T", "middle": [], "last": "Iwata", "suffix": ""}], "year": 2016, "venue": "Scientific Reports", "volume": "6", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/srep33742"]}}, "BIBREF356": {"ref_id": "b356", "title": "Mechanisms of muscle wasting. The role of the ubiquitinproteasome pathway", "authors": [{"first": "W", "middle": ["E"], "last": "Mitch", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}], "year": 1996, "venue": "The New England Journal of Medicine", "volume": "335", "issn": "25", "pages": "1897--1905", "other_ids": {"DOI": ["10.1056/NEJM199612193352507"]}}, "BIBREF357": {"ref_id": "b357", "title": "The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications", "authors": [{"first": "N", "middle": [], "last": "Mitsiades", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Mitsiades", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "V", "middle": [], "last": "Poulaki", "suffix": ""}, {"first": "Y.-T", "middle": [], "last": "Tai", "suffix": ""}, {"first": "D", "middle": [], "last": "Chauhan", "suffix": ""}, {"first": "G", "middle": [], "last": "Fanourakis", "suffix": ""}, {"first": "X", "middle": [], "last": "Gu", "suffix": ""}, {"first": "C", "middle": [], "last": "Bailey", "suffix": ""}, {"first": "M", "middle": [], "last": "Joseph", "suffix": ""}, {"first": "T", "middle": ["A"], "last": "Libermann", "suffix": ""}, {"first": "R", "middle": [], "last": "Schlossman", "suffix": ""}, {"first": "N", "middle": ["C"], "last": "Munshi", "suffix": ""}, {"first": "T", "middle": [], "last": "Hideshima", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}], "year": 2003, "venue": "Blood", "volume": "101", "issn": "6", "pages": "2377--2380", "other_ids": {"DOI": ["10.1182/blood-2002-06-1768"]}}, "BIBREF358": {"ref_id": "b358", "title": "Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. The Lancet", "authors": [{"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "M", "middle": [], "last": "Attal", "suffix": ""}, {"first": "C", "middle": [], "last": "Hulin", "suffix": ""}, {"first": "B", "middle": [], "last": "Arnulf", "suffix": ""}, {"first": "K", "middle": [], "last": "Belhadj", "suffix": ""}, {"first": "L", "middle": [], "last": "Benboubker", "suffix": ""}, {"first": "M", "middle": ["C"], "last": "B\u00e9n\u00e9", "suffix": ""}, {"first": "A", "middle": [], "last": "Broijl", "suffix": ""}, {"first": "H", "middle": [], "last": "Caillon", "suffix": ""}, {"first": "D", "middle": [], "last": "Caillot", "suffix": ""}, {"first": "J", "middle": [], "last": "Corre", "suffix": ""}, {"first": "M", "middle": [], "last": "Delforge", "suffix": ""}, {"first": "T", "middle": [], "last": "Dejoie", "suffix": ""}, {"first": "C", "middle": [], "last": "Doyen", "suffix": ""}, {"first": "T", "middle": [], "last": "Facon", "suffix": ""}, {"first": "C", "middle": [], "last": "Sonntag", "suffix": ""}, {"first": "J", "middle": [], "last": "Fontan", "suffix": ""}, {"first": "L", "middle": [], "last": "Garderet", "suffix": ""}, {"first": "K.-S", "middle": [], "last": "Jie", "suffix": ""}, {"first": "P", "middle": [], "last": "Sonneveld", "suffix": ""}], "year": 2019, "venue": "", "volume": "394", "issn": "", "pages": "31240--31241", "other_ids": {"DOI": ["10.1016/S0140-6736(19"]}}, "BIBREF359": {"ref_id": "b359", "title": "Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma", "authors": [{"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "B", "middle": [], "last": "Kolb", "suffix": ""}, {"first": "M", "middle": [], "last": "Attal", "suffix": ""}, {"first": "D", "middle": [], "last": "Caillot", "suffix": ""}, {"first": "L", "middle": [], "last": "Benboubker", "suffix": ""}, {"first": "M", "middle": [], "last": "Tiab", "suffix": ""}, {"first": "C", "middle": [], "last": "Touzeau", "suffix": ""}, {"first": "X", "middle": [], "last": "Leleu", "suffix": ""}, {"first": "M", "middle": [], "last": "Roussel", "suffix": ""}, {"first": "C", "middle": [], "last": "Chaleteix", "suffix": ""}, {"first": "L", "middle": [], "last": "Planche", "suffix": ""}, {"first": "A", "middle": [], "last": "Chiffoleau", "suffix": ""}, {"first": "J", "middle": [], "last": "Fortin", "suffix": ""}, {"first": "H", "middle": [], "last": "Avet-Loiseau", "suffix": ""}, {"first": "J.-Y", "middle": [], "last": "Mary", "suffix": ""}, {"first": "C", "middle": [], "last": "Hulin", "suffix": ""}, {"first": "T", "middle": [], "last": "Facon", "suffix": ""}], "year": 2015, "venue": "Blood", "volume": "125", "issn": "20", "pages": "3100--3104", "other_ids": {"DOI": ["10.1182/blood-2015-02-626168"]}}, "BIBREF360": {"ref_id": "b360", "title": "Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized", "authors": [{"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "S", "middle": [], "last": "Kumar", "suffix": ""}, {"first": "R", "middle": [], "last": "Boccia", "suffix": ""}, {"first": "S", "middle": [], "last": "Iida", "suffix": ""}, {"first": "H", "middle": [], "last": "Goldschmidt", "suffix": ""}, {"first": "K", "middle": [], "last": "Cocks", "suffix": ""}, {"first": "A", "middle": [], "last": "Trigg", "suffix": ""}, {"first": "A", "middle": [], "last": "Zahlten-Kumeli", "suffix": ""}, {"first": "E", "middle": [], "last": "Yucel", "suffix": ""}, {"first": "S", "middle": ["S"], "last": "Panjabi", "suffix": ""}, {"first": "M", "middle": [], "last": "Dimopoulos", "suffix": ""}], "year": 2019, "venue": "A.R.R.O.W. study). Leukemia", "volume": "", "issn": "12", "pages": "2934--2946", "other_ids": {"DOI": ["10.1038/s41375-019-0480-2"]}}, "BIBREF361": {"ref_id": "b361", "title": "Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma", "authors": [{"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "T", "middle": [], "last": "Masszi", "suffix": ""}, {"first": "N", "middle": [], "last": "Grzasko", "suffix": ""}, {"first": "N", "middle": ["J"], "last": "Bahlis", "suffix": ""}, {"first": "M", "middle": [], "last": "Hansson", "suffix": ""}, {"first": "L", "middle": [], "last": "Pour", "suffix": ""}, {"first": "I", "middle": [], "last": "Sandhu", "suffix": ""}, {"first": "P", "middle": [], "last": "Ganly", "suffix": ""}, {"first": "B", "middle": ["W"], "last": "Baker", "suffix": ""}, {"first": "S", "middle": ["R"], "last": "Jackson", "suffix": ""}, {"first": "A.-M", "middle": [], "last": "Stoppa", "suffix": ""}, {"first": "D", "middle": ["R"], "last": "Simpson", "suffix": ""}, {"first": "P", "middle": [], "last": "Gimsing", "suffix": ""}, {"first": "A", "middle": [], "last": "Palumbo", "suffix": ""}, {"first": "L", "middle": [], "last": "Garderet", "suffix": ""}, {"first": "M", "middle": [], "last": "Cavo", "suffix": ""}, {"first": "S", "middle": [], "last": "Kumar", "suffix": ""}, {"first": "C", "middle": [], "last": "Touzeau", "suffix": ""}, {"first": "F", "middle": ["K"], "last": "Buadi", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}], "year": 2016, "venue": "New England Journal of Medicine", "volume": "374", "issn": "17", "pages": "1621--1634", "other_ids": {"DOI": ["10.1056/NEJMoa1516282"]}}, "BIBREF362": {"ref_id": "b362", "title": "Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma", "authors": [{"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "M.-V", "middle": [], "last": "Mateos", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Berenson", "suffix": ""}, {"first": "K", "middle": [], "last": "Weisel", "suffix": ""}, {"first": "A", "middle": [], "last": "Lazzaro", "suffix": ""}, {"first": "K", "middle": [], "last": "Song", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}, {"first": "M", "middle": [], "last": "Huang", "suffix": ""}, {"first": "A", "middle": [], "last": "Zahlten-Kumeli", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Stewart", "suffix": ""}], "year": 2018, "venue": "The Lancet. Oncology", "volume": "19", "issn": "7", "pages": "30354--30355", "other_ids": {"DOI": ["10.1016/S1470-2045"]}}, "BIBREF363": {"ref_id": "b363", "title": "Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study", "authors": [{"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "H", "middle": [], "last": "Pylypenko", "suffix": ""}, {"first": "S", "middle": [], "last": "Grosicki", "suffix": ""}, {"first": "I", "middle": [], "last": "Karamanesht", "suffix": ""}, {"first": "X", "middle": [], "last": "Leleu", "suffix": ""}, {"first": "M", "middle": [], "last": "Grishunina", "suffix": ""}, {"first": "G", "middle": [], "last": "Rekhtman", "suffix": ""}, {"first": "Z", "middle": [], "last": "Masliak", "suffix": ""}, {"first": "T", "middle": [], "last": "Robak", "suffix": ""}, {"first": "A", "middle": [], "last": "Shubina", "suffix": ""}, {"first": "B", "middle": [], "last": "Arnulf", "suffix": ""}, {"first": "M", "middle": [], "last": "Kropff", "suffix": ""}, {"first": "J", "middle": [], "last": "Cavet", "suffix": ""}, {"first": "D.-L", "middle": [], "last": "Esseltine", "suffix": ""}, {"first": "H", "middle": [], "last": "Feng", "suffix": ""}, {"first": "S", "middle": [], "last": "Girgis", "suffix": ""}, {"first": "H", "middle": [], "last": "Van De Velde", "suffix": ""}, {"first": "W", "middle": [], "last": "Deraedt", "suffix": ""}, {"first": "J.-L", "middle": [], "last": "Harousseau", "suffix": ""}], "year": 2011, "venue": "The Lancet. Oncology", "volume": "12", "issn": "5", "pages": "431--440", "other_ids": {"DOI": ["10.1016/S1470-2045(11)70081-X"]}}, "BIBREF364": {"ref_id": "b364", "title": "Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR", "authors": [{"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "K", "middle": ["A"], "last": "Stewart", "suffix": ""}, {"first": "M", "middle": [], "last": "Dimopoulos", "suffix": ""}, {"first": "D", "middle": [], "last": "Siegel", "suffix": ""}, {"first": "T", "middle": [], "last": "Facon", "suffix": ""}, {"first": "J", "middle": [], "last": "Berenson", "suffix": ""}, {"first": "N", "middle": [], "last": "Raje", "suffix": ""}, {"first": "J", "middle": ["G"], "last": "Berdeja", "suffix": ""}, {"first": "R", "middle": ["Z"], "last": "Orlowski", "suffix": ""}, {"first": "H", "middle": [], "last": "Yang", "suffix": ""}, {"first": "H", "middle": [], "last": "Ma", "suffix": ""}, {"first": "Z", "middle": [], "last": "Klippel", "suffix": ""}, {"first": "A", "middle": [], "last": "Zahlten-Kumeli", "suffix": ""}, {"first": "K", "middle": [], "last": "Mezzi", "suffix": ""}, {"first": "K", "middle": [], "last": "Iskander", "suffix": ""}, {"first": "M.-V", "middle": [], "last": "Mateos", "suffix": ""}], "year": null, "venue": "A.R.R.O.W., and CHAMPION-1 trials. Cancer Medicine", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF366": {"ref_id": "b366", "title": "KLICK syndrome: recognizable phenotype and hot-spot POMP mutation", "authors": [{"first": "F", "middle": [], "last": "Morice-Picard", "suffix": ""}, {"first": "N", "middle": [], "last": "Jonca", "suffix": ""}, {"first": "M", "middle": [], "last": "Pichery", "suffix": ""}, {"first": "D", "middle": [], "last": "Mermin", "suffix": ""}, {"first": "C", "middle": [], "last": "Leaut\u00e9-Labr\u00e8ze", "suffix": ""}, {"first": "A", "middle": [], "last": "Ta\u00efeb", "suffix": ""}, {"first": "J", "middle": [], "last": "Mazereeuw-Hautier", "suffix": ""}, {"first": "F", "middle": [], "last": "Boralevi", "suffix": ""}], "year": 2017, "venue": "Journal of the European Academy of Dermatology and Venereology: JEADV", "volume": "31", "issn": "3", "pages": "154--156", "other_ids": {"DOI": ["10.1111/jdv.13898"]}}, "BIBREF367": {"ref_id": "b367", "title": "Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging", "authors": [{"first": "R", "middle": ["I"], "last": "Morimoto", "suffix": ""}], "year": 2008, "venue": "Genes & Development", "volume": "22", "issn": "11", "pages": "1427--1438", "other_ids": {"DOI": ["10.1101/gad.1657108"]}}, "BIBREF368": {"ref_id": "b368", "title": "The effect of aging on the mineral status of female mice", "authors": [{"first": "A", "middle": [], "last": "Morita", "suffix": ""}, {"first": "M", "middle": [], "last": "Kimura", "suffix": ""}, {"first": "Y", "middle": [], "last": "Itokawa", "suffix": ""}], "year": 1994, "venue": "Biological Trace Element Research", "volume": "42", "issn": "2", "pages": "165--177", "other_ids": {"DOI": ["10.1007/BF02785387"]}}, "BIBREF369": {"ref_id": "b369", "title": "Proteasomes and Several Aspects of Their Heterogeneity Relevant to Cancer", "authors": [{"first": "A", "middle": ["V"], "last": "Morozov", "suffix": ""}, {"first": "V", "middle": ["L"], "last": "Karpov", "suffix": ""}], "year": 2019, "venue": "Frontiers in Oncology", "volume": "9", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3389/fonc.2019.00761"]}}, "BIBREF370": {"ref_id": "b370", "title": "Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice", "authors": [{"first": "M", "middle": [], "last": "Morris", "suffix": ""}, {"first": "G", "middle": ["M"], "last": "Knudsen", "suffix": ""}, {"first": "S", "middle": [], "last": "Maeda", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Trinidad", "suffix": ""}, {"first": "A", "middle": [], "last": "Ioanoviciu", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Burlingame", "suffix": ""}, {"first": "L", "middle": [], "last": "Mucke", "suffix": ""}], "year": 2015, "venue": "Nature Neuroscience", "volume": "18", "issn": "8", "pages": "1183--1189", "other_ids": {"DOI": ["10.1038/nn.4067"]}}, "BIBREF371": {"ref_id": "b371", "title": "The Parkinson's-associated protein DJ-1 regulates the 20S proteasome", "authors": [{"first": "O", "middle": [], "last": "Moscovitz", "suffix": ""}, {"first": "G", "middle": [], "last": "Ben-Nissan", "suffix": ""}, {"first": "I", "middle": [], "last": "Fainer", "suffix": ""}, {"first": "D", "middle": [], "last": "Pollack", "suffix": ""}, {"first": "L", "middle": [], "last": "Mizrachi", "suffix": ""}, {"first": "M", "middle": [], "last": "Sharon", "suffix": ""}], "year": 2015, "venue": "Nature Communications", "volume": "6", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/ncomms7609"]}}, "BIBREF372": {"ref_id": "b372", "title": "Betulinic acid, a natural compound with potent anticancer effects", "authors": [{"first": "F", "middle": ["B"], "last": "Mullauer", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Kessler", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Medema", "suffix": ""}], "year": 2010, "venue": "Anticancer Drugs", "volume": "21", "issn": "3", "pages": "215--227", "other_ids": {}}, "BIBREF374": {"ref_id": "b374", "title": "Modulation of protein quality control systems by food phytochemicals", "authors": [{"first": "A", "middle": [], "last": "Murakami", "suffix": ""}], "year": 2013, "venue": "Journal of Clinical Biochemistry and Nutrition", "volume": "52", "issn": "3", "pages": "215--227", "other_ids": {"DOI": ["10.3164/jcbn.12-126"]}}, "BIBREF375": {"ref_id": "b375", "title": "Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination", "authors": [{"first": "Y", "middle": [], "last": "Murakami", "suffix": ""}, {"first": "S", "middle": [], "last": "Matsufuji", "suffix": ""}, {"first": "T", "middle": [], "last": "Kameji", "suffix": ""}, {"first": "S", "middle": [], "last": "Hayashi", "suffix": ""}, {"first": "K", "middle": [], "last": "Igarashi", "suffix": ""}, {"first": "T", "middle": [], "last": "Tamura", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "A", "middle": [], "last": "Ichihara", "suffix": ""}], "year": 1992, "venue": "Nature", "volume": "360", "issn": "6404", "pages": "597--599", "other_ids": {"DOI": ["10.1038/360597a0"]}}, "BIBREF376": {"ref_id": "b376", "title": "Regulation of CD8+ T cell development by thymus-specific proteasomes", "authors": [{"first": "S", "middle": [], "last": "Murata", "suffix": ""}, {"first": "K", "middle": [], "last": "Sasaki", "suffix": ""}, {"first": "T", "middle": [], "last": "Kishimoto", "suffix": ""}, {"first": "S.-I", "middle": [], "last": "Niwa", "suffix": ""}, {"first": "H", "middle": [], "last": "Hayashi", "suffix": ""}, {"first": "Y", "middle": [], "last": "Takahama", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}], "year": 2007, "venue": "Science", "volume": "", "issn": "5829", "pages": "1349--1353", "other_ids": {"DOI": ["10.1126/science.1141915"]}}, "BIBREF377": {"ref_id": "b377", "title": "The immunoproteasome and thymoproteasome: functions, evolution and human disease", "authors": [{"first": "S", "middle": [], "last": "Murata", "suffix": ""}, {"first": "Y", "middle": [], "last": "Takahama", "suffix": ""}, {"first": "M", "middle": [], "last": "Kasahara", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}], "year": 2018, "venue": "Nature Immunology", "volume": "19", "issn": "9", "pages": "923--931", "other_ids": {"DOI": ["10.1038/s41590-018-0186-z"]}}, "BIBREF378": {"ref_id": "b378", "title": "Immunoproteasome assembly and antigen presentation in mice lacking both PA28\u03b1 and PA28\u03b2", "authors": [{"first": "S", "middle": [], "last": "Murata", "suffix": ""}, {"first": "H", "middle": [], "last": "Udono", "suffix": ""}, {"first": "N", "middle": [], "last": "Tanahashi", "suffix": ""}, {"first": "N", "middle": [], "last": "Hamada", "suffix": ""}, {"first": "K", "middle": [], "last": "Watanabe", "suffix": ""}, {"first": "K", "middle": [], "last": "Adachi", "suffix": ""}, {"first": "T", "middle": [], "last": "Yamano", "suffix": ""}, {"first": "K", "middle": [], "last": "Yui", "suffix": ""}, {"first": "N", "middle": [], "last": "Kobayashi", "suffix": ""}, {"first": "M", "middle": [], "last": "Kasahara", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "T", "middle": [], "last": "Chiba", "suffix": ""}], "year": 2001, "venue": "The EMBO Journal", "volume": "20", "issn": "21", "pages": "5898--5907", "other_ids": {"DOI": ["10.1093/emboj/20.21.5898"]}}, "BIBREF379": {"ref_id": "b379", "title": "Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Design", "authors": [{"first": "B", "middle": [], "last": "Muz", "suffix": ""}, {"first": "R", "middle": ["N"], "last": "Ghazarian", "suffix": ""}, {"first": "M", "middle": [], "last": "Ou", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Luderer", "suffix": ""}, {"first": "H", "middle": ["D"], "last": "Kusdono", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Azab", "suffix": ""}], "year": 2016, "venue": "Development and Therapy", "volume": "10", "issn": "", "pages": "217--226", "other_ids": {"DOI": ["10.2147/DDDT.S93602"]}}, "BIBREF380": {"ref_id": "b380", "title": "Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases", "authors": [{"first": "N", "middle": [], "last": "Myeku", "suffix": ""}, {"first": "K", "middle": ["E"], "last": "Duff", "suffix": ""}], "year": 2018, "venue": "Trends in Molecular Medicine", "volume": "24", "issn": "1", "pages": "18--29", "other_ids": {}}, "BIBREF382": {"ref_id": "b382", "title": "Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling", "authors": [{"first": "N", "middle": [], "last": "Myeku", "suffix": ""}, {"first": "C", "middle": ["L"], "last": "Clelland", "suffix": ""}, {"first": "S", "middle": [], "last": "Emrani", "suffix": ""}, {"first": "N", "middle": ["V"], "last": "Kukushkin", "suffix": ""}, {"first": "W", "middle": ["H"], "last": "Yu", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}, {"first": "K", "middle": ["E"], "last": "Duff", "suffix": ""}], "year": 2016, "venue": "Nature Medicine", "volume": "22", "issn": "1", "pages": "46--53", "other_ids": {"DOI": ["10.1038/nm.4011"]}}, "BIBREF383": {"ref_id": "b383", "title": "Lack of proteasome active site allostery as revealed by subunit-specific inhibitors", "authors": [{"first": "J", "middle": [], "last": "Myung", "suffix": ""}, {"first": "K", "middle": ["B"], "last": "Kim", "suffix": ""}, {"first": "K", "middle": [], "last": "Lindsten", "suffix": ""}, {"first": "N", "middle": ["P"], "last": "Dantuma", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Crews", "suffix": ""}], "year": 2001, "venue": "Molecular Cell", "volume": "7", "issn": "2", "pages": "411--420", "other_ids": {"DOI": ["10.1016/s1097-2765(01)00188-5"]}}, "BIBREF384": {"ref_id": "b384", "title": "Light exposure induces ubiquitin conjugation and degradation activities in the rat retina", "authors": [{"first": "M", "middle": ["I"], "last": "Naash", "suffix": ""}, {"first": "M", "middle": ["R"], "last": "Al-Ubaidi", "suffix": ""}, {"first": "R", "middle": ["E"], "last": "Anderson", "suffix": ""}], "year": 1997, "venue": "Investigative Ophthalmology & Visual Science", "volume": "38", "issn": "11", "pages": "2344--2354", "other_ids": {}}, "BIBREF385": {"ref_id": "b385", "title": "Ultrastructure of the human retina in aging and various pathological states", "authors": [{"first": "T", "middle": ["C"], "last": "Nag", "suffix": ""}, {"first": "S", "middle": [], "last": "Wadhwa", "suffix": ""}], "year": 1993, "venue": "Micron", "volume": "43", "issn": "7", "pages": "759--781", "other_ids": {}}, "BIBREF387": {"ref_id": "b387", "title": "Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance", "authors": [{"first": "S", "middle": [], "last": "Narayanan", "suffix": ""}, {"first": "C.-Y", "middle": [], "last": "Cai", "suffix": ""}, {"first": "Y", "middle": ["G"], "last": "Assaraf", "suffix": ""}, {"first": "H.-Q", "middle": [], "last": "Guo", "suffix": ""}, {"first": "Q", "middle": [], "last": "Cui", "suffix": ""}, {"first": "L", "middle": [], "last": "Wei", "suffix": ""}, {"first": "J.-J", "middle": [], "last": "Huang", "suffix": ""}, {"first": "C", "middle": ["R"], "last": "Ashby", "suffix": ""}, {"first": "Z.-S", "middle": [], "last": "Chen", "suffix": ""}], "year": 2020, "venue": "Drug Resistance Updates", "volume": "48", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.drup.2019.100663"]}}, "BIBREF388": {"ref_id": "b388", "title": "Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance", "authors": [{"first": "S", "middle": [], "last": "Narayanan", "suffix": ""}, {"first": "C.-Y", "middle": [], "last": "Cai", "suffix": ""}, {"first": "Y", "middle": ["G"], "last": "Assaraf", "suffix": ""}, {"first": "H.-Q", "middle": [], "last": "Guo", "suffix": ""}, {"first": "Q", "middle": [], "last": "Cui", "suffix": ""}, {"first": "L", "middle": [], "last": "Wei", "suffix": ""}, {"first": "J.-J", "middle": [], "last": "Huang", "suffix": ""}, {"first": "C", "middle": ["R"], "last": "Ashby", "suffix": ""}, {"first": "Z.-S", "middle": [], "last": "Chen", "suffix": ""}], "year": 2020, "venue": "Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy", "volume": "48", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.drup.2019.100663"]}}, "BIBREF389": {"ref_id": "b389", "title": "Endoplasmic reticulum stress activates autophagy but not the proteasome in neuronal cells: implications for Alzheimer's disease", "authors": [{"first": "D", "middle": ["A T"], "last": "Nijholt", "suffix": ""}, {"first": "T", "middle": ["R"], "last": "De Graaf", "suffix": ""}, {"first": "E", "middle": ["S"], "last": "Van Haastert", "suffix": ""}, {"first": "A", "middle": ["O"], "last": "Oliveira", "suffix": ""}, {"first": "C", "middle": ["R"], "last": "Berkers", "suffix": ""}, {"first": "R", "middle": [], "last": "Zwart", "suffix": ""}, {"first": "H", "middle": [], "last": "Ovaa", "suffix": ""}, {"first": "F", "middle": [], "last": "Baas", "suffix": ""}, {"first": "J", "middle": ["J M"], "last": "Hoozemans", "suffix": ""}, {"first": "W", "middle": [], "last": "Scheper", "suffix": ""}], "year": 2011, "venue": "Cell Death and Differentiation", "volume": "18", "issn": "6", "pages": "1071--1081", "other_ids": {"DOI": ["10.1038/cdd.2010.176"]}}, "BIBREF390": {"ref_id": "b390", "title": "DJ-1-binding compound B enhances Nrf2 activity through the PI3-kinase-Akt pathway by DJ-1-dependent inactivation of PTEN", "authors": [{"first": "T", "middle": [], "last": "Niki", "suffix": ""}, {"first": "J", "middle": [], "last": "Endo", "suffix": ""}, {"first": "K", "middle": [], "last": "Takahashi-Niki", "suffix": ""}, {"first": "T", "middle": [], "last": "Yasuda", "suffix": ""}, {"first": "A", "middle": [], "last": "Okamoto", "suffix": ""}, {"first": "Y", "middle": [], "last": "Saito", "suffix": ""}, {"first": "H", "middle": [], "last": "Ariga", "suffix": ""}, {"first": "S", "middle": ["M M"], "last": "Iguchi-Ariga", "suffix": ""}], "year": 2020, "venue": "Brain Research", "volume": "1729", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.brainres.2019.146641"]}}, "BIBREF391": {"ref_id": "b391", "title": "Thymoproteasome shapes immunocompetent repertoire of CD8+ T cells", "authors": [{"first": "T", "middle": [], "last": "Nitta", "suffix": ""}, {"first": "S", "middle": [], "last": "Murata", "suffix": ""}, {"first": "K", "middle": [], "last": "Sasaki", "suffix": ""}, {"first": "H", "middle": [], "last": "Fujii", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Ripen", "suffix": ""}, {"first": "N", "middle": [], "last": "Ishimaru", "suffix": ""}, {"first": "S", "middle": [], "last": "Koyasu", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "Y", "middle": [], "last": "Takahama", "suffix": ""}], "year": 2010, "venue": "Immunity", "volume": "32", "issn": "1", "pages": "29--40", "other_ids": {"DOI": ["10.1016/j.immuni.2009.10.009"]}}, "BIBREF392": {"ref_id": "b392", "title": "Can you teach old drugs new tricks?", "authors": [{"first": "N", "middle": [], "last": "Nosengo", "suffix": ""}], "year": 2016, "venue": "Nature", "volume": "534", "issn": "7607", "pages": "314--316", "other_ids": {"DOI": ["10.1038/534314a"]}}, "BIBREF393": {"ref_id": "b393", "title": "Proteasome Inhibitors: Structure and Function", "authors": [{"first": "A", "middle": ["T"], "last": "Nunes", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Annunziata", "suffix": ""}], "year": 2017, "venue": "Seminars in Oncology", "volume": "44", "issn": "6", "pages": "377--380", "other_ids": {"DOI": ["10.1053/j.seminoncol.2018.01.004"]}}, "BIBREF394": {"ref_id": "b394", "title": "Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update", "authors": [{"first": "K", "middle": [], "last": "Nuytemans", "suffix": ""}, {"first": "J", "middle": [], "last": "Theuns", "suffix": ""}, {"first": "M", "middle": [], "last": "Cruts", "suffix": ""}, {"first": "C", "middle": [], "last": "Van Broeckhoven", "suffix": ""}], "year": 2010, "venue": "Human Mutation", "volume": "", "issn": "7", "pages": "763--780", "other_ids": {"DOI": ["10.1002/humu.21277"]}}, "BIBREF395": {"ref_id": "b395", "title": "Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial", "authors": [{"first": "O", "middle": ["A"], "last": "O&apos;connor", "suffix": ""}, {"first": "C", "middle": [], "last": "Moskowitz", "suffix": ""}, {"first": "C", "middle": [], "last": "Portlock", "suffix": ""}, {"first": "P", "middle": [], "last": "Hamlin", "suffix": ""}, {"first": "D", "middle": [], "last": "Straus", "suffix": ""}, {"first": "O", "middle": [], "last": "Dumitrescu", "suffix": ""}, {"first": "D", "middle": [], "last": "Sarasohn", "suffix": ""}, {"first": "M", "middle": [], "last": "Gonen", "suffix": ""}, {"first": "J", "middle": [], "last": "Butos", "suffix": ""}, {"first": "E", "middle": [], "last": "Neylon", "suffix": ""}, {"first": "R", "middle": [], "last": "Hamelers", "suffix": ""}, {"first": "", "middle": [], "last": "Mac-Gregor", "suffix": ""}, {"first": "B", "middle": [], "last": "Cortelli", "suffix": ""}, {"first": "S", "middle": [], "last": "Blumel", "suffix": ""}, {"first": "A", "middle": ["D"], "last": "Zelenetz", "suffix": ""}, {"first": "L", "middle": [], "last": "Gordon", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Wright", "suffix": ""}, {"first": "J", "middle": [], "last": "Vose", "suffix": ""}, {"first": "B", "middle": [], "last": "Cooper", "suffix": ""}, {"first": "J", "middle": [], "last": "Winter", "suffix": ""}], "year": 2009, "venue": "British Journal of Haematology", "volume": "145", "issn": "1", "pages": "34--39", "other_ids": {"DOI": ["10.1111/j.1365-2141.2008.07466.x"]}}, "BIBREF396": {"ref_id": "b396", "title": "A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies", "authors": [{"first": "O", "middle": ["A"], "last": "O&apos;connor", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Stewart", "suffix": ""}, {"first": "M", "middle": [], "last": "Vallone", "suffix": ""}, {"first": "C", "middle": ["J"], "last": "Molineaux", "suffix": ""}, {"first": "L", "middle": ["A"], "last": "Kunkel", "suffix": ""}, {"first": "J", "middle": ["F"], "last": "Gerecitano", "suffix": ""}, {"first": "R", "middle": ["Z"], "last": "Orlowski", "suffix": ""}], "year": 2009, "venue": "Clinical Cancer Research: An Official Journal of the American Association for Cancer Research", "volume": "15", "issn": "22", "pages": "7085--7091", "other_ids": {"DOI": ["10.1158/1078-0432.CCR-09-0822"]}}, "BIBREF397": {"ref_id": "b397", "title": "Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma", "authors": [{"first": "O", "middle": ["A"], "last": "O&apos;connor", "suffix": ""}, {"first": "J", "middle": [], "last": "Wright", "suffix": ""}, {"first": "C", "middle": [], "last": "Moskowitz", "suffix": ""}, {"first": "J", "middle": [], "last": "Muzzy", "suffix": ""}, {"first": "B", "middle": [], "last": "Macgregor-Cortelli", "suffix": ""}, {"first": "M", "middle": [], "last": "Stubblefield", "suffix": ""}, {"first": "D", "middle": [], "last": "Straus", "suffix": ""}, {"first": "C", "middle": [], "last": "Portlock", "suffix": ""}, {"first": "P", "middle": [], "last": "Hamlin", "suffix": ""}, {"first": "E", "middle": [], "last": "Choi", "suffix": ""}, {"first": "O", "middle": [], "last": "Dumetrescu", "suffix": ""}, {"first": "D", "middle": [], "last": "Esseltine", "suffix": ""}, {"first": "E", "middle": [], "last": "Trehu", "suffix": ""}, {"first": "J", "middle": [], "last": "Adams", "suffix": ""}, {"first": "D", "middle": [], "last": "Schenkein", "suffix": ""}, {"first": "A", "middle": ["D"], "last": "Zelenetz", "suffix": ""}], "year": 2005, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "23", "issn": "4", "pages": "676--684", "other_ids": {"DOI": ["10.1200/JCO.2005.02.050"]}}, "BIBREF398": {"ref_id": "b398", "title": "Macular versus Retinal Nerve Fiber Layer Parameters for Diagnosing Manifest Glaucoma: A Systematic Review of Diagnostic Accuracy Studies", "authors": [{"first": "F", "middle": [], "last": "Oddone", "suffix": ""}, {"first": "E", "middle": [], "last": "Lucenteforte", "suffix": ""}, {"first": "M", "middle": [], "last": "Michelessi", "suffix": ""}, {"first": "S", "middle": [], "last": "Rizzo", "suffix": ""}, {"first": "S", "middle": [], "last": "Donati", "suffix": ""}, {"first": "M", "middle": [], "last": "Parravano", "suffix": ""}, {"first": "G", "middle": [], "last": "Virgili", "suffix": ""}], "year": 2016, "venue": "Ophthalmology", "volume": "123", "issn": "5", "pages": "939--949", "other_ids": {"DOI": ["10.1016/j.ophtha.2015.12.041"]}}, "BIBREF399": {"ref_id": "b399", "title": "Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein", "authors": [{"first": "R", "middle": [], "last": "Oerlemans", "suffix": ""}, {"first": "N", "middle": ["E"], "last": "Franke", "suffix": ""}, {"first": "Y", "middle": ["G"], "last": "Assaraf", "suffix": ""}, {"first": "J", "middle": [], "last": "Cloos", "suffix": ""}, {"first": "I", "middle": [], "last": "Van Zantwijk", "suffix": ""}, {"first": "C", "middle": ["R"], "last": "Berkers", "suffix": ""}, {"first": "G", "middle": ["L"], "last": "Scheffer", "suffix": ""}, {"first": "K", "middle": [], "last": "Debipersad", "suffix": ""}, {"first": "K", "middle": [], "last": "Vojtekova", "suffix": ""}, {"first": "C", "middle": [], "last": "Lemos", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Van Der Heijden", "suffix": ""}, {"first": "B", "middle": [], "last": "Ylstra", "suffix": ""}, {"first": "G", "middle": ["J"], "last": "Peters", "suffix": ""}, {"first": "G", "middle": ["L"], "last": "Kaspers", "suffix": ""}, {"first": "B", "middle": ["A C"], "last": "Dijkmans", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Scheper", "suffix": ""}, {"first": "G", "middle": [], "last": "Jansen", "suffix": ""}], "year": 2008, "venue": "Blood", "volume": "112", "issn": "6", "pages": "2489--2499", "other_ids": {"DOI": ["10.1182/blood-2007-08-104950"]}}, "BIBREF400": {"ref_id": "b400", "title": "An evidencebased review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma", "authors": [{"first": "M", "middle": [], "last": "Offidani", "suffix": ""}, {"first": "L", "middle": [], "last": "Corvatta", "suffix": ""}, {"first": "P", "middle": [], "last": "Caraffa", "suffix": ""}, {"first": "S", "middle": [], "last": "Gentili", "suffix": ""}, {"first": "L", "middle": [], "last": "Maracci", "suffix": ""}, {"first": "P", "middle": [], "last": "Leoni", "suffix": ""}], "year": 2014, "venue": "OncoTargets and Therapy", "volume": "7", "issn": "", "pages": "1793--1800", "other_ids": {"DOI": ["10.2147/OTT.S49187"]}}, "BIBREF401": {"ref_id": "b401", "title": "Synthesis and biological evaluation of thielocin B1 analogues as protein-protein interaction inhibitors of PAC3 homodimer", "authors": [{"first": "K", "middle": [], "last": "Ohsawa", "suffix": ""}, {"first": "M", "middle": [], "last": "Yoshida", "suffix": ""}, {"first": "M", "middle": [], "last": "Izumikawa", "suffix": ""}, {"first": "M", "middle": [], "last": "Takagi", "suffix": ""}, {"first": "K", "middle": [], "last": "Shin-Ya", "suffix": ""}, {"first": "N", "middle": [], "last": "Goshima", "suffix": ""}, {"first": "T", "middle": [], "last": "Hirokawa", "suffix": ""}, {"first": "T", "middle": [], "last": "Natsume", "suffix": ""}, {"first": "T", "middle": [], "last": "Doi", "suffix": ""}], "year": 2018, "venue": "Bioorganic & Medicinal Chemistry", "volume": "26", "issn": "", "pages": "6023--6034", "other_ids": {"DOI": ["10.1016/j.bmc.2018.11.001"]}}, "BIBREF402": {"ref_id": "b402", "title": "p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria", "authors": [{"first": "K", "middle": [], "last": "Okatsu", "suffix": ""}, {"first": "K", "middle": [], "last": "Saisho", "suffix": ""}, {"first": "M", "middle": [], "last": "Shimanuki", "suffix": ""}, {"first": "K", "middle": [], "last": "Nakada", "suffix": ""}, {"first": "H", "middle": [], "last": "Shitara", "suffix": ""}, {"first": "Y", "middle": [], "last": "Sou", "suffix": ""}, {"first": "M", "middle": [], "last": "Kimura", "suffix": ""}, {"first": "S", "middle": [], "last": "Sato", "suffix": ""}, {"first": "N", "middle": [], "last": "Hattori", "suffix": ""}, {"first": "M", "middle": [], "last": "Komatsu", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "N", "middle": [], "last": "Matsuda", "suffix": ""}], "year": 2010, "venue": "Genes to Cells", "volume": "15", "issn": "8", "pages": "887--900", "other_ids": {"DOI": ["10.1111/j.1365-2443.2010.01426.x"]}}, "BIBREF403": {"ref_id": "b403", "title": "Proteasome inhibitors for multiple myeloma", "authors": [{"first": "K", "middle": [], "last": "Okazuka", "suffix": ""}, {"first": "T", "middle": [], "last": "Ishida", "suffix": ""}], "year": 2018, "venue": "Japanese Journal of Clinical Oncology", "volume": "48", "issn": "9", "pages": "785--793", "other_ids": {"DOI": ["10.1093/jjco/hyy108"]}}, "BIBREF404": {"ref_id": "b404", "title": "Posttranslational modifications and proteinopathies: how guardians of the proteome are defeated", "authors": [{"first": "H", "middle": [], "last": "Olzscha", "suffix": ""}], "year": 2019, "venue": "Biological Chemistry", "volume": "400", "issn": "7", "pages": "895--915", "other_ids": {"DOI": ["10.1515/hsz-2018-0458"]}}, "BIBREF405": {"ref_id": "b405", "title": "Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions", "authors": [{"first": "H", "middle": [], "last": "Olzscha", "suffix": ""}, {"first": "S", "middle": ["M"], "last": "Schermann", "suffix": ""}, {"first": "A", "middle": ["C"], "last": "Woerner", "suffix": ""}, {"first": "S", "middle": [], "last": "Pinkert", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Hecht", "suffix": ""}, {"first": "G", "middle": ["G"], "last": "Tartaglia", "suffix": ""}, {"first": "M", "middle": [], "last": "Vendruscolo", "suffix": ""}, {"first": "M", "middle": [], "last": "Hayer-Hartl", "suffix": ""}, {"first": "F", "middle": ["U"], "last": "Hartl", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Vabulas", "suffix": ""}], "year": 2011, "venue": "Cell", "volume": "144", "issn": "1", "pages": "67--78", "other_ids": {"DOI": ["10.1016/j.cell.2010.11.050"]}}, "BIBREF406": {"ref_id": "b406", "title": "Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2)", "authors": [{"first": "C", "middle": [], "last": "Opazo", "suffix": ""}, {"first": "X", "middle": [], "last": "Huang", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Cherny", "suffix": ""}, {"first": "R", "middle": ["D"], "last": "Moir", "suffix": ""}, {"first": "A", "middle": ["E"], "last": "Roher", "suffix": ""}, {"first": "A", "middle": ["R"], "last": "White", "suffix": ""}, {"first": "R", "middle": [], "last": "Cappai", "suffix": ""}, {"first": "C", "middle": ["L"], "last": "Masters", "suffix": ""}, {"first": "R", "middle": ["E"], "last": "Tanzi", "suffix": ""}, {"first": "N", "middle": ["C"], "last": "Inestrosa", "suffix": ""}, {"first": "A", "middle": ["I"], "last": "Bush", "suffix": ""}], "year": 2002, "venue": "The Journal of Biological Chemistry", "volume": "277", "issn": "43", "pages": "40302--40308", "other_ids": {"DOI": ["10.1074/jbc.M206428200"]}}, "BIBREF407": {"ref_id": "b407", "title": "Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma", "authors": [{"first": "E", "middle": [], "last": "Orciuolo", "suffix": ""}, {"first": "G", "middle": [], "last": "Buda", "suffix": ""}, {"first": "M", "middle": [], "last": "Pelosini", "suffix": ""}, {"first": "M", "middle": [], "last": "Petrini", "suffix": ""}], "year": 2010, "venue": "British Journal of Haematology", "volume": "148", "issn": "5", "pages": "810--812", "other_ids": {"DOI": ["10.1111/j.1365-2141.2009.07998.x"]}}, "BIBREF408": {"ref_id": "b408", "title": "A multicatalytic protease complex from pituitary that forms enkephalin and enkephalin containing peptides", "authors": [{"first": "M", "middle": [], "last": "Orlowski", "suffix": ""}, {"first": "S", "middle": [], "last": "Wilk", "suffix": ""}], "year": null, "venue": "Biochemical and Biophysical Research Communications", "volume": "101", "issn": "3", "pages": "814--822", "other_ids": {"DOI": ["10.1016/0006-291x(81)91823-4"]}}, "BIBREF409": {"ref_id": "b409", "title": "Regulation of the Peptidylglutamyl-Peptide Hydrolyzing Activity of the Pituitary Multicatalytic Proteinase Complex", "authors": [{"first": "M", "middle": [], "last": "Orlowski", "suffix": ""}, {"first": "C", "middle": [], "last": "Cardozo", "suffix": ""}, {"first": "M", "middle": ["C"], "last": "Hidalgo", "suffix": ""}, {"first": "C", "middle": [], "last": "Michaud", "suffix": ""}], "year": 1991, "venue": "Biochemistry", "volume": "30", "issn": "24", "pages": "5999--6005", "other_ids": {"DOI": ["10.1021/bi00238a025"]}}, "BIBREF410": {"ref_id": "b410", "title": "Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma", "authors": [{"first": "R", "middle": ["Z"], "last": "Orlowski", "suffix": ""}, {"first": "A", "middle": [], "last": "Nagler", "suffix": ""}, {"first": "P", "middle": [], "last": "Sonneveld", "suffix": ""}, {"first": "J", "middle": [], "last": "Blad\u00e9", "suffix": ""}, {"first": "R", "middle": [], "last": "Hajek", "suffix": ""}, {"first": "A", "middle": [], "last": "Spencer", "suffix": ""}, {"first": "T", "middle": [], "last": "Robak", "suffix": ""}, {"first": "A", "middle": [], "last": "Dmoszynska", "suffix": ""}, {"first": "N", "middle": [], "last": "Horvath", "suffix": ""}, {"first": "I", "middle": [], "last": "Spicka", "suffix": ""}, {"first": "H", "middle": ["J"], "last": "Sutherland", "suffix": ""}, {"first": "A", "middle": ["N"], "last": "Suvorov", "suffix": ""}, {"first": "L", "middle": [], "last": "Xiu", "suffix": ""}, {"first": "A", "middle": [], "last": "Cakana", "suffix": ""}, {"first": "T", "middle": [], "last": "Parekh", "suffix": ""}, {"first": "J", "middle": ["F"], "last": "San-Miguel", "suffix": ""}], "year": 2016, "venue": "Cancer", "volume": "122", "issn": "13", "pages": "2050--2056", "other_ids": {}}, "BIBREF413": {"ref_id": "b413", "title": "Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies", "authors": [{"first": "R", "middle": ["Z"], "last": "Orlowski", "suffix": ""}, {"first": "T", "middle": ["E"], "last": "Stinchcombe", "suffix": ""}, {"first": "B", "middle": ["S"], "last": "Mitchell", "suffix": ""}, {"first": "T", "middle": ["C"], "last": "Shea", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Baldwin", "suffix": ""}, {"first": "S", "middle": [], "last": "Stahl", "suffix": ""}, {"first": "J", "middle": [], "last": "Adams", "suffix": ""}, {"first": "D.-L", "middle": [], "last": "Esseltine", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Elliott", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Pien", "suffix": ""}, {"first": "R", "middle": [], "last": "Guerciolini", "suffix": ""}, {"first": "J", "middle": ["K"], "last": "Anderson", "suffix": ""}, {"first": "N", "middle": ["D"], "last": "Depcik-Smith", "suffix": ""}, {"first": "R", "middle": [], "last": "Bhagat", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Lehman", "suffix": ""}, {"first": "S", "middle": ["C"], "last": "Novick", "suffix": ""}, {"first": "O", "middle": ["A"], "last": "O&apos;connor", "suffix": ""}, {"first": "S", "middle": ["L"], "last": "Soignet", "suffix": ""}], "year": 2002, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "20", "issn": "22", "pages": "4420--4427", "other_ids": {"DOI": ["10.1200/JCO.2002.01.133"]}}, "BIBREF414": {"ref_id": "b414", "title": "Aneuploidy: implications for protein homeostasis and disease", "authors": [{"first": "A", "middle": ["B"], "last": "Oromendia", "suffix": ""}, {"first": "A", "middle": [], "last": "Amon", "suffix": ""}], "year": 2014, "venue": "Disease Models & Mechanisms", "volume": "7", "issn": "1", "pages": "15--20", "other_ids": {"DOI": ["10.1242/dmm.013391"]}}, "BIBREF415": {"ref_id": "b415", "title": "Ubiquitin-proteasome system involvement in Huntington's disease", "authors": [{"first": "Z", "middle": [], "last": "Ortega", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Lucas", "suffix": ""}], "year": 2014, "venue": "Frontiers in Molecular Neuroscience", "volume": "7", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3389/fnmol.2014.00077"]}}, "BIBREF416": {"ref_id": "b416", "title": "New Peptide-Based Pharmacophore Activates 20S Proteasome", "authors": [{"first": "P", "middle": ["A"], "last": "Osmulski", "suffix": ""}, {"first": "P", "middle": [], "last": "Karpowicz", "suffix": ""}, {"first": "E", "middle": [], "last": "Jankowska", "suffix": ""}, {"first": "J", "middle": [], "last": "Bohmann", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Pickering", "suffix": ""}, {"first": "M", "middle": [], "last": "Gaczy\u0144ska", "suffix": ""}], "year": 2020, "venue": "Molecules", "volume": "", "issn": "6", "pages": "", "other_ids": {"DOI": ["10.3390/molecules25061439"]}}, "BIBREF417": {"ref_id": "b417", "title": "Quantitative live-cell imaging reveals spatio-temporal dynamics and cytoplasmic assembly of the 26S proteasome", "authors": [{"first": "C.-G", "middle": [], "last": "Pack", "suffix": ""}, {"first": "H", "middle": [], "last": "Yukii", "suffix": ""}, {"first": "A", "middle": [], "last": "Toh-E", "suffix": ""}, {"first": "T", "middle": [], "last": "Kudo", "suffix": ""}, {"first": "H", "middle": [], "last": "Tsuchiya", "suffix": ""}, {"first": "A", "middle": [], "last": "Kaiho", "suffix": ""}, {"first": "E", "middle": [], "last": "Sakata", "suffix": ""}, {"first": "S", "middle": [], "last": "Murata", "suffix": ""}, {"first": "H", "middle": [], "last": "Yokosawa", "suffix": ""}, {"first": "Y", "middle": [], "last": "Sako", "suffix": ""}, {"first": "W", "middle": [], "last": "Baumeister", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "Y", "middle": [], "last": "Saeki", "suffix": ""}], "year": 2014, "venue": "Nature Communications", "volume": "5", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/ncomms4396"]}}, "BIBREF418": {"ref_id": "b418", "title": "Assembly of an Evolutionarily Conserved Alternative Proteasome Isoform in Human Cells", "authors": [{"first": "A", "middle": [], "last": "Padmanabhan", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Vuong", "suffix": ""}, {"first": "", "middle": [], "last": ".-T", "suffix": ""}, {"first": "M", "middle": [], "last": "Hochstrasser", "suffix": ""}], "year": 2016, "venue": "Cell Reports", "volume": "14", "issn": "12", "pages": "2962--2974", "other_ids": {"DOI": ["10.1016/j.celrep.2016.02.068"]}}, "BIBREF419": {"ref_id": "b419", "title": "Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation", "authors": [{"first": "G", "middle": [], "last": "Palladini", "suffix": ""}, {"first": "V", "middle": [], "last": "Perfetti", "suffix": ""}, {"first": "L", "middle": [], "last": "Obici", "suffix": ""}, {"first": "R", "middle": [], "last": "Caccialanza", "suffix": ""}, {"first": "A", "middle": [], "last": "Semino", "suffix": ""}, {"first": "F", "middle": [], "last": "Adami", "suffix": ""}, {"first": "G", "middle": [], "last": "Cavallero", "suffix": ""}, {"first": "R", "middle": [], "last": "Rustichelli", "suffix": ""}, {"first": "G", "middle": [], "last": "Virga", "suffix": ""}, {"first": "G", "middle": [], "last": "Merlini", "suffix": ""}], "year": 2004, "venue": "Blood", "volume": "103", "issn": "8", "pages": "2936--2938", "other_ids": {"DOI": ["10.1182/blood-2003-08-2788"]}}, "BIBREF420": {"ref_id": "b420", "title": "Low Erythrocyte Levels of Proteasome and Acyl-Peptide Hydrolase (APEH) Activities in Alzheimer's Disease: A Sign of Defective Proteostasis", "authors": [{"first": "G", "middle": [], "last": "Palmieri", "suffix": ""}, {"first": "E", "middle": [], "last": "Cocca", "suffix": ""}, {"first": "M", "middle": [], "last": "Gogliettino", "suffix": ""}, {"first": "R", "middle": [], "last": "Valentino", "suffix": ""}, {"first": "M", "middle": [], "last": "Ruvo", "suffix": ""}, {"first": "G", "middle": [], "last": "Cristofano", "suffix": ""}, {"first": "A", "middle": [], "last": "Angiolillo", "suffix": ""}, {"first": "M", "middle": [], "last": "Balestrieri", "suffix": ""}, {"first": "M", "middle": [], "last": "Rossi", "suffix": ""}, {"first": "A", "middle": [], "last": "Di Costanzo", "suffix": ""}], "year": 2017, "venue": "Journal of Alzheimer's Disease", "volume": "60", "issn": "3", "pages": "1097--1106", "other_ids": {"DOI": ["10.3233/JAD-170389"]}}, "BIBREF422": {"ref_id": "b422", "title": "Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomibthalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival", "authors": [], "year": null, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "32", "issn": "7", "pages": "634--640", "other_ids": {}}, "BIBREF424": {"ref_id": "b424", "title": "Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma", "authors": [{"first": "A", "middle": [], "last": "Palumbo", "suffix": ""}, {"first": "S", "middle": [], "last": "Bringhen", "suffix": ""}, {"first": "D", "middle": [], "last": "Rossi", "suffix": ""}, {"first": "M", "middle": [], "last": "Cavalli", "suffix": ""}, {"first": "A", "middle": [], "last": "Larocca", "suffix": ""}, {"first": "R", "middle": [], "last": "Ria", "suffix": ""}, {"first": "M", "middle": [], "last": "Offidani", "suffix": ""}, {"first": "F", "middle": [], "last": "Patriarca", "suffix": ""}, {"first": "C", "middle": [], "last": "Nozzoli", "suffix": ""}, {"first": "T", "middle": [], "last": "Guglielmelli", "suffix": ""}, {"first": "G", "middle": [], "last": "Benevolo", "suffix": ""}, {"first": "V", "middle": [], "last": "Callea", "suffix": ""}, {"first": "L", "middle": [], "last": "Baldini", "suffix": ""}, {"first": "F", "middle": [], "last": "Morabito", "suffix": ""}, {"first": "M", "middle": [], "last": "Grasso", "suffix": ""}, {"first": "A", "middle": [], "last": "Palumbo", "suffix": ""}, {"first": "A", "middle": [], "last": "Chanan-Khan", "suffix": ""}, {"first": "K", "middle": [], "last": "Weisel", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Nooka", "suffix": ""}, {"first": "T", "middle": [], "last": "Masszi", "suffix": ""}, {"first": "M", "middle": [], "last": "Beksac", "suffix": ""}, {"first": "I", "middle": [], "last": "Spicka", "suffix": ""}, {"first": "V", "middle": [], "last": "Hungria", "suffix": ""}, {"first": "M", "middle": [], "last": "Munder", "suffix": ""}, {"first": "M", "middle": ["V"], "last": "Mateos", "suffix": ""}, {"first": "T", "middle": ["M"], "last": "Mark", "suffix": ""}, {"first": "M", "middle": [], "last": "Qi", "suffix": ""}, {"first": "J", "middle": [], "last": "Schecter", "suffix": ""}, {"first": "H", "middle": [], "last": "Amin", "suffix": ""}, {"first": "X", "middle": [], "last": "Qin", "suffix": ""}, {"first": "W", "middle": [], "last": "Deraedt", "suffix": ""}, {"first": "T", "middle": [], "last": "Ahmadi", "suffix": ""}, {"first": "A", "middle": [], "last": "Spencer", "suffix": ""}, {"first": "P", "middle": [], "last": "Sonneveld", "suffix": ""}], "year": 2016, "venue": "New England Journal of Medicine", "volume": "375", "issn": "8", "pages": "754--766", "other_ids": {"DOI": ["10.1056/NEJMoa1606038"]}}, "BIBREF425": {"ref_id": "b425", "title": "The productivity crisis in pharmaceutical R&D", "authors": [{"first": "F", "middle": [], "last": "Pammolli", "suffix": ""}, {"first": "L", "middle": [], "last": "Magazzini", "suffix": ""}, {"first": "M", "middle": [], "last": "Riccaboni", "suffix": ""}], "year": 2011, "venue": "Nature Reviews. Drug Discovery", "volume": "10", "issn": "6", "pages": "428--438", "other_ids": {"DOI": ["10.1038/nrd3405"]}}, "BIBREF426": {"ref_id": "b426", "title": "Not4 E3 ligase contributes to proteasome assembly and functional integrity in part through Ecm29", "authors": [{"first": "O", "middle": ["O"], "last": "Panasenko", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Collart", "suffix": ""}], "year": 2011, "venue": "Molecular and Cellular Biology", "volume": "31", "issn": "8", "pages": "1610--1623", "other_ids": {"DOI": ["10.1128/MCB.01210-10"]}}, "BIBREF427": {"ref_id": "b427", "title": "Cotranslational assembly of proteasome subunits in NOT1-containing assemblysomes", "authors": [{"first": "O", "middle": ["O"], "last": "Panasenko", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Somasekharan", "suffix": ""}, {"first": "Z", "middle": [], "last": "Villanyi", "suffix": ""}, {"first": "M", "middle": [], "last": "Zagatti", "suffix": ""}, {"first": "F", "middle": [], "last": "Bezrukov", "suffix": ""}, {"first": "R", "middle": [], "last": "Rashpa", "suffix": ""}, {"first": "J", "middle": [], "last": "Cornut", "suffix": ""}, {"first": "J", "middle": [], "last": "Iqbal", "suffix": ""}, {"first": "M", "middle": [], "last": "Longis", "suffix": ""}, {"first": "S", "middle": ["H"], "last": "Carl", "suffix": ""}, {"first": "C", "middle": [], "last": "Pe\u00f1a", "suffix": ""}, {"first": "V", "middle": ["G"], "last": "Panse", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Collart", "suffix": ""}], "year": 2019, "venue": "Nature Structural & Molecular Biology", "volume": "26", "issn": "2", "pages": "110--120", "other_ids": {"DOI": ["10.1038/s41594-018-0179-5"]}}, "BIBREF428": {"ref_id": "b428", "title": "Proteasome inhibitors induce p53-independent apoptosis in human cancer cells", "authors": [{"first": "B", "middle": [], "last": "Pandit", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Gartel", "suffix": ""}], "year": 2011, "venue": "The American Journal of Pathology", "volume": "178", "issn": "1", "pages": "355--360", "other_ids": {}}, "BIBREF430": {"ref_id": "b430", "title": "Sodium diethyldithiocarbamate, an AIDS progression inhibitor and a copper-binding compound, has proteasome-inhibitory and apoptosisinducing activities in cancer cells", "authors": [{"first": "H", "middle": [], "last": "Pang", "suffix": ""}, {"first": "D", "middle": [], "last": "Chen", "suffix": ""}, {"first": "Q", "middle": ["C"], "last": "Cui", "suffix": ""}, {"first": "Q", "middle": [], "last": "Dou", "suffix": ""}], "year": 2007, "venue": "International Journal of Molecular Medicine", "volume": "19", "issn": "5", "pages": "809--816", "other_ids": {}}, "BIBREF431": {"ref_id": "b431", "title": "Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity", "authors": [{"first": "K.-C", "middle": [], "last": "Pao", "suffix": ""}, {"first": "N", "middle": ["T"], "last": "Wood", "suffix": ""}, {"first": "A", "middle": [], "last": "Knebel", "suffix": ""}, {"first": "K", "middle": [], "last": "Rafie", "suffix": ""}, {"first": "M", "middle": [], "last": "Stanley", "suffix": ""}, {"first": "P", "middle": ["D"], "last": "Mabbitt", "suffix": ""}, {"first": "R", "middle": [], "last": "Sundaramoorthy", "suffix": ""}, {"first": "K", "middle": [], "last": "Hofmann", "suffix": ""}, {"first": "D", "middle": ["M F"], "last": "Van Aalten", "suffix": ""}, {"first": "S", "middle": [], "last": "Virdee", "suffix": ""}], "year": 2018, "venue": "Nature", "volume": "556", "issn": "7701", "pages": "381--385", "other_ids": {"DOI": ["10.1038/s41586-018-0026-1"]}}, "BIBREF432": {"ref_id": "b432", "title": "A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors", "authors": [{"first": "K", "middle": ["P"], "last": "Papadopoulos", "suffix": ""}, {"first": "H", "middle": ["A"], "last": "Burris", "suffix": ""}, {"first": "M", "middle": [], "last": "Gordon", "suffix": ""}, {"first": "P", "middle": [], "last": "Lee", "suffix": ""}, {"first": "E", "middle": ["A"], "last": "Sausville", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Rosen", "suffix": ""}, {"first": "A", "middle": [], "last": "Patnaik", "suffix": ""}, {"first": "R", "middle": ["E"], "last": "Cutler", "suffix": ""}, {"first": "Z", "middle": [], "last": "Wang", "suffix": ""}, {"first": "S", "middle": [], "last": "Lee", "suffix": ""}, {"first": "S", "middle": ["F"], "last": "Jones", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Infante", "suffix": ""}], "year": 2013, "venue": "Cancer Chemotherapy and Pharmacology", "volume": "72", "issn": "4", "pages": "861--868", "other_ids": {"DOI": ["10.1007/s00280-013-2267-x"]}}, "BIBREF433": {"ref_id": "b433", "title": "Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma", "authors": [{"first": "K", "middle": ["P"], "last": "Papadopoulos", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Siegel", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Vesole", "suffix": ""}, {"first": "P", "middle": [], "last": "Lee", "suffix": ""}, {"first": "S", "middle": ["T"], "last": "Rosen", "suffix": ""}, {"first": "N", "middle": [], "last": "Zojwalla", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Holahan", "suffix": ""}, {"first": "S", "middle": [], "last": "Lee", "suffix": ""}, {"first": "Z", "middle": [], "last": "Wang", "suffix": ""}, {"first": "A", "middle": [], "last": "Badros", "suffix": ""}], "year": 2015, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "33", "issn": "7", "pages": "732--739", "other_ids": {"DOI": ["10.1200/JCO.2013.52.3522"]}}, "BIBREF434": {"ref_id": "b434", "title": "Alzheimer's disease progression in caenorhabditis elegans and neuronal cultures", "authors": [], "year": null, "venue": "Antioxidants and Redox Signaling", "volume": "25", "issn": "16", "pages": "855--869", "other_ids": {"DOI": ["10.1089/ars.2015.6494"]}}, "BIBREF435": {"ref_id": "b435", "title": "Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer", "authors": [{"first": "C", "middle": ["N"], "last": "Papandreou", "suffix": ""}, {"first": "D", "middle": ["D"], "last": "Daliani", "suffix": ""}, {"first": "D", "middle": [], "last": "Nix", "suffix": ""}, {"first": "H", "middle": [], "last": "Yang", "suffix": ""}, {"first": "T", "middle": [], "last": "Madden", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Pien", "suffix": ""}, {"first": "R", "middle": ["E"], "last": "Millikan", "suffix": ""}, {"first": "S.-M", "middle": [], "last": "Tu", "suffix": ""}, {"first": "L", "middle": [], "last": "Pagliaro", "suffix": ""}, {"first": "J", "middle": [], "last": "Kim", "suffix": ""}, {"first": "J", "middle": [], "last": "Adams", "suffix": ""}, {"first": "P", "middle": [], "last": "Elliott", "suffix": ""}, {"first": "D", "middle": [], "last": "Esseltine", "suffix": ""}, {"first": "A", "middle": [], "last": "Petrusich", "suffix": ""}, {"first": "P", "middle": [], "last": "Dieringer", "suffix": ""}, {"first": "C", "middle": [], "last": "Perez", "suffix": ""}, {"first": "C", "middle": ["J"], "last": "Logothetis", "suffix": ""}], "year": 2004, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "22", "issn": "11", "pages": "2108--2121", "other_ids": {"DOI": ["10.1200/JCO.2004.02.106"]}}, "BIBREF437": {"ref_id": "b437", "title": "Morphological and functional retinal impairment in Alzheimer's disease patients", "authors": [], "year": null, "venue": "Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology", "volume": "112", "issn": "10", "pages": "1860--1867", "other_ids": {"DOI": ["10.1016/s1388-2457(01)00620-4"]}}, "BIBREF438": {"ref_id": "b438", "title": "Evidence of the neuroprotective role of citicoline in glaucoma patients", "authors": [{"first": "Vincenzo", "middle": [], "last": "Parisi", "suffix": ""}, {"first": "G", "middle": [], "last": "Coppola", "suffix": ""}, {"first": "M", "middle": [], "last": "Centofanti", "suffix": ""}, {"first": "F", "middle": [], "last": "Oddone", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Angrisani", "suffix": ""}, {"first": "L", "middle": [], "last": "Ziccardi", "suffix": ""}, {"first": "B", "middle": [], "last": "Ricci", "suffix": ""}, {"first": "L", "middle": [], "last": "Quaranta", "suffix": ""}, {"first": "G", "middle": [], "last": "Manni", "suffix": ""}], "year": 2008, "venue": "Progress in Brain Research", "volume": "173", "issn": "", "pages": "541--554", "other_ids": {"DOI": ["10.1016/S0079-6123(08)01137-"]}}, "BIBREF439": {"ref_id": "b439", "title": "Enhancement of Retinal Function and of Neural Conduction Along the Visual Pathway Induced by Treatment with Citicoline Eye Drops in Liposomal Formulation in Open Angle Glaucoma: A Pilot Electrofunctional Study", "authors": [{"first": "Vincenzo", "middle": [], "last": "Parisi", "suffix": ""}, {"first": "F", "middle": [], "last": "Oddone", "suffix": ""}, {"first": "G", "middle": [], "last": "Roberti", "suffix": ""}, {"first": "L", "middle": [], "last": "Tanga", "suffix": ""}, {"first": "C", "middle": [], "last": "Carnevale", "suffix": ""}, {"first": "L", "middle": [], "last": "Ziccardi", "suffix": ""}, {"first": "G", "middle": [], "last": "Manni", "suffix": ""}], "year": 2019, "venue": "Advances in Therapy", "volume": "36", "issn": "4", "pages": "987--996", "other_ids": {"DOI": ["10.1007/s12325-019-0897-z"]}}, "BIBREF440": {"ref_id": "b440", "title": "Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function", "authors": [{"first": "Vincenzo", "middle": [], "last": "Parisi", "suffix": ""}, {"first": "F", "middle": [], "last": "Oddone", "suffix": ""}, {"first": "L", "middle": [], "last": "Ziccardi", "suffix": ""}, {"first": "G", "middle": [], "last": "Roberti", "suffix": ""}, {"first": "G", "middle": [], "last": "Coppola", "suffix": ""}, {"first": "G", "middle": [], "last": "Manni", "suffix": ""}], "year": 2018, "venue": "Current Neuropharmacology", "volume": "16", "issn": "7", "pages": "919--932", "other_ids": {"DOI": ["10.2174/1570159X15666170703111729"]}}, "BIBREF441": {"ref_id": "b441", "title": "Next-generation proteasome inhibitors for cancer therapy", "authors": [{"first": "J", "middle": ["E"], "last": "Park", "suffix": ""}, {"first": "Z", "middle": [], "last": "Miller", "suffix": ""}, {"first": "Y", "middle": [], "last": "Jun", "suffix": ""}, {"first": "W", "middle": [], "last": "Lee", "suffix": ""}, {"first": "K", "middle": ["B"], "last": "Kim", "suffix": ""}], "year": 2018, "venue": "Translational Research: The Journal of Laboratory and Clinical Medicine", "volume": "198", "issn": "", "pages": "1--16", "other_ids": {"DOI": ["10.1016/j.trsl.2018.03.002"]}}, "BIBREF442": {"ref_id": "b442", "title": "Structural defects in the regulatory particle-core particle interface of the proteasome induce a novel proteasome stress response", "authors": [{"first": "S", "middle": [], "last": "Park", "suffix": ""}, {"first": "W", "middle": [], "last": "Kim", "suffix": ""}, {"first": "G", "middle": [], "last": "Tian", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Gygi", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}], "year": 2011, "venue": "The Journal of Biological Chemistry", "volume": "286", "issn": "42", "pages": "36652--36666", "other_ids": {"DOI": ["10.1074/jbc.M111.285924"]}}, "BIBREF443": {"ref_id": "b443", "title": "Reconfiguration of the proteasome during chaperone-mediated assembly", "authors": [{"first": "S", "middle": [], "last": "Park", "suffix": ""}, {"first": "X", "middle": [], "last": "Li", "suffix": ""}, {"first": "H", "middle": ["M"], "last": "Kim", "suffix": ""}, {"first": "C", "middle": ["R"], "last": "Singh", "suffix": ""}, {"first": "G", "middle": [], "last": "Tian", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Hoyt", "suffix": ""}, {"first": "S", "middle": [], "last": "Lovell", "suffix": ""}, {"first": "K", "middle": ["P"], "last": "Battaile", "suffix": ""}, {"first": "M", "middle": [], "last": "Zolkiewski", "suffix": ""}, {"first": "P", "middle": [], "last": "Coffino", "suffix": ""}, {"first": "J", "middle": [], "last": "Roelofs", "suffix": ""}, {"first": "Y", "middle": [], "last": "Cheng", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}], "year": 2013, "venue": "Nature", "volume": "497", "issn": "7450", "pages": "512--516", "other_ids": {}}, "BIBREF445": {"ref_id": "b445", "title": "Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome", "authors": [{"first": "F", "middle": [], "last": "Parlati", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Lee", "suffix": ""}, {"first": "M", "middle": [], "last": "Aujay", "suffix": ""}, {"first": "E", "middle": [], "last": "Suzuki", "suffix": ""}, {"first": "K", "middle": [], "last": "Levitsky", "suffix": ""}, {"first": "J", "middle": ["B"], "last": "Lorens", "suffix": ""}, {"first": "D", "middle": ["R"], "last": "Micklem", "suffix": ""}, {"first": "P", "middle": [], "last": "Ruurs", "suffix": ""}, {"first": "C", "middle": [], "last": "Sylvain", "suffix": ""}, {"first": "Y", "middle": [], "last": "Lu", "suffix": ""}, {"first": "K", "middle": ["D"], "last": "Shenk", "suffix": ""}, {"first": "M", "middle": ["K"], "last": "Bennett", "suffix": ""}], "year": 2009, "venue": "Blood", "volume": "114", "issn": "16", "pages": "3439--3447", "other_ids": {"DOI": ["10.1182/blood-2009-05-223677"]}}, "BIBREF446": {"ref_id": "b446", "title": "Functional retinal impairment in type 1 diabetic patients without any signs of retinopathy", "authors": [{"first": "M", "middle": [], "last": "Parravano", "suffix": ""}, {"first": "F", "middle": [], "last": "Oddone", "suffix": ""}, {"first": "B", "middle": [], "last": "Boccassini", "suffix": ""}, {"first": "M", "middle": [], "last": "Centofanti", "suffix": ""}, {"first": "L", "middle": [], "last": "Tanga", "suffix": ""}, {"first": "A", "middle": [], "last": "Cacciamani", "suffix": ""}, {"first": "P", "middle": [], "last": "Borboni", "suffix": ""}, {"first": "M", "middle": [], "last": "Varano", "suffix": ""}], "year": 2013, "venue": "Ophthalmic Research", "volume": "50", "issn": "2", "pages": "108--112", "other_ids": {"DOI": ["10.1159/000350412"]}}, "BIBREF447": {"ref_id": "b447", "title": "The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together", "authors": [{"first": "G", "middle": ["R"], "last": "Pathare", "suffix": ""}, {"first": "I", "middle": [], "last": "Nagy", "suffix": ""}, {"first": "S", "middle": [], "last": "Bohn", "suffix": ""}, {"first": "P", "middle": [], "last": "Unverdorben", "suffix": ""}, {"first": "A", "middle": [], "last": "Hubert", "suffix": ""}, {"first": "R", "middle": [], "last": "K\u00f6rner", "suffix": ""}, {"first": "S", "middle": [], "last": "Nickell", "suffix": ""}, {"first": "K", "middle": [], "last": "Lasker", "suffix": ""}, {"first": "A", "middle": [], "last": "Sali", "suffix": ""}, {"first": "T", "middle": [], "last": "Tamura", "suffix": ""}, {"first": "T", "middle": [], "last": "Nishioka", "suffix": ""}, {"first": "F", "middle": [], "last": "F\u00f6rster", "suffix": ""}, {"first": "W", "middle": [], "last": "Baumeister", "suffix": ""}, {"first": "A", "middle": [], "last": "Bracher", "suffix": ""}], "year": 2012, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "109", "issn": "", "pages": "149--154", "other_ids": {"DOI": ["10.1073/pnas.1117648108"]}}, "BIBREF448": {"ref_id": "b448", "title": "Crystal structure of the proteasomal deubiquitylation module Rpn8-Rpn11", "authors": [{"first": "G", "middle": ["R"], "last": "Pathare", "suffix": ""}, {"first": "I", "middle": [], "last": "Nagy", "suffix": ""}, {"first": "P", "middle": [], "last": "\u015aled\u017a", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Anderson", "suffix": ""}, {"first": "H.-J", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "E", "middle": [], "last": "Pardon", "suffix": ""}, {"first": "J", "middle": [], "last": "Steyaert", "suffix": ""}, {"first": "F", "middle": [], "last": "F\u00f6rster", "suffix": ""}, {"first": "A", "middle": [], "last": "Bracher", "suffix": ""}, {"first": "W", "middle": [], "last": "Baumeister", "suffix": ""}], "year": 2014, "venue": "Proceedings of the National Academy of Sciences", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1073/pnas.1400546111"]}}, "BIBREF449": {"ref_id": "b449", "title": "Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metabolism and Disposition: The Biological Fate of Chemicals", "authors": [{"first": "T", "middle": [], "last": "Pekol", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Daniels", "suffix": ""}, {"first": "J", "middle": [], "last": "Labutti", "suffix": ""}, {"first": "I", "middle": [], "last": "Parsons", "suffix": ""}, {"first": "D", "middle": [], "last": "Nix", "suffix": ""}, {"first": "E", "middle": [], "last": "Baronas", "suffix": ""}, {"first": "F", "middle": [], "last": "Hsieh", "suffix": ""}, {"first": "L.-S", "middle": [], "last": "Gan", "suffix": ""}, {"first": "G", "middle": [], "last": "Miwa", "suffix": ""}], "year": 2005, "venue": "", "volume": "33", "issn": "", "pages": "771--777", "other_ids": {"DOI": ["10.1124/dmd.104.002956"]}}, "BIBREF450": {"ref_id": "b450", "title": "Bortezomib-induced syndrome of inappropriate antidiuresis in a patient with multiple myeloma: A case report and literature review", "authors": [{"first": "B", "middle": [], "last": "Peng", "suffix": ""}, {"first": "H", "middle": [], "last": "Chen", "suffix": ""}, {"first": "X", "middle": [], "last": "Lou", "suffix": ""}], "year": 2017, "venue": "International Journal of Clinical Pharmacology and Therapeutics", "volume": "55", "issn": "12", "pages": "910--914", "other_ids": {"DOI": ["10.5414/CP203109"]}}, "BIBREF451": {"ref_id": "b451", "title": "Ubiquitin-mediated proteasome degradation regulates optic fissure fusion", "authors": [{"first": "W", "middle": [], "last": "Pereira Piedade", "suffix": ""}, {"first": "S", "middle": [], "last": "Veith", "suffix": ""}, {"first": "J", "middle": ["K"], "last": "Famulski", "suffix": ""}], "year": 2019, "venue": "Biology Open", "volume": "8", "issn": "6", "pages": "", "other_ids": {"DOI": ["10.1242/bio.044974"]}}, "BIBREF452": {"ref_id": "b452", "title": "Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains", "authors": [{"first": "G", "middle": [], "last": "Perry", "suffix": ""}, {"first": "R", "middle": [], "last": "Friedman", "suffix": ""}, {"first": "G", "middle": [], "last": "Shaw", "suffix": ""}, {"first": "V", "middle": [], "last": "Chau", "suffix": ""}], "year": 1987, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "84", "issn": "", "pages": "3033--3036", "other_ids": {"DOI": ["10.1073/pnas.84.9.3033"]}}, "BIBREF453": {"ref_id": "b453", "title": "CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation", "authors": [{"first": "L", "middle": [], "last": "Petrucelli", "suffix": ""}, {"first": "D", "middle": [], "last": "Dickson", "suffix": ""}, {"first": "K", "middle": [], "last": "Kehoe", "suffix": ""}, {"first": "J", "middle": [], "last": "Taylor", "suffix": ""}, {"first": "H", "middle": [], "last": "Snyder", "suffix": ""}, {"first": "A", "middle": [], "last": "Grover", "suffix": ""}, {"first": "M", "middle": [], "last": "De Lucia", "suffix": ""}, {"first": "E", "middle": [], "last": "Mcgowan", "suffix": ""}, {"first": "J", "middle": [], "last": "Lewis", "suffix": ""}, {"first": "G", "middle": [], "last": "Prihar", "suffix": ""}, {"first": "J", "middle": [], "last": "Kim", "suffix": ""}, {"first": "W", "middle": ["H"], "last": "Dillmann", "suffix": ""}, {"first": "S", "middle": ["E"], "last": "Browne", "suffix": ""}, {"first": "A", "middle": [], "last": "Hall", "suffix": ""}, {"first": "R", "middle": [], "last": "Voellmy", "suffix": ""}, {"first": "Y", "middle": [], "last": "Tsuboi", "suffix": ""}, {"first": "T", "middle": ["M"], "last": "Dawson", "suffix": ""}, {"first": "B", "middle": [], "last": "Wolozin", "suffix": ""}, {"first": "J", "middle": [], "last": "Hardy", "suffix": ""}, {"first": "M", "middle": [], "last": "Hutton", "suffix": ""}], "year": 2004, "venue": "Human Molecular Genetics", "volume": "13", "issn": "7", "pages": "703--714", "other_ids": {"DOI": ["10.1093/hmg/ddh083"]}}, "BIBREF454": {"ref_id": "b454", "title": "Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis", "authors": [{"first": "L", "middle": ["V"], "last": "Pham", "suffix": ""}, {"first": "A", "middle": ["T"], "last": "Tamayo", "suffix": ""}, {"first": "L", "middle": ["C"], "last": "Yoshimura", "suffix": ""}, {"first": "P", "middle": [], "last": "Lo", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Ford", "suffix": ""}], "year": 1950, "venue": "Journal of Immunology", "volume": "171", "issn": "1", "pages": "88--95", "other_ids": {}}, "BIBREF455": {"ref_id": "b455", "title": "Association between Early Neuroretinal Dysfunction and Peripheral Motor Unit Loss in Patients with Type 1 Diabetes Mellitus", "authors": [{"first": "F", "middle": [], "last": "Picconi", "suffix": ""}, {"first": "G", "middle": [], "last": "Mataluni", "suffix": ""}, {"first": "L", "middle": [], "last": "Ziccardi", "suffix": ""}, {"first": "M", "middle": [], "last": "Parravano", "suffix": ""}, {"first": "A", "middle": [], "last": "Di Renzo", "suffix": ""}, {"first": "D", "middle": [], "last": "Ylli", "suffix": ""}, {"first": "P", "middle": [], "last": "Pasqualetti", "suffix": ""}, {"first": "V", "middle": [], "last": "Studer", "suffix": ""}, {"first": "L", "middle": [], "last": "Chioma", "suffix": ""}, {"first": "G", "middle": ["A"], "last": "Marfia", "suffix": ""}, {"first": "S", "middle": [], "last": "Frontoni", "suffix": ""}], "year": 2018, "venue": "Journal of Diabetes Research", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1155/2018/9763507"]}}, "BIBREF456": {"ref_id": "b456", "title": "Activation of retinal M\u00fcller cells in response to glucose variability", "authors": [{"first": "F", "middle": [], "last": "Picconi", "suffix": ""}, {"first": "M", "middle": [], "last": "Parravano", "suffix": ""}, {"first": "F", "middle": [], "last": "Sciarretta", "suffix": ""}, {"first": "C", "middle": [], "last": "Fulci", "suffix": ""}, {"first": "M", "middle": [], "last": "Nali", "suffix": ""}, {"first": "S", "middle": [], "last": "Frontoni", "suffix": ""}, {"first": "M", "middle": [], "last": "Varano", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Caccuri", "suffix": ""}], "year": 2019, "venue": "Endocrine", "volume": "65", "issn": "3", "pages": "542--549", "other_ids": {"DOI": ["10.1007/s12020-019-02017-5"]}}, "BIBREF457": {"ref_id": "b457", "title": "Mechanisms underlying ubiquitination", "authors": [{"first": "C", "middle": ["M"], "last": "Pickart", "suffix": ""}], "year": 2001, "venue": "Annual Review of Biochemistry", "volume": "70", "issn": "", "pages": "503--533", "other_ids": {"DOI": ["10.1146/annurev.biochem.70.1.503"]}}, "BIBREF458": {"ref_id": "b458", "title": "Differential roles of proteasome and immunoproteasome regulators Pa28\u03b1\u03b2, Pa28\u03b3 and Pa200 in the degradation of oxidized proteins", "authors": [{"first": "A", "middle": ["M"], "last": "Pickering", "suffix": ""}, {"first": "K", "middle": ["J A"], "last": "Davies", "suffix": ""}], "year": 2012, "venue": "Archives of Biochemistry and Biophysics", "volume": "523", "issn": "2", "pages": "181--190", "other_ids": {}}, "BIBREF460": {"ref_id": "b460", "title": "THE IMMUNOPROTEASOME, THE 20S PROTEASOME, AND THE PA28\u03b1\u03b2 PROTEASOME REGULATOR ARE OXIDATIVE-STRESS-ADAPTIVE PROTEOLYTIC COMPLEXES", "authors": [{"first": "A", "middle": ["M"], "last": "Pickering", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Koop", "suffix": ""}, {"first": "C", "middle": ["Y"], "last": "Teoh", "suffix": ""}, {"first": "G", "middle": [], "last": "Ermak", "suffix": ""}, {"first": "T", "middle": [], "last": "Grune", "suffix": ""}, {"first": "K", "middle": ["J A"], "last": "Davies", "suffix": ""}], "year": 2010, "venue": "", "volume": "432", "issn": "", "pages": "585--594", "other_ids": {"DOI": ["10.1042/BJ20100878"]}}, "BIBREF462": {"ref_id": "b462", "title": "Oxidative Stress is the Principal Contributor to Inflammasome Activation in Retinal Pigment Epithelium Cells with Defunct Proteasomes and Autophagy", "authors": [], "year": null, "venue": "Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology", "volume": "49", "issn": "1", "pages": "359--367", "other_ids": {"DOI": ["10.1159/000492886"]}}, "BIBREF463": {"ref_id": "b463", "title": "CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib", "authors": [{"first": "R", "middle": [], "last": "Piva", "suffix": ""}, {"first": "B", "middle": [], "last": "Ruggeri", "suffix": ""}, {"first": "M", "middle": [], "last": "Williams", "suffix": ""}, {"first": "G", "middle": [], "last": "Costa", "suffix": ""}, {"first": "I", "middle": [], "last": "Tamagno", "suffix": ""}, {"first": "D", "middle": [], "last": "Ferrero", "suffix": ""}, {"first": "V", "middle": [], "last": "Giai", "suffix": ""}, {"first": "M", "middle": [], "last": "Coscia", "suffix": ""}, {"first": "S", "middle": [], "last": "Peola", "suffix": ""}, {"first": "M", "middle": [], "last": "Massaia", "suffix": ""}, {"first": "G", "middle": [], "last": "Pezzoni", "suffix": ""}, {"first": "C", "middle": [], "last": "Allievi", "suffix": ""}, {"first": "N", "middle": [], "last": "Pescalli", "suffix": ""}, {"first": "M", "middle": [], "last": "Cassin", "suffix": ""}, {"first": "S", "middle": [], "last": "Di Giovine", "suffix": ""}, {"first": "P", "middle": [], "last": "Nicoli", "suffix": ""}, {"first": "P", "middle": [], "last": "De Feudis", "suffix": ""}, {"first": "I", "middle": [], "last": "Strepponi", "suffix": ""}, {"first": "I", "middle": [], "last": "Roato", "suffix": ""}, {"first": "G", "middle": [], "last": "Inghirami", "suffix": ""}], "year": 2008, "venue": "Blood", "volume": "111", "issn": "5", "pages": "2765--2775", "other_ids": {"DOI": ["10.1182/blood-2007-07-100651"]}}, "BIBREF465": {"ref_id": "b465", "title": "Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration", "authors": [], "year": null, "venue": "Blood", "volume": "98", "issn": "2", "pages": "428--435", "other_ids": {"DOI": ["10.1182/blood.v98.2.428"]}}, "BIBREF466": {"ref_id": "b466", "title": "Heterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome", "authors": [{"first": "M", "middle": ["C"], "last": "Poli", "suffix": ""}, {"first": "F", "middle": [], "last": "Ebstein", "suffix": ""}, {"first": "S", "middle": ["K"], "last": "Nicholas", "suffix": ""}, {"first": "M", "middle": ["M"], "last": "De Guzman", "suffix": ""}, {"first": "L", "middle": ["R"], "last": "Forbes", "suffix": ""}, {"first": "I", "middle": ["K"], "last": "Chinn", "suffix": ""}, {"first": "E", "middle": ["M"], "last": "Mace", "suffix": ""}, {"first": "T", "middle": ["P"], "last": "Vogel", "suffix": ""}, {"first": "A", "middle": ["F"], "last": "Carisey", "suffix": ""}, {"first": "F", "middle": [], "last": "Benavides", "suffix": ""}, {"first": "Z", "middle": ["H"], "last": "Coban-Akdemir", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Gibbs", "suffix": ""}, {"first": "S", "middle": ["N"], "last": "Jhangiani", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Muzny", "suffix": ""}, {"first": "C", "middle": ["M B"], "last": "Carvalho", "suffix": ""}, {"first": "D", "middle": ["A"], "last": "Schady", "suffix": ""}, {"first": "M", "middle": [], "last": "Jain", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Rosenfeld", "suffix": ""}, {"first": "L", "middle": [], "last": "Emrick", "suffix": ""}, {"first": "", "middle": [], "last": "Orange", "suffix": ""}], "year": 2018, "venue": "American Journal of Human Genetics", "volume": "102", "issn": "6", "pages": "1126--1142", "other_ids": {"DOI": ["10.1016/j.ajhg.2018.04.010"]}}, "BIBREF467": {"ref_id": "b467", "title": "Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials", "authors": [{"first": "B", "middle": ["C"], "last": "Potts", "suffix": ""}, {"first": "M", "middle": ["X"], "last": "Albitar", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}, {"first": "S", "middle": [], "last": "Baritaki", "suffix": ""}, {"first": "C", "middle": [], "last": "Berkers", "suffix": ""}, {"first": "B", "middle": [], "last": "Bonavida", "suffix": ""}, {"first": "J", "middle": [], "last": "Chandra", "suffix": ""}, {"first": "D", "middle": [], "last": "Chauhan", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Cusack", "suffix": ""}, {"first": "W", "middle": [], "last": "Fenical", "suffix": ""}, {"first": "I", "middle": ["M"], "last": "Ghobrial", "suffix": ""}, {"first": "M", "middle": [], "last": "Groll", "suffix": ""}, {"first": "P", "middle": ["R"], "last": "Jensen", "suffix": ""}, {"first": "K", "middle": ["S"], "last": "Lam", "suffix": ""}, {"first": "G", "middle": ["K"], "last": "Lloyd", "suffix": ""}, {"first": "W", "middle": [], "last": "Mcbride", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Mcconkey", "suffix": ""}, {"first": "C", "middle": ["P"], "last": "Miller", "suffix": ""}, {"first": "S", "middle": ["T C"], "last": "Neuteboom", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Palladino", "suffix": ""}], "year": 2011, "venue": "Current Cancer Drug Targets", "volume": "11", "issn": "3", "pages": "254--284", "other_ids": {}}, "BIBREF470": {"ref_id": "b470", "title": "Drug repurposing: progress, challenges and recommendations", "authors": [{"first": "S", "middle": [], "last": "Pushpakom", "suffix": ""}, {"first": "F", "middle": [], "last": "Iorio", "suffix": ""}, {"first": "P", "middle": ["A"], "last": "Eyers", "suffix": ""}, {"first": "K", "middle": ["J"], "last": "Escott", "suffix": ""}, {"first": "S", "middle": [], "last": "Hopper", "suffix": ""}, {"first": "A", "middle": [], "last": "Wells", "suffix": ""}, {"first": "A", "middle": [], "last": "Doig", "suffix": ""}, {"first": "T", "middle": [], "last": "Guilliams", "suffix": ""}, {"first": "J", "middle": [], "last": "Latimer", "suffix": ""}, {"first": "C", "middle": [], "last": "Mcnamee", "suffix": ""}, {"first": "A", "middle": [], "last": "Norris", "suffix": ""}, {"first": "P", "middle": [], "last": "Sanseau", "suffix": ""}, {"first": "D", "middle": [], "last": "Cavalla", "suffix": ""}, {"first": "M", "middle": [], "last": "Pirmohamed", "suffix": ""}], "year": 2019, "venue": "Nature Reviews. Drug Discovery", "volume": "18", "issn": "1", "pages": "41--58", "other_ids": {"DOI": ["10.1038/nrd.2018.168"]}}, "BIBREF471": {"ref_id": "b471", "title": "Acetylation-mediated proteasomal degradation of core histones during DNA repair and spermatogenesis", "authors": [{"first": "M.-X", "middle": [], "last": "Qian", "suffix": ""}, {"first": "Y", "middle": [], "last": "Pang", "suffix": ""}, {"first": "C", "middle": ["H"], "last": "Liu", "suffix": ""}, {"first": "K", "middle": [], "last": "Haratake", "suffix": ""}, {"first": "B.-Y", "middle": [], "last": "Du", "suffix": ""}, {"first": "D.-Y", "middle": [], "last": "Ji", "suffix": ""}, {"first": "G.-F", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Q.-Q", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "W", "middle": [], "last": "Song", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yu", "suffix": ""}, {"first": "X.-X", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "H.-T", "middle": [], "last": "Huang", "suffix": ""}, {"first": "S", "middle": [], "last": "Miao", "suffix": ""}, {"first": "L.-B", "middle": [], "last": "Chen", "suffix": ""}, {"first": "Z.-H", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "Y.-N", "middle": [], "last": "Liang", "suffix": ""}, {"first": "S", "middle": [], "last": "Liu", "suffix": ""}, {"first": "H", "middle": [], "last": "Cha", "suffix": ""}, {"first": "D", "middle": [], "last": "Yang", "suffix": ""}, {"first": "X.-B", "middle": [], "last": "Qiu", "suffix": ""}], "year": 2013, "venue": "Cell", "volume": "153", "issn": "5", "pages": "1012--1024", "other_ids": {"DOI": ["10.1016/j.cell.2013.04.032"]}}, "BIBREF472": {"ref_id": "b472", "title": "Acetylation-mediated proteasomal degradation of core histones during DNA repair and spermatogenesis", "authors": [{"first": "M.-X", "middle": [], "last": "Qian", "suffix": ""}, {"first": "Y", "middle": [], "last": "Pang", "suffix": ""}, {"first": "C", "middle": ["H"], "last": "Liu", "suffix": ""}, {"first": "K", "middle": [], "last": "Haratake", "suffix": ""}, {"first": "B.-Y", "middle": [], "last": "Du", "suffix": ""}, {"first": "D.-Y", "middle": [], "last": "Ji", "suffix": ""}, {"first": "G.-F", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Q.-Q", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "W", "middle": [], "last": "Song", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yu", "suffix": ""}, {"first": "X.-X", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "H.-T", "middle": [], "last": "Huang", "suffix": ""}, {"first": "S", "middle": [], "last": "Miao", "suffix": ""}, {"first": "L.-B", "middle": [], "last": "Chen", "suffix": ""}, {"first": "Z.-H", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "Y.-N", "middle": [], "last": "Liang", "suffix": ""}, {"first": "S", "middle": [], "last": "Liu", "suffix": ""}, {"first": "H", "middle": [], "last": "Cha", "suffix": ""}, {"first": "D", "middle": [], "last": "Yang", "suffix": ""}, {"first": "X.-B", "middle": [], "last": "Qiu", "suffix": ""}], "year": 2013, "venue": "Cell", "volume": "153", "issn": "5", "pages": "1012--1024", "other_ids": {"DOI": ["10.1016/j.cell.2013.04.032"]}}, "BIBREF474": {"ref_id": "b474", "title": "/ADRM1/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37", "authors": [], "year": null, "venue": "", "volume": "25", "issn": "", "pages": "5742--5753", "other_ids": {"DOI": ["10.1038/sj.emboj.7601450"]}}, "BIBREF475": {"ref_id": "b475", "title": "Cellular processing of myocilin", "authors": [{"first": "Y", "middle": [], "last": "Qiu", "suffix": ""}, {"first": "X", "middle": [], "last": "Shen", "suffix": ""}, {"first": "R", "middle": [], "last": "Shyam", "suffix": ""}, {"first": "B", "middle": ["Y J T"], "last": "Yue", "suffix": ""}, {"first": "H", "middle": [], "last": "Ying", "suffix": ""}], "year": 2014, "venue": "PloS One", "volume": "9", "issn": "4", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0092845"]}}, "BIBREF476": {"ref_id": "b476", "title": "Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study", "authors": [{"first": "H", "middle": [], "last": "Quach", "suffix": ""}, {"first": "D", "middle": [], "last": "White", "suffix": ""}, {"first": "A", "middle": [], "last": "Spencer", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Ho", "suffix": ""}, {"first": "D", "middle": [], "last": "Bhutani", "suffix": ""}, {"first": "M", "middle": [], "last": "White", "suffix": ""}, {"first": "S", "middle": [], "last": "Inamdar", "suffix": ""}, {"first": "C", "middle": [], "last": "Morris", "suffix": ""}, {"first": "Y", "middle": [], "last": "Ou", "suffix": ""}, {"first": "M", "middle": [], "last": "Gyger", "suffix": ""}], "year": 2017, "venue": "Cancer Chemotherapy and Pharmacology", "volume": "79", "issn": "6", "pages": "1067--1076", "other_ids": {"DOI": ["10.1007/s00280-017-3287-8"]}}, "BIBREF477": {"ref_id": "b477", "title": "Quality of Life in Glaucoma: A Review of the Literature", "authors": [{"first": "L", "middle": [], "last": "Quaranta", "suffix": ""}, {"first": "I", "middle": [], "last": "Riva", "suffix": ""}, {"first": "C", "middle": [], "last": "Gerardi", "suffix": ""}, {"first": "F", "middle": [], "last": "Oddone", "suffix": ""}, {"first": "I", "middle": [], "last": "Floriano", "suffix": ""}, {"first": "A", "middle": ["G P"], "last": "Konstas", "suffix": ""}], "year": 2016, "venue": "Advances in Therapy", "volume": "33", "issn": "6", "pages": "959--981", "other_ids": {"DOI": ["10.1007/s12325-016-0333-6"]}}, "BIBREF478": {"ref_id": "b478", "title": "Inhibition of nitric oxide and inflammatory cytokines in LPS-stimulated murine macrophages by resveratrol, a potent proteasome inhibitor", "authors": [{"first": "A", "middle": ["A"], "last": "Qureshi", "suffix": ""}, {"first": "X", "middle": ["Q"], "last": "Guan", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Reis", "suffix": ""}, {"first": "C", "middle": ["J"], "last": "Papasian", "suffix": ""}, {"first": "S", "middle": [], "last": "Jabre", "suffix": ""}, {"first": "D", "middle": ["C"], "last": "Morrison", "suffix": ""}, {"first": "N", "middle": [], "last": "Qureshi", "suffix": ""}], "year": 2012, "venue": "Lipids in Health and Disease", "volume": "11", "issn": "1", "pages": "", "other_ids": {"DOI": ["10.1186/1476-511X-11-76"]}}, "BIBREF479": {"ref_id": "b479", "title": "an important role during various stages of the coronavirus infection cycle", "authors": [], "year": null, "venue": "Journal of Virology", "volume": "84", "issn": "15", "pages": "7869--7879", "other_ids": {"DOI": ["10.1128/JVI.00485-10"]}}, "BIBREF480": {"ref_id": "b480", "title": "Diverse polyubiquitin interaction properties of ubiquitin-associated domains", "authors": [{"first": "S", "middle": [], "last": "Raasi", "suffix": ""}, {"first": "R", "middle": [], "last": "Varadan", "suffix": ""}, {"first": "D", "middle": [], "last": "Fushman", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Pickart", "suffix": ""}], "year": 2005, "venue": "Nature Structural & Molecular Biology", "volume": "12", "issn": "8", "pages": "708--714", "other_ids": {"DOI": ["10.1038/nsmb962"]}}, "BIBREF481": {"ref_id": "b481", "title": "Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases", "authors": [{"first": "J", "middle": [], "last": "Rabl", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Smith", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yu", "suffix": ""}, {"first": "S.-C", "middle": [], "last": "Chang", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}, {"first": "Y", "middle": [], "last": "Cheng", "suffix": ""}], "year": 2008, "venue": "Molecular Cell", "volume": "30", "issn": "3", "pages": "360--368", "other_ids": {"DOI": ["10.1016/j.molcel.2008.03.004"]}}, "BIBREF482": {"ref_id": "b482", "title": "The ubiquitin-proteasome system meets angiogenesis", "authors": [{"first": "N", "middle": [], "last": "Rahimi", "suffix": ""}], "year": 2012, "venue": "Molecular Cancer Therapeutics", "volume": "11", "issn": "3", "pages": "538--548", "other_ids": {"DOI": ["10.1158/1535-7163.MCT-11-0555"]}}, "BIBREF483": {"ref_id": "b483", "title": "Functionally different \u03b1-synuclein inclusions yield insight into Parkinson's disease pathology", "authors": [{"first": "C", "middle": ["C"], "last": "Raiss", "suffix": ""}, {"first": "T", "middle": ["S"], "last": "Braun", "suffix": ""}, {"first": "I", "middle": ["B M"], "last": "Konings", "suffix": ""}, {"first": "H", "middle": [], "last": "Grabmayr", "suffix": ""}, {"first": "G", "middle": ["C"], "last": "Hassink", "suffix": ""}, {"first": "A", "middle": [], "last": "Sidhu", "suffix": ""}, {"first": "J", "middle": [], "last": "Le Feber", "suffix": ""}, {"first": "A", "middle": ["R"], "last": "Bausch", "suffix": ""}, {"first": "C", "middle": [], "last": "Jansen", "suffix": ""}, {"first": "V", "middle": [], "last": "Subramaniam", "suffix": ""}, {"first": "M", "middle": ["M A E"], "last": "Claessens", "suffix": ""}], "year": 2016, "venue": "Scientific Reports", "volume": "6", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/srep23116"]}}, "BIBREF484": {"ref_id": "b484", "title": "New investigational drugs with single-agent activity in multiple myeloma", "authors": [{"first": "A", "middle": ["M"], "last": "Rajan", "suffix": ""}, {"first": "S", "middle": [], "last": "Kumar", "suffix": ""}], "year": 2016, "venue": "Blood Cancer Journal", "volume": "6", "issn": "7", "pages": "", "other_ids": {"DOI": ["10.1038/bcj.2016.53"]}}, "BIBREF485": {"ref_id": "b485", "title": "A mammalian nervous system-specific plasma membrane proteasome complex that modulates neuronal function", "authors": [{"first": "K", "middle": ["V"], "last": "Ramachandran", "suffix": ""}, {"first": "S", "middle": ["S"], "last": "Margolis", "suffix": ""}], "year": 2017, "venue": "Nature Structural & Molecular Biology", "volume": "24", "issn": "4", "pages": "419--430", "other_ids": {"DOI": ["10.1038/nsmb.3389"]}}, "BIBREF486": {"ref_id": "b486", "title": "PACemakers of proteasome core particle assembly", "authors": [{"first": "P", "middle": ["C"], "last": "Ramos", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Dohmen", "suffix": ""}], "year": 1993, "venue": "Structure", "volume": "16", "issn": "9", "pages": "1296--1304", "other_ids": {"DOI": ["10.1016/j.str.2008.07.001"]}}, "BIBREF487": {"ref_id": "b487", "title": "Protein Kinase G Positively Regulates Proteasome-Mediated Degradation of Misfolded Proteins", "authors": [{"first": "M", "middle": ["J"], "last": "Ranek", "suffix": ""}, {"first": "E", "middle": ["J M"], "last": "Terpstra", "suffix": ""}, {"first": "J", "middle": [], "last": "Li", "suffix": ""}, {"first": "D", "middle": ["A"], "last": "Kass", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}], "year": 2013, "venue": "Circulation", "volume": "128", "issn": "4", "pages": "365--376", "other_ids": {"DOI": ["10.1161/CIRCULATIONAHA.113.001971"]}}, "BIBREF488": {"ref_id": "b488", "title": "p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells", "authors": [{"first": "L", "middle": ["P"], "last": "Rangel", "suffix": ""}, {"first": "G", "middle": ["D S"], "last": "Ferretti", "suffix": ""}, {"first": "C", "middle": ["L"], "last": "Costa", "suffix": ""}, {"first": "S", "middle": ["M M V"], "last": "Andrade", "suffix": ""}, {"first": "R", "middle": ["S"], "last": "Carvalho", "suffix": ""}, {"first": "D", "middle": ["C F"], "last": "Costa", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Silva", "suffix": ""}], "year": 2019, "venue": "The Journal of Biological Chemistry", "volume": "294", "issn": "10", "pages": "3670--3682", "other_ids": {"DOI": ["10.1074/jbc.RA118.004671"]}}, "BIBREF489": {"ref_id": "b489", "title": "Enhanced rate of degradation of basic proteins by 26S immunoproteasomes", "authors": [{"first": "M", "middle": [], "last": "Raule", "suffix": ""}, {"first": "F", "middle": [], "last": "Cerruti", "suffix": ""}, {"first": "P", "middle": [], "last": "Cascio", "suffix": ""}], "year": 2014, "venue": "Biochimica Et Biophysica Acta", "volume": "1843", "issn": "9", "pages": "1942--1947", "other_ids": {}}, "BIBREF491": {"ref_id": "b491", "title": "PA28\u03b1\u03b2 reduces size and increases hydrophilicity of 20S immunoproteasome peptide products", "authors": [{"first": "M", "middle": [], "last": "Raule", "suffix": ""}, {"first": "F", "middle": [], "last": "Cerruti", "suffix": ""}, {"first": "N", "middle": [], "last": "Benaroudj", "suffix": ""}, {"first": "R", "middle": [], "last": "Migotti", "suffix": ""}, {"first": "J", "middle": [], "last": "Kikuchi", "suffix": ""}, {"first": "A", "middle": [], "last": "Bachi", "suffix": ""}, {"first": "A", "middle": [], "last": "Navon", "suffix": ""}, {"first": "G", "middle": [], "last": "Dittmar", "suffix": ""}, {"first": "P", "middle": [], "last": "Cascio", "suffix": ""}], "year": 2014, "venue": "Chemistry & Biology", "volume": "21", "issn": "4", "pages": "470--480", "other_ids": {}}, "BIBREF493": {"ref_id": "b493", "title": "Degradation of oxidized proteins by the proteasome: Distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways", "authors": [{"first": "R", "middle": [], "last": "Raynes", "suffix": ""}, {"first": "L", "middle": ["C D"], "last": "Pomatto", "suffix": ""}, {"first": "K", "middle": ["J A"], "last": "Davies", "suffix": ""}], "year": 2016, "venue": "Molecular Aspects of Medicine", "volume": "50", "issn": "", "pages": "41--55", "other_ids": {"DOI": ["10.1016/j.mam.2016.05.001"]}}, "BIBREF494": {"ref_id": "b494", "title": "Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors", "authors": [{"first": "M", "middle": [], "last": "Rechsteiner", "suffix": ""}, {"first": "C", "middle": ["P"], "last": "Hill", "suffix": ""}], "year": 2005, "venue": "Trends in Cell Biology", "volume": "15", "issn": "1", "pages": "27--33", "other_ids": {}}, "BIBREF496": {"ref_id": "b496", "title": "Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma", "authors": [{"first": "D", "middle": ["E"], "last": "Reece", "suffix": ""}, {"first": "D", "middle": [], "last": "Sullivan", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonial", "suffix": ""}, {"first": "A", "middle": ["F"], "last": "Mohrbacher", "suffix": ""}, {"first": "G", "middle": [], "last": "Chatta", "suffix": ""}, {"first": "C", "middle": [], "last": "Shustik", "suffix": ""}, {"first": "H", "middle": [], "last": "Burris", "suffix": ""}, {"first": "K", "middle": [], "last": "Venkatakrishnan", "suffix": ""}, {"first": "R", "middle": [], "last": "Neuwirth", "suffix": ""}, {"first": "W", "middle": ["J"], "last": "Riordan", "suffix": ""}, {"first": "M", "middle": [], "last": "Karol", "suffix": ""}, {"first": "L", "middle": ["L"], "last": "Von Moltke", "suffix": ""}, {"first": "M", "middle": [], "last": "Acharya", "suffix": ""}, {"first": "P", "middle": [], "last": "Zannikos", "suffix": ""}, {"first": "A", "middle": [], "last": "Stewart", "suffix": ""}], "year": 2011, "venue": "Cancer Chemotherapy and Pharmacology", "volume": "67", "issn": "1", "pages": "57--67", "other_ids": {"DOI": ["10.1007/s00280-010-1283-3"]}}, "BIBREF497": {"ref_id": "b497", "title": "Resveratrol reduces amyloid-beta (A\u03b2\u2081\u208b\u2084\u2082)-induced paralysis through targeting proteostasis in an Alzheimer model of Caenorhabditis elegans", "authors": [{"first": "C", "middle": [], "last": "Regitz", "suffix": ""}, {"first": "E", "middle": [], "last": "Fitzenberger", "suffix": ""}, {"first": "F", "middle": ["L"], "last": "Mahn", "suffix": ""}, {"first": "L", "middle": ["M"], "last": "Du\u00dfling", "suffix": ""}, {"first": "U", "middle": [], "last": "&amp;wenzel", "suffix": ""}], "year": 2016, "venue": "European Journal of Nutrition", "volume": "55", "issn": "2", "pages": "741--747", "other_ids": {}}, "BIBREF499": {"ref_id": "b499", "title": "Comparative resistance of the 20S and 26S proteasome to oxidative stress", "authors": [{"first": "T", "middle": [], "last": "Reinheckel", "suffix": ""}, {"first": "N", "middle": [], "last": "Sitte", "suffix": ""}, {"first": "O", "middle": [], "last": "Ullrich", "suffix": ""}, {"first": "U", "middle": [], "last": "Kuckelkorn", "suffix": ""}, {"first": "K", "middle": ["J"], "last": "Davies", "suffix": ""}, {"first": "T", "middle": [], "last": "Grune", "suffix": ""}], "year": 1998, "venue": "The Biochemical Journal", "volume": "335", "issn": "", "pages": "637--642", "other_ids": {"DOI": ["10.1042/bj3350637"]}}, "BIBREF500": {"ref_id": "b500", "title": "Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress", "authors": [{"first": "T", "middle": [], "last": "Reinheckel", "suffix": ""}, {"first": "O", "middle": [], "last": "Ullrich", "suffix": ""}, {"first": "N", "middle": [], "last": "Sitte", "suffix": ""}, {"first": "T", "middle": [], "last": "Grune", "suffix": ""}], "year": 2000, "venue": "Archives of Biochemistry and Biophysics", "volume": "377", "issn": "1", "pages": "65--68", "other_ids": {"DOI": ["10.1006/abbi.2000.1717"]}}, "BIBREF501": {"ref_id": "b501", "title": "Glaucoma-associated myocilin: A better understanding but much more to learn", "authors": [{"first": "Z", "middle": ["T"], "last": "Resch", "suffix": ""}, {"first": "M", "middle": ["P"], "last": "Fautsch", "suffix": ""}], "year": 2009, "venue": "Experimental Eye Research", "volume": "88", "issn": "4", "pages": "704--712", "other_ids": {}}, "BIBREF503": {"ref_id": "b503", "title": "Management of treatment-emergent peripheral neuropathy in multiple myeloma", "authors": [{"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "M", "middle": [], "last": "Delforge", "suffix": ""}, {"first": "M", "middle": [], "last": "Beksac", "suffix": ""}, {"first": "P", "middle": [], "last": "Wen", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Jongen", "suffix": ""}, {"first": "O", "middle": [], "last": "Sezer", "suffix": ""}, {"first": "E", "middle": [], "last": "Terpos", "suffix": ""}, {"first": "N", "middle": [], "last": "Munshi", "suffix": ""}, {"first": "A", "middle": [], "last": "Palumbo", "suffix": ""}, {"first": "S", "middle": ["V"], "last": "Rajkumar", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Harousseau", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "H", "middle": [], "last": "Avet-Loiseau", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Lee", "suffix": ""}, {"first": "M", "middle": [], "last": "Cavo", "suffix": ""}, {"first": "G", "middle": [], "last": "Merlini", "suffix": ""}, {"first": "P", "middle": [], "last": "Voorhees", "suffix": ""}, {"first": "W", "middle": ["J"], "last": "Chng", "suffix": ""}, {"first": "A", "middle": [], "last": "Mazumder", "suffix": ""}, {"first": "P", "middle": [], "last": "Sonneveld", "suffix": ""}], "year": 2012, "venue": "Leukemia", "volume": "26", "issn": "4", "pages": "595--608", "other_ids": {"DOI": ["10.1038/leu.2011.346"]}}, "BIBREF504": {"ref_id": "b504", "title": "Ixazomib for the treatment of multiple myeloma", "authors": [{"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "S", "middle": [], "last": "Zweegman", "suffix": ""}, {"first": "E", "middle": ["K"], "last": "O&apos;donnell", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Laubach", "suffix": ""}, {"first": "N", "middle": [], "last": "Raje", "suffix": ""}, {"first": "P", "middle": [], "last": "Voorhees", "suffix": ""}, {"first": "R", "middle": ["H"], "last": "Ferrari", "suffix": ""}, {"first": "T", "middle": [], "last": "Skacel", "suffix": ""}, {"first": "S", "middle": ["K"], "last": "Kumar", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonial", "suffix": ""}], "year": 2018, "venue": "Expert Opinion on Pharmacotherapy", "volume": "19", "issn": "17", "pages": "1949--1968", "other_ids": {}}, "BIBREF506": {"ref_id": "b506", "title": "Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial", "authors": [{"first": "Paul", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "B", "middle": [], "last": "Barlogie", "suffix": ""}, {"first": "J", "middle": [], "last": "Berenson", "suffix": ""}, {"first": "S", "middle": [], "last": "Singhal", "suffix": ""}, {"first": "S", "middle": [], "last": "Jagannath", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Irwin", "suffix": ""}, {"first": "S", "middle": ["V"], "last": "Rajkumar", "suffix": ""}, {"first": "G", "middle": [], "last": "Srkalovic", "suffix": ""}, {"first": "M", "middle": [], "last": "Alsina", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}], "year": 2006, "venue": "Cancer", "volume": "106", "issn": "6", "pages": "1316--1319", "other_ids": {"DOI": ["10.1002/cncr.21740"]}}, "BIBREF508": {"ref_id": "b508", "title": "A phase 2 study of bortezomib in relapsed, refractory myeloma", "authors": [], "year": null, "venue": "The New England Journal of Medicine", "volume": "348", "issn": "26", "pages": "2609--2617", "other_ids": {"DOI": ["10.1056/NEJMoa030288"]}}, "BIBREF509": {"ref_id": "b509", "title": "Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients", "authors": [{"first": "Paul", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "R", "middle": [], "last": "Baz", "suffix": ""}, {"first": "M", "middle": [], "last": "Wang", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Jakubowiak", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Laubach", "suffix": ""}, {"first": "R", "middle": ["D"], "last": "Harvey", "suffix": ""}, {"first": "M", "middle": [], "last": "Talpaz", "suffix": ""}, {"first": "D", "middle": [], "last": "Berg", "suffix": ""}, {"first": "G", "middle": [], "last": "Liu", "suffix": ""}, {"first": "J", "middle": [], "last": "Yu", "suffix": ""}, {"first": "N", "middle": [], "last": "Gupta", "suffix": ""}, {"first": "A", "middle": [], "last": "Di Bacco", "suffix": ""}, {"first": "A.-M", "middle": [], "last": "Hui", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonial", "suffix": ""}], "year": 2014, "venue": "Blood", "volume": "124", "issn": "7", "pages": "1038--1046", "other_ids": {"DOI": ["10.1182/blood-2014-01-548826"]}}, "BIBREF510": {"ref_id": "b510", "title": "Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib", "authors": [{"first": "Paul", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "H", "middle": [], "last": "Briemberg", "suffix": ""}, {"first": "S", "middle": [], "last": "Jagannath", "suffix": ""}, {"first": "P", "middle": ["Y"], "last": "Wen", "suffix": ""}, {"first": "B", "middle": [], "last": "Barlogie", "suffix": ""}, {"first": "J", "middle": [], "last": "Berenson", "suffix": ""}, {"first": "S", "middle": [], "last": "Singhal", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Siegel", "suffix": ""}, {"first": "D", "middle": [], "last": "Irwin", "suffix": ""}, {"first": "M", "middle": [], "last": "Schuster", "suffix": ""}, {"first": "G", "middle": [], "last": "Srkalovic", "suffix": ""}, {"first": "R", "middle": [], "last": "Alexanian", "suffix": ""}, {"first": "S", "middle": ["V"], "last": "Rajkumar", "suffix": ""}, {"first": "S", "middle": [], "last": "Limentani", "suffix": ""}, {"first": "M", "middle": [], "last": "Alsina", "suffix": ""}, {"first": "R", "middle": ["Z"], "last": "Orlowski", "suffix": ""}, {"first": "K", "middle": [], "last": "Najarian", "suffix": ""}, {"first": "D", "middle": [], "last": "Esseltine", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}, {"first": "A", "middle": ["A"], "last": "Amato", "suffix": ""}], "year": 2006, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "24", "issn": "19", "pages": "3113--3120", "other_ids": {}}, "BIBREF512": {"ref_id": "b512", "title": "Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma", "authors": [{"first": "Paul", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "C", "middle": ["C"], "last": "Hofmeister", "suffix": ""}, {"first": "C", "middle": ["A"], "last": "Rosenbaum", "suffix": ""}, {"first": "M", "middle": [], "last": "Htut", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Vesole", "suffix": ""}, {"first": "J", "middle": ["G"], "last": "Berdeja", "suffix": ""}, {"first": "M", "middle": [], "last": "Liedtke", "suffix": ""}, {"first": "A", "middle": [], "last": "Chari", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Smith", "suffix": ""}, {"first": "D", "middle": [], "last": "Lebovic", "suffix": ""}, {"first": "N", "middle": [], "last": "Raje", "suffix": ""}, {"first": "C", "middle": [], "last": "Byrne", "suffix": ""}, {"first": "E", "middle": [], "last": "Liao", "suffix": ""}, {"first": "N", "middle": [], "last": "Gupta", "suffix": ""}, {"first": "A", "middle": ["D"], "last": "Bacco", "suffix": ""}, {"first": "J", "middle": [], "last": "Estevam", "suffix": ""}, {"first": "D", "middle": [], "last": "Berg", "suffix": ""}, {"first": "R", "middle": [], "last": "Baz", "suffix": ""}], "year": 2018, "venue": "British Journal of Haematology", "volume": "182", "issn": "2", "pages": "231--244", "other_ids": {"DOI": ["10.1111/bjh.15394"]}}, "BIBREF513": {"ref_id": "b513", "title": "Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor", "authors": [{"first": "Paul", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "C", "middle": ["C"], "last": "Hofmeister", "suffix": ""}, {"first": "C", "middle": ["A"], "last": "Rosenbaum", "suffix": ""}, {"first": "M", "middle": [], "last": "Htut", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Vesole", "suffix": ""}, {"first": "J", "middle": [], "last": "Berdeja", "suffix": ""}, {"first": "M", "middle": [], "last": "Liedtke", "suffix": ""}, {"first": "A", "middle": [], "last": "Chari", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Smith", "suffix": ""}, {"first": "D", "middle": [], "last": "Lebovic", "suffix": ""}, {"first": "D", "middle": [], "last": "Berg", "suffix": ""}, {"first": "E", "middle": [], "last": "Liao", "suffix": ""}, {"first": "N", "middle": [], "last": "Gupta", "suffix": ""}, {"first": "A", "middle": [], "last": "Di Bacco", "suffix": ""}, {"first": "J", "middle": [], "last": "Estevam", "suffix": ""}, {"first": "A.-M", "middle": [], "last": "Hui", "suffix": ""}, {"first": "R", "middle": [], "last": "Baz", "suffix": ""}], "year": 2013, "venue": "Combination With Lenalidomide (Len) and", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF514": {"ref_id": "b514", "title": "Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data", "authors": [], "year": null, "venue": "Blood", "volume": "122", "issn": "21", "pages": "535--535", "other_ids": {}}, "BIBREF516": {"ref_id": "b516", "title": "Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label", "authors": [{"first": "Paul", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "A", "middle": [], "last": "Oriol", "suffix": ""}, {"first": "M", "middle": [], "last": "Beksac", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Liberati", "suffix": ""}, {"first": "M", "middle": [], "last": "Galli", "suffix": ""}, {"first": "F", "middle": [], "last": "Schjesvold", "suffix": ""}, {"first": "J", "middle": [], "last": "Lindsay", "suffix": ""}, {"first": "K", "middle": [], "last": "Weisel", "suffix": ""}, {"first": "D", "middle": [], "last": "White", "suffix": ""}, {"first": "T", "middle": [], "last": "Facon", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Miguel", "suffix": ""}, {"first": "K", "middle": [], "last": "Sunami", "suffix": ""}, {"first": "P", "middle": [], "last": "O&apos;gorman", "suffix": ""}, {"first": "P", "middle": [], "last": "Sonneveld", "suffix": ""}, {"first": "P", "middle": [], "last": "Robak", "suffix": ""}, {"first": "S", "middle": [], "last": "Semochkin", "suffix": ""}, {"first": "S", "middle": [], "last": "Schey", "suffix": ""}, {"first": "X", "middle": [], "last": "Yu", "suffix": ""}, {"first": "T", "middle": [], "last": "Doerr", "suffix": ""}, {"first": "A", "middle": [], "last": "Yee", "suffix": ""}], "year": 2019, "venue": "The Lancet Oncology", "volume": "20", "issn": "6", "pages": "781--794", "other_ids": {"DOI": ["10.1016/S1470-2045(19)30152-4"]}}, "BIBREF518": {"ref_id": "b518", "title": "Bortezomib or high-dose dexamethasone for relapsed multiple myeloma", "authors": [], "year": null, "venue": "The New England Journal of Medicine", "volume": "352", "issn": "24", "pages": "2487--2498", "other_ids": {"DOI": ["10.1056/NEJMoa043445"]}}, "BIBREF519": {"ref_id": "b519", "title": "Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial", "authors": [{"first": "Paul", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "P", "middle": [], "last": "Sonneveld", "suffix": ""}, {"first": "M", "middle": [], "last": "Schuster", "suffix": ""}, {"first": "D", "middle": [], "last": "Irwin", "suffix": ""}, {"first": "E", "middle": [], "last": "Stadtmauer", "suffix": ""}, {"first": "T", "middle": [], "last": "Facon", "suffix": ""}, {"first": "J.-L", "middle": [], "last": "Harousseau", "suffix": ""}, {"first": "D", "middle": [], "last": "Ben-Yehuda", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonial", "suffix": ""}, {"first": "H", "middle": [], "last": "Goldschmidt", "suffix": ""}, {"first": "D", "middle": [], "last": "Reece", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Miguel", "suffix": ""}, {"first": "J", "middle": [], "last": "Blad\u00e9", "suffix": ""}, {"first": "M", "middle": [], "last": "Boccadoro", "suffix": ""}, {"first": "J", "middle": [], "last": "Cavenagh", "suffix": ""}, {"first": "M", "middle": [], "last": "Alsina", "suffix": ""}, {"first": "S", "middle": ["V"], "last": "Rajkumar", "suffix": ""}, {"first": "M", "middle": [], "last": "Lacy", "suffix": ""}, {"first": "A", "middle": [], "last": "Jakubowiak", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}], "year": 2007, "venue": "Blood", "volume": "110", "issn": "10", "pages": "3557--3560", "other_ids": {"DOI": ["10.1182/blood-2006-08-036947"]}}, "BIBREF521": {"ref_id": "b521", "title": "Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma", "authors": [], "year": null, "venue": "Blood", "volume": "116", "issn": "5", "pages": "679--686", "other_ids": {"DOI": ["10.1182/blood-2010-02-268862"]}}, "BIBREF522": {"ref_id": "b522", "title": "A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma", "authors": [{"first": "Paul", "middle": ["G"], "last": "Richardson", "suffix": ""}, {"first": "W", "middle": [], "last": "Xie", "suffix": ""}, {"first": "S", "middle": [], "last": "Jagannath", "suffix": ""}, {"first": "A", "middle": [], "last": "Jakubowiak", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonial", "suffix": ""}, {"first": "N", "middle": ["S"], "last": "Raje", "suffix": ""}, {"first": "M", "middle": [], "last": "Alsina", "suffix": ""}, {"first": "I", "middle": ["M"], "last": "Ghobrial", "suffix": ""}, {"first": "R", "middle": ["L"], "last": "Schlossman", "suffix": ""}, {"first": "N", "middle": ["C"], "last": "Munshi", "suffix": ""}, {"first": "A", "middle": [], "last": "Mazumder", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Vesole", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Kaufman", "suffix": ""}, {"first": "K", "middle": [], "last": "Colson", "suffix": ""}, {"first": "M", "middle": [], "last": "Mckenney", "suffix": ""}, {"first": "L", "middle": ["E"], "last": "Lunde", "suffix": ""}, {"first": "J", "middle": [], "last": "Feather", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Maglio", "suffix": ""}, {"first": "D", "middle": [], "last": "Warren", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}], "year": 2014, "venue": "Blood", "volume": "123", "issn": "10", "pages": "1461--1469", "other_ids": {"DOI": ["10.1182/blood-2013-07-517276"]}}, "BIBREF523": {"ref_id": "b523", "title": "Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later", "authors": [{"first": "P", "middle": [], "last": "Robak", "suffix": ""}, {"first": "T", "middle": [], "last": "Robak", "suffix": ""}], "year": 2019, "venue": "Drugs in R&D", "volume": "19", "issn": "2", "pages": "73--92", "other_ids": {"DOI": ["10.1007/s40268-019-0269-9"]}}, "BIBREF524": {"ref_id": "b524", "title": "Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma", "authors": [{"first": "T", "middle": [], "last": "Robak", "suffix": ""}, {"first": "H", "middle": [], "last": "Huang", "suffix": ""}, {"first": "J", "middle": [], "last": "Jin", "suffix": ""}, {"first": "J", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "T", "middle": [], "last": "Liu", "suffix": ""}, {"first": "O", "middle": [], "last": "Samoilova", "suffix": ""}, {"first": "H", "middle": [], "last": "Pylypenko", "suffix": ""}, {"first": "G", "middle": [], "last": "Verhoef", "suffix": ""}, {"first": "N", "middle": [], "last": "Siritanaratkul", "suffix": ""}, {"first": "E", "middle": [], "last": "Osmanov", "suffix": ""}, {"first": "J", "middle": [], "last": "Alexeeva", "suffix": ""}, {"first": "J", "middle": [], "last": "Pereira", "suffix": ""}, {"first": "J", "middle": [], "last": "Drach", "suffix": ""}, {"first": "J", "middle": [], "last": "Mayer", "suffix": ""}, {"first": "X", "middle": [], "last": "Hong", "suffix": ""}, {"first": "R", "middle": [], "last": "Okamoto", "suffix": ""}, {"first": "L", "middle": [], "last": "Pei", "suffix": ""}, {"first": "B", "middle": [], "last": "Rooney", "suffix": ""}, {"first": "H", "middle": [], "last": "Van De Velde", "suffix": ""}, {"first": "F", "middle": [], "last": "Cavalli", "suffix": ""}], "year": 2015, "venue": "New England Journal of Medicine", "volume": "372", "issn": "10", "pages": "944--953", "other_ids": {"DOI": ["10.1056/NEJMoa1412096"]}}, "BIBREF525": {"ref_id": "b525", "title": "Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP", "authors": [{"first": "T", "middle": [], "last": "Robak", "suffix": ""}, {"first": "H", "middle": [], "last": "Huang", "suffix": ""}, {"first": "J", "middle": [], "last": "Jin", "suffix": ""}, {"first": "J", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "T", "middle": [], "last": "Liu", "suffix": ""}, {"first": "O", "middle": [], "last": "Samoilova", "suffix": ""}, {"first": "H", "middle": [], "last": "Pylypenko", "suffix": ""}, {"first": "G", "middle": [], "last": "Verhoef", "suffix": ""}, {"first": "N", "middle": [], "last": "Siritanaratkul", "suffix": ""}, {"first": "E", "middle": [], "last": "Osmanov", "suffix": ""}, {"first": "J", "middle": [], "last": "Pereira", "suffix": ""}, {"first": "J", "middle": [], "last": "Mayer", "suffix": ""}, {"first": "X", "middle": [], "last": "Hong", "suffix": ""}, {"first": "R", "middle": [], "last": "Okamoto", "suffix": ""}, {"first": "L", "middle": [], "last": "Pei", "suffix": ""}, {"first": "B", "middle": [], "last": "Rooney", "suffix": ""}, {"first": "H", "middle": [], "last": "Van De Velde", "suffix": ""}, {"first": "F", "middle": [], "last": "Cavalli", "suffix": ""}], "year": 2019, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF527": {"ref_id": "b527", "title": "Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study", "authors": [{"first": "T", "middle": [], "last": "Robak", "suffix": ""}, {"first": "J", "middle": [], "last": "Jin", "suffix": ""}, {"first": "H", "middle": [], "last": "Pylypenko", "suffix": ""}, {"first": "G", "middle": [], "last": "Verhoef", "suffix": ""}, {"first": "N", "middle": [], "last": "Siritanaratkul", "suffix": ""}, {"first": "J", "middle": [], "last": "Drach", "suffix": ""}, {"first": "M", "middle": [], "last": "Raderer", "suffix": ""}, {"first": "J", "middle": [], "last": "Mayer", "suffix": ""}, {"first": "J", "middle": [], "last": "Pereira", "suffix": ""}, {"first": "G", "middle": [], "last": "Tumyan", "suffix": ""}, {"first": "R", "middle": [], "last": "Okamoto", "suffix": ""}, {"first": "S", "middle": [], "last": "Nakahara", "suffix": ""}, {"first": "P", "middle": [], "last": "Hu", "suffix": ""}, {"first": "C", "middle": [], "last": "Appiani", "suffix": ""}, {"first": "S", "middle": [], "last": "Nemat", "suffix": ""}, {"first": "F", "middle": [], "last": "Cavalli", "suffix": ""}], "year": 2018, "venue": "The Lancet. Oncology", "volume": "19", "issn": "11", "pages": "30685--30690", "other_ids": {"DOI": ["10.1016/S1470-2045"]}}, "BIBREF528": {"ref_id": "b528", "title": "Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management", "authors": [{"first": "G", "middle": [], "last": "Roberti", "suffix": ""}, {"first": "F", "middle": [], "last": "Oddone", "suffix": ""}, {"first": "L", "middle": [], "last": "Agnifili", "suffix": ""}, {"first": "A", "middle": [], "last": "Katsanos", "suffix": ""}, {"first": "M", "middle": [], "last": "Michelessi", "suffix": ""}, {"first": "L", "middle": [], "last": "Mastropasqua", "suffix": ""}, {"first": "L", "middle": [], "last": "Quaranta", "suffix": ""}, {"first": "I", "middle": [], "last": "Riva", "suffix": ""}, {"first": "L", "middle": [], "last": "Tanga", "suffix": ""}, {"first": "G", "middle": [], "last": "Manni", "suffix": ""}], "year": 2020, "venue": "Survey of Ophthalmology", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.survophthal.2020.01.002"]}}, "BIBREF530": {"ref_id": "b530", "title": "Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives", "authors": [], "year": null, "venue": "International Journal of Molecular Sciences", "volume": "16", "issn": "12", "pages": "28401--28417", "other_ids": {"DOI": ["10.3390/ijms161226099"]}}, "BIBREF531": {"ref_id": "b531", "title": "Chaperone-mediated pathway of proteasome regulatory particle assembly", "authors": [{"first": "J", "middle": [], "last": "Roelofs", "suffix": ""}, {"first": "S", "middle": [], "last": "Park", "suffix": ""}, {"first": "W", "middle": [], "last": "Haas", "suffix": ""}, {"first": "G", "middle": [], "last": "Tian", "suffix": ""}, {"first": "F", "middle": ["E"], "last": "Mcallister", "suffix": ""}, {"first": "Y", "middle": [], "last": "Huo", "suffix": ""}, {"first": "B.-H", "middle": [], "last": "Lee", "suffix": ""}, {"first": "F", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shi", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Gygi", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}], "year": 2009, "venue": "Nature", "volume": "", "issn": "7248", "pages": "861--865", "other_ids": {"DOI": ["10.1038/nature08063"]}}, "BIBREF532": {"ref_id": "b532", "title": "Positioning of proteasome inhibitors in therapy of solid malignancies", "authors": [{"first": "M", "middle": ["S F"], "last": "Roeten", "suffix": ""}, {"first": "J", "middle": [], "last": "Cloos", "suffix": ""}, {"first": "G", "middle": [], "last": "Jansen", "suffix": ""}], "year": 2018, "venue": "Cancer Chemotherapy and Pharmacology", "volume": "81", "issn": "2", "pages": "227--243", "other_ids": {}}, "BIBREF534": {"ref_id": "b534", "title": "Impaired Visual Search in Children with Rett Syndrome", "authors": [{"first": "S", "middle": ["A"], "last": "Rose", "suffix": ""}, {"first": "S", "middle": [], "last": "Wass", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Jankowski", "suffix": ""}, {"first": "J", "middle": ["F"], "last": "Feldman", "suffix": ""}, {"first": "A", "middle": [], "last": "Djukic", "suffix": ""}], "year": 2019, "venue": "Pediatric Neurology", "volume": "92", "issn": "", "pages": "26--31", "other_ids": {}}, "BIBREF536": {"ref_id": "b536", "title": "Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function", "authors": [{"first": "K", "middle": ["M"], "last": "Rosen", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "Moussa", "suffix": ""}, {"first": ".-H", "middle": [], "last": "Lee", "suffix": ""}, {"first": "H.-K", "middle": [], "last": "Kumar", "suffix": ""}, {"first": "P", "middle": [], "last": "Kitada", "suffix": ""}, {"first": "T", "middle": [], "last": "Qin", "suffix": ""}, {"first": "G", "middle": [], "last": "Fu", "suffix": ""}, {"first": "Q", "middle": [], "last": "Querfurth", "suffix": ""}, {"first": "H", "middle": ["W"], "last": "", "suffix": ""}], "year": 2010, "venue": "Journal of Neuroscience Research", "volume": "88", "issn": "1", "pages": "167--178", "other_ids": {}}, "BIBREF538": {"ref_id": "b538", "title": "PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma", "authors": [{"first": "C", "middle": ["L"], "last": "Rosenberg", "suffix": ""}, {"first": "E", "middle": [], "last": "Wong", "suffix": ""}, {"first": "E", "middle": ["M"], "last": "Petty", "suffix": ""}, {"first": "A", "middle": ["E"], "last": "Bale", "suffix": ""}, {"first": "Y", "middle": [], "last": "Tsujimoto", "suffix": ""}, {"first": "N", "middle": ["L"], "last": "Harris", "suffix": ""}, {"first": "A", "middle": [], "last": "Arnold", "suffix": ""}], "year": 1991, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "88", "issn": "", "pages": "9638--9642", "other_ids": {"DOI": ["10.1073/pnas.88.21.9638"]}}, "BIBREF539": {"ref_id": "b539", "title": "Degradation of ornithine decarboxylase in mammalian cells is ATP dependent but ubiquitin independent", "authors": [{"first": "Y", "middle": [], "last": "Rosenberg-Hasson", "suffix": ""}, {"first": "Z", "middle": [], "last": "Bercovich", "suffix": ""}, {"first": "A", "middle": [], "last": "Ciechanover", "suffix": ""}, {"first": "C", "middle": [], "last": "Kahana", "suffix": ""}], "year": 1989, "venue": "European Journal of Biochemistry", "volume": "185", "issn": "2", "pages": "469--474", "other_ids": {"DOI": ["10.1111/j.1432-1033.1989.tb15138.x"]}}, "BIBREF540": {"ref_id": "b540", "title": "Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma", "authors": [{"first": "L", "middle": [], "last": "Rosi\u00f1ol", "suffix": ""}, {"first": "A", "middle": [], "last": "Oriol", "suffix": ""}, {"first": "R", "middle": [], "last": "Rios", "suffix": ""}, {"first": "A", "middle": [], "last": "Sureda", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Blanchard", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Hern\u00e1ndez", "suffix": ""}, {"first": "R", "middle": [], "last": "Mart\u00ednez-Mart\u00ednez", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Moraleda", "suffix": ""}, {"first": "I", "middle": [], "last": "Jarque", "suffix": ""}, {"first": "J", "middle": [], "last": "Bargay", "suffix": ""}, {"first": "M", "middle": [], "last": "Gironella", "suffix": ""}, {"first": "F", "middle": [], "last": "De Arriba", "suffix": ""}, {"first": "L", "middle": [], "last": "Palomera", "suffix": ""}, {"first": "Y", "middle": [], "last": "Gonz\u00e1lez-Montes", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Mart\u00ed", "suffix": ""}, {"first": "I", "middle": [], "last": "Krsnik", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Argui\u00f1ano", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Gonz\u00e1lez", "suffix": ""}, {"first": "A", "middle": ["P"], "last": "Gonz\u00e1lez", "suffix": ""}, {"first": "J", "middle": [], "last": "Blad\u00e9", "suffix": ""}], "year": 2019, "venue": "Blood", "volume": "134", "issn": "16", "pages": "1337--1345", "other_ids": {}}, "BIBREF542": {"ref_id": "b542", "title": "Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study", "authors": [{"first": "L", "middle": [], "last": "Rosi\u00f1ol", "suffix": ""}, {"first": "A", "middle": [], "last": "Oriol", "suffix": ""}, {"first": "A", "middle": ["I"], "last": "Teruel", "suffix": ""}, {"first": "D", "middle": [], "last": "Hern\u00e1ndez", "suffix": ""}, {"first": "J", "middle": [], "last": "L\u00f3pez-Jim\u00e9nez", "suffix": ""}, {"first": "J", "middle": [], "last": "De La Rubia", "suffix": ""}, {"first": "M", "middle": [], "last": "Granell", "suffix": ""}, {"first": "J", "middle": [], "last": "Besalduch", "suffix": ""}, {"first": "L", "middle": [], "last": "Palomera", "suffix": ""}, {"first": "Y", "middle": [], "last": "Gonz\u00e1lez", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Etxebeste", "suffix": ""}, {"first": "J", "middle": [], "last": "D\u00edaz-Mediavilla", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Hern\u00e1ndez", "suffix": ""}, {"first": "F", "middle": [], "last": "De Arriba", "suffix": ""}, {"first": "N", "middle": ["C"], "last": "Guti\u00e9rrez", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Mart\u00edn-Ramos", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Cibeira", "suffix": ""}, {"first": "M", "middle": ["V"], "last": "Mateos", "suffix": ""}, {"first": "J", "middle": [], "last": "Mart\u00ednez", "suffix": ""}], "year": 2012, "venue": "Blood", "volume": "120", "issn": "8", "pages": "1589--1596", "other_ids": {"DOI": ["10.1182/blood-2012-02-408922"]}}, "BIBREF543": {"ref_id": "b543", "title": "An evolutionarily conserved pathway controls proteasome homeostasis", "authors": [{"first": "A", "middle": [], "last": "Rousseau", "suffix": ""}, {"first": "A", "middle": [], "last": "Bertolotti", "suffix": ""}], "year": 2016, "venue": "Nature", "volume": "536", "issn": "7615", "pages": "184--189", "other_ids": {"DOI": ["10.1038/nature18943"]}}, "BIBREF544": {"ref_id": "b544", "title": "Regulation of proteasome assembly and activity in health and disease", "authors": [{"first": "A", "middle": [], "last": "Rousseau", "suffix": ""}, {"first": "A", "middle": [], "last": "Bertolotti", "suffix": ""}], "year": 2018, "venue": "Nature Reviews Molecular Cell Biology", "volume": "19", "issn": "11", "pages": "697--712", "other_ids": {}}, "BIBREF546": {"ref_id": "b546", "title": "Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du My\u00e9lome", "authors": [{"first": "M", "middle": [], "last": "Roussel", "suffix": ""}, {"first": "V", "middle": [], "last": "Lauwers-Cances", "suffix": ""}, {"first": "N", "middle": [], "last": "Robillard", "suffix": ""}, {"first": "C", "middle": [], "last": "Hulin", "suffix": ""}, {"first": "X", "middle": [], "last": "Leleu", "suffix": ""}, {"first": "L", "middle": [], "last": "Benboubker", "suffix": ""}, {"first": "G", "middle": [], "last": "Marit", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "B", "middle": [], "last": "Pegourie", "suffix": ""}, {"first": "D", "middle": [], "last": "Caillot", "suffix": ""}, {"first": "C", "middle": [], "last": "Fruchart", "suffix": ""}, {"first": "A.-M", "middle": [], "last": "Stoppa", "suffix": ""}, {"first": "C", "middle": [], "last": "Gentil", "suffix": ""}, {"first": "S", "middle": [], "last": "Wuilleme", "suffix": ""}, {"first": "A", "middle": [], "last": "Huynh", "suffix": ""}, {"first": "B", "middle": [], "last": "Hebraud", "suffix": ""}, {"first": "J", "middle": [], "last": "Corre", "suffix": ""}, {"first": "M.-L", "middle": [], "last": "Chretien", "suffix": ""}, {"first": "T", "middle": [], "last": "Facon", "suffix": ""}, {"first": "M", "middle": [], "last": "Attal", "suffix": ""}], "year": 2014, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "32", "issn": "25", "pages": "2712--2717", "other_ids": {"DOI": ["10.1200/JCO.2013.54.8164"]}}, "BIBREF548": {"ref_id": "b548", "title": "Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma", "authors": [], "year": null, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "29", "issn": "6", "pages": "690--697", "other_ids": {"DOI": ["10.1200/JCO.2010.31.1142"]}}, "BIBREF549": {"ref_id": "b549", "title": "Active site mutants in the six regulatory particle ATPases reveal multiple roles for ATP in the proteasome", "authors": [{"first": "D", "middle": ["M"], "last": "Rubin", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Glickman", "suffix": ""}, {"first": "C", "middle": ["N"], "last": "Larsen", "suffix": ""}, {"first": "S", "middle": [], "last": "Dhruvakumar", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}], "year": 1998, "venue": "The EMBO Journal", "volume": "17", "issn": "17", "pages": "4909--4919", "other_ids": {"DOI": ["10.1093/emboj/17.17.4909"]}}, "BIBREF550": {"ref_id": "b550", "title": "Kinetic mechanism of activation by cardiolipin (diphosphatidylglycerol) of the rat liver multicatalytic proteinase", "authors": [{"first": "I", "middle": [], "last": "Ruiz De Mena", "suffix": ""}, {"first": "E", "middle": [], "last": "Mahillo", "suffix": ""}, {"first": "J", "middle": [], "last": "Arribas", "suffix": ""}, {"first": "J", "middle": ["G"], "last": "Casta\u00f1o", "suffix": ""}], "year": 1993, "venue": "Biochemical Journal", "volume": "296", "issn": "1", "pages": "93--97", "other_ids": {"DOI": ["10.1042/bj2960093"]}}, "BIBREF551": {"ref_id": "b551", "title": "The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia", "authors": [{"first": "S", "middle": [], "last": "Ruiz", "suffix": ""}, {"first": "Y", "middle": [], "last": "Krupnik", "suffix": ""}, {"first": "M", "middle": [], "last": "Keating", "suffix": ""}, {"first": "J", "middle": [], "last": "Chandra", "suffix": ""}, {"first": "M", "middle": [], "last": "Palladino", "suffix": ""}, {"first": "D", "middle": [], "last": "Mcconkey", "suffix": ""}], "year": 2006, "venue": "Molecular Cancer Therapeutics", "volume": "5", "issn": "7", "pages": "1836--1843", "other_ids": {"DOI": ["10.1158/1535-7163.MCT-06-0066"]}}, "BIBREF552": {"ref_id": "b552", "title": "The proteasome antechamber maintains substrates in an unfolded state", "authors": [{"first": "A", "middle": ["M"], "last": "Ruschak", "suffix": ""}, {"first": "T", "middle": ["L"], "last": "Religa", "suffix": ""}, {"first": "S", "middle": [], "last": "Breuer", "suffix": ""}, {"first": "S", "middle": [], "last": "Witt", "suffix": ""}, {"first": "L", "middle": ["E"], "last": "Kay", "suffix": ""}], "year": 2010, "venue": "Nature", "volume": "467", "issn": "7317", "pages": "868--871", "other_ids": {"DOI": ["10.1038/nature09444"]}}, "BIBREF553": {"ref_id": "b553", "title": "Christian de Duve: Explorer of the cell who discovered new organelles by using a centrifuge", "authors": [{"first": "D", "middle": ["D"], "last": "Sabatini", "suffix": ""}, {"first": "M", "middle": [], "last": "Adesnik", "suffix": ""}], "year": 2013, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "110", "issn": "", "pages": "13234--13235", "other_ids": {"DOI": ["10.1073/pnas.1312084110"]}}, "BIBREF554": {"ref_id": "b554", "title": "Structure of a Blm10 complex reveals common mechanisms for proteasome binding and gate opening", "authors": [{"first": "K", "middle": [], "last": "Sadre-Bazzaz", "suffix": ""}, {"first": "F", "middle": ["G"], "last": "Whitby", "suffix": ""}, {"first": "H", "middle": [], "last": "Robinson", "suffix": ""}, {"first": "T", "middle": [], "last": "Formosa", "suffix": ""}, {"first": "C", "middle": ["P"], "last": "Hill", "suffix": ""}], "year": 2010, "venue": "Molecular Cell", "volume": "37", "issn": "5", "pages": "728--735", "other_ids": {"DOI": ["10.1016/j.molcel.2010.02.002"]}}, "BIBREF555": {"ref_id": "b555", "title": "Assembly and function of the proteasome", "authors": [{"first": "Y", "middle": [], "last": "Saeki", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}], "year": 2012, "venue": "Methods in Molecular Biology", "volume": "832", "issn": "", "pages": "315--337", "other_ids": {"DOI": ["10.1007/978-1-61779-474-2_22"]}}, "BIBREF556": {"ref_id": "b556", "title": "Ubiquitin-like proteins and Rpn10 play cooperative roles in ubiquitin-dependent proteolysis", "authors": [{"first": "Y", "middle": [], "last": "Saeki", "suffix": ""}, {"first": "A", "middle": [], "last": "Saitoh", "suffix": ""}, {"first": "A", "middle": [], "last": "Toh-E", "suffix": ""}, {"first": "H", "middle": [], "last": "Yokosawa", "suffix": ""}], "year": 2002, "venue": "Biochemical and Biophysical Research Communications", "volume": "293", "issn": "3", "pages": "340--346", "other_ids": {"DOI": ["10.1016/S0006-291X(02"]}}, "BIBREF557": {"ref_id": "b557", "title": "Multiple Proteasome-Interacting Proteins Assist the Assembly of the Yeast 19S Regulatory Particle", "authors": [{"first": "Y", "middle": [], "last": "Saeki", "suffix": ""}, {"first": "A", "middle": [], "last": "Toh-E", "suffix": ""}, {"first": "T", "middle": [], "last": "Kudo", "suffix": ""}, {"first": "H", "middle": [], "last": "Kawamura", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}], "year": 2009, "venue": "Cell", "volume": "137", "issn": "5", "pages": "900--913", "other_ids": {"DOI": ["10.1016/j.cell.2009.05.005"]}}, "BIBREF558": {"ref_id": "b558", "title": "Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntington's disease", "authors": [{"first": "N", "middle": [], "last": "Safren", "suffix": ""}, {"first": "A", "middle": [], "last": "El Ayadi", "suffix": ""}, {"first": "L", "middle": [], "last": "Chang", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "Terrillion", "suffix": ""}, {"first": "T", "middle": ["D"], "last": "Gould", "suffix": ""}, {"first": "D", "middle": ["F"], "last": "Boehning", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Monteiro", "suffix": ""}], "year": 2014, "venue": "PloS One", "volume": "9", "issn": "1", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0087513"]}}, "BIBREF559": {"ref_id": "b559", "title": "Shaping proteostasis at the cellular, tissue, and organismal level", "authors": [{"first": "A", "middle": ["J"], "last": "Sala", "suffix": ""}, {"first": "L", "middle": ["C"], "last": "Bott", "suffix": ""}, {"first": "R", "middle": ["I"], "last": "Morimoto", "suffix": ""}], "year": 2017, "venue": "The Journal of Cell Biology", "volume": "216", "issn": "5", "pages": "1231--1241", "other_ids": {}}, "BIBREF562": {"ref_id": "b562", "title": "Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma", "authors": [{"first": "M", "middle": [], "last": "Delforge", "suffix": ""}, {"first": "B", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "M.-V", "middle": [], "last": "Mateos", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}, {"first": "D.-L", "middle": [], "last": "Esseltine", "suffix": ""}, {"first": "K", "middle": [], "last": "Liu", "suffix": ""}, {"first": "W", "middle": [], "last": "Deraedt", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}], "year": 2013, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "31", "issn": "4", "pages": "448--455", "other_ids": {"DOI": ["10.1200/JCO.2012.41.6180"]}}, "BIBREF563": {"ref_id": "b563", "title": "Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma", "authors": [{"first": "J", "middle": ["F"], "last": "San Miguel", "suffix": ""}, {"first": "R", "middle": [], "last": "Schlag", "suffix": ""}, {"first": "N", "middle": ["K"], "last": "Khuageva", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}, {"first": "O", "middle": [], "last": "Shpilberg", "suffix": ""}, {"first": "M", "middle": [], "last": "Kropff", "suffix": ""}, {"first": "I", "middle": [], "last": "Spicka", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Petrucci", "suffix": ""}, {"first": "A", "middle": [], "last": "Palumbo", "suffix": ""}, {"first": "O", "middle": ["S"], "last": "Samoilova", "suffix": ""}, {"first": "A", "middle": [], "last": "Dmoszynska", "suffix": ""}, {"first": "K", "middle": ["M"], "last": "Abdulkadyrov", "suffix": ""}, {"first": "R", "middle": [], "last": "Schots", "suffix": ""}, {"first": "B", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "M.-V", "middle": [], "last": "Mateos", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}, {"first": "D", "middle": ["L"], "last": "Esseltine", "suffix": ""}, {"first": "K", "middle": [], "last": "Liu", "suffix": ""}, {"first": "A", "middle": [], "last": "Cakana", "suffix": ""}, {"first": "\u2026", "middle": [], "last": "Vista", "suffix": ""}], "year": 2008, "venue": "The New England Journal of Medicine", "volume": "359", "issn": "9", "pages": "906--917", "other_ids": {"DOI": ["10.1056/NEJMoa0801479"]}}, "BIBREF564": {"ref_id": "b564", "title": "Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma", "authors": [{"first": "J", "middle": ["F"], "last": "San Miguel", "suffix": ""}, {"first": "R", "middle": [], "last": "Schlag", "suffix": ""}, {"first": "N", "middle": ["K"], "last": "Khuageva", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}, {"first": "O", "middle": [], "last": "Shpilberg", "suffix": ""}, {"first": "M", "middle": [], "last": "Kropff", "suffix": ""}, {"first": "I", "middle": [], "last": "Spicka", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Petrucci", "suffix": ""}, {"first": "A", "middle": [], "last": "Palumbo", "suffix": ""}, {"first": "O", "middle": ["S"], "last": "Samoilova", "suffix": ""}, {"first": "A", "middle": [], "last": "Dmoszynska", "suffix": ""}, {"first": "K", "middle": ["M"], "last": "Abdulkadyrov", "suffix": ""}, {"first": "R", "middle": [], "last": "Schots", "suffix": ""}, {"first": "B", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "M.-V", "middle": [], "last": "Mateos", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}, {"first": "D", "middle": ["L"], "last": "Esseltine", "suffix": ""}, {"first": "K", "middle": [], "last": "Liu", "suffix": ""}, {"first": "A", "middle": [], "last": "Cakana", "suffix": ""}, {"first": "\u2026", "middle": [], "last": "Vista", "suffix": ""}], "year": 2008, "venue": "The New England Journal of Medicine", "volume": "359", "issn": "9", "pages": "906--917", "other_ids": {"DOI": ["10.1056/NEJMoa0801479"]}}, "BIBREF565": {"ref_id": "b565", "title": "Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System. Anti-Cancer Drugs", "authors": [{"first": "A", "middle": [], "last": "Sanagawa", "suffix": ""}, {"first": "Y", "middle": [], "last": "Hotta", "suffix": ""}, {"first": "M", "middle": [], "last": "Kondo", "suffix": ""}, {"first": "R", "middle": [], "last": "Nishikawa", "suffix": ""}, {"first": "M", "middle": [], "last": "Tohkin", "suffix": ""}, {"first": "K", "middle": [], "last": "Kimura", "suffix": ""}], "year": 2020, "venue": "", "volume": "31", "issn": "", "pages": "183--189", "other_ids": {"DOI": ["10.1097/CAD.0000000000000862"]}}, "BIBREF566": {"ref_id": "b566", "title": "CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma", "authors": [{"first": "E", "middle": [], "last": "Sanchez", "suffix": ""}, {"first": "M", "middle": [], "last": "Li", "suffix": ""}, {"first": "J", "middle": [], "last": "Li", "suffix": ""}, {"first": "C", "middle": [], "last": "Wang", "suffix": ""}, {"first": "H", "middle": [], "last": "Chen", "suffix": ""}, {"first": "S", "middle": [], "last": "Jones-Bolin", "suffix": ""}, {"first": "K", "middle": [], "last": "Hunter", "suffix": ""}, {"first": "B", "middle": [], "last": "Ruggeri", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Berenson", "suffix": ""}], "year": 2012, "venue": "Leukemia Research", "volume": "36", "issn": "11", "pages": "1422--1427", "other_ids": {"DOI": ["10.1016/j.leukres.2012.07.018"]}}, "BIBREF567": {"ref_id": "b567", "title": "The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan", "authors": [{"first": "E", "middle": [], "last": "Sanchez", "suffix": ""}, {"first": "M", "middle": [], "last": "Li", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Steinberg", "suffix": ""}, {"first": "C", "middle": [], "last": "Wang", "suffix": ""}, {"first": "J", "middle": [], "last": "Shen", "suffix": ""}, {"first": "B", "middle": [], "last": "Bonavida", "suffix": ""}, {"first": "Z.-W", "middle": [], "last": "Li", "suffix": ""}, {"first": "H", "middle": [], "last": "Chen", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Berenson", "suffix": ""}], "year": 2010, "venue": "British Journal of Haematology", "volume": "148", "issn": "4", "pages": "569--581", "other_ids": {}}, "BIBREF569": {"ref_id": "b569", "title": "Antiangiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex)", "authors": [{"first": "E", "middle": [], "last": "Sanchez", "suffix": ""}, {"first": "M", "middle": [], "last": "Li", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Wang", "suffix": ""}, {"first": "G", "middle": [], "last": "Tang", "suffix": ""}, {"first": "A", "middle": [], "last": "Gillespie", "suffix": ""}, {"first": "H", "middle": [], "last": "Chen", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Berenson", "suffix": ""}], "year": 2017, "venue": "Leukemia Research", "volume": "57", "issn": "", "pages": "45--54", "other_ids": {"DOI": ["10.1016/j.leukres.2017.03.002"]}}, "BIBREF570": {"ref_id": "b570", "title": "Success in translational research: lessons from the development of bortezomib", "authors": [{"first": "I", "middle": [], "last": "S\u00e1nchez-Serrano", "suffix": ""}], "year": 2006, "venue": "Nature Reviews. Drug Discovery", "volume": "5", "issn": "2", "pages": "107--114", "other_ids": {"DOI": ["10.1038/nrd1959"]}}, "BIBREF571": {"ref_id": "b571", "title": "A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis", "authors": [{"first": "V", "middle": [], "last": "Sanchorawala", "suffix": ""}, {"first": "G", "middle": [], "last": "Palladini", "suffix": ""}, {"first": "V", "middle": [], "last": "Kukreti", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Zonder", "suffix": ""}, {"first": "A", "middle": ["D"], "last": "Cohen", "suffix": ""}, {"first": "D", "middle": ["C"], "last": "Seldin", "suffix": ""}, {"first": "A", "middle": [], "last": "Dispenzieri", "suffix": ""}, {"first": "A", "middle": [], "last": "Jaccard", "suffix": ""}, {"first": "S", "middle": ["O"], "last": "Sch\u00f6nland", "suffix": ""}, {"first": "D", "middle": [], "last": "Berg", "suffix": ""}, {"first": "H", "middle": [], "last": "Yang", "suffix": ""}, {"first": "N", "middle": [], "last": "Gupta", "suffix": ""}, {"first": "A.-M", "middle": [], "last": "Hui", "suffix": ""}, {"first": "R", "middle": ["L"], "last": "Comenzo", "suffix": ""}, {"first": "G", "middle": [], "last": "Merlini", "suffix": ""}], "year": 2017, "venue": "Blood", "volume": "130", "issn": "5", "pages": "597--605", "other_ids": {"DOI": ["10.1182/blood-2017-03-771220"]}}, "BIBREF573": {"ref_id": "b573", "title": "A phase I/II dose-escalation study investigating all-oral ixazomibmelphalan-prednisone induction followed by single-agent ixazomib maintenance in transplantineligible newly diagnosed multiple myeloma", "authors": [{"first": "H", "middle": [], "last": "Velde", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonial", "suffix": ""}], "year": 2018, "venue": "Haematologica", "volume": "103", "issn": "9", "pages": "1518--1526", "other_ids": {}}, "BIBREF575": {"ref_id": "b575", "title": "Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial", "authors": [{"first": "J", "middle": ["F"], "last": "San-Miguel", "suffix": ""}, {"first": "V", "middle": ["T M"], "last": "Hungria", "suffix": ""}, {"first": "S.-S", "middle": [], "last": "Yoon", "suffix": ""}, {"first": "M", "middle": [], "last": "Beksac", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}, {"first": "A", "middle": [], "last": "Elghandour", "suffix": ""}, {"first": "W", "middle": ["W"], "last": "Jedrzejczak", "suffix": ""}, {"first": "A", "middle": [], "last": "G\u00fcnther", "suffix": ""}, {"first": "T", "middle": ["N"], "last": "Nakorn", "suffix": ""}, {"first": "N", "middle": [], "last": "Siritanaratkul", "suffix": ""}, {"first": "P", "middle": [], "last": "Corradini", "suffix": ""}, {"first": "S", "middle": [], "last": "Chuncharunee", "suffix": ""}, {"first": "J.-J", "middle": [], "last": "Lee", "suffix": ""}, {"first": "R", "middle": ["L"], "last": "Schlossman", "suffix": ""}, {"first": "T", "middle": [], "last": "Shelekhova", "suffix": ""}, {"first": "K", "middle": [], "last": "Yong", "suffix": ""}, {"first": "D", "middle": [], "last": "Tan", "suffix": ""}, {"first": "T", "middle": [], "last": "Numbenjapon", "suffix": ""}, {"first": "J", "middle": ["D"], "last": "Cavenagh", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}], "year": 2014, "venue": "The Lancet. Oncology", "volume": "15", "issn": "11", "pages": "1195--1206", "other_ids": {"DOI": ["10.1016/S1470-2045(14)70440-1"]}}, "BIBREF576": {"ref_id": "b576", "title": "Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial", "authors": [{"first": "J", "middle": ["F"], "last": "San-Miguel", "suffix": ""}, {"first": "V", "middle": ["T M"], "last": "Hungria", "suffix": ""}, {"first": "S.-S", "middle": [], "last": "Yoon", "suffix": ""}, {"first": "M", "middle": [], "last": "Beksac", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}, {"first": "A", "middle": [], "last": "Elghandour", "suffix": ""}, {"first": "W", "middle": ["W"], "last": "Jedrzejczak", "suffix": ""}, {"first": "A", "middle": [], "last": "G\u00fcnther", "suffix": ""}, {"first": "T", "middle": ["N"], "last": "Nakorn", "suffix": ""}, {"first": "N", "middle": [], "last": "Siritanaratkul", "suffix": ""}, {"first": "P", "middle": [], "last": "Corradini", "suffix": ""}, {"first": "S", "middle": [], "last": "Chuncharunee", "suffix": ""}, {"first": "J.-J", "middle": [], "last": "Lee", "suffix": ""}, {"first": "R", "middle": ["L"], "last": "Schlossman", "suffix": ""}, {"first": "T", "middle": [], "last": "Shelekhova", "suffix": ""}, {"first": "K", "middle": [], "last": "Yong", "suffix": ""}, {"first": "D", "middle": [], "last": "Tan", "suffix": ""}, {"first": "T", "middle": [], "last": "Numbenjapon", "suffix": ""}, {"first": "J", "middle": ["D"], "last": "Cavenagh", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}], "year": 2014, "venue": "The Lancet. Oncology", "volume": "15", "issn": "11", "pages": "1195--1206", "other_ids": {"DOI": ["10.1016/S1470-2045(14)70440-1"]}}, "BIBREF577": {"ref_id": "b577", "title": "Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised", "authors": [{"first": "J", "middle": ["F"], "last": "San-Miguel", "suffix": ""}, {"first": "V", "middle": ["T M"], "last": "Hungria", "suffix": ""}, {"first": "S.-S", "middle": [], "last": "Yoon", "suffix": ""}, {"first": "M", "middle": [], "last": "Beksac", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}, {"first": "A", "middle": [], "last": "Elghandour", "suffix": ""}, {"first": "W", "middle": ["W"], "last": "Jedrzejczak", "suffix": ""}, {"first": "A", "middle": [], "last": "G\u00fcnther", "suffix": ""}, {"first": "T", "middle": ["N"], "last": "Nakorn", "suffix": ""}, {"first": "N", "middle": [], "last": "Siritanaratkul", "suffix": ""}, {"first": "R", "middle": ["L"], "last": "Schlossman", "suffix": ""}, {"first": "J", "middle": [], "last": "Hou", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonial", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Lee", "suffix": ""}, {"first": "H", "middle": [], "last": "Einsele", "suffix": ""}, {"first": "M", "middle": [], "last": "Sopala", "suffix": ""}, {"first": "B.-R", "middle": [], "last": "Bengoudifa", "suffix": ""}, {"first": "F", "middle": [], "last": "Binlich", "suffix": ""}, {"first": "P", "middle": ["G"], "last": "Richardson", "suffix": ""}], "year": 2016, "venue": "The Lancet. Haematology", "volume": "3", "issn": "11", "pages": "30147--30155", "other_ids": {"DOI": ["10.1016/S2352-3026"]}}, "BIBREF578": {"ref_id": "b578", "title": "Pyrazolones Activate the Proteasome by Gating Mechanisms and Protect Neuronal Cells from \u03b2-Amyloid Toxicity", "authors": [{"first": "A", "middle": ["M"], "last": "Santoro", "suffix": ""}, {"first": "V", "middle": [], "last": "Lanza", "suffix": ""}, {"first": "F", "middle": [], "last": "Bellia", "suffix": ""}, {"first": "D", "middle": [], "last": "Sbardella", "suffix": ""}, {"first": "G", "middle": ["R"], "last": "Tundo", "suffix": ""}, {"first": "A", "middle": [], "last": "Cannizzo", "suffix": ""}, {"first": "G", "middle": [], "last": "Grasso", "suffix": ""}, {"first": "M", "middle": [], "last": "Arizzi", "suffix": ""}, {"first": "V", "middle": ["G"], "last": "Nicoletti", "suffix": ""}, {"first": "S", "middle": [], "last": "Alcaro", "suffix": ""}, {"first": "G", "middle": [], "last": "Costa", "suffix": ""}, {"first": "A", "middle": [], "last": "Pietropaolo", "suffix": ""}, {"first": "G", "middle": [], "last": "Malgieri", "suffix": ""}, {"first": "G", "middle": [], "last": "D&apos;abrosca", "suffix": ""}, {"first": "R", "middle": [], "last": "Fattorusso", "suffix": ""}, {"first": "S", "middle": [], "last": "Garc\u00eda-Vi\u00f1uales", "suffix": ""}, {"first": "I", "middle": ["M M"], "last": "Ahmed", "suffix": ""}, {"first": "M", "middle": [], "last": "Coletta", "suffix": ""}, {"first": "D", "middle": [], "last": "Milardi", "suffix": ""}], "year": 2020, "venue": "", "volume": "15", "issn": "", "pages": "302--316", "other_ids": {"DOI": ["10.1002/cmdc.201900612"]}}, "BIBREF579": {"ref_id": "b579", "title": "Copper(II) ions affect the gating dynamics of the 20S proteasome: a molecular and in cell study", "authors": [{"first": "A", "middle": ["M"], "last": "Santoro", "suffix": ""}, {"first": "I", "middle": [], "last": "Monaco", "suffix": ""}, {"first": "F", "middle": [], "last": "Attanasio", "suffix": ""}, {"first": "V", "middle": [], "last": "Lanza", "suffix": ""}, {"first": "G", "middle": [], "last": "Pappalardo", "suffix": ""}, {"first": "M", "middle": ["F"], "last": "Tomasello", "suffix": ""}, {"first": "A", "middle": [], "last": "Cunsolo", "suffix": ""}, {"first": "E", "middle": [], "last": "Rizzarelli", "suffix": ""}, {"first": "A", "middle": ["D"], "last": "Luigi", "suffix": ""}, {"first": "M", "middle": [], "last": "Salmona", "suffix": ""}, {"first": "D", "middle": [], "last": "Milardi", "suffix": ""}], "year": 2016, "venue": "Scientific Reports", "volume": "6", "issn": "1", "pages": "1--10", "other_ids": {"DOI": ["10.1038/srep33444"]}}, "BIBREF580": {"ref_id": "b580", "title": "Cationic porphyrins are tunable gatekeepers of the 20S proteasome", "authors": [{"first": "A", "middle": ["M"], "last": "Santoro", "suffix": ""}, {"first": "A", "middle": [], "last": "Cunsolo", "suffix": ""}, {"first": "A", "middle": [], "last": "D&apos;urso", "suffix": ""}, {"first": "D", "middle": [], "last": "Sbardella", "suffix": ""}, {"first": "G", "middle": ["R"], "last": "Tundo", "suffix": ""}, {"first": "C", "middle": [], "last": "Ciaccio", "suffix": ""}, {"first": "M", "middle": [], "last": "Coletta", "suffix": ""}, {"first": "D", "middle": [], "last": "Diana", "suffix": ""}, {"first": "R", "middle": [], "last": "Fattorusso", "suffix": ""}, {"first": "M", "middle": [], "last": "Persico", "suffix": ""}, {"first": "A", "middle": [], "last": "Di Dato", "suffix": ""}, {"first": "C", "middle": [], "last": "Fattorusso", "suffix": ""}, {"first": "D", "middle": [], "last": "Milardi", "suffix": ""}, {"first": "R", "middle": [], "last": "Purrello", "suffix": ""}], "year": 2016, "venue": "Chemical Science", "volume": "7", "issn": "2", "pages": "1286--1297", "other_ids": {"DOI": ["10.1039/c5sc03312h"]}}, "BIBREF582": {"ref_id": "b582", "title": "Cationic Porphyrins Are Reversible Proteasome Inhibitors", "authors": [], "year": null, "venue": "Journal of the American Chemical Society", "volume": "134", "issn": "25", "pages": "10451--10457", "other_ids": {"DOI": ["10.1021/ja300781u"]}}, "BIBREF583": {"ref_id": "b583", "title": "Parkin truncating variants result in a loss-of-function phenotype", "authors": [{"first": "M", "middle": [], "last": "Santos", "suffix": ""}, {"first": "S", "middle": [], "last": "Morais", "suffix": ""}, {"first": "C", "middle": [], "last": "Pereira", "suffix": ""}, {"first": "J", "middle": [], "last": "Sequeiros", "suffix": ""}, {"first": "I", "middle": [], "last": "Alonso", "suffix": ""}], "year": 2019, "venue": "Scientific Reports", "volume": "9", "issn": "1", "pages": "", "other_ids": {"DOI": ["10.1038/s41598-019-52534-6"]}}, "BIBREF584": {"ref_id": "b584", "title": "Proteasome biology is compromised in white matter after asphyxic cardiac arrest in neonatal piglets", "authors": [{"first": "P", "middle": ["T"], "last": "Santos", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "O&apos;brien", "suffix": ""}, {"first": "M", "middle": ["W"], "last": "Chen", "suffix": ""}, {"first": "C", "middle": ["D"], "last": "Hopkins", "suffix": ""}, {"first": "S", "middle": [], "last": "Adams", "suffix": ""}, {"first": "E", "middle": [], "last": "Kulikowicz", "suffix": ""}, {"first": "R", "middle": [], "last": "Singh", "suffix": ""}, {"first": "R", "middle": ["C"], "last": "Koehler", "suffix": ""}, {"first": "L", "middle": ["J"], "last": "Martin", "suffix": ""}, {"first": "J", "middle": ["K"], "last": "Lee", "suffix": ""}], "year": 2018, "venue": "Journal of the American Heart Association", "volume": "7", "issn": "20", "pages": "", "other_ids": {"DOI": ["10.1161/JAHA.118.009415"]}}, "BIBREF585": {"ref_id": "b585", "title": "PAC1 gene knockout reveals an essential role of chaperone-mediated 20S proteasome biogenesis and latent 20S proteasomes in cellular homeostasis", "authors": [{"first": "K", "middle": [], "last": "Sasaki", "suffix": ""}, {"first": "J", "middle": [], "last": "Hamazaki", "suffix": ""}, {"first": "M", "middle": [], "last": "Koike", "suffix": ""}, {"first": "Y", "middle": [], "last": "Hirano", "suffix": ""}, {"first": "M", "middle": [], "last": "Komatsu", "suffix": ""}, {"first": "Y", "middle": [], "last": "Uchiyama", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "S", "middle": [], "last": "Murata", "suffix": ""}], "year": 2010, "venue": "Molecular and Cellular Biology", "volume": "30", "issn": "15", "pages": "3864--3874", "other_ids": {"DOI": ["10.1128/MCB.00216-10"]}}, "BIBREF586": {"ref_id": "b586", "title": "Thymoproteasomes produce unique peptide motifs for positive selection of CD8 + T cells", "authors": [{"first": "K", "middle": [], "last": "Sasaki", "suffix": ""}, {"first": "K", "middle": [], "last": "Takada", "suffix": ""}, {"first": "Y", "middle": [], "last": "Ohte", "suffix": ""}, {"first": "H", "middle": [], "last": "Kondo", "suffix": ""}, {"first": "H", "middle": [], "last": "Sorimachi", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "Y", "middle": [], "last": "Takahama", "suffix": ""}, {"first": "S", "middle": [], "last": "Murata", "suffix": ""}], "year": 2015, "venue": "Nature Communications", "volume": "6", "issn": "1", "pages": "1--10", "other_ids": {"DOI": ["10.1038/ncomms8484"]}}, "BIBREF587": {"ref_id": "b587", "title": "Human erythrocyte multicatalytic proteinase: activation and binding to sulfated galactoand lactosylceramides", "authors": [{"first": "M", "middle": [], "last": "Sasaki", "suffix": ""}], "year": 1991, "venue": "Biochemical and Biophysical Research Communications", "volume": "174", "issn": "3", "pages": "1133--1140", "other_ids": {"DOI": ["10.1016/0006-291x(91)91538-n"]}}, "BIBREF588": {"ref_id": "b588", "title": "Molecular and Structural Basis of the Proteasome \u03b1 Subunit Assembly Mechanism Mediated by the Proteasome-Assembling Chaperone PAC3-PAC4 Heterodimer", "authors": [{"first": "T", "middle": [], "last": "Satoh", "suffix": ""}, {"first": "M", "middle": [], "last": "Yagi-Utsumi", "suffix": ""}, {"first": "K", "middle": [], "last": "Okamoto", "suffix": ""}, {"first": "E", "middle": [], "last": "Kurimoto", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "K", "middle": [], "last": "Kato", "suffix": ""}], "year": 2019, "venue": "International Journal of Molecular Sciences", "volume": "", "issn": "9", "pages": "", "other_ids": {"DOI": ["10.3390/ijms20092231"]}}, "BIBREF589": {"ref_id": "b589", "title": "A ratiometric naphthalimide sensor for live cell imaging of copper(i)", "authors": [{"first": "C", "middle": [], "last": "Satriano", "suffix": ""}, {"first": "G", "middle": ["T"], "last": "Sfrazzetto", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Amato", "suffix": ""}, {"first": "F", "middle": ["P"], "last": "Ballistreri", "suffix": ""}, {"first": "A", "middle": [], "last": "Copani", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Giuffrida", "suffix": ""}, {"first": "G", "middle": [], "last": "Grasso", "suffix": ""}, {"first": "A", "middle": [], "last": "Pappalardo", "suffix": ""}, {"first": "E", "middle": [], "last": "Rizzarelli", "suffix": ""}, {"first": "G", "middle": ["A"], "last": "Tomaselli", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Toscano", "suffix": ""}], "year": 2013, "venue": "Chemical Communications", "volume": "49", "issn": "49", "pages": "5565--5567", "other_ids": {}}, "BIBREF590": {"ref_id": "b590", "title": "Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse", "authors": [{"first": "M", "middle": ["H"], "last": "Savolainen", "suffix": ""}, {"first": "K", "middle": [], "last": "Albert", "suffix": ""}, {"first": "M", "middle": [], "last": "Airavaara", "suffix": ""}, {"first": "T", "middle": ["T"], "last": "My\u00f6h\u00e4nen", "suffix": ""}], "year": 2017, "venue": "Experimental Brain Research", "volume": "235", "issn": "7", "pages": "2189--2202", "other_ids": {"DOI": ["10.1007/s00221-017-4962-z"]}}, "BIBREF591": {"ref_id": "b591", "title": "Structural and functional evidence for citicoline binding and modulation of 20S proteasome activity: Novel insights into its pro-proteostatic effect", "authors": [{"first": "D", "middle": [], "last": "Sbardella", "suffix": ""}, {"first": "A", "middle": [], "last": "Coletta", "suffix": ""}, {"first": "G", "middle": ["R"], "last": "Tundo", "suffix": ""}, {"first": "I", "middle": ["M M"], "last": "Ahmed", "suffix": ""}, {"first": "F", "middle": [], "last": "Bellia", "suffix": ""}, {"first": "F", "middle": [], "last": "Oddone", "suffix": ""}, {"first": "G", "middle": [], "last": "Manni", "suffix": ""}, {"first": "M", "middle": [], "last": "Coletta", "suffix": ""}], "year": 2020, "venue": "Biochemical Pharmacology", "volume": "177", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.bcp.2020.113977"]}}, "BIBREF592": {"ref_id": "b592", "title": "Retention of Mitochondria in Mature Human Red Blood Cells as the Result of", "authors": [{"first": "D", "middle": [], "last": "Sbardella", "suffix": ""}, {"first": "G", "middle": ["R"], "last": "Tundo", "suffix": ""}, {"first": "L", "middle": [], "last": "Campagnolo", "suffix": ""}, {"first": "G", "middle": [], "last": "Valacchi", "suffix": ""}, {"first": "A", "middle": [], "last": "Orlandi", "suffix": ""}, {"first": "P", "middle": [], "last": "Curatolo", "suffix": ""}, {"first": "G", "middle": [], "last": "Borsellino", "suffix": ""}, {"first": "M", "middle": [], "last": "D&apos;esposito", "suffix": ""}, {"first": "C", "middle": [], "last": "Ciaccio", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Cesare", "suffix": ""}, {"first": "D", "middle": ["D"], "last": "Pierro", "suffix": ""}, {"first": "C", "middle": [], "last": "Galasso", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Santarone", "suffix": ""}, {"first": "J", "middle": [], "last": "Hayek", "suffix": ""}, {"first": "M", "middle": [], "last": "Coletta", "suffix": ""}, {"first": "S", "middle": [], "last": "Marini", "suffix": ""}], "year": 2017, "venue": "Autophagy Impairment in Rett Syndrome. Scientific Reports", "volume": "7", "issn": "1", "pages": "", "other_ids": {"DOI": ["10.1038/s41598-017-12069-0"]}}, "BIBREF593": {"ref_id": "b593", "title": "The insulin-degrading enzyme is an allosteric modulator of the 20S proteasome and a potential competitor of the 19S", "authors": [{"first": "D", "middle": [], "last": "Sbardella", "suffix": ""}, {"first": "G", "middle": ["R"], "last": "Tundo", "suffix": ""}, {"first": "A", "middle": [], "last": "Coletta", "suffix": ""}, {"first": "J", "middle": [], "last": "Marcoux", "suffix": ""}, {"first": "E", "middle": ["I"], "last": "Koufogeorgou", "suffix": ""}, {"first": "C", "middle": [], "last": "Ciaccio", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Santoro", "suffix": ""}, {"first": "D", "middle": [], "last": "Milardi", "suffix": ""}, {"first": "G", "middle": [], "last": "Grasso", "suffix": ""}, {"first": "P", "middle": [], "last": "Cozza", "suffix": ""}, {"first": "M.-P", "middle": [], "last": "Bousquet-Dubouch", "suffix": ""}, {"first": "S", "middle": [], "last": "Marini", "suffix": ""}, {"first": "M", "middle": [], "last": "Coletta", "suffix": ""}], "year": 2018, "venue": "Cellular and Molecular Life Sciences: CMLS", "volume": "75", "issn": "18", "pages": "3441--3456", "other_ids": {"DOI": ["10.1007/s00018-018-2807-y"]}}, "BIBREF594": {"ref_id": "b594", "title": "The insulin-degrading enzyme is an allosteric modulator of the 20S proteasome and a potential competitor of the 19S", "authors": [{"first": "D", "middle": [], "last": "Sbardella", "suffix": ""}, {"first": "G", "middle": ["R"], "last": "Tundo", "suffix": ""}, {"first": "A", "middle": [], "last": "Coletta", "suffix": ""}, {"first": "J", "middle": [], "last": "Marcoux", "suffix": ""}, {"first": "E", "middle": ["I"], "last": "Koufogeorgou", "suffix": ""}, {"first": "C", "middle": [], "last": "Ciaccio", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Santoro", "suffix": ""}, {"first": "D", "middle": [], "last": "Milardi", "suffix": ""}, {"first": "G", "middle": [], "last": "Grasso", "suffix": ""}, {"first": "P", "middle": [], "last": "Cozza", "suffix": ""}, {"first": "M.-P", "middle": [], "last": "Bousquet-Dubouch", "suffix": ""}, {"first": "S", "middle": [], "last": "Marini", "suffix": ""}, {"first": "M", "middle": [], "last": "Coletta", "suffix": ""}], "year": 2018, "venue": "Cellular and Molecular Life Sciences: CMLS", "volume": "75", "issn": "18", "pages": "3441--3456", "other_ids": {"DOI": ["10.1007/s00018-018-2807-y"]}}, "BIBREF595": {"ref_id": "b595", "title": "The insulin-degrading enzyme is an allosteric modulator of the 20S proteasome and a potential competitor of the 19S", "authors": [{"first": "D", "middle": [], "last": "Sbardella", "suffix": ""}, {"first": "G", "middle": ["R"], "last": "Tundo", "suffix": ""}, {"first": "A", "middle": [], "last": "Coletta", "suffix": ""}, {"first": "J", "middle": [], "last": "Marcoux", "suffix": ""}, {"first": "E", "middle": ["I"], "last": "Koufogeorgou", "suffix": ""}, {"first": "C", "middle": [], "last": "Ciaccio", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Santoro", "suffix": ""}, {"first": "D", "middle": [], "last": "Milardi", "suffix": ""}, {"first": "G", "middle": [], "last": "Grasso", "suffix": ""}, {"first": "P", "middle": [], "last": "Cozza", "suffix": ""}, {"first": "M.-P", "middle": [], "last": "Bousquet-Dubouch", "suffix": ""}, {"first": "S", "middle": [], "last": "Marini", "suffix": ""}, {"first": "M", "middle": [], "last": "Coletta", "suffix": ""}], "year": 2018, "venue": "Cellular and Molecular Life Sciences: CMLS", "volume": "75", "issn": "18", "pages": "3441--3456", "other_ids": {"DOI": ["10.1007/s00018-018-2807-y"]}}, "BIBREF596": {"ref_id": "b596", "title": "Defective proteasome biogenesis into skin fibroblasts isolated from Rett syndrome subjects with MeCP2 nonsense mutations", "authors": [{"first": "D", "middle": [], "last": "Sbardella", "suffix": ""}, {"first": "G", "middle": ["R"], "last": "Tundo", "suffix": ""}, {"first": "V", "middle": [], "last": "Cunsolo", "suffix": ""}, {"first": "G", "middle": [], "last": "Grasso", "suffix": ""}, {"first": "R", "middle": [], "last": "Cascella", "suffix": ""}, {"first": "V", "middle": [], "last": "Caputo", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Santoro", "suffix": ""}, {"first": "D", "middle": [], "last": "Milardi", "suffix": ""}, {"first": "A", "middle": [], "last": "Pecorelli", "suffix": ""}, {"first": "C", "middle": [], "last": "Ciaccio", "suffix": ""}, {"first": "D", "middle": [], "last": "Di Pierro", "suffix": ""}, {"first": "S", "middle": [], "last": "Leoncini", "suffix": ""}, {"first": "L", "middle": [], "last": "Campagnolo", "suffix": ""}, {"first": "V", "middle": [], "last": "Pironi", "suffix": ""}, {"first": "F", "middle": [], "last": "Oddone", "suffix": ""}, {"first": "P", "middle": [], "last": "Manni", "suffix": ""}, {"first": "S", "middle": [], "last": "Foti", "suffix": ""}, {"first": "E", "middle": [], "last": "Giardina", "suffix": ""}, {"first": "C", "middle": [], "last": "De Felice", "suffix": ""}, {"first": "S", "middle": [], "last": "Marini", "suffix": ""}], "year": 2020, "venue": "Biochimica Et Biophysica Acta. Molecular Basis of Disease", "volume": "", "issn": "7", "pages": "", "other_ids": {"DOI": ["10.1016/j.bbadis.2020.165793"]}}, "BIBREF597": {"ref_id": "b597", "title": "Proteasome Activity Is Affected by Fluctuations in Insulin-Degrading Enzyme Distribution", "authors": [{"first": "D", "middle": [], "last": "Sbardella", "suffix": ""}, {"first": "G", "middle": ["R"], "last": "Tundo", "suffix": ""}, {"first": "F", "middle": [], "last": "Sciandra", "suffix": ""}, {"first": "M", "middle": [], "last": "Bozzi", "suffix": ""}, {"first": "M", "middle": [], "last": "Gioia", "suffix": ""}, {"first": "C", "middle": [], "last": "Ciaccio", "suffix": ""}, {"first": "U", "middle": [], "last": "Tarantino", "suffix": ""}, {"first": "A", "middle": [], "last": "Brancaccio", "suffix": ""}, {"first": "M", "middle": [], "last": "Coletta", "suffix": ""}, {"first": "S", "middle": [], "last": "Marini", "suffix": ""}], "year": 2015, "venue": "PLoS ONE", "volume": "", "issn": "7", "pages": "", "other_ids": {}}, "BIBREF599": {"ref_id": "b599", "title": "Proteasome Activity Is Affected by Fluctuations in Insulin-Degrading Enzyme Distribution", "authors": [{"first": "D", "middle": [], "last": "Sbardella", "suffix": ""}, {"first": "G", "middle": ["R"], "last": "Tundo", "suffix": ""}, {"first": "F", "middle": [], "last": "Sciandra", "suffix": ""}, {"first": "M", "middle": [], "last": "Bozzi", "suffix": ""}, {"first": "M", "middle": [], "last": "Gioia", "suffix": ""}, {"first": "C", "middle": [], "last": "Ciaccio", "suffix": ""}, {"first": "U", "middle": [], "last": "Tarantino", "suffix": ""}, {"first": "A", "middle": [], "last": "Brancaccio", "suffix": ""}, {"first": "M", "middle": [], "last": "Coletta", "suffix": ""}, {"first": "S", "middle": [], "last": "Marini", "suffix": ""}], "year": 2015, "venue": "PloS One", "volume": "10", "issn": "7", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0132455"]}}, "BIBREF600": {"ref_id": "b600", "title": "Diagnosing the decline in pharmaceutical R&D efficiency", "authors": [{"first": "J", "middle": ["W"], "last": "Scannell", "suffix": ""}, {"first": "A", "middle": [], "last": "Blanckley", "suffix": ""}, {"first": "H", "middle": [], "last": "Boldon", "suffix": ""}, {"first": "B", "middle": [], "last": "Warrington", "suffix": ""}], "year": 2012, "venue": "Nature Reviews Drug Discovery", "volume": "11", "issn": "3", "pages": "191--200", "other_ids": {"DOI": ["10.1038/nrd3681"]}}, "BIBREF601": {"ref_id": "b601", "title": "Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline", "authors": [{"first": "A", "middle": ["W"], "last": "Schaler", "suffix": ""}, {"first": "N", "middle": [], "last": "Myeku", "suffix": ""}], "year": 2018, "venue": "Translational Research: The Journal of Laboratory and Clinical Medicine", "volume": "193", "issn": "", "pages": "31--41", "other_ids": {}}, "BIBREF603": {"ref_id": "b603", "title": "Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade", "authors": [{"first": "M", "middle": [], "last": "Scheffner", "suffix": ""}, {"first": "U", "middle": [], "last": "Nuber", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Huibregtse", "suffix": ""}], "year": 1995, "venue": "Nature", "volume": "373", "issn": "6509", "pages": "81--83", "other_ids": {"DOI": ["10.1038/373081a0"]}}, "BIBREF604": {"ref_id": "b604", "title": "Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo", "authors": [{"first": "E", "middle": [], "last": "Scherzinger", "suffix": ""}, {"first": "R", "middle": [], "last": "Lurz", "suffix": ""}, {"first": "M", "middle": [], "last": "Turmaine", "suffix": ""}, {"first": "L", "middle": [], "last": "Mangiarini", "suffix": ""}, {"first": "B", "middle": [], "last": "Hollenbach", "suffix": ""}, {"first": "R", "middle": [], "last": "Hasenbank", "suffix": ""}, {"first": "G", "middle": ["P"], "last": "Bates", "suffix": ""}, {"first": "S", "middle": ["W"], "last": "Davies", "suffix": ""}, {"first": "H", "middle": [], "last": "Lehrach", "suffix": ""}, {"first": "E", "middle": ["E"], "last": "Wanker", "suffix": ""}], "year": 1997, "venue": "Cell", "volume": "90", "issn": "3", "pages": "549--558", "other_ids": {"DOI": ["10.1016/S0092-8674(00)80514-0"]}}, "BIBREF605": {"ref_id": "b605", "title": "The Ubiquitin-Proteasome System in Huntington's Disease: Are Proteasomes Impaired, Initiators of Disease, or Coming to the Rescue?", "authors": [{"first": "S", "middle": [], "last": "Schipper-Krom", "suffix": ""}, {"first": "K", "middle": [], "last": "Juenemann", "suffix": ""}, {"first": "E", "middle": ["A J"], "last": "Reits", "suffix": ""}], "year": 2012, "venue": "Biochemistry Research International", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1155/2012/837015"]}}, "BIBREF606": {"ref_id": "b606", "title": "Regulation of proteasome activity in health and disease", "authors": [{"first": "M", "middle": [], "last": "Schmidt", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}], "year": 2014, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF609": {"ref_id": "b609", "title": "The HEAT repeat protein Blm10 regulates the yeast proteasome by capping the core particle", "authors": [], "year": null, "venue": "Nature Structural & Molecular Biology", "volume": "12", "issn": "4", "pages": "294--303", "other_ids": {"DOI": ["10.1038/nsmb914"]}}, "BIBREF610": {"ref_id": "b610", "title": "Analysis of mammalian 20S proteasome biogenesis: the maturation of beta-subunits is an ordered two-step mechanism involving autocatalysis", "authors": [{"first": "G", "middle": [], "last": "Schmidtke", "suffix": ""}, {"first": "R", "middle": [], "last": "Kraft", "suffix": ""}, {"first": "S", "middle": [], "last": "Kostka", "suffix": ""}, {"first": "P", "middle": [], "last": "Henklein", "suffix": ""}, {"first": "C", "middle": [], "last": "Fr\u00f6mmel", "suffix": ""}, {"first": "J", "middle": [], "last": "L\u00f6we", "suffix": ""}, {"first": "R", "middle": [], "last": "Huber", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Kloetzel", "suffix": ""}, {"first": "M", "middle": [], "last": "Schmidt", "suffix": ""}], "year": 1996, "venue": "The EMBO Journal", "volume": "15", "issn": "24", "pages": "6887--6898", "other_ids": {}}, "BIBREF611": {"ref_id": "b611", "title": "Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain", "authors": [{"first": "M", "middle": [], "last": "Schneider", "suffix": ""}, {"first": "K", "middle": [], "last": "Ackermann", "suffix": ""}, {"first": "M", "middle": [], "last": "Stuart", "suffix": ""}, {"first": "C", "middle": [], "last": "Wex", "suffix": ""}, {"first": "U", "middle": [], "last": "Protzer", "suffix": ""}, {"first": "H", "middle": ["M"], "last": "Sch\u00e4tzl", "suffix": ""}, {"first": "S", "middle": [], "last": "Gilch", "suffix": ""}], "year": 2012, "venue": "Journal of Virology", "volume": "86", "issn": "18", "pages": "10112--10122", "other_ids": {"DOI": ["10.1128/JVI.01001-12"]}}, "BIBREF612": {"ref_id": "b612", "title": "The dynamic state of body constituents", "authors": [{"first": "R", "middle": [], "last": "Schoenheimer", "suffix": ""}], "year": 1946, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF613": {"ref_id": "b613", "title": "Studies in Protein Metabolism Vii. the Metabolism of Tyrosine", "authors": [{"first": "R", "middle": [], "last": "Schoenheimer", "suffix": ""}, {"first": "S", "middle": [], "last": "Ratner", "suffix": ""}, {"first": "D", "middle": [], "last": "Rittenberg", "suffix": ""}], "year": 1939, "venue": "Journal of Biological Chemistry", "volume": "127", "issn": "1", "pages": "333--344", "other_ids": {}}, "BIBREF614": {"ref_id": "b614", "title": "The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design", "authors": [{"first": "J", "middle": [], "last": "Schrader", "suffix": ""}, {"first": "F", "middle": [], "last": "Henneberg", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Mata", "suffix": ""}, {"first": "K", "middle": [], "last": "Tittmann", "suffix": ""}, {"first": "T", "middle": ["R"], "last": "Schneider", "suffix": ""}, {"first": "H", "middle": [], "last": "Stark", "suffix": ""}, {"first": "G", "middle": [], "last": "Bourenkov", "suffix": ""}, {"first": "A", "middle": [], "last": "Chari", "suffix": ""}], "year": 2016, "venue": "Science", "volume": "353", "issn": "6299", "pages": "594--598", "other_ids": {"DOI": ["10.1126/science.aaf8993"]}}, "BIBREF615": {"ref_id": "b615", "title": "Immunoproteasome deficiency protects in the retina after optic nerve crush", "authors": [{"first": "N", "middle": ["J"], "last": "Schuld", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Hussong", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Kapphahn", "suffix": ""}, {"first": "U", "middle": [], "last": "Lehmann", "suffix": ""}, {"first": "H", "middle": [], "last": "Roehrich", "suffix": ""}, {"first": "A", "middle": ["A"], "last": "Rageh", "suffix": ""}, {"first": "N", "middle": ["D"], "last": "Heuss", "suffix": ""}, {"first": "W", "middle": [], "last": "Bratten", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Gregerson", "suffix": ""}, {"first": "D", "middle": ["A"], "last": "Ferrington", "suffix": ""}], "year": 2015, "venue": "PloS One", "volume": "10", "issn": "5", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0126768"]}}, "BIBREF616": {"ref_id": "b616", "title": "Autocatalytic processing of the 20S proteasome", "authors": [{"first": "E", "middle": [], "last": "Seemuller", "suffix": ""}, {"first": "A", "middle": [], "last": "Lupas", "suffix": ""}, {"first": "W", "middle": [], "last": "Baumeister", "suffix": ""}], "year": 1996, "venue": "Nature", "volume": "382", "issn": "6590", "pages": "468--471", "other_ids": {"DOI": ["10.1038/382468a0"]}}, "BIBREF617": {"ref_id": "b617", "title": "Proteasome from Thermoplasma acidophilum: a threonine protease", "authors": [{"first": "E", "middle": [], "last": "Seem\u00fcller", "suffix": ""}, {"first": "A", "middle": [], "last": "Lupas", "suffix": ""}, {"first": "D", "middle": [], "last": "Stock", "suffix": ""}, {"first": "J", "middle": [], "last": "L\u00f6we", "suffix": ""}, {"first": "R", "middle": [], "last": "Huber", "suffix": ""}, {"first": "W", "middle": [], "last": "Baumeister", "suffix": ""}], "year": 1995, "venue": "Science", "volume": "", "issn": "5210", "pages": "579--582", "other_ids": {"DOI": ["10.1126/science.7725107"]}}, "BIBREF618": {"ref_id": "b618", "title": "O-GlcNAcylation Signal Mediates Proteasome Inhibitor Resistance in Cancer Cells by Stabilizing NRF1", "authors": [{"first": "H", "middle": [], "last": "Sekine", "suffix": ""}, {"first": "K", "middle": [], "last": "Okazaki", "suffix": ""}, {"first": "K", "middle": [], "last": "Kato", "suffix": ""}, {"first": "M", "middle": ["M"], "last": "Alam", "suffix": ""}, {"first": "H", "middle": [], "last": "Shima", "suffix": ""}, {"first": "F", "middle": [], "last": "Katsuoka", "suffix": ""}, {"first": "T", "middle": [], "last": "Tsujita", "suffix": ""}, {"first": "N", "middle": [], "last": "Suzuki", "suffix": ""}, {"first": "A", "middle": [], "last": "Kobayashi", "suffix": ""}, {"first": "K", "middle": [], "last": "Igarashi", "suffix": ""}, {"first": "M", "middle": [], "last": "Yamamoto", "suffix": ""}, {"first": "H", "middle": [], "last": "Motohashi", "suffix": ""}], "year": 2018, "venue": "Molecular and Cellular Biology", "volume": "", "issn": "17", "pages": "", "other_ids": {"DOI": ["10.1128/MCB.00252-18"]}}, "BIBREF619": {"ref_id": "b619", "title": "Expression of mutated mouse myocilin induces open-angle glaucoma in transgenic mice", "authors": [{"first": "V", "middle": [], "last": "Senatorov", "suffix": ""}, {"first": "I", "middle": [], "last": "Malyukova", "suffix": ""}, {"first": "R", "middle": [], "last": "Fariss", "suffix": ""}, {"first": "E", "middle": ["F"], "last": "Wawrousek", "suffix": ""}, {"first": "S", "middle": [], "last": "Swaminathan", "suffix": ""}, {"first": "S", "middle": ["K"], "last": "Sharan", "suffix": ""}, {"first": "S", "middle": [], "last": "Tomarev", "suffix": ""}], "year": 2006, "venue": "The Journal of Neuroscience: The Official Journal of the Society for Neuroscience", "volume": "26", "issn": "46", "pages": "11903--11914", "other_ids": {"DOI": ["10.1523/JNEUROSCI.3020-06.2006"]}}, "BIBREF620": {"ref_id": "b620", "title": "Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib", "authors": [{"first": "T", "middle": ["B"], "last": "Shabaneh", "suffix": ""}, {"first": "S", "middle": ["L"], "last": "Downey", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Goddard", "suffix": ""}, {"first": "M", "middle": [], "last": "Screen", "suffix": ""}, {"first": "M", "middle": ["M"], "last": "Lucas", "suffix": ""}, {"first": "A", "middle": [], "last": "Eastman", "suffix": ""}, {"first": "A", "middle": ["F"], "last": "Kisselev", "suffix": ""}], "year": 2013, "venue": "PloS One", "volume": "8", "issn": "2", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0056132"]}}, "BIBREF621": {"ref_id": "b621", "title": "The size of the proteasomal substrate determines whether its degradation will be mediated by mono-or polyubiquitylation", "authors": [{"first": "N", "middle": [], "last": "Shabek", "suffix": ""}, {"first": "Y", "middle": [], "last": "Herman-Bachinsky", "suffix": ""}, {"first": "S", "middle": [], "last": "Buchsbaum", "suffix": ""}, {"first": "O", "middle": [], "last": "Lewinson", "suffix": ""}, {"first": "M", "middle": [], "last": "Haj-Yahya", "suffix": ""}, {"first": "M", "middle": [], "last": "Hejjaoui", "suffix": ""}, {"first": "H", "middle": ["A"], "last": "Lashuel", "suffix": ""}, {"first": "T", "middle": [], "last": "Sommer", "suffix": ""}, {"first": "A", "middle": [], "last": "Brik", "suffix": ""}, {"first": "A", "middle": [], "last": "Ciechanover", "suffix": ""}], "year": 2012, "venue": "Molecular Cell", "volume": "48", "issn": "1", "pages": "87--97", "other_ids": {"DOI": ["10.1016/j.molcel.2012.07.011"]}}, "BIBREF622": {"ref_id": "b622", "title": "Transition metal complexes as proteasome inhibitors for cancer treatment", "authors": [{"first": "", "middle": [], "last": "Shagufta", "suffix": ""}, {"first": "I", "middle": [], "last": "Ahmad", "suffix": ""}], "year": 2020, "venue": "Inorganica Chimica Acta", "volume": "506", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.ica.2020.119521"]}}, "BIBREF623": {"ref_id": "b623", "title": "Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials", "authors": [{"first": "C", "middle": [], "last": "Shah", "suffix": ""}, {"first": "R", "middle": [], "last": "Bishnoi", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wang", "suffix": ""}, {"first": "F", "middle": [], "last": "Zou", "suffix": ""}, {"first": "H", "middle": [], "last": "Bejjanki", "suffix": ""}, {"first": "S", "middle": [], "last": "Master", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Moreb", "suffix": ""}], "year": 2018, "venue": "Oncotarget", "volume": "9", "issn": "34", "pages": "23704--23717", "other_ids": {}}, "BIBREF625": {"ref_id": "b625", "title": "Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma", "authors": [{"first": "J", "middle": [], "last": "Shah", "suffix": ""}, {"first": "S", "middle": [], "last": "Usmani", "suffix": ""}, {"first": "E", "middle": ["A"], "last": "Stadtmauer", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Rifkin", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Berenson", "suffix": ""}, {"first": "J", "middle": ["G"], "last": "Berdeja", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Lyons", "suffix": ""}, {"first": "Z", "middle": [], "last": "Klippel", "suffix": ""}, {"first": "Y.-L", "middle": [], "last": "Chang", "suffix": ""}, {"first": "R", "middle": [], "last": "Niesvizky", "suffix": ""}], "year": 2019, "venue": "Clinical Lymphoma, Myeloma & Leukemia", "volume": "19", "issn": "9", "pages": "570--578", "other_ids": {"DOI": ["10.1016/j.clml.2019.05.017"]}}, "BIBREF626": {"ref_id": "b626", "title": "Synthesis, Structure, and Anticancer Activity of Gallium(III) Complexes with Asymmetric Tridentate Ligands: Growth Inhibition and Apoptosis Induction of Cisplatin-Resistant Neuroblastoma Cells. Inorganic Chemistry", "authors": [{"first": "R", "middle": [], "last": "Shakya", "suffix": ""}, {"first": "F", "middle": [], "last": "Peng", "suffix": ""}, {"first": "J", "middle": [], "last": "Liu", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Heeg", "suffix": ""}, {"first": "C", "middle": ["N"], "last": "Verani", "suffix": ""}], "year": 2006, "venue": "", "volume": "45", "issn": "", "pages": "6263--6268", "other_ids": {"DOI": ["10.1021/ic060106g"]}}, "BIBREF627": {"ref_id": "b627", "title": "Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma", "authors": [{"first": "M", "middle": ["A"], "last": "Shammas", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Shmookler Reis", "suffix": ""}, {"first": "M", "middle": [], "last": "Akiyama", "suffix": ""}, {"first": "H", "middle": [], "last": "Koley", "suffix": ""}, {"first": "D", "middle": [], "last": "Chauhan", "suffix": ""}, {"first": "T", "middle": [], "last": "Hideshima", "suffix": ""}, {"first": "R", "middle": ["K"], "last": "Goyal", "suffix": ""}, {"first": "L", "middle": ["H"], "last": "Hurley", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}, {"first": "N", "middle": ["C"], "last": "Munshi", "suffix": ""}], "year": 2003, "venue": "Molecular Cancer Therapeutics", "volume": "2", "issn": "9", "pages": "825--833", "other_ids": {}}, "BIBREF628": {"ref_id": "b628", "title": "Role of the ubiquitin-proteasome in protein quality control and signaling: implication in the pathogenesis of eye diseases", "authors": [{"first": "F", "middle": [], "last": "Shang", "suffix": ""}, {"first": "A", "middle": [], "last": "Taylor", "suffix": ""}], "year": 2012, "venue": "Progress in Molecular Biology and Translational Science", "volume": "109", "issn": "", "pages": "347--396", "other_ids": {"DOI": ["10.1016/B978-0-12-397863-9.00010-9"]}}, "BIBREF629": {"ref_id": "b629", "title": "Insulin-degrading enzyme is activated by the C-terminus of \u03b1-synuclein", "authors": [{"first": "S", "middle": ["K"], "last": "Sharma", "suffix": ""}, {"first": "E", "middle": [], "last": "Chorell", "suffix": ""}, {"first": "P", "middle": [], "last": "Wittung-Stafshede", "suffix": ""}], "year": 2015, "venue": "Biochemical and Biophysical Research Communications", "volume": "466", "issn": "2", "pages": "192--195", "other_ids": {"DOI": ["10.1016/j.bbrc.2015.09.002"]}}, "BIBREF630": {"ref_id": "b630", "title": "Insulin-degrading enzyme prevents \u03b1-synuclein fibril formation in a nonproteolytical manner", "authors": [{"first": "S", "middle": ["K"], "last": "Sharma", "suffix": ""}, {"first": "E", "middle": [], "last": "Chorell", "suffix": ""}, {"first": "P", "middle": [], "last": "Steneberg", "suffix": ""}, {"first": "E", "middle": [], "last": "Vernersson-Lindahl", "suffix": ""}, {"first": "H", "middle": [], "last": "Edlund", "suffix": ""}, {"first": "P", "middle": [], "last": "Wittung-Stafshede", "suffix": ""}], "year": 2015, "venue": "Scientific Reports", "volume": "5", "issn": "1", "pages": "1--10", "other_ids": {"DOI": ["10.1038/srep12531"]}}, "BIBREF631": {"ref_id": "b631", "title": "Structural Organization of the 19S Proteasome Lid: Insights from MS of Intact Complexes", "authors": [{"first": "M", "middle": [], "last": "Sharon", "suffix": ""}, {"first": "T", "middle": [], "last": "Taverner", "suffix": ""}, {"first": "X", "middle": ["I"], "last": "Ambroggio", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Deshaies", "suffix": ""}, {"first": "C", "middle": ["V"], "last": "Robinson", "suffix": ""}], "year": 2006, "venue": "PLOS Biology", "volume": "4", "issn": "8", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pbio.0040267"]}}, "BIBREF633": {"ref_id": "b633", "title": "Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination", "authors": [], "year": null, "venue": "Molecular Cell", "volume": "5", "issn": "2", "pages": "80435--80444", "other_ids": {"DOI": ["10.1016/s1097-2765(00"]}}, "BIBREF634": {"ref_id": "b634", "title": "The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy", "authors": [{"first": "J", "middle": [], "last": "Shen", "suffix": ""}, {"first": "G", "middle": [], "last": "Song", "suffix": ""}, {"first": "M", "middle": [], "last": "An", "suffix": ""}, {"first": "X", "middle": [], "last": "Li", "suffix": ""}, {"first": "N", "middle": [], "last": "Wu", "suffix": ""}, {"first": "K", "middle": [], "last": "Ruan", "suffix": ""}, {"first": "J", "middle": [], "last": "Hu", "suffix": ""}, {"first": "R", "middle": [], "last": "Hu", "suffix": ""}], "year": 2014, "venue": "Biomaterials", "volume": "35", "issn": "1", "pages": "316--326", "other_ids": {}}, "BIBREF636": {"ref_id": "b636", "title": "Mutations in the ubiquitinbinding domain of OPTN/optineurin interfere with autophagy-mediated degradation of misfolded proteins by a dominant-negative mechanism", "authors": [{"first": "W.-C", "middle": [], "last": "Shen", "suffix": ""}, {"first": "H.-Y", "middle": [], "last": "Li", "suffix": ""}, {"first": "G.-C", "middle": [], "last": "Chen", "suffix": ""}, {"first": "Y", "middle": [], "last": "Chern", "suffix": ""}, {"first": "P.-H", "middle": [], "last": "Tu", "suffix": ""}], "year": 2015, "venue": "Autophagy", "volume": "11", "issn": "4", "pages": "685--700", "other_ids": {}}, "BIBREF638": {"ref_id": "b638", "title": "Processing of optineurin in neuronal cells", "authors": [{"first": "X", "middle": [], "last": "Shen", "suffix": ""}, {"first": "H", "middle": [], "last": "Ying", "suffix": ""}, {"first": "Y", "middle": [], "last": "Qiu", "suffix": ""}, {"first": "J.-S", "middle": [], "last": "Park", "suffix": ""}, {"first": "R", "middle": [], "last": "Shyam", "suffix": ""}, {"first": "Z.-L", "middle": [], "last": "Chi", "suffix": ""}, {"first": "T", "middle": [], "last": "Iwata", "suffix": ""}, {"first": "B", "middle": ["Y J T"], "last": "Yue", "suffix": ""}], "year": 2011, "venue": "The Journal of Biological Chemistry", "volume": "286", "issn": "5", "pages": "3618--3629", "other_ids": {"DOI": ["10.1074/jbc.M110.175810"]}}, "BIBREF639": {"ref_id": "b639", "title": "Rod bipolar cells dysfunction occurs before ganglion cells loss in excitotoxin-damaged mouse retina", "authors": [{"first": "Y", "middle": [], "last": "Shen", "suffix": ""}, {"first": "X", "middle": [], "last": "Luo", "suffix": ""}, {"first": "S", "middle": [], "last": "Liu", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shen", "suffix": ""}, {"first": "S", "middle": [], "last": "Nawy", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shen", "suffix": ""}], "year": 2019, "venue": "Cell Death & Disease", "volume": "10", "issn": "12", "pages": "", "other_ids": {"DOI": ["10.1038/s41419-019-2140-x"]}}, "BIBREF640": {"ref_id": "b640", "title": "Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease", "authors": [{"first": "D", "middle": ["J"], "last": "Sherman", "suffix": ""}, {"first": "J", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "Molecules", "volume": "25", "issn": "3", "pages": "", "other_ids": {"DOI": ["10.3390/molecules25030671"]}}, "BIBREF641": {"ref_id": "b641", "title": "Rpn1 provides adjacent receptor sites for substrate binding and deubiquitination by the proteasome", "authors": [{"first": "Y", "middle": [], "last": "Shi", "suffix": ""}, {"first": "X", "middle": [], "last": "Chen", "suffix": ""}, {"first": "S", "middle": [], "last": "Elsasser", "suffix": ""}, {"first": "B", "middle": ["B"], "last": "Stocks", "suffix": ""}, {"first": "G", "middle": [], "last": "Tian", "suffix": ""}, {"first": "B.-H", "middle": [], "last": "Lee", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shi", "suffix": ""}, {"first": "N", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "S", "middle": ["A H"], "last": "De Poot", "suffix": ""}, {"first": "F", "middle": [], "last": "Tuebing", "suffix": ""}, {"first": "S", "middle": [], "last": "Sun", "suffix": ""}, {"first": "J", "middle": [], "last": "Vannoy", "suffix": ""}, {"first": "S", "middle": ["G"], "last": "Tarasov", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Engen", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}, {"first": "K", "middle": ["J"], "last": "Walters", "suffix": ""}], "year": 2016, "venue": "Science", "volume": "", "issn": "6275", "pages": "", "other_ids": {"DOI": ["10.1126/science.aad9421"]}}, "BIBREF642": {"ref_id": "b642", "title": "Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease", "authors": [{"first": "H", "middle": [], "last": "Shimura", "suffix": ""}, {"first": "M", "middle": ["G"], "last": "Schlossmacher", "suffix": ""}, {"first": "N", "middle": [], "last": "Hattori", "suffix": ""}, {"first": "M", "middle": ["P"], "last": "Frosch", "suffix": ""}, {"first": "A", "middle": [], "last": "Trockenbacher", "suffix": ""}, {"first": "R", "middle": [], "last": "Schneider", "suffix": ""}, {"first": "Y", "middle": [], "last": "Mizuno", "suffix": ""}, {"first": "K", "middle": ["S"], "last": "Kosik", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Selkoe", "suffix": ""}], "year": 2001, "venue": "Science", "volume": "", "issn": "5528", "pages": "263--269", "other_ids": {"DOI": ["10.1126/science.1060627"]}}, "BIBREF643": {"ref_id": "b643", "title": "CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival", "authors": [{"first": "H", "middle": [], "last": "Shimura", "suffix": ""}, {"first": "D", "middle": [], "last": "Schwartz", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Gygi", "suffix": ""}, {"first": "K", "middle": ["S"], "last": "Kosik", "suffix": ""}], "year": 2004, "venue": "The Journal of Biological Chemistry", "volume": "279", "issn": "6", "pages": "4869--4876", "other_ids": {"DOI": ["10.1074/jbc.M305838200"]}}, "BIBREF644": {"ref_id": "b644", "title": "Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome", "authors": [{"first": "R", "middle": [], "last": "Shringarpure", "suffix": ""}, {"first": "T", "middle": [], "last": "Grune", "suffix": ""}, {"first": "J", "middle": [], "last": "Mehlhase", "suffix": ""}, {"first": "K", "middle": ["J A"], "last": "Davies", "suffix": ""}], "year": 2003, "venue": "The Journal of Biological Chemistry", "volume": "278", "issn": "1", "pages": "311--318", "other_ids": {"DOI": ["10.1074/jbc.M206279200"]}}, "BIBREF645": {"ref_id": "b645", "title": "A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma", "authors": [{"first": "D", "middle": ["S"], "last": "Siegel", "suffix": ""}, {"first": "T", "middle": [], "last": "Martin", "suffix": ""}, {"first": "M", "middle": [], "last": "Wang", "suffix": ""}, {"first": "R", "middle": [], "last": "Vij", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Jakubowiak", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonial", "suffix": ""}, {"first": "S", "middle": [], "last": "Trudel", "suffix": ""}, {"first": "V", "middle": [], "last": "Kukreti", "suffix": ""}, {"first": "N", "middle": [], "last": "Bahlis", "suffix": ""}, {"first": "M", "middle": [], "last": "Alsina", "suffix": ""}, {"first": "A", "middle": [], "last": "Chanan-Khan", "suffix": ""}, {"first": "F", "middle": [], "last": "Buadi", "suffix": ""}, {"first": "F", "middle": ["J"], "last": "Reu", "suffix": ""}, {"first": "G", "middle": [], "last": "Somlo", "suffix": ""}, {"first": "J", "middle": [], "last": "Zonder", "suffix": ""}, {"first": "K", "middle": [], "last": "Song", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Stewart", "suffix": ""}, {"first": "E", "middle": [], "last": "Stadtmauer", "suffix": ""}, {"first": "L", "middle": [], "last": "Kunkel", "suffix": ""}, {"first": "S", "middle": [], "last": "Jagannath", "suffix": ""}], "year": 2012, "venue": "Blood", "volume": "120", "issn": "14", "pages": "2817--2825", "other_ids": {"DOI": ["10.1182/blood-2012-05-425934"]}}, "BIBREF646": {"ref_id": "b646", "title": "Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies", "authors": [{"first": "D", "middle": [], "last": "Siegel", "suffix": ""}, {"first": "T", "middle": [], "last": "Martin", "suffix": ""}, {"first": "A", "middle": [], "last": "Nooka", "suffix": ""}, {"first": "R", "middle": ["D"], "last": "Harvey", "suffix": ""}, {"first": "R", "middle": [], "last": "Vij", "suffix": ""}, {"first": "R", "middle": [], "last": "Niesvizky", "suffix": ""}, {"first": "A", "middle": ["Z"], "last": "Badros", "suffix": ""}, {"first": "S", "middle": [], "last": "Jagannath", "suffix": ""}, {"first": "L", "middle": [], "last": "Mcculloch", "suffix": ""}, {"first": "K", "middle": [], "last": "Rajangam", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonial", "suffix": ""}], "year": 2013, "venue": "Haematologica", "volume": "98", "issn": "11", "pages": "1753--1761", "other_ids": {"DOI": ["10.3324/haematol.2013.089334"]}}, "BIBREF647": {"ref_id": "b647", "title": "The role of the proteasome activator PA28 in MHC class I antigen processing", "authors": [{"first": "A", "middle": [], "last": "Sijts", "suffix": ""}, {"first": "Y", "middle": [], "last": "Sun", "suffix": ""}, {"first": "K", "middle": [], "last": "Janek", "suffix": ""}, {"first": "S", "middle": [], "last": "Kral", "suffix": ""}, {"first": "A", "middle": [], "last": "Paschen", "suffix": ""}, {"first": "D", "middle": [], "last": "Schadendorf", "suffix": ""}, {"first": "P.-M", "middle": [], "last": "Kloetzel", "suffix": ""}], "year": 2002, "venue": "Molecular Immunology", "volume": "39", "issn": "3-4", "pages": "99--107", "other_ids": {"DOI": ["10.1016/s0161-5890(02"]}}, "BIBREF648": {"ref_id": "b648", "title": "The role of the proteasome in the generation of MHC class I ligands and immune responses", "authors": [{"first": "E", "middle": ["J A M"], "last": "Sijts", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Kloetzel", "suffix": ""}], "year": 2011, "venue": "Cellular and Molecular Life Sciences: CMLS", "volume": "68", "issn": "9", "pages": "1491--1502", "other_ids": {"DOI": ["10.1007/s00018-011"]}}, "BIBREF649": {"ref_id": "b649", "title": "The role of the proteasome in the generation of MHC class I ligands and immune responses", "authors": [{"first": "E", "middle": ["J A M"], "last": "Sijts", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Kloetzel", "suffix": ""}], "year": 2011, "venue": "Cellular and Molecular Life Sciences: CMLS", "volume": "68", "issn": "9", "pages": "1491--1502", "other_ids": {"DOI": ["10.1007/s00018-011-0657-y"]}}, "BIBREF650": {"ref_id": "b650", "title": "Of Mice and Men: Proteasome's Role in LPS-Induced Inflammation and Tolerance", "authors": [{"first": "N", "middle": [], "last": "Silswal", "suffix": ""}, {"first": "J", "middle": [], "last": "Reis", "suffix": ""}, {"first": "A", "middle": ["A"], "last": "Qureshi", "suffix": ""}, {"first": "C", "middle": [], "last": "Papasian", "suffix": ""}, {"first": "N", "middle": [], "last": "Qureshi", "suffix": ""}], "year": 2017, "venue": "Shock", "volume": "47", "issn": "4", "pages": "445--454", "other_ids": {"DOI": ["10.1097/SHK.0000000000000743"]}}, "BIBREF651": {"ref_id": "b651", "title": "The release of labeled amino acids from the proteins of rat liver slices", "authors": [{"first": "M", "middle": ["V"], "last": "Simpson", "suffix": ""}], "year": 1953, "venue": "The Journal of Biological Chemistry", "volume": "201", "issn": "1", "pages": "143--154", "other_ids": {}}, "BIBREF652": {"ref_id": "b652", "title": "Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology", "authors": [{"first": "N", "middle": [], "last": "Sin", "suffix": ""}, {"first": "K", "middle": ["B"], "last": "Kim", "suffix": ""}, {"first": "M", "middle": [], "last": "Elofsson", "suffix": ""}, {"first": "L", "middle": [], "last": "Meng", "suffix": ""}, {"first": "H", "middle": [], "last": "Auth", "suffix": ""}, {"first": "B", "middle": ["H"], "last": "Kwok", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Crews", "suffix": ""}], "year": 1999, "venue": "Bioorganic & Medicinal Chemistry Letters", "volume": "9", "issn": "15", "pages": "2283--2288", "other_ids": {}}, "BIBREF654": {"ref_id": "b654", "title": "Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model", "authors": [{"first": "A", "middle": ["V"], "last": "Singh", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Palladino", "suffix": ""}, {"first": "G", "middle": ["K"], "last": "Lloyd", "suffix": ""}, {"first": "B", "middle": ["C"], "last": "Potts", "suffix": ""}, {"first": "D", "middle": [], "last": "Chauhan", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}], "year": 2010, "venue": "British Journal of Haematology", "volume": "149", "issn": "4", "pages": "550--559", "other_ids": {"DOI": ["10.1111/j.1365-2141.2010.08144.x"]}}, "BIBREF655": {"ref_id": "b655", "title": "Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy", "authors": [{"first": "B", "middle": ["N"], "last": "Singh", "suffix": ""}, {"first": "B", "middle": ["K"], "last": "Malhotra", "suffix": ""}], "year": 2004, "venue": "Clinical Pharmacokinetics", "volume": "43", "issn": "15", "pages": "1127--1156", "other_ids": {"DOI": ["10.2165/00003088-200443150-00005"]}}, "BIBREF656": {"ref_id": "b656", "title": "Defects in autophagy caused by glaucoma-associated mutations in optineurin", "authors": [{"first": "K", "middle": [], "last": "Sirohi", "suffix": ""}, {"first": "G", "middle": [], "last": "Swarup", "suffix": ""}], "year": 2016, "venue": "Experimental Eye Research", "volume": "144", "issn": "", "pages": "54--63", "other_ids": {"DOI": ["10.1016/j.exer.2015.08.020"]}}, "BIBREF657": {"ref_id": "b657", "title": "Proteasome dysfunction in alveolar type 2 epithelial cells is associated with acute respiratory distress syndrome", "authors": [{"first": "S", "middle": [], "last": "Sitaraman", "suffix": ""}, {"first": "C.-L", "middle": [], "last": "Na", "suffix": ""}, {"first": "L", "middle": [], "last": "Yang", "suffix": ""}, {"first": "A", "middle": [], "last": "Filuta", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Bridges", "suffix": ""}, {"first": "T", "middle": ["E"], "last": "Weaver", "suffix": ""}], "year": 2019, "venue": "Scientific Reports", "volume": "9", "issn": "1", "pages": "1--15", "other_ids": {"DOI": ["10.1038/s41598-019-49020-4"]}}, "BIBREF658": {"ref_id": "b658", "title": "Distinct Proteasome Subpopulations in the Alveolar Space of Patients with the Acute Respiratory Distress Syndrome", "authors": [{"first": "S", "middle": ["U"], "last": "Sixt", "suffix": ""}, {"first": "R", "middle": [], "last": "Alami", "suffix": ""}, {"first": "J", "middle": [], "last": "Hakenbeck", "suffix": ""}, {"first": "M", "middle": [], "last": "Adamzik", "suffix": ""}, {"first": "A", "middle": [], "last": "Klo\u00df", "suffix": ""}, {"first": "U", "middle": [], "last": "Costabel", "suffix": ""}, {"first": "P", "middle": ["R"], "last": "Jungblut", "suffix": ""}, {"first": "B", "middle": [], "last": "Dahlmann", "suffix": ""}, {"first": "J", "middle": [], "last": "Peters", "suffix": ""}], "year": 2012, "venue": "Mediators of Inflammation", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1155/2012/204250"]}}, "BIBREF659": {"ref_id": "b659", "title": "Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndrome", "authors": [{"first": "Stephan", "middle": [], "last": "Sixt", "suffix": ""}, {"first": "", "middle": [], "last": "Urs", "suffix": ""}, {"first": "M", "middle": [], "last": "Adamzik", "suffix": ""}, {"first": "D", "middle": [], "last": "Spyrka", "suffix": ""}, {"first": "B", "middle": [], "last": "Saul", "suffix": ""}, {"first": "J", "middle": [], "last": "Hakenbeck", "suffix": ""}, {"first": "J", "middle": [], "last": "Wohlschlaeger", "suffix": ""}, {"first": "U", "middle": [], "last": "Costabel", "suffix": ""}, {"first": "A", "middle": [], "last": "Kloss", "suffix": ""}, {"first": "J", "middle": [], "last": "Giesebrecht", "suffix": ""}, {"first": "B", "middle": [], "last": "Dahlmann", "suffix": ""}, {"first": "J", "middle": [], "last": "Peters", "suffix": ""}], "year": 2009, "venue": "American Journal of Respiratory and Critical Care Medicine", "volume": "179", "issn": "12", "pages": "1098--1106", "other_ids": {"DOI": ["10.1164/rccm.200802-199OC"]}}, "BIBREF660": {"ref_id": "b660", "title": "O-GlcNAc signalling: implications for cancer cell biology", "authors": [{"first": "C", "middle": [], "last": "Slawson", "suffix": ""}, {"first": "G", "middle": ["W"], "last": "Hart", "suffix": ""}], "year": 2011, "venue": "Nature Reviews. Cancer", "volume": "11", "issn": "9", "pages": "678--684", "other_ids": {"DOI": ["10.1038/nrc3114"]}}, "BIBREF661": {"ref_id": "b661", "title": "Structure of the 26S proteasome with ATP-\u03b3S bound provides insights into the mechanism of nucleotide-dependent substrate translocation", "authors": [{"first": "P", "middle": [], "last": "\u015aled\u017a", "suffix": ""}, {"first": "P", "middle": [], "last": "Unverdorben", "suffix": ""}, {"first": "F", "middle": [], "last": "Beck", "suffix": ""}, {"first": "G", "middle": [], "last": "Pfeifer", "suffix": ""}, {"first": "A", "middle": [], "last": "Schweitzer", "suffix": ""}, {"first": "F", "middle": [], "last": "F\u00f6rster", "suffix": ""}, {"first": "W", "middle": [], "last": "Baumeister", "suffix": ""}], "year": 2013, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "110", "issn": "", "pages": "7264--7269", "other_ids": {"DOI": ["10.1073/pnas.1305782110"]}}, "BIBREF662": {"ref_id": "b662", "title": "Phase 1 study of ixazomib, an investigational proteasome inhibitor, in J o u r n a l P r e -p r o o f advanced non-hematologic malignancies", "authors": [{"first": "D", "middle": ["C"], "last": "Smith", "suffix": ""}, {"first": "T", "middle": [], "last": "Kalebic", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Infante", "suffix": ""}, {"first": "L", "middle": ["L"], "last": "Siu", "suffix": ""}, {"first": "D", "middle": [], "last": "Sullivan", "suffix": ""}, {"first": "G", "middle": [], "last": "Vlahovic", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Kauh", "suffix": ""}, {"first": "F", "middle": [], "last": "Gao", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Berger", "suffix": ""}, {"first": "S", "middle": [], "last": "Tirrell", "suffix": ""}, {"first": "N", "middle": [], "last": "Gupta", "suffix": ""}, {"first": "A", "middle": [], "last": "Di Bacco", "suffix": ""}, {"first": "D", "middle": [], "last": "Berg", "suffix": ""}, {"first": "G", "middle": [], "last": "Liu", "suffix": ""}, {"first": "J", "middle": [], "last": "Lin", "suffix": ""}, {"first": "A.-M", "middle": [], "last": "Hui", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Thompson", "suffix": ""}], "year": 2015, "venue": "Investigational New Drugs", "volume": "33", "issn": "3", "pages": "652--663", "other_ids": {"DOI": ["10.1007/s10637-015-0230-x"]}}, "BIBREF663": {"ref_id": "b663", "title": "Reversal of long-term dendritic spine alterations in Alzheimer disease models", "authors": [{"first": "D", "middle": ["L"], "last": "Smith", "suffix": ""}, {"first": "J", "middle": [], "last": "Pozueta", "suffix": ""}, {"first": "B", "middle": [], "last": "Gong", "suffix": ""}, {"first": "O", "middle": [], "last": "Arancio", "suffix": ""}, {"first": "M", "middle": [], "last": "Shelanski", "suffix": ""}], "year": 2009, "venue": "Proceedings of the National Academy of Sciences", "volume": "106", "issn": "39", "pages": "16877--16882", "other_ids": {"DOI": ["10.1073/pnas.0908706106"]}}, "BIBREF664": {"ref_id": "b664", "title": "Could a Common Mechanism of Protein Degradation Impairment Underlie Many Neurodegenerative Diseases?", "authors": [{"first": "D", "middle": ["M"], "last": "Smith", "suffix": ""}], "year": 2018, "venue": "Journal of Experimental Neuroscience", "volume": "12", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1177/1179069518794675"]}}, "BIBREF665": {"ref_id": "b665", "title": "Could a Common Mechanism of Protein Degradation Impairment Underlie Many Neurodegenerative Diseases?", "authors": [{"first": "D", "middle": ["M"], "last": "Smith", "suffix": ""}], "year": 2018, "venue": "Journal of Experimental Neuroscience", "volume": "12", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1177/1179069518794675"]}}, "BIBREF667": {"ref_id": "b667", "title": "Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's alpha ring opens the gate for substrate entry", "authors": [], "year": null, "venue": "Molecular Cell", "volume": "27", "issn": "5", "pages": "731--744", "other_ids": {}}, "BIBREF669": {"ref_id": "b669", "title": "Docking of the Proteasomal ATPases' C-termini in the 20S Proteasomes alpha Ring Opens the Gate for Substrate Entry", "authors": [{"first": "D", "middle": ["M"], "last": "Smith", "suffix": ""}, {"first": "S.-C", "middle": [], "last": "Chang", "suffix": ""}, {"first": "S", "middle": [], "last": "Park", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}, {"first": "Y", "middle": [], "last": "Cheng", "suffix": ""}, {"first": "A", "middle": [], "last": "Goldberg", "suffix": ""}], "year": 2007, "venue": "Molecular Cell", "volume": "27", "issn": "5", "pages": "731--744", "other_ids": {"DOI": ["10.1016/j.molcel.2007.06.033"]}}, "BIBREF670": {"ref_id": "b670", "title": "ATP Binding to PAN or the 26S ATPases Causes Association with the 20S Proteasome, Gate Opening, and Translocation of Unfolded Proteins", "authors": [{"first": "D", "middle": ["M"], "last": "Smith", "suffix": ""}, {"first": "G", "middle": [], "last": "Kafri", "suffix": ""}, {"first": "Y", "middle": [], "last": "Cheng", "suffix": ""}, {"first": "D", "middle": [], "last": "Ng", "suffix": ""}, {"first": "T", "middle": [], "last": "Walz", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}], "year": 2005, "venue": "Molecular Cell", "volume": "20", "issn": "5", "pages": "687--698", "other_ids": {}}, "BIBREF672": {"ref_id": "b672", "title": "Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders", "authors": [{"first": "P", "middle": [], "last": "Smolewski", "suffix": ""}, {"first": "D", "middle": [], "last": "Rydygier", "suffix": ""}], "year": 2019, "venue": "Expert Opinion on Investigational Drugs", "volume": "28", "issn": "5", "pages": "421--433", "other_ids": {"DOI": ["10.1080/13543784.2019.1596258"]}}, "BIBREF673": {"ref_id": "b673", "title": "Targeting the proteostasis network in Huntington's disease", "authors": [{"first": "T", "middle": ["R"], "last": "Soares", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Reis", "suffix": ""}, {"first": "B", "middle": ["R"], "last": "Pinho", "suffix": ""}, {"first": "M", "middle": ["R"], "last": "Duchen", "suffix": ""}, {"first": "J", "middle": ["M A"], "last": "Oliveira", "suffix": ""}], "year": 2019, "venue": "Ageing Research Reviews", "volume": "49", "issn": "", "pages": "92--103", "other_ids": {"DOI": ["10.1016/j.arr.2018.11.006"]}}, "BIBREF674": {"ref_id": "b674", "title": "Proteasome Activation is Mediated via a Functional Switch of the Rpt6 C-terminal Tail Following Chaperone-dependent Assembly", "authors": [{"first": "V", "middle": [], "last": "Sokolova", "suffix": ""}, {"first": "F", "middle": [], "last": "Li", "suffix": ""}, {"first": "G", "middle": [], "last": "Polovin", "suffix": ""}, {"first": "S", "middle": [], "last": "Park", "suffix": ""}], "year": 2015, "venue": "Scientific Reports", "volume": "5", "issn": "1", "pages": "1--15", "other_ids": {"DOI": ["10.1038/srep14909"]}}, "BIBREF675": {"ref_id": "b675", "title": "Sem1p is a novel subunit of the 26 S proteasome from Saccharomyces cerevisiae", "authors": [{"first": "T", "middle": [], "last": "Sone", "suffix": ""}, {"first": "Y", "middle": [], "last": "Saeki", "suffix": ""}, {"first": "A", "middle": [], "last": "Toh-E", "suffix": ""}, {"first": "H", "middle": [], "last": "Yokosawa", "suffix": ""}], "year": 2004, "venue": "The Journal of Biological Chemistry", "volume": "279", "issn": "27", "pages": "28807--28816", "other_ids": {"DOI": ["10.1074/jbc.M403165200"]}}, "BIBREF676": {"ref_id": "b676", "title": "Parkin promotes proteasomal degradation of p62: implication of selective vulnerability of neuronal cells in the pathogenesis of Parkinson's disease", "authors": [{"first": "P", "middle": [], "last": "Song", "suffix": ""}, {"first": "S", "middle": [], "last": "Li", "suffix": ""}, {"first": "H", "middle": [], "last": "Wu", "suffix": ""}, {"first": "R", "middle": [], "last": "Gao", "suffix": ""}, {"first": "G", "middle": [], "last": "Rao", "suffix": ""}, {"first": "D", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Z", "middle": [], "last": "Chen", "suffix": ""}, {"first": "B", "middle": [], "last": "Ma", "suffix": ""}, {"first": "H", "middle": [], "last": "Wang", "suffix": ""}, {"first": "N", "middle": [], "last": "Sui", "suffix": ""}, {"first": "H", "middle": [], "last": "Deng", "suffix": ""}, {"first": "Z", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "T", "middle": [], "last": "Tang", "suffix": ""}, {"first": "Z", "middle": [], "last": "Tan", "suffix": ""}, {"first": "Z", "middle": [], "last": "Han", "suffix": ""}, {"first": "T", "middle": [], "last": "Lu", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "Q", "middle": [], "last": "Chen", "suffix": ""}], "year": 2016, "venue": "Protein & Cell", "volume": "7", "issn": "2", "pages": "114--129", "other_ids": {"DOI": ["10.1007/s13238-015-0230-9"]}}, "BIBREF678": {"ref_id": "b678", "title": "Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials", "authors": [{"first": "D.-L", "middle": [], "last": "Esseltine", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}], "year": 2013, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "31", "issn": "26", "pages": "3279--3287", "other_ids": {"DOI": ["10.1200/JCO.2012.48.4626"]}}, "BIBREF679": {"ref_id": "b679", "title": "Sorting out the trash: the spatial nature of eukaryotic protein quality control", "authors": [{"first": "E", "middle": ["M"], "last": "Sontag", "suffix": ""}, {"first": "W", "middle": ["I M"], "last": "Vonk", "suffix": ""}, {"first": "J", "middle": [], "last": "Frydman", "suffix": ""}], "year": 2014, "venue": "Current Opinion in Cell Biology", "volume": "26", "issn": "", "pages": "139--146", "other_ids": {"DOI": ["10.1016/j.ceb.2013.12.006"]}}, "BIBREF680": {"ref_id": "b680", "title": "Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits", "authors": [{"first": "E", "middle": ["K"], "last": "Speliotes", "suffix": ""}, {"first": "L", "middle": ["M"], "last": "Yerges-Armstrong", "suffix": ""}, {"first": "J", "middle": [], "last": "Wu", "suffix": ""}, {"first": "R", "middle": [], "last": "Hernaez", "suffix": ""}, {"first": "L", "middle": ["J"], "last": "Kim", "suffix": ""}, {"first": "C", "middle": ["D"], "last": "Palmer", "suffix": ""}, {"first": "V", "middle": [], "last": "Gudnason", "suffix": ""}, {"first": "G", "middle": [], "last": "Eiriksdottir", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Garcia", "suffix": ""}, {"first": "L", "middle": ["J"], "last": "Launer", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Nalls", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Clark", "suffix": ""}, {"first": "B", "middle": ["D"], "last": "Mitchell", "suffix": ""}, {"first": "A", "middle": ["R"], "last": "Shuldiner", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Butler", "suffix": ""}, {"first": "M", "middle": [], "last": "Tomas", "suffix": ""}, {"first": "U", "middle": [], "last": "Hoffmann", "suffix": ""}, {"first": "S.-J", "middle": [], "last": "Hwang", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Massaro", "suffix": ""}, {"first": "\u2026", "middle": [], "last": "Gold Consortium", "suffix": ""}], "year": 2011, "venue": "PLoS Genetics", "volume": "7", "issn": "3", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pgen.1001324"]}}, "BIBREF681": {"ref_id": "b681", "title": "A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results", "authors": [{"first": "A", "middle": [], "last": "Spencer", "suffix": ""}, {"first": "S", "middle": [], "last": "Harrison", "suffix": ""}, {"first": "J", "middle": [], "last": "Zonder", "suffix": ""}, {"first": "A", "middle": [], "last": "Badros", "suffix": ""}, {"first": "J", "middle": [], "last": "Laubach", "suffix": ""}, {"first": "K", "middle": [], "last": "Bergin", "suffix": ""}, {"first": "A", "middle": [], "last": "Khot", "suffix": ""}, {"first": "T", "middle": [], "last": "Zimmerman", "suffix": ""}, {"first": "D", "middle": [], "last": "Chauhan", "suffix": ""}, {"first": "N", "middle": [], "last": "Levin", "suffix": ""}, {"first": "A", "middle": [], "last": "Maclaren", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Reich", "suffix": ""}, {"first": "M", "middle": [], "last": "Trikha", "suffix": ""}, {"first": "P", "middle": [], "last": "Richardson", "suffix": ""}], "year": 2018, "venue": "British Journal of Haematology", "volume": "180", "issn": "1", "pages": "41--51", "other_ids": {"DOI": ["10.1111/bjh.14987"]}}, "BIBREF682": {"ref_id": "b682", "title": "Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR", "authors": [{"first": "A", "middle": [], "last": "Spencer", "suffix": ""}, {"first": "S", "middle": [], "last": "Lentzsch", "suffix": ""}, {"first": "K", "middle": [], "last": "Weisel", "suffix": ""}, {"first": "H", "middle": [], "last": "Avet-Loiseau", "suffix": ""}, {"first": "T", "middle": ["M"], "last": "Mark", "suffix": ""}, {"first": "I", "middle": [], "last": "Spicka", "suffix": ""}, {"first": "T", "middle": [], "last": "Masszi", "suffix": ""}, {"first": "B", "middle": [], "last": "Lauri", "suffix": ""}, {"first": "M.-D", "middle": [], "last": "Levin", "suffix": ""}, {"first": "A", "middle": [], "last": "Bosi", "suffix": ""}, {"first": "V", "middle": [], "last": "Hungria", "suffix": ""}, {"first": "M", "middle": [], "last": "Cavo", "suffix": ""}, {"first": "J.-J", "middle": [], "last": "Lee", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Nooka", "suffix": ""}, {"first": "H", "middle": [], "last": "Quach", "suffix": ""}, {"first": "C", "middle": [], "last": "Lee", "suffix": ""}, {"first": "W", "middle": [], "last": "Barreto", "suffix": ""}, {"first": "P", "middle": [], "last": "Corradini", "suffix": ""}, {"first": "C.-K", "middle": [], "last": "Min", "suffix": ""}, {"first": "M.-V", "middle": [], "last": "Mateos", "suffix": ""}], "year": 2018, "venue": "Haematologica", "volume": "", "issn": "12", "pages": "2079--2087", "other_ids": {}}, "BIBREF684": {"ref_id": "b684", "title": "The Proteasome: More Than a Means to an End", "authors": [{"first": "L", "middle": [], "last": "Spyracopoulos", "suffix": ""}], "year": 1993, "venue": "Structure", "volume": "24", "issn": "8", "pages": "1221--1223", "other_ids": {"DOI": ["10.1016/j.str.2016.07.005"]}}, "BIBREF685": {"ref_id": "b685", "title": "VIEWPOINT An English I'ranslation of Alzheimer's 1907 Paper, \" ijber eine eigenartige Erlranliung der Hirnrinde", "authors": [{"first": "R", "middle": ["A"], "last": "Stelzma", "suffix": ""}, {"first": "H", "middle": ["N"], "last": "Schnitzlein", "suffix": ""}, {"first": "F", "middle": ["R"], "last": "Murllagh", "suffix": ""}], "year": 1995, "venue": "Clinical Anatomy", "volume": "8", "issn": "", "pages": "429--443", "other_ids": {}}, "BIBREF686": {"ref_id": "b686", "title": "Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma", "authors": [{"first": "A", "middle": ["K"], "last": "Stewart", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}, {"first": "T", "middle": [], "last": "Masszi", "suffix": ""}, {"first": "I", "middle": [], "last": "\u0160pi\u010dka", "suffix": ""}, {"first": "A", "middle": [], "last": "Oriol", "suffix": ""}, {"first": "R", "middle": [], "last": "H\u00e1jek", "suffix": ""}, {"first": "L", "middle": [], "last": "Rosi\u00f1ol", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Siegel", "suffix": ""}, {"first": "R", "middle": [], "last": "Niesvizky", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Jakubowiak", "suffix": ""}, {"first": "J", "middle": ["F"], "last": "San-Miguel", "suffix": ""}, {"first": "H", "middle": [], "last": "Ludwig", "suffix": ""}, {"first": "J", "middle": [], "last": "Buchanan", "suffix": ""}, {"first": "K", "middle": [], "last": "Cocks", "suffix": ""}, {"first": "X", "middle": [], "last": "Yang", "suffix": ""}, {"first": "B", "middle": [], "last": "Xing", "suffix": ""}, {"first": "N", "middle": [], "last": "Zojwalla", "suffix": ""}, {"first": "M", "middle": [], "last": "Tonda", "suffix": ""}, {"first": "P", "middle": [], "last": "Moreau", "suffix": ""}, {"first": "A", "middle": [], "last": "Palumbo", "suffix": ""}], "year": 2016, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "34", "issn": "32", "pages": "3921--3930", "other_ids": {}}, "BIBREF688": {"ref_id": "b688", "title": "Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple", "authors": [{"first": "A", "middle": ["K"], "last": "Stewart", "suffix": ""}, {"first": "S", "middle": ["V"], "last": "Rajkumar", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Dimopoulos", "suffix": ""}, {"first": "T", "middle": [], "last": "Masszi", "suffix": ""}, {"first": "I", "middle": [], "last": "\u0160pi\u010dka", "suffix": ""}, {"first": "A", "middle": [], "last": "Oriol", "suffix": ""}, {"first": "R", "middle": [], "last": "H\u00e1jek", "suffix": ""}, {"first": "L", "middle": [], "last": "Rosi\u00f1ol", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Siegel", "suffix": ""}, {"first": "G", "middle": ["G"], "last": "Mihaylov", "suffix": ""}, {"first": "V", "middle": [], "last": "Goranova-Marinova", "suffix": ""}, {"first": "P", "middle": [], "last": "Rajnics", "suffix": ""}, {"first": "A", "middle": [], "last": "Suvorov", "suffix": ""}, {"first": "R", "middle": [], "last": "Niesvizky", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Jakubowiak", "suffix": ""}, {"first": "J", "middle": ["F"], "last": "San-Miguel", "suffix": ""}, {"first": "H", "middle": [], "last": "Ludwig", "suffix": ""}, {"first": "M", "middle": [], "last": "Wang", "suffix": ""}, {"first": "V", "middle": [], "last": "Maisnar", "suffix": ""}, {"first": "\u2026", "middle": [], "last": "Aspire", "suffix": ""}], "year": 2015, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF689": {"ref_id": "b689", "title": "The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial", "authors": [{"first": "A", "middle": [], "last": "Striha", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Ashcroft", "suffix": ""}, {"first": "A", "middle": [], "last": "Hockaday", "suffix": ""}, {"first": "D", "middle": ["A"], "last": "Cairns", "suffix": ""}, {"first": "K", "middle": [], "last": "Boardman", "suffix": ""}, {"first": "G", "middle": [], "last": "Jacques", "suffix": ""}, {"first": "C", "middle": [], "last": "Williams", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Snowden", "suffix": ""}, {"first": "M", "middle": [], "last": "Garg", "suffix": ""}, {"first": "J", "middle": [], "last": "Cavenagh", "suffix": ""}, {"first": "K", "middle": [], "last": "Yong", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Drayson", "suffix": ""}, {"first": "R", "middle": [], "last": "Owen", "suffix": ""}, {"first": "M", "middle": [], "last": "Cook", "suffix": ""}, {"first": "G", "middle": [], "last": "Cook", "suffix": ""}], "year": 2018, "venue": "Trials", "volume": "19", "issn": "1", "pages": "", "other_ids": {"DOI": ["10.1186/s13063-018-2524-8"]}}, "BIBREF690": {"ref_id": "b690", "title": "Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains", "authors": [{"first": "S", "middle": ["W"], "last": "Suh", "suffix": ""}, {"first": "K", "middle": ["B"], "last": "Jensen", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Jensen", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Silva", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Kesslak", "suffix": ""}, {"first": "G", "middle": [], "last": "Danscher", "suffix": ""}, {"first": "C", "middle": ["J"], "last": "Frederickson", "suffix": ""}], "year": 2000, "venue": "Brain Research", "volume": "852", "issn": "2", "pages": "274--278", "other_ids": {}}, "BIBREF691": {"ref_id": "b691", "title": "Proteasome inhibition promotes mono-ubiquitination and nuclear translocation of mature (52 kDa) PINK1. Biochemical and Biophysical Research Communications", "authors": [{"first": "L", "middle": [], "last": "Sun", "suffix": ""}, {"first": "H", "middle": [], "last": "B\u00fceler", "suffix": ""}], "year": 2019, "venue": "", "volume": "517", "issn": "", "pages": "376--382", "other_ids": {"DOI": ["10.1016/j.bbrc.2019.07.051"]}}, "BIBREF692": {"ref_id": "b692", "title": "Novel proteasome inhibitor PS-341 inhibits activation of nuclear factorkappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma", "authors": [{"first": "J", "middle": ["B"], "last": "Sunwoo", "suffix": ""}, {"first": "Z", "middle": [], "last": "Chen", "suffix": ""}, {"first": "G", "middle": [], "last": "Dong", "suffix": ""}, {"first": "N", "middle": [], "last": "Yeh", "suffix": ""}, {"first": "C", "middle": [], "last": "Bancroft", "suffix": ""}, {"first": "E", "middle": [], "last": "Sausville", "suffix": ""}, {"first": "J", "middle": [], "last": "Adams", "suffix": ""}, {"first": "P", "middle": [], "last": "Elliott", "suffix": ""}, {"first": "C", "middle": [], "last": "Van Waes", "suffix": ""}], "year": 2001, "venue": "Clinical Cancer Research: An Official Journal of the American Association for Cancer Research", "volume": "7", "issn": "5", "pages": "1419--1428", "other_ids": {}}, "BIBREF693": {"ref_id": "b693", "title": "Altered Functions and Interactions of Glaucoma-Associated Mutants of Optineurin", "authors": [{"first": "G", "middle": [], "last": "Swarup", "suffix": ""}, {"first": "Z", "middle": [], "last": "Sayyad", "suffix": ""}], "year": 2018, "venue": "Frontiers in Immunology", "volume": "9", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3389/fimmu.2018.01287"]}}, "BIBREF694": {"ref_id": "b694", "title": "Protein misfolding in neurodegenerative diseases: implications and strategies", "authors": [{"first": "P", "middle": [], "last": "Sweeney", "suffix": ""}, {"first": "H", "middle": [], "last": "Park", "suffix": ""}, {"first": "M", "middle": [], "last": "Baumann", "suffix": ""}, {"first": "J", "middle": [], "last": "Dunlop", "suffix": ""}, {"first": "J", "middle": [], "last": "Frydman", "suffix": ""}, {"first": "R", "middle": [], "last": "Kopito", "suffix": ""}, {"first": "A", "middle": [], "last": "Mccampbell", "suffix": ""}, {"first": "G", "middle": [], "last": "Leblanc", "suffix": ""}, {"first": "A", "middle": [], "last": "Venkateswaran", "suffix": ""}, {"first": "A", "middle": [], "last": "Nurmi", "suffix": ""}, {"first": "R", "middle": [], "last": "Hodgson", "suffix": ""}], "year": 2017, "venue": "Translational Neurodegeneration", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1186/s40035-017-0077-5"]}}, "BIBREF695": {"ref_id": "b695", "title": "Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response", "authors": [{"first": "A", "middle": [], "last": "Szokalska", "suffix": ""}, {"first": "M", "middle": [], "last": "Makowski", "suffix": ""}, {"first": "D", "middle": [], "last": "Nowis", "suffix": ""}, {"first": "G", "middle": ["M"], "last": "Wilczy\u0144ski", "suffix": ""}, {"first": "M", "middle": [], "last": "Kujawa", "suffix": ""}, {"first": "C", "middle": [], "last": "W\u00f3jcik", "suffix": ""}, {"first": "I", "middle": [], "last": "M\u0142ynarczuk-Bia\u0142y", "suffix": ""}, {"first": "P", "middle": [], "last": "Salwa", "suffix": ""}, {"first": "J", "middle": [], "last": "Bil", "suffix": ""}, {"first": "S", "middle": [], "last": "Janowska", "suffix": ""}, {"first": "P", "middle": [], "last": "Agostinis", "suffix": ""}, {"first": "T", "middle": [], "last": "Verfaillie", "suffix": ""}, {"first": "M", "middle": [], "last": "Bugajski", "suffix": ""}, {"first": "J", "middle": [], "last": "Gietka", "suffix": ""}, {"first": "T", "middle": [], "last": "Issat", "suffix": ""}, {"first": "E", "middle": [], "last": "G\u0142odkowska", "suffix": ""}, {"first": "P", "middle": [], "last": "Mr\u00f3wka", "suffix": ""}, {"first": "T", "middle": [], "last": "Stoklosa", "suffix": ""}, {"first": "M", "middle": ["R"], "last": "Hamblin", "suffix": ""}, {"first": "J", "middle": [], "last": "Golab", "suffix": ""}], "year": 2009, "venue": "Cancer Research", "volume": "69", "issn": "10", "pages": "4235--4243", "other_ids": {"DOI": ["10.1158/0008-5472.CAN-08-3439"]}}, "BIBREF696": {"ref_id": "b696", "title": "Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction", "authors": [{"first": "H.-C", "middle": [], "last": "Tai", "suffix": ""}, {"first": "E", "middle": ["M"], "last": "Schuman", "suffix": ""}], "year": 2008, "venue": "Nature Reviews. Neuroscience", "volume": "9", "issn": "11", "pages": "826--838", "other_ids": {"DOI": ["10.1038/nrn2499"]}}, "BIBREF697": {"ref_id": "b697", "title": "The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system", "authors": [{"first": "H.-C", "middle": [], "last": "Tai", "suffix": ""}, {"first": "A", "middle": [], "last": "Serrano-Pozo", "suffix": ""}, {"first": "T", "middle": [], "last": "Hashimoto", "suffix": ""}, {"first": "M", "middle": ["P"], "last": "Frosch", "suffix": ""}, {"first": "T", "middle": ["L"], "last": "Spires-Jones", "suffix": ""}, {"first": "B", "middle": ["T"], "last": "Hyman", "suffix": ""}], "year": 2012, "venue": "The American Journal of Pathology", "volume": "181", "issn": "4", "pages": "1426--1435", "other_ids": {"DOI": ["10.1016/j.ajpath.2012.06.033"]}}, "BIBREF698": {"ref_id": "b698", "title": "TCR affinity for thymoproteasome-dependent positively selecting peptides conditions antigen responsiveness in CD8+ T cells", "authors": [{"first": "K", "middle": [], "last": "Takada", "suffix": ""}, {"first": "F", "middle": [], "last": "Van Laethem", "suffix": ""}, {"first": "Y", "middle": [], "last": "Xing", "suffix": ""}, {"first": "K", "middle": [], "last": "Akane", "suffix": ""}, {"first": "H", "middle": [], "last": "Suzuki", "suffix": ""}, {"first": "S", "middle": [], "last": "Murata", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "S", "middle": ["C"], "last": "Jameson", "suffix": ""}, {"first": "A", "middle": [], "last": "Singer", "suffix": ""}, {"first": "Y", "middle": [], "last": "Takahama", "suffix": ""}], "year": 2015, "venue": "Nature Immunology", "volume": "16", "issn": "10", "pages": "1069--1076", "other_ids": {}}, "BIBREF700": {"ref_id": "b700", "title": "Pathophysiology of diabetic retinopathy", "authors": [{"first": "J", "middle": ["M"], "last": "Tarr", "suffix": ""}, {"first": "K", "middle": [], "last": "Kaul", "suffix": ""}, {"first": "M", "middle": [], "last": "Chopra", "suffix": ""}, {"first": "E", "middle": ["M"], "last": "Kohner", "suffix": ""}, {"first": "R", "middle": [], "last": "Chibber", "suffix": ""}], "year": 2013, "venue": "ISRN Ophthalmology", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1155/2013/343560"]}}, "BIBREF701": {"ref_id": "b701", "title": "Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative", "authors": [{"first": "A", "middle": ["T N"], "last": "Tebbenkamp", "suffix": ""}, {"first": "C", "middle": [], "last": "Green", "suffix": ""}, {"first": "G", "middle": [], "last": "Xu", "suffix": ""}, {"first": "E", "middle": ["M"], "last": "Denovan-Wright", "suffix": ""}, {"first": "A", "middle": ["C"], "last": "Rising", "suffix": ""}, {"first": "S", "middle": ["E"], "last": "Fromholt", "suffix": ""}, {"first": "H", "middle": ["H"], "last": "Brown", "suffix": ""}, {"first": "D", "middle": [], "last": "Swing", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Mandel", "suffix": ""}, {"first": "L", "middle": [], "last": "Tessarollo", "suffix": ""}, {"first": "D", "middle": ["R"], "last": "Borchelt", "suffix": ""}], "year": 2011, "venue": "Human Molecular Genetics", "volume": "20", "issn": "14", "pages": "2770--2782", "other_ids": {}}, "BIBREF703": {"ref_id": "b703", "title": "Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies", "authors": [{"first": "B", "middle": ["W"], "last": "Teh", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Harrison", "suffix": ""}, {"first": "L", "middle": ["J"], "last": "Worth", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Slavin", "suffix": ""}], "year": 2016, "venue": "Leukemia & Lymphoma", "volume": "57", "issn": "7", "pages": "1719--1722", "other_ids": {"DOI": ["10.3109/10428194.2015.1106538"]}}, "BIBREF704": {"ref_id": "b704", "title": "The proteasome inhibitor PS-341 in cancer therapy", "authors": [{"first": "B", "middle": ["A"], "last": "Teicher", "suffix": ""}, {"first": "G", "middle": [], "last": "Ara", "suffix": ""}, {"first": "R", "middle": [], "last": "Herbst", "suffix": ""}, {"first": "V", "middle": ["J"], "last": "Palombella", "suffix": ""}, {"first": "J", "middle": [], "last": "Adams", "suffix": ""}], "year": 1999, "venue": "Clinical Cancer Research: An Official Journal of the American Association for Cancer Research", "volume": "5", "issn": "9", "pages": "2638--2645", "other_ids": {}}, "BIBREF706": {"ref_id": "b706", "title": "Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group", "authors": [{"first": "M", "middle": [], "last": "Glabbeke", "suffix": ""}, {"first": "R", "middle": [], "last": "Somers", "suffix": ""}, {"first": "L", "middle": [], "last": "Bijnens", "suffix": ""}, {"first": "E", "middle": ["M"], "last": "Noordijk", "suffix": ""}, {"first": "C", "middle": ["D"], "last": "Peeters", "suffix": ""}], "year": 1995, "venue": "Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology", "volume": "13", "issn": "11", "pages": "2819--2826", "other_ids": {}}, "BIBREF708": {"ref_id": "b708", "title": "A Practical Review of Proteasome Pharmacology", "authors": [{"first": "T", "middle": ["A"], "last": "Thibaudeau", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Smith", "suffix": ""}], "year": 2019, "venue": "Pharmacological Reviews", "volume": "71", "issn": "2", "pages": "170--197", "other_ids": {"DOI": ["10.1124/pr.117.015370"]}}, "BIBREF709": {"ref_id": "b709", "title": "A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers", "authors": [{"first": "T", "middle": ["A"], "last": "Thibaudeau", "suffix": ""}, {"first": "R", "middle": ["T"], "last": "Anderson", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "Smith", "suffix": ""}], "year": 2018, "venue": "Nature Communications", "volume": "9", "issn": "1", "pages": "", "other_ids": {"DOI": ["10.1038/s41467-018-03509-0"]}}, "BIBREF710": {"ref_id": "b710", "title": "Proteomic analysis of protein phosphorylation and ubiquitination in Alzheimer's disease", "authors": [{"first": "S", "middle": ["N"], "last": "Thomas", "suffix": ""}, {"first": "D", "middle": [], "last": "Cripps", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Yang", "suffix": ""}], "year": 2009, "venue": "Methods in Molecular Biology", "volume": "566", "issn": "", "pages": "109--121", "other_ids": {"DOI": ["10.1007/978-1-59745-562-6_8"]}}, "BIBREF712": {"ref_id": "b712", "title": "An asymmetric interface between the regulatory and core particles of the proteasome", "authors": [], "year": null, "venue": "Nature Structural & Molecular Biology", "volume": "18", "issn": "11", "pages": "1259--1267", "other_ids": {"DOI": ["10.1038/nsmb.2147"]}}, "BIBREF713": {"ref_id": "b713", "title": "Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells", "authors": [{"first": "Z", "middle": [], "last": "Tian", "suffix": ""}, {"first": "J", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "Y.-T", "middle": [], "last": "Tai", "suffix": ""}, {"first": "S", "middle": ["B"], "last": "Amin", "suffix": ""}, {"first": "Y", "middle": [], "last": "Hu", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Berger", "suffix": ""}, {"first": "P", "middle": [], "last": "Richardson", "suffix": ""}, {"first": "D", "middle": [], "last": "Chauhan", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Anderson", "suffix": ""}], "year": 2012, "venue": "Blood", "volume": "120", "issn": "19", "pages": "3958--3967", "other_ids": {"DOI": ["10.1182/blood-2012-01-401794"]}}, "BIBREF716": {"ref_id": "b716", "title": "alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome", "authors": [{"first": "G", "middle": ["K"], "last": "Tofaris", "suffix": ""}, {"first": "R", "middle": [], "last": "Layfield", "suffix": ""}, {"first": "M", "middle": ["G"], "last": "Spillantini", "suffix": ""}], "year": 2001, "venue": "FEBS Letters", "volume": "509", "issn": "1", "pages": "22--26", "other_ids": {"DOI": ["10.1016/s0014-5793(01)03115-5"]}}, "BIBREF717": {"ref_id": "b717", "title": "Decreased proteasomal activity causes age-related phenotypes and promotes the development of metabolic abnormalities", "authors": [{"first": "U", "middle": [], "last": "Tomaru", "suffix": ""}, {"first": "S", "middle": [], "last": "Takahashi", "suffix": ""}, {"first": "A", "middle": [], "last": "Ishizu", "suffix": ""}, {"first": "Y", "middle": [], "last": "Miyatake", "suffix": ""}, {"first": "A", "middle": [], "last": "Gohda", "suffix": ""}, {"first": "S", "middle": [], "last": "Suzuki", "suffix": ""}, {"first": "A", "middle": [], "last": "Ono", "suffix": ""}, {"first": "J", "middle": [], "last": "Ohara", "suffix": ""}, {"first": "T", "middle": [], "last": "Baba", "suffix": ""}, {"first": "S", "middle": [], "last": "Murata", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "M", "middle": [], "last": "Kasahara", "suffix": ""}], "year": 2012, "venue": "The American Journal of Pathology", "volume": "180", "issn": "3", "pages": "963--972", "other_ids": {"DOI": ["10.1016/j.ajpath.2011.11.012"]}}, "BIBREF718": {"ref_id": "b718", "title": "New comprehensive studies of a gold(III) Dithiocarbamate complex with proven anticancer properties: Aqueous dissolution with cyclodextrins, pharmacokinetics and upstream inhibition of the ubiquitin-proteasome pathway", "authors": [{"first": "M", "middle": ["F"], "last": "Tomasello", "suffix": ""}, {"first": "C", "middle": [], "last": "Nardon", "suffix": ""}, {"first": "V", "middle": [], "last": "Lanza", "suffix": ""}, {"first": "G", "middle": [], "last": "Di Natale", "suffix": ""}, {"first": "N", "middle": [], "last": "Pettenuzzo", "suffix": ""}, {"first": "S", "middle": [], "last": "Salmaso", "suffix": ""}, {"first": "D", "middle": [], "last": "Milardi", "suffix": ""}, {"first": "P", "middle": [], "last": "Caliceti", "suffix": ""}, {"first": "G", "middle": [], "last": "Pappalardo", "suffix": ""}, {"first": "D", "middle": [], "last": "Fregona", "suffix": ""}], "year": 2017, "venue": "European Journal of Medicinal Chemistry", "volume": "138", "issn": "", "pages": "115--127", "other_ids": {}}, "BIBREF720": {"ref_id": "b720", "title": "Incorporation of the Rpn12 Subunit Couples Completion of Proteasome Regulatory Particle Lid Assembly to Lid-Base Joining", "authors": [{"first": "R", "middle": ["J"], "last": "Tomko", "suffix": ""}, {"first": "M", "middle": [], "last": "Hochstrasser", "suffix": ""}], "year": 2011, "venue": "Molecular Cell", "volume": "44", "issn": "6", "pages": "907--917", "other_ids": {"DOI": ["10.1016/j.molcel.2011.11.020"]}}, "BIBREF721": {"ref_id": "b721", "title": "The intrinsically disordered Sem1 protein functions as a molecular tether during proteasome lid biogenesis", "authors": [{"first": "R", "middle": ["J"], "last": "Tomko", "suffix": ""}, {"first": "M", "middle": [], "last": "Hochstrasser", "suffix": ""}], "year": 2014, "venue": "Molecular Cell", "volume": "53", "issn": "3", "pages": "433--443", "other_ids": {"DOI": ["10.1016/j.molcel.2013.12.009"]}}, "BIBREF722": {"ref_id": "b722", "title": "Heterohexameric ring arrangement of the eukaryotic proteasomal ATPases: implications for proteasome structure and assembly", "authors": [{"first": "R", "middle": ["J"], "last": "Tomko", "suffix": ""}, {"first": "M", "middle": [], "last": "Funakoshi", "suffix": ""}, {"first": "K", "middle": [], "last": "Schneider", "suffix": ""}, {"first": "J", "middle": [], "last": "Wang", "suffix": ""}, {"first": "M", "middle": [], "last": "Hochstrasser", "suffix": ""}], "year": 2010, "venue": "Molecular Cell", "volume": "38", "issn": "3", "pages": "393--403", "other_ids": {"DOI": ["10.1016/j.molcel.2010.02.035"]}}, "BIBREF724": {"ref_id": "b724", "title": "A Single \u03b1 Helix Drives Extensive Remodeling of the Proteasome Lid and Completion of Regulatory Particle Assembly", "authors": [], "year": null, "venue": "Cell", "volume": "163", "issn": "2", "pages": "432--444", "other_ids": {"DOI": ["10.1016/j.cell.2015.09.022"]}}, "BIBREF725": {"ref_id": "b725", "title": "Identification of aneuploidy-tolerating mutations", "authors": [{"first": "E", "middle": ["M"], "last": "Torres", "suffix": ""}, {"first": "N", "middle": [], "last": "Dephoure", "suffix": ""}, {"first": "A", "middle": [], "last": "Panneerselvam", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Tucker", "suffix": ""}, {"first": "C", "middle": ["A"], "last": "Whittaker", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Gygi", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Dunham", "suffix": ""}, {"first": "A", "middle": [], "last": "Amon", "suffix": ""}], "year": 2010, "venue": "Cell", "volume": "143", "issn": "1", "pages": "71--83", "other_ids": {"DOI": ["10.1016/j.cell.2010.08.038"]}}, "BIBREF726": {"ref_id": "b726", "title": "Effects of aneuploidy on cellular physiology and cell division in haploid yeast", "authors": [{"first": "E", "middle": ["M"], "last": "Torres", "suffix": ""}, {"first": "T", "middle": [], "last": "Sokolsky", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "Tucker", "suffix": ""}, {"first": "L", "middle": ["Y"], "last": "Chan", "suffix": ""}, {"first": "M", "middle": [], "last": "Boselli", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Dunham", "suffix": ""}, {"first": "A", "middle": [], "last": "Amon", "suffix": ""}], "year": 2007, "venue": "Science", "volume": "", "issn": "5840", "pages": "916--924", "other_ids": {"DOI": ["10.1126/science.1142210"]}}, "BIBREF727": {"ref_id": "b727", "title": "Aneuploidy: cells losing their balance", "authors": [{"first": "E", "middle": ["M"], "last": "Torres", "suffix": ""}, {"first": "B", "middle": ["R"], "last": "Williams", "suffix": ""}, {"first": "A", "middle": [], "last": "Amon", "suffix": ""}], "year": 2008, "venue": "Genetics", "volume": "179", "issn": "2", "pages": "737--746", "other_ids": {"DOI": ["10.1534/genetics.108.090878"]}}, "BIBREF728": {"ref_id": "b728", "title": "A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B", "authors": [{"first": "E", "middle": ["B"], "last": "Traenckner", "suffix": ""}, {"first": "S", "middle": [], "last": "Wilk", "suffix": ""}, {"first": "P", "middle": ["A"], "last": "Baeuerle", "suffix": ""}], "year": 1994, "venue": "The EMBO Journal", "volume": "13", "issn": "22", "pages": "5433--5441", "other_ids": {}}, "BIBREF730": {"ref_id": "b730", "title": "Pyrazolone Small Molecules Displaying Therapeutic Potential in Amyotrophic Lateral Sclerosis", "authors": [], "year": null, "venue": "ACS Chemical Neuroscience", "volume": "5", "issn": "9", "pages": "823--829", "other_ids": {"DOI": ["10.1021/cn500147v"]}}, "BIBREF731": {"ref_id": "b731", "title": "Neuroprotective Effects of Betulin in Pharmacological and Transgenic Caenorhabditis elegans Models of Parkinson's Disease", "authors": [{"first": "C", "middle": ["W"], "last": "Tsai", "suffix": ""}, {"first": "R", "middle": ["T"], "last": "Tsai", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Liu", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Chen", "suffix": ""}, {"first": "M", "middle": ["C"], "last": "Tsai", "suffix": ""}, {"first": "S", "middle": ["H"], "last": "Chien", "suffix": ""}, {"first": "H", "middle": ["S"], "last": "Hung", "suffix": ""}, {"first": "S", "middle": ["Z"], "last": "Lin", "suffix": ""}, {"first": "W", "middle": ["C"], "last": "Shyu", "suffix": ""}, {"first": "R", "middle": ["H"], "last": "Fu", "suffix": ""}], "year": 2017, "venue": "Cell Transplantation", "volume": "26", "issn": "12", "pages": "1903--1918", "other_ids": {"DOI": ["10.1177/0963689717738785"]}}, "BIBREF732": {"ref_id": "b732", "title": "Abeta inhibits the proteasome and enhances amyloid and tau accumulation", "authors": [{"first": "B", "middle": ["P"], "last": "Tseng", "suffix": ""}, {"first": "K", "middle": ["N"], "last": "Green", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Chan", "suffix": ""}, {"first": "M", "middle": [], "last": "Blurton-Jones", "suffix": ""}, {"first": "F", "middle": ["M"], "last": "Laferla", "suffix": ""}], "year": 2008, "venue": "Neurobiology of Aging", "volume": "29", "issn": "11", "pages": "1607--1618", "other_ids": {"DOI": ["10.1016/j.neurobiolaging.2007.04.014"]}}, "BIBREF733": {"ref_id": "b733", "title": "Porphyrin as Diagnostic and Therapeutic Agent", "authors": [{"first": "N", "middle": [], "last": "Tsolekile", "suffix": ""}, {"first": "S", "middle": [], "last": "Nelana", "suffix": ""}, {"first": "O", "middle": ["S"], "last": "Oluwafemi", "suffix": ""}], "year": 2019, "venue": "Molecules", "volume": "24", "issn": "14", "pages": "", "other_ids": {"DOI": ["10.3390/molecules24142669"]}}, "BIBREF734": {"ref_id": "b734", "title": "Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome", "authors": [{"first": "P", "middle": [], "last": "Tsvetkov", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Mendillo", "suffix": ""}, {"first": "J", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "J", "middle": ["E"], "last": "Carette", "suffix": ""}, {"first": "P", "middle": ["H"], "last": "Merrill", "suffix": ""}, {"first": "D", "middle": [], "last": "Cikes", "suffix": ""}, {"first": "M", "middle": [], "last": "Varadarajan", "suffix": ""}, {"first": "F", "middle": ["R"], "last": "Van Diemen", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Penninger", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}, {"first": "T", "middle": ["R"], "last": "Brummelkamp", "suffix": ""}, {"first": "S", "middle": [], "last": "Santagata", "suffix": ""}, {"first": "S", "middle": [], "last": "Lindquist", "suffix": ""}], "year": 2015, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.7554/eLife.08467"]}}, "BIBREF735": {"ref_id": "b735", "title": "Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers", "authors": [{"first": "P", "middle": [], "last": "Tsvetkov", "suffix": ""}, {"first": "E", "middle": [], "last": "Sokol", "suffix": ""}, {"first": "D", "middle": [], "last": "Jin", "suffix": ""}, {"first": "Z", "middle": [], "last": "Brune", "suffix": ""}, {"first": "P", "middle": [], "last": "Thiru", "suffix": ""}, {"first": "M", "middle": [], "last": "Ghandi", "suffix": ""}, {"first": "L", "middle": ["A"], "last": "Garraway", "suffix": ""}, {"first": "P", "middle": ["B"], "last": "Gupta", "suffix": ""}, {"first": "S", "middle": [], "last": "Santagata", "suffix": ""}, {"first": "L", "middle": [], "last": "Whitesell", "suffix": ""}, {"first": "S", "middle": [], "last": "Lindquist", "suffix": ""}], "year": 2017, "venue": "Proceedings of the National Academy of Sciences", "volume": "114", "issn": "2", "pages": "382--387", "other_ids": {"DOI": ["10.1073/pnas.1619067114"]}}, "BIBREF736": {"ref_id": "b736", "title": "Insights into Proteasome Conformation Dynamics and Intersubunit Communication", "authors": [{"first": "G", "middle": ["R"], "last": "Tundo", "suffix": ""}, {"first": "D", "middle": [], "last": "Sbardella", "suffix": ""}, {"first": "M", "middle": [], "last": "Coletta", "suffix": ""}], "year": 2018, "venue": "Trends in Biochemical Sciences", "volume": "43", "issn": "11", "pages": "852--853", "other_ids": {"DOI": ["10.1016/j.tibs.2018.08.002"]}}, "BIBREF737": {"ref_id": "b737", "title": "Multiple functions of insulindegrading enzyme: a metabolic crosslight?", "authors": [{"first": "G", "middle": ["R"], "last": "Tundo", "suffix": ""}, {"first": "D", "middle": [], "last": "Sbardella", "suffix": ""}, {"first": "C", "middle": [], "last": "Ciaccio", "suffix": ""}, {"first": "G", "middle": [], "last": "Grasso", "suffix": ""}, {"first": "M", "middle": [], "last": "Gioia", "suffix": ""}, {"first": "A", "middle": [], "last": "Coletta", "suffix": ""}, {"first": "F", "middle": [], "last": "Polticelli", "suffix": ""}, {"first": "D", "middle": [], "last": "Di Pierro", "suffix": ""}, {"first": "D", "middle": [], "last": "Milardi", "suffix": ""}, {"first": "P", "middle": [], "last": "Van Endert", "suffix": ""}, {"first": "S", "middle": [], "last": "Marini", "suffix": ""}, {"first": "M", "middle": [], "last": "Coletta", "suffix": ""}], "year": 2017, "venue": "Critical Reviews in Biochemistry and Molecular Biology", "volume": "52", "issn": "5", "pages": "554--582", "other_ids": {"DOI": ["10.1080/10409238.2017.1337707"]}}, "BIBREF738": {"ref_id": "b738", "title": "On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment", "authors": [{"first": "G", "middle": ["R"], "last": "Tundo", "suffix": ""}, {"first": "D", "middle": [], "last": "Sbardella", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Lacal", "suffix": ""}, {"first": "G", "middle": [], "last": "Graziani", "suffix": ""}, {"first": "S", "middle": [], "last": "Marini", "suffix": ""}], "year": 2019, "venue": "Chemotherapy", "volume": "64", "issn": "2", "pages": "62--80", "other_ids": {"DOI": ["10.1159/000500902"]}}, "BIBREF739": {"ref_id": "b739", "title": "Characterization of the testis-specific proteasome subunit \u03b14s in mammals", "authors": [{"first": "H", "middle": [], "last": "Uechi", "suffix": ""}, {"first": "J", "middle": [], "last": "Hamazaki", "suffix": ""}, {"first": "S", "middle": [], "last": "Murata", "suffix": ""}], "year": 2014, "venue": "The Journal of Biological Chemistry", "volume": "289", "issn": "18", "pages": "12365--12374", "other_ids": {"DOI": ["10.1074/jbc.M114.558866"]}}, "BIBREF740": {"ref_id": "b740", "title": "Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in \u03b1-Synuclein Aggregation Disorders. EBioMedicine", "authors": [{"first": "S", "middle": [], "last": "Ugras", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Daniels", "suffix": ""}, {"first": "H", "middle": [], "last": "Fazelinia", "suffix": ""}, {"first": "N", "middle": ["S"], "last": "Gould", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Yocum", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Luk", "suffix": ""}, {"first": "E", "middle": [], "last": "Luna", "suffix": ""}, {"first": "H", "middle": [], "last": "Ding", "suffix": ""}, {"first": "C", "middle": [], "last": "Mckennan", "suffix": ""}, {"first": "S", "middle": [], "last": "Seeholzer", "suffix": ""}, {"first": "D", "middle": [], "last": "Martinez", "suffix": ""}, {"first": "P", "middle": [], "last": "Evans", "suffix": ""}, {"first": "D", "middle": [], "last": "Brown", "suffix": ""}, {"first": "J", "middle": ["E"], "last": "Duda", "suffix": ""}, {"first": "H", "middle": [], "last": "Ischiropoulos", "suffix": ""}], "year": 2018, "venue": "", "volume": "31", "issn": "", "pages": "307--319", "other_ids": {}}, "BIBREF742": {"ref_id": "b742", "title": "Parkin directly modulates 26S proteasome activity", "authors": [{"first": "J", "middle": ["W"], "last": "Um", "suffix": ""}, {"first": "E", "middle": [], "last": "Im", "suffix": ""}, {"first": "H", "middle": ["J"], "last": "Lee", "suffix": ""}, {"first": "B", "middle": [], "last": "Min", "suffix": ""}, {"first": "L", "middle": [], "last": "Yoo", "suffix": ""}, {"first": "J", "middle": [], "last": "Yoo", "suffix": ""}, {"first": "H", "middle": [], "last": "L\u00fcbbert", "suffix": ""}, {"first": "C", "middle": [], "last": "Stichel-Gunkel", "suffix": ""}, {"first": "H.-S", "middle": [], "last": "Cho", "suffix": ""}, {"first": "J", "middle": ["B"], "last": "Yoon", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Chung", "suffix": ""}], "year": 2010, "venue": "The Journal of Neuroscience: The Official Journal of the Society for Neuroscience", "volume": "30", "issn": "35", "pages": "11805--11814", "other_ids": {"DOI": ["10.1523/JNEUROSCI.2862-09.2010"]}}, "BIBREF743": {"ref_id": "b743", "title": "Parkin ubiquitinates and promotes the degradation of RanBP2", "authors": [{"first": "J", "middle": ["W"], "last": "Um", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Min", "suffix": ""}, {"first": "H", "middle": [], "last": "Rhim", "suffix": ""}, {"first": "J", "middle": [], "last": "Kim", "suffix": ""}, {"first": "S", "middle": ["R"], "last": "Paik", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Chung", "suffix": ""}], "year": 2006, "venue": "The Journal of Biological Chemistry", "volume": "281", "issn": "6", "pages": "3595--3603", "other_ids": {"DOI": ["10.1074/jbc.M504994200"]}}, "BIBREF744": {"ref_id": "b744", "title": "The structure of the mammalian 20S proteasome at 2.75 A resolution", "authors": [{"first": "M", "middle": [], "last": "Unno", "suffix": ""}, {"first": "T", "middle": [], "last": "Mizushima", "suffix": ""}, {"first": "Y", "middle": [], "last": "Morimoto", "suffix": ""}, {"first": "Y", "middle": [], "last": "Tomisugi", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "N", "middle": [], "last": "Yasuoka", "suffix": ""}, {"first": "T", "middle": [], "last": "Tsukihara", "suffix": ""}], "year": 1993, "venue": "Structure", "volume": "10", "issn": "5", "pages": "748--755", "other_ids": {"DOI": ["10.1016/s0969-2126(02"]}}, "BIBREF745": {"ref_id": "b745", "title": "PA200, a nuclear proteasome activator involved in DNA repair", "authors": [{"first": "V", "middle": [], "last": "Ustrell", "suffix": ""}, {"first": "L", "middle": [], "last": "Hoffman", "suffix": ""}, {"first": "G", "middle": [], "last": "Pratt", "suffix": ""}, {"first": "M", "middle": [], "last": "Rechsteiner", "suffix": ""}], "year": 2002, "venue": "The EMBO Journal", "volume": "21", "issn": "13", "pages": "3516--3525", "other_ids": {}}, "BIBREF747": {"ref_id": "b747", "title": "Purification and assay of proteasome activator PA200", "authors": [{"first": "V", "middle": [], "last": "Ustrell", "suffix": ""}, {"first": "G", "middle": [], "last": "Pratt", "suffix": ""}, {"first": "C", "middle": [], "last": "Gorbea", "suffix": ""}, {"first": "M", "middle": [], "last": "Rechsteiner", "suffix": ""}], "year": 2005, "venue": "Methods in Enzymology", "volume": "398", "issn": "", "pages": "321--329", "other_ids": {"DOI": ["10.1016/S0076-"]}}, "BIBREF748": {"ref_id": "b748", "title": "Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metabolism and Disposition: The Biological Fate of Chemicals", "authors": [{"first": "V", "middle": [], "last": "Uttamsingh", "suffix": ""}, {"first": "C", "middle": [], "last": "Lu", "suffix": ""}, {"first": "G", "middle": [], "last": "Miwa", "suffix": ""}, {"first": "L.-S", "middle": [], "last": "Gan", "suffix": ""}], "year": 2005, "venue": "", "volume": "33", "issn": "", "pages": "1723--1728", "other_ids": {"DOI": ["10.1124/dmd.105.005710"]}}, "BIBREF749": {"ref_id": "b749", "title": "Chaperoning the Cancer: The Proteostatic Functions of the Heat Shock Proteins in Cancer", "authors": [{"first": "S", "middle": [], "last": "Vahid", "suffix": ""}, {"first": "D", "middle": [], "last": "Thaper", "suffix": ""}, {"first": "A", "middle": [], "last": "Zoubeidi", "suffix": ""}], "year": 2017, "venue": "Recent Patents on Anti-Cancer Drug Discovery", "volume": "12", "issn": "1", "pages": "35--47", "other_ids": {"DOI": ["10.2174/1574892811666161102125252"]}}, "BIBREF751": {"ref_id": "b751", "title": "Proteasome inhibition and oxidative reactions disrupt cellular homeostasis during heme stress", "authors": [], "year": null, "venue": "Cell Death and Differentiation", "volume": "22", "issn": "4", "pages": "597--611", "other_ids": {"DOI": ["10.1038/cdd.2014.154"]}}, "BIBREF752": {"ref_id": "b752", "title": "Cancer and dementia: Two sides of the same coin?", "authors": [{"first": "K", "middle": ["D"], "last": "Van Der Willik", "suffix": ""}, {"first": "S", "middle": ["B"], "last": "Schagen", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Ikram", "suffix": ""}], "year": 2018, "venue": "European Journal of Clinical Investigation", "volume": "", "issn": "11", "pages": "", "other_ids": {}}, "BIBREF754": {"ref_id": "b754", "title": "The dynamics of early-state transcriptional changes and J o u r n a l P r e -p r o o f aggregate formation in a Huntington's disease cell model", "authors": [{"first": "M", "middle": [], "last": "Van Hagen", "suffix": ""}, {"first": "D", "middle": ["G E"], "last": "Piebes", "suffix": ""}, {"first": "W", "middle": ["C"], "last": "De Leeuw", "suffix": ""}, {"first": "I", "middle": ["M"], "last": "Vuist", "suffix": ""}, {"first": "W", "middle": ["M C"], "last": "Van Roon-Mom", "suffix": ""}, {"first": "P", "middle": ["D"], "last": "Moerland", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Verschure", "suffix": ""}], "year": 2017, "venue": "BMC Genomics", "volume": "18", "issn": "1", "pages": "", "other_ids": {"DOI": ["10.1186/s12864-017-3745-z"]}}, "BIBREF755": {"ref_id": "b755", "title": "Nuclear factor-kappaB in development, prevention, and therapy of cancer", "authors": [{"first": "C", "middle": [], "last": "Van Waes", "suffix": ""}], "year": 2007, "venue": "Clinical Cancer Research: An Official Journal of the American Association for Cancer Research", "volume": "13", "issn": "4", "pages": "1076--1082", "other_ids": {"DOI": ["10.1158/1078-0432.CCR-06-2221"]}}, "BIBREF756": {"ref_id": "b756", "title": "Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism", "authors": [{"first": "R", "middle": ["T"], "last": "Vanderlinden", "suffix": ""}, {"first": "C", "middle": ["W"], "last": "Hemmis", "suffix": ""}, {"first": "T", "middle": [], "last": "Yao", "suffix": ""}, {"first": "H", "middle": [], "last": "Robinson", "suffix": ""}, {"first": "C", "middle": ["P"], "last": "Hill", "suffix": ""}], "year": 2017, "venue": "The Journal of Biological Chemistry", "volume": "292", "issn": "23", "pages": "9493--9504", "other_ids": {"DOI": ["10.1074/jbc.M117.785287"]}}, "BIBREF757": {"ref_id": "b757", "title": "The early history of the ubiquitin field", "authors": [{"first": "A", "middle": [], "last": "Varshavsky", "suffix": ""}], "year": 2006, "venue": "Protein Science : A Publication of the Protein Society", "volume": "15", "issn": "3", "pages": "647--654", "other_ids": {"DOI": ["10.1110/ps.052012306"]}}, "BIBREF758": {"ref_id": "b758", "title": "Plasticity in eucaryotic 20S proteasome ring assembly revealed by a subunit deletion in yeast", "authors": [{"first": "I", "middle": [], "last": "Velichutina", "suffix": ""}, {"first": "P", "middle": ["L"], "last": "Connerly", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Arendt", "suffix": ""}, {"first": "X", "middle": [], "last": "Li", "suffix": ""}, {"first": "M", "middle": [], "last": "Hochstrasser", "suffix": ""}], "year": 2004, "venue": "The EMBO Journal", "volume": "23", "issn": "3", "pages": "500--510", "other_ids": {"DOI": ["10.1038/sj.emboj.7600059"]}}, "BIBREF759": {"ref_id": "b759", "title": "Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study", "authors": [{"first": "K", "middle": [], "last": "Venkatakrishnan", "suffix": ""}, {"first": "M", "middle": [], "last": "Rader", "suffix": ""}, {"first": "R", "middle": ["K"], "last": "Ramanathan", "suffix": ""}, {"first": "S", "middle": [], "last": "Ramalingam", "suffix": ""}, {"first": "E", "middle": [], "last": "Chen", "suffix": ""}, {"first": "W", "middle": [], "last": "Riordan", "suffix": ""}, {"first": "W", "middle": [], "last": "Trepicchio", "suffix": ""}, {"first": "M", "middle": [], "last": "Cooper", "suffix": ""}, {"first": "M", "middle": [], "last": "Karol", "suffix": ""}, {"first": "L", "middle": [], "last": "Von Moltke", "suffix": ""}, {"first": "R", "middle": [], "last": "Neuwirth", "suffix": ""}, {"first": "M", "middle": [], "last": "Egorin", "suffix": ""}, {"first": "G", "middle": [], "last": "Chatta", "suffix": ""}], "year": 2009, "venue": "Clinical Therapeutics", "volume": "31", "issn": "", "pages": "2444--2458", "other_ids": {"DOI": ["10.1016/j.clinthera.2009.11.012"]}}, "BIBREF760": {"ref_id": "b760", "title": "Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival", "authors": [{"first": "C", "middle": ["P"], "last": "Venner", "suffix": ""}, {"first": "T", "middle": [], "last": "Lane", "suffix": ""}, {"first": "D", "middle": [], "last": "Foard", "suffix": ""}, {"first": "L", "middle": [], "last": "Rannigan", "suffix": ""}, {"first": "S", "middle": ["D J"], "last": "Gibbs", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Pinney", "suffix": ""}, {"first": "C", "middle": ["J"], "last": "Whelan", "suffix": ""}, {"first": "H", "middle": ["J"], "last": "Lachmann", "suffix": ""}, {"first": "J", "middle": ["D"], "last": "Gillmore", "suffix": ""}, {"first": "P", "middle": ["N"], "last": "Hawkins", "suffix": ""}, {"first": "A", "middle": ["D"], "last": "Wechalekar", "suffix": ""}], "year": 2012, "venue": "Blood", "volume": "119", "issn": "19", "pages": "4387--4390", "other_ids": {}}, "BIBREF762": {"ref_id": "b762", "title": "Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis", "authors": [{"first": "S", "middle": ["E"], "last": "Verbrugge", "suffix": ""}, {"first": "Y", "middle": ["G"], "last": "Assaraf", "suffix": ""}, {"first": "B", "middle": ["A C"], "last": "Dijkmans", "suffix": ""}, {"first": "G", "middle": ["L"], "last": "Scheffer", "suffix": ""}, {"first": "M", "middle": [], "last": "Al", "suffix": ""}, {"first": "D", "middle": [], "last": "Den Uyl", "suffix": ""}, {"first": "R", "middle": [], "last": "Oerlemans", "suffix": ""}, {"first": "E", "middle": ["T"], "last": "Chan", "suffix": ""}, {"first": "C", "middle": ["J"], "last": "Kirk", "suffix": ""}, {"first": "G", "middle": ["J"], "last": "Peters", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Van Der Heijden", "suffix": ""}, {"first": "T", "middle": ["D"], "last": "De Gruijl", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Scheper", "suffix": ""}, {"first": "G", "middle": [], "last": "Jansen", "suffix": ""}], "year": 2012, "venue": "The Journal of Pharmacology and Experimental Therapeutics", "volume": "341", "issn": "1", "pages": "174--182", "other_ids": {"DOI": ["10.1124/jpet.111.187542"]}}, "BIBREF763": {"ref_id": "b763", "title": "Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome", "authors": [{"first": "R", "middle": [], "last": "Verma", "suffix": ""}, {"first": "L", "middle": [], "last": "Aravind", "suffix": ""}, {"first": "R", "middle": [], "last": "Oania", "suffix": ""}, {"first": "W", "middle": ["H"], "last": "Mcdonald", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Yates", "suffix": ""}, {"first": "E", "middle": ["V"], "last": "Koonin", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Deshaies", "suffix": ""}], "year": 2002, "venue": "Science", "volume": "", "issn": "5593", "pages": "611--615", "other_ids": {"DOI": ["10.1126/science.1075898"]}}, "BIBREF764": {"ref_id": "b764", "title": "2D-and 3D-cultures of human trabecular meshwork cells: A preliminary assessment of an in vitro model for glaucoma study", "authors": [{"first": "S", "middle": [], "last": "Vernazza", "suffix": ""}, {"first": "S", "middle": [], "last": "Tirendi", "suffix": ""}, {"first": "S", "middle": [], "last": "Scarf\u00ec", "suffix": ""}, {"first": "M", "middle": [], "last": "Passalacqua", "suffix": ""}, {"first": "F", "middle": [], "last": "Oddone", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "Traverso", "suffix": ""}, {"first": "I", "middle": [], "last": "Rizzato", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Bassi", "suffix": ""}, {"first": "S", "middle": ["C"], "last": "Sacc\u00e0", "suffix": ""}], "year": 2019, "venue": "PloS One", "volume": "14", "issn": "9", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0221942"]}}, "BIBREF765": {"ref_id": "b765", "title": "Regulating protein breakdown through proteasome phosphorylation", "authors": [{"first": "J", "middle": ["J S"], "last": "Verplank", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}], "year": 2017, "venue": "The Biochemical Journal", "volume": "474", "issn": "19", "pages": "3355--3371", "other_ids": {}}, "BIBREF767": {"ref_id": "b767", "title": "Exploring the regulation of proteasome function by subunit phosphorylation", "authors": [{"first": "J", "middle": ["J S"], "last": "Verplank", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}], "year": 2018, "venue": "Methods in Molecular Biology", "volume": "1844", "issn": "", "pages": "309--319", "other_ids": {"DOI": ["10.1007/978-1-4939-8706-1_20"]}}, "BIBREF768": {"ref_id": "b768", "title": "26S Proteasomes are rapidly activated by diverse hormones and physiological states that raise cAMP and cause Rpn6 phosphorylation", "authors": [{"first": "J", "middle": ["J S"], "last": "Verplank", "suffix": ""}, {"first": "S", "middle": [], "last": "Lokireddy", "suffix": ""}, {"first": "J", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}], "year": 2019, "venue": "Proceedings of the National Academy of Sciences", "volume": "116", "issn": "", "pages": "4228--4237", "other_ids": {"DOI": ["10.1073/pnas.1809254116"]}}, "BIBREF769": {"ref_id": "b769", "title": "On the Trails of the Proteasome Fold: Structural and Functional Analysis of the Ancestral \u03b2-Subunit Protein Anbu", "authors": [{"first": "M.-T", "middle": [], "last": "Vielberg", "suffix": ""}, {"first": "V", "middle": ["C"], "last": "Bauer", "suffix": ""}, {"first": "M", "middle": [], "last": "Groll", "suffix": ""}], "year": 2018, "venue": "Journal of Molecular Biology", "volume": "430", "issn": "5", "pages": "628--640", "other_ids": {"DOI": ["10.1016/j.jmb.2018.01.004"]}}, "BIBREF770": {"ref_id": "b770", "title": "Hemin Inhibits Ubiquitin-Dependent Proteolysis in both a Higher Plant and Yeast", "authors": [{"first": "R", "middle": ["D"], "last": "Vierstra", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Sullivan", "suffix": ""}], "year": 1988, "venue": "Biochemistry", "volume": "27", "issn": "9", "pages": "3290--3295", "other_ids": {"DOI": ["10.1021/bi00409a025"]}}, "BIBREF771": {"ref_id": "b771", "title": "Linkage between the proteasome pathway and neurodegenerative diseases and aging", "authors": [{"first": "S", "middle": [], "last": "Vigouroux", "suffix": ""}, {"first": "M", "middle": [], "last": "Briand", "suffix": ""}, {"first": "Y", "middle": [], "last": "Briand", "suffix": ""}], "year": 2004, "venue": "Molecular Neurobiology", "volume": "30", "issn": "2", "pages": "201--221", "other_ids": {}}, "BIBREF773": {"ref_id": "b773", "title": "An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma", "authors": [{"first": "R", "middle": [], "last": "Vij", "suffix": ""}, {"first": "M", "middle": [], "last": "Wang", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Kaufman", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonial", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Jakubowiak", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Stewart", "suffix": ""}, {"first": "V", "middle": [], "last": "Kukreti", "suffix": ""}, {"first": "S", "middle": [], "last": "Jagannath", "suffix": ""}, {"first": "K", "middle": ["T"], "last": "Mcdonagh", "suffix": ""}, {"first": "M", "middle": [], "last": "Alsina", "suffix": ""}, {"first": "N", "middle": ["J"], "last": "Bahlis", "suffix": ""}, {"first": "F", "middle": ["J"], "last": "Reu", "suffix": ""}, {"first": "N", "middle": ["Y"], "last": "Gabrail", "suffix": ""}, {"first": "A", "middle": [], "last": "Belch", "suffix": ""}, {"first": "J", "middle": ["V"], "last": "Matous", "suffix": ""}, {"first": "P", "middle": [], "last": "Lee", "suffix": ""}, {"first": "P", "middle": [], "last": "Rosen", "suffix": ""}, {"first": "M", "middle": [], "last": "Sebag", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Vesole", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Siegel", "suffix": ""}], "year": 2012, "venue": "Blood", "volume": "119", "issn": "24", "pages": "5661--5670", "other_ids": {}}, "BIBREF775": {"ref_id": "b775", "title": "Structure of ubiquitin refined at 1.8 A resolution", "authors": [{"first": "S", "middle": [], "last": "Vijay-Kumar", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "Bugg", "suffix": ""}, {"first": "W", "middle": ["J"], "last": "Cook", "suffix": ""}], "year": 1987, "venue": "Journal of Molecular Biology", "volume": "194", "issn": "3", "pages": "90679--90685", "other_ids": {"DOI": ["10.1016/0022-2836"]}}, "BIBREF777": {"ref_id": "b777", "title": "Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling", "authors": [], "year": null, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "99", "issn": "", "pages": "13217--13221", "other_ids": {}}, "BIBREF779": {"ref_id": "b779", "title": "Cancer genome landscapes", "authors": [{"first": "B", "middle": [], "last": "Vogelstein", "suffix": ""}, {"first": "N", "middle": [], "last": "Papadopoulos", "suffix": ""}, {"first": "V", "middle": ["E"], "last": "Velculescu", "suffix": ""}, {"first": "S", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "L", "middle": ["A"], "last": "Diaz", "suffix": ""}, {"first": "K", "middle": ["W"], "last": "Kinzler", "suffix": ""}], "year": 2013, "venue": "Science", "volume": "", "issn": "6127", "pages": "1546--1558", "other_ids": {"DOI": ["10.1126/science.1235122"]}}, "BIBREF780": {"ref_id": "b780", "title": "Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma", "authors": [{"first": "D", "middle": ["T"], "last": "Vogl", "suffix": ""}, {"first": "T", "middle": ["G"], "last": "Martin", "suffix": ""}, {"first": "R", "middle": [], "last": "Vij", "suffix": ""}, {"first": "P", "middle": [], "last": "Hari", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Mikhael", "suffix": ""}, {"first": "D", "middle": [], "last": "Siegel", "suffix": ""}, {"first": "K", "middle": ["L"], "last": "Wu", "suffix": ""}, {"first": "M", "middle": [], "last": "Delforge", "suffix": ""}, {"first": "C", "middle": [], "last": "Gasparetto", "suffix": ""}], "year": 2017, "venue": "Leukemia & Lymphoma", "volume": "58", "issn": "8", "pages": "1872--1879", "other_ids": {"DOI": ["10.1080/10428194.2016.1263842"]}}, "BIBREF781": {"ref_id": "b781", "title": "Ocular antigen does not cause disease unless presented in the context of inflammation", "authors": [{"first": "V", "middle": [], "last": "Voigt", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Wikstrom", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Kezic", "suffix": ""}, {"first": "I", "middle": ["S"], "last": "Schuster", "suffix": ""}, {"first": "P", "middle": [], "last": "Fleming", "suffix": ""}, {"first": "K", "middle": [], "last": "Makinen", "suffix": ""}, {"first": "S", "middle": ["R"], "last": "Daley", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "Andoniou", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Degli-Esposti", "suffix": ""}, {"first": "J", "middle": ["V"], "last": "Forrester", "suffix": ""}], "year": 2017, "venue": "Scientific Reports", "volume": "7", "issn": "1", "pages": "", "other_ids": {"DOI": ["10.1038/s41598-017-14618"]}}, "BIBREF782": {"ref_id": "b782", "title": "Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management", "authors": [{"first": "J", "middle": ["M"], "last": "Vose", "suffix": ""}], "year": 2017, "venue": "American Journal of Hematology", "volume": "92", "issn": "8", "pages": "806--813", "other_ids": {}}, "BIBREF784": {"ref_id": "b784", "title": "VEGF release by retinal glia depends on both oxygen and glucose supply", "authors": [{"first": "W", "middle": [], "last": "", "suffix": ""}, {"first": "E", "middle": [], "last": "", "suffix": ""}, {"first": "H", "middle": [], "last": "", "suffix": ""}, {"first": "K", "middle": [], "last": "", "suffix": ""}, {"first": "S", "middle": [], "last": "", "suffix": ""}, {"first": "H", "middle": [], "last": "", "suffix": ""}, {"first": "P", "middle": [], "last": "", "suffix": ""}, {"first": "W", "middle": [], "last": "&amp; A", "suffix": ""}, {"first": "R", "middle": [], "last": "", "suffix": ""}], "year": 2000, "venue": "Neuroreport", "volume": "11", "issn": "16", "pages": "3533--3537", "other_ids": {"DOI": ["10.1097/00001756-200011090-00026"]}}, "BIBREF785": {"ref_id": "b785", "title": "The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates", "authors": [{"first": "K", "middle": [], "last": "Wakabayashi", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanji", "suffix": ""}, {"first": "F", "middle": [], "last": "Mori", "suffix": ""}, {"first": "H", "middle": [], "last": "Takahashi", "suffix": ""}], "year": 2007, "venue": "Neuropathology: Official Journal of the Japanese Society of Neuropathology", "volume": "27", "issn": "5", "pages": "494--506", "other_ids": {"DOI": ["10.1111/j.1440-1789"]}}, "BIBREF786": {"ref_id": "b786", "title": "The Lewy body in Parkinson's disease and related neurodegenerative disorders", "authors": [{"first": "K", "middle": [], "last": "Wakabayashi", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanji", "suffix": ""}, {"first": "S", "middle": [], "last": "Odagiri", "suffix": ""}, {"first": "Y", "middle": [], "last": "Miki", "suffix": ""}, {"first": "F", "middle": [], "last": "Mori", "suffix": ""}, {"first": "H", "middle": [], "last": "Takahashi", "suffix": ""}], "year": 2013, "venue": "Molecular Neurobiology", "volume": "47", "issn": "2", "pages": "495--508", "other_ids": {"DOI": ["10.1007/s12035-012-8280-y"]}}, "BIBREF787": {"ref_id": "b787", "title": "Physiological function of myocilin and its role in the pathogenesis of glaucoma in the trabecular meshwork (Review)", "authors": [{"first": "H", "middle": [], "last": "Wang", "suffix": ""}, {"first": "M", "middle": [], "last": "Li", "suffix": ""}, {"first": "Z", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "H", "middle": [], "last": "Xue", "suffix": ""}, {"first": "X", "middle": [], "last": "Chen", "suffix": ""}, {"first": "Y", "middle": [], "last": "Ji", "suffix": ""}], "year": 2019, "venue": "International Journal of Molecular Medicine", "volume": "43", "issn": "2", "pages": "671--681", "other_ids": {"DOI": ["10.3892/ijmm.2018.3992"]}}, "BIBREF788": {"ref_id": "b788", "title": "M\u00fcller Cell-Derived VEGF Is Essential for Diabetes-Induced Retinal Inflammation and Vascular Leakage", "authors": [{"first": "J", "middle": [], "last": "Wang", "suffix": ""}, {"first": "X", "middle": [], "last": "Xu", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Elliott", "suffix": ""}, {"first": "M", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "Y.-Z", "middle": [], "last": "Le", "suffix": ""}], "year": 2010, "venue": "Diabetes", "volume": "59", "issn": "9", "pages": "2297--2305", "other_ids": {"DOI": ["10.2337/db09-1420"]}}, "BIBREF789": {"ref_id": "b789", "title": "Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma", "authors": [{"first": "M", "middle": [], "last": "Wang", "suffix": ""}, {"first": "T", "middle": [], "last": "Martin", "suffix": ""}, {"first": "W", "middle": [], "last": "Bensinger", "suffix": ""}, {"first": "M", "middle": [], "last": "Alsina", "suffix": ""}, {"first": "D", "middle": ["S"], "last": "Siegel", "suffix": ""}, {"first": "E", "middle": [], "last": "Kavalerchik", "suffix": ""}, {"first": "M", "middle": [], "last": "Huang", "suffix": ""}, {"first": "R", "middle": ["Z"], "last": "Orlowski", "suffix": ""}, {"first": "R", "middle": [], "last": "Niesvizky", "suffix": ""}], "year": 2013, "venue": "Blood", "volume": "122", "issn": "18", "pages": "3122--3128", "other_ids": {"DOI": ["10.1182/blood-2013-07-511170"]}}, "BIBREF790": {"ref_id": "b790", "title": "Interactions of SARS coronavirus nucleocapsid protein with the host cell proteasome subunit p42", "authors": [{"first": "Q", "middle": [], "last": "Wang", "suffix": ""}, {"first": "C", "middle": [], "last": "Li", "suffix": ""}, {"first": "Q", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "T", "middle": [], "last": "Wang", "suffix": ""}, {"first": "J", "middle": [], "last": "Li", "suffix": ""}, {"first": "W", "middle": [], "last": "Guan", "suffix": ""}, {"first": "J", "middle": [], "last": "Yu", "suffix": ""}, {"first": "M", "middle": [], "last": "Liang", "suffix": ""}, {"first": "D", "middle": [], "last": "Li", "suffix": ""}], "year": 2010, "venue": "Virology Journal", "volume": "7", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1186/1743-422X-7-99"]}}, "BIBREF791": {"ref_id": "b791", "title": "The proteasome-interacting Ecm29 protein disassembles the 26S proteasome in response to oxidative stress", "authors": [{"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "I", "middle": ["E"], "last": "Chemmama", "suffix": ""}, {"first": "C", "middle": [], "last": "Yu", "suffix": ""}, {"first": "A", "middle": [], "last": "Huszagh", "suffix": ""}, {"first": "Y", "middle": [], "last": "Xu", "suffix": ""}, {"first": "R", "middle": [], "last": "Viner", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Block", "suffix": ""}, {"first": "P", "middle": [], "last": "Cimermancic", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Rychnovsky", "suffix": ""}, {"first": "Y", "middle": [], "last": "Ye", "suffix": ""}, {"first": "A", "middle": [], "last": "Sali", "suffix": ""}, {"first": "L", "middle": [], "last": "Huang", "suffix": ""}], "year": 2017, "venue": "The Journal of Biological Chemistry", "volume": "292", "issn": "39", "pages": "16310--16320", "other_ids": {"DOI": ["10.1074/jbc.M117.803619"]}}, "BIBREF792": {"ref_id": "b792", "title": "Regulation of the 26S proteasome complex during oxidative stress", "authors": [{"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "J", "middle": [], "last": "Yen", "suffix": ""}, {"first": "P", "middle": [], "last": "Kaiser", "suffix": ""}, {"first": "L", "middle": [], "last": "Huang", "suffix": ""}], "year": 2010, "venue": "Science Signaling", "volume": "3", "issn": "151", "pages": "", "other_ids": {"DOI": ["10.1126/scisignal.2001232"]}}, "BIBREF793": {"ref_id": "b793", "title": "Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metabolism and Disposition: The Biological Fate of Chemicals", "authors": [{"first": "Zhengping", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Yang", "middle": [], "last": "", "suffix": ""}, {"first": "J", "middle": [], "last": "Kirk", "suffix": ""}, {"first": "C", "middle": [], "last": "Fang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Alsina", "suffix": ""}, {"first": "M", "middle": [], "last": "Badros", "suffix": ""}, {"first": "A", "middle": [], "last": "Papadopoulos", "suffix": ""}, {"first": "K", "middle": [], "last": "Wong", "suffix": ""}, {"first": "A", "middle": [], "last": "Woo", "suffix": ""}, {"first": "T", "middle": [], "last": "Bomba", "suffix": ""}, {"first": "D", "middle": [], "last": "Li", "suffix": ""}, {"first": "J", "middle": [], "last": "Infante", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "", "suffix": ""}], "year": 2013, "venue": "", "volume": "41", "issn": "", "pages": "230--237", "other_ids": {"DOI": ["10.1124/dmd.112.047662"]}}, "BIBREF794": {"ref_id": "b794", "title": "In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s", "authors": [{"first": "Zhican", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Fang", "suffix": ""}, {"first": "J", "middle": [], "last": "Teague", "suffix": ""}, {"first": "H", "middle": [], "last": "Wong", "suffix": ""}, {"first": "C", "middle": [], "last": "Morisseau", "suffix": ""}, {"first": "B", "middle": ["D"], "last": "Hammock", "suffix": ""}, {"first": "D", "middle": ["A"], "last": "Rock", "suffix": ""}, {"first": "Z", "middle": [], "last": "Wang", "suffix": ""}], "year": 2017, "venue": "Drug Metabolism and Disposition", "volume": "45", "issn": "7", "pages": "712--720", "other_ids": {"DOI": ["10.1124/dmd.117.075226"]}}, "BIBREF795": {"ref_id": "b795", "title": "Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis", "authors": [{"first": "A", "middle": ["J"], "last": "Waxman", "suffix": ""}, {"first": "S", "middle": [], "last": "Clasen", "suffix": ""}, {"first": "W.-T", "middle": [], "last": "Hwang", "suffix": ""}, {"first": "A", "middle": [], "last": "Garfall", "suffix": ""}, {"first": "D", "middle": ["T"], "last": "Vogl", "suffix": ""}, {"first": "J", "middle": [], "last": "Carver", "suffix": ""}, {"first": "R", "middle": [], "last": "O&apos;quinn", "suffix": ""}, {"first": "A", "middle": ["D"], "last": "Cohen", "suffix": ""}, {"first": "E", "middle": ["A"], "last": "Stadtmauer", "suffix": ""}, {"first": "B", "middle": [], "last": "Ky", "suffix": ""}, {"first": "B", "middle": ["M"], "last": "Weiss", "suffix": ""}], "year": 2018, "venue": "JAMA Oncology", "volume": "4", "issn": "3", "pages": "", "other_ids": {"DOI": ["10.1001/jamaoncol.2017.4519"]}}, "BIBREF796": {"ref_id": "b796", "title": "Does aneuploidy cause cancer?", "authors": [{"first": "B", "middle": ["A A"], "last": "Weaver", "suffix": ""}, {"first": "D", "middle": ["W"], "last": "Cleveland", "suffix": ""}], "year": 2006, "venue": "Current Opinion in Cell Biology", "volume": "18", "issn": "6", "pages": "658--667", "other_ids": {"DOI": ["10.1016/j.ceb.2006.10.002"]}}, "BIBREF797": {"ref_id": "b797", "title": "A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma -long-term results of a multicenter observation study", "authors": [{"first": "O", "middle": [], "last": "Weigert", "suffix": ""}, {"first": "E", "middle": [], "last": "Weidmann", "suffix": ""}, {"first": "R", "middle": [], "last": "Mueck", "suffix": ""}, {"first": "M", "middle": [], "last": "Bentz", "suffix": ""}, {"first": "C", "middle": [], "last": "Schilling", "suffix": ""}, {"first": "R", "middle": [], "last": "Rohrberg", "suffix": ""}, {"first": "K", "middle": [], "last": "Jentsch-Ullrich", "suffix": ""}, {"first": "W", "middle": [], "last": "Hiddemann", "suffix": ""}, {"first": "M", "middle": [], "last": "Dreyling", "suffix": ""}], "year": 2009, "venue": "Leukemia & Lymphoma", "volume": "50", "issn": "5", "pages": "716--722", "other_ids": {"DOI": ["10.1080/10428190902856790"]}}, "BIBREF798": {"ref_id": "b798", "title": "The Pathophysiology and Treatment of Glaucoma", "authors": [{"first": "R", "middle": ["N"], "last": "Weinreb", "suffix": ""}, {"first": "T", "middle": [], "last": "Aung", "suffix": ""}, {"first": "F", "middle": ["A"], "last": "Medeiros", "suffix": ""}], "year": 2014, "venue": "JAMA", "volume": "", "issn": "18", "pages": "1901--1911", "other_ids": {"DOI": ["10.1001/jama.2014.3192"]}}, "BIBREF799": {"ref_id": "b799", "title": "Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group", "authors": [{"first": "D", "middle": ["D"], "last": "Weisenburger", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Vose", "suffix": ""}, {"first": "T", "middle": ["C"], "last": "Greiner", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Lynch", "suffix": ""}, {"first": "W", "middle": ["C"], "last": "Chan", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Bierman", "suffix": ""}, {"first": "B", "middle": ["J"], "last": "Dave", "suffix": ""}, {"first": "W", "middle": ["G"], "last": "Sanger", "suffix": ""}, {"first": "J", "middle": ["O"], "last": "Armitage", "suffix": ""}], "year": 2000, "venue": "American Journal of Hematology", "volume": "64", "issn": "3", "pages": "190--196", "other_ids": {"DOI": ["10.1002/1096-8652"]}}, "BIBREF800": {"ref_id": "b800", "title": "Inhibition of Proteasome Activity Induces Formation of Alternative Proteasome Complexes", "authors": [{"first": "V", "middle": [], "last": "Welk", "suffix": ""}, {"first": "O", "middle": [], "last": "Coux", "suffix": ""}, {"first": "V", "middle": [], "last": "Kleene", "suffix": ""}, {"first": "C", "middle": [], "last": "Abeza", "suffix": ""}, {"first": "D", "middle": [], "last": "Tr\u00fcmbach", "suffix": ""}, {"first": "O", "middle": [], "last": "Eickelberg", "suffix": ""}, {"first": "S", "middle": [], "last": "Meiners", "suffix": ""}], "year": 2016, "venue": "The Journal of Biological Chemistry", "volume": "291", "issn": "25", "pages": "13147--13159", "other_ids": {"DOI": ["10.1074/jbc.M116.717652"]}}, "BIBREF801": {"ref_id": "b801", "title": "How we treat glioblastoma", "authors": [{"first": "M", "middle": [], "last": "Weller", "suffix": ""}, {"first": "E", "middle": [], "last": "Le Rhun", "suffix": ""}, {"first": "M", "middle": [], "last": "Preusser", "suffix": ""}, {"first": "J.-C", "middle": [], "last": "Tonn", "suffix": ""}, {"first": "P", "middle": [], "last": "Roth", "suffix": ""}], "year": 2019, "venue": "ESMO Open", "volume": "4", "issn": "2", "pages": "", "other_ids": {"DOI": ["10.1136/esmoopen-2019-000520"]}}, "BIBREF802": {"ref_id": "b802", "title": "Structurally-defined deubiquitinase inhibitors provide opportunities to investigate disease mechanisms", "authors": [{"first": "I", "middle": ["E"], "last": "Wertz", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Murray", "suffix": ""}], "year": 2019, "venue": "Drug Discovery Today. Technologies", "volume": "31", "issn": "", "pages": "109--123", "other_ids": {"DOI": ["10.1016/j.ddtec.2019.02.003"]}}, "BIBREF803": {"ref_id": "b803", "title": "Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial", "authors": [{"first": "R", "middle": [], "last": "Wester", "suffix": ""}, {"first": "B", "middle": [], "last": "Holt", "suffix": ""}, {"first": "", "middle": [], "last": "Van Der", "suffix": ""}, {"first": "E", "middle": [], "last": "Asselbergs", "suffix": ""}, {"first": "S", "middle": [], "last": "Zweegman", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Kersten", "suffix": ""}, {"first": "E", "middle": [], "last": "Vellenga", "suffix": ""}, {"first": "M", "middle": [], "last": "Kooy", "suffix": ""}, {"first": "M", "middle": [], "last": "Van", "suffix": ""}, {"first": "O", "middle": [], "last": "Weerdt", "suffix": ""}, {"first": "", "middle": [], "last": "De", "suffix": ""}, {"first": "M", "middle": [], "last": "Minnema", "suffix": ""}, {"first": "S", "middle": [], "last": "Lonergan", "suffix": ""}, {"first": "A", "middle": [], "last": "Palumbo", "suffix": ""}, {"first": "H", "middle": [], "last": "Lokhorst", "suffix": ""}, {"first": "A", "middle": [], "last": "Broijl", "suffix": ""}, {"first": "P", "middle": [], "last": "Sonneveld", "suffix": ""}], "year": 2019, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3324/haematol.2018.205476"]}}, "BIBREF804": {"ref_id": "b804", "title": "Synthetic peptide-based activators of the proteasome", "authors": [{"first": "S", "middle": [], "last": "Wilk", "suffix": ""}, {"first": "W", "middle": ["E"], "last": "Chen", "suffix": ""}], "year": 1997, "venue": "Molecular Biology Reports", "volume": "24", "issn": "1-2", "pages": "119--124", "other_ids": {"DOI": ["10.1023/a:1006851428691"]}}, "BIBREF805": {"ref_id": "b805", "title": "Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme", "authors": [{"first": "S", "middle": [], "last": "Wilk", "suffix": ""}, {"first": "M", "middle": [], "last": "Orlowski", "suffix": ""}], "year": 1980, "venue": "Journal of Neurochemistry", "volume": "35", "issn": "5", "pages": "1172--1182", "other_ids": {"DOI": ["10.1111/j.1471-4159.1980.tb07873.x"]}}, "BIBREF806": {"ref_id": "b806", "title": "Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex", "authors": [{"first": "S", "middle": [], "last": "Wilk", "suffix": ""}, {"first": "M", "middle": [], "last": "Orlowski", "suffix": ""}], "year": 1983, "venue": "Journal of Neurochemistry", "volume": "40", "issn": "3", "pages": "842--849", "other_ids": {}}, "BIBREF808": {"ref_id": "b808", "title": "The discovery of ubiquitin-dependent proteolysis", "authors": [{"first": "K", "middle": ["D"], "last": "Wilkinson", "suffix": ""}], "year": 2005, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "102", "issn": "", "pages": "15280--15282", "other_ids": {"DOI": ["10.1073/pnas.0504842102"]}}, "BIBREF809": {"ref_id": "b809", "title": "Aneuploidy -Cancer's Fatal Flaw?", "authors": [{"first": "B", "middle": ["R"], "last": "Williams", "suffix": ""}, {"first": "A", "middle": [], "last": "Amon", "suffix": ""}], "year": 2009, "venue": "Cancer Research", "volume": "69", "issn": "13", "pages": "5289--5291", "other_ids": {"DOI": ["10.1158/0008-5472.CAN-09-0944"]}}, "BIBREF810": {"ref_id": "b810", "title": "Two different classes of E2 ubiquitin-conjugating enzymes are required for the mono-ubiquitination of proteins and elongation by polyubiquitin chains with a specific topology", "authors": [{"first": "M", "middle": [], "last": "Windheim", "suffix": ""}, {"first": "M", "middle": [], "last": "Peggie", "suffix": ""}, {"first": "P", "middle": [], "last": "Cohen", "suffix": ""}], "year": 2008, "venue": "The Biochemical Journal", "volume": "409", "issn": "3", "pages": "723--729", "other_ids": {}}, "BIBREF812": {"ref_id": "b812", "title": "Crystal structure of a low molecular weight activator Blm-pep with yeast 20S proteasome -insights into the enzyme activation mechanism", "authors": [{"first": "J", "middle": [], "last": "Witkowska", "suffix": ""}, {"first": "M", "middle": [], "last": "Gi\u017cy\u0144ska", "suffix": ""}, {"first": "P", "middle": [], "last": "Grudnik", "suffix": ""}, {"first": "P", "middle": [], "last": "Golik", "suffix": ""}, {"first": "P", "middle": [], "last": "Karpowicz", "suffix": ""}, {"first": "A", "middle": [], "last": "Gie\u0142do\u0144", "suffix": ""}, {"first": "G", "middle": [], "last": "Dubin", "suffix": ""}, {"first": "E", "middle": [], "last": "Jankowska", "suffix": ""}], "year": 2017, "venue": "Scientific Reports", "volume": "7", "issn": "1", "pages": "1--11", "other_ids": {"DOI": ["10.1038/s41598-017-05997-4"]}}, "BIBREF813": {"ref_id": "b813", "title": "Characterisation of the newly identified human Ump1 homologue POMP and analysis of LMP7(beta 5i) incorporation into 20 S proteasomes", "authors": [{"first": "E", "middle": [], "last": "Witt", "suffix": ""}, {"first": "D", "middle": [], "last": "Zantopf", "suffix": ""}, {"first": "M", "middle": [], "last": "Schmidt", "suffix": ""}, {"first": "R", "middle": [], "last": "Kraft", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Kloetzel", "suffix": ""}, {"first": "E", "middle": [], "last": "Kr\u00fcger", "suffix": ""}], "year": 2000, "venue": "Journal of Molecular Biology", "volume": "301", "issn": "1", "pages": "1--9", "other_ids": {"DOI": ["10.1006/jmbi.2000.3959"]}}, "BIBREF814": {"ref_id": "b814", "title": "Proteasome activator (PA28) subunits, alpha, beta and gamma (Ki antigen", "authors": [{"first": "C", "middle": [], "last": "W\u00f3jcik", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "N", "middle": [], "last": "Paweletz", "suffix": ""}, {"first": "U", "middle": [], "last": "Naab", "suffix": ""}, {"first": "S", "middle": [], "last": "Wilk", "suffix": ""}], "year": 1998, "venue": "NT2 neuronal precursor cells and HeLa S3 cells", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF816": {"ref_id": "b816", "title": "Accessory proteins 8b and 8ab of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferon regulatory factor 3", "authors": [{"first": "H", "middle": ["H"], "last": "Wong", "suffix": ""}, {"first": "T", "middle": ["S"], "last": "Fung", "suffix": ""}, {"first": "S", "middle": [], "last": "Fang", "suffix": ""}, {"first": "M", "middle": [], "last": "Huang", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Le", "suffix": ""}, {"first": "D", "middle": ["X"], "last": "Liu", "suffix": ""}], "year": 2018, "venue": "Virology", "volume": "515", "issn": "", "pages": "165--175", "other_ids": {"DOI": ["10.1016/j.virol.2017.12.028"]}}, "BIBREF817": {"ref_id": "b817", "title": "An AAA Motor-Driven Mechanical Switch in Rpn11 Controls Deubiquitination at the 26S Proteasome", "authors": [{"first": "E", "middle": ["J"], "last": "Worden", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Dong", "suffix": ""}, {"first": "A", "middle": [], "last": "Martin", "suffix": ""}], "year": 2017, "venue": "Molecular Cell", "volume": "67", "issn": "5", "pages": "799--811", "other_ids": {"DOI": ["10.1016/j.molcel.2017.07.023"]}}, "BIBREF818": {"ref_id": "b818", "title": "Structure of the Rpn11-Rpn8 dimer reveals mechanisms of substrate deubiquitination during proteasomal degradation", "authors": [{"first": "E", "middle": ["J"], "last": "Worden", "suffix": ""}, {"first": "C", "middle": [], "last": "Padovani", "suffix": ""}, {"first": "A", "middle": [], "last": "Martin", "suffix": ""}], "year": 2014, "venue": "Nature Structural & Molecular Biology", "volume": "21", "issn": "3", "pages": "220--227", "other_ids": {"DOI": ["10.1038/nsmb.2771"]}}, "BIBREF819": {"ref_id": "b819", "title": "Cellular calcium deficiency plays a role in neuronal death caused by proteasome inhibitors", "authors": [{"first": "S", "middle": [], "last": "Wu", "suffix": ""}, {"first": "K", "middle": ["L"], "last": "Hyrc", "suffix": ""}, {"first": "K", "middle": ["L"], "last": "Moulder", "suffix": ""}, {"first": "Y", "middle": [], "last": "Lin", "suffix": ""}, {"first": "T", "middle": [], "last": "Warmke", "suffix": ""}, {"first": "B", "middle": ["J"], "last": "Snider", "suffix": ""}], "year": 2009, "venue": "Journal of Neurochemistry", "volume": "109", "issn": "5", "pages": "1225--1236", "other_ids": {"DOI": ["10.1111/j.1471-4159.2009.06037.x"]}}, "BIBREF820": {"ref_id": "b820", "title": "PAC1-PAC2 proteasome assembly chaperone retains the core \u03b14-\u03b17 assembly intermediates in the cytoplasm", "authors": [{"first": "W", "middle": [], "last": "Wu", "suffix": ""}, {"first": "K", "middle": [], "last": "Sahara", "suffix": ""}, {"first": "S", "middle": [], "last": "Hirayama", "suffix": ""}, {"first": "X", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "A", "middle": [], "last": "Watanabe", "suffix": ""}, {"first": "J", "middle": [], "last": "Hamazaki", "suffix": ""}, {"first": "H", "middle": [], "last": "Yashiroda", "suffix": ""}, {"first": "S", "middle": [], "last": "Murata", "suffix": ""}], "year": 2018, "venue": "Genes to Cells: Devoted to Molecular & Cellular Mechanisms", "volume": "23", "issn": "10", "pages": "839--848", "other_ids": {"DOI": ["10.1111/gtc.12631"]}}, "BIBREF821": {"ref_id": "b821", "title": "Increased plasma levels of 20S proteasome alpha-subunit in glaucoma patients: an observational pilot study", "authors": [{"first": "K", "middle": [], "last": "Wunderlich", "suffix": ""}, {"first": "O", "middle": [], "last": "Golubnitschaja", "suffix": ""}, {"first": "M", "middle": [], "last": "Pache", "suffix": ""}, {"first": "A.-N", "middle": [], "last": "Eberle", "suffix": ""}, {"first": "J", "middle": [], "last": "Flammer", "suffix": ""}], "year": 2002, "venue": "Molecular Vision", "volume": "8", "issn": "", "pages": "431--435", "other_ids": {}}, "BIBREF822": {"ref_id": "b822", "title": "Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide", "authors": [{"first": "X", "middle": [], "last": "Xia", "suffix": ""}, {"first": "C", "middle": [], "last": "Huang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Liao", "suffix": ""}, {"first": "Y", "middle": [], "last": "Liu", "suffix": ""}, {"first": "J", "middle": [], "last": "He", "suffix": ""}, {"first": "Z", "middle": [], "last": "Guo", "suffix": ""}, {"first": "L", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "J", "middle": [], "last": "Liu", "suffix": ""}, {"first": "H", "middle": [], "last": "Huang", "suffix": ""}], "year": 2019, "venue": "Journal of Experimental & Clinical Cancer Research", "volume": "38", "issn": "1", "pages": "", "other_ids": {"DOI": ["10.1186/s13046-019-1227-7"]}}, "BIBREF823": {"ref_id": "b823", "title": "Thymoproteasome subunit-\u03b25T generates peptide-MHC complexes specialized for positive selection", "authors": [{"first": "Y", "middle": [], "last": "Xing", "suffix": ""}, {"first": "S", "middle": ["C"], "last": "Jameson", "suffix": ""}, {"first": "K", "middle": ["A"], "last": "Hogquist", "suffix": ""}], "year": 2013, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "110", "issn": "", "pages": "6979--6984", "other_ids": {}}, "BIBREF825": {"ref_id": "b825", "title": "Proteasome Activators, PA28\u03b1 and PA28\u03b2, Govern Development of Microvascular Injury in Diabetic Nephropathy and Retinopathy", "authors": [{"first": "Yadranji", "middle": [], "last": "Aghdam", "suffix": ""}, {"first": "S", "middle": [], "last": "Mahmoudpour", "suffix": ""}, {"first": "A", "middle": [], "last": "", "suffix": ""}], "year": 2016, "venue": "International Journal of Nephrology", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1155/2016/3846573"]}}, "BIBREF826": {"ref_id": "b826", "title": "Aggregated Myocilin Induces Russell Bodies and Causes Apoptosis", "authors": [{"first": "G", "middle": ["H"], "last": "Yam", "suffix": ""}, {"first": ".-F", "middle": [], "last": "Gaplovska-Kysela", "suffix": ""}, {"first": "K", "middle": [], "last": "Zuber", "suffix": ""}, {"first": "C", "middle": [], "last": "Roth", "suffix": ""}, {"first": "J", "middle": [], "last": "", "suffix": ""}], "year": 2007, "venue": "The American Journal of Pathology", "volume": "170", "issn": "1", "pages": "100--109", "other_ids": {"DOI": ["10.2353/ajpath.2007.060806"]}}, "BIBREF827": {"ref_id": "b827", "title": "Irreversible potent activation and reversible inhibition of trypsin-like activity of 20S proteasome purified from Xenopus oocytes by fatty acid", "authors": [{"first": "S", "middle": [], "last": "Yamada", "suffix": ""}, {"first": "J", "middle": [], "last": "Yamada", "suffix": ""}, {"first": "K", "middle": [], "last": "Sato", "suffix": ""}, {"first": "T", "middle": [], "last": "Tokumoto", "suffix": ""}, {"first": "M", "middle": [], "last": "Yasutomi", "suffix": ""}, {"first": "K", "middle": [], "last": "Ishikawa", "suffix": ""}], "year": 1998, "venue": "Zoological Science", "volume": "15", "issn": "1", "pages": "43--49", "other_ids": {"DOI": ["10.2108/zsj.15.43"]}}, "BIBREF828": {"ref_id": "b828", "title": "Hsp90-mediated assembly of the 26 S proteasome is involved in major histocompatibility complex class I antigen processing", "authors": [{"first": "T", "middle": [], "last": "Yamano", "suffix": ""}, {"first": "S", "middle": [], "last": "Mizukami", "suffix": ""}, {"first": "S", "middle": [], "last": "Murata", "suffix": ""}, {"first": "T", "middle": [], "last": "Chiba", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "H", "middle": [], "last": "Udono", "suffix": ""}], "year": 2008, "venue": "The Journal of Biological Chemistry", "volume": "283", "issn": "42", "pages": "28060--28065", "other_ids": {"DOI": ["10.1074/jbc.M803077200"]}}, "BIBREF829": {"ref_id": "b829", "title": "Isostructurality Among 5 Solvatomorphs of Betulin: X-Ray Structure and Characterization", "authors": [{"first": "D", "middle": [], "last": "Yang", "suffix": ""}, {"first": "N", "middle": [], "last": "Gong", "suffix": ""}, {"first": "L", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Lu", "suffix": ""}], "year": 2016, "venue": "Journal of Pharmaceutical Science", "volume": "105", "issn": "6", "pages": "1867--1873", "other_ids": {"DOI": ["10.1016/j.xphs.2016.03.015"]}}, "BIBREF830": {"ref_id": "b830", "title": "Crosstalk between the proteasome system and autophagy in the clearance of \u03b1-synuclein", "authors": [{"first": "F", "middle": [], "last": "Yang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yang", "suffix": ""}, {"first": "C", "middle": [], "last": "Mao", "suffix": ""}, {"first": "L", "middle": [], "last": "Liu", "suffix": ""}, {"first": "H", "middle": [], "last": "Zheng", "suffix": ""}, {"first": "L", "middle": [], "last": "Hu", "suffix": ""}, {"first": "C", "middle": [], "last": "Liu", "suffix": ""}], "year": 2013, "venue": "Acta Pharmacologica Sinica", "volume": "34", "issn": "5", "pages": "674--680", "other_ids": {"DOI": ["10.1038/aps.2013.29"]}}, "BIBREF831": {"ref_id": "b831", "title": "Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment", "authors": [{"first": "H", "middle": [], "last": "Yang", "suffix": ""}, {"first": "K", "middle": ["R"], "last": "Landis-Piwowar", "suffix": ""}, {"first": "D", "middle": [], "last": "Chen", "suffix": ""}, {"first": "V", "middle": [], "last": "Milacic", "suffix": ""}, {"first": "Q", "middle": ["P"], "last": "Dou", "suffix": ""}], "year": 2008, "venue": "Current Protein & Peptide Science", "volume": "9", "issn": "3", "pages": "227--239", "other_ids": {"DOI": ["10.2174/138920308784533998"]}}, "BIBREF832": {"ref_id": "b832", "title": "Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metabolism and Disposition: The Biological Fate of Chemicals", "authors": [{"first": "J", "middle": [], "last": "Yang", "suffix": ""}, {"first": "Z", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Fang", "suffix": ""}, {"first": "J", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "F", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "H", "middle": [], "last": "Wong", "suffix": ""}, {"first": "M", "middle": ["K"], "last": "Bennett", "suffix": ""}, {"first": "C", "middle": ["J"], "last": "Molineaux", "suffix": ""}, {"first": "C", "middle": ["J"], "last": "Kirk", "suffix": ""}], "year": 2011, "venue": "", "volume": "39", "issn": "", "pages": "1873--1882", "other_ids": {"DOI": ["10.1124/dmd.111.039164"]}}, "BIBREF833": {"ref_id": "b833", "title": "Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling", "authors": [{"first": "Y", "middle": [], "last": "Yang", "suffix": ""}, {"first": "S", "middle": [], "last": "Gehrke", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Haque", "suffix": ""}, {"first": "Y", "middle": [], "last": "Imai", "suffix": ""}, {"first": "J", "middle": [], "last": "Kosek", "suffix": ""}, {"first": "L", "middle": [], "last": "Yang", "suffix": ""}, {"first": "M", "middle": ["F"], "last": "Beal", "suffix": ""}, {"first": "I", "middle": [], "last": "Nishimura", "suffix": ""}, {"first": "K", "middle": [], "last": "Wakamatsu", "suffix": ""}, {"first": "S", "middle": [], "last": "Ito", "suffix": ""}, {"first": "R", "middle": [], "last": "Takahashi", "suffix": ""}, {"first": "B", "middle": [], "last": "Lu", "suffix": ""}], "year": 2005, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "102", "issn": "", "pages": "13670--13675", "other_ids": {"DOI": ["10.1073/pnas.0504610102"]}}, "BIBREF834": {"ref_id": "b834", "title": "Inhibiting autophagy reduces retinal degeneration caused by protein misfolding", "authors": [{"first": "J", "middle": [], "last": "Yao", "suffix": ""}, {"first": "Y", "middle": [], "last": "Qiu", "suffix": ""}, {"first": "E", "middle": [], "last": "Frontera", "suffix": ""}, {"first": "L", "middle": [], "last": "Jia", "suffix": ""}, {"first": "N", "middle": ["W"], "last": "Khan", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Klionsky", "suffix": ""}, {"first": "T", "middle": ["A"], "last": "Ferguson", "suffix": ""}, {"first": "D", "middle": ["A"], "last": "Thompson", "suffix": ""}, {"first": "D", "middle": ["N"], "last": "Zacks", "suffix": ""}], "year": 2018, "venue": "Autophagy", "volume": "14", "issn": "7", "pages": "1226--1238", "other_ids": {"DOI": ["10.1080/15548627.2018.1463121"]}}, "BIBREF835": {"ref_id": "b835", "title": "A cryptic protease couples deubiquitination and degradation by the proteasome", "authors": [{"first": "T", "middle": [], "last": "Yao", "suffix": ""}, {"first": "R", "middle": ["E"], "last": "Cohen", "suffix": ""}], "year": 2002, "venue": "Nature", "volume": "", "issn": "6905", "pages": "403--407", "other_ids": {"DOI": ["10.1038/nature01071"]}}, "BIBREF836": {"ref_id": "b836", "title": "Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1", "authors": [{"first": "T", "middle": [], "last": "Yao", "suffix": ""}, {"first": "L", "middle": [], "last": "Song", "suffix": ""}, {"first": "W", "middle": [], "last": "Xu", "suffix": ""}, {"first": "G", "middle": ["N"], "last": "Demartino", "suffix": ""}, {"first": "L", "middle": [], "last": "Florens", "suffix": ""}, {"first": "S", "middle": ["K"], "last": "Swanson", "suffix": ""}, {"first": "M", "middle": ["P"], "last": "Washburn", "suffix": ""}, {"first": "R", "middle": ["C"], "last": "Conaway", "suffix": ""}, {"first": "J", "middle": ["W"], "last": "Conaway", "suffix": ""}, {"first": "R", "middle": ["E"], "last": "Cohen", "suffix": ""}], "year": 2006, "venue": "Nature Cell Biology", "volume": "8", "issn": "9", "pages": "994--1002", "other_ids": {"DOI": ["10.1038/ncb1460"]}}, "BIBREF837": {"ref_id": "b837", "title": "N-Terminal Ubiquitination of Amyloidogenic Proteins Triggers Removal of Their Oligomers by the Proteasome Holoenzyme", "authors": [{"first": "Y", "middle": [], "last": "Ye", "suffix": ""}, {"first": "D", "middle": [], "last": "Klenerman", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}], "year": 2020, "venue": "Journal of Molecular Biology", "volume": "432", "issn": "2", "pages": "585--596", "other_ids": {"DOI": ["10.1016/j.jmb.2019.08.021"]}}, "BIBREF838": {"ref_id": "b838", "title": "A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease", "authors": [{"first": "I", "middle": ["J"], "last": "Yeo", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Lee", "suffix": ""}, {"first": "A", "middle": [], "last": "Baek", "suffix": ""}, {"first": "Z", "middle": [], "last": "Miller", "suffix": ""}, {"first": "D", "middle": [], "last": "Bhattarai", "suffix": ""}, {"first": "Y", "middle": ["M"], "last": "Baek", "suffix": ""}, {"first": "H", "middle": ["J"], "last": "Jeong", "suffix": ""}, {"first": "Y", "middle": ["K"], "last": "Kim", "suffix": ""}, {"first": "D.-E", "middle": [], "last": "Kim", "suffix": ""}, {"first": "J", "middle": ["T"], "last": "Hong", "suffix": ""}, {"first": "K", "middle": ["B"], "last": "Kim", "suffix": ""}], "year": 2019, "venue": "Scientific Reports", "volume": "", "issn": "1", "pages": "", "other_ids": {"DOI": ["10.1038/s41598-019-54846-z"]}}, "BIBREF839": {"ref_id": "b839", "title": "Induction of autophagy in rats upon overexpression of wild-type and mutant optineurin gene", "authors": [{"first": "H", "middle": [], "last": "Ying", "suffix": ""}, {"first": "S", "middle": [], "last": "Turturro", "suffix": ""}, {"first": "T", "middle": [], "last": "Nguyen", "suffix": ""}, {"first": "X", "middle": [], "last": "Shen", "suffix": ""}, {"first": "R", "middle": [], "last": "Zelkha", "suffix": ""}, {"first": "E", "middle": ["C"], "last": "Johnson", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Morrison", "suffix": ""}, {"first": "B", "middle": ["Y J T"], "last": "Yue", "suffix": ""}], "year": 2015, "venue": "BMC Cell Biology", "volume": "16", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1186/s12860-015-0060-x"]}}, "BIBREF840": {"ref_id": "b840", "title": "The ubiquitin-proteasome system facilitates the transfer of murine coronavirus from endosome to cytoplasm during virus entry", "authors": [{"first": "G.-Y", "middle": [], "last": "Yu", "suffix": ""}, {"first": "M", "middle": ["M C"], "last": "Lai", "suffix": ""}], "year": 2005, "venue": "Journal of Virology", "volume": "79", "issn": "1", "pages": "644--648", "other_ids": {"DOI": ["10.1128/JVI.79.1.644-648.2005"]}}, "BIBREF841": {"ref_id": "b841", "title": "The deubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease", "authors": [{"first": "L", "middle": [], "last": "Zeng", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Tallaksen-Greene", "suffix": ""}, {"first": "B", "middle": [], "last": "Wang", "suffix": ""}, {"first": "R", "middle": ["L"], "last": "Albin", "suffix": ""}, {"first": "H", "middle": ["L"], "last": "Paulson", "suffix": ""}], "year": 2013, "venue": "Journal of Huntington's Disease", "volume": "2", "issn": "2", "pages": "201--215", "other_ids": {}}, "BIBREF843": {"ref_id": "b843", "title": "O -GlcNAc Modification Is an Endogenous Inhibitor of the Proteasome", "authors": [{"first": "F", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "K", "middle": [], "last": "Su", "suffix": ""}, {"first": "X", "middle": [], "last": "Yang", "suffix": ""}, {"first": "D", "middle": ["B"], "last": "Bowe", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Paterson", "suffix": ""}, {"first": "J", "middle": ["E"], "last": "Kudlow", "suffix": ""}], "year": 2003, "venue": "Cell", "volume": "115", "issn": "6", "pages": "974--981", "other_ids": {"DOI": ["10.1016/S0092-8674(03"]}}, "BIBREF844": {"ref_id": "b844", "title": "Structural insights into the regulatory particle of the proteasome from Methanocaldococcus jannaschii", "authors": [{"first": "Fan", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "M", "middle": [], "last": "Hu", "suffix": ""}, {"first": "G", "middle": [], "last": "Tian", "suffix": ""}, {"first": "P", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "D", "middle": [], "last": "Finley", "suffix": ""}, {"first": "P", "middle": ["D"], "last": "Jeffrey", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shi", "suffix": ""}], "year": 2009, "venue": "Molecular Cell", "volume": "34", "issn": "4", "pages": "473--484", "other_ids": {"DOI": ["10.1016/j.molcel.2009.04.021"]}}, "BIBREF846": {"ref_id": "b846", "title": "Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6", "authors": [], "year": null, "venue": "The Journal of Biological Chemistry", "volume": "282", "issn": "31", "pages": "22460--22471", "other_ids": {}}, "BIBREF848": {"ref_id": "b848", "title": "Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors", "authors": [{"first": "L", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "D", "middle": [], "last": "Lin", "suffix": ""}, {"first": "X", "middle": [], "last": "Sun", "suffix": ""}, {"first": "U", "middle": [], "last": "Curth", "suffix": ""}, {"first": "C", "middle": [], "last": "Drosten", "suffix": ""}, {"first": "L", "middle": [], "last": "Sauerhering", "suffix": ""}, {"first": "S", "middle": [], "last": "Becker", "suffix": ""}, {"first": "K", "middle": [], "last": "Rox", "suffix": ""}, {"first": "R", "middle": [], "last": "Hilgenfeld", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1126/science.abb3405"]}}, "BIBREF849": {"ref_id": "b849", "title": "MnFe2O4 nanoparticles accelerate the clearance of mutant huntingtin selectively through ubiquitin-proteasome system", "authors": [{"first": "L", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "P.-F", "middle": [], "last": "Wei", "suffix": ""}, {"first": "Y.-H", "middle": [], "last": "Song", "suffix": ""}, {"first": "L", "middle": [], "last": "Dong", "suffix": ""}, {"first": "Y.-D", "middle": [], "last": "Wu", "suffix": ""}, {"first": "Z.-Y", "middle": [], "last": "Hao", "suffix": ""}, {"first": "S", "middle": [], "last": "Fan", "suffix": ""}, {"first": "S", "middle": [], "last": "Tai", "suffix": ""}, {"first": "J.-L", "middle": [], "last": "Meng", "suffix": ""}, {"first": "Y", "middle": [], "last": "Lu", "suffix": ""}, {"first": "J", "middle": [], "last": "Xue", "suffix": ""}, {"first": "C.-Z", "middle": [], "last": "Liang", "suffix": ""}, {"first": "L.-P", "middle": [], "last": "Wen", "suffix": ""}], "year": 2019, "venue": "Biomaterials", "volume": "216", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.biomaterials.2019.119248"]}}, "BIBREF850": {"ref_id": "b850", "title": "l-Tryptophan Schiff base cadmium(II) complexes as a new class of proteasome inhibitors and apoptosis inducers in human breast cancer cells", "authors": [{"first": "N", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Fan", "suffix": ""}, {"first": "G", "middle": [], "last": "Huang", "suffix": ""}, {"first": "D", "middle": [], "last": "Buac", "suffix": ""}, {"first": "C", "middle": [], "last": "Bi", "suffix": ""}, {"first": "Y", "middle": [], "last": "Ma", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Z", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "X", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "Q", "middle": ["P"], "last": "Dou", "suffix": ""}], "year": 2017, "venue": "Inorganica Chimica Acta", "volume": "466", "issn": "", "pages": "478--485", "other_ids": {"DOI": ["10.1016/j.ica.2017.07.006"]}}, "BIBREF851": {"ref_id": "b851", "title": "Redox-Active Metal Complexes for Anticancer Therapy", "authors": [{"first": "P", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Sadler", "suffix": ""}], "year": 2017, "venue": "European Journal of Inorganic Chemistry", "volume": "", "issn": "12", "pages": "1541--1548", "other_ids": {}}, "BIBREF853": {"ref_id": "b853", "title": "Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redoxdependent and -independent processes", "authors": [{"first": "X", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "M", "middle": [], "last": "Frezza", "suffix": ""}, {"first": "V", "middle": [], "last": "Milacic", "suffix": ""}, {"first": "L", "middle": [], "last": "Ronconi", "suffix": ""}, {"first": "Y", "middle": [], "last": "Fan", "suffix": ""}, {"first": "C", "middle": [], "last": "Bi", "suffix": ""}, {"first": "D", "middle": [], "last": "Fregona", "suffix": ""}, {"first": "Q", "middle": ["P"], "last": "Dou", "suffix": ""}], "year": 2010, "venue": "Journal of Cellular Biochemistry", "volume": "109", "issn": "1", "pages": "162--172", "other_ids": {"DOI": ["10.1002/jcb.22394"]}}, "BIBREF855": {"ref_id": "b855", "title": "Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP", "authors": [], "year": null, "venue": "Molecular Cell", "volume": "59", "issn": "2", "pages": "243--257", "other_ids": {"DOI": ["10.1016/j.molcel.2015.05.036"]}}, "BIBREF856": {"ref_id": "b856", "title": "Coagulopathy and Antiphospholipid Antibodies in Patients with SARS-Cov-2", "authors": [{"first": "Y", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "M", "middle": [], "last": "Xiao", "suffix": ""}, {"first": "S", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "P", "middle": [], "last": "Xia", "suffix": ""}, {"first": "W", "middle": [], "last": "Cao", "suffix": ""}, {"first": "W", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "H", "middle": [], "last": "Chen", "suffix": ""}, {"first": "X", "middle": [], "last": "Ding", "suffix": ""}, {"first": "H", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "H", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "C", "middle": [], "last": "Wang", "suffix": ""}, {"first": "J", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "X", "middle": [], "last": "Sun", "suffix": ""}, {"first": "R", "middle": [], "last": "Tian", "suffix": ""}, {"first": "W", "middle": [], "last": "Wu", "suffix": ""}, {"first": "D", "middle": [], "last": "Wu", "suffix": ""}, {"first": "J", "middle": [], "last": "Ma", "suffix": ""}, {"first": "Y", "middle": [], "last": "Chen", "suffix": ""}, {"first": "D", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "S", "middle": [], "last": "Zhang", "suffix": ""}], "year": 2020, "venue": "New England Journal of Medicine", "volume": "0", "issn": "0", "pages": "", "other_ids": {"DOI": ["10.1056/NEJMc2007575"]}}, "BIBREF857": {"ref_id": "b857", "title": "Organic cadmium complexes as proteasome inhibitors and apoptosis inducers in human breast cancer cells", "authors": [{"first": "Z", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "C", "middle": [], "last": "Bi", "suffix": ""}, {"first": "D", "middle": [], "last": "Buac", "suffix": ""}, {"first": "Y", "middle": [], "last": "Fan", "suffix": ""}, {"first": "X", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "J", "middle": [], "last": "Zuo", "suffix": ""}, {"first": "P", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "N", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "L", "middle": [], "last": "Dong", "suffix": ""}, {"first": "Q", "middle": ["P"], "last": "Dou", "suffix": ""}], "year": 2013, "venue": "Journal of Inorganic Biochemistry", "volume": "123", "issn": "", "pages": "1--10", "other_ids": {}}, "BIBREF859": {"ref_id": "b859", "title": "Cefepime, a fourth-generation cephalosporin, in complex with manganese, inhibits proteasome activity and induces the apoptosis of human breast cancer cells", "authors": [{"first": "Z", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "C", "middle": [], "last": "Bi", "suffix": ""}, {"first": "Y", "middle": [], "last": "Fan", "suffix": ""}, {"first": "H", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Bao", "suffix": ""}], "year": 2015, "venue": "International Journal of Molecular Medicine", "volume": "36", "issn": "4", "pages": "1143--1150", "other_ids": {"DOI": ["10.3892/ijmm.2015.2297"]}}, "BIBREF860": {"ref_id": "b860", "title": "A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy", "authors": [{"first": "C", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "X", "middle": [], "last": "Chen", "suffix": ""}, {"first": "D", "middle": [], "last": "Zang", "suffix": ""}, {"first": "X", "middle": [], "last": "Lan", "suffix": ""}, {"first": "S", "middle": [], "last": "Liao", "suffix": ""}, {"first": "C", "middle": [], "last": "Yang", "suffix": ""}, {"first": "P", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "J", "middle": [], "last": "Wu", "suffix": ""}, {"first": "X", "middle": [], "last": "Li", "suffix": ""}, {"first": "N", "middle": [], "last": "Liu", "suffix": ""}, {"first": "Y", "middle": [], "last": "Liao", "suffix": ""}, {"first": "H", "middle": [], "last": "Huang", "suffix": ""}, {"first": "X", "middle": [], "last": "Shi", "suffix": ""}, {"first": "L", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "X", "middle": [], "last": "Liu", "suffix": ""}, {"first": "Z", "middle": [], "last": "He", "suffix": ""}, {"first": "Q", "middle": ["P"], "last": "Dou", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "J", "middle": [], "last": "Liu", "suffix": ""}], "year": 2016, "venue": "Oncogene", "volume": "35", "issn": "45", "pages": "5916--5927", "other_ids": {"DOI": ["10.1038/onc.2016.114"]}}, "BIBREF861": {"ref_id": "b861", "title": "FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells", "authors": [{"first": "J", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Brault", "suffix": ""}, {"first": "A", "middle": [], "last": "Schild", "suffix": ""}, {"first": "P", "middle": [], "last": "Cao", "suffix": ""}, {"first": "M", "middle": [], "last": "Sandri", "suffix": ""}, {"first": "S", "middle": [], "last": "Schiaffino", "suffix": ""}, {"first": "S", "middle": ["H"], "last": "Lecker", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}], "year": 2007, "venue": "Cell Metabolism", "volume": "6", "issn": "6", "pages": "472--483", "other_ids": {"DOI": ["10.1016/j.cmet.2007.11.004"]}}, "BIBREF862": {"ref_id": "b862", "title": "mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy", "authors": [{"first": "J", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "B", "middle": [], "last": "Zhai", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Gygi", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Goldberg", "suffix": ""}], "year": 2015, "venue": "Proceedings of the National Academy of Sciences of the United States of America", "volume": "112", "issn": "", "pages": "15790--15797", "other_ids": {"DOI": ["10.1073/pnas.1521919112"]}}, "BIBREF863": {"ref_id": "b863", "title": "A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321", "authors": [{"first": "Y", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "N", "middle": ["R"], "last": "Foster", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Meyers", "suffix": ""}, {"first": "S", "middle": ["P"], "last": "Thomas", "suffix": ""}, {"first": "D", "middle": ["W"], "last": "Northfelt", "suffix": ""}, {"first": "K", "middle": ["M"], "last": "Rowland", "suffix": ""}, {"first": "B", "middle": ["I"], "last": "Mattar", "suffix": ""}, {"first": "D", "middle": ["B"], "last": "Johnson", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Molina", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Mandrekar", "suffix": ""}, {"first": "S", "middle": ["E"], "last": "Schild", "suffix": ""}, {"first": "J", "middle": ["D"], "last": "Bearden", "suffix": ""}, {"first": "M.-C", "middle": [], "last": "Aubry", "suffix": ""}, {"first": "A", "middle": ["A"], "last": "Adjei", "suffix": ""}], "year": 2015, "venue": "Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer", "volume": "10", "issn": "1", "pages": "172--180", "other_ids": {}}, "BIBREF865": {"ref_id": "b865", "title": "Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice", "authors": [{"first": "S", "middle": [], "last": "Zheng", "suffix": ""}, {"first": "E", "middle": ["B D"], "last": "Clabough", "suffix": ""}, {"first": "S", "middle": [], "last": "Sarkar", "suffix": ""}, {"first": "M", "middle": [], "last": "Futter", "suffix": ""}, {"first": "D", "middle": ["C"], "last": "Rubinsztein", "suffix": ""}, {"first": "S", "middle": ["O"], "last": "Zeitlin", "suffix": ""}], "year": 2010, "venue": "PLoS Genetics", "volume": "6", "issn": "2", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pgen.1000838"]}}, "BIBREF866": {"ref_id": "b866", "title": "Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction network", "authors": [{"first": "Z", "middle": [], "last": "Zheng", "suffix": ""}, {"first": "T", "middle": [], "last": "Liu", "suffix": ""}, {"first": "J", "middle": [], "last": "Zheng", "suffix": ""}, {"first": "J", "middle": [], "last": "Hu", "suffix": ""}], "year": 2017, "venue": "OncoTargets and Therapy", "volume": "10", "issn": "", "pages": "1327--1334", "other_ids": {}}, "BIBREF868": {"ref_id": "b868", "title": "Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)", "authors": [{"first": "H.-J", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Aujay", "suffix": ""}, {"first": "M", "middle": ["K"], "last": "Bennett", "suffix": ""}, {"first": "M", "middle": [], "last": "Dajee", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Demo", "suffix": ""}, {"first": "Y", "middle": [], "last": "Fang", "suffix": ""}, {"first": "M", "middle": ["N"], "last": "Ho", "suffix": ""}, {"first": "J", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "C", "middle": ["J"], "last": "Kirk", "suffix": ""}, {"first": "G", "middle": ["J"], "last": "Laidig", "suffix": ""}, {"first": "E", "middle": ["R"], "last": "Lewis", "suffix": ""}, {"first": "Y", "middle": [], "last": "Lu", "suffix": ""}, {"first": "T", "middle": [], "last": "Muchamuel", "suffix": ""}, {"first": "F", "middle": [], "last": "Parlati", "suffix": ""}, {"first": "E", "middle": [], "last": "Ring", "suffix": ""}, {"first": "K", "middle": ["D"], "last": "Shenk", "suffix": ""}, {"first": "J", "middle": [], "last": "Shields", "suffix": ""}, {"first": "P", "middle": ["J"], "last": "Shwonek", "suffix": ""}, {"first": "T", "middle": [], "last": "Stanton", "suffix": ""}, {"first": "J", "middle": [], "last": "Yang", "suffix": ""}], "year": 2009, "venue": "Journal of Medicinal Chemistry", "volume": "52", "issn": "9", "pages": "3028--3038", "other_ids": {"DOI": ["10.1021/jm801329v"]}}, "BIBREF869": {"ref_id": "b869", "title": "Transgenic mice expressing the Tyr437His mutant of human myocilin protein develop glaucoma", "authors": [{"first": "Y", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "O", "middle": [], "last": "Grinchuk", "suffix": ""}, {"first": "S", "middle": ["I"], "last": "Tomarev", "suffix": ""}], "year": 2008, "venue": "Investigative Ophthalmology & Visual Science", "volume": "49", "issn": "5", "pages": "1932--1939", "other_ids": {"DOI": ["10.1167/iovs.07-1339"]}}, "BIBREF870": {"ref_id": "b870", "title": "An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro", "authors": [{"first": "H", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "T", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Z", "middle": [], "last": "Xin", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhan", "suffix": ""}, {"first": "G", "middle": [], "last": "Gu", "suffix": ""}, {"first": "X", "middle": [], "last": "Li", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "S", "middle": [], "last": "Yang", "suffix": ""}, {"first": "C", "middle": [], "last": "Liu", "suffix": ""}], "year": 2019, "venue": "Acta Biochimica Et Biophysica Sinica", "volume": "51", "issn": "10", "pages": "1034--1040", "other_ids": {"DOI": ["10.1093/abbs/gmz093"]}}, "BIBREF871": {"ref_id": "b871", "title": "MG132 enhances the radiosensitivity of lung cancer cells in vitro and in vivo", "authors": [{"first": "W", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "J", "middle": [], "last": "Liu", "suffix": ""}, {"first": "J", "middle": [], "last": "Nie", "suffix": ""}, {"first": "W", "middle": [], "last": "Sheng", "suffix": ""}, {"first": "H", "middle": [], "last": "Cao", "suffix": ""}, {"first": "W", "middle": [], "last": "Shen", "suffix": ""}, {"first": "A", "middle": [], "last": "Dong", "suffix": ""}, {"first": "J", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "Y", "middle": [], "last": "Jiao", "suffix": ""}, {"first": "S", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "J", "middle": [], "last": "Cao", "suffix": ""}], "year": 2015, "venue": "Oncology Reports", "volume": "34", "issn": "4", "pages": "2083--2089", "other_ids": {"DOI": ["10.3892/or.2015.4169"]}}, "BIBREF872": {"ref_id": "b872", "title": "The proteasome maturation protein POMP increases proteasome assembly and activity in psoriatic lesional skin", "authors": [{"first": "B", "middle": ["A"], "last": "Zieba", "suffix": ""}, {"first": "L", "middle": [], "last": "Henry", "suffix": ""}, {"first": "M", "middle": [], "last": "Lacroix", "suffix": ""}, {"first": "M", "middle": [], "last": "Jema\u00e0", "suffix": ""}, {"first": "T", "middle": [], "last": "Lavabre-Bertrand", "suffix": ""}, {"first": "L", "middle": [], "last": "Meunier", "suffix": ""}, {"first": "O", "middle": [], "last": "Coux", "suffix": ""}, {"first": "P.-E", "middle": [], "last": "Stoebner", "suffix": ""}], "year": 2017, "venue": "Journal of Dermatological Science", "volume": "88", "issn": "1", "pages": "10--19", "other_ids": {"DOI": ["10.1016/j.jdermsci.2017.04.009"]}}, "BIBREF873": {"ref_id": "b873", "title": "Proteasome impairment by \u03b1-synuclein", "authors": [{"first": "L", "middle": [], "last": "Zondler", "suffix": ""}, {"first": "M", "middle": [], "last": "Kostka", "suffix": ""}, {"first": "P", "middle": [], "last": "Garidel", "suffix": ""}, {"first": "U", "middle": [], "last": "Heinzelmann", "suffix": ""}, {"first": "B", "middle": [], "last": "Hengerer", "suffix": ""}, {"first": "B", "middle": [], "last": "Mayer", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Weishaupt", "suffix": ""}, {"first": "F", "middle": [], "last": "Gillardon", "suffix": ""}, {"first": "K", "middle": ["M"], "last": "Danzer", "suffix": ""}], "year": 2017, "venue": "PloS One", "volume": "12", "issn": "9", "pages": "", "other_ids": {"DOI": ["10.1371/journal.pone.0184040"]}}, "BIBREF874": {"ref_id": "b874", "title": "Critical elements in proteasome assembly", "authors": [{"first": "P", "middle": [], "last": "Zwickl", "suffix": ""}, {"first": "J", "middle": [], "last": "Kleinz", "suffix": ""}, {"first": "W", "middle": [], "last": "Baumeister", "suffix": ""}], "year": 1994, "venue": "Nature Structural Biology", "volume": "1", "issn": "11", "pages": "765--770", "other_ids": {"DOI": ["10.1038/nsb1194-765"]}}}, "ref_entries": {"FIGREF0": {"text": "phase 3 PANORAMA-1 clinical trial, which demonstrated an improvement in PFS of 7.8 months for the three-drug combination compared with placebo plus bortezomib and dexamethasone in this patient population (11.99 vs. 8.08, P<0.0001), even though several adverse events were more frequently observed in the panobinostat group(San-Miguel et al., 2014 a; San-Miguel et al., 2014 b;San-Miguel et al., 2016).", "latex": null, "type": "figure"}, "FIGREF1": {"text": "randomized to receive either melphalan and prednisone or the same schedule with the addition of bortezomib (at the dose of 1.3 mg/ml). At the initial analysis, the time to disease progression was 24.0 months in the bortezomib group and 16.6 months in the control group (HR for the bortezomib group = 0.48; P<0.001). The interim and final analyses confirmed the efficacy of the triplet regimen: after median follow-ups of 36.7 months and 60.1 months, 35% and 31% risk of death reduction were reported, respectively, in the bortezomib-containing group versus the control group (HR= 0.653; P<0.001 and 0.695; P<0.001, respectively)(Mateos et al., 2010; San-  Miguel et al., 2013). The final reported median OS was 56.4 vs 43.1 months(San-Miguel et al.,   2013). Even in this case, peripheral neuropathy events were more frequently documented in the bortezomib group. Interestingly, an italian phase 3 study introduced thalidomide in the triplet regimen of the VISTA trial: 511 patients were randomly assigned to receive nine cycles of the fourdrug combination bortezomib-melphalan-prednisone-thalidomide followed by continuous bortezomib-thalidomide as maintenance (VMPT-VT), or bortezomib-melphalan-prednisone (VMP, control group) at the same doses. In the initial analysis, the median PFS was not reached in the VMPT-VT arm and was 27.3 months in the VMP group; the 3-year PFS was 56% in patients receiving VMPT-VT and 41% in those receiving VMP (HR=0.67; P = 0.008)(Palumbo et al., 2010).A longer follow up confirmed the higher survival benefit of the VMPT-VT protocol compared to the triplet combination (median PFS 35.3 months versus 24.8 months; HR=0.58; P< J o u r n a l P r e -p r o o f 0.001) (Palumbo et al., 2014). Thereafter, several randomized, open label, phase 3 clinical trials (IFM 2005-01; GIMEMA; PETHEMA/GEM and MMY-3006) tested bortezomib-dexamethasone doublet regimen or bortezomib-dexamethasone-thalidomide triplet regimen in patients with previously untreated MM as induction therapy before SCT. These and other clinical trials demonstrated a statistically significant improvement in the post-transplantation complete response rate as a consequence of bortezomib inclusion in the induction regimens, even though the incidence of peripheral neuropathy was increased (Horousseau et al., 2010; Cavo et al., 2010; Rosinol et al, 2012; Sonneveld 2013). The results of these studies led to EMA approval in 2013 of bortezomib with dexamethasone or with dexamethasone plus thalidomide for the induction treatment of patients", "latex": null, "type": "figure"}, "FIGREF2": {"text": "in this clinical setting(Rosi\u00f1ol et al., 2019). Recently, a phase 3 trial has evaluated this regimen with respect to lenalidomide-dexamethasone in patients with previously untreated MM, who were not planned for immediate SCT, demonstrating a significant improvement in terms of PFS (43 months vs 30 months, HR=0.712, P=0.0018) and OS (75 months vs 64 months, HR=0,709, P =0.025) with an acceptable risk-benefit profile(Durie et al., 2017). Therefore, although, as above mentioned, high-dose chemotherapy plus autologous SCT is the standard treatment for NDMM in adults up to 65 years of age, the use of combination therapy with lenalidomide, bortezomib and dexamethasone has raised questions about the role and timing of transplantation(Attal et al., 2017;Okazuka and Ishida, 2018).As in the case of RRMM treatment, bortezomib is always the backbone for therapeutic regimens for NDMM in combination with other novel targeted agents(Seval and Beksac, 2018). Accordingly, two therapeutic regimens, including the monoclonal antibody daratumumab, have been approved by both FDA and EMA: 2018, bortezomib, daratumumab, melphalan and prednisone combination for NDMM patients, who are ineligible for ASCT. This approval was based on the results of the open-label, multicentre phase 3 ALCYONE (MMY3007) study, in which patients ineligible for high-dose chemotherapy followed by ASCT (age >65 years or comorbidities), were randomized to receive either daratumumab-bortezomib-melphalan-prednisone (D-VMP) or bortezomib-melphalan-prednisone (VMP, control group). The 3-year OS was significantly higher in the D-VMP group than in the VMP group (78% vs 67.9%); the PFS was also improved in the D-VMP arm (HR= 0.42 for daratumumab group; P<0\u00b70001)(Mateos et al., 2020);2) in 2019 (FDA) and 2020 (EMA), daratumumab, bortezomib, thalidomide and dexamethasone for NDMM patients, who are eligible for ASCT, based on the results of the open-label, phase 3 CASSIOPEIA trial. In this study, patients were randomly assigned to receive four pretransplantation induction and two post-transplantation consolidation cycles of bortezomib, thalidomide and dexamethasone alone or the same regimen plus daratumumab. At day 100 after transplantation, 39% patients in the daratumumab group achieved a complete response or better versus 26% in the control group (p<0.0001), with acceptable safety (Moreau et al., 2019 a).", "latex": null, "type": "figure"}, "FIGREF3": {"text": "LoRusso et al., 2012;. In a first phase 1 clinical trial, the pharmacokinetics and safety of bortezomib in patients with varying degrees of hepatic impairment were evaluated, revealing that patients with mild hepatic impairment did not require a starting dose adjustment, whereas patients with moderate or severe hepatic impairment required a reduced dose of 0.7 mg/m 2 , and constantly monitoring during treatment(Lo Russo et al., 2012). These data were also confirmed by the VISTA trial, and specific dosing recommendations for patients with hepatic impairment are inserted into the drug label.Bortezomib efficacy has been also investigated in other haematological malignancies, and several trials are currently ongoing, including Light Chain Amyloidosis (ALA), Waldenstrom Macroglobulinemia, Acute Lymphoblastic and Myeloid Leukemia, Indolent B-cell non-Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, T-cell lymphomas, as also recently reviewed elsewhere (Robak and Robak, 2019). Moreover, bortezomib is used off-label in refractory or relapsed T-cell lymphomas, Waldenstr\u00f6m Macroglobulinemia and ALA (Du et al., 2016; Robak and Robak, 2019). The most promising results have been reported for ALA, in which bortezomib, dexamethasone and cyclophosphamide, or bortezomib, dexamethasone and melphalan represent the most commonly used first-line treatments, although several opened questions demand further J o u r n a l P r e -p r o o f", "latex": null, "type": "figure"}, "FIGREF4": {"text": "the clinical efficacy of bortezomib as single agent was investigated in patients with relapsed and refractory MCL(Goy et al., 2005;O'Connor et al., 2005;Goy et al., 2009;). In 2006, the results of a pivotal open-label, single arm, multicentre phase 2 trials (PINNACLE) led to bortezomib approval by FDA for the treatment of MCL in patients who had received at least one prior treatment. In this trial, 155 patients with progressive MCL, who had undergone at least one prior therapy received, 1.3 mg/m 2 of bortezomib on day 1, 2, 5, and 11 of each 3-weeks cycle. The results showed an OR rate of 31% (median duration, 9.3 months), a complete response rate (CR + unconfirmed CR) of 8% (median duration, 15.4 months), a median time to response of 40 days (range, 31 to 204 days), and a median time to progression of 6.2 months. Adverse events were similar to those reported in other studies with bortezomib, such as peripheral neuropathies and gastrointestinal symptoms(Fisher et al., 2006). An extended follow-up confirmed the positive trend, reporting a median OS of 35.4 months in responding patients(Goy et al., 2009). Combined regimens, including bortezomib, have been evaluated in phase 2 clinical trials with a small number of patients, showing improved efficacy that needs to be confirmed by further investigation: bendamustine-bortezomib-rituximab (of 29 patients evaluable for efficacy, 83%", "latex": null, "type": "figure"}, "FIGREF5": {"text": "in place of vincristine (VR-CAP). After a median follow-up of 40 months, PFS was 14.4 months in the R-CHOP group versus 24.7 months in the VR-CAP group (HR=0.63; P<0.001). Moreover, the final analysis after a median follow-up of 82 months revealed a significantly longer OS in the VR-CAP group than in the R-CHOP group (90.7 months vs 55.7 months; HR =0.66, P=0.001), with a manageable toxicity profile. These data led to FDA and EMA approval of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated MCL, who are unsuitable for SCT (Robak et al., 2015; Robak et al., 2018; Drach et al., 2018; Robak et al. 2019). Another strategy, combining bortezomib or lenalidomide with bendamustine and rituximab, has shown efficacy in both first-line and salvage therapy for MCL (Campo and Rule, 2015; Albertsson-Lindblad et al., 2016). Accordingly, in a prospective, multicentre phase 2 study evaluating rituximab, bendamustine, bortezomib and dexamethasone as first-line treatment for patients with MCL aged 65 years or older, at median follow-up of 52 months, the 2-year PFS was 70%, clearly demonstrating that this regimen is active and demands further evaluation (Gressin et al., 2019). Despite other investigations have reported promising data, the results of a recent phase 2 trial for newly diagnosed MCL, in which bortezomib was administered as maintenance treatment after induction therapy with three cycles of R-CHOP, two cycles of high-dose cytarabine, BEAM (carmustine, etoposide, cytarabine, melphalan) and ASCT, demonstrated no positive effects of bortezomib as maintenance therapy (Doorduijn et al., 2020).", "latex": null, "type": "figure"}, "FIGREF6": {"text": "G2/M radiosensitive phase of cell cycle and modulation of radio-resistance mechanisms (i.e., NF-kB activation, loss of p53 and DNA DSBs repair)(Cron et al., 2013;Zhu et al., 2015;Roeten et al., 2018). Additionally, bortezomib might act as chemosensitizer in combination with standard chemotherapy as demonstrated in models of chemo-resistant small cell lung cancer xenografts(Taromi et al., 2017). An impressive number of clinical trials on bortezomib (897) are reported in clinical trial.com. A number of these trials have been also performed in different solid tumours (see", "latex": null, "type": "figure"}, "FIGREF7": {"text": "Small cell lung cancer and non-small lung cancer, in which bortezomib as single agent have revealed limited efficacy, whereas combination therapy with paclitaxel, carboplatin, and concurrent thoracic radiation seemed more encouraging (Gatti et al., 2013; Zhao et al., 2015); (b) Head and neck squamous cell carcinoma, in which, despite promising preclinical studies, clinical trials revealed poor results (Lin et al., 2012; Li et al., 2013 b; Gilbert et al., 2013); Different mechanisms have been proposed to justify the different bortezomib activity between solid tumours and haematological malignancies, including: (i) alterations and mutations of the proteasome subunit composition; (ii) drug penetration; (iii) activation of compensatory mechanisms, such as autophagy;", "latex": null, "type": "figure"}, "FIGREF8": {"text": "Demo et al., 2007; Deshaies et al., 2014). Thus, through a medicinal chemistry approach, epoxomicin became the scaffold for the synthesis of a more potent tetrapeptide epoxyketone, YU-101 (the parent lead compound of PR-171 or carfilzomib), an injectable drug, which is quickly cleared from plasma(Demo et al., 2007;Myung et al., 2001; Kim and Crews, 2013; Deshaies et   al., 2014). As a matter of fact, for carfilzomib an antitumor activity greater than that of bortezomib was reported in a human tumour xenograft model(Demo et al., 2007).Thereafter, based on the results of in vitro and in vivo preclinical studies, carfilzomib (Kyprolis) safety profile and clinical efficacy were evaluated in two pioneering studies, in which two different schedules were tested in patients with relapsed or refractory haematological malignancies. In the first phase 1 dose-escalating clinical trial (PX-171-001), carfilzomib doses ranging from 1.2 to 20 mg/m 2 were administered intravenously on five consecutive days following 9 days of rest in 14-day cycles, until occurrence of unacceptable toxicity or disease progression. This study revealed that the drug was well tolerated (a dose of 15 mg/m 2 was established as the maximum tolerated dose J o u r n a l P r e -p r o o f[MTD]), and was active in patients with MM or Waldenstr\u00f6m macroglobulinemia that were treatment-refractory or relapsed after at least two lines of treatment(Connor et al., 2009). In the second phase I trial (PX-171-002), carfilzomib (1.2-27 mg/m 2 ) was administered twice a week on two consecutive days for 3 weeks in a 4-week cycle; the results showed that this treatment schedule was well-tolerated, being the majority of adverse events manageable and low-grade in severity, and showed activity in particular againstRRMM (Alsina et al., 2012). This regimen was then selected for the subsequent clinical studies, including the PX-171-003A1 and ASPIRE trials. In 2012, in consideration of the results of an open-label, single-arm phase 2 study (PX-171-003-A1), which enrolled 266 patients, carfilzomib received accelerated approval by FDA as single agent for the treatment of MM in patients with clinical evidence of disease progression after at least two prior therapies, including bortezomib and an immunomodulatory agent. In this study, bortezomib was administered at the dose of 20 mg/m 2 to a patient population in the majority (89%) resistant to bortezomib and the reported overall response rate was 23.7% with median duration of response of 7.8 months(Herndon et al. 2013). Over the last years, several phase 1 and 2 studies were run both on newly diagnosed MM and, mainly on RRMM, by using different schedules of carfilzomib as monotherapy, or in combination with other agents, such as low-dose of dexamethasone and lenalidomide (being lenalidomide plus dexamethasone a reference treatment for RRMM). These trials generated a bulk of clinical data which demonstrated the efficacy and tolerability of this PI (see clinicaltrials.gov)Siegel et al., 2013;Moreau et al., 2015;Papadopoulos et al., 2015; Berenson et al., 2016). The results of these phase 2 studies supported the progression into phase 3 trials, which have further led in 2015 to the EMA approval of carfilzomib.In particular, based on the results of open label ASPIRE phase 3 study (NCT01080391), EMA approved carfilzomib in combination with either lenalidomide and dexamethasone, or dexamethasone alone, for the treatment of adult patients with MM, who have received at least one prior therapy. Furthermore, in 2016, FDA approved carfilzomib in combination with lenalidomide", "latex": null, "type": "figure"}, "FIGREF9": {"text": "median 47.6 months versus 40.0 months; HR 0.791; 95%, P=0.010) (Dimopoulos et al., 2017; Ludwing et al., 2019; Dimopoulos et al., 2019). In 2018, FDA extended the use of carfilzomib to include a once-weekly dosing option in combination with dexamethasone (once-weekly Kd70) for patients with RRMM. This approval was based on data from the randomized, open-label, phase 3 A.R.R.O.W. trial, in which 478 patients", "latex": null, "type": "figure"}, "FIGREF10": {"text": "what concerns pharmacokinetics, preclinical and clinical studies have shown that carfilzomib has an extremely short half-life of about 12-40 minutes(Demo et al., 2007;Yang et al., 2011;Park et al., 2018). Furthermore, it displays a rapid systemic clearance (116-123 l/h) and a large distribution volume at steady state (9-28 L)). At all doses tested, carfilzomib clearance exceeded hepatic blood flow, envisaging a contribution of extra-hepatic mechanisms, via peptidase cleavage and epoxide hydrolysis, to its overall elimination. Cytochrome P450-mediated metabolism plays a minor role, suggesting that carfilzomib pharmacokinetic profile is poorly altered by administration of CYP inducers or inhibitors. Furthermore, no meaningful differences in carfilzomib pharmacokinetics are detected between patients with normal renal function and those with renal impairment", "latex": null, "type": "figure"}, "FIGREF11": {"text": "or as a component of combined regimens in patients with RRMM. In particular, its combination with dexamethasone provided encouraging results. However, grade \u22653 adverse events occurred in approximately 80% of patients and the most common adverse events of any grade were gastrointestinal disorders (up to 84.8%), underscoring the requirement of novel oprozomib formulations to improve its gastrointestinal tolerability. Recently, based on preclinical studies that have indicated greater efficacy of oprozomib in combination with dexamethasone and pomalidomide compared to oprozomib monotherapy, a phase 1b trial has evaluated this triplet regimen in 31 patients with RRMM(Sanchez et al., 2017;Shah et al., 2019).The results of this study showed encouraging results in terms of efficacy but also confirmed the toxicity profile and the high pharmacokinetics variability of the original bortezomib formulation tested(Shah et al., 2019), stimulating further clinical trials in order to evaluate novel drug formulations with improved gastrointestinal tolerability. Moreover, a phase 1b/2 study where oprozomib was tested as single agent revealed promising results in terms of ORR and tolerability also in patients with Waldenstr\u00f6m Macroglobulinemia(Ghobrial et al., 2019). Recently, two multicentre open-label 1b/2 phase studies evaluated three oprozomib-based regimens in transplantineligible NDMM patients: oprozomib-dexamethasone plus lenalidomide or cyclophosphamide (oprozomib003) and oprozomib-melphalan-prednisone (oprozomib006).Although anti-myeloma activity was reported also in NDMM patients, gastrointestinal toxicities and the inter-individual pharmacokinetics variability limits oprozomib efficacy and clinical use, reinforcing the need of novel formulations. Accordingly, a phase 1b doseexploration study (NCT02939183) in RRMM is currently ongoing in the attempt to evaluate two new oprozomib formulations clinicaltrials.gov). Despite encouraging clinical results in MM and promising data obtained in preclinical models of solid tumours, in a first doseescalation study in patients with advanced refractory or recurrent NSCLC and colorectal cancer, oprozomib as single agent showed minimal antitumour activity, with clinically relevant gastrointestinal toxicity(Zang et al., 2012;Infante et al., 2016).", "latex": null, "type": "figure"}, "FIGREF12": {"text": "the clinical use. Yet, their very versatile chemistry has allowed to get formulations for topical and systemic treatments thanks to the possibility to synthesize an almost unlimited number of watersoluble derivatives. Easy functionalization of the core (in particular in the meso-position) allows to tune their solubility, aggregation tendency and electronic properties by only choosing the nature, number and reciprocal topology of substituents. In addition to the chemistry related to the periphery, the central core also has a manifold role in determining the steric and physicochemical behavior (e.g., absorption and emission properties) of porphyrins.It is difficult to overstate the physiological relevance of porphyrins, since their biological role (such as oxygen carrier or storage and redox balance among other) indeed depends on the correct cell localization and on the matching between their structural features and those of the hosting cavity/compartment. For example, anionic porphyrins (e.g., Uro, Copro, PP-IX, with their carboxylates) tend to localize in the acidic compartment of the lysosome. The role of porphyrins (natural or synthetic) and their relevance in affecting biological processes is underlined by the evidence that uncontrolled endogenous porphyrins exposure, caused by hemoproteins release (i.e., ectopic porphyrins) and their subsequent binding to essential proteins may impair protein function, inducing an oxidative damage and altering cellular functions.In addition to the well-known cellular damage, resulting by reactive oxygen species (ROS), photogenerated by porphyrins catalysed reactions, several experimental observations have recently remarked porphyrin toxicity in the dark, that seems to be correlated to inhibition phenomena involving HSP90, (Woo Hyung telomerase(Masood A et al, 2003),(Cory et al,   2002)  and proteasome. Other observations(Szokalska et al., 2009) demonstrate that the cytotoxic effects, caused by a porphyrin photosensitizer in PDT, could be potentiated through inhibition of", "latex": null, "type": "figure"}, "FIGREF13": {"text": "cellular homeostasis through the combined activities of oxidative damage and proteasome inhibition, thus resulting in the accumulation of damaged proteins that contribute to the triggering of cell death. As far as it concerns their interactions with proteasome, porphyrins can either induce a partial competitive occlusion by hindering the substrate access into the catalytic chamber or else behave as an allosteric modulator, regulating the occurrence of conformational change(s) that affect(s) the dynamic equilibrium between the open and the closed state of the proteasome gates.", "latex": null, "type": "figure"}, "FIGREF14": {"text": "the effectiveness of the metal complex should strongly depend on the metal-ligand species formed and, once inside the cell, the copper shuttling complex should induce proteasome inhibition by releasing the copper ions, which become available to coordinate with proteasome, involving amino acids capable of forming Cu-N,Cu-S, or Cu-O bonds (Hindo et al., 2009).", "latex": null, "type": "figure"}, "FIGREF15": {"text": "general, the major component of insoluble deposits is a specific-disease related protein, such as \u03b2amyloid and tau in Alzheimer disease (AD), \u03b1-synuclein in Parkinson Disease (PD), and huntingtin in Huntington Disease (HD), even though overlapping similarities between syndromes are reported(Jellinger et al., 2012;McAlary et al., 2019).", "latex": null, "type": "figure"}, "FIGREF16": {"text": "SEM) experiments have shown that A\u03b2 peptide binds the 20S and inhibits its proteolytic activity(Gregori et al., 1997). These findings also reconcile with experiments outlining that neuronal cells incubated with amyloid A\u03b2 peptides do exhibit inhibitory effect on proteasome activity(Cecarini et al., 2008;Lopez Salon et al., 2003;Tseng et al., 2008). Impaired tau metabolism has been also associated with abnormal UPS activity; thus, tau may be ubiquitinated at diverse sites and UPS impairment is involved in tauopathies(Cripps et al., 2006;David et al., 2002;Han et al., 2014;Keck et al., 2003;Metcalfe et al., 2012;Morris et al., 2015;Tai et al., 2012;Thomas et al., 2009).", "latex": null, "type": "figure"}, "FIGREF17": {"text": "Cliffe et al., 2019). Neurotoxic 30-mer A\u03b2 assemblies (termed amylo-spheroids) are present in AD brains, showing to be the main responsible of neuronal cells death. Although it is still unclear how amylo-spheroids form in the brain and activate neurodegenerative processes, proteasome inhibition was shown to dramatically promoted by their accumulation in the trans-Golgi network of excitatory neurons, altering dendritic transport (Komura et al., 2019).", "latex": null, "type": "figure"}, "FIGREF18": {"text": "II) ions inhibit all proteolytic activities of the20S (Grasso et al., 2017;.Human neuroblastoma cell lines SH-SY5Y, differentiated with retinoic acid, reproduce the neuronal morphology and function and are for this reason widely employed to mimic primary neurons. Low doses of MG-115, a known PI, brought about tau hyperphosphorylation, microtubule destabilization, and an impaired dendritic development in SH-SY5Y cell lines. Moreover, an inhibited proteasome activity induced increased the levels of signal proteins involved in AD pathogenesis, such as c-Jun N-terminal kinase, c-Jun and extracellular signal-regulated protein kinase (ERK). Notably, in the same study it came out evident that an inhibition of c-Jun and ERK was able to nullify the effects of proteasome inhibition. These results suggest that a reduced proteasome activity may induce an activation of c-jun/ERK signaling and, in turn, in a cascade of adverse events leading to neuronal death(Agholme et al., 2014).Indirect proteasome inactivation may also play a significant role in AD development. For example, ubiquitin hydrolase (Uch-L1) is known to raise cytosolic mono-ubiquitin levels, thus enhancing J o u r n a l P r e -p r o o f Journal Pre-proof protein degradation by the proteasome; not surprisingly, low Uch-L1 levels are correlated with amyloid accumulation. Furthermore, a neuron F-box protein Fbx2 may act as an E3 ligase,", "latex": null, "type": "figure"}, "FIGREF19": {"text": "HDAC6, GRB1, NUB1, c-Abl among the others), which either selectively bind \u03b1-synuclein or modulate its solubility and interacting properties through insertion of post-translational modifications, such as phosphorylation (further discussed below)(Anisimov et al., 2019; Takahashi   et al., 2018;Mahul-Mellier et al., 2014; Tanji et al., 2010). Finally, under healthy conditions an J o u r n a l P r e -p r o o f", "latex": null, "type": "figure"}, "FIGREF20": {"text": "inherited familiar variants and idiopathic forms of the disease indicate that PD is probably the neurodegenerative disorder displaying the highest degree of association with a multi-faceted dysregulation of E3-ligases and of proteasome proteolytic activities early at disease onset(Bentea et al.,   2017;Krebiehl et al., 2010;Savolainen et al., 2017;Ugras et al., 2018).Remarkably, although \u03b1-synucleinis a valid natural substrate of 20S proteasome, widely used to monitor its proteolytic activity under different experimental conditions, structural conformational changes of \u03b1-synuclein have been reported to transform it in an inhibitor of the 20S proteolytic activity(Dachsel et al., 2005;Zondler et al., 2017). On the other hand, since IDE was shown to halt in vitro the oligomerisation of \u03b1-synuclein, as well as that of other amyloidogenic substrates(Sharma et al., 2015a; Sharma et al., 2015b; de Tullio et al., 2013), an important still unexplored aspect is the role of IDE and, possibly, of IDE::20S complexes; thus, interaction of the enzyme with the 20S might stimulate further information on the functionality of these pathways in fighting the proteo-toxic stress in PD.By analogy with other neurodegenerative disorders, the metabolic dysregulation, which stimulates neuron loss in PD, deals with redox imbalance, proteo-toxicity and metal-ions dys-homeostasis(Bentea et al., 2017;Zondler et al., 2017;Kumar et al., 2018; Le et al., 2014;Janda et al., 2012).Nonetheless, extensive redox imbalance chemically induced by rotenone and paraquat (e.g., mitochondrial respiratory chain inhibitors), leads to the development of specific forms of parkinsonism.Interestingly, \u03b1-synuclein in LB is often phosphorylated at Ser129, a post-translational modification which reduces the aggregating propensity of the protein; impairment of the phosphorylation at Ser129, brough about by redox nitrosylation of neighbouring Tyr residues together with di-tyrosine cross-linking, especially at the C-terminus of the protein, induces pathological structural alterations of the protein(Kleinknecht et al., 2016).", "latex": null, "type": "figure"}, "FIGREF21": {"text": "ligase parkin, which plays a plethora of intracellular functions linked to PD pathogenesis. Mutations in the UBL domain of parkin, as well as those observed in inherited PD cases, render the protein highly unstable, making it possible the parkin detection in the cell lines only in the presence of PI.However, it is debated whether parkin genetic mutations impair the ability of carrying out ubiquitin conjugation of substrates or else disruption of the UBL domain enhances auto-catalytic selfubiquitination of parkin promoting its self-clearance (Chaugule et al., 2011). As a matter of fact, integrity of UBL is crucial for the regulation of parkin function in cells, and it has been proposed that parkin mutations lead to its altered sub-cellular localization and may further increase the aggregating-propensity of parkin(Santos et al., 2019).Parkin binds concurrently substrates and proteasome through interaction with 19S subunits, especially Rpn1, even though additional receptors have been identified(Um et al., 2010;Kabayama et al., 2017; Chaugule et al., 2011). Specifically, parkin was found to further bind Rpn13 through the UBL domain. On its turn, Rpn13 may regulate protein turnover of parkin, since Rpn13 silencing increases parkin bio-availability in cell(Aguileta et al., 2015).Although the affinity of parkin for 19S subunits is not very high, being likely in the \u00b5M range, it has been proposed that this interaction regulates an allosteric mechanism which activates parkin ubiquitin ligase activity(Chaugule et al., 2011; Aguileta et al., 2015). Conversely, it looks still controversial whether parkin binds also the 20S, and the divergent findings are probably dependent on the experimental models used(Dachsel et al., 2005).", "latex": null, "type": "figure"}, "FIGREF22": {"text": "mitophagy)(Greene et al., 2012;Gao et al., 2016; Fedorowicz et al., 2014;Rosen et al., 2010;Sun et al., 2019).", "latex": null, "type": "figure"}, "FIGREF23": {"text": "From the clinical point of view, the disease is characterised by the anticipation phenomenon, that is an increase in the CAG triplet repetitions, and thus of polyQ length, over generations, bringing about an early onset of the disease through a more severe phenotype which further strengthens the pathogenic relevance of the polyQ stretch length (Labbadia andMorimoto, 2013).Although several neuronal cells are affected during disease progression, medium-spiny neurons of striatum are those displaying the highest degree of alteration. This feature might be due to the glutamergic cytotoxicity through an exceedingly high N-methyl D-aspartate receptor (NMDAR) activity (Labbadia and Morimoto 2013). However, differences in synaptic and extra-synaptic activities of these receptors have suggested that dysfunction of neuronal circuits might derive from a primary dysregulation of intracellular pathways, including those regulating proteostasis, through largely unknown mechanisms.Molecular research on Htt has clarified that the toxicity of the mutated protein is given by the release of N-terminal fragments, which hold the polyQ stretch, upon cleavage of the full-length protein by intracellular proteases, most likely caspase 6(Tebbenkamp et al., 2011;Soares et al., 2019).From the early research on HD, multi-faceted interactions between mHtt fragments and intracellular proteolytic pathways have been sketched and therapeutic strategies proposed to improve the clearance of the proteins(Harding and Dong, 2018;Zhang et al., 2019). Scherzinger first reported that poly-glutamine expansion had an amyloidogenic-like behaviour(Scherzinger et al., 1997). As a matter of fact, cellular aggregates in cell-based models and, most notably, in post-mortem CNS explants of human subjects display positivity to either ubiquitin, proteasome subunits and several E3 ligases staining, thus envisaging a specific recruitment of proteasome complexes in growing aggregates(Di Figlia et al., 1997;Juenemann et al., 2015;Dasgupta et al., 2015). However, soluble mHtt is not efficiently targeted by the 26S proteasome and the lack of efficient ubiquitination for proteasomal degradation leads to intracellular aggregation driven by the intrinsic disordered J o u r n a l P r e -p r o o f structure of mHtt(Schipper-Krom et al., 2012;Juenemann et al., 2015). Conversely, mHtt fragments are extensively targeted by E3 ligases and aggregates formation lead to the progressive sequestration of them with severe consequences for the cell metabolism. More recently, the isolated mutated exon-1 of Htt appears to be a ubiquitin-independent substrate of free 20S, even though a direct proteasome inhibition by exon1-Htt, as occurring for other amyloidogenic proteins, is not expected to be a major mechanism of proteo-toxicity in HD(Juenemann et al., 2018). It is instead more likely that Htt perturbs UPS functionality through the modulation of metabolic pathways and through transcriptional and post-translational events mostly involving the Ubiquitin-Conjugating Enzymes which are discussed below. In fact, it is well known that expression of mHtt stimulates a deep re-arrangement of the genes being transcribed, which are, among others, mitochondrial membranes, chromatin remodelling, lipid binding proteins, protein folding and a plethora of E3 ligases(Tang et al., 2011). Furthermore, mHtt expression was reported to affect cell cycle, which obviously is not an issue for neurons, but it may affect glial cells and their mechanisms of preservation of CNS homeostasis(van Hagen et al., 2017).", "latex": null, "type": "figure"}, "FIGREF24": {"text": ", a subgroup of the Forkhead transcription factors (human cells encode fourFOXO proteins,   FOXO1, FOXO3a, FOXO4 and FOXO6), which are central regulators of cell metabolism. Remarkably, HD iPSCs start lacking proteasome activity and expression upon differentiation into neural cells, an occurrence which appears to be dependent on FOXO4, which is downregulated during differentiation. Such a downregulation appeared to be dependent on the enhanced activation of Akt, a serine-threonine kinase which acts as an upstream regulator of FOXOs by mediating their clearance, in HD iPSC-derived neurons. However, activated and total Akt levels strongly vary among different HD experimental models adopted and they were reported to be reduced in a rat HD model and in post-mortem brain extracts from patients withHD (Colin et al., 2005). Thus, further studies are demanded to address the relevance of this key metabolic pathway in preserving the PN in HD.", "latex": null, "type": "figure"}, "FIGREF25": {"text": "London et   al., 2013). Clinical and molecular investigation into this highly specialised nervous tissue has been long considered promising to search for early diagnostic and prognostic bio-markers of CNS disorders, such as AD, through non-invasive approaches. The identification of either quantifiable metabolic by-products, released in main eye fluids (e.g., vitreous, humour aqueous, tears), or of ultra-structural alterations pathognomonic of a given diseases would fulfil this clinical opportunity.With respect to the second point, non-invasive imaging approaches, such as (i) retinal fiber layer imaging with spectral domain optical coherence tomography (OCT), (ii) Visual Evoked Potentials (VEPs) and (iii) Doppler haemodynamic parameters of retinal veins(Parisi et al., 2001; Berisha et   al., 2007;Iseri et al., 2006; Dehabadi et al., 2014), have been already used to detect early morphological alterations in AD subjects and the advancement in imaging techniques will certainly allow to improve the sensibility and specificity of the proposed diagnostic tools.Conversely, the identification of biomarkers in eye fluids is still devoid of solid evidences and a much greater knowledge of the retina metabolism is required to address this task. However, research on this topic is limited by technical and histological issues, namely (a) the difficulty inisolating vital retina tissue from human post-mortem explants, and, mostly, (b) the technical inability in obtaining homogeneous primary cultures of individual retina cells. In fact, retina is arranged into complex three-dimensional layers in the posterior segment of the eye populated by (i) photoreceptor cells (i.e., rod and cones), which carry out the physical to chemical transduction of the light stimulus during vision, (ii) bi-polar cells, which transduce rod and cones signal to (iii) Retinal Ganglion Cells (RGCs) which, finally, convey this information to the visual cortex through the optic nerve their axons generate (Belenky et al., 2003; Lobanova et al., 2018). In addition, optimization of the light stimulus perception and transduction along with cells nourishment and survey of tissue homeostasis is carried out by a multitude of different cell lineages (i.e., amacrine J o u r n a l P r e -p r o o f cells, horizontal cells, retinal pigment epithelium, muller glia cells), which lie in the retina layers.An extensive ultrastructural organization of the retina and other segments of the eye is provided elsewhere(Gupta et al., 2016;Nag et al., 2012).Being terminally differentiated, photoreceptors, bi-polar cells and RGC, like any other post-mitotic cell, are vulnerable to proteostasis unbalance which may originate from either inherited or acquired disorders. A clearcut example are the metabolic complications of glaucoma and diabetic retinopathy (DR), discussed below to a greater detail, and the inheritance of mutated alleles of proteins, either tissue specific (e.g., rhodopsin, a protein which sense light in photoreceptors) or not (i.e., optineurin), which pose an amyloidogenic threat in retinal degenerative diseases and genetic variants of glaucoma, respectively(Lobanova et al., 2018;Swarup and Sayyad, 2018;Minegishi et al., 2016;Shen et al., 2011;Yao et al., 2018; Fernandez-Godino et al., 2018;Piippo et al., 2018;   Felszeghy et al., 2019;Shen et al., 2019;Sirohi et al., 2016;Ying et al., 2015;Shen et al., 2015;   Caballero et al., 2004; Caballero et al., 2003). Furthermore, the physiological enhanced metabolism of this tissue is sustained through the maintenance of a lipid profile extremely rich in long-chain poly-unsaturated fatty acids and very long chain poly-unsaturated fatty acids for membrane stability, and a high O 2 tension which are both sources of ROS production, proteo-toxicity, lipid peroxidation and membrane damage(Gorusupudi et al., 2016) .Whilst autophagy activation shows controversial issues, being also an apoptosis inducer in photoreceptors after prolonged proteo-toxicity, such as in models of inherited retinal degeneration, UPS activation appears to bring about only metabolic benefits(Yao et al., 2018; Blasiak et al.,   2019)  inasmuch proteasome loss leads to pathogenic events. Accordingly, proteasome pharmacological inhibition in rodents quickly turns out in retina degeneration. Nonetheless, a deepening on the molecular insights of UPS into the retina would help addressing several unresolved issues regarding UPS biology. In fact, highly specific mechanisms of regulation of protein turn-over are supposed to have evolved since metabolic activity follows a circadian rhythm with alternance of light and dark hours. Such an alternance is mirrored by a specular overall proteolytic burden and the molecular clock(s), which are finalized to turn the UPS off once light hours are over are unknown. No evidence for recruitment of specific PIPs and/or post-translational modification of UPS members is reported, but their identification might pave the road to novel mechanisms of regulation of proteasome proteolytic activity", "latex": null, "type": "figure"}, "FIGREF26": {"text": "Interestingly, whilst MeCP2 is ubiquitous in human tissues and maximally abundant in the CNS, it is poorly J o u r n a l P r e -p r o o f expressed in the retina and this may outline the absence of morphological and functional alterations of the retina and the visual pathways in this disease. It has been recently unveiled that primary fibroblasts, isolated from skin biopsies of RTT subjects harbouring non-sense MeCP2 mutations, suffer from a defective proteasome biogenesis (see Section 2.2.2) due to the MeCP2 dependent down-regulation of PAC1 and PAC2 along with the \u03b17 subunit of 20S (Sbardella et al., 2020). Upon MeCP2 silencing, this defect shows up in human neuron-derived cells envisaging a general contribution of this transcription regulator in proteasome biogenesis. Thus, molecular investigation into retina might help addressing unresolved issues about the contribution of individual proteasome assemblies in PN and in immune responses and further clarify the transcriptional and molecular dynamics of proteasome biogenesis. Among the neuro-degenerative eye disorders leading to irreversible blindness, which display the highest prevalence in western countries, there are (a) diabetic retinopathy (DR), that is a microvascular complication of diabetes, and (b) glaucoma. The clinical and epidemiological features", "latex": null, "type": "figure"}, "FIGREF27": {"text": "Disease etiology displays multi-factorial profile, wherefore genetic and acquired factors concur in determining its onset and progression. Among the acquired factors, redox imbalance and increased Intraocular Pressure (IOP) are likely the most relevant ones. In POAG, IOP increase is sustained especially through a pathogenic mechanism linked to the altered metabolism of an endothelial-like cell histo-type called Trabecular Meshwork Cell (TMC). TMCs synthesize and secrete the trabecular meshwork (TM), a specialized form of extracellular matrix localized in the anterior segment of the eye (at the sclero-corneal limit), which drains the aqueous humour, a fluid which shapes the eye-globe and nourishes the lining cells(Agarwal et al., 2019;Weinreb et al., 2014).Upon metabolic dysregulation, TMs acquire a senescent-like phenotype and display enhanced apoptosis which leads to a pathological remodelling of TM associated to an obstruction for the outflow of aqueous humor(Agarwal et al., 2019;Weinreb et al., 2014;Micera et al., 2016;Vernazza et al., 2019). This brings about the increase in intraocular pressure (IOP) thereby exerting J o u r n a l P r e -p r o o f a mechanical compression of the retina and optic nerve, localized in the posterior eye, ultimately", "latex": null, "type": "figure"}, "FIGREF28": {"text": "Systemic administration of oleuropein in pigs increased 20S activity in the subcortical white matter, reducing the damaged proteins accumulation after hypoxia and hypothermia and protecting the myelin (Polan et al., 2018). The triterpene betulinic acid, extracted from the lipid fraction of the algae Phaeodactylum tricornutum and of many other medicinal plants, activates preferentially the CT-L activity (Huang and Chen, 2007) with minor effects on T-L and PGCH-L activities. Some neuroprotective effects are reported in the transgenic C. elegans PD model, where betulinic acid decreased \u03b1-synuclein accumulation and the 6-hydroxydopamine-induced dopaminergic neuron degeneration.", "latex": null, "type": "figure"}, "FIGREF29": {"text": "beta cells. Recently, fatty acid derivatives have been designed to obtain gate-opening 20S stimulators with drug-like properties (Coleman, 2019). Using an arachidonic acid derivative AM-404, a very potent but toxic molecule, a series of molecules containing the aminophenol head group linked to aliphatic chains of varying length and degree of unsaturation have been synthesized and characterized. Their effect on the 20S activity indicates that, beside the chain length, saturated chains are generally not able to stimulate the activity of the 20S, while the most important structural J o u r n a l P r e -p r o o f feature useful to induce the stimulator activity on 20S, is the cis-double bond in the carbon chain.", "latex": null, "type": "figure"}, "FIGREF30": {"text": "or see Figs. 5A and 6A inSantoro et al., 2019). MALDI-MS experiments, performed using as a substrate A\u03b21-28, a water-soluble fragment of the amyloid peptide, further demonstrated that aminopyrine may enhance the rate of peptide degradation. Cell viability assays, carried out on differentiated SH-SY5Y neuroblastoma cells, underscored the neuroprotective properties of aminopyrine, and further experiments, conducted in the presence of the proteasome inhibitor bortezomib, demonstrated that aminopyrine rescues neuron-like cells from", "latex": null, "type": "figure"}, "FIGREF31": {"text": "The most studied models for SARS-CoV infection encompass: (i) original strains of SARS-CoV isolated from human subjects for infection of cell cultures in vitro; (ii) the Coronavirus Mouse Hepatitis virus (MHV) infection in murine models. MHV belongs to the same coronavirus genus of SARS-CoV and displays significant similarity concerning both structural features and pathogenesis,", "latex": null, "type": "figure"}, "FIGREF32": {"text": "in 19S particles; as a consequence, proteasome inhibition would appear as a strategy to halt the antigenic processing of virus proteins. If so, this process should be properly J o u r n a l P r e -p r o o f balanced, since proteasome activity is further relevant for advancement of cell cycle, especially G1-S transition which allows the virus to replicate.", "latex": null, "type": "figure"}, "FIGREF33": {"text": "ineffective in the assembly of virus(Raaben et al., 2010a; Raaben et al., 2010b). Although proteasome inhibition appears ineffective in the assembly of virus(Raaben et al., 2010a; Raaben et   al., 2010b), the role of the UPS in the virus infectious cycle is a relevant topic, and its putative role was suggested to rely in M-calpain rather than proteasome inhibition(Schneider et al., 2012). What looks more convincing is that the UPS plays a key role in handling the immune response to the pathogen, but also in the aberrant inflammatory response the virus may elicit.From the first point of view, bortezomib treatment increased disease progression in the liver of mice infected by MHV, underscoring the relevance of the protective role UPS in inflammatory response against the viral agent (Raaben et al., 2010b). Several independent investigations on different microbial pathogens J o u r n a l P r e -p r o o f", "latex": null, "type": "figure"}, "FIGREF34": {"text": "Recent studies have shown that different kinases, such as CaMKII, PKG, DYRK2 and PKA, induce the phosphorylation of proteasome subunits. In particular, the activation of PKA, which follows the increase of cAMP level, results in the phosphorylation of serine14 of Rpn6, leading to proteasome activity enhancement (VerPlank andGoldberg, 2018). In vitro and in vivo studies have shown that a series of hormones with J o u r n a l P r e -p r o o f different biological functions, spanning from energy control (i.e., glucagon and epinephrine) to water resorption (i.e., antidiuretic hormone), stimulate adenylate cyclase, thus raising cAMP level and enhancing, through the Rpn6 phosphorylation, degradation by 26S proteasome of short-lived regulatory proteins and/or damaged proteins (VerPlank et al., 2019). These findings suggest that proteasome activation mediated by CAMKII and cAMP-PKA could be a common cellular mechanism to answer a series of endocrine stimuli which, inducing a quick destruction of regulatory and/or damaged proteins, should help cells to adapt their proteome to the novel conditions determined by the hormones exposure(VerPlank et al., 2019). O-linked Nacetylglucosamine (O-GlcNAc) is a post-translational modification that occurs at serine or threonine residues, which are also a target site of phosphorylation. It is catalyzed by the enzyme Olinked N-acetylglucosamine transferase, which modulates the addition of a GlcNAc moiety to target", "latex": null, "type": "figure"}, "FIGREF35": {"text": "Structure of 20S.", "latex": null, "type": "figure"}, "FIGREF36": {"text": "Overall organization of the proteasome 26S particle.Left: the \"Core Particle\" (20S proteasome) is represented as protein ribbons, in yellow and magenta the two \u03b1-subunit rings, in blue and green the two \u03b2-subunit rings. The two regulatory particles (19S proteasome), attached on both ends of the 20S particle, are represented as protein ribbons. The group of regulatory AAA-ATPases (Rpt1-6) are coloured in dark and pale green, the non-ATPase regulators (Rpn) are coloured in violet and orange. Right: close-up of the 26S regulatory particle with the various non-ATPase subunits highlighted and labelled. The particle is shown from various point of view: on the top panel it is shown from the top; on the lower panel two opposite side views are shown.", "latex": null, "type": "figure"}, "FIGREF37": {"text": "Regulation of NF-kB/E2F/Rb and p53/p21 pathways by proteasome.", "latex": null, "type": "figure"}, "FIGREF38": {"text": "Proteasome binding structures of PIs. The structures of proteasome binding to carfilzomib (panel A), bortezomib (panel B), Salinosporamide (marizomib) (panel C); ixazomib (panel D)", "latex": null, "type": "figure"}, "FIGREF39": {"text": "Aguileta, M. A., Korac, J., Durcan, T. M., Trempe, J.-F., Haber, M., Gehring, K., Elsasser, S., Waidmann, O., Fon, E. A., & Husnjak, K. (2015a). The E3 ubiquitin ligase parkin is recruited to the 26 S proteasome via the proteasomal ubiquitin receptor Rpn13. The Journal of Biological Chemistry, 290(12), 7492-7505. https://doi.org/10.1074/jbc.M114.614925 Akopian, T. N., Kisselev, A. F., & Goldberg, A. L. (1997). Processive degradation of proteins and other catalytic properties of the proteasome from Thermoplasma acidophilum. The Journal of Biological Chemistry, 272(3), 1791-1798. https://doi.org/10.1074/jbc.272.3.1791 Al Mamun, A., Uddin, M. S., Kabir, M. T., Khanum, S., Sarwar, M. S., Mathew, B., Rauf, A., Ahmed, M., & Ashraf, G. M. (2020). Exploring the Promise of Targeting Ubiquitin-Lindblad, A., Kolstad, A., Laurell, A., R\u00e4ty, R., Gr\u00f8nbaek, K., Sundberg, J., Pedersen, L. B., Ralfkiaer, E., Karjalainen-Lindsberg, M.-L., Sundstr\u00f6m, C., Ehinger, M., Geisler, C., & Jerkeman, M. (2016", "latex": null, "type": "figure"}, "FIGREF40": {"text": "J. B., & Cohen, G. M. (2002). The proteasome: a novel target for cancer chemotherapy. Leukemia, 16(4), 433-443. https://doi.org/10.1038/sj.leu.2402417 Alsina, M., Trudel, S., Furman, R. R., Rosen, P. J., O'Connor, O. A., Comenzo, R. L., Wong, A., Kunkel, L. A., Molineaux, C. J., & Goy, A. (2012). A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 18(17), 4830-4840. https://doi.org/10.1158/1078-0432.CCR-11-3007 Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., & Zoghbi, H. Y. (1999). Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nature Genetics, 23(2), 185-188. https://doi.org/10.1038/13810 Amor-Guti\u00e9rrez, O., Costa-Rama, E., Arce-Varas, N., Mart\u00ednez-Rodr\u00edguez, C., Novelli, A., Fern\u00e1ndez-S\u00e1nchez, M. T., & Costa-Garc\u00eda, A. (2020). Competitive electrochemical immunosensor for the detection of unfolded p53 protein in blood as biomarker for Alzheimer's disease. Analytica Chimica Acta, 1093, 28-34. https://doi.org/10.1016/j.aca.2019.09.042 Anandhan, A., Rodriguez-Rocha, H., Bohovych, I., Griggs, A. M., Zavala-Flores, L., Reyes-Reyes, E. M., Seravalli, J., Stanciu, L. A., Lee, J., Rochet, J.-C., Khalimonchuk, O., & Franco, R. (2015). Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways. Neurobiology of Disease, 81, 76-92. https://doi.org/10.1016/j.nbd.2014.11.018 Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. (2020). The proximal origin of SARS-CoV-2. Nature Medicine, 26(4), 450-452. https://doi.org/10.1038/s41591-020-0820-9 Anisimov, S., Takahashi, M., Kakihana, T., Katsuragi, Y., Kitaura, H., Zhang, L., Kakita, A., & Fujii, M. (2019). G3BP1 inhibits ubiquitinated protein aggregations induced by p62 and USP10. Scientific Reports, 9(1), 12896. https://doi.org/10.1038/s41598-019-46237-1 Ao, L., Reichel, D., Hu, D., Jeong, H., Kim, K. B., Bae, Y., & Lee, W. (2015). Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines. The Journal of Pharmacology and Experimental Therapeutics, 355(2), 168-173. https://doi.org/10.1124/jpet.115.226993 M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., Roussel, M., Payen, C., Mathiot, C., Fermand, J. P., Meuleman, N., Rollet, S., Maglio, M. E., Zeytoonjian, A. A., Weller, E. A., \u2026 Moreau, P. (2017). Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. New England Journal of Medicine, 376(14), 1311-1320. https://doi.org/10.1056/NEJMoa1611750 Aubin-Tam, M.-E., Olivares, A. O., Sauer, R. T., Baker, T. A., & Lang, M. J. (2011). Singlemolecule protein unfolding and translocation by an ATP-fueled proteolytic machine. Cell, 145(2), 257-267. https://doi.org/10.1016/j.cell.2011.03.036 Avet-Loiseau, H., Fonseca, R., Siegel, D., Dimopoulos, M. A., \u0160pi\u010dka, I., Masszi, T., H\u00e1jek, R., Rosi\u00f1ol, L., Goranova-Marinova, V., Mihaylov, G., Maisnar, V., Mateos, M.-V., Wang, M., Niesvizky, R., Oriol, A., Jakubowiak, A., Minarik, J., Palumbo, A., Bensinger, W., \u2026 Moreau, P. (2016). Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood, 128(9), 1174-1180. https://doi.org/10.1182/blood-2016-03-707596 Baden, L. R., & Rubin, E. J. (2020). SARS-Cov-2 -The Search for Effective Therapy. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMe2005477 Badros, A. Z., Vij, R., Martin, T., Zonder, J. A., Kunkel, L., Wang, Z., Lee, S., Wong, A. F., & Niesvizky, R. (2013). Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia, 27(8), 1707-1714. https://doi.org/10.1038/leu.2013.29 Bajorek, M., & Glickman, M. H. (2004). Keepers at the final gates: regulatory complexes and gating of the proteasome channel. Cellular and Molecular Life Sciences: CMLS, 61(13), 1579-1588. https://doi.org/10.1007/s00018-004-4131-y Bajorek, Monika, Finley, D., & Glickman, M. H. (2003). Proteasome disassembly and downregulation is correlated with viability during stationary phase. Current Biology: CB, 13(13), 1140-1144. https://doi.org/10.1016/s0960-9822(03)00417-2 Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008). Adapting proteostasis for disease intervention. Science (New York, N.Y.), 319(5865), 916-919. https://doi.org/10.1126/science.1141448 Banerjee, S., Ji, C., Mayfield, J. E., Goel, A., Xiao, J., Dixon, J. E., & Guo, X. (2018). Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosineregulated kinase 2. Proceedings of the National Academy of Sciences of the United States of America, 115(32), 8155-8160. https://doi.org/10.1073/pnas.1806797115 Banks, P. M., Chan, J., Cleary, M. L., Delsol, G., De Wolf-Peeters, C., Gatter, K., Grogan, T. M., Harris, N. L., Isaacson, P. G., & Jaffe, E. S. (1992). Mantle cell lymphoma. A proposal for J o u r n a l P r e -p r o o f Bersuker, K., & Olzmann, J. A. (2017). Establishing the lipid droplet proteome: Mechanisms of lipid droplet protein targeting and degradation. Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids, 1862(10 Pt B), 1166-1177. https://doi.org/10.1016/j.bbalip.2017.06.006 Besse, A., Stolze, S. C., Rasche, L., Weinhold, N., Morgan, G. J., Kraus, M., Bader, J., Overkleeft, H. S., Besse, L., & Driessen, C. (2018). Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia, 32(2), 391-401. https://doi.org/10.1038/leu.2017.212 Bhat, K. P., Yan, S., Wang, C.-E., Li, S., & Li, X.-J. (2014). Differential ubiquitination and degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A. Proceedings of the National Academy of Sciences of the United States of America, 111(15), 5706-5711. https://doi.org/10.1073/pnas.1402215111", "latex": null, "type": "figure"}, "FIGREF41": {"text": ", A. V., Aujay, M., Kirk, C. J., Bandi, M., Ciccarelli, B., Raje, N.,Richardson,  P., & Anderson, K. C. (2010). A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.Blood, 116(23),4906-4915.  https://doi.org/10.1182/blood-2010-04-276626    Chauhan, D.,Singh, A. V., Ciccarelli, B., Richardson, P. G., Palladino, M. A., & Anderson, K. C.  (2010). Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood, 115(4),834-845.  https://doi.org/10.1182/blood-2009-03-213009    Chauhan, D.,Tian, Z., Zhou, B., Kuhn, D., Orlowski, R., Raje, N., Richardson, P., & Anderson, K.  C. (2011). In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clinical Cancer Research: //doi.org/10.1101/cshperspect.a004374Chen, D., Cui, Q. C.,Yang, H., & Dou, Q. P. (2006). Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.Cancer Research, 66(21), 10425-10433. Scopus. https://doi.org/10.1158/0008-5472.CAN-06-2126 Chen, D., Daniel, K.J., Chen, M.S., Kuhn, D.J., Landis-Piwowar, K.R. & Dou, Q.P. (2005) Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochemical Pharmacology, 69(10), 1421-1432. Chen, P., & Hochstrasser, M. (1995). Biogenesis, structure and function of the yeast 20S proteasome. The EMBO Journal, 14(11), 2620-2630. Chen, P., & Hochstrasser, M. (1996). Autocatalytic subunit processing couples active site formation X., Barton, L. F., Chi, Y., Clurman, B. E., & Roberts, J. M. (2007). Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Molecular Cell, 26(6), 843-852. https://doi.org/10.1016/j.molcel.2007.05.022 Chen, Y.-J., Wu, H., & Shen, X.-Z. (2016). The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy. Cancer Letters, 379(2), 245-252. https://doi.org/10.1016/j.canlet.2015.06.023 Chen, Z., Hagler, J., Palombella, V. J., Melandri, F., Scherer, D., Ballard, D., & Maniatis, T. (1995). Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitinproteasome pathway. Genes & Development, 9(13), 1586-1597. https://doi.org/10.1101/gad.9.13.1586 J o u r n a l P r e -p r o o f Ciechanover, Aaron, Hod, Y., & Hershko, A. (2012). A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. 1978. Biochemical and Biophysical Research Communications, 425(3), 565-570. https://doi.org/10.1016/j.bbrc.2012.08.025 Ciechanover, Aaron. (2005). Proteolysis: from the lysosome to ubiquitin and the proteasome. Nature Reviews. Molecular Cell Biology, 6(1), 79-87. https://doi.org/10.1038/nrm1552 Ciechanover, Aaron. (2013). Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Bioorganic & Medicinal Chemistry, 21(12), 3400-3410. https://doi.org/10.1016/j.bmc.2013.01.056 Cliffe, R., Sang, J. C., Kundel, F., Finley, D., Klenerman, D., & Ye, Y. (2019). Filamentous Aggregates Are Fragmented by the Proteasome Holoenzyme. Cell Reports, 26(8), 2140-2149.e3. https://doi.org/10.1016/j.celrep.2019.01.096 Coelho, S. C., Almeida, G. M., Santos-Silva, F., Pereira, M. C., & Coelho, M. A. N. (2016). Enhancing the efficiency of bortezomib conjugated to pegylated gold nanoparticles: an in vitro study on human pancreatic cancer cells and adenocarcinoma human lung alveolar basal R. A., Muli, C. S., Zhao, Y., Bhardwaj, A., Newhouse, T. R., & Trader, D. J. (2019). Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators. Bioorganic and Medicinal Chemistry Letters, 29(3), 420-423. https://doi.org/10.1016/j.bmcl.2018.12.030 Colledge, M., Snyder, E. M., Crozier, R. A., Soderling, J. A., Jin, Y., Langeberg, L. K., Lu, H., Bear, M. F., & Scott, J. D. (2003). Ubiquitination regulates PSD-95 degradation and AMPA G. A., & Goldberg, A. L. (2017). The Logic of the 26S Proteasome. Cell, 169(5), 792-806. https://doi.org/10.1016/j.cell.2017.04.023 Comer, F. I., & Hart, G. W. (2000). O-Glycosylation of Nuclear and Cytosolic Proteins DYNAMIC INTERPLAY BETWEEN O-GlcNAc ANDO-PHOSPHATE. Journal of Biological Chemistry, 275(38), 29179-29182. https://doi.org/10.1074/jbc.R000010200 Corpas, R., Gri\u00f1\u00e1n-Ferr\u00e9, C., Rodr\u00edguez-Farr\u00e9, E., Pall\u00e0s, M., & Sanfeliu, C. (2019). Resveratrol Induces Brain Resilience Against Alzheimer Neurodegeneration Through Proteostasis Enhancement. Molecular Neurobiology, 56(2), 1502-1516. https://doi: 10.1007/s12035-018-1157-y. Coughlin, K., Anchoori, R., Iizuka, Y., Meints, J., MacNeill, L., Vogel, R. I., Orlowski, R. Z., Lee, M. K., Roden, R. B., & Bazzaro, M. (2014). Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer in Vitro and in Vivo Via Exacerbating Unfolded Protein Responses. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 20(12), 3174-3186. https://doi.org/10.1158/1078-0432.CCR-13-2658 Coux, O., Tanaka, K., & Goldberg, A. L. (1996). Structure and functions of the 20S and 26S proteasomes. Annual Review of Biochemistry, 65, 801-847. https://doi.org/10.1146/annurev.bi.65.070196.004101", "latex": null, "type": "figure"}, "FIGREF42": {"text": ", 10825-10838. https://doi.org/10.1074/jbc.M512786200 Cron, K. R.,Zhu, K., Kushwaha, D. S., Hsieh, G., Merzon, D., Rameseder, J., Chen, C. C.,  D'Andrea, A. D., & Kozono, D. (2013). Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer. PloS One, 8(9), e73710. https://doi.org/10.1371/journal.pone.0073710 Cuanalo-Contreras, K., & Moreno-Gonzalez, I. (2019). Natural products as modulators of the proteostasis machinery: Implications in neurodegenerative diseases. International Journal of Molecular Sciences, 20(19). https://doi.org/10.3390/ijms20194666 Cundiff, M. D., Hurley, C. M., Wong, J. D., Boscia, J. A., Bashyal, A., Rosenberg, J., Reichard, E. L., Nassif, N. D., Brodbelt, J. S., & Kraut, D. A. (2019). Ubiquitin receptors are required for substrate-mediated activation of the proteasome's unfolding ability. Scientific Reports, 9(1), 14506. https://doi.org/10.1038/s41598-019-50857-y D\u00e4chsel, J. C., L\u00fccking, C. B., Deeg, S., Schultz, E., Lalowski, M., Casademunt, E., Corti, O., Hampe, C., Patenge, N., Vaupel, K., Yamamoto, A., Dichgans, M., Brice, A., Wanker, E. E., Kahle, P. J., & Gasser, T. (2005). Parkin interacts with the proteasome subunit alpha4. FEBS Letters, 579(18), 3913-3919. https://doi.org/10.1016/j.febslet.2005.06.003 Dahlmann, B. (2016). Mammalian proteasome subtypes: Their diversity in structure and function. Archives of Biochemistry and Biophysics, 591, 132-140. https://doi.org/10.1016/j.abb.2015.12.012 Dahlmann, B., Becher, B., Sobek, A., Ehlers, C., Kopp, F., & Kuehn, L. (1993) In vitro activation of the 20S proteasome. Enzyme & Protein, 47(4-6), 274-284. https:// doi:10.1159/000468685 Dahlmann, B., Rutschmann. M., Kuehn, L., & Reinauer, H. (1985) Activation of the multicatalytic proteinase from rat skeletal muscle by fatty acids or sodium dodecyl sulphate. Biochemical Journal, 228(1),171-177. https://doi:10.1042/bj2280171", "latex": null, "type": "figure"}, "FIGREF43": {"text": "-associated Protein Ecm29 Inhibits Proteasomal ATPase Activity and in Vivo Protein Degradation by the Proteasome. The Journal of Biological Chemistry, 288(41), 29467-29481. https://doi.org/10.1074/jbc.M113.491662 de la Pe\u00f1a, A. H., Goodall, E. A., Gates, S. N., Lander, G. C., & Martin, A. (2018). Substrateengaged 26S proteasome structures reveal mechanisms for ATP-hydrolysis-driven translocation. Science (New York, N.Y.), 362(6418). https://doi.org/10.1126/science.aav0725 de Poot, S. A. H., Tian, G., & Finley, D. (2017). Meddling with fate: doi.org/10.1016/j.jmb.2017.09.015 de Tullio, M. B., Castelletto, V., Hamley, I. W., Martino Adami, P. V., Morelli, L., & Casta\u00f1o, E. M. (2013). Proteolytically Inactive Insulin-Degrading Enzyme Inhibits doi.org/10.1371/journal.pone.0059113 de Vrij, F. M. S., Fischer, D. F., van Leeuwen, F. W., & Hol, E. M. (2004). Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Progress in Neurobiology, 74(5), 249-270. https://doi.org/10.1016/j.pneurobio.2004.10.001 Dehabadi, M. H., Davis, B. M., Wong, T. K., & Cordeiro, M. F. (2014). //doi.org/10.2217/nmt.14.19 Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., Shenk, K. D., Smyth, M. S., Sun, C. M., Vallone, M. K., Woo, T. M., Molineaux, C. J., & Bennett, M. K. (2007). Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Research, 67(13), 6383-6391. https://doi.org/10.1158/0008-5472.CAN-06-4086 Deriziotis, P., Andr\u00e9, R., Smith, D. M., Goold, R., Kinghorn, K. J., Kristiansen, M., Nathan, J. A., Rosenzweig, R., Krutauz, D., Glickman, M. H., Collinge, J., Goldberg, A. L., & Tabrizi, S. J. (2011). Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry. The EMBO Journal, 30(15), 3065-3077. https://doi.org/10.1038/emboj.2011.224 Desch\u00eanes-Simard, X., Lessard, F., Gaumont-Leclerc, M.-F., Bardeesy, N., & Ferbeyre, G. M. A., Goldschmidt, H., Niesvizky, R., Joshua, D., Chng, W.-J., Oriol, A., Orlowski, R. Z., Ludwig, H., Facon, T., Hajek, R., Weisel, K., Hungria, V., Minuk, L., Feng, S., Zahlten-Kumeli, A., Kimball, A. S., & Moreau, P. (2017). Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-M. A., Mateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Shpilberg, O., Kropff, M., Spicka, I., Palumbo, A., Wu, K. L., Esseltine, D.-L., Liu, K., Deraedt, W., Cakana, A., Van De Velde, H., & San Miguel, J. F. (2011). Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. European Journal of Haematology, 86(1), 23-31. https://doi.org/10.1111/j.1600-0609.2010.01533.x Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., H\u00e1jek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosi\u00f1ol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., M. A., Roussou, M., Gavriatopoulou, M., Psimenou, E., Ziogas, D., Eleutherakis-Papaiakovou, E., Fotiou, D., Migkou, M., Kanellias, N., Panagiotidis, I., Ntalianis, A., Papadopoulou, E., Stamatelopoulos, K., Manios, E., Pamboukas, C., Kontogiannis, S., Terpos, E., & Kastritis, E. (2017). Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Advances, 1(7), 449-454. https://doi.org/10.1182/bloodadvances.2016003269 Dimopoulos, M., Siegel, D., White, D. J., Boccia, R., Iskander, K. S., Yang, Z., Kimball, A. S., Mezzi, K., Ludwig, H., & Niesvizky, R. (2019). Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood, 133(2), 147-155. https://doi.org/10.1182/blood-2018-06-860015 Ditzel, L., Huber, R., Mann, K., Heinemeyer, W., Wolf, D. H., & Groll, M. (1998). Conformational constraints for protein self-cleavage in the proteasome. Journal of Molecular Biology, 279(5), 1187-1191. https://doi.org/10.1006/jmbi.1998.1818 Djakovic, S. N., Marquez-Lona, E. M., Jakawich, S. K., Wright, R., Chu, C., Sutton, M. A., & Patrick, G. N. (2012). Phosphorylation of Rpt6 regulates synaptic strength in hippocampal neurons. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 32(15), 5126-5131. https://doi.org/10.1523/JNEUROSCI.4427-11.2012 Djakovic, S. N., Schwarz, L. A., Barylko, B., DeMartino, G. N., & Patrick, G. N. (2009). Regulation of the proteasome by neuronal activity and calcium/calmodulin-//doi.org/10.1074/jbc.M109.021956 Djuranovic, S., Hartmann, M. D., Habeck, M., Ursinus, A., Zwickl, P., Martin, J., Lupas, A. N., & Zeth, K. (2009). Structure and activity of the N-terminal substrate recognition domains in //doi.org/10.1016/j.molcel.2009.04.030 Dong, Y., Zhang, S., Wu, Z., Li, X., Wang, W. L., Zhu, Y., Stoilova-McPhie, S., Lu, Y., Finley, D., & Mao, Y. (2019). Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome. Nature, 565(7737), 49-55. https://doi.org/10.1038/s41586-018-0736-4 Dong, Z., & Cui, H. (2018). The Autophagy-Lysosomal Pathways and Their Emerging Roles in Modulating Proteostasis in Tumors. Cells, 8(1). https://doi.org/10.3390/cells8010004 Doorduijn, J. K., Zijlstra, J. M., Lugtenburg, P. J., Kersten, M. J., B\u00f6hmer, L. H., Minnema, M. C., MacKenzie, M. A., Kooij, R. van M., Jongh, E. de, Snijders, T. J. F., Weerdt, O. de, Gelder, M. van, Hoogendoorn, M., Leys, R. B. L., Kibbelaar, R. E., Jong, D. de, Chitu, D. A., Veer, M. B. V., & Kluin-Nelemans, H. C. (n.d.). Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. British Journal of Haematology, n/a(n/a). https://doi.org/10.1111/bjh.16567 Dorsey, B. D., Iqbal, M., Chatterjee, S., Menta, E., Bernardini, R., Bernareggi, A., Cassar\u00e0, P. G., D'Arasmo, G., Ferretti, E., De Munari, S., Oliva, A., Pezzoni, G., Allievi, C., Strepponi, I., Ruggeri,", "latex": null, "type": "figure"}, "FIGREF44": {"text": ", 896-903. https://doi.org/10.1080/10428194.2017.1365855 DU, H.-P., YANG, Q.-Q., & ZHANG, Y. (2016). Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature. Oncology Letters, 11(3), 2310-2314. https://doi.org/10.3892/ol.2016.4213 Dur\u00e3es, F., Pinto, M., & Sousa, E. (2018). Old Drugs as New Treatments for Neurodegenerative Diseases. Pharmaceuticals, 11(2), 44. https://doi.org/10.3390/ph11020044 Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., Orlowski, R. Z., Barlogie, B., & Dispenzieri, A. (2017). Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet (London, England), 389(10068), 519-527. https://doi.org/10.1016/S0140-6736(16)31594-X Dyson, H. J., & Wright, P. E. (2005). Intrinsically unstructured proteins and their functions. Nature Reviews. Molecular Cell Biology, 6(3), 197-208. https://doi.org/10.1038/nrm1589 Eberhardt, R., Birbamer, G., Gerstenbrand, F., Rainer, E., & Traegner, H. (1990). Citicoline in the treatment of Parkinson's disease. Clinical Therapeutics, 12(6), 489-495. Ebstein, F., Poli Harlowe, M. C., Studencka-Turski, M., & Kr\u00fcger, E. (2019). Contribution of the Unfolded Protein Response (UPR) to the Pathogenesis of Proteasome-//doi.org/10.3389/fimmu.2019.02756 Ehlinger, A., Park, S., Fahmy, A., Lary, J. W., Cole, J. L., Finley, D., & Walters, K. J. (2013). Conformational dynamics of the Rpt6 ATPase in proteasome assembly and Rpn14 binding. Structure (London, England: 1993), 21(5), 753-765. https://doi.org/10.1016/j.str.2013.02.021 Eisele, M. R., Reed, R. G., Rudack, T., Schweitzer, A., Beck, F., Nagy, I., Pfeifer, G., Plitzko, J. M., Baumeister, W., Tomko, R. J., & Sakata, E. (2018). Expanded Coverage of the 26S Proteasome Conformational Landscape Reveals Mechanisms of Peptidase Gating. Cell Reports, 24(5), 1301-1315.e5. https://doi.org/10.1016/j.celrep.2018.07.004 Elsasser, S., Chandler-Militello, D., M\u00fcller, B., Hanna, J., & Finley, D. (2004). Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome. The Journal of Biological Chemistry, 279(26), 26817-26822. https://doi.org/10.1074/jbc.M404020200 Toret, S., Vonk, W. I. M., & Frydman, J. (2013). Spatial sequestration of misfolded proteins by a dynamic chaperone pathway enhances cellular fitness during stress. Nature Cell Biology, 15(10), 1231-1243. https://doi.org/10.1038/ncb2838 Eskandari, S. K., Seelen, M. a. J., Lin, G., & Azzi, J. R. (2017). The immunoproteasome: An old player with a novel and emerging role in alloimmunity. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 17(12), 3033-3039. https://doi.org/10.1111/ajt.14435 Estrin, E., Lopez-Blanco, J. R., Chac\u00f3n, P., & Martin, A. (2013). Formation of an intricate helical bundle dictates the assembly of the 26S proteasome lid. Structure (London, England: 1993), 21(9), 1624-1635. https://doi.org/10.1016/j.str.2013.06.023 Etlinger, J. D., & Goldberg, A. L. (1977). A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proceedings of the National Academy of Sciences of the United States of America, 74(1), 54-58. https://doi.org/10.1073/pnas.74.1.54 Etlinger, J. D., & Goldberg, A. L. (1980). Control of protein degradation in reticulocytes and reticulocyte extracts by hemin. Journal of Biological Chemistry, 255(10), 4563-4568.", "latex": null, "type": "figure"}, "FIGREF45": {"text": ", 7751-7755. https://doi.org/10.1073/pnas.86.20.7751 Fabre, B., Lambour, T., Garrigues, L., Ducoux-Petit, M., Amalric, F., Monsarrat, B., Burlet-Schiltz, O., & Bousquet-Dubouch, M.-P. (2014). Label-free quantitative proteomics reveals the dynamics of proteasome complexes composition and stoichiometry in a wide range of human cell lines. Journal of Proteome Research, 13(6), 3027-3037. https://doi.org/10.1021/pr500193k Faiq, M. A., Wollstein, G., Schuman, J. S., & Chan, K. C. (2019). Cholinergic nervous system and glaucoma: From basic science to clinical applications. Progress in Retinal and Eye Research, 72, 100767. https://doi.org/10.1016/j.preteyeres.2019.06.003 Fan, J.-Y., Agyekum, B., Venkatesan, A., Hall, D. R., Keightley, A., Bjes, E. S., Bouyain, S., & Price, J. L. (2013). Noncanonical FK506-binding protein BDBT binds DBT to enhance its circadian function and forms foci at night. Neuron, 80(4), 984-996. https://doi.org/10.1016/j.neuron.2013.08.004Fardini, Y., Dehennaut, V., Lefebvre, T., & Issad, T. (2013). O-GlcNAcylation: A New Cancer Hallmark? Frontiers in Endocrinology, 4, 99. https://doi.org/10.3389/fendo.2013.00099 S., Viiri, J., Paterno, J. J., Hyttinen, J. M. T., Koskela, A., Chen, M., Leinonen, H., Tanila, H., Kivinen, N., Koistinen, A., Toropainen, E., Amadio, M., Smedowski, A., Reinisalo, M., Winiarczyk, M., Mackiewicz, J., Mutikainen, M., Ruotsalainen, A.-K., Kettunen, M., \u2026 Kaarniranta, K. (2019). Loss of NRF-2 and PGC-1\u03b1 genes leads to retinal pigment epithelium damage resembling dry age-related macular degeneration. Redox Biology, 20, 1-12. https://doi.org/10.1016/j.redox.2018.09.011 Fernandez-Godino, R., & Pierce, E. A. (2018). C3a triggers formation of sub-retinal pigment epithelium deposits via the ubiquitin proteasome pathway. Scientific Reports, 8(1), 9679. https://doi.org/10.1038/s41598-018-28143-0 Ferrara, N. (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews, 25(4), 581-611. https://doi.org/10.1210/er.2003-0027 Ferrara, N. (2005). VEGF as a therapeutic target in cancer. Oncology, 69 Suppl 3, 11-16. https://doi.org/10.1159/000088479 Ferrington, D. A., & Gregerson, D. S. (2012). Immunoproteasomes: structure, function, and antigen presentation. Progress in Molecular Biology and Translational Science, 109, 75-112. https://doi.org/10.1016/B978-0-12-397863-9.00003-1 Finley, D. (2009). Recognition and processing of ubiquitin-protein conjugates by the proteasome. //doi.org/10.1146/annurev.biochem.78.081507.101607 Finley, D., & Prado, M. A. (2019). The Proteasome and Its Network: Engineering for Adaptability. Cold Spring Harbor Perspectives in Biology, a033985. https://doi.org/10.1101/cshperspect.a033985 Finley, D., Chen, X., & Walters, K. J. (2016). Gates, Channels, and Switches: //doi.org/10.1016/j.tibs.2015.10.009 Finley, D., Chen, X., & Walters, K. J. (2016). Gates, channels, and switches: elements of the //doi.org/10.1016/j.tibs.2015.10.009 Fischer, D. F., De Vos, R. a. I., Van Dijk, R., De Vrij, F. M. S., Proper, E. A., Sonnemans, M. a. F., Verhage, M. C., Sluijs, J. A., Hobo, B., Zouambia, M., Steur, E. N. H. J., Kamphorst, W., Hol, E. M., & Van Leeuwen, F. W. (2003). Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. The FASEB Journal, 17(14), 2014-2024. https://doi.org/10.1096/fj.03-0205com Fisher, R. I., Dahlberg, S., Nathwani, B. N., Banks, P. M., Miller, T. P., & Grogan, T. M. (1995). A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood, 85(4), 1075-1082. the proteasome lid in Saccharomyces cerevisiae. Biochemical and Biophysical Research Communications, 396(4), 1048-1053. https://doi.org/10.1016/j.bbrc.2010.05.061 Funakoshi, M., Tomko, R. J., Kobayashi, H., & Hochstrasser, M. (2009). Multiple Assembly Chaperones Govern Biogenesis of the Proteasome Regulatory Particle Base. Cell, 137(5), 887-899. https://doi.org/10.1016/j.cell.2009.04.061 Furtado, M., Johnson, R., Kruger, A., Turner, D., & Rule, S. (2015). Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. British Journal of Haematology, 168(1), 55-62. https://doi.org/10.1111/bjh.13101 Gaczynska, M., & Osmulski, P. A. (2014). Harnessing Proteasome Dynamics and Allostery in doi.org/10.1016/j.tibs.2013.05.003 Labbadia, J., & Morimoto, R. I. (2015). The biology of proteostasis in aging and disease. Annual Review of Biochemistry, 84, 435-464. https://doi.org/10.1146/annurev-biochem-060614-033955 Lacal, P. M., & Graziani, G. (2018). Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and nonF. (2017). MHC class II expression and potential antigen-presenting cells in the retina during experimental autoimmune uveitis. Journal of Neuroinflammation, 14(1), 136. https://doi.org/10.1186/s12974-017-0915-5 Litwak, S. A., Wali, J. A., Pappas, E. G., Saadi, H., Stanley, W. J., Varanasi, L. C., Kay, T. W. H., Thomas, H. E., & Gurzov, E. N. (2015). Lipotoxic Stress Induces Pancreatic \u03b2-Cell Apoptosis through Modulation of Bcl-2 Proteins by the Ubiquitin-Proteasome System. Journal of Diabetes Research, 280615. https://doi.org/10.1155/2015/280615Liu, C.-W.,Li, X., Thompson, D., Wooding, K., Chang, T., Tang, Z., Yu, H., Thomas, P. J., &  DeMartino, G. N. (2006). ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome. Molecular Cell, 24(1), 39-50. https://doi.org/10.1016/j.molcel.2006.08.025 Liu, D. X., Fung, T. S., Chong, K. K.-L., Shukla, A., & Hilgenfeld, R. (2014). doi.org/10.1016/j.antiviral.2014.06.013 Liu, Y., Hettinger, C. L., Zhang, D., Rezvani, K., Wang, X., & Wang, H. (2014). The proteasome function reporter GFPu accumulates in young brains of the APPswe/PS1dE9 Alzheimer'Y., Qiao, F., Leiferman, P. C., Ross, A., Schlenker, E. H., & Wang, H. (2017). FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington'E. S., Finkelstein, S., Li, J., Travis, A. M., Hao, Y., Klingeborn, M., Skiba, N. P., Deshaies, R. J., & Arshavsky, V. Y. (2018). Increased proteasomal activity supports photoreceptor S., Kukushkin, N. V., & Goldberg, A. L. (2015). cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proceedings of the National Academy of Sciences of the United States of America, 112(52), E7176-7185. https://doi.org/10.1073/pnas.1522332112 Lombardo, M., Parravano, M., Serrao, S., Ducoli, P., Stirpe, M., & Lombardo, G. (2013). Analysis of retinal capillaries in patients with type 1 diabetes and nonproliferative diabetic retinopathy A., Benhar, I., & Schwartz, M. (2013). The retina as a window to the brain-from eye research to CNS disorders. Nature Reviews. Neurology, 9(1), 44-53. https://doi.org/10.1038/nrneurol.2012.227 J o u r n a l P r e -p r o o f", "latex": null, "type": "figure"}, "FIGREF46": {"text": ", 1580-1585. https://doi.org/10.1083/jcb.96.6.1580 Tanaka, K. (2009). The proteasome: Overview of structure and functions. Proceedings of the doi.org/10.2183/pjab.85.12 Tanaka, K., Yoshimura, T., Kumatori, A., Ichihara, A., Ikai, A., Nishigai, M., Kameyama, K., & Takagi, T. (1988). Proteasomes (multi-protease complexes) as 20 S ring-shaped particles in a variety of eukaryotic cells. The Journal of Biological Chemistry, 263(31), 16209-16217. Tanaka, Keiji. (2009). The proteasome: overview of structure and functions. //doi.org/10.2183/pjab.85.12 Tang, B., Seredenina, T., Coppola, G., Kuhn, A., Geschwind, D. H., Luthi-Carter, R., & Thomas, E. A. (2011). Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease. Neurobiology of Disease, 42(3), 459-467. https://doi.org/10.1016/j.nbd.2011.02.008", "latex": null, "type": "figure"}, "FIGREF47": {"text": ", 240-246. https://doi.org/10.1007/s00216-004-2697-8 Taromi, S., Lewens, F., Arsenic, R., Sedding, D., S\u00e4nger, J., Kunze, A., M\u00f6bs, M., Benecke, J., Freitag, H., Christen, F., Kaemmerer, D., Lupp, A., Heilmann, M., Lammert, H., Schneider, C.-P., Richter, K., Hummel, M., Siegmund, B., Burger, M., \u2026 Grabowski, P. (2017). Proteasome", "latex": null, "type": "figure"}, "FIGREF48": {"text": "Figure 2", "latex": null, "type": "figure"}, "FIGREF49": {"text": "Figure 3", "latex": null, "type": "figure"}, "FIGREF50": {"text": "Figure 4", "latex": null, "type": "figure"}, "TABREF0": {"text": "Currently, three clinically approved PIs are available, namely: (i) bortezomib (Velcade, recently introduced in the market also in its generic version) (approved in 2003 and 2004, by FDA and EMA, respectively), (ii) carfilzomib (Kyprolis) (approved in 2012 and 2015, by FDA and EMA, respectively), and (iii) the first oral proteasome inhibitor, ixazomib (Ninlaro) (approved in 2015 and 2016 by FDA and EMA, respectively)", "latex": null, "type": "table"}, "TABREF1": {"text": "FDA and EMA for the treatment of patients who had received at least two prior therapies, including bortezomib and an immunomodulatory drug.", "latex": null, "type": "table"}, "TABREF3": {"text": "A regional expansion of TOURMALINE-MM1 study in China population supported the clinical benefit of the ixazomib-containing triplet therapy, further reporting a significantly increase in OS (ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-desamethason: median OS 25.8 vs 15.8 months, after median follow-up of 20.2 and 19.1 months, respectively; HR= 0.419; P=0.001) (Hou et al.", "latex": null, "type": "table"}, "TABREF5": {"text": "Clinical trials with bortezomib in non-haematological cancers.* See https://clinicaltrials.gov/ , accessed April 27, 2020.", "latex": null, "type": "table"}, "TABREF6": {"text": "Clinical trials with carflizomb and ixazomib in non-haematological cancers. J o u r n a l P r e -p r o o f * See https://clinicaltrials.gov/ , accessed April 27, 2020.", "latex": null, "type": "table"}, "TABREF7": {"text": "Clinical trials with oprozomib, marizomib and delazomib. See https://clinicaltrials.gov/ , accessed April 27, 2020. Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y. T., Plamondon, L., & Stein, R. L. (1998). Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorganic & Medicinal Chemistry Letters, 8(4), 333-338. https://doi.org/10.1016/s0960-894x(98)00029-8 J o u r n a l P r e -p r o o f Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J., Destree, A., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999). Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research, 59(11), 2615-2622. Agarwal, R., Gupta, S. K., Agarwal, P., Saxena, R., & Agrawal, S. S. (2009). Current concepts in the pathophysiology of glaucoma. Indian Journal of Ophthalmology, 57(4), 257-266. https://doi.org/10.4103/0301-4738.53049 Agathocleous, A., Rohatiner, A., Rule, S., Hunter, H., Kerr, J. P., Neeson, S. M., Matthews, J., Strauss, S., Montoto, S., Johnson, P., Radford, J., & Lister, A. (2010). Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstr\u00f6m macroglobulinaemia. British Journal of Haematology, 151(4), 346-353. https://doi.org/10.1111/j.1365-2141.2010.08340.x Aggarwal, B. B. (2004). Nuclear factor-kappaB: the enemy within. Cancer Cell, 6(3), 203-208. https://doi.org/10.1016/j.ccr.2004.09.003 Aghdam, S. Y., Gurel, Z., Ghaffarieh, A., Sorenson, C. M., & Sheibani, N. (2013). High glucose and diabetes modulate cellular proteasome function: Implications in the pathogenesis of diabetes complications. Biochemical and Biophysical Research Communications, 432(2), 339-344. https://doi.org/10.1016/j.bbrc.2013.01.101 Agholme, L., Nath, S., Domert, J., Marcusson, J., K\u00e5gedal, K., & Hallbeck, M. (2014). Proteasome inhibition induces stress kinase dependent transport deficits -Implications for Alzheimer's disease. https://doi.org/10.1016/j.mcn.2013.11.001", "latex": null, "type": "table"}, "TABREF8": {"text": "). Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. Blood, 128(14), 1814-1820. https://doi.org/10.1182/blood-2016-03-704023 https://doi.org/10.1001/jama.208.9.1680 Ali, R.E., & Rattan, S.I. (2006). Curcumin's biphasic hormetic response on proteasome activity and heat-shock protein synthesis in human keratinocytes. Annals of New York Academy of Sciences, 1067, 394-399. https://doi:10.1196/annals.1354.05", "latex": null, "type": "table"}, "TABREF9": {"text": ", 83-93. https://doi.org/10.1016/0092-8674(81)90233-6 Bingol, B., & Schuman, E. M. (2004). A proteasome-sensitive connection between PSD-95 and https://doi.org/10.1016/j.neuropharm.2004.07.028 Bingol, B., & Schuman, E. M. (2006). Activity-dependent dynamics and sequestration of https://doi.org/10.1038/nature04769 Bingol, B., & Schuman, E. M. (2006). Activity-dependent dynamics and sequestration of https://doi.org/10.1038/nature04769 Bingol, B., Wang, C.-F., Arnott, D., Cheng, D., Peng, J., & Sheng, M. (2010). Autophosphorylated CaMKIIalpha acts as a scaffold to recruit proteasomes to dendritic spines. Cell, 140(4), 567-578. https://doi.org/10.1016/j.cell.2010.01.024 Blasiak, J., Pawlowska, E., Szczepanska, J., & Kaarniranta, K. (2019). Interplay between Autophagy and the Ubiquitin-Proteasome System and Its Role in the Pathogenesis of Age-Related //doi.org/10.3390/ijms20010210 Bochtler, M., Ditzel, L., Groll, M., Hartmann, C., & Huber, R. (1999). The proteasome. Annual https://doi.org/10.1146/annurev.biophys.28.1.295 Bogyo, M., Shin, S., McMaster, J. S., & Ploegh, H. L. (1998). Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chemistry & Biology, 5(6), 307-320. https://doi.org/10.1016/s1074-5521(98)90169-7Bohn, S., Sakata, E., Beck, F., Pathare, G. R., Schnitger, J., N\u00e1gy, I.,Baumeister, W., & F\u00f6rster, F. (2013). Localization of the regulatory particle subunit Sem1 in the 26S proteasome. Biochemical https://doi.org/10.1016/j.bbrc.2013.04.069", "latex": null, "type": "table"}, "TABREF10": {"text": ", 596-603. https://doi.org/10.1016/j.ajhg.2010.02.018 Dahlqvist, J., T\u00f6rm\u00e4, H., Badhai, J., & Dahl, N. (2012). siRNA Silencing of Proteasome Maturation Protein (POMP) Activates the Unfolded Protein Response and Constitutes a Model for KLICK Genodermatosis. PLOS ONE, 7(1), e29471. https://doi.org/10.1371/journal.pone.0029471 Dai, C., Dai, S., & Cao, J. (2012). Proteotoxic stress of cancer: implication of the heat-shock https://doi.org/10.1002/jcp.24017 Dal Vechio, F. H., Cerqueira, F., Augusto, O., Lopes, R., & Demasi, M. (2014). Peptides that activate the 20S proteasome by gate opening increased oxidized protein removal and reduced https://doi.org/10.1016/j.freeradbiomed.2013.11.017", "latex": null, "type": "table"}, "TABREF11": {"text": ", 5101-5109. https://doi.org/10.1200/JCO.2010.29.8216 https://doi.org/10.1056/NEJMoa1411321", "latex": null, "type": "table"}, "TABREF12": {"text": "https://doi.org/10.1016/j.bbrc.2016.01.093", "latex": null, "type": "table"}, "TABREF13": {"text": "TABLE 1: Clinical trials with bort gical cancers.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Erlotinib </td><td>NCT00895687 </td><td>1 </td><td>Completed </td><td>cervix cancer Advanced cancer </td></tr><tr><td>Mitoxantrone </td><td>NCT00059631 </td><td>1 </td><td>Completed </td><td>Prostate cancer </td></tr><tr><td>Vorinostat </td><td>NCT00731952 </td><td>1 </td><td>Completed </td><td>NSCLC </td></tr><tr><td>Cetuximab with or without cisplatinum </td><td>NCT01445405 </td><td>1 </td><td>Completed </td><td>Head and neck cancer </td></tr><tr><td>Placlitaxel </td><td>NCT00030368 </td><td>1 </td><td>Completed </td><td>Advanced or metastatic solid tumors </td></tr><tr><td>Trastuzumab </td><td>NCT00199212 </td><td>1 </td><td>Completed </td><td>Overexpressing Her-2 breast cancer </td></tr><tr><td>Bevacizumab </td><td>NCT00428545 </td><td>1 </td><td>Completed </td><td>Advanced malignancies </td></tr><tr><td>Gemcitabine, carboplatin </td><td>NCT00052338 </td><td>1 </td><td>Completed </td><td>NSCLC </td></tr><tr><td>Carboplatin, etoposide </td><td>NCT00027898 </td><td>1 </td><td>Completed </td><td>Advanced solid tumours </td></tr><tr><td>Fluorouracil, leucovorin </td><td>\u00a0</td><td>\u00a0</td><td>of\n</td><td>Metastatic solid tumor </td></tr><tr><td>Radiotherapy </td><td>\u00a0</td><td>\u00a0</td><td>e-proCompleted Completed Completed Completed Completed </td><td>Head and neck cancer </td></tr><tr><td>Topotecan </td><td>\u00a0</td><td>\u00a0</td><td>Advanced malignancies </td></tr><tr><td>Topotecan </td><td>\u00a0</td><td>\u00a0</td><td>Advanced solid tumours </td></tr><tr><td>Pegylated liposomal doxorubicin, gemcitabine </td><td>\u00a0</td><td>\u00a0</td><td>Advanced solid tumours </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Omeprazole </td><td>al Pr1 C1 C1 C1 C</td><td>ompleted ompleted ompleted ompleted Completed Completed Completed Completed Completed </td><td>Advanced solid tumours or Non-Hodgkin's lymphoma </td></tr><tr><td>Cetuximab </td><td>Advanced solid tumors </td></tr><tr><td>Gemcitabine </td><td>Advanced solid tumors </td></tr><tr><td>Paclitaxel </td><td>Metastatic or unresectable malignant solid tumors </td></tr><tr><td>Varinostat </td><td>Metastatic or unresectable solid tumours </td></tr><tr><td>Paclitaxel, carboplatin </td><td>JournNCT00007878 NCT00011778 NCT00068484 NCT00541359 NCT00500422 NCT00298779 NCT00622674 NCT00620295 NCT00667641 NCT00227513 NCT00028587 NCT01074411 NCT00348985 NCT00994500 </td><td>\u00a0</td><td>Advanced solid tumours </td></tr><tr><td>Carboplatin </td><td>\u00a0</td><td>Ovarian epithelial, fallopian tube or primary peritoneal cancer Advanced solid tumours </td></tr><tr><td>Belinostat </td><td>\u00a0</td></tr><tr><td>Vorinostat </td><td>1 1 1 1 1 1 1 1 1 1 </td><td>Advanced solid tumours </td></tr><tr><td>Doxorubicin </td><td>NCT00023855 </td><td>1 </td><td>Completed </td><td>Advanced solid tumours </td></tr><tr><td>Irinotecan </td><td>NCT00644696 </td><td>1 </td><td>Completed </td><td>Neuroblastoma </td></tr><tr><td>Interferon \u03b1-2b </td><td>NCT01462773 </td><td>1 </td><td>Completed </td><td>Melanoma </td></tr><tr><td>Sorafenib </td><td>NCT01078961 </td><td>1 </td><td>Completed </td><td>Melanoma </td></tr><tr><td>Temozolomide, bevacizumab </td><td>NCT01435395 </td><td>1 </td><td>Completed </td><td>Recurrent glioblastoma </td></tr><tr><td>Clofarabine </td><td>NCT02211755 </td><td>1 </td><td>Recruiting </td><td>Relapsed solid tumours </td></tr><tr><td>NK cells </td><td>NCT00720785 </td><td>1 </td><td>Recruiting </td><td>Advanced cancers </td></tr><tr><td>Gemcitabine, doxorubicin </td><td>NCT00479128 </td><td>1 </td><td>Active, not recruiting </td><td>Solid tumours </td></tr><tr><td>DFMO </td><td>NCT02139397 </td><td>1 </td><td>Active, not yet recruiting </td><td>Relapsed and refractory neuroblastoma </td></tr><tr><td>Pembrolizumab, cisplatin </td><td>NCT04265872 </td><td>1 </td><td>Not yet recruiting </td><td>Breast cancer </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>102 </td></tr></table></body></html>"}, "TABREF14": {"text": "TABLE 2: Clinical trials with carflizomb and ixazomib in non-haematological cancers.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Drug </td><td>Combined </td><td>NCT </td><td>Phase </td><td>Status </td><td>Setting </td></tr><tr><td>Carfilzomib </td><td>agent </td><td>identifier </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Dexamethasone </td><td>NCT02257476 </td><td>1 </td><td>Completed </td><td>Advanced solid tumours </td></tr><tr><td>\u00a0</td><td>Cyclophosphamide, etoposide </td><td>\u00a0</td><td>\u00a0</td><td>of\nRe</td><td>Pediatric relap\u00e8sed and refractory solid tumours </td></tr><tr><td>\u00a0</td><td>INCB052793, gemcitabine, nab-placlitaxel, dexamethasone, bortezomib, lenalidomide, azacitidine, pomalidomide, </td><td>\u00a0</td><td>e-pro1/2 Te</td><td>cruiting rminated Completed Completed Completed Completed Completed </td><td>Advanced solid tumours </td></tr><tr><td>\u00a0</td><td>INCB050465, INCB039110 </td><td>Pr</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Carboplatin, etoposide </td><td>rnal NCT019NCT005</td><td>\u00a0</td><td>Small cell lung cancer </td></tr><tr><td>\u00a0</td><td>Dexamethasone </td><td>\u00a0</td><td>Solid tumours, lymphoma, RRMM </td></tr><tr><td>\u00a0</td><td>/ </td><td>NCT02512926 NCT02265510 87232 31284 CT01775930 CT00884312 CT02047253 </td><td>\u00a0</td><td>Refractory renal cell carcinoma </td></tr><tr><td>\u00a0</td><td>/ </td><td>\u00a0</td><td>Solid tumours and MM </td></tr><tr><td>\u00a0</td><td>JouNNDexamethasone, acyclovir N</td><td>1 1/2 1/2 2 2 2 </td><td>Prostate cancer </td></tr><tr><td>\u00a0</td><td>/ </td><td>NCT02318784 </td><td>2 </td><td>Active non recruiting </td><td>Neuroendocrine cancers </td></tr><tr><td>Ixazomib </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Fulvestrant </td><td>NCT02384746 </td><td>1 </td><td>Terminated </td><td>Breast cancer </td></tr><tr><td>\u00a0</td><td>/ </td><td>NCT00830869 </td><td>1 </td><td>Completed </td><td>Advanced non haematological malignancies </td></tr><tr><td>\u00a0</td><td>/ </td><td>NCT01830816 </td><td>1 </td><td>Completed </td><td>Advanced solid tumours and RRMM </td></tr><tr><td>\u00a0</td><td>/ </td><td>NCT01912222 </td><td>1 </td><td>Completed </td><td>Solid tumours and haematological </td></tr></table></body></html>"}}, "back_matter": [{"text": "The authors woulk like to thank Prof. G. Manni for his fruitful discussion. This work was supported by the Italian Ministery of University and Research (PRIN", "cite_spans": [], "ref_spans": [], "section": "Acknowledgement"}, {"text": "Grasso, G., Salomone, F., Tundo, G. R., Pappalardo, G., Ciaccio, C., Spoto, G., Pietropaolo, A., Coletta, M., & Rizzarelli, E. (2012) . Metal ions affect insulin-degrading enzyme activity. Journal of Inorganic Biochemistry, 117, [351] [352] [353] [354] [355] [356] [357] [358] Grasso, G., Santoro, A. M., Lanza, V., Sbardella, D., Tundo, G. R., Ciaccio, C., Marini, S., Coletta, M., & Milardi, D. (2017) . The double faced role of copper in A? homeostasis: A survey on the interrelationship between metal dyshomeostasis, UPS functioning and autophagy in neurodegeneration. Coordination Chemistry Reviews, 347, 1-22.Grasso, G., Santoro, A. M., Lanza, V., Sbardella, D., Tundo, G. R., Ciaccio, C., Marini, S., Coletta, M., & Milardi, D. (2017) . The double faced role of copper in A\u03b2 homeostasis: A survey on the interrelationship between metal dyshomeostasis, UPS functioning and autophagy in neurodegeneration.Coordination Gregori, L., Hainfeld, J. F., Simon, M. N., & Goldgaber, D. (1997) . Binding of amyloid beta protein to the 20 S proteasome. The Journal of Biological Chemistry, 272(1), 58-62.Gressin, R., Daguindau, N., Tempescul, A., Moreau, A., Carras, S., Tchernonog, E., Schmitt, A., Houot, R., Dartigeas, C., Pignon, J. M., Corm, S., Banos, A., Mounier, C., Dupuis, J., Macro, M., Fleury, J., Jardin, F., Sarkozy, C., Damaj, G., \u2026 Lymphoma Study Association. (2019 Hershko, A., Ciechanover, A., Heller, H., Haas, A. L., & Rose, I. A. (1980) . Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATPdependent proteolysis. Proceedings of the National Academy of Sciences of the United States of America, 77(4), 1783-1786. https://doi.org/10. 1073/pnas.77.4.1783 Hershko, A., Eytan, E., Ciechanover, A., & Haas, A. L. (1982) . Immunochemical analysis of the turnover of ubiquitin-protein conjugates in intact cells. Relationship to the breakdown of abnormal proteins. The Journal of Biological Chemistry, 257 (23) Huang, Z., Wu, Y., Zhou, X., Xu, J., Zhu, W., Shu, Y., & Liu, P. (2014) . Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncology (London, England), 10(10), 1795-1807. https://doi.org/10.2217/fon.14.30Huber, E. M., Heinemeyer, W., Li, X., Arendt, C. S., Hochstrasser, M., & Groll, M. (2016) . A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome. Nature Communications, 7(1), 1-10. https://doi.org/10.1038/ncomms10900Husnjak, K., Elsasser, S., Zhang, N., Chen, X., Randles, L., Shi, Y., Hofmann, K., Walters, K., Finley, D., & Dikic, I. (2008) . Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature, 453 (7194) ", "cite_spans": [{"start": 26, "end": 133, "text": "Tundo, G. R., Pappalardo, G., Ciaccio, C., Spoto, G., Pietropaolo, A., Coletta, M., & Rizzarelli, E. (2012)", "ref_id": null}, {"start": 210, "end": 223, "text": "Biochemistry,", "ref_id": null}, {"start": 224, "end": 228, "text": "117,", "ref_id": null}, {"start": 229, "end": 234, "text": "[351]", "ref_id": null}, {"start": 235, "end": 240, "text": "[352]", "ref_id": null}, {"start": 241, "end": 246, "text": "[353]", "ref_id": null}, {"start": 247, "end": 252, "text": "[354]", "ref_id": null}, {"start": 253, "end": 258, "text": "[355]", "ref_id": null}, {"start": 259, "end": 264, "text": "[356]", "ref_id": null}, {"start": 265, "end": 270, "text": "[357]", "ref_id": null}, {"start": 271, "end": 276, "text": "[358]", "ref_id": null}, {"start": 289, "end": 403, "text": "Santoro, A. M., Lanza, V., Sbardella, D., Tundo, G. R., Ciaccio, C., Marini, S., Coletta, M., & Milardi, D. (2017)", "ref_id": null}, {"start": 627, "end": 741, "text": "Santoro, A. M., Lanza, V., Sbardella, D., Tundo, G. R., Ciaccio, C., Marini, S., Coletta, M., & Milardi, D. (2017)", "ref_id": null}, {"start": 923, "end": 989, "text": "Gregori, L., Hainfeld, J. F., Simon, M. N., & Goldgaber, D. (1997)", "ref_id": null}, {"start": 1390, "end": 1452, "text": "Ciechanover, A., Heller, H., Haas, A. L., & Rose, I. A. (1980)", "ref_id": null}, {"start": 1709, "end": 1728, "text": "1073/pnas.77.4.1783", "ref_id": null}, {"start": 1753, "end": 1790, "text": "Ciechanover, A., & Haas, A. L. (1982)", "ref_id": null}, {"start": 1991, "end": 2051, "text": "Wu, Y., Zhou, X., Xu, J., Zhu, W., Shu, Y., & Liu, P. (2014)", "ref_id": null}, {"start": 2270, "end": 2321, "text": "Arendt, C. S., Hochstrasser, M., & Groll, M. (2016)", "ref_id": null}, {"start": 2509, "end": 2608, "text": "Zhang, N., Chen, X., Randles, L., Shi, Y., Hofmann, K., Walters, K., Finley, D., & Dikic, I. (2008)", "ref_id": null}], "ref_spans": [], "section": "annex"}]}